backgroundcas
studi
recent
public
report
red
cell
transfus
previous
pregnant
femal
donor
markedli
increas
mortal
transfus
male
patient
find
clinic
administr
implic
manag
blood
suppli
howev
result
may
influenc
bias
introduc
statist
analysi
studi
designmethod
separ
analyz
data
three
link
blood
donor
recipi
cohort
includ
data
us
scandinavia
long
time
period
patient
follow
time
first
red
cell
transfus
occurr
mortal
use
separ
cox
regress
model
estim
associ
number
red
cell
transfus
femal
donor
previous
pregnant
donor
donor
treat
risk
death
control
total
number
red
cell
transfus
receiv
use
stratifi
cox
model
analys
perform
overal
effect
stratifi
recipi
sex
age
resultsfind
includ
total
patient
death
patient
death
patient
death
longer
follow
cohort
ii
iii
respect
associ
donor
characterist
mortal
three
cohort
tabl
hazard
ratio
per
transfus
unit
parou
femal
donor
rang
result
similar
effect
donor
sex
mortal
tabl
well
mortal
two
cohort
data
shown
effect
estim
differ
recipi
sex
andor
age
categor
analys
show
neg
effect
heavili
expos
patient
conclus
joint
analysi
data
three
larg
cohort
transfus
patient
found
evid
associ
donor
sex
pariti
either
patient
surviv
null
find
use
similar
statist
approach
across
million
patient
heterogen
clinic
set
differ
countri
indic
prior
find
seem
unlik
reflect
true
biolog
effect
backgroundcas
studi
platelet
essenti
optim
haemostasi
preserv
endotheli
glycocalyx
resuscit
shock
howev
day
convent
store
platelet
mean
usual
avail
outsid
larg
hospit
cryopreserv
dimethylsuphoxid
extend
year
reconstitut
plasma
requir
minim
time
specialis
equip
train
howev
despit
encourag
preclin
phase
data
one
phase
ii
trial
patient
receiv
cryopreserv
platelet
publish
clip
trial
program
seek
provid
suffici
phase
iii
trial
data
regulatori
approv
studi
designmethod
juli
decemb
hospit
enrol
cardiac
surgic
patient
particularli
high
risk
periop
bleed
identifi
use
trust
criteria
alghamdi
et
al
transfus
pilot
trial
patient
randomis
receiv
either
cryopreserv
platelet
treat
clinician
decid
platelet
transfus
indic
cryopreserv
platelet
prepar
australian
red
cross
blood
servic
use
method
base
netherland
militari
blood
bank
modif
origin
protocol
describ
us
navi
resultsfind
total
patient
randomis
receiv
platelet
transfus
studi
group
baselin
signific
differ
effect
outcom
trend
cryopreserv
group
requir
fewer
red
blood
cell
unit
transfus
median
iqr
vs
unit
trend
toward
cryopreserv
group
less
blood
chest
drain
median
iqr
vs
ml
composit
outcom
defin
bleed
academ
research
consortium
barc
trend
superior
cryopreserv
platelet
group
vs
clinic
import
differ
measur
advers
event
conclus
pilot
trial
cryopreserv
platelet
associ
evid
harm
small
trend
reduc
requir
red
cell
transfus
reduc
postop
blood
loss
light
data
clear
logist
advantag
cryopreserv
definit
studi
design
test
volum
postop
bleed
primari
outcom
warrant
improv
identif
patient
high
risk
platelet
transfus
use
transfus
risk
predict
score
increas
effici
phase
iii
trial
backgroundcas
studi
chang
deferr
polici
msm
fda
approv
dec
allow
previous
defer
donor
report
msm
ever
donat
activ
report
prior
month
elig
criteria
met
new
donor
elig
polici
implement
phase
american
red
cross
begin
dec
review
infecti
diseas
id
histori
number
donor
prior
msm
histori
qualifi
donat
compar
gener
donor
popul
studi
designmethod
queri
develop
identifi
indefinit
defer
msm
donor
otherwis
elig
blood
donat
identifi
elig
msm
deferr
remov
queri
cover
deferr
jan
reinstat
occur
dec
addit
queri
develop
track
subsequ
donationsdeferr
reinstat
donor
elig
commun
assum
criteria
remain
accept
includ
absenc
msm
prior
year
follow
telephon
call
number
reinstat
donor
also
recruit
donat
base
current
elig
reinstat
donor
requir
meet
donor
requir
donor
rate
id
marker
reinstat
donor
compar
test
gener
donor
popul
donat
resultsfind
donor
return
donat
indefinit
msm
deferr
remov
donor
id
deferr
follow
reinstat
confirm
syphili
occas
histori
prior
reinstat
reactiv
post
reinstat
note
reactiv
donor
also
incid
hiv
nat
convert
addit
donor
return
donat
subsequ
msm
deferr
id
deferr
follow
reinstat
confirm
syphili
one
donor
also
hiv
antibodynat
posit
acknowledg
ongo
msm
overal
rate
id
marker
routin
donor
compar
reinstat
indefinit
defer
msm
donor
p
odd
ratio
confid
interv
ci
reinstat
defer
msm
donor
p
ci
conclus
feder
fund
program
investig
variat
hbv
hcv
hiv
preval
incid
yet
detect
signific
chang
indic
compar
safeti
polici
chang
howev
review
msm
reinstat
donor
versu
gener
donor
show
trend
requir
care
monitor
backgroundcas
studi
warm
autoantibodi
waa
panreact
autoantibodi
complic
compat
test
caus
clinic
hemolysi
rate
patient
waa
develop
red
blood
cell
rbc
alloimmun
well
understood
singl
center
studi
cite
rate
patient
substanti
laboratori
resourc
use
evalu
rbc
select
howev
uniform
approach
activ
goal
studi
understand
preval
waa
risk
rbc
alloimmun
popul
whether
rbc
select
practic
impact
alloimmun
studi
designmethod
record
patient
year
age
antibodi
detect
test
iat
evid
waa
includ
determin
incid
rbc
alloimmun
patient
waa
patient
receiv
rbc
transfus
iat
day
later
review
determin
impact
rbc
product
select
approach
patient
subdivid
receiv
prophylact
antigen
match
pam
rbc
transfus
resultsfind
eight
center
countri
collect
review
patient
iat
patient
test
transfus
servic
laboratori
tsl
waa
rang
one
center
combin
tsl
immunohematolog
refer
laboratori
irl
patient
waa
rang
preval
waa
detect
tsl
center
tsl
patient
waa
evid
rbc
alloimmun
either
prior
time
waa
identif
patient
waa
detect
patient
waa
transfus
receiv
rbc
transfus
detect
waa
patient
waa
transfus
patient
receiv
pam
rbc
rhesu
kell
antigen
minimum
median
rbc
receiv
rbc
unit
median
rbc
patient
receiv
pam
rbc
subsequ
antibodi
detect
test
day
post
transfus
patient
number
patient
develop
rbc
alloantibodi
differ
two
group
pam
group
patient
group
p
conclus
largest
known
assimil
laboratori
result
patient
waa
overal
preval
waa
quit
low
slightli
higher
enrich
irl
result
data
provid
evid
approxim
one
third
patient
waa
alloantibodi
concomitantli
nearli
patient
waa
requir
rbc
transfus
waa
subsequ
develop
alloimmun
use
pam
appear
protect
subsequ
rbc
alloimmun
howev
studi
number
type
serolog
evalu
may
impact
use
pam
approach
backgroundcas
studi
hospit
children
incid
venou
thromboembol
vte
reportedli
rise
rbc
transfus
commonli
perform
period
children
howev
relationship
thrombot
event
remain
unclear
recent
propos
relationship
adult
goel
tobian
et
al
jama
surgeri
press
studi
examin
relationship
periop
rbc
transfus
vte
within
day
surgeri
children
year
studi
designmethod
use
pediatr
databas
american
colleg
surgeon
nation
surgic
qualiti
improv
program
ped
outcom
vte
deep
venou
thrombosi
dvt
pulmonari
embol
pe
pediatr
patient
year
undergo
electiveurgentemerg
surgeri
compar
univari
follow
multivari
logist
regress
perform
resultsfind
children
infant
year
neonat
day
evalu
underw
elect
urgent
emerg
procedur
commonest
surgeri
type
gener
surgeri
orthoped
urolog
otolaryngolog
neurosurg
children
infant
neonat
receiv
transfus
within
hour
surgeri
six
percent
children
infant
neonat
receiv
rbc
transfus
intraop
start
surgeri
hr
transfus
respons
bleed
children
infant
neonat
vte
includ
case
pe
rbc
transfus
associ
higher
risk
vte
adjust
odd
ratio
adjor
p
account
variou
put
risk
factor
tabl
associ
stronger
infant
adjor
ci
p
neonat
adjor
ci
p
rbc
transfus
independ
associ
vte
children
adjor
p
infant
adjor
ci
p
neonat
adjor
ci
p
conclus
prospect
registri
studi
children
undergo
surgeri
rbc
transfus
associ
higher
risk
adjust
odd
vte
relationship
also
seen
subgroup
analysi
infant
neonat
find
valid
prospect
set
pediatr
patient
blood
manag
strategi
need
explor
patient
optim
transfus
children
backgroundcas
studi
recent
assess
massiv
transfus
protocol
outcom
identifi
earli
transfus
plasma
result
improv
hemostasi
shorter
ventil
time
increas
surviv
infus
use
plasma
red
blood
cell
also
demonstr
signific
decreas
morbid
mortal
plasma
fdp
product
success
use
altern
plasma
ffp
howev
current
fdp
product
prepar
glass
bottl
limit
widespread
adopt
fdp
environ
battlefield
new
fdp
product
contain
reconstitut
plastic
blood
bag
use
ml
usp
steril
water
inject
within
less
two
minut
recent
develop
studi
designmethod
prospect
pair
open
label
phase
studi
determin
safeti
autolog
infus
whole
blood
cpd
deriv
fdp
plasmapheresi
acd
deriv
fdp
normal
healthi
subject
fdp
product
manufactur
minimum
volum
ml
ffp
three
cohort
subject
per
cohort
includ
result
infus
ml
cohort
cpd
acd
fdp
infus
ml
cohort
cpd
acd
fdp
infus
ml
cohort
acd
fdp
acd
ffp
infus
cohort
random
crossov
studi
compar
clinic
laboratori
level
thrombogenesi
biomark
fdp
vs
ffp
infus
clinic
laboratori
perform
minut
hour
hour
day
vitro
biochem
coagul
paramet
includ
ph
osmol
aptt
naptt
inr
factor
v
viii
viia
protein
antithrombin
iii
total
protein
level
also
analyz
data
safeti
monitor
board
review
subject
data
complet
infus
cohort
resultsfind
date
total
subject
screen
subject
enrol
assign
treatment
cohort
subject
infus
fdp
product
fdp
unit
reconstitut
less
two
minut
subject
seriou
advers
event
sae
relat
product
infus
occurr
predetermin
treatment
emerg
advers
event
teae
includ
thromboembol
event
infect
evid
unusu
bleedingbruis
elev
level
observ
physic
examin
show
signific
chang
vital
sign
well
score
four
ae
relat
fdp
product
infus
observ
cohort
rhiniti
transient
weakli
posit
dat
hyperglycaemia
transient
mild
increas
liver
transaminas
ae
identifi
cohort
sign
either
local
system
allerg
reaction
observ
infus
cohort
infus
ongo
result
cohort
present
conclus
preliminari
data
suggest
fdp
well
toler
normal
healthi
volunt
sae
safeti
concern
backgroundcas
studi
autoantibodi
rbc
may
lead
autoimmun
hemolyt
anemia
sever
sometim
fatal
diseas
b
cell
escap
central
toler
retain
abil
secret
autoantibodi
stringent
cell
toler
prevent
autoimmun
howev
toler
mechan
unknown
recent
thymic
emigr
rte
highli
suscept
toler
herein
test
hypothesi
rte
involv
toler
rbc
autoantigen
studi
designmethod
hod
mice
express
transgen
consist
hen
egg
lysozym
ovalbumin
ova
human
duffi
hod
mice
bred
otii
mice
wherebi
cell
specif
ova
within
hod
hodxotii
immun
ovacfa
thymi
week
wk
old
hodxotii
stain
identifi
otii
regulatori
cell
treg
hod
mice
bred
aka
hodxrt
gfp
detect
rte
wk
post
thymic
egress
gfp
otii
rte
evalu
anerg
surfac
marker
transcript
factor
kinas
assess
function
mice
receiv
sort
gfp
otii
rte
hodxrt
follow
hod
rbc
rte
prolifer
assess
day
stain
resultsfind
ovacfa
immun
fail
induc
immun
respons
hodotii
mice
indic
robust
toler
strong
antibodi
respons
observ
control
thymi
neither
total
otii
cell
number
frequenc
treg
signific
differ
hodotii
control
therebi
indic
central
toler
mechan
affect
autoreact
cell
rte
hodxrt
divid
gfphi
wk
gfpint
wk
gfpneg
matur
analysi
gfphi
rte
hodrt
mice
significantli
higher
express
transcript
factor
helio
phosphoryl
mtor
akt
compar
p
experi
anerg
surfac
marker
gitr
increas
express
hodrt
matur
rte
mice
display
phenotyp
throughout
matur
wherea
autoreact
rte
becam
effector
cell
follow
gfp
otii
adopt
transfer
hod
rbc
transfus
rte
mice
prolifer
wherea
decreas
capac
prolifer
matur
rte
observ
rte
hodrt
mice
experi
rte
gfphi
gfpint
gfpneg
conclus
data
herein
show
autoreact
cell
subject
central
toler
mechan
novel
find
rbc
autoantigen
instead
anergi
program
initi
rte
matur
data
provid
key
insight
cell
toler
mechan
identifi
window
toler
demonstr
disrupt
rte
matur
toler
may
lead
rbc
autoimmun
backgroundcas
studi
substanti
variabl
well
store
human
rbc
circul
howev
basi
variabl
poorli
understood
report
like
human
rbc
genet
distinct
strain
mice
store
differ
genet
element
respons
differ
storag
mice
store
well
fvb
mice
store
poorli
map
studi
designmethod
individu
mice
gener
fvb
cross
analyz
regard
rbc
recoveri
ptr
high
resolut
metabolom
snp
base
genotyp
phenotyp
driven
backcross
also
carri
poorli
store
progeni
cross
mice
gener
congen
strain
new
transgen
mice
engin
overexpress
rbc
known
human
variant
human
clone
express
cho
cell
activ
measur
resultsfind
quantit
trait
locu
qtl
analysi
mice
identifi
mb
region
chr
associ
ptr
narrow
mb
contain
code
gene
mrna
level
quantifi
gene
erythroid
precursor
one
gene
show
significantli
differ
express
fvb
mice
compar
p
anova
bonferroni
correct
two
mrna
transcript
variant
mice
compar
fvb
mice
wild
type
transcript
fold
higher
transcript
fold
lower
p
p
respect
anova
bonferroni
correct
rbc
fvb
mice
twice
activ
fold
higher
protein
level
rbc
overexpress
transgen
mice
result
signific
decreas
ptr
store
rbc
compar
p
lipid
oxid
correl
poor
ptr
cohort
refin
cluster
oxylipin
carri
strain
transgen
mice
known
natur
variant
human
wide
varieti
activ
conclus
multipl
line
evid
use
differ
approach
identifi
genet
element
regul
ptr
ferrireductas
convert
suggest
mechan
promot
fenton
reaction
ensu
oxid
lipid
human
mice
share
orthologu
ident
amino
acid
level
null
mice
defici
human
similar
anemia
knowledg
report
first
indic
role
biolog
matur
rbc
human
variant
differ
activ
test
rbc
storag
test
hypothesi
human
would
requir
studi
ptr
rbc
donor
genet
variat
gene
involv
base
pathway
backgroundcas
studi
alloimmun
red
blood
cell
rbc
antigen
remain
signific
clinic
problem
transfus
medicin
presenc
rbc
alloantibodi
lead
delay
transfus
reaction
result
signific
morbid
occasion
mortal
transfus
rbc
repres
uniqu
immun
stimulu
lack
tradit
pathogen
signal
stimul
innat
immun
respons
molecular
cellular
mechan
involv
stimul
immun
respons
transfus
rbc
remain
unclear
recent
work
mous
model
shown
storag
rbc
prior
transfus
lead
signific
enhanc
alloimmun
studi
independ
implic
macrophag
spleen
critic
immun
respons
store
rbc
splenic
margin
zone
macrophag
mzm
report
stimul
innat
immun
also
promot
adapt
immun
respons
certain
pathogen
addit
splenic
mzm
specif
phagocytos
intraven
inject
apoptot
cell
result
immun
suppress
toward
apoptot
cell
antigen
uptak
apoptot
cell
mzm
critic
depend
exposur
phosphatidylserin
ps
cell
surfac
exposur
ps
surfac
rbc
increas
rbc
age
significantli
enhanc
storag
hypothes
splenic
mzm
phagocytos
transfus
store
rbc
unlik
apoptot
cell
stimul
innat
adapt
immun
respons
rbc
antigen
studi
designmethod
investig
role
mzm
rbc
alloantibodi
gener
util
hod
mous
model
compar
alloimmun
wt
liver
x
receptor
ko
mice
transcript
factor
essenti
gener
splenic
mzm
ko
mice
show
complet
lack
splenic
mzm
abnorm
respons
pathogen
wt
ko
mice
transfus
fresh
store
hod
rbc
result
serum
igg
alloantibodi
titer
compar
resultsfind
surprisingli
lack
mzm
affect
gener
igg
alloantibodi
respons
either
fresh
store
hod
rbc
wt
ko
mice
gener
alloantibodi
respons
transfus
fresh
store
hod
rbc
experi
micegroup
serum
level
igg
titer
equival
wt
mice
respons
transfus
fresh
p
experi
micegroup
store
hod
rbc
p
experi
micegroup
u
test
use
calcul
valu
lower
consid
statist
signific
conclus
splenic
mzm
requir
primari
alloantibodi
respons
transfus
fresh
store
hod
rbc
result
suggest
splenic
immun
respons
transfus
rbc
util
mechan
distinct
regul
immun
respons
apoptot
cell
pathogen
studi
highlight
uniqu
natur
rbc
immun
stimulu
stress
need
continu
investig
molecular
cellular
mechan
regul
rbc
alloimmun
backgroundcas
studi
prophylact
administr
polyclon
women
prevent
matern
alloimmun
howev
certain
condit
prepar
paradox
enhanc
alloimmun
underli
mechan
behind
modul
humor
alloimmun
unknown
howev
recent
becom
appreci
differ
igg
subtyp
antibodi
may
differenti
regul
alloimmun
herein
take
reductionist
approach
passiv
immun
mice
monoclon
alloantibodi
wherebi
antibodi
specif
differ
igg
subtyp
test
igg
subtyp
regul
rbc
alloimmun
studi
designmethod
new
monoclon
isol
sequenc
differ
mous
igg
subtyp
individu
subtyp
passiv
infus
mice
follow
transfus
pack
leukoreduc
rbc
consist
hod
label
lipophil
dye
allow
track
hod
rbc
express
tripl
fusion
protein
consist
hen
egg
lysozym
ovalbumin
ova
human
duffi
recipi
receiv
adopt
transfer
otii
cell
recogn
ova
contain
within
hod
present
recipi
mhcii
alloantibodi
assess
day
measur
flow
crossmatch
hod
control
rbc
target
resultsfind
passiv
immun
enhanc
alloantibodi
product
experi
p
led
increas
neither
modul
alloimmun
compar
control
addit
mechanist
studi
focus
passiv
immun
acceler
hod
rbc
clearanc
circul
everi
time
point
analyz
compar
syngen
rbc
addit
treatment
led
signific
increas
hod
rbc
consumpt
p
experi
increas
observ
dendrit
cell
dc
dc
red
pulp
macrophag
lesser
extent
plasmacytoid
dc
neutrophil
cumul
effect
alter
rbc
consumpt
pattern
mice
result
signific
increas
otii
prolifer
p
experi
conclus
current
find
indic
alloantibodi
modul
futur
rbc
alloantibodi
product
particular
enhanc
alloantibodi
product
acceler
rbc
clearanc
shift
pattern
consumpt
individu
immunostimulatori
antigen
present
cell
subset
cumul
effect
chang
enhanc
cell
activ
prolifer
lead
increas
rbc
alloantibodi
polyclon
contain
multipl
antibodi
subtyp
vari
ratio
find
may
provid
insight
prepar
rhd
certain
condit
enhanc
alloimmun
backgroundcas
studi
addit
better
known
effector
function
antibodi
also
known
regul
primari
immun
respons
eg
administr
polyclon
prevent
matern
alloimmun
attempt
gener
monoclon
complic
iron
prepar
enhanc
rather
suppress
human
trial
likewis
administr
plasma
deriv
caus
enhanc
set
underli
factor
andor
mechan
regul
enhanc
suppress
poorli
understood
investig
process
use
tractabl
mous
model
express
variant
kell
rbc
allow
transfus
rbc
recipi
allotransfus
studi
designmethod
monoclon
isol
sequenc
recombin
dna
technolog
use
express
variabl
domain
differ
mous
igg
subtyp
isol
subtyp
infus
mice
follow
transfus
one
unit
rbc
microlit
alloimmun
measur
test
serum
igm
day
igg
day
via
flow
crossmatch
rbc
recipi
mice
includ
target
delet
common
gamma
chain
fcgr
fcgri
fcgriii
tradit
cellular
surfac
plasmon
reson
spr
assay
perform
assess
affin
differ
fcgr
resultsfind
significantli
enhanc
alloimmun
exampl
combin
data
experi
treat
vs
control
mice
igm
vs
p
igg
vs
p
enhanc
observ
use
antibodi
antigen
likewis
signal
detect
mice
receiv
antibodi
transfus
addit
mechanist
studi
focus
subtyp
enhanc
lost
mice
delet
common
fc
gamma
chain
suggest
fcgri
fcgriii
fcgriv
combin
requir
enhanc
enhanc
elimin
mice
unalt
mice
addit
spr
analysi
reveal
affin
highest
fcgri
find
demonstr
fcgri
fcgriii
requir
mediat
enhanc
alloantibodi
respons
rbc
conclus
current
find
indic
antibodi
influenc
humor
alloimmun
process
depend
upon
igg
subtyp
enhanc
alloimmun
mechanist
enhanc
requir
fcgri
enhanc
lost
fcgri
null
mice
none
fcgr
suffici
enhanc
rule
may
involv
backgroundcas
studi
dehydrogenas
defici
found
approxim
million
human
like
provid
resist
malaria
caus
missens
mutat
destabil
enzym
result
decreas
activ
rbc
age
although
typic
healthi
individu
experi
profound
hemolysi
upon
exposur
oxid
stress
diet
drug
diseas
howev
mani
cellular
biolog
particular
remain
poorli
understood
partli
due
lack
anim
model
enzymat
instabl
seen
human
studi
designmethod
code
region
sever
human
variant
knock
mous
locu
background
mous
rbc
assess
vivo
life
span
well
recoveri
ptr
storag
oxid
stress
induc
vivo
phenylhydrazin
phz
altern
rbc
expos
diamid
vitro
high
resolut
metabolom
analys
perform
rbc
challeng
phz
diamid
includ
vitro
incub
stabl
isotop
label
compar
glycolysi
vs
pentos
phosphat
pathway
ppp
resultsfind
rbc
mice
activ
p
metabol
trace
confirm
decreas
ppp
flux
especi
diamid
treat
rbc
baselin
observ
differ
vivo
rbc
lifespan
compar
mice
howev
phz
challeng
caus
mark
hemoglobinuria
significantli
increas
rbc
clearanc
compar
mice
time
cours
p
mice
treat
phz
low
steadi
state
level
sedoheptulos
phosphat
gluconolacton
parallel
increas
ampatp
ratio
decreas
atp
increas
polyamin
bilirubin
nicotinamid
recent
human
studi
shown
small
signific
decreas
ptr
store
rbc
defici
donor
compar
donor
vs
differ
observ
ptr
vs
mice
conclus
like
mani
human
mice
hematolog
normal
healthi
condit
absenc
oxid
stress
howev
expos
environment
oxid
stress
rbc
undergo
increas
damag
rapid
destruct
metabolom
analysi
provid
uniqu
insight
insult
rbc
suffer
expos
oxid
stress
addit
provid
novel
mechanist
insight
oxid
hemolysi
rbc
model
present
new
tractabl
platform
investig
multipl
hypothes
regard
oxid
stress
health
diseas
backgroundcas
studi
circulatori
overload
taco
one
lead
caus
major
morbid
mortal
hydrostat
pulmonari
edema
key
major
risk
factor
includ
speed
volum
transfus
date
preclin
studi
investig
infus
speed
volum
pulmonari
capillari
pressur
aim
studi
develop
rat
model
taco
investig
influenc
risk
factor
studi
designmethod
rat
model
develop
use
lewi
rat
blood
harvest
donor
rat
use
make
red
blood
cell
unit
rbc
follow
nation
blood
bank
practic
gener
anesthesia
cardiac
pressur
transduc
place
isovolem
anemia
induc
replac
circul
volum
colloid
solut
larg
myocardi
infarct
induc
ligat
descend
coronari
arteri
anim
random
per
group
receiv
unit
rbc
minut
anim
primari
outcom
differ
pressur
dlvedp
gold
standard
measur
increas
pulmonari
pressur
hallmark
taco
secondari
outcom
includ
lung
ratio
wdr
hemodynam
paramet
resultsfind
lvedp
mmhg
iqr
follow
transfus
signific
increas
dlvedp
seen
vs
vs
unit
resp
p
p
higher
transfus
speed
trend
toward
higher
pressur
significantli
differ
elev
lvedp
baselin
persist
hour
transfus
unit
group
ns
wdr
show
differ
unit
transfus
speed
conclus
first
anim
transfus
model
investig
effect
transfus
speed
pulmonari
hydrostat
pressur
key
featur
taco
strong
effect
transfus
volum
pulmonari
hydrostat
pressur
found
higher
transfus
speed
show
trend
toward
higher
pressur
signific
model
futur
experi
model
allow
test
intervent
therapeut
strategi
prevent
taco
backgroundcas
studi
cultur
residu
compon
detect
septic
transfus
reaction
str
accord
aabb
criteria
signssymptom
suggest
str
includ
fever
rise
plu
follow
rigor
hypotens
shock
tachycardia
dyspnea
andor
nauseavomit
isol
hypotens
limit
criteria
includ
hypotens
tachycardia
undefin
fever
may
occur
absenc
signssymptom
fever
may
occur
patient
antipyret
goal
project
develop
improv
criteria
detect
str
cultur
residu
product
adult
patient
studi
designmethod
collect
retrospect
data
transfus
reaction
adult
year
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
product
cultur
result
enrich
dataset
posit
result
modifi
aabb
criteria
defin
hypotens
systol
blood
pressur
mmhg
andor
diastol
blood
pressur
mmhg
decreas
baselin
tachycardia
increas
baselin
also
modifi
recommend
cultur
fever
absenc
signssymptom
absenc
fever
patient
signssymptom
present
retrospect
determin
sensit
specif
modifi
criteria
detect
posit
cultur
residu
compon
base
cultur
result
resultsfind
institut
submit
complet
reaction
data
cultur
residu
compon
posit
cultur
result
six
consid
definit
str
patient
cultur
grew
organ
consid
possibl
str
patient
cultur
neg
discord
patient
cultur
perform
modifi
criteria
compar
aabb
criteria
shown
tabl
modifi
criteria
identifi
definit
str
aabb
criteria
would
miss
one
cultur
reaction
consist
modifi
criteria
aabb
criteria
conclus
modifi
criteria
cultur
residu
compon
suspect
str
adult
patient
offer
better
sensit
detect
posit
cultur
result
less
specif
backgroundcas
studi
septic
transfus
reaction
str
suspect
aabb
bulletin
recommend
test
return
product
bacteri
contamin
well
draw
blood
sampl
patient
cultur
grow
bacteri
speci
two
sourc
support
diagnosi
str
howev
patient
blood
cultur
neg
set
true
str
patient
antibiot
therapi
time
transfus
multicent
retrospect
intern
studi
describ
rate
patient
cultur
set
product
cultur
organ
detect
cultur
studi
designmethod
collect
data
transfus
reaction
residu
product
cultur
calendar
year
includ
recipi
demograph
data
type
product
implic
patient
andor
product
cultur
result
data
set
addit
enrich
case
product
cultur
posit
imput
clinic
signific
posit
product
cultur
defin
definit
str
patient
cultur
grew
organ
possibl
str
patient
cultur
cultur
neg
grew
differ
organ
product
resultsfind
transfus
reaction
product
cultur
institut
patient
concurr
cultur
product
cultur
grew
bacteri
organ
posit
product
cultur
concord
patient
cultur
definit
imput
organ
implic
either
member
skin
microbiota
staphylococcu
spp
gastrointestin
tract
escherichia
coli
case
patient
blood
cultur
grew
organ
tabl
case
patient
cultur
neg
possibl
imput
remain
case
patient
cultur
unabl
assess
imput
conclus
minor
patient
concurr
blood
cultur
obtain
residu
product
cultur
workup
str
imput
therefor
could
assign
posit
product
cultur
isol
bacteri
speci
patient
product
allow
assign
definit
imput
case
posit
product
cultur
transfus
reaction
sign
symptom
warrant
cultur
residu
product
patient
blood
cultur
collect
concurr
aid
interpret
product
cultur
result
backgroundcas
studi
transfus
blood
compon
contamin
bacteria
may
result
septic
transfus
reaction
str
result
morbid
andor
mortal
transfus
recipi
cultur
residu
compon
suspect
str
import
may
guid
manag
patient
although
guidelin
exist
cultur
residu
compon
set
suspect
str
current
practic
unknown
aim
project
measur
reaction
report
residu
compon
cultur
rate
assess
institut
polici
detect
str
cultur
residu
compon
studi
designmethod
retrospect
collect
data
total
number
transfus
transfus
reaction
report
cultur
residu
compon
transfus
reaction
calendar
year
stratifi
implic
compon
type
red
blood
cell
rbc
plasma
platelet
plt
contextu
data
survey
distribut
studi
particip
assess
institut
polici
investig
str
resultsfind
data
survey
respons
receiv
center
encompass
transfus
report
reaction
cultur
reaction
mark
variat
reaction
report
cultur
rate
across
center
although
reaction
report
rate
lower
plasma
compar
plt
rbc
p
differ
reaction
cultur
rate
compon
type
observ
tabl
survey
result
demonstr
mark
variat
institut
cultur
polici
major
center
use
publish
criteria
cultur
str
center
allow
cultur
residu
unit
without
medic
director
approv
formal
review
process
trigger
str
investig
center
report
histor
clinic
relev
str
overal
higher
reaction
cultur
rate
vs
p
suggest
recal
bia
may
driver
increas
cultur
conclus
mark
variat
institut
practic
surround
cultur
residu
compon
detect
str
histor
report
clinic
relev
str
appear
result
higher
cultur
rate
opportun
practic
standard
backgroundcas
studi
circulatori
overload
taco
one
lead
caus
morbid
mortal
definit
taco
caus
hydrostat
pulmonari
edema
due
circulatori
overload
exact
pathophysiolog
howev
unclear
case
occur
transfus
unit
date
anim
model
abl
induc
taco
sinc
healthi
heart
abl
deal
larg
infus
volum
hypothes
underli
volum
incompli
eg
cardiac
dysfunct
subsequ
transfus
caus
taco
aim
induc
taco
anim
model
investig
pathophysiolog
studi
designmethod
taco
model
develop
use
lewi
rat
gener
anesthesia
catheter
use
colloid
circul
volum
replac
induc
isovolem
anemia
larg
myocardi
infarct
induc
ligat
descend
coronari
arteri
rat
random
per
group
receiv
unit
rbc
prepar
donor
rat
similar
volum
lactat
ringer
lr
minut
anim
follow
primari
outcom
pressur
lvedp
gold
standard
measur
increas
pulmonari
capillari
pressur
hallmark
taco
secondari
outcom
lung
resultsfind
baselin
hemodynam
similar
group
lvedp
mmhg
iqr
larg
increas
lvedp
tabl
seen
directli
infus
rbc
lr
p
lvedp
dissip
rapidli
fluid
infus
group
minut
p
signific
anymor
lung
differ
group
conclus
model
anem
rat
underli
cardiac
dysfunct
blood
fluid
infus
increas
pulmonari
capillari
pressur
taco
model
first
compar
fluid
blood
product
measur
direct
pulmonari
capillari
pressur
pulmonari
edema
blood
transfus
profoundli
differ
effect
capillari
pressur
lung
studi
current
underpow
detect
differ
pulmonari
edema
howev
inclus
ongo
data
suggest
taco
pathophysiolog
sole
fluid
overload
backgroundcas
studi
circulatori
overload
taco
common
often
sever
advers
reaction
blood
transfus
associ
increas
morbid
mortal
sought
develop
predict
algorithm
would
use
patient
characterist
identifi
patient
high
risk
develop
taco
transfus
studi
designmethod
case
control
studi
four
academ
hospit
util
activ
surveil
enrol
case
taco
well
match
transfus
control
without
pulmonari
edema
measur
cardiac
stress
natriuret
peptid
measur
case
taco
control
prior
follow
transfus
case
detect
algorithm
identifi
patient
highest
risk
taco
develop
use
classif
regress
tree
cart
analys
evalu
approxim
risk
factor
produc
rank
import
predictor
order
rel
import
predict
taco
algorithm
perform
evalu
use
misclassif
error
rate
averag
squar
error
ase
sensit
specif
receiv
oper
characterist
curv
analys
use
determin
accuraci
clinic
predictor
differenti
taco
control
resultsfind
inform
determin
case
taco
versu
control
statu
sf
ratio
level
hospit
set
histori
hypertens
elev
systol
blood
pressur
respiratori
rate
hemoglobin
level
gdl
patient
sf
ratio
less
level
greater
orpacu
emerg
depart
procedur
suit
set
highest
probabl
develop
taco
patient
sf
ratio
greater
respiratori
rate
less
lowest
probabl
develop
taco
algorithm
perform
excel
discrimin
taco
vs
control
area
curv
cart
analysi
achiev
misclassif
rate
ase
sensit
specif
conclus
screen
algorithm
differenti
case
taco
transfus
control
use
clinic
data
set
classif
tree
algorithm
may
improv
identif
patient
risk
develop
taco
prospect
studi
need
assess
util
predict
algorithm
plu
clinic
intervent
prevent
taco
hospit
patient
cohort
backgroundcas
studi
mandatori
report
advers
reaction
monthli
transfus
activ
nation
healthcar
safeti
network
nhsn
place
massachusett
sinc
june
report
incid
mechan
acut
hemolyt
transfus
reaction
ahtr
period
studi
designmethod
ahtr
report
met
nhsn
case
definit
imput
criteria
definit
possibl
probabl
includ
facil
analyz
categor
reaction
mechan
immun
versu
sever
implic
blood
compon
recipi
characterist
transfus
compon
aborh
type
use
sa
rate
calcul
per
unit
transfus
resultsfind
ahtr
report
mean
rate
per
unit
transfus
product
type
approxim
major
ahtr
report
larger
facil
bed
rate
per
unit
transfus
compar
per
unit
transfus
facil
bed
immun
mechan
account
ahtr
abo
antibodi
respons
immun
ahtr
involv
group
apheresi
platelet
without
platelet
addit
solut
transfus
group
ab
recipi
incid
ahtr
platelet
transfus
per
platelet
unit
approxim
abo
ahtr
case
involv
red
blood
cell
rbc
transfus
stem
cell
transplant
recipi
subgroup
patient
one
case
erron
rbc
unit
group
ab
transfus
surgeri
patient
group
autoantibodi
account
immun
ahtr
case
involv
warm
autoantibodi
alloantibodi
case
case
account
remaind
immun
ahtr
incid
ahtr
rbc
transfus
per
rbc
approxim
although
reaction
categor
sever
one
reaction
note
major
sequela
case
involv
patient
requir
massiv
transfus
alloantibodi
c
k
n
conclus
group
apheresi
platelet
transfus
group
ab
recipi
repres
largest
categori
immun
ahtr
period
follow
autoantibodi
implic
red
blood
cell
transfus
hemovigil
report
use
nhsn
allow
standard
analysi
time
identifi
opportun
improv
find
reassur
ahtr
rare
massachusett
backgroundcas
studi
massachusett
blood
bank
requir
massachusett
depart
public
health
mdph
submit
monthli
transfus
activ
advers
reaction
data
nation
healthcar
safeti
network
nhsn
hemovigil
modul
sinc
june
standard
statewid
data
collect
allow
comprehens
analys
includ
potenti
gener
local
benchmark
circulatori
overload
taco
current
interest
due
intern
discuss
propos
modif
current
surveil
case
definit
result
perceiv
local
increas
taco
incid
examin
data
submit
involv
taco
report
find
studi
designmethod
taco
reaction
meet
nhsn
case
definit
imput
criteria
possibl
probabl
definit
facil
includ
analyz
age
gender
product
receiv
transfus
indic
hospit
bed
size
select
clinic
criteria
use
sa
rate
calcul
per
unit
transfus
resultsfind
taco
reaction
report
mean
femal
age
age
year
notabl
two
age
facil
bed
report
taco
reaction
occur
bed
bed
rate
taco
per
unit
transfus
facil
bed
bed
bed
indic
transfus
document
medic
frequent
follow
malign
intern
bleed
hematolog
disord
surgeri
season
variat
observ
lowest
incid
taco
occur
june
juli
rate
taco
increas
unit
transfus
studi
period
taco
rate
per
unit
transfus
product
type
plasma
platelet
highest
rbc
conclus
modest
increas
taco
observ
period
well
age
distribut
among
case
season
variat
higher
rate
among
smaller
facil
provid
guidanc
target
awar
potenti
intervent
limit
includ
lack
extern
data
valid
possibl
inconsist
case
definit
interpret
applic
studi
demonstr
util
nhsn
trend
identif
select
reaction
analysi
target
transfus
safeti
effort
backgroundcas
studi
norwegian
hemovigil
system
implement
voluntari
report
system
becom
mandatori
seriou
advers
event
norwegian
hemovigil
system
ibct
report
transfus
complic
even
patient
experi
symptom
studi
designmethod
ibct
defin
transfus
blood
compon
intend
anoth
patient
transfus
blood
compon
compli
specifi
requir
clinic
reaction
sever
well
caus
error
regist
includ
error
order
blood
compon
select
issu
label
test
bedsid
patient
identif
resultsfind
period
norwegian
hemovigil
system
receiv
case
ibct
includ
case
blood
compon
transfus
wrong
patient
case
blood
compon
meet
specifi
requir
four
addit
case
blood
compon
fail
meet
expect
requir
transfus
wrong
patient
exampl
regard
lack
specifi
requir
blood
compon
lack
irradi
requir
transfus
incompat
red
cell
presenc
previous
identifi
red
cell
antibodi
report
ibct
occur
patient
age
twenti
case
transfus
blood
compon
meet
specifi
requir
total
number
case
multipl
error
report
hemolyt
transfus
reaction
caus
ibct
twenti
abo
incompat
case
six
case
caus
incompat
blood
group
system
abo
even
antibodi
known
prior
transfus
nine
blood
transfus
less
sever
reaction
ten
seriou
three
fatal
two
patient
known
anaphylact
reaction
transfus
red
blood
cell
concentr
patient
receiv
incorrect
blood
compon
advers
reaction
error
frequent
relat
order
blood
compon
clinic
depart
select
issu
blood
compon
blood
bank
inadequ
bedsid
patient
identif
prior
transfus
one
assum
case
patient
receiv
blood
compon
intend
anoth
patient
bedsid
patient
ident
control
perform
accord
local
guidelin
conclus
error
occur
area
transfus
chain
high
number
case
multipl
error
made
case
blood
compon
transfus
wrong
patient
could
prevent
adequ
bedsid
patient
identif
perform
main
caus
lead
ibct
error
regard
order
blood
product
inadequ
bedsid
patient
identif
patient
age
twenti
main
caus
ibct
transfus
blood
compon
meet
specifi
requir
especi
irradi
norwegian
hemovigil
system
strongli
recommend
use
electron
patient
identif
transfus
reduc
number
transfus
blood
compon
intend
anoth
patient
hospit
norway
implement
system
backgroundcas
studi
interdisciplinari
task
forc
recommend
obstetr
ob
patient
rhd
agglutin
result
grade
manag
neg
unless
weak
wkd
genotyp
confirm
wkd
type
case
manag
rhd
transfus
devis
educ
survey
wkd
rbc
sampl
benchmark
current
practic
wkd
test
rhig
manag
studi
designmethod
particip
laboratori
receiv
two
unknown
blind
rbc
suspens
two
case
histori
mother
rhd
babi
mother
newborn
babi
mother
babi
sampl
creat
wkd
blood
donor
particip
laboratori
instruct
use
routin
rhd
tube
type
method
sampl
particip
provid
serolog
reaction
rhd
type
interpret
rhig
recommend
fetomatern
hemorrhag
fmh
screen
method
facil
rhd
genotyp
experi
wkd
mother
comparison
center
respons
util
fisher
exact
test
resultsfind
result
mainli
us
lab
ob
servic
analyz
mother
lab
would
given
rhig
tabl
lab
reactiv
less
like
give
rhig
lab
neg
v
lab
perform
antiglobulin
test
agt
result
less
like
give
rhig
vs
p
reagent
yield
differ
rate
babi
lab
would
fetal
rosett
test
frt
excess
fmh
mother
includ
babi
type
agt
lab
use
divers
verbiag
rh
report
neg
wkd
rhd
indetermin
du
respond
lab
rhd
genotyp
done
select
wkd
ob
case
conclus
particip
obtain
broad
rang
rhd
type
reaction
wkd
rbc
influenc
reagent
affect
use
rhig
frt
miss
excess
fmh
wkd
babi
lab
would
use
confus
array
terminolog
use
report
wkd
type
backgroundcas
studi
transfus
entail
risk
acut
disturb
febril
f
allerg
andor
cardiorespiratori
c
present
although
overal
odd
transfus
reaction
tr
low
minor
respiratori
transfus
reaction
rtr
likeli
sever
lead
caus
morbid
mortal
rtr
may
cardiogen
circulatori
overload
taco
andor
latter
rang
direct
insult
acut
lung
injuri
trali
allerg
bronchopulmonari
transfus
reaction
abtr
indirect
manifest
injuri
bacteri
contamin
acut
hemolyt
incompat
criteria
met
harm
underli
diseas
progress
play
role
diagnosi
exclus
transfus
associ
dyspnea
tad
tr
rtr
particular
challeng
investig
patient
complex
comorbid
work
environ
inform
gap
extent
tr
patient
present
multipl
disturb
extent
review
reach
conclus
certain
mere
possibl
interest
measur
tr
investig
especi
rtr
studi
designmethod
hemovigil
databas
academ
adult
healthcar
institut
compris
site
transfus
componentsyear
consecut
tr
retrospect
analyz
mode
present
fac
multipl
mode
present
count
measur
complex
final
conclus
respect
certaintyimput
underw
review
gaug
diagnost
confid
rtr
also
analyz
number
conclus
reach
per
case
frequenc
taco
trali
abtr
tad
conclus
respect
certainti
resultsfind
year
tr
investig
transfus
laboratori
team
fever
occur
case
rtr
note
referr
one
disturb
eg
fc
occur
case
referr
provision
diagnosi
tr
referr
ultim
certain
possibl
case
rtr
conclus
reach
valu
greater
number
referr
conclus
stratifi
low
confid
possibl
rule
versu
high
confid
probabl
definit
weight
low
rtr
categori
taco
trali
tad
versu
abtr
respect
overal
ratio
low
confid
high
confid
rtr
conclus
tad
code
time
commonest
conclus
taco
conclus
overal
tr
present
one
disturb
referr
tr
reach
conclus
better
possibl
likeliest
provision
diagnosi
rtr
compar
problemat
conclus
reach
case
major
conclus
uncertain
improv
diagnost
approach
need
rtr
contemporari
practic
environ
academ
center
limit
capac
gener
confid
classif
hemovigil
effort
backgroundcas
studi
wrong
blood
tube
wbit
error
pretransfus
sampl
collect
lead
transfus
previous
wbit
error
report
approxim
blood
bank
sampl
electron
patient
identif
id
system
eg
bar
code
scan
patient
wristband
sampl
collect
develop
reduc
phlebotomi
error
electron
id
system
impact
wbit
error
systemat
evalu
studi
designmethod
blood
bank
sampl
number
wbit
error
collect
retrospect
hospit
countri
year
wbit
error
defin
case
abo
type
current
sampl
fail
match
histor
abo
type
wbit
rate
compar
site
use
manual
patient
id
n
versu
site
use
electron
patient
id
n
wbit
rate
adjust
proport
repeat
sampl
site
silent
wbit
error
adjust
abo
group
distribut
descript
data
collect
individu
wbit
case
resultsfind
among
site
use
manual
patient
id
blood
bank
sampl
collect
site
wbit
error
identifi
among
sampl
overal
unadjust
wbit
rate
tabl
among
site
use
electron
id
site
wbit
error
sampl
significantli
lower
unadjust
wbit
rate
p
overal
adjust
wbit
rate
site
use
manual
patient
id
versu
electron
patient
id
respect
among
site
use
manual
id
wbit
error
caus
patient
misidentif
fail
label
sampl
bedsid
among
site
use
electron
id
phlebotomi
patient
wear
wristband
common
caus
wbit
error
conclus
electron
patient
id
system
reduc
elimin
blood
bank
sampl
wbit
error
studi
site
use
electron
patient
id
time
phlebotomi
approxim
lower
wbit
rate
compar
site
use
manual
patient
id
backgroundcas
studi
zika
viru
zikv
flaviviru
caus
asymptomat
infect
blood
donor
transmit
transfus
blood
center
us
territori
screen
blood
donat
univers
individu
donat
nucleic
acid
test
id
nat
start
puerto
rico
april
number
case
us
state
territori
peak
case
respect
sinc
decreas
dramat
mathemat
model
use
evalu
minipool
nucleic
acid
test
mp
nat
screen
strategi
compar
id
nat
detect
zikv
infect
outbreak
compar
size
one
puerto
rico
studi
designmethod
develop
comput
model
simul
outbreak
puerto
rico
determin
number
donat
would
detect
mp
nat
compar
id
nat
model
input
includ
monthli
report
number
id
igmigg
neg
unit
puerto
rico
report
doubl
time
zikv
rna
blood
infect
macaqu
lower
detect
limit
id
nat
use
puerto
rico
outbreak
estim
differenti
sensit
mp
nat
base
report
sensit
dilut
factor
zikv
rna
donat
resultsfind
probabl
detect
first
id
unit
outbreak
percentil
percentil
one
donat
detect
mp
nat
model
predict
probabl
miss
one
id
donat
probabl
miss
unit
mp
nat
constant
cours
outbreak
tabl
conclus
model
predict
probabl
candid
mp
nat
detect
first
id
unit
outbreak
remain
constant
cours
outbreak
backgroundcas
studi
babesia
microti
intraerythrocyt
parasit
endem
northeast
upper
midwest
us
risk
babesiosi
ttb
well
establish
case
report
recent
fda
approv
two
screen
assay
array
fluoresc
immunoassay
antibodi
detect
pcr
dna
detect
mitig
risk
ttb
blood
screen
occur
endem
area
investig
test
protocol
sinc
although
donat
also
test
antibodi
summar
result
blood
screen
two
investig
babesia
nucleic
acid
test
nat
present
frequenc
state
studi
designmethod
blood
donat
obtain
ct
mn
wi
june
decemb
screen
pcr
detect
b
microti
dna
imugen
donat
collect
new
england
area
june
novemb
screen
use
procleix
babesia
assay
qualit
vitro
nat
detect
ribosom
rna
multipl
babesia
speci
use
amplif
tma
pcrtma
reactiv
confirm
antibodi
repeat
reactiv
primari
altern
nat
assay
index
ttb
case
compar
screen
vs
unscreen
blood
determin
efficaci
resultsfind
donat
sampl
screen
pcr
posit
detect
ct
mn
wi
tma
perform
sampl
detect
donor
result
donat
nh
nj
ny
pa
sampl
antibodi
neg
sampl
reactiv
tma
antibodi
posit
data
collect
ct
demonstr
declin
report
ttb
case
screen
vs
unscreen
blood
vs
respect
conclus
babesia
nat
demonstr
high
preval
rate
multipl
state
previou
report
ttb
blood
donat
screen
ct
associ
signific
reduct
ttb
screen
consid
area
demonstr
risk
due
posit
donor
ttb
case
backgroundcas
studi
babesia
protozoan
parasit
infect
red
blood
cell
lead
infecti
caus
mortal
transfus
recipi
report
fda
babesia
usual
transmit
via
tick
may
transfus
transmit
ttb
mother
child
pregnanc
deliveri
prospect
test
blood
donat
endem
area
us
reveal
donor
posit
babesia
dna
antibodi
us
fda
current
requir
donor
screen
babesia
plan
issu
draft
guidanc
recommend
reduc
ttb
risk
includ
requir
screen
blood
donat
studi
designmethod
coba
babesia
use
coba
system
qualit
polymeras
chain
reaction
nucleic
acid
amplif
test
develop
detect
whole
blood
wb
donor
sampl
babesia
speci
caus
human
diseas
b
microti
b
duncani
b
divergen
b
venatorum
fda
approv
use
test
investig
new
drug
applic
test
began
octob
wb
collect
proprietari
medium
lyse
red
blood
cell
stabil
babesia
rna
dna
minimum
donat
collect
state
high
low
babesia
screen
individu
blood
donor
idt
sampl
reactiv
index
donat
retest
simul
minipool
plu
addit
idt
coba
babesia
reactiv
index
donat
also
test
valid
altern
babesia
nat
babesia
igm
igg
antibodi
donor
reactiv
result
invit
enrol
studi
test
addit
evid
infect
resultsfind
date
valid
donat
screen
coba
babesia
reactiv
confirm
tabl
coba
babesia
show
overal
specif
exact
ci
conclus
coba
babesia
test
success
identifi
donat
late
fall
winter
includ
state
babesia
endem
screen
coba
babesia
continu
sever
laboratori
coba
babesia
fda
licens
avail
commerci
backgroundcas
studi
donor
confirm
hepat
infect
hcv
serolog
neg
nat
yield
concern
recent
risk
exposur
may
disclos
time
donat
nat
yield
infect
also
direct
indic
infect
current
acquir
donor
recent
center
diseas
control
cdc
report
acut
hcv
infect
rate
risen
dramat
sinc
object
studi
determin
subgenotyp
distribut
recent
acquir
hcv
infect
link
find
avail
geograph
data
determin
rate
recent
hcv
infect
rise
blood
donor
well
studi
designmethod
four
larg
blood
collect
organ
provid
plasma
sampl
index
whole
blood
donat
test
confirm
posit
hcv
nat
seroneg
base
routin
screen
period
nest
pcr
rt
use
amplif
hcv
rna
follow
label
pool
amplicon
sequenc
ng
deconstruct
donor
specif
hcv
sequenc
ng
read
viral
sequenc
analyz
determin
phylogenet
cladesubtyp
use
lo
alamo
nation
laboratori
sequenc
databas
associ
demograph
donat
characterist
includ
geograph
locat
base
depart
health
human
servic
hh
region
assess
compar
infect
group
standard
statist
test
use
compar
group
consid
evid
statist
signific
resultsfind
hcv
nat
yield
rate
larg
sampl
blood
donor
repres
us
suppli
per
ci
donat
hcv
nat
yield
sampl
avail
sequenc
analysi
studi
period
success
sequenc
sampl
frequenc
hcv
subgenotyp
demograph
donat
factor
associ
hcv
nat
yield
subgenotyp
conclus
find
support
trend
stabl
decreas
increas
hcv
preval
rate
us
blood
donor
similar
blood
donor
data
report
delwart
et
al
j
infect
di
mar
gener
popul
patient
data
report
xie
et
al
lab
med
may
subtyp
particularli
preval
individu
inject
drug
across
europ
us
backgroundcas
studi
us
implement
univers
individu
donat
nucleic
acid
test
zika
viru
zikv
move
minipool
test
trigger
outbreak
late
polici
studi
studi
designmethod
microsimul
model
develop
estim
lifetim
health
consequ
societ
cost
accru
year
screen
screen
context
fifti
unit
state
district
columbia
individu
recipi
blood
compon
exposur
sampl
data
advers
health
event
experienc
transfus
recipi
sexual
partner
infant
born
recipi
sexual
partner
captur
model
run
vari
zikv
rate
unit
everi
blood
unit
collect
everi
million
estim
uncertainti
calcul
use
probabilist
sensit
analysi
assum
threshold
million
per
life
year
gain
qali
resultsfind
estim
donor
popul
zikv
rate
exce
posit
unit
per
thousand
trigger
strategi
popul
zikv
rate
exce
per
thousand
zikv
rate
per
million
estim
zikv
would
result
one
case
mild
febril
ill
everi
month
ci
month
one
case
everi
year
ci
year
one
case
congenit
zika
syndrom
everi
year
ci
year
screen
estim
outcom
variou
zikv
rate
report
tabl
conclus
peak
zika
epidem
america
zikv
rate
among
donor
fifti
unit
state
approach
threshold
univers
would
consid
threshold
even
million
per
qali
exclus
screen
donor
group
higher
expect
zikv
rate
donor
recent
travel
resid
area
experienc
autochthon
zika
transmiss
may
evid
analysi
consid
alongsid
risk
benefit
backgroundcas
studi
zika
viru
zikv
flaviviru
relat
spondweni
dengu
virus
spread
aed
mosquito
also
transmit
human
human
sexual
contact
mother
fetu
pregnanc
blood
transfus
zikv
infect
asymptomat
seriou
diseas
manifest
includ
neurolog
disord
birth
defect
microcephali
may
occur
zika
diseas
becam
threat
public
health
us
addit
case
local
transmiss
report
continent
us
us
blood
suppli
screen
zikv
rna
sinc
use
investig
later
nucleic
acid
test
nat
mutat
viral
genom
may
potenti
neg
affect
zikv
blood
screen
caus
mismatch
viral
sequenc
primersprob
detect
nat
therefor
studi
aim
analyz
genet
divers
human
zikv
isol
us
panama
studi
designmethod
anonym
plasma
sampl
obtain
variou
blood
collect
facil
isol
expand
cultur
vero
cell
viral
rna
purifi
cell
supernat
sequenc
use
sanger
method
complet
zikv
genom
isol
collect
epidem
puerto
rico
florida
sequenc
addit
analyz
clinic
isol
panama
zikv
sequenc
align
use
mega
softwar
zikv
genom
also
subject
bayesian
maximum
likelihood
phylogenet
analysi
resultsfind
viral
isol
blood
donor
collect
show
averag
nucleotid
diverg
compar
ancestor
micronesia
strain
genbank
usual
among
flavivirus
nucleotid
chang
silent
transit
number
nucleotid
mutat
rang
result
amino
acid
substitut
isol
geograph
locat
genet
similar
phylogenet
zikv
isol
florida
cluster
togeth
isol
hondura
nicaragua
isol
puerto
rico
panama
cluster
caribbean
clade
togeth
isol
puerto
rico
panama
colombia
conclus
level
zikv
genet
divers
observ
studi
warrant
monitor
zikv
among
human
popul
ensur
suitabl
current
licens
investig
blood
donor
screen
assay
determin
whether
zikv
divers
may
associ
function
chang
viral
gene
backgroundcas
studi
follicular
regulatori
tfr
cell
recent
identifi
special
subset
regulatori
treg
cell
locat
germin
center
gc
suppress
follicular
helper
tfh
cell
b
cell
antibodi
product
tfr
cell
play
import
regulatori
role
pathogenesi
autoimmun
diseas
like
sle
addit
baicalin
natur
compound
isol
chines
herb
report
promot
express
differenti
treg
cell
amelior
kidney
inflamm
mrllpr
mice
thu
specul
tfr
cell
plu
baicalin
might
promis
cellular
therapeut
approach
treatment
autoimmun
diseas
studi
determin
baicalin
could
effect
induc
cell
cell
tfr
cell
also
could
reliev
lupu
nephriti
mous
model
studi
designmethod
vitro
naiv
cell
first
purifi
spleen
mice
stimul
baicalin
plu
ab
term
tfr
cell
phenotyp
prolifer
seriou
cytokin
product
suppress
tfr
cell
assess
meanwhil
tfr
cell
tfr
cell
transfer
iv
mrllpr
mice
week
last
week
control
mice
treat
pb
urin
protein
measur
everi
week
histopatholog
test
kidney
antibodi
titer
cytokin
serum
subset
spleen
analyz
mice
treat
tfr
cell
week
resultsfind
baicalin
induct
day
vitro
percent
cell
cell
increas
significantli
treg
cell
show
posit
express
high
level
key
marker
tfr
cell
baicalin
could
promot
tfr
cell
differenti
accompani
induc
product
tfr
cell
could
effect
inhibit
tfh
cell
prolifer
suppress
secret
induc
tfh
cell
apoptosi
vitro
determin
suppress
function
tfr
cell
vivo
sle
mous
model
use
treatment
remark
activ
improv
clinic
renal
score
histolog
kidney
found
group
group
treatment
tfr
cell
could
significantli
decreas
antibodi
titer
serum
reduc
urin
protein
tfr
cell
treatment
moreov
transfus
tfr
cell
result
obviou
decreas
percentag
cell
lower
level
conclus
result
indic
tfr
cell
induc
baicalin
show
effect
suppress
vitro
reduc
markedli
sever
progress
lupu
nephriti
tfr
cell
sle
mous
model
associ
modul
tfhthr
polar
secret
vivo
studi
highlight
baicalin
might
assist
stimul
tfr
cell
expans
tfr
cell
show
potenti
therapeut
util
lupu
backgroundcas
studi
mesenchym
stromal
cell
msc
show
promis
treatment
trauma
although
mechan
action
fulli
understood
msc
possess
properti
may
limit
damag
promot
heal
modulatori
activ
msc
interact
affect
function
sever
immun
cell
type
studi
investig
interact
msc
innat
lymphoid
cell
ilc
ilc
import
rapid
respond
infect
like
also
import
respons
trauma
beyond
previous
identifi
cytotox
natur
killer
nk
cell
sever
subtyp
describ
differ
function
propos
subtyp
thu
subtyp
ratio
import
may
chang
injuri
treatment
light
interact
msc
immun
cell
propos
interact
ilc
interact
alter
function
cell
type
studi
designmethod
msc
commerci
sourc
use
earli
passag
human
peripher
blood
mononuclear
cell
pbmc
isol
human
whole
blood
collect
isr
research
blood
bank
approv
standard
oper
procedur
ilc
subtyp
identif
perform
flow
cytometri
ilc
enrich
whole
blood
use
easysep
human
magnet
enrich
kit
stemcel
technolog
perform
rpmi
medium
supplement
fb
day
cell
subject
flow
cytometri
identif
ilc
subtyp
resultsfind
ilc
subtyp
character
whole
blood
perform
individu
donor
high
degre
variat
donor
observ
magnet
enrich
pbmc
increas
number
ilc
total
event
compar
unenrich
pbmc
allow
accur
ilc
subtyp
character
human
pbmc
cultur
presenc
absenc
human
msc
differ
subtyp
distribut
observ
day
pbmc
alon
compar
pbmc
msc
conclus
base
current
studi
conclud
identifi
whole
human
blood
pbmc
flow
cytometri
variabl
subset
distribut
differ
donor
enrich
ilc
magnet
separ
allow
greater
accuraci
subtyp
identif
flow
cytometri
msc
influenc
ilc
subtyp
distribut
sinc
differ
ilc
subset
differ
function
interplay
two
cell
type
could
meaning
effect
immunomodul
backgroundcas
studi
antibodi
respons
carbohydr
antigen
specif
abo
blood
group
system
import
foundat
aspect
transfus
transplant
medicin
seek
molecularli
defin
antibodi
involv
abo
carbohydr
blood
group
recognit
investig
antibodi
somat
hypermut
level
isotyp
makeup
clonal
antibodi
healthi
human
also
assess
presenc
stereotyp
converg
antibodi
express
differ
individu
studi
designmethod
use
fluoresc
label
abo
antigen
perform
fac
identifi
healthi
human
peripher
blood
surfac
immunoglobulin
specif
blood
group
antigen
perform
dna
sequenc
rearrang
immunoglobulin
heavi
chain
vdj
locu
character
antibodi
sequenc
sequenc
pars
analyz
specif
antibodi
characterist
ighv
usag
sequenc
ighv
mutat
rate
resultsfind
discov
compris
hundr
clone
express
isotyp
show
evid
ighv
gene
restrict
isotyp
antibodi
compris
approxim
igm
igd
igg
iga
ige
among
gener
popul
antibodi
respons
also
appear
polyclon
within
individu
exampl
averag
antibodi
clone
per
group
person
interestingli
report
prior
literatur
also
found
exist
abo
antibodi
eg
antibodi
group
individu
found
evid
ighv
gene
restrict
signific
differ
ighv
usag
among
abo
blood
group
antibodi
among
differ
individu
furthermor
found
reactiv
blood
group
exhibit
higher
mutat
rate
unsort
igm
vs
p
vs
p
antibodi
final
identifi
hundr
converg
antibodi
cluster
appear
multipl
blood
group
individu
exhibit
significantli
higher
mutat
rate
compar
converg
antibodi
found
individu
blood
group
p
blood
group
ab
p
individu
blood
group
b
p
conclus
data
provid
new
molecular
insight
antibodi
may
provid
new
avenu
studi
antibodi
across
divers
biomed
field
find
potenti
impact
transfus
transplant
medicin
direct
relev
clinic
signific
event
hemolyt
diseas
newborn
organ
transplant
reject
backgroundcas
studi
humor
alloimmun
hla
lead
refractori
state
patient
requir
platelet
transfus
problem
patient
subsequ
requir
transplant
also
lead
trali
caus
donat
product
contain
alloimmun
hla
requir
exposur
alloantigen
overal
degre
mhc
mismatch
affect
immunogen
individu
alloantigen
unclear
studi
designmethod
mice
mhc
haplotyp
expos
kd
alloantigen
infus
leukocyt
differ
context
kd
isol
cell
novel
mous
express
kd
singl
mhc
alloantigen
background
context
multipl
mismatch
alloantigen
eg
whole
haplotyp
balbc
mice
congen
anim
alloimmun
assess
incub
serum
balbc
target
follow
floresc
ig
analysi
flow
cytometri
alloimmun
calcul
mean
floresc
intens
mfi
mice
precursor
frequenc
cell
specif
kd
alloantigen
modifi
adopt
transfer
cell
cell
receptor
transgen
mice
specif
immunodomin
kd
peptid
present
mhcii
cell
immun
immunodomin
peptid
kd
resultsfind
compar
control
mice
detect
alloantibodi
mfi
strong
respons
observ
singl
exposur
leukocyt
mice
express
whole
haplotyp
mfi
mice
experi
p
contrast
signific
alloimmun
observ
respons
kd
isol
alloantigen
despit
repeat
exposur
adopt
transfer
cell
kd
peptid
result
strong
alloimmun
respons
subsequ
infus
leukocyt
express
kd
isol
alloantigen
equival
leukocyt
express
whole
locu
mfi
p
artifact
induct
maneuv
increas
cell
number
neither
peptid
immun
induc
detect
conclus
find
indic
immunogen
singl
alloantigen
affect
context
encount
isol
kd
induc
signific
alloantibodi
respons
howev
strong
respons
observ
multipl
mismatch
present
mechan
effect
involv
magnitud
cell
help
challeng
notion
mhci
alloantigen
intrins
strong
immunogen
indic
rather
cooper
effect
differ
mismatch
mhc
alloantigen
encount
togeth
backgroundcas
studi
previous
pregnant
women
higher
rate
alloimmun
platelet
plt
transfus
refractori
note
secondari
analys
prospect
trial
util
anim
model
isol
pregnanc
independ
variabl
test
pregnanc
impact
alloimmun
plt
transfus
studi
designmethod
femal
mice
bred
balbc
male
follow
weekli
transfus
filter
leukoreduc
plt
cross
mice
repres
haploident
exposur
alloantigen
utero
control
nonspecif
effect
pregnanc
transfus
femal
bred
male
transfus
plt
neg
control
transfus
alloantibodi
serum
measur
incub
balbc
splenocyt
target
follow
floresc
globulin
analyz
flow
cytometri
alloimmun
defin
mean
fluoresc
intens
mfi
time
standard
deviat
sd
neg
control
refractori
measur
surviv
transfus
green
floresc
protein
gfp
plt
express
alloantigen
ie
sd
mean
hour
plt
recoveri
control
result
analyz
softwar
via
test
fisher
resultsfind
follow
transfus
mice
bred
balbc
male
higher
rate
alloimmun
mice
bred
male
vs
p
significantli
higher
rate
plt
refractori
compar
control
vs
p
contrast
mice
bred
balbc
sire
transfus
plt
signific
plt
refractori
signific
rate
alloimmun
albeit
mfi
fold
lower
balbc
sire
group
transfus
plt
pregnanc
requir
alloimmun
fulli
mismatch
donor
plt
balbc
howev
lower
dose
alloantigen
plt
immun
occur
despit
exposur
antigen
unless
prime
first
occur
pregnanc
conclus
find
indic
exposur
alloantigen
pregnanc
andor
deliveri
prime
alloimmun
subsequ
plt
transfus
notabl
alloimmun
occur
mice
despit
exposur
pregnanc
transfus
thu
addit
factor
like
involv
tractabl
natur
murin
model
allow
ongo
mechanist
studi
backgroundcas
studi
despit
preval
clinic
signific
red
blood
cell
rbc
alloantibodi
known
laboratori
test
predict
patient
may
form
antibodi
transfus
also
known
fc
gamma
express
monocyt
marker
type
interferon
signatur
autoimmun
diseas
given
autoimmun
associ
rbc
alloimmun
type
interferon
shown
play
role
rbc
alloimmun
anim
model
hypothes
express
monocyt
may
correl
rbc
alloimmun
studi
designmethod
adult
sickl
cell
diseas
recruit
demograph
inform
red
blood
cell
alloantibodi
histori
extract
electron
medic
record
flow
cytometri
complet
peripher
blood
low
cell
classifi
classic
monocyt
high
cell
classifi
intermedi
monocyt
high
cell
classifi
inflammatori
monocyt
mean
fluoresc
intens
mfi
monocyt
subset
calcul
resultsfind
patient
document
receiv
rbc
transfus
studi
institut
refer
percent
femal
mean
age
year
rang
year
compar
alloimmun
respond
patient
alloimmun
patient
femal
mean
age
year
rang
year
patient
total
antibodi
identifi
primarili
e
k
antigen
statist
signific
differ
percentag
total
classic
intermedi
monocyt
respond
show
trend
higher
express
total
monocyt
mfi
mean
sd
compar
respond
mfi
mean
sd
higher
express
classic
monocyt
mfi
mean
sd
compar
respond
mfi
mean
sd
well
intermedi
monocyt
mfi
mean
sd
compar
respond
mfi
mean
sd
conclus
contrari
hypothesi
observ
lower
express
classic
intermedi
monocyt
alloimmun
patient
sickl
cell
diseas
compar
possibl
type
interferon
signal
impact
alloimmun
anim
model
way
respons
alter
express
one
potenti
mechan
previous
shown
vitro
may
involv
type
interferon
mitig
abil
interferon
gamma
upregul
backgroundcas
studi
screen
platelet
concentr
pc
bacteri
contamin
perform
use
autom
cultur
system
sinc
august
pc
extend
day
improv
bacteri
test
algorithm
delay
test
hour
post
collect
inocul
aerob
anaerob
cultur
bottl
screen
doubl
apheresi
pc
three
aerob
bottl
one
anaerob
bottl
quarantin
hour
contamin
pc
neg
screen
result
found
qualiti
control
qc
test
outdat
pc
report
transfus
reaction
studi
designmethod
august
februari
buffi
coat
bc
pool
apheresi
unit
screen
routin
test
addit
outdat
pc
posit
result
classifi
confirm
posit
bacterium
isol
initi
confirmatori
cultur
implic
associ
compon
fals
posit
bacteria
isol
posit
screen
cultur
unconfirm
posit
initi
posit
cultur
result
could
confirm
fals
neg
unit
neg
screen
result
posit
qc
test
involv
septic
transfus
reaction
sinc
march
associ
fals
posit
result
bc
pool
releas
inventori
resultsfind
three
cultur
result
categor
confirm
posit
routin
screen
bc
pool
apheresi
unit
respect
bacteria
isol
bc
pool
propionibacterium
acn
nine
confirm
posit
involv
initi
cultur
pc
pool
confirmatori
test
associ
rbc
contamin
p
acn
one
three
confirm
posit
apheresi
pc
also
identifi
p
acn
bacteria
detect
includ
staphylococcu
aureu
streptococcu
spp
coagulas
neg
staphylococci
fals
posit
result
bc
apheresi
pc
respect
one
fals
neg
result
report
investig
transfus
reaction
involv
bc
pool
contamin
staphylococcu
epidermidi
conclus
compar
result
confirm
posit
cultur
pc
show
enhanc
detect
contamin
pc
mostli
p
acn
detect
contamin
pc
increas
aerob
bacteria
apheresi
bc
pc
respect
cultur
anaerob
organ
includ
detect
contamin
pool
apheresi
unit
increas
respect
longer
surveil
period
necessari
evalu
valu
anaerob
cultur
adequ
analyz
residu
safeti
risk
backgroundcas
studi
pathogen
reduct
pr
system
use
amustalin
glutathion
gsh
develop
inactiv
pathogen
leukocyt
red
blood
cell
rbc
compon
amustalin
form
adduct
nucleic
acid
prevent
replic
contamin
pathogen
leukocyt
object
studi
qualifi
two
research
blood
center
prepar
pr
treat
rbc
compar
vitro
function
untreat
rbc
studi
designmethod
leukocyt
reduc
rbc
prepar
cpd
whole
blood
day
abo
match
pair
rbc
pool
sampl
pool
divid
prepar
untreat
control
c
test
test
rbc
treat
mm
mm
amustalin
within
hour
collect
includ
overnight
hold
exchang
addit
control
unit
store
post
treatment
pair
unit
sampl
togeth
analysi
vitro
paramet
resultsfind
follow
pr
treatment
hemoglobin
recoveri
extracellular
protein
lower
c
higher
atp
osmot
fragil
compar
c
lower
ph
k
glucos
mchc
rbc
deform
morpholog
hemolysi
equival
higher
atp
glucos
mchc
c
lower
hemolysi
ph
k
rbc
deform
osmot
fragil
equival
morpholog
score
although
post
treatment
lower
due
overnight
hold
rejuven
higher
tabl
conclus
amustalinegsh
pr
rbc
success
perform
two
us
research
blood
center
measur
vitro
paramet
amustalinegsh
treat
rbc
indic
suitabl
transfus
backgroundcas
studi
chikungunya
chikv
dengu
denv
zika
zikv
arbovirus
transmit
aed
albopictu
speci
mosquito
vector
result
geograph
distribut
overlap
result
area
three
virus
circul
time
increas
likelihood
patient
becom
virus
recent
report
sever
endem
countri
larg
number
asymptomat
arboviru
infect
rais
possibl
infect
tti
risk
chikv
denv
zikv
tti
whether
alon
combin
reduc
use
photochem
blood
system
pathogen
reduct
pr
technolog
previous
demonstr
effect
multipl
arbovirus
includ
chikv
denv
zikv
report
treatment
amotosalenuva
inactiv
combin
chikv
denv
zikv
platelet
concentr
pc
plasma
studi
designmethod
plasma
pc
platelet
addit
solut
pa
unit
chikv
zikv
treat
amotosalen
uva
light
infecti
viral
titer
determin
plaqu
assay
inactiv
determin
compar
log
titer
treatment
resultsfind
follow
amotosalenuva
treatment
three
virus
simultan
inactiv
limit
detect
pc
plasma
see
tabl
result
log
chikv
log
log
zikv
inactiv
pc
log
chikv
log
log
zikv
inactiv
plasma
result
consist
inactiv
achiev
viru
separ
log
chikv
log
log
zikv
pc
log
chikv
log
log
zikv
plasma
conclus
studi
demonstr
robust
simultan
inactiv
three
differ
virus
contamin
plasma
pc
pa
unit
amotosalenuva
treatment
system
effici
concurr
inactiv
multipl
arbovirus
demonstr
potenti
blood
donor
backgroundcas
studi
advanc
final
fda
guidanc
bacteri
safeti
blood
center
bc
evalu
method
balanc
safeti
platelet
suppli
mainten
adequ
inventori
bc
assess
implement
split
volum
adjust
apheresi
collect
increas
compat
current
fda
approv
pathogen
reduct
pr
technolog
apheresi
platelet
collect
set
determin
split
rate
sr
pr
compat
vari
bc
warrant
evalu
studi
designmethod
collect
retrospect
analyz
anonym
bc
vari
sr
bc
group
cohort
base
sr
collect
analyz
per
group
bc
sr
bc
sr
bc
sr
bc
sr
collect
data
analyz
current
volum
concentr
yield
set
determin
convent
baselin
sr
pr
assess
pr
elig
current
product
devic
set
evalu
convent
product
minimum
dose
singl
doubl
tripl
donat
requir
evalu
pr
product
minimum
dose
requir
minimum
dose
provid
high
likelihood
result
dose
dose
use
actual
lab
measur
target
program
apheresi
devic
set
volum
concentr
yield
valu
collect
dataset
actual
target
multipli
volum
yield
establish
per
collect
valu
subsequ
appli
multipli
target
set
optim
compat
pr
perform
split
volum
adjust
step
determin
like
volum
concentr
yield
per
collect
set
final
donat
analyz
individu
optim
product
split
volum
adjust
optim
volum
concentr
yield
pr
elig
evalu
pr
elig
product
elig
pr
treatment
without
result
fewer
dose
convent
process
includ
avoid
impact
sr
conclus
implement
optim
techniqu
increas
pr
elig
adjust
apheresi
target
set
result
overal
sr
improv
continu
monitor
result
refin
collect
set
assess
apheresi
donor
base
increas
elig
sr
backgroundcas
studi
vitro
product
human
platelet
offer
promis
altern
platelet
concentr
field
transfus
multipl
sourc
hematopoiet
stem
cell
hsc
current
use
cultur
differenti
megakaryocyt
precursor
platelet
vitro
studi
designmethod
studi
hsc
isol
either
umbil
cord
blood
ucb
regular
peripher
blood
pb
mobil
peripher
blood
mpb
evalu
expans
differenti
toward
megakaryocyt
cultur
platelet
product
obtain
perfus
cultur
cell
von
willebrand
microfluid
flow
chamber
platelet
product
yield
perfus
flow
chamber
compar
surfac
receptor
express
produc
platelet
also
investig
resultsfind
percentag
isol
hsc
per
total
nucleat
cell
pb
significantli
lower
compar
ucb
p
mpb
prolifer
hsc
pb
significantli
lower
ucb
shown
increas
cell
number
day
pb
versu
ucb
p
prolifer
hsc
mpb
day
differenti
hsc
megakaryocyt
less
effici
start
pb
cultur
cell
posit
platelet
marker
compar
ucb
p
despit
platelet
product
vitro
flow
effici
megakaryocyt
cultur
pb
particl
per
input
cell
compar
ucb
yield
particl
per
input
cell
start
mpb
platelet
surfac
receptor
express
compar
platelet
produc
ucb
pb
conclus
vitro
product
particl
possibl
start
hsc
isol
ucb
pb
mpb
absolut
number
platelet
obtain
ucb
effici
isol
prolifer
rel
number
effici
platelet
product
per
cultur
megakaryocyt
higher
pb
backgroundcas
studi
apheresi
platelet
ap
pathogen
reduct
pr
technolog
fda
approv
method
provid
safe
blood
product
patient
reduc
risk
infect
increas
product
wastag
may
occur
donor
center
implement
pr
technolog
due
necess
meet
pr
process
guard
band
center
execut
dual
manufactur
process
creat
inventori
convent
platelet
cp
pr
platelet
product
effort
maxim
platelet
collect
reduc
unnecessari
product
discard
maintain
collect
split
rate
report
impact
dual
inventori
cp
pr
platelet
product
transfus
servic
april
march
studi
designmethod
ap
unit
collect
plasma
donor
center
monday
saturday
perform
preliminari
platelet
count
unit
yield
visual
inspect
occur
upon
receipt
compon
process
laboratori
cpl
determin
process
pr
cp
prepar
perform
use
establish
blood
system
ceru
corpor
guard
band
product
meet
guard
band
criteria
includ
tripl
collect
doubl
collect
met
criteria
would
potenti
affect
current
split
rate
due
known
product
loss
pr
process
process
cp
resultsfind
studi
period
cpl
consist
process
approxim
monthli
ap
collect
pr
process
remain
cp
tabl
maintain
tripl
collect
doubl
collect
process
pr
cp
maintain
split
rate
discard
rate
addit
pr
unit
avail
transfus
two
day
collect
cp
unit
three
day
collect
thu
provid
platelet
releas
blood
bank
inventori
conclus
dual
inventori
pr
cp
platelet
allow
preserv
multipl
product
collect
without
impact
split
rate
addit
implement
pr
platelet
allow
daili
releas
platelet
blood
bank
improv
inventori
manag
backgroundcas
studi
antibodi
medic
reject
amr
cardiac
transplant
patient
pt
primarili
mediat
donor
specif
antibodi
dsa
associ
reduc
graft
surviv
wherea
amr
renal
transplant
pt
gener
carri
excel
prognosi
amr
cardiac
transplant
pt
denot
poor
prognosi
treatment
option
less
well
understood
standard
studi
designmethod
review
record
heart
transplant
pt
refer
immunotherapi
treat
amr
median
age
pt
time
reject
year
year
old
pt
male
pt
present
symptom
congest
heart
failur
diastol
andor
systol
dysfunct
decreas
eject
fraction
ef
pt
endomyocardi
biopsi
result
consist
amr
pt
evid
circul
dsa
time
reject
includ
pt
evid
concurr
acut
cellular
reject
time
amr
pt
dsa
crossmatch
neg
time
cardiac
transplant
median
time
transplant
amr
bimod
yr
yr
pt
yr
yr
pt
pt
receiv
follow
immunotherapi
protocol
plasma
exchang
tpe
everi
day
treatment
tx
follow
intraven
immun
globulin
ivig
gramkgday
x
day
pt
receiv
high
dose
cs
serial
dsa
measur
obtain
pharmacolog
intervent
refractori
recurr
amr
pt
receiv
weekli
rituximab
dose
pt
receiv
bortezomib
dose
resultsfind
pt
underw
cours
tpe
coursespt
follow
ivig
pt
moder
improv
allograft
function
pt
show
substanti
improv
systol
andor
diastol
dysfunct
ef
pt
signific
reduct
elimin
class
ii
dsa
resolut
amr
cours
tx
pt
requir
minimum
cours
tx
amr
pt
refractori
amr
requir
cours
tx
common
dsa
present
refractori
amr
includ
class
ii
pt
refractori
amr
receiv
monthli
ivig
intermitt
cours
tpe
bortezomib
mean
yr
yr
time
amr
cardiac
transplant
amr
pt
lost
allograft
reject
wherea
mean
yr
yr
renal
transplant
amr
pt
lost
allograft
p
group
treat
rel
similar
protocol
amr
conclus
plasma
exchang
ivig
rituximab
bortezomib
use
treatment
modal
cardiac
transplant
pt
amr
suppress
refractori
class
ii
dq
dr
dsa
may
critic
provid
durabl
allograft
rescu
develop
effect
protocol
treat
refractori
recurr
amr
cardiac
transplant
pt
need
backgroundcas
studi
autom
red
cell
exchang
rce
therapi
sickl
cell
diseas
scd
mainten
therapi
emerg
intervent
quantif
hemoglobin
speci
use
determin
goal
rce
achiev
howev
recent
public
includ
formula
estim
hemoglobin
hb
use
platelet
count
correct
factor
xm
creat
deriv
fraction
platelet
remain
dfpr
close
approxim
fraction
cell
remain
fcr
keiser
et
al
dfpr
platelet
count
platelet
countxm
certain
situat
could
use
lieu
tradit
labori
hb
determin
perform
extern
valid
formula
scd
patient
determin
generaliz
formula
studi
designmethod
retrospect
studi
queri
institut
apheresi
databas
identifi
rce
procedur
perform
scd
patient
hb
use
hb
platelet
count
appli
formula
scd
popul
deriv
estim
procedur
wilcoxon
sign
rank
test
perform
compar
deriv
actual
hb
valu
statist
signific
defin
p
resultsfind
appli
formula
rce
procedur
perform
patient
procedur
deriv
hb
within
actual
hb
measur
high
perform
liquid
chromatographi
quantif
hemoglobin
speci
statist
differ
dfpr
fcr
deriv
hb
actual
hb
variat
note
patient
rce
procedur
account
half
deriv
hb
valu
discrep
actual
valu
rce
perform
emerg
versu
elect
mainten
therapi
bear
formula
accuraci
conclus
formula
accur
approxim
hb
use
platelet
count
patient
hb
scd
patient
popul
instanc
tradit
hb
determin
may
take
consider
time
formula
may
use
instead
expedit
remov
temporari
vascular
access
time
discharg
addit
investig
necessari
better
character
formula
perform
less
well
small
proport
scd
patient
backgroundcas
studi
mtp
rapidli
provid
recurr
issu
blood
product
specif
ratio
patient
risk
exsanguin
follow
initi
rollout
institut
larg
amc
level
trauma
center
design
mtp
usag
pattern
chang
dramat
mtp
activ
frequenc
maf
rose
steadili
concomit
increas
frequenc
trauma
patient
sinc
mtp
demand
signific
effort
larg
increas
maf
potenti
indic
seriou
misalloc
resourc
sought
understand
reason
maf
increas
identifi
effect
solut
studi
designmethod
extens
lean
process
undertaken
problem
statement
develop
follow
process
map
fishbon
diagram
priorit
grid
solut
propos
discuss
deploy
toward
end
assess
efficaci
data
collect
vs
outcom
maf
across
equival
pre
vs
post
time
period
outcom
includ
rbc
u
transfus
per
activ
rta
indic
bleed
sever
product
wastag
usd
resultsfind
maf
rose
rta
fell
vs
mean
sd
p
stdnt
indic
mtp
increasingli
activ
patient
lesser
bleed
sever
storm
cloud
reveal
probabl
caus
dramat
chang
maf
rta
sustain
educ
compon
decis
support
tool
low
clinician
confid
standard
blood
order
feedback
appropri
mtp
activ
solut
developeddeploy
comprehens
educ
campaign
use
orthogon
approach
decis
support
tool
incorpor
patient
vital
sign
abc
score
creation
altern
pathway
rapidli
issu
small
number
rbcplasma
time
mtp
review
mechan
provid
feedback
compar
day
respect
maf
drop
vs
rta
trend
upward
vs
p
product
wastag
fell
usd
conclus
comprehens
root
caus
analysi
involv
multipl
stakehold
identifi
underli
base
increas
misus
mtp
allow
us
develop
test
solut
address
like
caus
chang
mtp
usag
pattern
result
alter
usag
align
mtp
primari
purpos
provid
blood
rapidli
exsanguin
patient
backgroundcas
studi
heart
transplant
cur
therapi
heart
failur
limit
organ
avail
often
requir
use
ventricular
assist
devic
vad
bridg
patient
transplant
vad
allow
recipi
benefit
otherwis
unattain
transplant
associ
complic
increas
hla
sensit
rate
hla
sensit
associ
neg
clinic
outcom
includ
increas
reject
increas
mortal
hla
sensit
consequ
blood
product
transfus
associ
thorac
surgeri
though
factor
determin
incid
extent
alloantibodi
format
remain
undefin
examin
examin
transfus
effect
subsequ
transplant
studi
designmethod
perform
retrospect
cohort
studi
patient
receiv
vad
hospit
januari
septemb
medic
record
data
includ
transfus
blood
product
antibodi
test
crossmatch
test
time
transplant
evalu
categor
data
analyz
fisher
exact
test
quantit
data
analyz
use
test
multivari
analys
perform
use
stata
softwar
resultsfind
patient
receiv
averag
rang
rbc
rang
singl
donor
platelet
transfus
associ
vad
surgeri
increas
incid
hla
antibodi
vad
surgeri
approxim
higher
rate
describ
literatur
among
potenti
organ
transplant
recipi
receiv
transfus
multivari
analys
indic
develop
new
antibodi
directli
correl
volum
type
blood
product
exposur
relat
patient
hla
sensit
statu
rel
risk
new
antibodi
vad
recipi
alloantibodi
higher
patient
without
prior
alloantibodi
develop
new
antibodi
associ
increas
time
transplant
versu
conclus
find
concur
literatur
describ
vad
associ
increas
rate
hla
sensit
uniqu
studi
indic
presenc
antibodi
signific
risk
factor
develop
addit
antibodi
suggest
subset
patient
may
predispos
alloantibodi
format
increas
risk
develop
antibodi
identif
patient
import
develop
strategi
minim
hla
sensit
prevent
potenti
avoid
barrier
subsequ
transplant
backgroundcas
studi
patient
hla
antibodi
without
avail
apheresi
platelet
map
unknown
pool
platelet
pp
compar
random
apheresi
platelet
rap
aim
studi
compar
respons
rap
pp
map
hla
sensit
patient
studi
designmethod
retrospect
studi
compar
respons
platelet
transfus
patient
class
calcul
panel
reactiv
antibodi
cpra
januari
april
data
collect
platelet
transfus
day
prior
day
cpra
sampl
collect
respons
transfus
determin
correct
count
increment
cci
hour
complet
transfus
cci
consid
success
test
test
dunn
multipl
comparison
use
appropri
resultsfind
cci
avail
patient
femal
receiv
platelet
transfus
median
age
year
rang
year
median
cpra
rap
pp
map
transfus
tabl
mean
cci
confid
interv
ci
rap
pp
map
respect
p
analysi
reveal
statist
signific
differ
compar
rap
vs
map
p
rap
vs
pp
p
pp
vs
map
p
cci
rang
rap
pp
map
respect
transfus
success
rate
rap
pp
map
respect
signific
associ
success
rate
type
platelet
compar
type
togeth
p
compar
rap
map
p
compar
pp
map
p
associ
success
rate
type
platelet
compar
rap
pp
p
patient
receiv
least
rap
pp
map
respect
mean
cci
ci
per
patient
receiv
rap
pp
map
p
mean
cci
per
patient
significantli
differ
receiv
rap
vs
map
p
rap
vs
pp
p
pp
vs
map
p
conclus
map
superior
rap
pp
patient
elev
cpra
whether
pp
clinic
superior
rap
unclear
addit
studi
need
determin
optim
platelet
support
map
unavail
backgroundcas
studi
last
year
resurg
interest
whole
blood
wb
transfus
manag
civilian
trauma
patient
believ
wb
provid
sever
benefit
tradit
compon
therapi
includ
less
dilut
blood
compon
fewer
donor
exposur
opportun
simplifi
logist
resuscit
report
detail
initi
experi
implement
oper
monitor
use
wb
set
level
trauma
center
studi
designmethod
wb
initi
implement
resuscit
massiv
bleed
patient
unknown
blood
type
emerg
depart
ed
life
flight
lf
memori
medic
center
leukocyt
reduc
type
low
titer
wb
unit
use
maximum
unit
stock
ed
unit
flight
patient
receiv
wb
transfus
hemolysi
panel
test
day
transfus
time
time
time
hour
blood
bank
servic
evalu
patient
receiv
wb
issu
report
physician
notif
case
suspect
andor
undetermin
hemolysi
statu
evalu
includ
dat
extend
laboratori
perform
resultsfind
six
month
wb
transfus
use
patient
total
unit
unit
use
lf
blood
type
unknown
patient
mainli
due
earli
mortal
none
patent
given
evid
hemolysi
major
case
singl
wb
unit
transfus
switch
compon
maximum
use
instanc
wb
wastag
notic
first
month
implement
like
due
shorter
shelf
life
product
staff
unfamiliar
wb
avail
ed
hemolysi
laboratori
studi
occasion
overlook
given
frequent
shift
chang
ed
addit
educ
conduct
cover
staff
member
blood
bank
evalu
within
hour
transfus
abl
captur
requir
laboratori
find
patient
monitor
electron
wb
order
set
schedul
ensur
process
case
wastag
month
incomplet
hemolysi
marker
case
conclus
effort
wb
program
implement
facil
success
follow
institut
guidelin
hemolyt
transfus
complic
detect
first
month
continu
staff
educ
process
monitor
essenti
success
backgroundcas
studi
train
major
medic
traine
obtain
inform
consent
blood
transfus
literatur
demonstr
inform
consent
transfus
time
incomplet
poorli
understood
hurri
andor
inaccur
part
due
lack
educ
resourc
gold
standard
narr
would
help
ensur
true
patient
inform
consent
util
teach
traine
risk
benefit
transfus
studi
designmethod
modifi
delphi
approach
use
survey
purpos
select
intern
group
transfus
medicin
tm
expert
experi
consent
patient
transfus
critic
knowledg
regard
risk
benefit
transfus
case
scenario
woman
gastrointestin
bleed
present
particip
ask
draft
narr
script
obtain
inform
consent
patient
use
techniqu
qualit
descript
content
analysi
smaller
steer
committe
tm
expert
analyz
script
core
theme
topic
common
theme
categori
identifi
eg
risk
transfus
benefit
transfus
etc
specif
topicsitem
eg
possibl
allerg
reaction
possibl
hiv
infect
etc
affect
structur
content
also
captur
eg
manner
engag
second
survey
develop
base
collat
topic
theme
first
survey
redistribut
particip
first
survey
pilot
particip
particip
ask
rate
topic
point
scale
low
import
high
importanceessenti
content
valid
index
cvi
item
calcul
narr
develop
use
topic
score
cvi
higher
resultsfind
survey
complet
tm
expert
span
countri
pilot
particip
major
particip
year
experi
practic
tm
half
year
content
analysi
identifi
high
level
theme
specif
topic
narr
includ
second
round
delphi
second
survey
complet
particip
complet
first
survey
origin
pilot
particip
respons
rate
forti
topic
cvi
greater
incorpor
narr
develop
meet
flesch
kincaid
grade
level
topic
cvi
ask
patient
question
ask
directli
consent
blood
transfus
discuss
risk
transfus
discuss
risk
transfus
transmit
diseas
low
given
high
incid
transfus
associ
circulatori
overload
taco
high
mortal
associ
transfus
relat
acut
lung
injuri
trali
surpris
see
low
cvi
score
relat
topic
state
possibl
lung
injuri
state
possibl
fluid
overload
state
gener
possibl
short
breath
transfus
conclus
use
delphi
approach
gold
standard
narr
obtain
inform
consent
blood
transfus
develop
plan
valid
narr
healthcar
provid
patient
use
survey
focu
group
elucid
feedback
refin
narr
backgroundcas
studi
variant
diseas
vcjd
rare
human
prion
diseas
caus
infect
bovin
prion
although
clinic
case
vcjd
evalu
prion
protein
gene
prnp
methionin
homozygot
codon
year
first
definit
heterozyg
vcjd
patient
methionin
valin
mv
genotyp
recent
describ
unit
kingdom
patient
met
diagnost
criteria
probabl
sporad
cjd
scjd
neuropatholog
molecular
analysi
prion
strain
type
autopsi
confirm
vcjd
recent
public
underlin
previou
concern
possibl
second
wave
vcjd
case
attribut
altern
genotyp
codon
secondari
transmiss
iatrogen
transmiss
vcjd
blood
transfus
alreadi
document
three
recipi
red
blood
cell
concentr
donor
incub
diseas
one
addit
probabl
case
vcjd
transmiss
blood
transfus
reveal
autopsi
mv
patient
die
disord
vcjd
prion
protein
detect
spleen
highli
sensit
specif
test
discrimin
mv
vcjd
scjd
urgent
need
rapidli
accur
diagnos
futur
mv
vcjd
patient
studi
designmethod
protein
misfold
cyclic
amplif
pmca
alreadi
demonstr
high
perform
detect
vcjd
prion
blood
clinic
patient
allow
detect
silent
carriag
prion
clinic
onset
two
blood
donor
later
develop
vcjd
ultrasensit
technolog
adapt
specif
detect
vcjd
cerebrospin
fluid
identifi
vcjd
infect
individu
includ
recent
mv
patient
resultsfind
among
csf
sampl
analys
blind
diagnosi
identifi
specif
vcjd
sampl
thu
achiev
diagnost
sensit
confid
interv
ci
importantli
assay
allow
discrimin
heterozyg
mv
vcjd
case
mv
neuropatholog
confirm
scjd
patient
test
also
show
analyt
specif
ci
none
potenti
csf
specimen
patient
scjd
genet
cjd
alzheim
diseas
diseas
give
posit
result
conclus
result
indic
may
allow
identif
mv
vcjd
life
combin
test
csf
convers
accur
discrimin
scjd
presenc
infect
blood
first
definit
mv
vcjd
patient
involv
studi
uncertain
requir
investig
backgroundcas
studi
platelet
cryopreserv
dmso
increas
day
year
cryopreserv
platelet
result
signific
increas
expos
phosphatidylserin
releas
microparticl
mediat
procoagul
function
understand
procoagul
natur
platelet
defin
discret
phenotyp
popul
area
continu
interest
content
platelet
biolog
procoagul
platelet
refer
activ
coat
apoptot
necrot
thu
aim
studi
determin
whether
phenotyp
attribut
cryopreserv
platelet
align
current
definit
constitut
procoagul
platelet
studi
designmethod
buffi
platelet
frozen
dmso
final
concentr
cryopreserv
platelet
thaw
reconstitut
unit
thaw
plasma
vitro
test
pair
unit
carri
prior
freez
fresh
thaw
use
flow
cytometri
western
blot
data
analys
use
pair
p
consid
statist
signific
resultsfind
phosphatidylserin
externalis
significantli
increas
cryopreserv
platelet
measur
lactadherin
bind
mitochondri
damag
evid
cryopreserv
platelet
evidenc
reduct
tetramethylrhodamin
tmre
sequestr
cryopreserv
platelet
display
higher
intracellular
calcium
superoxid
anion
format
dihydroethidium
dhe
stain
fresh
platelet
use
western
blot
member
intrins
bak
bax
extrins
fadd
fa
apoptot
pathway
differenti
alter
cryopreserv
chang
clearli
indic
state
activ
cleavag
greater
cryopreserv
platelet
howev
activ
execution
molecul
similar
cryopreserv
fresh
platelet
interestingli
cleavag
characterist
procoagul
platelet
observ
cryopreserv
platelet
conclus
cryopreserv
platelet
acquir
mani
classic
featur
use
defin
procoagul
platelet
mani
overlap
apoptot
necrot
pathway
work
requir
fulli
dissect
molecular
event
occur
cryopreserv
platelet
understand
chang
may
influenc
clinic
util
backgroundcas
studi
intercept
blood
system
rbc
ceru
corpor
ca
use
amustalin
glutathion
gsh
inactiv
broad
spectrum
virus
bacteria
protozoa
transfus
depend
thalassemia
tdt
patient
requir
chronic
rbc
transfus
combin
iron
chelat
lifetim
exposur
increas
risk
infect
studi
designmethod
aim
random
control
studi
evalu
lr
rbc
comparison
control
method
tdt
patient
enrol
baselin
exclus
criteria
includ
natur
antibodi
rbc
dat
hypersplen
anticip
splenectomi
pregnanc
breast
feed
patient
underw
transfus
episod
rbc
control
rbc
period
crossov
design
maintain
pretransfus
hb
threshold
hemoglobin
hb
gdl
primari
efficaci
endpoint
rbc
hb
consumpt
transfus
episod
treatment
period
total
hb
mass
transfus
adjust
bodi
weight
kg
durat
support
hb
gkg
day
non
inferior
defin
predetermin
margin
mean
hb
consumpt
primari
safeti
endpoint
antibodi
rbc
resultsfind
subject
enrol
transfus
two
site
itali
one
turkey
mean
age
year
rang
male
age
year
eleven
percent
patient
rbc
alloantibodi
intent
treat
itt
popul
mean
exposur
rbc
rang
rang
control
rbc
mean
transfus
interv
test
control
day
total
transfus
hb
rbc
test
period
gram
g
versu
g
hb
p
control
period
total
mean
hb
consumpt
efficaci
evalu
period
gkgday
rbc
gkgday
control
rbc
non
inferior
robustli
achiev
treatment
differ
gkgday
margin
rbc
alloantibodi
antibodi
detect
advers
event
balanc
test
control
period
death
grade
advers
event
event
certain
like
relat
rbc
transfus
conclus
control
rbc
patient
thalassemia
base
hb
consumpt
safeti
profil
differ
control
rbc
antibodi
detect
rbc
backgroundcas
studi
hemoglobin
hb
base
oxygen
carrier
hboc
propos
altern
red
blood
cell
rbc
transfus
medicin
decad
lack
mechanist
analysi
side
effect
earli
hboc
formul
lead
clinic
evalu
low
molecular
weight
mw
product
fail
due
myriad
hb
associ
toxic
seen
trial
increas
mw
hboc
decreas
side
effect
confin
hboc
vascular
space
increas
nitric
oxid
gener
via
vascular
mechanotransduct
hboc
advantag
blood
includ
properti
potenti
use
hb
sourc
among
other
studi
compar
efficaci
fresh
blood
store
blood
freshli
synthes
polymer
bovin
hb
polybhb
polybhb
store
year
restor
cardiac
function
hemorrhag
shock
studi
designmethod
polybhb
synthes
low
oxygen
affin
state
ratio
glutaraldehyd
bovin
hb
subject
cycl
diafiltr
result
polybhb
solut
contain
polymer
hb
molecul
um
polybhb
frozen
store
use
fresh
red
blood
cell
prepar
blood
remov
hemorrhag
centrifug
minut
remov
buffi
coat
remov
plasma
hematocrit
store
red
blood
cell
store
week
leukodeplet
rat
hemorrhag
blood
volum
held
hypovolemia
minut
resuscit
recov
blood
pressur
fresh
autolog
blood
fresh
blood
blood
polybhb
gener
within
month
studi
polybhb
polybhb
gener
two
year
prior
studi
polybhb
resultsfind
shock
result
impair
oxygen
deliveri
cardiac
function
resuscit
fresh
blood
store
blood
polybhb
polybhb
restor
cardiac
function
system
vascular
resist
store
blood
requir
significantli
larger
volum
achiev
slightli
higher
volum
polybhb
infus
compar
fresh
blood
restor
map
fresh
blood
polybhb
fresh
store
impair
cardiac
contractil
caus
excess
vasoconstrict
rel
store
blood
conclus
studi
indic
polybhb
efficaci
fresh
blood
restor
cardiac
function
rat
hemorrhag
shock
addit
polybhb
safe
store
two
year
retain
efficaci
unlik
red
blood
cell
lose
efficaci
storag
backgroundcas
studi
sinc
approv
health
canada
order
prothrombin
complex
concentr
pcc
academ
tertiari
care
hospit
requir
approv
hematopathologist
hp
except
intracrani
hemorrhag
ich
due
high
acuiti
march
year
experi
order
ppo
implement
streamlin
hp
approv
process
urgent
warfarin
revers
scenario
simplifi
expedit
pcc
administr
goal
ppo
standard
pcc
vitamin
k
dose
decreas
tat
reduc
call
hp
purpos
qualiti
assur
studi
review
pcc
usag
implement
determin
impact
ppo
achiev
goal
studi
designmethod
retrospect
chart
review
pcc
usag
perform
two
year
implement
march
march
respect
relev
medic
inform
includ
pcc
indic
dose
use
vitamin
k
thrombosi
event
mortal
record
appropri
pcc
dosag
adjud
use
canadian
nation
advisori
committe
nac
pcc
guidelin
appropri
pcc
indic
adjud
base
chart
review
bleed
episod
verifi
review
clinic
note
endoscopi
report
imag
report
surgic
start
time
document
anesthet
record
urgent
surgeri
defin
less
hour
pcc
order
resultsfind
baselin
characterist
patient
receiv
pcc
similar
includ
sex
age
warfarin
use
inr
level
proport
patient
receiv
pcc
dose
within
iu
nac
guidelin
significantli
higher
period
vs
administr
least
intraven
vitamin
k
frequent
follow
ppo
introduct
vs
signific
differ
observ
tat
addit
dose
pcc
red
cell
transfus
inr
correct
thrombosi
mortal
introduct
ppo
call
volum
hp
pcc
approv
significantli
lower
vs
p
ppo
use
releas
pcc
inappropri
indic
time
case
patient
warfarin
urgent
surgeri
surgeri
hour
pcc
order
case
patient
warfarin
without
hp
consult
conclus
mani
goal
ppo
achiev
increas
appropri
pcc
dose
vitamin
k
usag
pcc
order
process
streamlin
reduct
call
volum
hp
prevent
unnecessari
delay
pcc
administr
although
ppo
use
inappropri
one
quarter
case
guid
refin
ppo
improv
appropri
pcc
util
backgroundcas
studi
mesenchym
stromal
cell
msc
show
tremend
promis
treatment
militari
civilian
trauma
base
abil
regul
inflamm
promot
wound
heal
studi
implement
assay
design
compar
angiogen
potenti
msc
cellular
therapi
product
investig
relationship
cellular
metabol
studi
designmethod
human
umbil
vein
endotheli
cell
huvec
human
msc
obtain
commerci
sourc
mrna
isol
earli
passag
huvec
transwel
use
gener
cdna
huvec
express
gene
relat
angiogenesi
vegf
tissu
factor
tf
signal
metabol
evalu
tube
format
assay
perform
huvec
plate
onto
geltrex
ldev
densiti
presenc
condit
media
msc
plate
transwel
insert
angiogenesi
determin
quantit
tube
format
use
imag
j
express
huvec
cellular
protein
transwel
visual
western
blot
quantit
odyssey
scanner
bioenerget
analysi
via
extracellular
flux
measur
carri
confluent
cell
sea
hors
xfe
resultsfind
huvec
respond
msc
increas
tf
protein
express
well
increas
express
angiogen
mrna
hr
alter
profil
increas
oxygen
consumpt
ratio
ocr
spare
respiratori
capac
huvec
cell
either
increas
tube
format
huvec
increas
respect
condit
medium
umbil
msc
less
potent
assay
conclus
use
tube
format
assay
western
blot
bioenerget
analysi
evalu
angiogen
potenti
msc
cell
therapi
product
preliminari
result
suggest
potenc
differ
exist
msc
deriv
differ
tissu
sourc
direct
contact
huvec
msc
requir
stimul
angiogenesi
msc
suggest
paracrin
mechan
primarili
respons
evalu
profil
sampl
allow
investig
relationship
angiogenesi
cellular
metabol
increas
angiogen
activ
accompani
increas
tf
express
potenti
increas
thrombot
risk
msc
therapi
studi
warrant
explor
metabol
activ
gene
express
backgroundcas
studi
allogen
transplant
cur
treatment
patient
sickl
cell
diseas
scd
howev
relat
donor
scd
patient
least
probabl
sickl
cell
trait
sct
mobil
peripher
blood
mononuclear
cell
pbmnc
sct
donor
graft
often
cryopreserv
collect
ensur
success
outcom
thaw
pbmnc
must
contain
adequ
quantiti
hematopoiet
progenitor
cell
hpc
studi
designmethod
data
mobil
pbmnc
graft
thaw
transplant
scd
patient
review
graft
donor
sct
sctd
compar
normal
healthi
donor
nhd
graft
data
stratifi
product
immedi
cryopreserv
ic
post
apheresi
held
overnight
delay
cryopreserv
dc
vs
hour
resultsfind
mean
pt
total
nucleat
cell
tnc
viabil
vs
tnc
viabl
recoveri
vr
vs
pt
vr
vs
show
trend
toward
lower
sctd
compar
nhd
howev
differ
note
pt
vs
pt
vr
vs
stratifi
data
tabl
show
significantli
lower
pt
tnc
viabil
vr
dc
compar
ic
sctd
pt
vr
pt
similar
group
nhd
pt
vr
lower
dc
differ
seen
sctd
nhd
graft
ic
dc
graft
base
time
platelet
neutrophil
engraft
durat
cryopreserv
impact
pt
vr
either
sctd
nhd
graft
conclus
pt
tnc
viabil
pt
vr
sctd
graft
lower
nhd
graft
especi
graft
underw
dc
pt
hpc
recoveri
coloni
form
capabl
platelet
neutrophil
engraft
unaffect
like
due
inher
durabl
hpc
compar
eas
logist
dc
sctd
graft
may
feasibl
howev
caution
must
exercis
regard
product
holdov
given
definit
decreas
overal
viabil
donor
lymphocyt
infus
plan
pbmnc
dose
pt
viabl
count
may
use
backgroundcas
studi
umbil
cord
uc
blood
cryopreserv
long
term
storag
function
hematopoiet
progenitor
cell
recov
year
suitabl
use
sourc
materi
induc
pluripot
stem
cell
ipsc
gener
broxmey
et
al
advanc
ipsc
technolog
includ
develop
varieti
cgmp
compat
approach
reprogram
use
gener
ipsc
small
amount
peripher
uc
blood
zhou
et
al
translat
autom
platform
paull
et
al
uc
tissu
rich
msc
easili
expand
ex
vivo
without
compromis
attribut
consid
import
futur
clinic
applic
explor
util
uc
tissu
cryopreserv
composit
materi
newborn
stem
cell
bank
ipsc
reprogram
use
reprogram
method
translat
platform
ipsc
coloni
isol
subsequ
cultur
studi
designmethod
uc
tissu
collect
consent
mother
cryopreserv
composit
materi
msc
isol
thaw
tissu
explant
outgrowth
describ
skile
et
al
cell
line
expand
reprogram
ipsc
use
nyscf
global
stem
cell
paull
et
al
footprint
free
modifi
mrna
encod
transcript
factor
nuclear
gfp
ngfp
reprogram
also
perform
parallel
use
sendai
reprogram
kit
ipsc
expand
autom
qualiti
control
steril
mycoplasma
pluripot
karyotyp
ident
differenti
potenti
resultsfind
uc
cell
line
expand
autom
platform
pass
qualiti
control
test
prepar
reprogram
two
method
ipsc
reprogram
mrna
sendai
viru
valid
lead
gener
success
reprogram
ipsc
uc
cell
display
strong
abil
transfect
mrna
encod
ngfp
howev
success
mrna
reprogram
limit
high
toxic
observ
express
confirm
presenc
coloni
prior
enrich
cell
display
normal
marker
pluripot
differenti
capac
karyotyp
expect
conclus
uc
cell
isol
thaw
uc
tissu
util
gener
ipsc
amen
semi
fulli
autom
reprogram
method
donor
variabl
method
depend
reprogram
effici
highlight
import
method
optim
may
cell
popul
specif
effort
import
consider
greater
util
autom
technolog
reprogram
ipsc
line
propag
well
increas
interest
altern
start
materi
neonat
tissu
backgroundcas
studi
despit
gener
clinic
success
car
cart
therapi
patient
abl
achiev
clinic
respons
concern
cart
manufactur
intermedi
process
step
may
impact
final
cell
fold
expans
fe
phenotyp
characterist
specif
studi
enrich
peripher
blood
mononuclear
cell
pbmnc
use
ficol
cell
densiti
gradient
separ
dg
impact
final
cart
product
studi
designmethod
data
two
clinic
trial
retrospect
analyz
composit
cell
leukapheresi
sampl
final
cart
product
effect
dg
evalu
chang
cell
composit
sampl
compar
leukapheresi
sampl
effect
cell
type
final
cart
product
characterist
fe
studi
resultsfind
cart
product
studi
clinic
protocol
mean
cart
dose
cellskg
dg
result
signific
deplet
rbc
p
platelet
p
neutrophil
signific
enrich
monocyt
p
rel
lymphocyt
prior
cart
cultur
initi
result
similar
protocol
univari
analys
neutrophil
deplet
effici
follow
dg
posit
correl
final
cart
transduct
effici
te
lymphocyt
fraction
sampl
correl
higher
p
convers
greater
monocyt
proport
sampl
correl
higher
ratio
p
transform
mix
effect
model
compris
rbc
platelet
neutrophil
monocyt
lymphocyt
count
rbc
count
platelet
count
strong
neg
posit
predictor
te
final
product
respect
p
neutrophil
monocyt
minim
neg
impact
te
cell
composit
affect
cell
fe
conclus
dg
deplet
rbc
platelet
neutrophil
enrich
monocyt
significantli
lymphocyt
start
materi
cart
cultur
te
significantli
improv
neutrophil
deplet
effici
interestingli
higher
rbc
count
sampl
worsen
te
wherea
platelet
opposit
effect
regard
rbc
deplet
method
may
studi
monocyt
increas
ratio
possibl
impact
final
cart
product
characterist
analysi
overal
combin
effect
dg
final
cart
critic
characterist
underway
backgroundcas
studi
given
rel
low
number
hematopoiet
progenitor
cell
hpc
umbil
cord
blood
ucb
proper
select
unit
use
set
singl
unit
transplant
becom
paramount
import
ucb
unit
typic
select
base
hla
match
nucleat
cell
dose
addit
test
perform
upon
thaw
prior
infus
includ
total
nucleat
cell
tnc
count
viabil
cell
enumer
steril
cfu
assay
cfu
assay
vitro
assay
assess
biolog
function
hpc
studi
document
influenc
cfu
dose
engraft
ucb
transplant
studi
designmethod
attempt
investig
potenti
impact
count
qualiti
efficaci
ucb
retrospect
studi
transplant
outcom
patient
malign
diseas
receiv
singl
ucb
transplant
evalu
independ
effect
cell
count
use
fine
gray
regress
model
endpoint
platelet
neutrophil
engraft
also
correl
count
unit
graft
characterist
hope
optim
select
criteria
ucb
data
analysi
includ
total
nucleat
cell
viabil
cell
content
nucleat
red
blood
cell
hematocrit
frozen
storag
time
ucb
bank
resultsfind
infus
dose
high
kg
cumul
incid
neutrophil
platelet
engraft
patient
undergo
singl
ucb
unit
transplant
respect
demonstr
associ
dose
speed
neutrophil
platelet
engraft
myeloabl
malign
patient
cell
dose
dose
highli
correl
howev
observ
interact
show
addit
benefit
top
patient
receiv
lowest
quartil
cell
dose
increas
risk
platelet
engraft
everi
one
unit
increas
p
increas
risk
neutrophil
engraft
everi
one
unit
increas
cell
dose
dose
includ
model
control
hla
dispar
type
diseas
condit
intens
hla
dispar
advers
impact
either
platelet
neutrophil
engraft
p
evalu
ucb
unit
show
despit
potenti
standard
issu
ie
test
bank
test
transplant
center
show
moder
correl
measur
paramet
show
weak
correl
post
thaw
thaw
influenc
storag
time
impact
ucb
bank
p
conclus
measur
facil
time
unit
thaw
seem
provid
effect
measur
qualiti
efficaci
ucb
cell
count
low
analysi
suggest
cd
cell
enumer
reflect
unit
potenc
thu
cell
enumer
provid
bank
could
consid
addit
select
criterion
particularli
hla
match
nucleat
cell
dose
equival
among
avail
option
backgroundcas
studi
thrombocytopenia
qualit
platelet
disord
requir
platelet
transfus
howev
platelet
transfus
limit
alloimmun
suppli
cost
increas
effort
focus
stem
cell
deriv
vitro
platelet
product
fail
gener
platelet
scale
requir
platelet
transfus
henc
aim
understand
basic
molecular
aspect
megakaryopoiesi
thrombopoiesi
enabl
greater
yield
megakaryocyt
mk
platelet
vitro
studi
designmethod
hematopoiet
stem
cell
isol
human
umbil
cord
blood
grown
serum
free
stem
cell
media
supplement
stem
cell
factor
thrombopoietin
day
favor
mk
growth
cultur
studi
mk
marker
apoptosi
signal
proplatelet
format
rna
sequenc
analysi
cultur
mk
identifi
encod
candid
apoptosi
regul
significantli
correl
platelet
count
healthi
individu
cultur
mk
achiev
lentivir
transduct
vitro
platelet
product
studi
resultsfind
mk
cultur
three
distinct
cell
popul
name
observ
flow
cytometri
defin
forward
side
scatter
day
cell
show
increas
mk
marker
vs
vs
activ
respons
platelet
agonist
thrombin
collagen
relat
peptid
morpholog
characterist
similar
matur
mk
cell
show
featur
apoptosi
annexin
v
cell
show
similar
normal
human
platelet
cultur
mk
increas
function
mk
importantli
mk
proplatelet
format
increas
ultim
result
increas
platelet
vitro
platelet
function
demonstr
activ
releas
overal
result
show
restrain
apoptosi
cultur
mk
promot
proplatelet
format
cultur
platelet
activ
associ
human
platelet
number
conclus
novel
target
improv
mk
platelet
yield
cultur
system
enforc
express
may
facilit
vitro
mk
platelet
product
backgroundcas
studi
low
birth
weight
vlbw
infant
highli
transfus
popul
estim
transfus
rate
remain
poorli
character
popul
rate
blood
product
util
may
inform
design
transfus
studi
provid
data
individu
discuss
parent
probabl
vlbw
infant
receiv
blood
transfus
studi
designmethod
secondari
analysi
prospect
multicent
observ
cohort
studi
infant
birth
weight
g
transfus
admiss
includ
follow
day
discharg
death
blood
product
transfus
includ
time
prospect
record
blood
product
util
rate
along
confid
interv
estim
transfus
red
blood
cell
rbc
fresh
frozen
plasma
ffp
platelet
plt
cryoprecipit
cryo
per
hospit
day
birth
weight
ga
specif
estim
calcul
rel
transfus
rate
compar
use
incid
rate
ratio
resultsfind
among
studi
cohort
vlbw
infant
blood
product
transfus
record
infant
day
blood
transfus
occur
infant
rbc
rate
ci
plt
rate
ffp
cryo
among
birth
weight
strata
blood
transfus
occur
infant
g
rate
g
rate
infant
g
rate
rbc
transfus
rate
decreas
increas
ga
tabl
rate
wk
ga
fold
higher
ci
infant
wk
ga
observ
similar
trend
plt
ffp
cryo
conclus
among
vlbw
infant
blood
product
util
rbc
plt
ffp
cryo
decreas
increas
ga
transfus
rate
may
inform
discuss
famili
guid
need
earli
proactiv
consent
data
may
also
help
inform
design
futur
studi
examin
blood
product
transfus
vlbw
infant
backgroundcas
studi
septic
transfus
reaction
str
signific
risk
blood
product
transfus
pediatr
patient
heavili
transfus
suffer
higher
rate
acut
transfus
reaction
atr
compar
adult
patient
versu
per
transfus
respect
uniform
approach
detect
contamin
blood
product
use
product
cultur
follow
atr
pediatr
neonat
patient
goal
project
develop
improv
criteria
detect
str
cultur
residu
product
neonat
pediatr
patient
studi
designmethod
collect
retrospect
data
transfus
reaction
occur
neonat
pediatr
patient
year
age
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
product
cultur
result
enrich
dataset
posit
result
use
current
aabb
criteria
cultur
blood
compon
follow
atr
refer
point
clinic
paramet
cultur
result
compar
determin
modifi
criteria
includ
use
object
definit
hypotens
tachycardia
would
increas
sensit
detect
posit
residu
product
cultur
tabl
resultsfind
institut
submit
complet
reaction
data
cultur
residu
compon
pediatr
neonat
patient
posit
cultur
result
platelet
rbc
product
two
consid
definit
str
patient
cultur
grew
organ
consid
possibl
str
patient
cultur
neg
discord
patient
cultur
sensit
aabb
criteria
detect
posit
cultur
definit
possibl
ci
specif
ci
modifi
criteria
appli
sensit
improv
ci
specif
decreas
ci
conclus
modifi
criteria
cultur
residu
compon
suspect
str
neonat
pediatr
patient
offer
better
sensit
detect
posit
cultur
result
less
specif
backgroundcas
studi
advers
event
transfus
well
report
adult
recipi
howev
literatur
scarc
pediatr
recipi
primari
object
compar
rate
variou
advers
transfus
reaction
atr
report
quebec
hemovigil
system
qh
among
year
age
recipi
children
versu
adult
studi
designmethod
atr
investig
report
transfus
safeti
offic
locat
design
hospit
quebec
standard
definit
atr
use
data
valid
hospit
blood
bank
hematologist
provinci
tso
medic
epidemiologist
consult
hematologist
rate
comparison
made
use
data
four
pediatr
hospit
report
atr
among
children
actual
number
unit
transfus
hospit
use
rate
calcul
resultsfind
blood
compon
transfus
quebec
hospit
includ
transfus
children
total
atr
deem
possibl
probabl
definit
associ
transfus
report
occur
among
children
atr
infant
year
old
repres
atr
among
children
rate
atr
labil
product
unit
transfus
describ
tabl
pediatr
recipi
like
experienc
febril
allerg
acut
hemolyt
reaction
wherea
adult
recipi
like
present
circulatori
overload
incid
fatal
atr
similar
group
rate
atr
children
higher
apheresi
platelet
follow
red
blood
cell
conclus
atr
rate
twice
common
children
compar
adult
mostli
due
higher
occurr
allerg
febril
reaction
whether
due
physiolog
differ
better
report
remain
determin
backgroundcas
studi
despit
introduct
leukodeplet
blood
compon
shown
donor
leukocyt
engraft
microchimer
remain
consequ
red
blood
cell
rbc
transfus
patient
group
incid
microchimer
tam
may
affect
intern
differ
blood
process
method
transfus
practic
patient
type
australia
found
incid
microchimer
tam
trauma
patient
howev
incid
tam
extens
studi
outsid
trauma
set
studi
conduct
determin
incid
tam
australian
pediatr
recipi
rbc
unit
studi
designmethod
pediatr
patient
studi
defin
patient
year
age
time
admiss
patient
n
transfus
least
one
red
blood
cell
rbc
unit
approach
particip
studi
incid
tam
determin
use
pcr
analysi
panel
insertiondelet
indel
biallel
polymorph
resultsfind
sampl
return
potenti
particip
mostli
hematologyoncolog
patient
diagnos
bone
marrow
failur
usual
result
acut
lymphoblast
leukemia
seventeen
femal
fifteen
male
median
age
time
transfus
year
old
median
number
rbc
unit
transfus
per
patient
platelet
unit
whether
apheresi
pool
mean
storag
age
rbc
unit
transfus
day
preliminari
analysi
indic
n
indel
pattern
consist
presenc
tam
patient
may
exposur
blood
howev
patient
exposur
blood
compon
potenti
microchimer
patient
diagnos
bone
marrow
failur
conclus
preliminari
result
studi
show
potenti
microchimer
chronic
transfus
pediatr
patient
popul
confirm
would
first
report
find
transfus
associ
consequ
within
patient
popul
would
also
indic
leukodepletionirradi
rbc
unit
elimin
risk
outcom
australian
govern
fund
australian
red
cross
blood
servic
provid
blood
blood
product
servic
australian
commun
backgroundcas
studi
platelet
transfus
use
thrombocytopen
pediatr
patient
prevent
treat
bleed
mitig
risk
transfus
platelet
began
migrat
institut
platelet
inventori
conv
platelet
pr
platelet
product
patient
includ
pediatr
patient
novemb
fda
approv
age
restrict
due
inventori
limit
blood
supplier
convers
period
dual
inventori
conv
pr
platelet
necess
maintain
offer
opportun
analyz
period
pr
versu
conv
platelet
regard
platelet
usag
pattern
incid
transfus
reaction
patient
year
studi
designmethod
decemb
januari
dual
platelet
inventori
maintain
conv
platelet
analyz
bacteri
detect
assay
safeti
measur
pr
platelet
use
standard
care
platelet
request
either
product
issu
per
blood
bank
inventori
manag
polici
review
transfus
period
assess
platelet
usag
pattern
transfus
reaction
conv
pr
platelet
product
pediatr
patient
popul
transfus
reaction
ascrib
appropri
platelet
product
base
proxim
transfus
categor
per
nation
hemovigil
network
guidelin
statist
sd
signific
p
resultsfind
patient
year
receiv
total
transfus
time
period
conv
platelet
pr
platelet
transfus
administ
uniqu
patient
patient
receiv
one
type
platelet
conv
pr
patient
receiv
type
platelet
includ
analysi
transfus
reaction
patient
receiv
conv
product
transfus
administ
patient
transfusionspati
patient
receiv
pr
product
transfus
given
patient
transfusionspati
total
transfus
reaction
report
time
reaction
associ
conv
platelet
transfus
associ
pr
platelet
transfus
case
trali
septic
reaction
transfus
transmit
infect
report
either
group
patient
month
receiv
ultraviolet
blue
light
phototherapi
pr
platelet
reaction
attribut
pr
transfus
report
conclus
pr
product
similar
conv
platelet
regard
platelet
util
pattern
number
transfus
episod
per
patient
use
pr
platelet
pediatr
patient
also
appear
safe
similar
number
transfus
reaction
compar
conv
platelet
backgroundcas
studi
red
cell
rbc
show
declin
atp
store
blood
bank
condit
result
rbc
higher
oxygen
affin
result
poorer
oxygen
deliveri
tissu
defect
correct
within
hour
transfus
immedi
oxygen
deliveri
overal
rbc
qualiti
atp
level
close
valu
found
fresh
whole
blood
experiment
rbc
addit
solut
ra
phosphat
adenin
bicarbon
glucos
mannitol
absenc
sodium
chlorid
optim
qualiti
rbc
storag
key
maintain
intern
ph
enzym
phosphoglycer
mutas
remain
abl
synthes
without
decreas
atp
achiev
high
extern
ph
also
absenc
chlorid
ra
addit
ra
lead
chlorid
move
rbc
maintain
electrolyt
balanc
hydrogen
enter
cell
thu
increas
intern
ph
chlorid
shift
extra
bicarbon
ra
serv
addit
buffer
prevent
drop
intern
ph
guanosin
known
shift
rbc
metabol
toward
pentos
phosphat
pathway
result
synthesi
nadhp
use
synthes
atp
aim
studi
effect
addit
extra
bicarbon
guanosin
ra
vitro
qualiti
store
rbc
concentr
studi
designmethod
one
leukoreduc
pack
rbc
concentr
split
equal
part
part
ml
ad
part
standard
composit
mm
bicarbon
part
b
extra
mm
bicarbon
mm
total
part
c
mm
guanosin
part
extra
mm
bicarbon
mm
total
mm
guanosin
concentr
store
day
weekli
sampl
determin
variou
vitro
qualiti
paramet
replic
experi
resultsfind
result
shown
tabl
addit
bicarbon
led
increas
extern
intern
ph
due
chlorid
shift
howev
effect
level
minor
effect
atp
content
presenc
guanosin
addit
adenin
led
signific
increas
atp
storag
addit
bicarbon
benefici
even
slightli
deleteri
effect
conclus
extra
bicarbon
ra
increas
ph
ultim
effect
atp
content
storag
addit
guanosin
increas
atp
level
even
day
conform
accept
criteria
store
rbc
concentr
backgroundcas
studi
previous
shown
donor
could
classifi
platelet
plt
good
averag
poor
storag
properti
recent
studi
demonstr
plt
storag
perform
consist
donor
main
differ
good
poor
storag
properti
involv
metabol
activ
result
faster
declin
ph
storag
poor
plt
concentr
pc
might
caus
mitochondri
defect
associ
age
diseas
like
metabol
syndrom
type
diabet
aim
test
hypothesi
plt
obtain
young
whole
blood
wb
donor
better
storag
properti
plt
age
donor
studi
designmethod
fifteen
wb
donor
donor
year
select
overnight
hold
collect
wb
pc
spc
prepar
buffi
coat
ml
plasma
spc
store
day
suboptim
condit
ml
contain
flatb
shaker
sampl
day
determin
vitro
qualiti
diabet
marker
determin
red
cell
cholesterol
triglycerid
level
plasma
storag
data
analys
use
unpair
resultsfind
young
donor
year
age
age
donor
year
age
donor
higher
blood
pressur
donat
vs
mmhg
p
higher
vs
mmolmol
total
cholesterol
vs
mmoll
vs
mmoll
young
donor
young
donor
within
normal
rang
mmolmol
age
donor
mmolmol
indic
type
diabet
spc
group
volum
vs
ml
plt
content
vs
day
spc
young
donor
show
lower
lactat
product
vs
plt
p
higher
vs
p
young
group
one
outlier
wherea
age
group
contain
spc
ph
outlier
includ
two
donor
high
also
vitro
variabl
reflect
better
vitro
qualiti
young
group
age
group
howev
differ
mitochondri
membran
potenti
measur
detect
conclus
pc
prepar
buffi
coat
obtain
young
wb
donor
show
better
storag
perform
age
donor
may
impact
donor
select
platelet
product
especi
apheresi
product
higher
glycolysi
rate
plt
age
donor
indic
partial
mitochondri
dysfunct
due
age
andor
pre
diabet
howev
reflect
reduct
membran
potenti
backgroundcas
studi
buffi
coat
bc
donor
use
pain
medic
like
aspirin
diclofenac
ibuprofen
naproxen
day
prior
donat
discard
centr
known
side
effect
drug
inhibit
platelet
aggreg
drug
inhibit
enzym
revers
irrevers
manner
therebi
block
synthesi
thromboxan
arachidon
acid
aa
previous
littl
deviat
observ
singl
platelet
concentr
pc
prepar
bc
plasma
obtain
donor
use
ibuprofen
includ
aggreg
properti
adp
collagen
explain
known
fast
hour
disappear
ibuprofen
blood
circul
revers
bind
platelet
level
ibuprofen
pc
mgl
aim
investig
effect
differ
ibuprofen
dose
vitro
qualiti
pc
storag
particular
aggreg
properti
studi
designmethod
day
leukoreduc
pc
prepar
bc
ml
aliquot
unit
ml
unit
ml
ibuprofen
sandoz
granular
solut
ad
adjust
reach
final
concentr
mgl
control
unit
ml
nacl
ad
pc
store
flatb
shaker
ml
contain
sampl
day
vitro
qualiti
light
transmiss
aggregometri
perform
stimul
aa
also
day
minut
addit
ibuprofen
repeat
measur
anova
dunnett
appli
statist
analysi
resultsfind
storag
differ
ph
lactat
product
express
annexin
bind
swirl
effect
mpv
group
observ
data
shown
aggreg
aa
revers
inhibit
lower
concentr
ibuprofen
mgl
aggreg
fulli
recov
minut
mgl
aggreg
almost
fulli
recov
hour
p
pc
mgl
recoveri
aggreg
observ
throughout
storag
conclus
storag
properti
pc
ad
ibuprofen
compar
control
confirm
former
result
aggreg
aa
show
clear
effect
rang
almost
immedi
full
recoveri
mgl
ibuprofen
full
impair
day
mgl
expect
level
bc
donor
use
ibuprofen
mgl
use
bc
obtain
donor
use
ibuprofen
consid
still
feasibl
pool
bc
due
dilut
vitro
qualiti
pc
investig
best
case
scenario
bc
obtain
donor
backgroundcas
studi
biolog
manufactur
variabl
recogn
key
factor
impact
red
blood
cell
storag
potenti
transfus
outcom
metabolom
approach
use
assess
impact
factor
phenotyp
store
pack
red
blood
cell
prbc
studi
designmethod
multi
center
studi
enrol
whole
blood
donor
four
differ
us
blood
center
base
day
rbc
hemolysi
measur
spontan
osmot
stress
oxid
stress
select
donor
end
hemolysi
spectrum
measur
recal
donat
second
unit
prbc
studi
sampl
drawn
prbc
unit
day
snap
frozen
later
process
pressur
liquid
chromatographi
coupl
mass
spectrometri
vanquish
q
exact
thermo
fisher
featur
compound
assign
perform
via
compound
discover
thermo
fisher
basi
accur
intact
mass
isotop
pattern
retent
time
hous
standard
librari
pure
chemic
compound
stabl
intern
standard
includ
previous
establish
marker
metabol
age
prbc
msm
valid
transit
fingerprint
resultsfind
untarget
metabolom
analys
includ
sampl
donor
strong
impact
prbc
storag
durat
varianc
blood
center
collect
varianc
metabol
phenotyp
latter
differ
attribut
addit
solut
use
differ
site
vs
area
receiv
oper
characterist
curv
note
minimum
varianc
observ
across
blood
center
use
suggest
overal
consist
standard
blood
process
protocol
metabol
phenotyp
sampl
store
differ
differ
beyond
compon
addit
formul
eg
sampl
store
load
character
higher
level
compound
increas
glycolyt
rate
higher
atp
dpg
total
glutathion
level
factor
significantli
correl
rbc
propens
hemolyz
challeng
agent
dihydrochlorid
increas
methionin
metabol
activ
pathway
note
sampl
process
site
use
conclus
studi
highlight
impact
storag
addit
metabol
heterogen
hemolyt
phenotyp
sampl
process
largest
rbc
metabolom
studi
conduct
date
observ
may
contribut
explain
differ
result
laboratori
studi
clinic
trial
age
blood
backgroundcas
studi
due
short
requir
bacteri
cultur
releas
test
platelet
present
signific
inventori
manag
challeng
recent
fda
clearanc
rapid
test
platform
bacteri
contamin
safeti
measur
hospit
transfus
servic
may
extend
platelet
mani
circumst
pediatr
transfus
servic
recent
implement
test
platform
soon
thereaft
extend
test
includ
platelet
unit
two
adult
hospit
transfus
servic
within
hospit
network
describ
metric
associ
implement
studi
designmethod
data
gather
period
platelet
receiv
inventori
pediatr
transfus
servic
well
two
affili
adult
transfus
servic
januari
septemb
descript
statist
regard
platelet
transfus
expir
compar
period
octob
march
pediatr
transfus
servic
period
januari
march
affili
adult
transfus
servic
platelet
product
consist
entir
apheresi
unit
unit
consid
expir
reach
outdat
prior
transfus
use
aliquot
prepar
resultsfind
period
pediatr
transfus
servic
receiv
apheresi
platelet
unit
expir
prior
use
period
two
combin
adult
transfus
servic
receiv
apheresi
platelet
unit
expir
prior
use
period
pediatr
transfus
servic
receiv
apheresi
platelet
unit
unit
expir
prior
use
period
platelet
unit
pgd
test
unit
test
unit
test
twice
total
test
estim
spent
test
test
unit
use
transfus
repres
approxim
save
addit
outdat
unit
provid
addit
day
platelet
stock
estim
amount
addit
cost
avoid
replac
unit
purchas
period
test
extend
platelet
affili
adult
transfus
servic
unit
transfus
total
number
expir
unit
repres
signific
decreas
period
save
transfus
extend
platelet
short
period
time
estim
conclus
describ
recent
implement
rapid
bacteri
test
platelet
safeti
measur
achiev
outdat
pediatr
transfus
servic
subsequ
extens
practic
posit
impact
inventori
manag
two
associ
adult
transfus
servic
continu
improv
logist
process
believ
test
continu
decreas
platelet
wastag
increas
platelet
avail
patient
safeti
backgroundcas
studi
storag
properti
apheresi
platelet
suspend
experiment
addit
solut
plasma
may
affect
collect
instrument
storag
contain
studi
evalu
impact
amicu
trima
collect
platform
platelet
collect
donor
store
either
two
manufactur
contain
studi
designmethod
consent
donor
provid
platelet
concurr
plasma
target
yield
platelet
occas
plasma
follow
collect
platelet
rest
hour
centrifug
rpm
ace
plasma
express
resuspend
yield
unit
plasma
follow
hour
rest
platelet
place
agit
either
maintain
origin
storag
contain
transfer
manufactur
storag
contain
place
agit
day
unit
assay
vitro
test
includ
platelet
count
ph
blood
gase
mitochondri
membran
potenti
reactiv
oxygen
speci
extent
shape
chang
esc
hypoton
shock
respons
aggreg
adp
collagen
glucos
lactat
bicarbon
morpholog
annexin
v
bind
data
analyz
repeat
measur
anova
bonferroni
anova
p
valu
consid
signific
due
repeat
measur
resultsfind
averag
unit
volum
yield
percent
plasma
ml
respect
compar
collect
either
apheresi
instrument
store
either
manufactur
contain
day
platelet
activ
similar
either
collect
instrument
contain
except
ph
day
day
esc
day
everi
paramet
similar
apheresi
platform
manufactur
contain
day
valu
ph
esc
given
tabl
ph
valu
unit
day
storag
except
unit
collect
store
contain
ph
day
ph
day
conclus
base
vitro
measur
storag
platelet
suspend
plasma
feasibl
origin
manufactur
contain
day
base
level
contain
greater
ga
exchang
contain
backgroundcas
studi
intern
normal
ratio
inr
commonli
use
bleed
risk
assess
prior
invas
procedur
practic
may
sub
optim
inr
develop
monitor
warfarin
therapi
primarili
affect
factor
vii
activ
sever
societi
guidelin
recommend
correct
inr
prior
procedur
mitig
bleed
risk
evid
base
plasma
transfus
prothrombin
complex
concentr
pcc
without
vitamin
k
administr
usual
use
purpos
teg
whole
blood
assay
measur
full
spectrum
primari
secondari
hemostasi
may
superior
tool
risk
assess
studi
designmethod
record
patient
undergo
intervent
radiolog
procedur
collect
period
retrospect
review
patient
teg
addit
tradit
laboratori
screen
assay
run
prior
procedur
patient
characterist
medic
condit
laboratori
result
advers
event
collect
analyz
tabl
resultsfind
averag
age
cohort
year
common
diagnosi
pulmonari
disord
coronari
arteri
diseas
andor
renal
failur
intervent
radiolog
procedur
perform
biopsi
central
line
cathet
placement
thoracentesi
drain
placement
renal
liver
chemistri
profil
show
mild
moder
liver
abnorm
renal
failur
nine
patient
warfarin
patient
direct
oral
anticoagul
apixiban
patient
aspirin
although
inr
averag
teg
result
larg
normal
suggest
low
risk
bleed
tabl
bleed
complic
blood
product
transfus
vitamin
k
administr
given
conclus
pilot
studi
teg
appear
superior
assay
assess
bleed
risk
patient
undergo
invas
intervent
radiolog
procedur
particularli
patient
receiv
oral
although
inr
higher
suggest
guidelin
patient
signific
bleed
complic
studi
use
larger
cohort
warrant
evalu
consist
trend
backgroundcas
studi
data
exist
guid
dose
platelet
plt
oncolog
outpati
center
special
coordin
assign
plt
oncolog
patient
recommend
either
one
two
singl
donor
apheresi
plt
transfus
base
pt
medic
transfus
histori
eg
abo
type
hla
antibodi
statu
splenomegali
bodi
mass
respons
previou
transfus
well
plt
attribut
abo
type
plt
yield
volum
studi
sought
determin
whether
transfus
one
versu
two
unit
apheresi
plt
effect
plt
count
time
next
transfus
plt
count
prior
next
plt
transfus
studi
designmethod
obtain
irb
approv
retrospect
studi
adult
oncolog
pt
receiv
outpati
transfus
collect
date
time
transfus
unit
number
date
time
plt
count
resultsfind
total
pt
receiv
plt
transfus
cumul
studi
period
major
pt
variabl
transfus
plt
per
outpati
visit
minor
transfus
exclus
strategi
throughout
studi
period
vast
major
plt
given
patient
receiv
mixtur
transfus
studi
period
summar
tabl
transfus
plt
count
interv
outpati
visit
medic
similar
although
statist
differ
regardless
transfus
strategi
addit
pt
receiv
plt
return
next
clinic
visit
plt
count
patient
receiv
plt
conclus
studi
adult
oncolog
pt
vs
plt
transfus
strategi
appear
clinic
signific
impact
platelet
count
time
clinic
visit
retrospect
dataset
clear
whether
repres
limit
util
plt
transfus
strategi
influenc
transfus
coordin
select
unit
pt
base
factor
work
ideal
random
clinic
trial
need
determin
optim
platelet
dose
adult
oncolog
pt
backgroundcas
studi
hematopoiet
stem
cell
transplant
hsct
patient
among
highest
util
allogen
red
blood
cell
rbc
platelet
plt
product
yet
impact
patient
blood
manag
pbm
effort
healthcar
deliveri
outcom
patient
remain
incomplet
defin
studi
designmethod
observ
studi
conduct
irb
approv
multidisciplinari
pbm
program
initi
includ
educ
dissemin
aabb
best
practic
guidelin
electron
clinic
decis
support
transfus
order
cohort
includ
patient
receiv
hsct
cohort
outcom
assess
hsct
day
healthcar
deliveri
outcom
includ
frequenc
proport
rbc
plt
transfus
total
transfus
quantiti
transfus
occur
outsid
guidelin
cost
transfus
rbc
administ
hemoglobin
valu
greater
gdl
plt
transfus
plt
count
greater
consid
outsid
guidelin
though
sensit
analys
perform
account
accept
discord
eg
coronari
diseas
neutropen
fever
outcom
includ
mortal
hospit
icu
admiss
rate
transfus
reaction
cerebrovascular
coronari
ischem
event
infect
resultsfind
patient
receiv
hsct
cohort
share
similar
demograph
comorbid
profil
patient
transfus
rbc
compar
p
transfus
volum
lower
median
iqr
vs
unit
respect
rbc
transfus
total
unit
unit
rbc
transfus
occur
outsid
guidelin
compar
p
regard
plt
transfus
patient
transfus
versu
median
transfus
quantiti
unit
compar
unit
higher
transfus
total
vs
unit
plt
transfus
occur
outsid
guidelin
versu
p
transfus
cost
respect
signific
differ
outcom
conclus
pbm
program
implement
set
hsct
associ
reduct
total
transfus
transfus
occur
outsid
guidelin
cost
save
exceed
period
chang
outcom
backgroundcas
studi
anemia
preval
hospit
patient
independ
risk
factor
hospit
readmiss
prolong
length
stay
diminish
qualiti
life
increas
risk
morbid
mortal
mitig
risk
multidisciplinari
program
implement
manag
anemia
patient
blood
manag
pbm
initi
studi
designmethod
patient
present
elect
cardiac
surgeri
screen
anemia
hgb
patient
found
anem
refer
anemia
workup
determin
caus
appropri
manag
patient
found
iron
defici
anemia
deem
anem
due
reason
histor
cohort
patient
undergo
elect
cardiac
surgeri
hgb
serv
control
group
comparison
control
age
sex
procedur
primari
outcom
periop
blood
transfus
secondari
outcom
hgb
red
blood
cell
rbc
transfusedpati
cost
analysi
resultsfind
two
common
treatment
intraven
iron
folat
folat
patient
receiv
treatment
diagnos
hematolog
malign
none
patient
receiv
iv
iron
ferehem
complic
reaction
studi
patient
significantli
lower
rate
rbc
transfus
compar
histor
cohort
vs
p
higher
hgb
vs
gdl
p
tabl
studi
patient
also
decreas
blood
util
rbc
unitspati
p
analysi
rbc
acquisit
cost
transfus
cost
also
show
signific
save
respect
conclus
pilot
anemia
program
start
one
group
surgic
patient
show
signific
reduct
rbc
transfus
rate
cost
although
measur
studi
patient
outcom
safeti
hospitalicu
length
stay
would
import
aspect
consider
futur
studi
backgroundcas
studi
appropri
transfus
blood
product
paramount
import
patient
safeti
howev
broad
variat
physician
order
practic
overutil
blood
product
common
despit
transfus
guidelin
although
medic
error
associ
patient
harm
due
transfus
monitor
transfus
medicin
servic
current
benchmark
prevent
patient
harm
due
inappropri
transfus
order
report
prevent
patient
harm
caus
transfus
reaction
due
inappropri
blood
product
order
studi
designmethod
retrospect
studi
transfus
reaction
occur
januari
march
hospit
affili
academ
institut
transfus
reaction
classifi
per
nation
healthcar
safeti
network
hemovigil
modul
review
case
interpret
appropri
order
question
indic
inappropri
order
compar
institut
transfus
guidelin
patient
harm
record
base
institut
scale
rel
absolut
rate
transfus
reaction
due
inappropri
order
calcul
resultsfind
total
transfus
reaction
report
studi
period
transfus
reaction
associ
transfus
red
blood
cell
rbc
platelet
fresh
frozen
plasma
reaction
report
cryoprecipit
transfus
review
blood
product
order
transfus
result
reaction
reveal
approxim
indic
question
transfus
indic
indic
transfus
reaction
mild
patient
impact
howev
three
reaction
sever
time
assess
includ
one
possibl
circulatori
overload
taco
requir
intub
rbc
product
order
patient
hemoglobin
gdl
indic
one
probabl
taco
rbc
product
order
patient
hemoglobin
gdl
question
indic
one
contamin
platelet
transfus
patient
platelet
count
indic
latter
requir
care
escal
eventu
result
death
month
transfus
absolut
rate
patient
harm
caus
transfus
reaction
inappropri
order
per
transfus
per
transfus
mild
sever
patient
harm
respect
fatal
relat
inappropri
blood
order
conclus
rel
absolut
rate
prevent
patient
harm
due
inappropri
blood
order
report
may
potenti
repres
qualiti
indic
transfus
practic
backgroundcas
studi
safeti
allogen
red
blood
cell
transfus
rbct
challeng
oncolog
patient
rbct
link
deleteri
immunomodulatori
effect
promot
cancer
recurr
decreas
surviv
patient
cur
surgeri
therefor
object
studi
assess
relat
periop
rbct
cancer
recurr
patient
undergo
surgic
tumor
debulk
due
primari
ovarian
cancer
studi
designmethod
patient
identifi
prospect
maintain
tumor
bank
ovarian
cancer
databas
patient
elig
underw
surgic
tumor
debulk
due
primari
ovarian
cancer
complet
cytoreduct
surgeri
primari
endpoint
surviv
df
propens
score
match
psm
use
remov
effect
confound
outcom
ethic
approv
obtain
ethic
committe
berlin
systemat
review
also
conduct
includ
cohort
studi
publish
januari
februari
incorpor
find
studi
systemat
review
regist
prospect
prospero
databas
resultsfind
total
patient
median
month
confid
interv
ci
elig
analysi
patient
receiv
periop
rbct
patient
characterist
highli
bias
regard
rbct
unadjust
analysi
rbct
associ
increas
risk
cancer
recurr
death
hazard
ratio
hr
df
ci
p
psm
adjust
analysi
confound
well
balanc
rbct
longer
increas
risk
cancer
recurr
death
find
trial
includ
data
studi
confirm
periop
rbct
affect
surviv
ovarian
cancer
surgeri
conclus
wors
oncolog
outcom
patient
without
macroscop
tumor
residu
surgeri
ovarian
cancer
receiv
periop
rbct
caus
clinic
circumst
requir
transfus
due
blood
transfus
concern
oncolog
outcom
issu
process
periop
rbct
backgroundcas
studi
snp
base
type
becom
common
place
facilit
extend
antigen
type
donor
patient
transfus
therapi
howev
cost
comprehens
snp
array
preclud
univers
extend
type
donor
recipi
addit
snp
array
test
predefin
nucleotid
chang
allow
ad
hoc
expans
next
gener
sequenc
ng
cost
continu
drop
precipit
enabl
determin
blood
group
antigen
interest
singl
assay
develop
molecular
invers
probe
mip
captur
target
ng
base
blood
group
type
studi
designmethod
mip
sequenc
captur
method
wherebi
numer
long
oligonucleotid
target
hundr
thousand
base
region
singl
target
sequenc
within
singl
strand
circl
form
polymeras
extens
ligat
set
barcod
primer
incorpor
illumina
sequenc
adapt
univers
amplifi
captur
sequenc
allow
creation
sequenc
librari
combin
thousand
sampl
singl
sequenc
run
test
initi
design
mip
probe
blood
group
antigen
across
blood
group
gene
abo
gypa
gypb
gype
rhd
rhce
kel
darc
ach
ermap
bsg
captur
sampl
sequenc
use
illumina
nextseq
nineti
five
sampl
blood
donor
previous
test
licens
snp
assay
use
comparison
test
select
repres
divers
set
antigen
phenotyp
use
bloodtyp
autom
blood
group
type
softwar
platform
interpret
ng
data
lane
wj
et
al
lancet
haematolog
press
bloodtyp
enhanc
analyz
mip
base
ng
data
mip
base
ng
result
compar
serolog
snp
type
antigen
b
n
u
c
c
e
e
v
vs
k
k
kp
kp
b
js
js
b
fy
fy
b
jk
jk
b
di
di
b
co
co
b
b
hy
jo
lw
lw
b
resultsfind
mip
base
ng
red
blood
cell
antigen
type
concord
serolog
snp
base
type
discord
restrict
antigen
c
v
vs
uvar
analysi
raw
data
indic
discord
fixabl
minor
optim
mip
probe
set
conclus
mip
base
ng
test
feasibl
blood
group
type
strategi
could
allow
inexpens
larg
scale
donor
test
mip
base
ng
blood
group
type
perform
estim
reagent
suppli
cost
per
sampl
bloodtyp
develop
type
molecularli
understood
blood
group
antigen
whole
genom
expans
overal
mip
approach
newli
discov
antigen
polymorph
would
requir
incorpor
new
captur
probe
backgroundcas
studi
next
gener
sequenc
ng
emerg
altern
genotyp
strategi
red
blood
cell
rbc
antigen
addit
establish
clinic
valu
rbc
genotyp
mani
clinic
scenario
ng
potenti
queri
everi
known
blood
group
variant
identifi
novel
variant
patient
donor
process
interpret
ng
output
file
requir
consider
comput
resourc
informat
expertis
facilit
applic
technolog
transfus
research
commun
present
softwar
design
predict
extend
rbc
phenotyp
ng
illustr
function
analysi
exom
sequenc
es
data
particip
sequenc
cohort
valid
predict
serolog
studi
designmethod
rylan
red
cell
lymphocyt
antigen
predict
ng
python
applic
take
ng
sort
binari
align
matrix
bam
file
index
input
softwar
interact
databas
encod
genom
coordin
phenotyp
interpret
rule
yield
predict
rbc
phenotyp
associ
qualiti
paramet
multipl
hard
filter
modifi
per
individu
coordin
output
provid
mongodb
document
facilit
complex
bulk
queri
statist
analysi
employ
rylan
analyz
es
ng
file
cohort
use
databas
known
blood
group
variant
valid
phenotyp
predict
serolog
assay
resultsfind
percent
particip
male
white
race
three
percent
cohort
identifi
hispaniclatino
asian
african
mix
unknown
race
averag
read
depth
posit
interest
averag
qual
valu
highest
variant
nucleotid
frequenc
observ
fyafyb
jkajkb
loci
predict
blood
phenotyp
frequenc
expect
ethnic
total
individu
report
heterozyg
homozyg
weak
kidd
allel
certain
region
bcam
kel
ermap
fail
qualiti
filter
repeatedli
care
review
reveal
captur
es
librari
serolog
valid
k
fya
fyb
jka
jkb
perform
rbc
sampl
particip
result
discrep
due
cleric
error
attribut
failur
antibodi
detect
express
weak
kidd
allel
ten
novel
frameshift
nonsens
variant
identifi
bcam
gene
predict
deleteri
enzymat
function
antigen
express
conclus
describ
informat
tool
translat
ng
data
predict
extend
rbc
phenotyp
demonstr
applic
analysi
es
file
result
corrobor
rel
high
frequenc
weak
kidd
allel
caucasian
popul
serolog
antigen
sampl
correl
ng
predict
latter
precis
detect
weak
kidd
express
one
percent
particip
carri
novel
blood
group
variant
predict
deleteri
nonsens
frameshift
mechan
current
investig
backgroundcas
studi
unravel
genet
base
blood
group
facilit
implement
novel
diagnost
tool
transfus
medicin
relat
field
system
except
one
resolv
allow
genotyp
antigen
predict
xga
antigen
report
pbdx
xg
identifi
underli
gene
howev
reason
men
women
lack
xga
remain
undefin
hypothet
regulatori
locu
xgr
propos
alreadi
govern
express
antigen
xg
system
xga
encod
xg
antigen
encod
neighbour
gene
xg
locat
region
sex
chromosom
disrupt
produc
protein
unknown
function
x
hypothes
express
transcript
control
polymorph
snp
within
xg
region
studi
designmethod
calcul
xg
allel
frequenc
differ
popul
compil
literatur
comparison
made
multipl
xg
variant
genom
project
express
quantit
trait
loci
eqtl
region
analyz
http
gtexportalorg
transcript
factor
bind
analyz
http
jaspargeneregnet
blood
sampl
blood
donor
anonym
gender
phenotyp
xga
genotyp
flow
cytometr
type
xga
perform
subset
donor
mrna
level
quantifi
electrophoret
mobil
shift
assay
emsa
luciferas
report
assay
assess
function
import
identifi
snp
resultsfind
among
investig
xg
variant
show
best
fit
xg
frequenc
histor
dataset
strikingli
snp
locat
kb
upstream
xg
transcript
start
site
also
eqtl
signific
impact
level
whole
blood
also
abolish
site
corrobor
clear
chip
seq
peak
dataset
erythropoiet
cell
genotyp
show
xg
donor
regardless
gender
carri
least
one
allel
one
femal
sampl
posit
flow
cytometri
xg
women
xg
men
homozyg
xg
men
c
accompani
g
presum
oppos
xg
donor
xg
show
level
bind
oligonucleotid
probe
c
shown
emsa
confirm
mass
spectrometri
follow
pulldown
experi
intact
motif
enhanc
transcript
luciferas
report
assay
final
express
rbc
also
correl
statu
gg
gc
cc
conclus
xg
phenotyp
depend
intact
site
upstream
xg
xg
due
impair
transcript
follow
disrupt
motif
data
open
genotyp
predict
xga
statu
level
rbc
backgroundcas
studi
caucasian
woman
metastat
ovarian
carcinoma
histori
pregnanc
transfus
type
serolog
weak
weakli
posit
gel
tube
sampl
reflex
rhd
genotyp
reveal
patient
rhd
weak
type
thereaft
manag
recommend
aabbcap
workgroup
guidelin
individu
weak
type
consid
risk
product
clinic
signific
receiv
rbc
day
chemotherapi
induc
anemia
unexplain
hemolysi
undergo
carboplatin
paclitaxel
therapi
four
week
last
transfus
present
worsen
anemia
plasma
studi
designmethod
plasma
investig
determin
serolog
test
standard
method
rhag
rhd
rhce
cdna
amplif
sequenc
perform
determin
mutat
rh
protein
part
rh
membran
complex
combin
g
p
associ
weak
type
could
potenti
explain
alloimmun
resultsfind
rbc
phenotyp
antibodi
screen
dat
neg
four
week
transfus
unit
present
worsen
anemia
gdl
slight
increas
bilirubin
clinic
concern
hemolysi
dat
neg
present
plasma
peg
iat
eluat
antibodi
carboplatin
paclitaxel
detect
refer
laboratori
test
suggest
plasma
adsorb
rr
rbc
contain
rule
react
variant
rbc
diii
div
dv
dvi
dvii
react
weak
type
rbc
test
patient
rbc
alba
advanc
partial
type
kit
gave
pattern
reactiv
consist
weak
type
sampl
test
parallel
sequenc
rhd
rhce
rhag
found
addit
chang
sampl
obtain
month
later
show
respect
lookback
indic
least
unit
also
k
sampl
test
month
last
transfus
unit
continu
show
although
react
weaker
prior
contrast
reactiv
equival
shown
titrat
plasma
adsorb
autolog
rbc
conclus
report
robust
product
patient
weak
type
weak
type
individu
consid
risk
base
observ
studi
primarili
europ
rare
except
known
date
associ
clinic
signific
rbc
destruct
patient
may
contribut
exacerb
anemia
howev
confound
clinic
histori
abnorm
lab
valu
make
definit
assess
challeng
transfus
least
dk
unit
sensit
antigen
suggest
may
act
synergist
complement
alloimmun
backgroundcas
studi
human
immunoglobulin
g
higg
includ
igg
subtyp
contain
differ
isoallotyp
due
genet
variat
contain
isoallotyp
describ
previous
shown
monoclon
fail
recogn
k
isoallotyp
indirect
antiglobulin
test
iat
failur
detect
two
antibodi
due
amino
acid
chang
isotyp
heavi
chain
second
common
caus
hemolyt
diseas
fetu
newborn
observ
rais
concern
potenti
clinic
impact
two
isoallotyp
want
examin
whether
isoallotyp
differenti
effect
human
monocytemacrophag
phagocytosi
compar
phagocyt
activ
purifi
recombin
isoallotyp
use
monocyt
monolay
assay
mma
studi
designmethod
novel
monoclon
recombin
antibodi
isol
use
creat
panel
isoallotyp
thu
monoclon
antibodi
ident
variabl
region
gene
recogn
k
antigen
epitop
differ
heavi
chain
region
antibodi
kk
kk
red
blood
cell
rbc
opson
rbc
examin
use
iat
tube
gel
flow
cytometri
use
chain
antibodi
avoid
variat
fc
heavi
chain
region
mma
resultsfind
dosag
effect
seen
mani
isoallotyp
kk
iat
result
lower
kk
particularli
opsonis
kk
rbc
optim
determin
flow
cytometri
analysi
differenti
effect
isoallotyp
induct
phagocytosi
compar
phagocyt
index
show
reduc
capac
induc
phagocytosi
pi
respect
howev
show
significantli
enhanc
abil
induc
phagocytosi
induc
clinic
signific
phagocytosi
requir
increas
concentr
achiev
pi
suggest
clinic
signific
conclus
certain
amino
acid
variat
fc
region
antibodi
may
lead
enhanc
reduc
capac
abil
induc
phagocytosi
result
indic
isoallotyp
clinic
signific
measur
mma
thu
antiglobulin
reagent
fail
detect
could
present
problem
backgroundcas
studi
lutheran
blood
group
system
consist
antigen
locat
adhes
glycoprotein
call
equilibr
one
antigen
report
date
protein
strongli
involv
interact
red
blood
cell
rbc
extracellular
matrix
aim
present
work
describ
novel
antigen
lutheran
system
investig
two
sister
produc
correspond
antibodi
studi
designmethod
blood
sampl
pregnant
woman
firstli
refer
laboratori
investig
antibodi
antibodi
identif
iat
perform
nativ
diagast
sigma
rbc
genom
dna
extract
peripher
blood
cell
fulli
autom
method
amplifi
lu
primer
sequenc
resultsfind
proband
group
yo
femal
patient
turkish
origin
first
pregnanc
serum
reactiv
nativ
rbc
nonreact
rbc
lunul
sampl
autolog
control
neg
lu
phenotyp
unambigu
lu
underli
alloantibodi
common
specif
rule
antibodi
final
conclud
antibodi
ie
antibodi
probabl
lu
antigen
unknown
specif
proband
anoth
child
two
year
later
without
complic
despit
stronger
reactiv
antibodi
blood
sampl
sibl
requir
compat
test
rbc
antibodi
screen
elder
sister
turn
compat
howev
investig
perform
time
antibodi
also
detect
proband
elder
sister
pregnanc
genom
dna
sequenc
reveal
presenc
sister
two
nucleotid
chang
homozyg
state
gene
lu
allel
basi
first
one
synonym
chang
exon
known
present
gener
popul
second
one
found
exon
respons
amino
acid
chang
mutat
report
frequenc
less
exom
aggreg
consortium
exac
databas
conclus
serolog
molecular
studi
allow
us
provid
evid
novel
antigen
lutheran
blood
group
system
importantli
identifi
specif
patient
antibodi
recommend
optim
transfus
polici
suggest
provision
assign
name
luya
proband
name
antigen
accord
structur
model
parson
et
al
blood
luya
express
predict
fourth
igsf
domain
bcam
antigen
backgroundcas
studi
case
posit
reaction
major
crossmatch
consult
blood
center
antibodi
screen
patient
plasma
neg
appli
variou
antibodi
relev
blood
product
could
identifi
antigen
name
sumi
first
proband
whose
rbc
carri
antigen
sumi
antigen
recogn
unidentifi
antigen
report
sumi
antigen
present
glycophorin
gpa
studi
designmethod
serolog
test
perform
standard
tube
method
autom
blood
group
machin
standard
method
also
appli
rbc
treatment
proteolyt
enzym
monoclon
cell
line
obtain
lymphocyt
posit
individu
hybridoma
method
captur
fluoresc
analysi
icfa
use
luminex
use
analyz
sumi
antigen
genom
dna
extract
peripher
white
blood
cell
individu
nucleotid
sequenc
gypa
examin
direct
sequenc
ta
clone
resultsfind
nine
sumi
posit
found
screen
japanes
blood
donor
human
monoclon
igm
antibodi
sumi
sensit
red
cell
treatment
trypsin
ficin
pronas
sialidas
dtt
higher
found
among
normal
sera
salin
tube
method
room
temperatur
strongest
antibodi
titer
hand
case
umbil
cord
blood
plasma
show
neg
reaction
rbc
icfa
assay
murin
monoclon
antibodi
intracellular
potion
gpa
show
sumi
antigen
locat
gpa
gypa
gene
analysi
show
mutat
c
p
thr
pro
mutat
recogn
sumi
sumi
show
antigen
posit
conclus
sumi
antigen
novel
low
frequenc
antigen
mn
blood
group
system
repres
substitut
gpa
frequenc
sumi
antigen
among
japanes
donor
famili
analysi
confirm
sumi
antigen
dominantli
inherit
detect
healthi
donor
consid
natur
occur
antibodi
igm
class
backgroundcas
studi
algorithm
donor
antigen
type
dna
analysi
polici
serolog
confirm
dna
test
order
lead
discoveri
multipl
rhce
discord
investig
six
sampl
conflict
result
e
donor
c
donor
ob
patient
studi
designmethod
autom
manual
tube
method
use
rbc
type
genom
dna
isol
wbc
rna
rbc
hea
precisetyp
rhce
beadchip
rhce
gene
sequenc
assay
done
cdna
analysi
perform
two
sampl
resultsfind
three
caucasian
donor
type
clone
reflex
hea
test
extend
rbc
profil
predict
rbc
e
tube
test
rbc
immucor
rhce
beadchip
indic
e
phenotyp
review
genotyp
result
show
sampl
heterozyg
g
gene
sequenc
primer
confirm
presenc
rhce
ce
caucasian
hispan
donor
c
clone
predict
hea
tube
test
sampl
immucor
ortho
bioclon
seraclon
multiplex
pcr
rhce
beadchip
sampl
lack
insert
intron
characterist
rh
c
rhce
exon
sequenc
howev
consist
rh
c
analysi
found
convent
rhce
transcript
indic
novel
allel
encod
c
phenotyp
lack
insert
hispan
ob
patient
patern
sampl
refer
rhce
genotyp
evalu
risk
hdfn
patern
sampl
genotyp
consist
serolog
children
predict
e
patient
rbc
predict
hea
serolog
confirm
rbc
cw
immucor
ortho
bioclon
singl
donor
sourc
albaclon
seraclon
singl
donor
sourc
rhce
beadchip
indic
phenotyp
genotyp
indic
heterozygos
analysi
show
chang
rhce
ce
indic
express
c
antigen
novel
allel
rhce
conclus
report
three
new
rhce
allel
rhce
associ
variabl
e
antigen
type
rhce
ce
lack
classic
intron
insert
associ
c
antigen
rhce
encod
variabl
c
antigen
express
report
two
rhce
allel
addit
chang
rhce
rhce
variabl
e
express
interestingli
rhce
found
three
midwest
caucasian
donor
continu
discoveri
rh
variant
knowledg
serolog
preval
allel
potenti
clinic
impact
import
design
futur
genotyp
assay
backgroundcas
studi
accept
peopl
uvar
rbc
make
product
also
observ
phenotyp
genet
mechan
caus
phenotyp
risk
includ
delet
gypb
exon
chang
exon
andor
intron
inherit
gyp
hybrid
perform
serolog
gypb
investig
two
women
african
ancestri
previous
transfus
present
parturit
appar
addit
unexplain
reactiv
studi
designmethod
standard
method
use
antigen
type
antibodi
test
licens
reagent
dna
isol
wbc
gypb
exon
amplifi
sequenc
sampl
id
core
grifol
perform
hea
precisetyp
immucor
gypb
long
rang
sequenc
exon
resultsfind
rbc
weakli
dat
igg
type
react
detect
u
variant
plasma
reactiv
liss
consist
liss
iat
igg
gel
plasma
react
cell
except
u
dantu
auto
control
consist
strongest
reaction
rbc
papain
treat
cell
react
eluat
rbc
react
gel
cell
except
id
core
detect
gypb
variant
predict
gypb
sequenc
reveal
homozyg
chang
exon
base
present
chang
encod
alter
gpb
rbc
type
react
detect
u
variant
glycin
soja
detect
plasma
react
liss
peg
iat
gel
papain
treat
rbc
nonreact
u
rbc
auto
control
hea
precisetyp
predict
phenotyp
gypb
sequenc
found
heterozyg
chang
exon
gypb
long
rang
pcr
confirm
reveal
novel
gyp
presum
tran
evidenc
plasma
adsorptionelut
confirm
lack
antigen
patient
rbc
conclus
report
three
novel
gypb
allel
two
patient
suspect
probabl
rbc
express
gpb
found
rare
allel
frequenc
african
exac
turn
compound
heterozygot
gypb
tran
gyp
hybrid
similar
one
previous
report
willemetz
et
al
vox
sang
may
caus
altern
exon
splice
known
chang
associ
reaction
rbc
g
soja
consist
reduc
glycosyl
would
observ
alter
reduc
level
gp
backgroundcas
studi
rh
current
compris
antigen
encod
two
highli
homolog
gene
rhd
rhce
rhd
protein
express
antigen
wherea
rhce
protein
carri
cc
ee
antigen
howev
rhd
variant
may
paradox
code
rhce
reactiv
rhd
rhd
respons
c
reactiv
clone
convers
rhce
allel
rhce
cehar
rhce
cecf
rhce
cert
rhce
cesl
may
express
rhd
epitop
less
detect
reagent
depend
clone
use
describ
serolog
molecular
investig
patient
western
european
descent
alloimmun
studi
designmethod
rhd
type
carri
standard
hemagglutin
techniqu
polyclon
monoclon
antibodi
test
perform
polyclon
acid
elut
method
genom
dna
amplifi
rhd
primer
sequenc
rhd
gene
also
investig
wrhd
devic
immucorbioarray
resultsfind
blood
sampl
group
yo
male
patient
spanish
origin
refer
march
refer
laboratori
explor
neg
dat
autocontrol
patient
conclud
carri
weak
phenotyp
refer
laboratori
like
consid
european
ancestri
observ
month
first
transfus
rbc
unit
june
patient
regularli
transfus
platelet
rbc
unit
year
weak
express
found
routin
techniqu
ortho
biovu
clone
reactiv
use
panel
monoclon
show
posit
reaction
clone
reactiv
clone
rhd
analysi
show
exon
amplif
new
blood
sampl
sent
anoth
transfus
episod
rhd
gene
found
patient
specul
reactiv
could
origin
rhce
variant
allel
confirm
presenc
heterozyg
g
mutat
exon
besid
studi
polyclon
found
neg
conclus
describ
novel
rhce
allel
rhce
genbank
number
express
epitop
detect
sever
commonli
use
monoclon
reagent
may
caus
type
especi
clone
reactiv
risk
alloimmun
seemingli
patient
especi
matter
concern
type
women
childbear
age
accord
rh
protein
structur
model
flegel
wa
curr
opin
hematol
locat
extracellular
domain
rhce
protein
within
rh
protein
vestibul
data
new
allel
seem
confirm
import
vestibul
area
term
rhd
epitop
express
propos
call
new
variant
rhce
cerg
rg
arg
gli
similarli
name
procedur
follow
rhce
cesl
rhce
cert
backgroundcas
studi
serolog
molecular
divers
rhd
antigen
without
question
list
rhd
variant
allel
continu
grow
investig
sampl
femal
refer
weaker
expect
type
rh
genotyp
studi
designmethod
genom
dna
isol
wbc
rhd
beadchip
assay
rhd
sequenc
perform
cdna
analysi
done
two
sampl
serolog
test
standard
method
multipl
albaclon
advanc
partial
rhd
type
kit
two
sampl
resultsfind
sampl
pregnant
woman
ethnic
unknown
whose
rbc
type
w
rbc
also
react
immedi
spin
iat
ortho
bioclon
immucor
seri
seri
quotient
blend
alpha
delta
rbc
also
type
vv
monoclonalpolyclon
three
clone
alba
partial
kit
rbc
pattern
match
indic
partial
rhd
beadchip
show
low
signal
exon
marker
suggest
hybrid
allel
rhd
exon
sequenc
analysi
confirm
hemizyg
hybrid
g
associ
c
antigen
silent
chang
exon
rhce
beadchip
detect
rhce
sampl
rbc
woman
unknown
ethnic
sent
rhd
genotyp
react
iat
seraclon
immucor
rhd
beadchip
detect
chang
exon
sequenc
identifi
heterozyg
chang
c
associ
partial
rhd
dvii
analysi
confirm
rhd
dvii
identifi
hybrid
addit
chang
g
exon
sampl
pregnant
woman
refer
variabl
type
rbc
react
iat
ortho
bioclon
immucor
seri
seri
seraclon
seraclon
blend
type
go
rbc
type
react
five
clone
alba
partial
kit
div
pattern
rhd
beadchip
detect
c
rhd
gene
sequenc
confirm
new
allel
conclus
report
new
rhd
allel
two
variabl
type
evid
encod
partial
phenotyp
one
silent
rh
hybrid
tran
dvii
sampl
found
new
hybrid
g
exon
chang
characterist
rhce
suggest
allel
aros
gene
convers
event
hybrid
report
without
g
chang
found
sampl
lastli
describ
new
allel
rhd
rbc
reactiv
pattern
div
alba
partial
kit
go
backgroundcas
studi
neg
patient
pt
routin
transfus
rbc
due
increas
immunogen
antigen
rate
alloimmun
antigen
follow
transfus
high
howev
immunosuppress
pt
may
less
like
becom
alloimmun
pt
undergo
liver
transplant
may
requir
larg
number
rbc
unit
risk
inventori
rbc
consid
rel
rare
donor
unit
compar
posit
rbc
blood
bank
may
forc
suppli
pt
rbc
due
inventori
constraint
though
process
provid
rbc
transplant
recipi
accept
blood
bank
practic
incid
alloimmun
liver
transplant
pt
well
defin
activ
liver
transplant
program
institut
studi
preval
format
liver
transplant
pt
receiv
rbc
periop
assist
success
patient
blood
manag
studi
designmethod
retrospect
studi
perform
singl
larg
academ
medic
center
studi
approv
institut
review
board
electron
medic
record
blood
bank
file
pt
underw
orthotop
liver
transplant
henri
ford
hospit
detroit
michigan
august
decemb
review
resultsfind
twelv
pt
receiv
blood
periop
tabl
summar
characterist
pt
median
age
year
rang
year
male
median
number
rbc
unit
transfus
unit
rang
unit
evid
alloimmun
patient
median
follow
month
rang
month
one
patient
die
surgeri
pt
liver
transplant
recipi
present
alloimmun
transplant
none
pt
transfus
blood
institut
conclus
studi
show
risk
alloimmun
antigen
orthotop
liver
transplant
recipi
receiv
rbc
periop
backgroundcas
studi
donor
plasma
select
albumin
therapeut
plasmapheresi
replac
fluid
function
compon
clot
factor
need
replet
plasma
also
contain
complement
protein
benefici
function
immun
inflamm
may
role
condit
transplant
reject
glomerular
diseas
complement
level
concern
select
patient
coagul
protein
fibrinogen
known
preserv
thaw
plasma
tp
stabil
report
multipl
refer
laboratori
stabil
comment
suggest
serum
complement
level
drop
three
day
storag
accordingli
studi
assay
refriger
tp
patient
serum
day
storag
studi
designmethod
measur
nephelometr
method
four
unit
donor
plasma
time
thaw
day
storag
also
measur
three
random
patient
sampl
store
condit
resultsfind
donor
tp
unit
level
averag
chang
valu
rang
day
thaw
tabl
patient
serum
sampl
initi
level
mgdl
refer
rang
mgdl
level
mgdl
refer
rang
mgdl
serum
level
chang
averag
respect
day
refriger
conclus
level
maintain
tp
plasmapheresi
case
mainten
complement
level
indic
would
advantag
use
immedi
thaw
plasma
prepar
store
tp
patient
lower
complement
concentr
desir
albumin
replac
prefer
clinic
accept
store
tp
would
provid
benefit
immedi
thaw
plasma
prepar
serum
level
also
appear
stabl
refriger
day
investig
allow
tertiari
caretrauma
center
confid
maintain
roll
inventori
tp
support
immedi
avail
emergencymass
transfus
need
addit
routin
use
tp
plasmapheresi
fluid
replac
curtail
expir
tp
product
inventori
backgroundcas
studi
two
larg
random
control
trial
rbc
storag
age
conduct
north
america
europ
recess
abl
studi
studi
show
signific
differ
outcom
recipi
rbc
unit
store
short
vs
long
period
group
collect
longitudin
blood
sampl
trial
particip
determin
chang
wide
array
coagul
immunolog
paramet
studi
designmethod
sampl
collect
transfus
day
thereaft
whole
blood
sampl
ship
central
lab
overnight
pbmc
process
plasma
separ
clinic
site
store
frozen
batch
ship
subject
recess
trial
subject
abl
trial
enrol
studi
level
coagul
paramet
regulatori
function
cell
cytokin
marker
extracellular
vesicl
ev
determin
use
commerci
assay
coagul
cytokin
test
flow
cytometri
cell
ev
character
resultsfind
recess
ancillari
studi
subject
receiv
fresh
age
rbc
transfus
paramet
test
show
signific
differ
earli
studi
arm
abil
cell
secret
plasma
higher
plasma
endotheli
growth
factor
level
concentr
extracellular
vesicl
ev
bear
b
cell
marker
lower
recipi
fresh
vs
age
rbc
multipl
paramet
show
signific
modul
transfus
analyt
chang
surgeri
differ
base
transfus
statu
sever
ev
marker
includ
two
associ
platelet
decreas
transfus
subject
underw
surgeri
without
transfus
abl
ancillari
studi
subject
receiv
fresh
age
rbc
chang
baselin
level
protein
c
factor
v
ev
express
phosphatidyl
serin
differ
recipi
fresh
age
rbc
unit
vast
major
coagul
ev
marker
cytokin
test
show
differ
studi
arm
although
analyt
show
differ
subject
fresh
age
arm
studi
coagul
paramet
cytokin
ev
paramet
chang
significantli
period
conclus
transfus
fresh
vs
age
rbc
result
substanti
chang
hemostasi
immun
paramet
recipi
possibl
transfus
modul
level
ev
requir
studi
patient
random
receipt
transfus
backgroundcas
studi
fibrinogen
fg
replac
essenti
compon
critic
bleed
manag
studi
suggest
earli
deliveri
fg
improv
critic
bleed
outcom
cryoprecipit
cryo
main
sourc
fg
replac
util
us
cryo
first
use
bleed
disord
eg
hemophilia
today
primarili
use
replac
fg
trauma
acquir
coagulopathi
cryo
guidelin
requir
use
within
hr
thaw
may
overli
restrict
cryo
use
fg
replac
assess
hemostat
qualiti
thaw
pool
cryo
store
refriger
room
temperatur
rt
day
studi
designmethod
cryo
pool
type
thaw
distribut
ml
aliquot
storag
cold
rt
cryo
dilut
pb
analyz
fg
fviii
hematolog
analyz
vwf
activ
quantifi
ristocetin
cofactor
assay
coagul
cryo
dilut
plasma
cpp
origin
ratio
measur
rotem
thrombin
gener
mixtur
quantifi
thrombogram
pack
red
cell
platelet
concentr
frozen
plasma
cryo
combin
simul
massiv
transfus
analyz
rotem
vwf
function
also
measur
adhes
platelet
surfac
flow
resultsfind
signific
differ
hemostat
properti
observ
group
pool
combin
result
summar
tabl
addit
signific
chang
observ
rotem
massiv
transfus
simul
precipit
observ
sampl
aggreg
easili
resuspend
upon
warm
water
bath
conclus
fg
concentr
cryo
significantli
decreas
thaw
shelf
life
cryo
use
fg
replac
could
extend
day
steril
could
maintain
refriger
minim
risk
bacteri
contamin
fg
concentr
hemostat
function
cryo
inferior
rt
cryo
vwf
thrombin
gener
significantli
better
preserv
would
reason
consid
revis
guidelin
extend
shelf
life
thaw
refriger
cryo
use
fg
replac
may
improv
product
utilizationmanag
decreas
wast
backgroundcas
studi
current
regul
requir
blood
collect
facil
ask
donor
cigarett
use
preval
nicotin
metabolit
blood
product
unknown
although
smoker
higher
hemoglobin
hb
level
smoke
may
affect
qualiti
donat
rbc
exampl
smoker
higher
carboxyhemoglobin
cohb
level
rbc
membran
abnorm
lead
prematur
hemolysi
herein
test
rbc
unit
cotinin
metabolit
nicotin
cohb
investig
transfus
outcom
recipi
cotinin
posit
unit
studi
designmethod
rbc
segment
uniqu
donor
test
cotinin
use
mass
spectrometri
assay
cohb
gem
premier
analyz
outcom
evalu
retrospect
adult
patient
receiv
rbc
unit
patient
receiv
rbc
unit
control
group
receiv
rbc
unit
hb
hct
vital
sign
wbc
count
within
hour
transfus
record
statist
test
u
wilcoxon
perform
resultsfind
thirteen
rbc
donor
segment
posit
cotinin
level
consist
activ
smoke
ngml
smoker
rbc
unit
show
significantli
greater
cohb
level
compar
control
group
unit
median
iqr
vs
median
iqr
patient
transfus
smoker
rbc
unit
show
reduc
hematocrit
increment
median
iqr
compar
patient
receiv
rbc
unit
median
iqr
trend
also
observ
hemoglobin
increment
reach
statist
signific
median
iqr
smoker
unit
vs
median
iqr
unit
transfus
reaction
observ
group
show
differ
mlkg
dose
patient
transfus
smoker
rbc
unit
signific
chang
vital
sign
oxygen
satur
wbc
count
follow
transfus
conclus
thirteen
percent
rbc
unit
test
posit
cotinin
level
consist
activ
smoke
accord
estim
cdc
nation
smoke
rate
preliminari
data
show
smoker
rbc
unit
greater
cohb
content
reduc
hematocrit
increment
follow
transfus
howev
result
must
valid
larger
sampl
size
smoker
rbc
unit
care
attent
potenti
confound
variabl
includ
age
gender
underli
diseas
recipi
influenc
smoke
blood
compon
compon
transfus
pediatr
patient
along
cohb
increment
recipi
smoker
rbc
also
consid
backgroundcas
studi
circul
blood
microparticl
mp
play
complex
dynam
physiolog
role
mediat
inflamm
hypercoagul
seventi
nineti
percent
mp
blood
releas
platelet
megakaryocyt
studi
suggest
high
mp
content
platelet
compon
indic
high
level
platelet
activ
may
limit
effect
platelet
transfus
activ
platelet
may
benefici
stop
activ
bleed
suggest
work
cryopreserv
platelet
convers
platelet
compon
low
mp
content
may
benefici
prophylact
platelet
transfus
bone
marrow
transplant
patient
popul
studi
investig
whether
pathogen
reduct
chang
activ
statu
singl
donor
platelet
studi
designmethod
receiv
convent
prt
pathogen
reduct
technolog
apheresi
platelet
plasma
region
blood
donor
center
platelet
compon
test
institut
use
thrombolux
system
lightintegra
technolog
inc
vancouv
canada
order
establish
mp
profil
prt
platelet
plasma
thrombolux
vitro
optic
test
util
dynam
light
scatter
character
platelet
compon
quantit
platelet
mp
present
sampl
data
analyz
statist
softwar
resultsfind
test
total
platelet
compon
includ
prt
convent
platelet
threshold
mp
separ
activ
platelet
establish
convent
prt
platelet
compon
plasma
prt
convent
platelet
compon
reveal
activ
platelet
statu
base
mp
content
mp
statist
analysi
mp
content
mp
prt
convent
platelet
compon
show
signific
differ
use
weibul
distribut
mean
mp
content
prt
convent
platelet
level
signific
p
valu
greater
consid
signific
conclus
studi
prt
convent
platelet
compon
plasma
show
similar
platelet
activ
distribut
base
mp
content
mp
prt
convent
platelet
inventori
test
activ
platelet
compon
low
high
activ
mp
content
mp
may
help
manag
platelet
inventori
target
use
prophylact
therapeut
applic
backgroundcas
studi
canada
deferr
men
sex
men
msm
decreas
even
one
time
sinc
deferr
deferr
monitor
donor
complianc
hiv
rate
studi
designmethod
month
octob
februari
randomli
select
male
donat
whole
blood
past
month
invit
particip
anonym
survey
donor
ask
msm
histori
hiv
rate
donat
monitor
januari
march
resultsfind
donor
complet
survey
msm
histori
percentag
donor
msm
histori
last
year
month
chang
p
project
number
elig
msm
donat
increas
criteria
chang
tabl
year
male
donor
msm
histori
last
month
number
hiv
posit
donat
per
year
rang
juli
per
donat
hiv
posit
donat
month
period
per
donat
month
per
donat
hiv
donat
femal
risk
factor
risk
factor
interview
identifi
hiv
posit
donor
motiv
donat
criteria
chang
conclus
rare
progress
reduct
deferr
period
impact
msm
last
month
small
increas
elig
msm
donat
half
current
donor
recent
msm
histori
last
month
hiv
rate
low
unchang
progress
shorter
deferr
period
backgroundcas
studi
june
ban
blood
donat
men
sex
men
msm
sinc
lift
israel
donat
accept
month
pass
sinc
last
sexual
contact
howev
chang
polici
met
dissatisfact
member
local
lgbt
commun
novel
approach
suggest
nation
blood
servic
follow
minor
opinion
member
public
committe
yl
appoint
minist
health
review
israel
blood
donat
polici
new
polici
includ
accept
msm
without
deferr
elig
criteria
keep
sole
plasma
frozen
quarantin
releas
transfus
futur
donat
month
later
found
neg
agent
approv
suggest
frozen
plasma
quarantin
polici
fpqp
examin
attitud
msm
sinc
donor
need
identifi
msm
donor
health
questionnair
dhq
know
plasma
compon
use
transfus
studi
designmethod
anonym
survey
publish
websit
collect
demograph
data
histori
blood
donat
attitud
toward
new
fpqp
resultsfind
respons
elig
msm
analyz
year
old
declar
donat
blood
least
recent
year
therefor
compli
current
month
deferr
polici
dhq
donat
blood
last
year
declar
plan
current
month
deferr
polici
although
sexual
intercours
anoth
man
last
year
rais
rate
blood
donor
among
msm
popul
particip
studi
respond
support
support
suggest
new
fpqp
introduc
would
consid
donat
blood
rais
rate
blood
donor
among
respond
addit
msm
donat
blood
last
year
state
agre
reveal
sexual
orient
dhq
order
includ
program
compar
current
month
deferr
polici
conclus
introduct
new
approach
need
increas
complianc
lgbt
commun
enabl
take
part
life
save
blood
donat
without
compromis
blood
recipi
safeti
suggest
plasma
quarantin
polici
bring
probabl
msm
donat
blood
truli
state
sexual
practic
retest
donor
futur
donat
significantli
increas
blood
safeti
compar
current
practic
accept
suggest
chang
polici
accompani
adequ
educ
campaign
blood
donor
recipi
backgroundcas
studi
retent
whole
blood
donor
ongo
challeng
blood
servic
larg
proport
donor
fail
donat
unfortun
intervent
demonstr
effect
improv
retent
new
donor
australian
red
cross
blood
servic
implement
new
strategi
wherebi
whole
blood
donor
receiv
sm
donat
detail
hospit
geograph
area
blood
dispatch
aim
studi
test
effect
sm
new
whole
blood
donor
analys
subsequ
donat
behaviour
studi
designmethod
new
whole
blood
donor
commenc
blood
donat
follow
month
statist
analys
compar
receiv
sm
follow
measur
return
rate
twelv
month
time
taken
return
result
broken
donor
rebook
time
last
donat
forward
book
resultsfind
overal
new
donor
donat
whole
blood
cohort
mean
age
year
slightli
larger
proport
femal
first
donat
rebook
next
donat
receiv
sm
among
donor
rebook
donor
center
receiv
sm
return
within
month
compar
receiv
sm
p
donor
rebook
donor
center
receiv
sm
return
within
month
compar
receiv
sm
p
independ
forward
book
donor
receiv
sm
return
donat
sooner
mean
day
donor
receiv
sm
mean
day
p
conclus
sm
improv
return
rate
month
even
new
whole
blood
donor
made
forward
appoint
leav
donor
center
research
suggest
sm
inform
donor
blood
sent
valuabl
strategi
bring
back
new
whole
blood
donor
set
backgroundcas
studi
mitig
iron
defici
young
donor
began
measur
ferritin
yo
donor
decemb
donor
low
ferritin
valu
femal
f
ngml
male
ngml
notifi
advis
take
iron
defer
subsequ
red
blood
cell
donat
f
month
month
studi
designmethod
analyz
month
data
pre
post
implement
period
summar
frequenc
allogen
donor
present
hemoglobin
hb
low
ferritin
deferr
gender
fm
donor
experi
first
time
ft
repeat
rd
percentag
donor
present
young
donor
hemoglobin
deferr
pre
post
ferritin
test
calcul
well
summari
statist
hemoglobin
measur
resultsfind
present
period
pre
post
ferritin
test
implement
present
donor
present
donor
made
young
donor
averag
presentationsdonor
decreas
pre
post
periodsther
decrement
proport
present
made
young
donor
pre
post
period
p
mainli
due
decreas
young
rdsof
young
donor
test
overal
rate
low
ferritin
specif
respectivelyhb
deferr
decreas
pre
post
period
decreas
p
mainli
due
decreas
rdsyoung
donor
mean
hb
increas
gdl
sd
pre
gdl
sd
toth
post
period
p
conclus
success
implement
ferritin
test
young
donor
appar
posit
impact
oper
donor
health
data
year
show
signific
decreas
hb
deferr
signific
increas
mean
donor
hb
post
implementationdon
loss
modestther
appreci
level
low
ferritin
ft
donorscontinu
monitor
warrant
assess
sustain
find
year
beyond
backgroundcas
studi
recent
research
confirm
high
preval
iron
deplet
id
high
blood
donor
higher
risk
id
compar
adult
donat
frequenc
aabb
industri
bulletin
recommend
limit
collect
yo
donor
one
unityear
unless
measur
taken
protect
iron
statu
earli
us
blood
center
implement
ferritin
test
red
cell
donor
yo
deferr
record
male
femal
donor
respect
low
ferritin
valu
studi
designmethod
donor
yo
test
ferritin
success
whole
blood
red
cell
apheresi
procedur
preval
absent
iron
store
ai
ferritin
ngml
low
ferritin
lf
ferritin
ngml
femal
ngml
male
estim
yo
donor
oper
databas
provid
demograph
donat
activ
prior
month
modifi
poisson
regress
assess
ai
lf
risk
demograph
donat
factor
resultsfind
donat
yo
donor
test
ferritin
preval
lf
overal
male
femal
vs
ai
overal
male
femal
lf
less
preval
vs
yo
unadjust
analysi
differ
disappear
adjust
regress
analysi
risk
lf
show
expect
gradient
risk
increas
donat
frequenc
shown
higher
risk
femal
risk
ratio
modest
differ
time
sinc
last
donat
see
tabl
ai
regress
model
stratifi
sex
differ
emerg
compar
model
lf
male
femal
risk
ai
statist
distinguish
yo
donor
rr
respect
also
impact
interv
sinc
last
donat
import
predictor
ai
risk
durat
week
follow
donat
control
covari
conclus
preval
lf
ai
yo
donor
vari
age
sex
donat
frequenc
adult
donor
analysi
indic
first
time
higher
ai
risk
yo
male
donor
compar
yo
import
interv
sinc
donat
strong
predictor
ai
lf
suggest
ai
may
relev
indic
physiolog
respons
stress
donat
analysi
longitudin
data
use
assess
impact
ferritin
test
optim
cutoff
donor
manag
appropri
deferr
length
backgroundcas
studi
donor
need
educ
time
make
inform
decis
proceed
declin
whole
blood
donat
goal
pilot
studi
evalu
acquir
knowledg
recent
develop
new
standard
donor
educ
materi
nem
compliant
prior
recommend
aabb
fda
blood
product
advisori
committe
versu
current
educ
materi
cem
donor
histori
questionnair
blood
donor
em
version
use
compar
format
nem
page
grade
comprehens
level
cem
page
grade
comprehens
level
nem
includ
current
educ
topic
iron
replac
found
cem
studi
irb
approv
exempt
protocol
studi
designmethod
two
month
multicent
random
control
pilot
studi
compar
donor
em
among
two
cohort
new
donor
nd
donat
year
return
donor
rd
given
year
three
donor
site
fifteen
volunt
donor
assign
four
group
sixti
donor
per
site
group
nd
nem
group
nd
cem
group
rd
nem
group
rd
cem
particip
complet
previous
valid
blood
donat
quiz
ten
question
use
singl
best
answer
includ
answer
option
nt
know
exampl
need
photo
identif
donat
blood
answer
option
true
fals
nt
know
resultsfind
demograph
quiz
result
shown
tabl
group
show
greater
knowledg
acquisit
use
nem
versu
group
use
cem
group
also
show
greater
reduct
nt
know
respons
incorrect
respons
conclus
donor
em
must
quickli
inform
donor
key
inform
appropri
comprehens
level
test
donor
em
essenti
step
develop
process
ensur
intend
knowledg
acquir
end
user
popul
next
step
expand
data
analysi
pilot
new
donor
em
backgroundcas
studi
identif
individu
antibodi
specif
multipli
alloimmun
patient
complex
rbc
donor
express
multipl
alloantigen
panel
extens
phenotyp
rbc
donor
must
use
antibodi
identif
ideal
substrat
would
rbc
express
one
one
human
alloantigen
hypothes
unlik
modifi
human
rbc
multipl
background
human
gene
product
mous
rbc
would
serv
blank
canva
without
human
rbc
alloantigen
could
engin
express
individu
human
alloantigen
studi
designmethod
transgen
mice
rbc
express
either
k
k
jkb
alloantigen
subject
extend
phenotyp
antibodi
common
human
rbc
alloantigen
transgen
mous
rbc
also
test
plasma
two
human
patient
known
identifi
alloantibodi
human
plasma
incub
mous
rbc
bound
antibodi
elut
test
carbohydr
bind
glycan
array
contain
differ
carbohydr
known
chemistri
resultsfind
mous
rbc
type
neg
rhd
rhc
rhc
rhe
rhe
fya
fyb
k
k
jkb
antigen
reactiv
natur
occur
alloantibodi
mous
rbc
igm
igg
detect
multipl
sampl
human
plasma
eluat
mous
rbc
incub
human
plasma
observ
strong
igg
signal
singl
carbohydr
structur
reactiv
seen
carbohydr
similar
structur
eg
human
antibodi
easili
absorb
use
rbc
result
plasma
free
activ
rbc
test
absorb
plasma
transgen
mous
rbc
k
k
jkb
correctli
identifi
two
separ
patient
specimen
flow
cytometri
test
immunohematolog
lab
conclus
studi
report
novel
approach
isol
individu
human
blood
group
antigen
one
time
mous
rbc
use
rbc
origin
provid
sever
advantag
includ
blank
canva
without
human
alloantigen
rbc
use
exist
immunohematolog
platform
stabl
sourc
rbc
anim
problem
includ
assess
basi
reactiv
mous
rbc
elimin
human
rbc
antibodi
although
absorpt
work
well
identifi
target
elimin
would
prefer
genet
modif
andor
enzymat
treatment
ongo
work
includ
expand
panel
transgen
line
understand
background
reactiv
backgroundcas
studi
globulin
ahg
central
compon
immunohematolog
howev
antibodi
common
antigen
eg
high
titer
low
affin
htla
complic
character
alloantibodi
human
encod
differ
subtyp
igg
htla
tend
isol
fda
licens
monoclon
ahg
clone
reactiv
allow
elimin
htla
signal
character
underli
alloantibodi
howev
recent
report
also
fail
recogn
two
natur
variant
found
ethnic
group
eastern
africa
middl
east
rais
concern
may
miss
clinic
signific
alloantibodi
patient
whose
genom
encod
andor
variant
studi
designmethod
sequenc
analysi
known
human
variant
igg
subtyp
carri
monoclon
antibodi
express
recombinantli
differ
variant
panel
use
target
assess
abil
bind
kk
target
incub
express
variant
follow
analyz
flow
cytometri
addit
mice
immun
human
igg
splenocyt
fuse
myeloma
partner
novel
monoclon
antibodi
clone
character
use
assay
resultsfind
amino
acid
residu
identifi
within
variant
analyz
common
canon
miss
variant
singl
amino
acid
e
posit
also
found
variant
recogn
q
express
variant
mutat
natur
e
posit
q
caus
gain
reactiv
moreov
q
instead
e
posit
amino
acid
differ
nonreact
reactiv
addit
new
monoclon
antibodi
isol
recogn
express
variant
variant
new
monoclon
ahg
map
posit
r
express
variant
q
variant
analyz
conclus
report
find
identifi
epitop
recogn
contain
amino
acid
polymorph
respons
unintend
lack
recognit
well
use
report
new
monoclon
maintain
virtu
remedi
defect
combin
new
monoclon
would
gener
ahg
mixtur
unlik
lose
reactiv
due
yet
undescrib
polymorph
backgroundcas
studi
daratumumab
dara
monoclon
wide
use
treat
multipl
myeloma
monoclon
clinic
trial
treat
variou
hematolog
solid
malign
blood
bank
test
main
focu
express
test
rbc
interfer
rbc
antibodi
screen
also
express
platelet
date
studi
report
interfer
platelet
antibodi
screen
crossmatch
test
purpos
studi
evalu
possibl
interfer
therapi
platelet
antibodi
detect
test
studi
designmethod
serum
sampl
eight
patient
dara
sampl
avail
parallel
test
therefor
sampl
studi
select
male
reduc
confound
result
due
possibl
might
exist
hla
antibodi
patient
femal
none
histori
platelet
transfus
sera
test
use
two
solid
phase
red
cell
adher
test
immucor
captur
p
captur
p
qualit
solid
phase
enzym
link
immunosorb
assay
immucor
pakplu
accord
manufactur
instruct
serum
iat
reactiv
rbc
establish
prior
platelet
test
reactiv
reactiv
use
ortho
resultsfind
test
result
shown
tabl
conclus
similar
dara
therapi
interf
rbc
antibodi
detect
serum
contain
may
complic
detect
antibodi
hla
class
platelet
specif
antibodi
presum
platelet
crossmatch
test
sampl
contain
dara
posit
screen
captur
p
captur
p
react
variabl
pakplu
assay
sera
patient
posit
screen
captur
p
method
neg
pakplu
assay
studi
demonstr
circul
dara
patient
serum
may
react
express
intact
platelet
platelet
membran
caus
fals
posit
platelet
antibodi
screen
crossmatch
depend
test
method
vast
major
captur
p
captur
p
test
gave
posit
result
contrast
pakplu
consist
monoclon
captur
affin
purifi
glycoprotein
gp
molecul
rather
intact
platelet
avoid
interfer
platelet
antibodi
screen
crossmatch
test
need
patient
receiv
therapi
posit
platelet
antibodi
detect
test
patient
interpret
caution
backgroundcas
studi
rh
antibodi
common
despit
serolog
transfus
patient
sickl
cell
diseas
rh
specif
complex
result
absenc
high
preval
rh
antigen
alter
rh
epitop
due
rh
gene
variat
antibodi
identif
complic
lack
reagent
red
cell
express
uncommon
rh
phenotyp
hypothes
human
induc
pluripot
stem
cell
could
reprogram
rare
donor
genet
engin
produc
red
cell
irbc
cultur
reagent
aid
complex
antibodi
identif
aim
gener
irbc
use
blood
bank
assay
studi
designmethod
gener
custom
ipsc
includ
rh
null
cell
cell
lack
high
preval
rh
antigen
hr
hrb
rh
null
line
use
genet
engin
wt
ipsc
line
disrupt
rh
allel
larg
delet
andor
via
frameshift
mutat
result
earli
stop
codon
line
lack
high
preval
rh
antigen
reprogram
group
donor
cell
whose
rh
genotyp
confirm
absenc
hr
hrb
antigen
respect
two
independ
clone
custom
line
character
pluripot
normal
karyotyp
confirm
resultsfind
differenti
custom
ipsc
embryoid
bodi
protocol
combin
hematopoiet
cytokin
harvest
hematopoiet
progenitor
day
cultur
cell
erythroid
specif
cytokin
demonstr
progress
matur
band
high
alpha
integrin
low
irbc
becam
smaller
size
condens
nuclei
rh
express
flow
cytometri
compar
irbc
compar
red
cell
rh
null
irbc
show
complet
absenc
cell
surfac
rh
assess
rbc
agglutin
gel
card
assay
cultur
untarget
rh
null
irbc
use
standard
rh
type
reagent
untarget
irbc
agglutin
expect
reagent
irbc
show
agglutin
common
rh
antibodi
dccee
test
patient
serum
contain
untarget
cultur
e
irbc
agglutin
rh
null
irbc
show
agglutin
similarli
test
patient
serum
contain
hr
irbc
agglutin
irbc
show
agglutin
conclus
custom
ipsc
reprogram
rare
donor
genet
engin
express
rare
blood
group
antigen
phenotyp
antigen
combin
difficult
imposs
find
donor
irbc
produc
custom
ipsc
use
blood
bank
reagent
potenti
standard
antibodi
identif
patient
complex
specif
technolog
avail
rh
null
irbc
could
use
univers
donor
cell
therapeut
applic
backgroundcas
studi
immun
thrombocytopenia
itp
result
autoimmun
platelet
antigen
result
autoantibodi
aab
consid
repres
major
mechan
thrombocytopenia
itp
induc
platelet
clearanc
circul
sever
line
evid
demonstr
aab
glycoprotein
gp
iibiiia
ibix
predomin
itp
patient
diseas
sever
treatment
respons
rate
specif
therapeut
associ
aab
pattern
gp
v
well
character
immun
target
thrombocytopenia
never
studi
systemat
itp
studi
designmethod
patient
suspect
diagnosi
primari
itp
includ
met
clinic
inclus
criteria
presenc
gp
gp
ibix
gp
aab
investig
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
patient
autolog
platelet
direct
maipa
serum
indirect
maipa
serum
igg
fraction
test
surfac
plasmon
reson
spr
technolog
presenc
v
aab
clearanc
human
platelet
circul
presenc
v
aab
studi
nodscid
mous
model
resultsfind
qualifi
patient
three
gp
specif
could
test
aab
detect
patient
v
aab
either
alon
togeth
specif
free
v
aab
detect
patient
indirect
maipa
spr
avid
aab
detect
method
significantli
higher
avid
aab
detect
spr
p
nodscid
mous
model
igg
prepar
type
v
aab
elimin
human
platelet
detect
differ
group
mean
platelet
surviv
min
rang
versu
rang
compar
platelet
clearanc
also
obtain
monoclon
antibodi
gp
v
conclus
v
often
detect
platelet
itp
patient
studi
import
implic
develop
laboratori
test
guidanc
clinic
decis
make
comparison
maipa
spr
reveal
free
aab
may
frequent
report
sinc
aab
appear
escap
detect
standard
laboratori
method
low
affin
v
induc
platelet
clearanc
predict
diseas
sever
andor
tailor
itp
therapi
restrict
previous
postul
differ
iibiiia
ibix
prospect
studi
requir
understand
impact
differ
platelet
aab
clinic
cours
itp
backgroundcas
studi
variant
rhce
allel
encod
weak
partial
antigen
express
result
fals
neg
type
licens
serolog
test
investig
donor
rbc
sampl
variant
c
e
e
antigen
express
found
discrep
beckman
coulter
hea
precisetyp
fulli
rh
genotyp
aim
see
variantparti
antigen
would
detect
crossmatch
test
immun
plasma
contain
correspond
antibodi
specif
studi
designmethod
compat
test
done
liss
peg
iat
gel
appropri
control
immun
test
rbc
alter
rh
antigen
express
alter
c
encod
rhce
ceva
cern
alter
e
encod
rhce
ceew
ceiv
alter
e
encod
rhce
cemo
sampl
tran
antigen
neg
also
variant
resultsfind
alter
c
rhce
ceva
detect
peg
iat
gel
liss
partial
c
rhce
cern
immun
gave
variabl
reaction
peg
gel
liss
result
neg
sampl
alter
e
express
rhce
ceew
encod
e
gave
reaction
peg
gel
w
liss
rhce
ceiv
encod
e
gave
reaction
peg
gel
liss
rhce
variant
encod
e
gave
reaction
peg
reaction
gel
liss
immun
test
peg
liss
detect
gel
gave
reaction
e
encod
rhce
cemo
control
normal
singl
dose
express
antigen
investig
react
test
plasma
give
reaction
equival
stronger
test
sampl
conclus
fda
licens
label
donor
unit
rhce
variant
rhce
ceva
ceew
ce
type
iv
cemo
cern
detect
antigen
posit
donor
unit
label
antigen
neg
iat
crossmatch
must
perform
patient
atyp
antibodi
howev
iat
crossmatch
test
variant
rhce
genotyp
rbc
batteri
immun
gave
variabl
result
miss
use
liss
enhanc
peg
consist
like
detect
reduc
antigen
express
clinic
signific
transfus
weak
partial
rh
antigen
posit
rbc
patient
correspond
antibodi
report
consid
compromis
surviv
transfus
rbc
note
backgroundcas
studi
exposur
citrat
anticoagul
apheresi
blood
donat
induc
signific
decreas
serum
ioniz
calcium
subsequ
perturb
parathyroid
hormon
vitamin
marker
bone
remodel
studi
bone
miner
densiti
bmd
among
apheresi
donor
exhibit
conflict
result
resolv
potenti
impact
highest
apheresi
donat
frequenc
associ
upper
limit
citrat
burden
repres
signific
knowledg
gap
ensur
adequ
protect
volunt
apheresi
blood
donor
studi
designmethod
altruyst
random
longitudin
control
clinic
trial
design
determin
repeat
exposur
citrat
apheresi
donat
reduc
bmd
male
donor
year
age
five
previou
apheresi
donat
diseas
bone
miner
metabol
agre
make
apheresi
donat
subsequ
one
year
period
absorptiometri
perform
baselin
random
high
frequenc
apheresi
apheresi
arm
one
year
particip
pair
use
assess
chang
mean
bmd
resultsfind
donor
apheresi
arm
made
median
apheresi
donat
rang
donat
studi
period
mean
donat
interv
day
control
made
zero
apheresi
donat
median
two
whole
blood
donat
rang
mean
lumbar
spine
bmd
end
studi
period
differ
begin
among
donor
control
arm
mean
ci
chang
among
donor
apheresi
arm
mean
ci
chang
mean
bmd
total
hip
statist
signific
control
donor
mean
ci
apheresi
donor
ci
test
differ
proport
donor
chang
bmd
exceed
least
signific
chang
lsc
lumbar
spine
apheresi
control
arm
either
posit
apheresi
control
neg
direct
apheresi
control
statist
proport
increas
apheresi
control
decreas
apheresi
control
also
significantli
differ
total
hip
conclus
present
prospect
longitudin
random
control
trial
evalu
role
high
frequenc
apheresi
blood
donat
chang
bmd
report
signific
alter
bmd
lumbar
spine
total
hip
backgroundcas
studi
antibodi
pose
risk
acut
hemolyt
transfus
reaction
recipi
correspond
antigen
debat
continu
titer
b
antibodi
class
igm
igg
test
ensur
optim
safeti
us
militari
use
singl
titer
cutoff
igm
b
safe
recipi
resurg
whole
blood
use
civilian
trauma
import
determin
preval
antibodi
current
donor
popul
studi
designmethod
rh
posit
male
fix
site
donor
histori
donat
select
test
studi
mitig
transfus
relat
acut
lung
injuri
allow
robust
commit
donor
pool
igm
igm
antibodi
determin
use
singl
titer
plasma
ethylenediaminetetraacet
acid
edta
sampl
test
use
salin
diluent
dilut
plasma
mix
commerci
avail
b
cell
incub
room
temperatur
minut
centrifug
second
rpm
read
agglutin
reactiv
either
constitut
posit
donor
age
retriev
blood
establish
comput
system
resultsfind
male
rh
posit
donor
test
test
posit
either
b
test
neg
donor
age
rang
year
tabl
show
data
stratifi
donor
age
use
fisher
exact
preval
igm
antibodi
statist
lower
male
age
conclus
popul
male
rh
posit
donor
andor
igm
titer
level
greater
preval
antibodi
declin
age
reach
statist
signific
male
data
use
plan
collect
whole
blood
unit
maxim
likelihood
collect
unit
low
igm
antibodi
backgroundcas
studi
biolog
practic
justif
treat
massiv
bleed
patient
low
titer
group
ltowb
studi
conduct
establish
valid
new
protocol
titer
b
group
donor
use
autom
blood
group
type
equip
creat
ltowb
donor
databas
studi
designmethod
critic
titer
b
ltowb
unit
chosen
equival
determin
manual
salin
tube
method
minut
room
temperatur
incub
refer
method
find
titer
autom
instrument
usa
equip
program
dilut
test
plasma
donor
sampl
sampl
dilut
use
titrat
protocol
plasma
sampl
automat
dilut
incub
hour
produc
reagent
donor
red
blood
cell
rbc
assay
agglutin
sampl
show
neg
result
dilut
test
rbc
minut
room
temperatur
incub
manual
inspect
agglutin
result
use
determin
dilut
perform
close
correl
agglutin
produc
refer
manual
dilut
agglutin
rbc
addit
sampl
dilut
compar
commerci
b
cell
immucor
usa
one
hundr
sampl
also
test
blend
commerci
b
cell
compar
refer
method
resultsfind
plasma
dilut
found
compar
dilut
perform
refer
salin
tube
method
sampl
dilut
test
refer
salin
tube
method
dilut
demonstr
agglutin
rbc
therefor
consid
ltowb
donor
plasma
sampl
low
titer
donor
test
rbc
agglutin
incub
commerci
mix
b
cell
moreov
low
titer
sampl
gave
fals
neg
result
test
refer
method
conclus
plasma
dilut
group
donor
test
incub
use
effect
safe
identifi
ltowb
donor
produc
rbc
seem
sensit
commerci
mix
b
cell
permit
use
situat
commerci
reagent
may
avail
use
autom
blood
type
method
enabl
medium
larg
size
blood
establish
perform
titrat
part
routin
blood
type
establish
ltowb
donor
data
base
help
maintain
consist
inventori
suppli
ltowb
unit
use
militari
civilian
well
set
backgroundcas
studi
polycythemia
increas
red
blood
cell
mass
common
side
effect
testosteron
replac
therapi
trt
typic
treat
via
frequent
blood
donat
fda
grant
blood
bank
varianc
allow
collect
distribut
rbc
trt
donor
without
special
label
donat
trt
recipi
frequent
everi
eight
week
howev
establish
safeti
guidelin
whenhow
often
therapeut
phlebotomi
occur
present
studi
aim
describ
male
donor
popul
first
step
examin
safeti
frequent
phlebotomi
men
receiv
hormon
replac
therapi
studi
designmethod
adult
male
year
donat
blood
identifi
blood
bank
databas
classifi
trt
donor
polycythemia
defin
hemoglobin
gdl
chi
squar
fisher
exact
test
mann
whitney
u
test
use
compar
subgroup
resultsfind
studi
period
donat
attempt
made
trt
donor
trt
donor
yield
unit
rbc
major
trt
donor
receiv
therapi
via
inject
remaind
use
unspecifi
method
last
receiv
trt
less
week
prior
donat
result
significantli
higher
hr
hgb
donat
frequenc
p
compar
trt
donor
last
receiv
therapi
greater
week
prior
donat
conclus
therapeut
phlebotomi
trt
donor
becom
signific
sourc
transfus
red
blood
cell
also
offer
potenti
benefit
donor
futur
studi
necessari
examin
iron
store
trt
donor
well
dose
rout
administr
order
better
understand
ratio
frequent
blood
donat
context
testosteron
therapi
backgroundcas
studi
blood
center
previous
use
standard
blood
shaker
whole
blood
collect
toward
end
center
switch
whole
blood
shaker
allow
variabl
collect
volum
base
nadler
formula
height
weight
gender
fix
site
locat
chang
implement
effort
decreas
vasovag
reaction
studi
designmethod
whole
blood
donor
vasovag
reaction
data
obtain
blood
establish
comput
system
elimin
season
variat
donor
reaction
data
decemb
april
collect
standard
blood
shaker
data
decemb
april
collect
new
blood
shaker
vasovag
donor
reaction
stratifi
mild
loss
conscious
moder
loss
conscious
less
minut
sever
loss
conscious
minut
longer
without
injuri
data
hematoma
infiltr
includ
studi
two
sampl
two
tail
use
statist
compar
group
resultsfind
decemb
fix
site
vasovag
reaction
compris
whole
blood
collect
use
standard
blood
shaker
decemb
april
fix
site
vasovag
reaction
compris
whole
blood
collect
use
variabl
collect
volum
blood
shaker
tabl
stratifi
data
donor
weight
mild
moder
sever
categori
vasovag
reaction
data
show
trend
toward
lower
categori
vasovag
reaction
donor
weight
group
decreas
reach
statist
signific
mild
categori
weight
group
conclus
implement
blood
shaker
use
nadler
formula
collect
variabl
blood
volum
decreas
mild
moder
sever
reaction
blood
center
fix
site
locat
decreas
reach
statist
signific
mild
categori
across
donor
weight
group
enhanc
blood
shaker
implement
mobil
blood
drive
decreas
vasovag
reaction
backgroundcas
studi
use
fresh
whole
blood
fwb
resuscit
shown
decreas
mortal
morbid
combat
wound
blood
type
donor
low
isohemagglutinin
titer
level
consid
univers
whole
blood
donor
due
decreas
likelihood
hemolyt
reaction
transfus
patient
screen
potenti
donor
deploy
auster
condit
assist
mitig
risk
identif
blood
type
transfus
transmit
diseas
ttd
well
evalu
isohemagglutinin
titer
us
armi
special
oper
forc
sof
recurr
rotat
auster
environ
sof
personnel
may
screen
sever
time
sever
year
isohemagglutinin
titer
repeat
candid
ltowb
donat
evalu
studi
designmethod
known
group
donor
igm
titer
level
determin
salin
tube
method
use
serial
dilut
donor
plasma
test
b
reagent
cell
asbp
design
low
titer
group
donor
isohemagglutinin
titer
sof
team
donor
enter
dod
oper
blood
system
record
result
one
sof
oper
unit
special
forc
group
evalu
repeat
screen
group
donor
repeat
screen
identifi
chang
isohemagglutinin
titer
low
high
assess
resultsfind
special
forc
group
fort
carson
co
soldier
screen
may
august
soldier
screen
posit
po
neg
neg
repeat
assess
group
soldier
document
group
soldier
soldier
observ
chang
high
low
titer
soldier
titer
chang
low
high
titer
titer
chang
rang
fold
fold
dilut
chang
observ
sampl
conclus
screen
group
walk
blood
bank
wbb
donor
inform
sof
medic
team
decis
regard
donor
elig
provid
ltowb
auster
environ
limit
data
present
indic
low
frequenc
titer
chang
donor
screen
two
separ
occas
donor
titer
chang
chang
often
result
donor
statu
switch
low
titer
elig
ltowb
donat
research
indic
determin
signific
reproduc
result
conclus
backgroundcas
studi
platelet
transfus
cornerston
therapi
patient
develop
thrombocytopenia
undergo
hematopoiet
stem
cell
transplant
hsct
mani
patient
demonstr
alloantibodi
mediat
platelet
transfus
refractori
ptr
requir
platelet
calcul
panel
reactiv
antibodi
cpra
use
tool
identifi
patient
risk
ptr
requir
manual
intervent
calcul
calcul
request
howev
routin
use
cpra
everi
hsct
use
exist
alloantibodi
result
could
identifi
ptr
earlier
effici
manag
complex
transfus
need
improv
patient
care
accomplish
goal
creat
electron
medic
record
emr
web
app
use
clinician
blood
bankdonor
center
tissu
type
lab
better
identifi
manag
ptr
patient
studi
designmethod
onlin
cpra
creat
electron
receiv
alloantibodi
data
return
cpra
valu
sever
differ
ethnic
addit
increas
flexibl
cpra
calcul
custom
user
defin
antigen
frequenc
epitop
util
cpra
ptr
web
app
creat
connect
sever
clinic
data
sourc
includ
tissu
type
lab
blood
bank
donor
center
emr
ptr
web
app
embed
emr
could
easili
view
care
patient
undergo
hsct
platelet
util
transfus
effect
compar
implement
resultsfind
cpra
allow
autom
comput
gener
cpra
make
feasibl
calcul
cpra
everi
hsct
patient
web
app
display
platelet
count
along
platelet
transfus
event
platelet
unit
inventori
section
clinic
care
team
lab
staff
commun
plan
make
cpra
publicli
avail
other
use
custom
conclus
built
customiz
cpra
platelet
transfus
visual
web
app
provid
better
access
real
time
cpra
valu
enabl
ptr
risk
stratif
hsct
patient
web
app
also
summar
key
clinic
data
effici
manag
prt
improv
platelet
usag
backgroundcas
studi
fda
propos
method
mitig
bacteri
contamin
risk
platelet
pc
impact
method
pc
avail
cost
must
evalu
herein
assess
financi
impact
hospit
associ
purchas
pc
undergon
either
bacteri
detect
cultur
bd
point
issu
poi
test
delay
larg
volum
cultur
per
split
unit
dlvc
bd
without
secondari
cultur
pathogen
reduct
pr
studi
designmethod
model
built
assess
product
econom
impact
bacteri
safeti
method
hospit
incorpor
revenu
assumpt
medicar
outpati
privat
insur
blood
center
sell
price
bd
pr
pc
dlvc
bd
ad
applic
scenario
determin
cost
addit
upcharg
irradi
appli
base
hospit
order
practic
secondari
bd
poi
test
cost
ad
proport
pc
reach
trigger
day
shelf
life
cost
consid
model
discuss
includ
transfus
associ
sepsi
ongo
train
pc
method
assess
resultsfind
see
tabl
conclus
model
predict
net
cost
delta
per
dose
compar
least
expens
method
dlvc
day
bd
day
hospit
would
recov
sa
rang
pc
acquisit
cost
via
insur
reimburs
cost
associ
sepsi
must
extrapol
well
save
due
addit
safeti
provid
pr
mitig
virus
parasit
backgroundcas
studi
bacteri
contamin
platelet
remain
lead
infecti
risk
blood
transfus
secondari
bacteri
cultur
sbc
propos
potenti
approach
could
implement
blood
center
transfus
servic
howev
date
comprehens
econom
evalu
compar
sbc
altern
risk
reduct
method
studi
designmethod
construct
compar
cost
three
bacteri
risk
control
strategi
pathogen
reduct
pr
test
port
sbc
mont
carlo
simul
assess
direct
medic
cost
platelet
acquisit
test
transfus
possibl
complic
input
paramet
includ
sensit
specif
approach
drawn
exist
literatur
cost
express
us
model
assum
leukoreduc
apheresi
platelet
provid
hospit
day
follow
collect
base
case
analysi
expir
would
occur
end
day
pr
sbc
day
port
pr
port
strategi
model
avail
technolog
sensit
analys
conduct
evalu
impact
variat
input
paramet
project
estim
resultsfind
project
total
cost
implement
pr
port
sbc
per
unit
respect
compar
pr
sbc
associ
signific
differ
bacteri
contamin
unit
transfus
unit
dispos
due
expir
would
lead
signific
increas
unit
dispos
due
posit
test
result
compar
port
sbc
associ
increas
unit
dispos
due
expir
decreas
contamin
unit
transfus
probabilist
sensit
analys
vari
input
paramet
simultan
yield
substanti
differ
estim
conclus
sbc
present
potenti
approach
mitig
risk
bacteri
contamin
platelet
transfus
compar
current
avail
altern
sbc
expect
result
fewer
contamin
unit
transfus
port
lead
reduc
cost
associ
complic
approv
sbc
day
storag
would
increas
cost
save
backgroundcas
studi
object
studi
report
genotyp
drug
resist
pattern
accord
stage
hiv
infect
time
donat
assess
hiv
subtyp
drug
resist
mutat
drm
associ
characterist
donor
studi
designmethod
four
larg
blood
collect
organ
provid
plasma
sampl
confirm
whole
blood
donat
base
routin
nucleic
acid
test
nat
serolog
screen
hiv
rna
serolog
sampl
test
use
sedia
bioscienc
lag
avid
assay
differenti
recent
infect
viral
load
quantit
use
holog
aptima
assay
nest
pcr
use
amplifi
segment
hiv
rna
pol
gene
includ
proteas
pr
revers
transcriptas
rt
region
follow
label
pool
amplicon
sequenc
ng
deconstruct
hiv
sequenc
ng
read
sequenc
analyz
determin
phylogenet
cladesubtyp
use
lo
alamo
nation
laboratori
sequenc
databas
b
drm
use
stanford
hiv
drug
resist
databas
standard
statist
test
use
compar
group
consid
evid
statist
signific
resultsfind
sampl
amplifi
genotyp
hiv
group
hiv
nat
yield
seroneg
hiv
concord
posit
concord
sampl
classifi
infect
common
subtyp
b
tabl
singl
subtyp
c
two
circul
recombin
form
crf
identifi
sampl
low
viral
load
twenti
evid
drm
pr
mutat
rt
mutat
rt
mutat
nucleosid
rt
inhibitor
rt
inhibitor
common
mutat
three
donor
infect
rt
mutat
younger
age
associ
recent
infect
demograph
donat
factor
associ
genotyp
drm
conclus
donor
select
subset
gener
popul
compar
publish
data
shown
hiv
infect
donor
defer
donat
appear
repres
hiv
infect
us
backgroundcas
studi
number
blood
program
recogn
opportun
blood
donat
provid
identifi
ostens
healthi
individu
might
unawar
risk
health
program
includ
along
mandat
serolog
test
assay
total
cholesterol
tc
hemoglobin
also
taken
step
notifi
individu
whose
result
suggest
risk
cardiovascular
diseas
diabet
sinc
program
long
histori
provid
donor
inform
tc
decid
find
individu
elev
tc
met
criteria
famili
hypercholesterolemia
fh
fh
preval
gener
popul
common
frequent
underdiagnos
genet
diseas
diseas
mark
sever
elev
cholesterol
evid
coronari
arteri
diseas
earli
age
untreat
earli
death
due
myocardi
infarct
screen
recommend
nation
lipid
associ
expert
panel
fh
studi
designmethod
review
unlink
total
cholesterol
result
volunt
donat
cholesterol
measur
chemistri
analyz
system
beckman
coulter
residu
blood
routin
test
infecti
diseas
marker
volunt
donat
includ
highest
tc
record
tc
classifi
american
heart
associ
aha
goal
metric
elev
mgmdl
mmoll
donor
year
age
mmoll
donor
year
age
appli
unit
state
center
diseas
control
cooper
medp
diagnost
criteria
fh
use
criteria
fh
diagnos
tc
exce
mgmdl
mmoll
individu
less
mgmdl
mmoll
individu
mggdl
mmoll
individu
mgmdl
mmoll
individu
year
age
older
resultsfind
uniqu
donor
studi
period
overal
preval
elev
cholesterol
preval
fh
equival
similar
publish
data
gener
popul
shown
tabl
preval
fh
highest
year
old
decreas
older
donor
preval
elev
tc
increas
age
conclus
subset
donor
age
elev
total
cholesterol
identifi
satisfi
famili
hypercholesterolemia
criteria
subset
might
benefit
along
close
famili
member
histori
examin
addit
test
backgroundcas
studi
platelet
current
investig
transfus
activ
bleed
patient
three
day
storag
limit
fda
varianc
sever
limit
platelet
avail
clinic
applic
far
forward
militari
scenario
effect
platelet
apoptosi
investig
thu
far
sought
test
apoptot
paramet
vitro
function
correl
vivo
recoveri
circulatori
lifespan
studi
designmethod
seventeen
healthi
human
subject
underw
apheresi
platelet
collect
platelet
csp
test
unit
store
either
day
plasma
platelet
sampl
vitro
platelet
test
extract
day
donat
design
storag
period
storag
unit
radiolabel
transfus
respect
donor
donor
came
back
week
provid
fresh
sampl
radiolabel
reinfus
resultsfind
storag
time
platelet
recoveri
declin
significantli
compar
fresh
p
day
day
platelet
surviv
decreas
significantli
fresh
day
day
day
p
intrins
apoptot
event
measur
mitochondri
membran
integr
decreas
storag
time
similarli
apoptosi
measur
activ
effector
caspas
increas
fresh
day
phosphatidyl
serin
exposur
measur
annexin
v
bind
increas
significantli
day
day
marker
platelet
activ
specif
microparticl
increas
significantli
day
respect
note
platelet
respons
collagen
stimul
reveal
function
signal
integrin
activ
compar
differ
fresh
platelet
day
storag
best
predictor
day
platelet
recoveri
surviv
integrin
activ
respect
conclus
perform
first
studi
extend
storag
cold
apheresi
platelet
day
fresh
compar
show
continu
loss
recoveri
day
storag
overal
continu
platelet
activ
hallmark
platelet
marker
caspas
activ
mitochondri
membran
integr
show
delay
apoptosi
platelet
function
test
show
preserv
integrin
activ
compar
fresh
day
storag
best
predictor
day
platelet
recoveri
surviv
integrin
activ
taken
togeth
storag
day
cold
appear
yield
accept
vitro
vivo
result
backgroundcas
studi
alloimmun
follow
platelet
transfus
lead
reject
subsequ
transfus
transplant
recipi
cell
key
mediat
alloimmun
respons
recogn
allogen
mhc
via
either
direct
bind
donor
cell
indirectli
donor
antigen
present
recipi
antigen
present
cell
prior
work
shown
pathogen
reduct
riboflavin
uv
light
uvr
allogen
platelet
rich
plasma
prp
prevent
alloimmun
mice
provid
partial
toler
subsequ
transfus
vitro
work
demonstr
mechan
uvr
treatment
prevent
alloimmun
associ
donor
cell
surfac
adhes
molecul
prevent
direct
recognit
allogen
cell
howev
role
cell
may
complex
vivo
involv
either
indirect
recognit
weak
direct
signal
better
understand
uvr
treatment
regul
alloimun
studi
provid
comprehens
evalu
cell
respons
allogen
prp
transfus
mice
studi
designmethod
white
blood
cell
wbc
prp
isol
donor
balbc
mice
left
untreat
treat
uvr
transfus
mice
evalu
impact
secondari
exposur
given
second
transfus
untreat
prp
two
week
later
cell
respons
measur
spleen
blood
recipi
mice
time
flow
cytometri
cell
activ
delet
anergi
examin
resultsfind
expect
signific
upregul
activ
marker
cell
blood
spleen
follow
transfus
untreat
allogen
prp
includ
ico
peak
day
p
contrast
mice
receiv
singl
uvr
transfus
show
cell
respons
blood
spleen
although
small
signific
enrich
ico
cell
observ
blood
seventh
day
challeng
p
mice
given
uvr
prp
follow
untreat
prp
display
earli
weaker
transient
respons
peak
around
day
p
evid
delet
anergi
observ
cell
compart
conclus
allogen
cell
respons
significantli
diminish
pathogen
reduct
uvr
treatment
howev
cell
allorecognit
vivo
complet
absent
small
signific
induct
activ
cell
observ
blood
failur
cell
allorespons
uvr
treatment
like
due
cell
delet
anergi
possibl
associ
activ
cell
toler
immun
avoid
backgroundcas
studi
antibodi
gener
red
blood
cell
rbc
antigen
respons
transfus
major
caus
morbid
mortal
chronic
transfus
patient
despit
clinic
signific
molecular
mechan
regul
immun
respons
transfus
rbc
remain
poorli
understood
previou
work
lab
arneja
et
al
demonstr
defici
mice
mount
significantli
lower
antibodi
respons
rbc
antigen
howev
alloantibodi
product
still
occur
absenc
suggest
altern
pathway
capabl
drive
rbc
alloimmun
sinc
observ
increas
skew
cytokin
respons
transfus
defici
mice
hypothes
key
cytokin
downstream
transcript
factor
also
drive
rbc
alloimmun
studi
designmethod
use
previous
establish
rbc
alloimmun
mous
model
contain
fusion
protein
hen
egg
lysozym
hel
ovalbumin
human
duffi
antigen
hod
rbc
model
rbc
alloimmun
wild
type
defici
defici
mice
transfus
store
hod
blood
sera
collect
mice
variou
time
point
week
post
transfus
total
igg
titer
measur
use
elisa
resultsfind
wild
type
mice
elicit
robust
igg
respons
hel
respons
defici
mice
lower
week
post
transfus
similarli
antibodi
respons
defici
mice
lower
week
post
transfus
interestingli
week
post
transfus
igg
titer
defici
mice
lower
p
compar
wild
type
demonstr
also
play
role
antibodi
evanesc
statist
done
use
student
test
use
correct
conclus
first
data
suggest
role
rbc
alloimmun
ongo
studi
lab
focus
uncov
specif
cell
type
activ
respons
transfus
rbc
pathway
interact
pathway
control
rbc
alloimmun
backgroundcas
studi
polyunsatur
fatti
acid
pufa
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
import
membran
fluiditi
cellular
signal
dietari
supplement
epa
dha
associ
improv
red
blood
cell
rbc
deform
hydrat
membran
fluiditi
along
reduc
irrevers
sickl
pain
episod
patient
sickl
cell
diseas
howev
pufa
complet
benign
highli
suscept
peroxid
oxid
environ
potenti
damag
rbc
structur
age
cold
storag
therefor
import
evalu
whether
diet
enrich
pufa
affect
rbc
lifespan
recoveri
ptr
studi
designmethod
mice
strain
known
good
poor
fvb
refriger
rbc
storag
fed
diet
enrich
safflow
fish
oil
micegroup
week
rbc
biotinyl
vivo
lifespan
measur
track
biotinyl
rbc
day
leukoreduc
blood
also
prepar
rbc
deform
lorca
microsphiltr
ptr
evalu
day
refriger
storag
metabolom
studi
fresh
store
blood
perform
resultsfind
rbc
lifespan
fvb
mice
safflow
diet
significantli
greater
strain
fish
oil
diet
fvb
p
safflow
oil
diet
baselin
rbc
deform
significantli
higher
compar
fvb
mice
furthermor
rbc
deform
significantli
decreas
strain
fish
oil
diet
rbc
transfus
storag
ptr
significantli
lower
fish
oil
group
strain
fvb
p
p
respect
also
strong
correl
ptr
deform
lorca
microsphiltr
metabolom
studi
plasma
rbc
reveal
markedli
lower
level
free
esterifi
carnitin
fish
oil
group
storag
conclus
data
suggest
diet
contain
high
level
dha
epa
fish
oil
kcal
associ
decreas
membran
deform
vivo
lifespan
ptr
cold
storag
carnitin
modul
rbc
fluiditi
due
role
phospholipid
repair
stabil
complex
sodiumpotassium
atpas
activ
strong
correl
decreas
carnitin
level
deform
rbc
lifespan
ptr
suggest
potenti
mechan
underli
effect
identifi
possibl
intervent
improv
rbc
qualiti
backgroundcas
studi
understand
megakaryocyt
mk
biolog
critic
understand
treat
diseas
affect
platelet
product
function
howev
procur
adequ
number
rare
myeloid
popul
remain
vitro
studi
reli
mk
differenti
hematopoiet
stem
cell
hsc
remain
lack
consensu
optim
method
present
optim
protocol
gener
matur
mk
peripher
blood
pb
cell
increas
platelet
product
studi
designmethod
assess
featur
function
mk
differenti
cultur
system
use
set
gold
standard
metric
includ
morphologyultrastructur
bright
field
electron
microscopi
em
cell
surfac
marker
express
ploidi
cell
size
flow
cytometri
cytoskelet
organ
granul
content
confoc
microscopi
protein
content
luminex
assay
also
quantifi
releas
static
cultur
bioreactor
set
character
result
platelet
rest
upon
activ
resultsfind
consist
megakaryopoiesi
decreas
cell
increas
cours
differenti
size
ploidi
differenti
cell
consist
valu
mk
cord
mk
mk
contain
cytoskelet
element
characterist
matur
mk
well
marker
vwf
dens
granul
thrombospondin
serotonin
differenti
cell
express
growth
factor
includ
egf
vegf
pdgf
level
similar
found
human
platelet
lysat
addit
differenti
mk
produc
proplatelet
function
platelet
day
static
cultur
increas
platelet
produc
use
novel
bioreactor
conclus
differenti
protocol
rapidli
consist
gener
matur
mk
pb
hsc
despit
resembl
cord
blood
mk
size
ploidi
cell
produc
larger
number
proplatelet
previous
report
earli
day
differenti
addit
differenti
mk
suitabl
seed
novel
bioreactor
gener
larg
number
platelet
basic
translat
studi
backgroundcas
studi
pathomechan
complic
due
blood
transfus
fulli
understood
elev
level
heme
deriv
store
rbc
thought
associ
transfus
reaction
especi
inflammatori
respons
recent
proinflammatori
effect
heme
wide
studi
howev
still
unknown
whether
heme
influenc
resolut
inflamm
key
step
inflammatori
respons
result
aggrav
inflamm
studi
designmethod
murin
model
periton
initi
zymosan
use
effect
hemin
resolut
assess
resolut
indic
western
blot
flow
cytometri
chemotaxi
assay
immunosorb
assay
luciferas
report
assay
lentiviru
infect
use
investig
possibl
mediat
mechan
neutrophil
differenti
cell
resultsfind
administr
hemin
significantli
increas
leukocyt
infiltr
entir
time
cours
h
enhanc
express
periton
lavag
murin
serum
prolong
resolut
interv
h
mous
periton
vitro
hemin
significantli
downregul
formyl
peptid
receptor
protein
level
p
key
resolut
receptor
lead
suppress
proresolut
respons
trigger
proresolut
ligand
resolvin
subsequ
four
predict
mirna
like
bind
identifi
two
predict
databas
among
significantli
upregul
hemin
p
inhibit
attenu
inhibitori
effect
hemin
protein
express
p
luciferas
report
assay
confirm
directli
bound
overexpress
significantli
downregul
protein
level
wherea
inhibit
led
signific
increas
p
conclus
result
suggest
hemin
prolong
resolut
inflamm
action
associ
downregul
mediat
find
demonstr
novel
mechan
hemin
deriv
store
rbc
inflammatori
respons
backgroundcas
studi
minim
amount
fibrinogen
present
cold
storag
platelet
plt
use
plt
addit
solut
pa
shown
decreas
activ
presum
increas
plt
shelf
life
one
pa
terumo
bct
lakewood
co
yet
evalu
us
fda
result
conduct
random
pair
studi
assess
vitro
qualiti
plt
store
cold
plasma
without
agit
day
evalu
current
standard
care
bleed
patient
ie
plt
store
plasma
either
room
temperatur
rt
day
cold
day
studi
designmethod
singl
unit
apheresi
platelet
ap
collect
donor
dilut
plasma
prior
cold
storag
ap
also
collect
donor
split
bag
serv
control
ctl
bag
one
bag
bag
sampl
day
collect
day
bag
sampl
day
respect
sampl
assess
day
assay
includ
plt
metabol
b
plt
count
c
aggreg
respons
clot
strength
rotem
e
extent
shape
chang
hypoton
shock
respons
f
activ
plt
microparticl
data
report
analyz
use
repeat
measur
anova
tukey
test
student
pairwis
comparison
resultsfind
day
storag
ph
signific
drop
glucos
level
concomit
rise
lactat
observ
b
plt
count
compar
day
day
day
c
aggreg
respons
compar
day
clot
strength
significantli
lower
day
day
fibrinolysi
observ
contrast
day
e
extent
shape
chang
hypoton
shock
respons
significantli
lower
sampl
day
compar
day
f
activ
significantli
increas
glycoprotein
express
preserv
mitochondri
depolar
exhibit
microparticl
express
similar
day
conclus
refriger
plt
store
day
met
ph
requir
fda
approv
suggest
safeti
method
storag
function
activ
metric
also
demonstr
viabil
store
plt
futur
work
need
valid
find
vivo
extend
shelf
life
plt
time
current
standard
care
would
invalu
asset
improv
trauma
care
battlefield
backgroundcas
studi
sodium
citrat
becom
prefer
anticoagul
use
apheresi
collect
platform
includ
platelet
addit
solut
sinc
suggest
sodium
citrat
includ
pa
prevent
spontan
aggreg
research
cancer
cell
line
demonstr
concentr
sodium
citrat
present
current
pa
formul
caus
apoptosi
light
data
evalu
whether
remov
sodium
citrat
could
posit
impact
platelet
storag
studi
designmethod
hyper
concentr
apheresi
platelet
unit
collect
amicu
normal
consent
donor
without
sodium
citrat
ad
ml
hyper
concentr
platelet
achiev
plateletplasma
pa
ratio
rest
unit
split
polyolefin
bag
seal
half
ad
bag
increas
concentr
sodium
citrat
ad
obtain
final
concentr
platelet
qualiti
function
assess
day
platelet
count
ph
glucos
lactat
blood
gase
measur
quantit
surfac
marker
evalu
flow
cytometri
includ
annexin
v
bind
reactiv
oxygen
speci
measur
use
platelet
function
assess
aggregometri
collagen
resultsfind
platelet
count
ph
accept
compar
throughout
day
storag
regardless
condit
platelet
store
day
without
sodium
citrat
cit
significantli
increas
glucos
level
cit
mm
cit
mm
significantli
decreas
lactat
level
cit
mm
cit
mm
ro
level
cit
mm
cit
mm
annexin
v
posit
cit
cit
express
cit
cit
compar
store
citrat
trend
toward
better
preserv
gpib
surfac
platelet
store
without
sodium
citrat
platelet
store
without
citrat
also
show
trend
toward
greater
extent
aggreg
compar
contain
citrat
collagen
aggreg
cit
cit
trap
aggreg
cit
cit
conclus
remov
sodium
citrat
result
spontan
platelet
aggreg
clot
could
lead
decreas
platelet
count
day
storag
absenc
sodium
citrat
improv
nearli
measur
paramet
demonstr
sodium
citrat
contribut
platelet
storag
lesion
remov
result
improv
cell
qualiti
function
backgroundcas
studi
alloimmun
common
follow
transfus
platelet
rich
plasma
prp
caus
complic
platelet
refractori
transplant
reject
previous
shown
pathogen
reduct
prp
riboflavin
uv
light
uvr
protect
alloimmun
mice
induc
partial
toler
subsequ
transfus
studi
evalu
rel
contribut
major
histocompat
antigen
mhc
minor
antigen
allorespons
prp
transfus
toler
induc
uvr
treatment
studi
designmethod
mice
transfus
prp
syngen
balbc
allogen
mhc
minor
antigen
allogen
mhc
uvr
uvr
follow
untreat
week
later
balbc
mice
transfus
prp
allogen
mhc
minor
antigen
allogen
minor
antigen
uvr
uvr
follow
untreat
week
later
two
week
final
transfus
blood
screen
antibodi
differ
donor
type
cell
splenocyt
challeng
ex
vivo
differ
donor
type
cell
cultur
cytokin
measur
evalu
prime
vivo
group
compar
use
anova
tukey
resultsfind
total
mhc
specif
antibodi
respons
highest
mhc
minor
antigen
mismatch
lower
antibodi
respons
observ
mhc
mismatch
alon
p
weak
signific
p
alloantibodi
respons
minor
antigen
uvr
treatment
protect
major
minor
antigen
alloimmun
allogen
mhc
minor
antigen
prime
enhanc
cytokin
respons
ex
vivo
though
weaker
minor
antigen
respons
block
uvr
treatment
reduc
cytokin
respons
observ
mice
given
uvr
treat
prp
follow
untreat
prp
allogen
mhc
balbc
mice
given
uvr
treat
prp
follow
untreat
prp
allogen
minor
antigen
conclus
allogen
mhc
suffici
drive
alloantibodi
product
model
respons
bulk
alloantibodi
respons
minor
alloantigen
induc
small
antibodi
respons
also
enhanc
respons
minor
alloantigen
induc
weak
cytokin
respons
allogen
mhc
necessari
suffici
induc
toler
use
pathogen
reduct
technolog
backgroundcas
studi
complic
transfus
red
blood
cell
rbc
alloimmun
despit
univers
alloantibodi
patient
transfus
complic
still
rel
common
occurr
delay
hemolyt
transfus
reaction
remain
third
lead
caus
fatal
usa
major
caus
morbid
mortal
remark
high
rate
evanesc
patient
alloantibodi
drop
level
detect
within
year
initi
product
molecular
cellular
control
high
rate
evanesc
complet
unknown
herein
studi
alloantibodi
evanesc
experiment
tractabl
mous
model
alloimmun
contrast
antibodi
respons
transfus
rbc
gener
respons
standard
vaccin
studi
designmethod
wild
type
mice
transfus
store
mous
rbc
express
hod
hen
egg
lysozym
ovalbumin
human
duffyb
antigen
vaccin
precipit
aluminum
hydroxid
total
igg
measur
sera
collect
week
elisa
presenc
plasma
cell
slpc
llpc
examin
elispot
day
week
immun
germin
center
gc
differenti
assess
percentag
gc
b
follicular
helper
tfh
cell
examin
flow
cytometri
day
immun
resultsfind
antibodi
evanesc
transfus
mice
compar
vaccin
alloantibodi
decreas
week
transfus
antibodi
decreas
p
vaccin
transfus
mice
gener
similar
gc
b
respect
p
tfh
cell
p
vaccin
mice
effici
produc
slpc
splenic
slpc
per
million
seed
slpc
product
transfus
mice
slpc
p
compar
unimmun
control
slpc
p
signific
differ
also
found
number
llpc
bone
marrow
vaccin
transfus
mice
week
immun
llpc
respect
p
conclus
studi
indic
hod
mous
model
blood
transfus
recapitul
high
rate
alloantibodi
evanesc
seen
patient
furthermor
higher
rate
evanesc
like
due
decreas
gener
slpc
llpc
rel
vaccin
given
transfus
vaccin
gener
similar
earli
gc
product
transfus
may
induc
select
defect
plasma
cell
product
backgroundcas
studi
mesenchym
stromal
cell
msc
show
promis
cellular
therapeut
treatment
trauma
ard
regen
medicin
immun
modulatori
effect
like
import
msc
typic
test
immunomodul
mix
lymphocyt
respons
mlr
assay
msc
known
block
abil
peripher
blood
mononuclear
cell
pbmc
respond
prolifer
stimulu
use
pbmc
prolifer
assay
typic
h
durat
studi
ask
whether
msc
interrupt
pbmc
prolifer
ad
time
within
assay
studi
designmethod
human
peripher
blood
mononuclear
cell
pbmc
isol
human
whole
blood
collect
isr
research
blood
bank
donor
approv
standard
oper
procedur
pool
frozen
later
use
pbmc
label
carboxyfluorescein
standard
method
use
well
plate
assay
per
well
human
bone
marrow
msc
obtain
commerci
sourc
use
earli
passag
use
cell
per
well
phytohaemagglutin
use
prolifer
stimulu
pbmc
pha
msc
initi
immedi
initi
pha
stimulu
popul
analyz
flow
cytometri
live
pbmc
popul
data
averag
duplic
experi
rang
resultsfind
preliminari
result
examin
two
separ
prepar
differ
donor
one
show
complet
suppress
pbmc
prolifer
ad
hr
high
dose
addit
pbmc
stimul
result
suppress
respect
suppress
seen
rang
suppress
seen
ad
h
suppress
seen
ad
h
later
second
prepar
retain
suppress
ad
midway
prolifer
assay
suppress
seen
h
addit
conclus
studi
suggest
dose
time
msc
administr
critic
immunomodulatori
activ
addit
msc
pbmc
prolif
program
initi
approxim
effect
suppress
prolifer
immedi
earli
within
h
administr
result
similar
clinic
experi
agvhd
patient
wherein
msc
must
given
earli
effect
gvhd
symptom
establish
data
also
suggest
differ
msc
prepar
might
distinguish
time
cours
effect
immun
modul
backgroundcas
studi
immun
thrombocytopenia
itp
autoimmun
disord
character
low
platelet
count
increas
risk
bleed
patient
format
pathogen
antiplatelet
antibodi
like
caus
acceler
platelet
destruct
decreas
platelet
product
rhig
effect
treatment
itp
pool
product
come
certain
limit
addit
also
carri
black
box
warn
seriou
complic
may
occur
patient
itp
address
potenti
side
effect
antibodi
separ
therapeut
activ
murin
model
passiv
itp
util
two
differ
antibodi
two
major
advers
event
evalu
anemia
defin
signific
decreas
rbc
count
mice
inflammatori
activ
defin
signific
chang
core
bodi
temperatur
studi
designmethod
monoclon
antibodi
recogn
differ
murin
erythrocyt
antigen
evalu
abil
amelior
itp
two
well
character
inbr
mous
strain
balbc
outbr
strain
mice
erythrocyt
number
evalu
day
compar
baselin
count
day
bodi
temperatur
mice
measur
rectal
minut
post
antibodi
inject
resultsfind
abl
amelior
itp
balbc
mice
caus
signific
anemia
nadir
day
three
mous
strain
caus
anemia
balbc
mice
dramat
reduct
core
bodi
temperatur
seen
post
inject
balbc
mice
signific
chang
temperatur
observ
mice
either
antibodi
conclus
abl
amelior
itp
three
strain
mice
anemia
observ
balbc
mice
therefor
conclud
anemia
strictli
requir
itp
amelior
antibodi
murin
passiv
itp
addit
chang
bodi
temperatur
major
advers
event
mice
observ
balbc
mice
mice
therefor
also
conclud
inflammatori
activ
assess
bodi
temperatur
requir
itp
amelior
murin
passiv
itp
base
conclus
may
possibl
develop
monoclon
antibodi
amelior
itp
without
caus
sever
advers
event
backgroundcas
studi
coagul
factor
f
ix
activ
pl
tissu
factor
result
fixab
convert
fx
fxa
coagul
cascad
sought
explor
underli
coagul
biochemistri
trauma
patient
present
increas
fibrinolysi
measur
thromboelastographi
teg
studi
designmethod
perform
seri
vitro
biochem
experi
use
recombin
coagul
protein
resultsfind
plasmin
presenc
specif
cleav
peptid
bond
chymotrypsin
number
proteas
domain
autolysi
loop
fixab
yield
fixag
fixag
migrat
indistinguish
fixab
nondenatur
gel
system
indic
residu
heavi
chain
remain
noncoval
associ
fixag
howev
compar
fixab
fixag
impair
synthet
substrat
cb
hydrolysi
fixag
higher
k
lower
k
cat
less
effect
activ
fx
system
contain
importantli
presenc
fviiia
fixag
less
effect
activ
fx
consist
data
fixag
bound
fviiia
reduc
affin
compar
fixab
moreov
plasmin
bound
fixag
kd
mm
fixab
interact
prevent
acid
treatment
fixag
carboxypeptidas
b
also
abrog
interact
indic
bind
fixag
newli
gener
fixag
enhanc
tissu
plasminogen
activ
plasminogen
conclus
plasmin
cleavag
fixab
peptid
bond
appear
play
role
inactiv
fixa
enhanc
fibrinolysi
similar
describ
fxa
convers
procoagul
enzym
fibrinolyt
cofactor
describ
fixa
like
provid
underli
biochem
etiolog
increas
fibrinolysi
seen
trauma
patient
evidenc
increas
percentag
teg
trace
backgroundcas
studi
transit
fresh
whole
blood
wb
compon
therapi
transfus
practic
develop
effort
eas
burden
maintain
fresh
wb
avail
improv
safeti
compon
store
differ
condit
improv
individu
compon
qualiti
transfus
logist
howev
studi
shown
treat
traumat
hemorrhag
blood
compon
lead
deliveri
dilut
less
function
product
transfus
wb
wb
blood
compon
wast
remain
challeng
studi
examin
hemostat
function
refriger
wb
store
anticoagul
cpd
day
studi
designmethod
singl
wb
unit
collect
cpd
healthi
donor
store
sampl
test
day
wb
hemostat
function
measur
rotem
extem
tissu
factor
tf
pathway
intem
contact
pathway
fibtem
fibrinogen
function
test
thrombin
fiia
gener
measur
use
thrombogram
phospholipid
pm
tf
deriv
plasma
pm
tf
alon
deriv
plasma
prp
platelet
function
measur
imped
aggregometri
multipl
agonist
aspi
adp
collagen
ristocetin
trap
platelet
adhes
collagen
observ
bioflux
microfluid
devic
arteri
patholog
shear
condit
fluoresc
label
platelet
calcein
quantifi
intensitycoverag
area
resultsfind
signific
differ
observ
cpd
hemoglobinhematocrit
remain
constant
day
platelet
count
declin
sharpli
first
day
drop
p
remain
constant
remaind
storag
peak
fiia
gener
climb
throughout
increas
platelet
aggreg
declin
similarli
prior
observ
apheresi
unit
wb
clot
strength
decreas
observ
earli
day
storag
drop
p
exceed
publish
valu
combin
red
cell
plasma
without
platelet
adhes
collagen
flow
preserv
format
aggreg
creat
popul
later
time
point
mean
result
shown
tabl
conclus
wb
experi
function
declin
time
maintain
signific
degre
hemostat
potenti
throughout
day
count
drop
platelet
continu
aggreg
adher
collagen
surfac
patient
like
receiv
wb
transfus
current
member
arm
servic
theater
conflict
would
often
receiv
platelet
otherwis
vivo
studi
wb
particularli
near
end
shelf
life
warrant
determin
efficaci
product
treatment
hemorrhag
part
massiv
transfus
protocol
effect
pretransfus
filtrat
macroaggreg
examin
vitro
backgroundcas
studi
platelet
plt
typic
store
room
temperatur
rt
agit
day
time
mediat
thromboxan
solubl
ligand
microparticl
releas
cold
store
plt
csp
releas
lower
level
mediat
better
preserv
aggreg
respons
caus
increas
level
plt
activ
plt
addit
solut
pass
mitig
csp
activ
dilut
plasma
fibrinogen
effect
storag
temperatur
pa
plt
inflammatori
respons
unknown
therefor
studi
examin
effect
storag
temperatur
pa
apheresi
platelet
vitro
model
immunomodul
mix
lymphocyt
reaction
mlr
studi
designmethod
apheresi
platelet
collect
plasma
terumobct
lakewood
co
plasma
follow
collect
test
articl
separ
mini
bag
bcsi
seattl
wa
storag
either
rt
cold
bag
sampl
day
storag
assay
mlr
mlr
reaction
peripher
blood
mononuclear
cell
pbmc
pool
human
donor
label
carboxyfluoresceinsuccinimidylest
incub
dilut
plt
rang
final
volum
rpmi
media
contain
heparin
autolog
ppp
gener
plt
sampl
achiev
correct
plt
dilut
pbmc
prolifer
stimul
phytohaemagglutinin
h
pbmc
prolifer
determin
flow
cytometri
live
pbmc
resultsfind
ppp
control
plasma
sampl
rt
csp
immunosuppress
decreas
stimul
overal
pbmc
prolifer
rpmi
day
immunosuppress
seen
ppp
control
sampl
signific
differ
observ
rt
csp
plasma
day
ppp
csp
caus
pbmc
prolifer
similar
day
rt
storag
plt
concentr
suppress
maxim
stimul
pbmc
prolifer
plasma
day
plt
immunosuppress
maxim
pbmc
stimul
conclus
transfus
relat
immunomodul
trim
known
respons
transfus
blood
product
particularli
plt
addit
store
plt
ppp
inhibit
pbmc
prolifer
media
control
suggest
trim
event
decreas
control
immunosuppress
like
due
reduct
plasma
storag
temperatur
equal
immunosuppress
maxim
pbmc
prolifer
immunosuppress
depend
storag
solut
storag
time
storag
temperatur
vitro
assay
backgroundcas
studi
lncrna
regul
gene
express
four
level
epigenet
transcript
translat
protein
modif
role
differenti
prolifer
apoptosi
biolog
process
lncrna
found
exist
platelet
howev
alter
function
lncrna
involv
platelet
storag
clear
studi
designmethod
platelet
sampl
collect
healthi
men
blood
group
lncrna
level
quantifi
human
platelet
store
day
shake
tank
use
affymetrix
human
lncrna
array
eight
lncrna
four
mrna
chosen
valid
bioinformat
method
appli
construct
lncrna
mrna
profil
go
kegg
pathway
analys
predict
lncrna
function
analysi
reveal
potenti
molecular
mechan
lncrna
target
gene
express
resultsfind
lncrna
express
level
shift
storag
day
compar
day
lncrna
express
level
shift
storag
day
compar
day
respect
lncrna
differenti
express
increas
decreas
day
addit
number
lncrna
increas
express
level
much
greater
increas
express
level
result
consist
microarray
express
level
increas
reduc
four
target
mrna
platelet
storag
go
kegg
pathway
analys
reveal
mani
lncrna
mrna
relat
platelet
aggreg
platelet
activ
endocytosi
addit
lncrna
might
express
gene
implic
platelet
physiolog
function
conclus
first
studi
analyz
stabil
lncrna
bank
platelet
mani
lncrna
alter
express
level
storag
moreov
shift
lncrna
like
role
regul
platelet
physiolog
function
backgroundcas
studi
blood
unit
store
pack
red
blood
cell
prbc
presum
minim
cell
lesion
howev
water
compact
pack
undergo
abnorm
structur
process
among
breakag
hydrogen
bond
affect
water
interact
neighbor
molecul
impli
routin
prbc
subject
repeat
temperatur
fluctuat
critic
temperatur
respect
volumedens
variat
anomali
expect
induc
acceler
prbc
lesion
studi
present
aim
test
hypothesi
studi
designmethod
six
prbc
unit
leukofiltr
store
sagm
employ
sampl
prbc
collect
unit
store
small
storag
bag
divid
two
group
unit
group
ga
store
routin
blood
bank
refriger
temperatur
fluctuat
unit
group
b
gb
store
assur
temperatur
go
prbc
lesion
monitor
chang
cell
deform
determin
immedi
process
prbc
day
day
storag
use
cell
flow
properti
analyz
cfa
cell
express
chang
cell
elong
ratio
er
calcul
cell
er
ab
b
major
minor
cell
axe
respect
cfa
imag
analysi
provid
er
distribut
larg
rbc
popul
fraction
low
deform
cell
ldfc
prbc
popul
deriv
resultsfind
accord
previous
obtain
result
deform
prbc
ga
decreas
consider
deform
prbc
gb
remain
unchang
entir
storag
period
tabl
particular
tabl
show
portion
rel
rigid
rbc
ldfc
ga
prbc
consider
higher
gb
conclus
present
studi
show
store
prbc
condit
expos
temperatur
fluctuat
around
ga
induc
consider
elev
rbc
rigid
wherea
exposur
condit
avoid
gb
rbc
deform
unchang
storag
although
limit
scope
studi
demonstr
prbc
qualiti
express
cell
deform
maintain
better
prbc
expos
repeat
temperatur
fluctuat
belowabov
critic
temperatur
cell
subject
water
anomali
backgroundcas
studi
despit
almost
univers
use
leukodeplet
blood
compon
shown
donor
leukocyt
engraft
microchimer
remain
consequ
red
blood
cell
rbc
transfus
patient
group
clinic
consequ
remain
cell
mechan
surviv
follow
blood
transfus
unclear
furthermor
incid
microchimer
tam
may
affect
intern
differ
blood
process
method
transfus
practic
australia
trauma
patient
found
tam
despit
introduct
univers
leukodeplet
rbc
unit
sinc
octob
incid
tam
extens
studi
outsid
trauma
set
studi
aim
analyz
incid
tam
patient
major
thermal
injuri
follow
rbc
transfus
studi
designmethod
australian
burn
patient
total
bodi
surfac
area
tbsa
burn
transfus
least
one
rbc
unit
januari
decemb
recruit
studi
incid
tam
determin
use
pcr
analysi
panel
insertiondelet
biallel
polymorph
resultsfind
patient
cohort
n
median
tbsa
burn
rang
patient
transfus
median
rbc
unit
rang
median
hospit
length
stay
day
rang
half
patient
transfus
univers
leukodeplet
rbc
one
patient
transfus
leukodeplet
rbc
unit
show
insertiondelet
pattern
indic
presenc
microchimer
conclus
number
patient
studi
still
small
cohort
thermal
injur
patient
incid
tam
rate
similar
studi
conduct
transfus
trauma
patient
furthermor
find
support
hypothesi
leukodeplet
rbc
unit
elimin
risk
outcom
australian
govern
fund
australian
red
cross
blood
servic
provid
blood
blood
product
servic
australian
commun
backgroundcas
studi
grow
concern
risk
transfus
pack
red
blood
cell
prbc
follow
numer
studi
report
neg
transfus
outcom
includ
reduc
blood
perfus
rbc
uniqu
properti
particularli
deform
adher
vascular
endotheli
cell
defin
rbc
hemodynam
function
hf
name
capac
affect
blood
flow
search
mechan
behind
neg
transfus
outcom
explor
effect
prbc
hf
transfus
outcom
tm
patient
routin
treat
frequent
transfus
elder
blood
recipi
anemia
studi
designmethod
effect
prbc
hf
examin
chang
recipi
skin
blood
flow
hematocrit
transfus
tibt
sbf
determin
use
prbc
deform
adher
determin
use
cell
analyz
cfa
resultsfind
group
patient
increas
increas
hf
transfus
prbc
highli
signific
correl
invers
proport
recipi
sbf
transfus
transfus
outcom
also
depend
hf
recipi
rbc
prbc
hf
higher
recipi
sbf
increas
invers
prbc
hf
lower
rbc
sbf
decreas
tm
patient
time
interv
consecut
transfus
increas
increas
prbc
hf
exhibit
highli
signific
depend
conclus
studi
provid
first
time
human
direct
evid
hf
transfus
prbc
potent
effector
transfus
outcom
determin
prbc
hf
vs
recipi
rbc
condit
transfus
use
select
blood
unit
current
prbc
test
exclus
immunolog
compat
suppli
primarili
fifo
criteria
function
hf
particular
complet
ignor
addit
test
rbc
hf
transfus
recipi
rbc
introduc
new
paradigm
technolog
would
contribut
substanti
improv
transfus
therapi
enabl
person
transfus
medicin
backgroundcas
studi
wnt
signal
play
crucial
role
mammalian
cell
regul
aspect
cell
fate
migrat
polar
platelet
poss
mani
protein
signal
pathway
howev
role
platelet
function
poorli
understood
one
studi
shown
inhibit
platelet
adhes
shape
chang
aggreg
studi
investig
role
signal
protein
synthesi
use
agonist
solubl
protein
wash
store
platelet
studi
designmethod
level
determin
immunoblot
analys
respect
protein
plasma
platelet
plt
prepar
whole
blood
collect
citrat
anticoagul
wash
buffer
incub
kept
untreat
control
presenc
puromycin
pm
follow
activ
adp
storag
experi
aliquot
apheresi
pc
store
small
prepar
bag
mimic
storag
featur
common
plt
bag
two
set
aliquot
spike
pm
store
day
respect
plt
vitro
qualiti
assess
use
platelet
activ
bind
respons
presenc
adp
assay
exposur
bind
metabol
activ
protein
synthesi
monitor
lysat
prepar
triton
buffer
immunoblot
analys
pm
determin
band
intens
use
odyssey
softwar
lycor
imagin
system
resultsfind
wash
activ
plt
show
strong
band
pattern
synthes
protein
affect
presenc
combin
reduc
presenc
alon
storag
studi
confirm
abund
amount
plasma
howev
level
low
detect
day
day
storag
show
concentr
depend
increas
pm
incorpor
respect
compar
untreat
control
trend
mirror
increas
glucos
consumpt
lactat
product
well
platelet
activ
respect
compar
untreat
control
subsequ
respons
adp
degranul
reduc
similar
fashion
lastli
notic
impact
detect
apoptosi
develop
conclus
wnt
signal
seem
protein
synthesi
activ
store
platelet
featur
parallel
platelet
function
hypothes
wnt
signal
might
protect
role
platelet
storag
backgroundcas
studi
donat
blood
process
blood
bank
storag
pack
red
blood
cell
prbc
process
pack
cell
prepar
pcp
blood
often
subject
remov
white
cell
leukofiltr
reduc
risk
advers
reaction
procedur
rbc
expos
high
level
shear
stress
induc
alter
cell
deform
present
studi
examin
effect
pack
cell
prepar
process
rbc
deform
studi
designmethod
blood
sampl
collect
healthi
volunt
donor
correspond
unit
follow
process
prbc
pcp
includ
leukofiltr
rbc
deform
determin
use
cell
analyz
cfa
cell
directli
visual
control
shear
stress
cell
deform
express
chang
cell
elong
ratio
er
calcul
cell
er
ab
b
major
minor
cell
axe
respect
cfa
imag
analysi
provid
er
distribut
larg
rbc
popul
sever
deform
paramet
deriv
includ
fraction
rigid
undeform
cell
rbc
popul
udfc
er
portion
undeform
cell
deriv
rbc
sampl
pcp
udfcb
udfca
respect
chang
calcul
udfc
udfca
udfcb
resultsfind
effect
pcp
level
undefrom
cell
depend
initi
level
blood
sampl
udfcb
higher
pcp
reduc
fraction
rigid
cell
contrast
initi
fraction
rigid
cell
lower
pcp
increas
udfcb
udfc
sampl
exhibit
clear
linear
correl
udfcb
r
signific
p
conclus
note
procedur
pack
cell
prepar
rbc
subject
high
shear
stress
probabl
provok
opposit
phenomena
removaldestruct
rigid
cell
therebi
reduc
level
one
side
b
mechan
damag
cell
membran
subsequ
reduct
cell
deform
therebi
increas
level
udfc
result
studi
support
exist
phenomenon
backgroundcas
studi
blood
group
b
antigen
abo
system
antigen
forssman
system
for
well
structur
relat
glycan
isoglobotriaosylceramid
synthes
action
evolutionarili
relat
nac
transferas
distinct
glycosyltransferas
activ
substrat
specif
blood
group
b
transferas
bt
forssman
glycolipid
synthas
fs
globotriaosylceramid
synthas
gt
respect
previous
shown
amino
acid
codon
human
atbt
crucial
defin
distinct
sugar
specif
elucid
molecular
genet
basi
abo
glycosyl
polymorph
clinic
import
transfus
transplant
medicin
studi
designmethod
better
understand
structur
basi
nac
transferas
diversif
prepar
eukaryot
express
construct
enzym
possess
alaglygli
leuglygli
metglyala
glyglyala
hisalaala
tripeptid
codon
correspond
human
atbt
perform
dna
transfect
use
appropri
recipi
cell
exist
newli
creat
immunolog
examin
appear
cell
surfac
oligosaccharid
antigen
resultsfind
immunocytochemistri
result
use
monoclon
antibodi
dna
transfect
express
construct
reveal
sever
tripeptid
origin
also
bestow
transferas
activ
surprisingli
howev
repertoir
function
amino
acid
vari
among
transferas
quantif
fac
immunocytometri
confirm
differenti
effect
substrat
specif
nac
transferas
interestingli
also
observ
transferas
activ
correspond
enzym
name
fs
activ
human
at
alaglygli
glyglyala
conclus
tripeptid
codon
correspond
human
atbt
also
affect
acceptor
substrat
specif
addit
known
function
determin
donor
specif
may
contribut
gener
divers
famili
nac
transferas
exclud
primat
leuglygli
predomin
alaglygli
tripeptid
frequent
present
at
mani
vertebr
speci
therefor
possibl
at
may
also
exhibit
fs
activ
certain
condit
appropri
acceptor
substrat
present
case
two
genet
loci
abo
rather
alon
may
specifi
express
speci
backgroundcas
studi
pathogen
reduct
pr
system
use
amustalin
glutathion
gsh
develop
inactiv
pathogen
leukocyt
red
blood
cell
rbc
compon
transfus
clinic
trial
ongo
plan
evalu
pr
rbc
adolesc
adult
patient
object
studi
evalu
potenti
advers
effect
postnat
growth
develop
support
transfus
pr
rbc
pediatr
neonat
patient
studi
designmethod
test
articl
tabl
includ
heterolog
rbc
treat
current
clinic
process
increas
concentr
reduc
gsh
level
rat
per
group
male
femal
given
pr
rbc
control
rbc
intraperiton
three
time
week
postnat
pnd
week
intraven
bolu
inject
three
time
week
pnd
week
matur
pnd
follow
paramet
endpoint
evalu
viabil
clinic
sign
bodi
weight
wt
gain
food
consumpt
ophthalmolog
sexual
matur
morri
water
maze
evalu
clinic
patholog
hematolog
coagul
clinic
chemistri
urinalysi
plasma
sampl
analysi
gross
necropsi
find
femur
measur
organ
weight
histopatholog
tissu
examin
resultsfind
death
clinic
observ
consid
relat
pr
rbc
bodi
wt
gain
food
consumpt
valu
gener
compar
among
three
dose
group
organ
wt
chang
recipi
rbc
group
includ
decreas
wt
pituitari
gland
wt
rel
bodi
wtwa
statist
significantli
differ
group
femal
statist
signific
reduct
ovari
wt
rel
bodi
wt
group
histolog
examin
tissu
organ
demonstr
evid
patholog
abnorm
physiolog
function
organ
growth
develop
conserv
effect
male
femal
rat
sexual
matur
perform
morri
water
maze
ophthalm
examin
hematolog
coagul
clinic
chemistri
urinalysi
necropsi
observ
femur
length
histopatholog
conclus
pr
rbc
transfus
neonat
rat
expect
clinic
exposur
show
conserv
normal
growth
develop
sexual
matur
patholog
abnorm
observ
organ
system
base
gross
microscop
histopatholog
observ
studi
demonstr
safeti
pr
rbc
support
use
neonat
patient
intercept
blood
system
red
blood
cell
approv
commerci
use
backgroundcas
studi
vitro
product
blood
platelet
import
goal
transfus
present
context
sustain
demand
control
product
free
infecti
immun
inflammatori
risk
current
possibl
produc
platelet
vitro
howev
cultur
platelet
consid
real
altern
transfus
paramount
import
demonstr
platelet
free
contamin
nucleat
cell
cellular
fragment
studi
designmethod
aim
studi
evalu
effect
fraction
devic
separ
newli
releas
platelet
residu
megakaryocyt
mk
cytoplasm
debri
cd
platelet
produc
vitro
peripher
progenitor
follow
protocol
describ
strassel
et
al
blood
platelet
releas
cell
suspens
follow
success
pipet
platelet
recoveri
puriti
compar
follow
standard
centrifug
fraction
use
devic
allow
separ
two
object
differ
acoust
properti
resultsfind
fraction
use
combin
two
acoust
devic
led
signific
reduct
number
residu
mk
cd
compar
standard
centrifug
residu
mk
cd
remov
respect
wherea
centrifug
allow
separ
cd
conclus
method
promis
altern
isol
cultur
platelet
high
level
puriti
provid
blood
product
compat
transfus
requir
backgroundcas
studi
pack
red
blood
cell
prbc
undergo
slow
detriment
chang
collect
term
storag
lesion
signific
express
releas
microvesicl
mv
cell
membran
process
associ
decreas
ratio
cell
surfac
area
volum
lead
impair
rbc
deform
present
studi
examin
correl
level
prbc
deform
releas
mv
rbc
supernat
studi
designmethod
rbc
sampl
obtain
seven
prbc
unit
unleukofiltr
store
day
mv
obtain
prbc
supernat
differenti
centrifug
count
flow
cytometri
concomitantli
rbc
deform
determin
use
cell
analyz
rbc
directli
visual
monitor
function
shear
stress
cell
deform
express
cell
elong
ratio
er
er
ab
b
long
short
axe
cell
respect
calcul
appli
cell
provid
er
distribut
larg
rbc
popul
enabl
deriv
sever
deform
measur
median
er
mer
percent
low
deform
cell
popul
ldfc
resultsfind
shown
tabl
mv
level
prbc
supernat
invers
correl
rbc
deform
mer
posit
correl
fraction
rel
rigid
cell
ldfc
measur
show
highli
signific
logarithm
depend
mv
level
conclus
format
mv
known
lead
decreas
content
rbc
membran
protein
eg
stomatin
flotillin
flotillin
accord
previous
report
rbc
becom
progress
rigid
stomatin
deplet
cell
membran
togeth
present
studi
show
clear
associ
mv
format
declin
rbc
deform
store
prbc
unit
propos
mv
format
signific
factor
account
increas
rbc
rigid
occur
storag
blood
unit
backgroundcas
studi
fresh
platelet
wide
use
clinic
treat
patient
thrombocytopenia
platelet
dysfunct
infus
exogen
platelet
treatment
hemorrhag
diseas
caus
thrombocytopenia
dysfunct
play
irreplac
role
compar
drug
increas
awar
blood
compon
transfus
demand
platelet
medic
institut
increas
year
year
due
shelf
life
limit
fresh
platelet
often
meet
clinic
need
order
save
live
time
manner
method
transfus
frozen
platelet
use
emerg
situat
meet
need
purpos
studi
compar
therapeut
effect
infus
deplet
frozen
platelet
fresh
platelet
studi
designmethod
patient
thrombocytopenia
select
includ
male
femal
age
year
given
first
blood
transfus
exclud
immun
factor
affect
platelet
transfus
efficaci
due
multipl
transfus
randomli
divid
two
group
patient
infus
deplet
frozen
platelet
patient
infus
fresh
platelet
infus
platelet
complet
within
minut
rate
patient
could
toler
patient
test
bleed
time
infus
hour
infus
elev
platelet
count
peripher
blood
hour
infus
data
statist
process
measur
data
check
test
enumer
data
analyz
test
resultsfind
signific
differ
gener
data
two
group
p
statist
signific
differ
bleed
time
min
vs
min
infus
fresh
platelet
frozen
platelet
p
platelet
count
vs
transfus
fresh
platelet
frozen
platelet
statist
signific
p
conclus
statist
signific
differ
bleed
time
infus
equival
amount
frozen
platelet
fresh
platelet
suggest
hemostat
function
two
exogen
platelet
patient
close
differ
platelet
count
statist
signific
platelet
count
increas
significantli
patient
receiv
fresh
platelet
bind
capac
cryopreserv
platelet
membran
surfac
adhes
receptor
significantli
enhanc
procoagul
activ
significantli
increas
therefor
infus
frozen
platelet
emerg
achiev
effect
rapid
hemostasi
backgroundcas
studi
human
platelet
lysat
hpl
contain
abund
growth
factor
cytokin
boost
vitro
cell
prolifer
grow
number
institut
use
hpl
altern
anim
sera
manufactur
medicin
product
addit
porcin
heparin
default
prevent
media
clot
achiev
anim
cultur
system
protocol
mechan
deplet
fibrinogen
coagul
factor
recent
introduc
studi
designmethod
studi
investig
far
unclear
influenc
heparin
gene
express
stromal
cell
deriv
umbil
cord
uc
white
adipos
tissu
wat
bone
marrow
bm
stromal
cell
isol
propag
use
hpl
plu
heparin
vs
hpl
plusminu
heparin
whole
genom
microarray
analyz
use
rbioconductor
follow
confirm
immunophenotyp
vitro
differenti
prolifer
clonogen
immunomodulatori
potenc
investig
cell
uptak
heparin
analyz
fluoresc
microscopi
flow
cytometri
resultsfind
depend
stromal
cell
origin
transcriptom
profil
reveal
differenti
regul
distinct
gene
set
heparin
uc
show
highest
number
alter
gene
signal
cascad
involv
prolifer
eg
wnt
tgfbeta
pdgf
fgf
egf
pathway
cell
adhes
integrin
cadherin
cell
fate
decis
inflamm
angiogenesi
differenti
affect
analys
phosphoryl
protein
signal
pathway
progress
also
observ
depend
intern
heparin
uc
stromal
cell
show
highest
heparin
uptak
compar
cell
sourc
independ
heparin
flow
cytometr
analysi
reveal
characterist
stromal
phenotyp
profil
compar
vitro
trilineag
differenti
prolif
capac
uc
bm
stromal
cell
increas
presenc
heparin
use
hpl
earli
passag
contrast
heparin
influenc
clonogen
vitro
immunomodulatori
potenti
conclus
depend
sourc
stromal
cell
heparin
regul
distinct
set
gene
signal
pathway
although
heparin
exert
mitogen
stimulu
uc
bm
human
stromal
cell
effici
expand
hpl
absenc
heparin
thu
provid
complet
condit
gener
stromal
cell
therapeut
backgroundcas
studi
mesenchym
stromal
cell
msc
demonstr
variabl
characterist
cultur
differ
strategi
differ
sourc
materi
purpos
studi
investig
much
variabl
attribut
cultur
strategi
much
due
sourc
materi
studi
designmethod
five
independ
laboratori
use
cultur
strategi
produc
msc
marrow
aspir
donor
two
lab
enrich
marrow
leukocyt
densiti
gradient
sediment
four
lab
cultur
msc
media
supplement
fb
lab
use
platelet
lysat
cell
seed
densiti
initi
outgrowth
ie
rang
second
seed
ie
total
number
passag
perform
rang
msc
harvest
frozen
thaw
assay
viabil
immunophenotyp
differenti
potenti
coloni
form
activ
gene
express
immunosuppress
capabl
resultsfind
transit
time
bm
aliquot
collect
deliveri
site
lab
locat
within
us
rang
hr
hr
lab
locat
asia
viabl
total
nucleat
cell
concentr
bm
bm
bm
coeffici
varianc
respect
viabil
rang
bm
bm
bm
respect
averag
number
per
msc
plate
bm
bm
bm
respect
substanti
differ
immunophenotyp
potenti
immunosuppress
activ
note
global
gene
express
analys
msc
indic
differ
msc
transcriptom
affect
manufactur
site
donor
center
effect
greater
conclus
despit
util
sourc
materi
function
differ
observ
among
msc
produc
differ
center
variat
msc
attribut
method
use
center
sourc
marrow
togeth
result
support
effort
standard
manufactur
process
decreas
msc
variabl
backgroundcas
studi
accur
precis
red
blood
cell
rbc
quantif
hematopoiet
stem
cell
transplant
sct
product
import
process
clinic
aspect
stem
cell
transplant
abo
antigenantibodi
mismatch
rbc
caus
deleteri
effect
sct
recipi
product
ml
may
subject
rbc
reduct
accept
level
infus
rbc
quantif
context
vari
total
product
volum
rbc
amount
perform
regularli
littl
report
specif
perform
characterist
rbc
quantif
hsct
product
differ
sourc
differ
quantiti
vari
rbc
amount
potenti
effect
sct
process
studi
designmethod
sct
product
sampl
cellular
therapi
laboratori
undergo
parallel
determin
rbc
content
base
hematocrit
hct
measur
manual
autom
method
manual
hematocrit
mhct
perform
centrifug
direct
observ
autom
hematocrit
ahct
perform
sysmex
autom
hematolog
analyz
dilut
rbc
volum
determin
multipli
hct
product
volum
ml
sampl
group
sct
sourc
apheresi
bone
marrow
harvest
product
subgroup
apheresi
instrument
use
spectra
optia
terumo
bct
amicu
freseniu
kabi
retrospect
analysi
mhct
ahct
perform
determin
statist
signific
differ
measur
exist
pair
student
test
result
cross
threshold
ml
rbc
volum
resultsfind
sct
product
analyz
product
product
sampl
collect
spectra
optia
amicu
apheresi
instrument
respect
product
cross
threshold
ml
rbc
volum
sct
product
ml
rbc
mhct
fell
threshold
ahct
sct
product
ml
rbc
mhct
cross
threshold
ahct
affect
product
collect
amicu
sct
product
rbc
either
method
sd
standard
deviat
conclus
hct
measur
method
result
sct
product
rbc
volum
differ
could
potenti
chang
need
process
case
mismatch
sct
product
cross
ml
rbc
volum
threshold
rbc
reduct
chang
need
addit
process
sct
product
note
addit
sampl
need
analyz
hct
differ
product
collect
amicu
addit
studi
warrant
determin
impact
cellular
therapi
laboratori
workflow
patient
outcom
backgroundcas
studi
exosom
intern
deriv
microvesicl
nm
gain
consider
interest
diseas
biomark
therapeut
agent
optim
exosom
isol
character
method
remain
undefin
analyz
uniform
function
spheroid
monolay
human
bone
marrow
mesenchym
stromal
exosom
respect
isol
two
differ
method
use
nanosight
endotheli
tube
format
assay
bioenerget
profil
studi
designmethod
hmsc
grown
hmsc
high
perform
basal
media
rooster
bio
usa
mhmsc
shmsc
pluron
coat
cultur
plate
cell
per
well
switch
serum
free
media
sfm
hour
exosom
isol
sfm
shmsc
mhmsc
ultracentrifug
mhmsc
qiagen
exo
easi
maxi
kit
qiagen
usa
size
distribut
analyz
nanosight
malvern
uk
normal
protein
content
human
umbil
vein
endotheli
cell
huvec
angiogenesi
tube
format
assay
n
perform
ibidi
slide
ibidi
usa
tissu
cultur
plate
tube
format
number
quantifi
use
imagej
sampl
bioenerget
profil
analyz
use
seahors
agil
usa
n
seahors
xf
media
agil
duplic
control
statist
analys
perform
use
anova
test
resultsfind
isol
ultracentrifug
fell
within
appropri
exosom
size
rang
commerci
kit
exosom
fell
within
nm
indic
less
pure
sampl
significantli
increas
huvec
tube
format
per
well
p
significantli
increas
basal
p
p
respect
spare
respiratori
p
p
respect
capac
oxygen
consumpt
rate
ocr
level
compar
control
bioenerget
health
index
bhi
significantli
chang
compar
control
p
bhi
signific
one
paramet
p
conclus
exosom
isol
use
ultracentrifug
result
uniform
sampl
better
abl
support
huvec
tube
format
mitochondri
capac
futur
studi
analyz
addit
function
activ
activ
use
isol
tissu
cultur
plate
backgroundcas
studi
hla
match
donor
patient
play
crucial
role
allogen
hematopoiet
stemprogenitor
cell
hspc
transplant
outcom
hla
type
may
perform
intermedi
high
resolut
colombia
candid
patient
umbil
cord
blood
ucb
transplant
type
intermedi
resolut
high
resolut
unit
request
mainli
spain
usa
presum
colombian
popul
may
genet
differ
current
avail
hla
studi
intermedi
resolut
hypothes
hla
genet
pool
differ
spain
usa
know
allel
haplotyp
higher
frequenc
hf
may
increas
probabl
find
suitabl
donor
nation
ucb
bank
studi
designmethod
analys
perform
type
ucb
unit
avail
transplant
public
bank
unit
collect
healthi
mother
sign
inform
consent
public
hospit
high
resolut
hla
type
perform
certifi
laboratori
six
allel
reduc
four
digit
g
group
may
includ
null
allel
serolog
allel
variant
frequenc
obtain
count
haplotyp
frequenc
calcul
use
softwar
via
em
algorithm
initi
haplotyp
frequenc
set
perturb
stop
algorithm
threshold
haplotyp
frequenc
cut
hardi
weinberg
equilibrium
ligat
disequilibrium
perform
genepop
softwar
resultsfind
fifti
allel
found
hf
hf
hf
hf
hf
frequent
haplotyp
repres
cumul
frequenc
estim
haplotyp
compar
spanish
hispan
usa
popul
one
two
frequent
allel
sampl
equal
repres
exhibit
highest
differ
compar
popul
colombia
spain
usa
colombia
spain
usa
conclus
comparison
serolog
allel
variant
frequenc
colombian
popul
sampl
exhibit
import
high
resolut
type
defin
hla
allel
variant
probabl
increas
match
patient
donor
also
first
hla
high
resolut
type
countri
point
need
deeper
analysi
popul
genet
regard
high
polymorph
hla
gene
system
data
demonstr
hla
colombian
genet
pool
entir
compar
usa
spain
mainli
although
transplant
ucb
unit
import
countri
also
want
set
attent
urgent
need
nation
donor
registri
colombia
backgroundcas
studi
stromal
cell
promis
candid
regen
medicin
optim
cell
sourc
expans
protocol
use
fetal
bovin
serum
fb
differ
prepar
human
platelet
lysat
hpl
still
debat
transplant
hepatocyt
pancreat
islet
cell
instant
inflammatori
reaction
ibmir
observ
rapidli
activ
complement
coagul
system
ibmir
due
stromal
cell
infus
result
sever
side
effect
pulmonari
embol
addit
rapid
deplet
therapeut
cell
lack
engraft
recent
differenti
activ
vivo
coagul
ibmir
associ
tissu
factor
tf
express
depend
stromal
cell
origin
aim
studi
investig
influenc
differ
medium
supplement
tf
express
vitro
hemocompat
umbil
cord
deriv
stromal
cell
ucsc
cultur
fresh
cryobank
frozen
rotat
thrombelastometri
rotem
studi
designmethod
ucsc
cultur
standard
hpl
hpl
fb
prolifer
clonogen
immunophenotyp
trilineag
differenti
immunomodul
fresh
ucsc
analyz
tf
express
fresh
frozen
ucsc
test
flow
cytometri
estim
vitro
procoagul
activ
rotem
perform
fresh
frozen
ucsc
ab
plasma
clot
time
ct
clot
format
time
cft
maximum
clot
firm
mcf
analyz
resultsfind
ucsc
prolifer
significantli
increas
modifi
compar
trilineag
potenti
maintain
flow
cytometri
reveal
phenotyp
immunomodulatori
capac
compar
ucsc
sampl
tf
express
significantli
higher
fresh
ucsc
cultur
compar
ratio
vs
p
compar
fresh
cell
frozen
ucsc
show
significantli
reduc
tf
express
ratio
hpl
p
fb
p
contrast
high
procoagul
activ
fresh
ucsc
hpl
affect
cryobank
ct
sec
frozen
fresh
wherea
fb
frozen
ucsc
show
significantli
shorten
ct
frozen
vs
fresh
p
sampl
show
significantli
reduc
ct
compar
plasma
ct
p
vitro
activ
ucsc
significantli
increas
higher
cell
dose
p
conclus
ucsc
prolifer
effici
media
also
show
higher
activ
fb
vitro
although
tf
express
declin
cryopreserv
high
procoagul
activ
compar
bone
marrow
stromal
cell
still
observ
indic
addit
mechan
concern
risk
ibmir
analysi
hemocompat
rotem
highli
recommend
prior
intraven
applic
backgroundcas
studi
genom
edit
engin
nucleas
nucleas
allow
target
genet
manipul
hold
great
promis
treatment
inherit
acquir
disord
howev
effici
genom
edit
limit
factor
larg
enough
quantiti
correctli
edit
cell
requir
recent
devis
robust
strategi
gener
domin
cellular
resist
ouabain
highli
potent
inhibitor
ubiquit
essenti
sodiumpotassium
pump
encod
gene
use
crispr
technolog
gener
allel
coselect
correct
edit
event
second
locu
interest
faith
vitro
model
erythropoiesi
studi
specif
genet
variant
would
use
tool
investig
gene
function
help
guid
manag
complex
clinic
case
field
transfus
medicin
studi
designmethod
work
exploit
gene
edit
ouabain
strategi
combin
differenti
protocol
develop
cellular
model
showcas
desir
genet
variant
use
cultur
method
effici
produc
cultur
red
blood
cell
crbc
hematopoiet
stem
progenitor
cell
hspc
resultsfind
procedur
yield
averag
expans
enucl
day
use
mobil
peripher
blood
hspc
cell
sourc
strategi
purifi
hspc
incub
erythroid
expans
medium
h
upon
thaw
electropor
ribonucleoprotein
rnp
complex
contain
hbb
guid
rna
along
ssodn
aim
insert
sickl
cell
mutat
hb
allel
three
day
follow
transfect
ouabain
treatment
ad
differenti
protocol
continu
day
day
cultur
precis
gene
modif
obtain
hbb
locu
conclus
summari
edit
strategi
present
reach
high
effici
desir
gene
modif
cultur
rbc
pave
way
model
genet
variant
clinic
signific
may
help
deciph
specif
role
physiolog
diseas
backgroundcas
studi
umbil
cord
blood
ucb
proven
sourc
hematopoiet
stem
cell
bone
marrow
transplant
sever
studi
previous
shown
ideal
time
interv
collect
cryopreserv
ucb
unit
brazil
consequ
vast
territori
time
requir
transport
sampl
collect
site
hospit
cord
blood
bank
cbb
long
brazilian
legisl
allow
ucb
sampl
cryopreserv
hour
collect
object
assess
impact
time
interv
collect
cryopreserv
cell
viabil
ucb
unit
store
cbb
studi
designmethod
analysi
ucb
unit
collect
differ
healthcar
profession
hospit
locat
citi
distanc
km
mile
laboratori
period
cryopreserv
cbb
paulo
brazil
sampl
transport
appropri
temperatur
condit
test
neg
microbi
contamin
cell
count
cell
viabil
perform
use
flow
cytometri
cell
viabil
result
analyz
hourli
interv
accord
time
elaps
collect
end
process
use
pearson
correl
factor
resultsfind
longer
time
interv
collect
cryopreserv
lower
cell
viabil
ucb
unit
correl
factor
p
interv
increas
percentag
viabl
cell
show
progress
reduct
hour
hour
hour
hour
hour
conclus
cell
viabil
increasingli
compromis
time
interv
collect
cryopreserv
ucb
unit
higher
especi
hour
collect
result
emphas
despit
logist
difficulti
transport
biolog
materi
ucb
countri
vast
territori
brazil
unit
ideal
process
within
hour
collect
order
ensur
mani
viabl
cell
possibl
backgroundcas
studi
hematopoiet
progenitor
cell
typic
cryopreserv
use
control
rate
freezer
crf
recent
lab
observ
increas
unaccept
freez
curv
ie
meet
expect
freez
curv
paramet
cryopreserv
bag
manufactur
origen
recommend
maximum
fill
volum
rang
suggest
optim
minimum
volum
theoriz
lower
optim
freez
volum
could
produc
unaccept
freez
curv
determin
minimum
volum
one
could
lessen
rate
unsatisfactori
freez
curv
studi
designmethod
retrospect
document
review
perform
clinic
cell
therapi
product
freez
curv
timefram
freez
curv
gener
suboptim
nearli
unaccept
curv
demonstr
addit
temperatur
spike
prior
heat
fusion
mani
variabl
examin
potenti
caus
includ
cell
type
cell
concentr
crf
calibr
date
prevent
mainten
perform
product
volum
product
unaccept
freez
curv
sampl
viabil
acridin
orangepropidium
iodid
use
frozen
tube
segment
explor
impact
product
volum
canist
measur
calip
obtain
depth
variou
volum
water
ad
origen
freez
bag
bag
fill
water
bag
fill
water
bag
place
press
depth
measur
record
variou
fill
volum
compar
depth
canist
resultsfind
common
factor
unaccept
freez
curv
low
product
volum
compar
recommend
maximum
fill
volum
viabil
thaw
segment
found
accept
conclus
fill
volum
play
critic
role
abil
sampl
probe
make
continu
contact
product
bag
fill
volum
low
bag
may
contain
suffici
weight
ensur
continu
contact
sampl
probe
undergo
appear
undergo
prematur
temperatur
spike
initi
cool
phase
crf
compar
fill
volum
depth
canist
determin
minimum
depth
bag
water
minimum
depth
bag
water
base
data
establish
minimum
volum
bag
bag
sinc
institut
minimum
fill
volum
frequenc
suboptim
freez
curv
decreas
backgroundcas
studi
optim
cell
concentr
cryopreserv
autolog
hpc
apheresi
product
publish
literatur
less
nucleat
cell
nc
per
ml
howev
product
higher
cell
concentr
pragmat
cell
process
facil
may
potenti
reduc
patient
complic
relat
total
volum
product
reinfus
studi
designmethod
perform
retrospect
analysi
viabil
neutrophil
recoveri
platelet
recoveri
compar
product
clinic
outcom
patient
receiv
lower
concentr
nc
per
ml
higher
concentr
nc
per
ml
product
autolog
hpc
apheresi
product
collect
consecut
mobil
patient
process
fix
final
product
volum
variabl
cell
concentr
cryopreserv
vv
dimethyl
sulfoxid
dmso
use
control
rate
freezer
held
vapor
phase
liquid
nitrogen
monitor
storag
resultsfind
cryopreserv
hpc
apheresi
product
multipl
myeloma
patient
lymphoma
patient
includ
product
outcom
analysi
see
tabl
median
cell
concentr
nc
per
ml
lower
concentr
group
compar
nc
per
ml
higher
concentr
group
differ
median
viabil
vs
patient
includ
clinic
outcom
analysi
receiv
least
total
cell
per
kilogram
see
tabl
exclus
differ
total
cell
per
kilogram
reinfus
vs
use
cibmtr
definit
recoveri
median
day
neutrophil
recoveri
vs
platelet
recoveri
vs
differ
conclus
viabil
neutrophil
recoveri
platelet
recoveri
differ
patient
receiv
lower
concentr
nc
per
ml
higher
concentr
nc
per
ml
product
addit
greater
simplic
cell
process
step
higher
cell
concentr
cryopreserv
product
offer
potenti
benefit
smaller
total
volum
reinfus
lower
total
dmso
dose
patient
undergo
autolog
transplant
backgroundcas
studi
long
term
storag
cellular
therapi
product
requir
vapor
phase
liquid
nitrogen
storag
tank
due
indefinit
retent
cryopreserv
product
footprint
larg
liquid
nitrogen
freezer
adequ
connect
suppli
space
requir
challeng
meet
storag
demand
storag
facil
commiss
transport
cellular
therapi
product
previous
describ
studi
designmethod
case
studi
resultsfind
primari
risk
involv
transport
product
damag
frozen
product
tank
transport
small
number
product
increas
likelihood
warm
event
well
need
handl
product
overal
time
reloc
would
prohibit
increas
therefor
move
fill
tank
select
trial
move
freezer
perform
assess
effect
measur
taken
run
map
smooth
road
absenc
pothol
railroad
track
etc
custom
pallet
air
dampen
cushion
hard
rubber
surfac
made
would
offer
shock
absorpt
support
weight
full
tank
precis
jack
lift
use
rais
lower
tank
full
control
masonit
sheet
laid
tile
hallway
smoother
transport
move
truck
air
suspens
system
use
transport
fulli
valid
function
tank
fill
frozen
product
either
mock
deceas
patient
product
tank
slowli
place
onto
pallet
use
jack
secur
strap
put
back
move
truck
pallet
secur
place
truck
ensur
nt
move
tank
also
strap
side
truck
extra
assur
would
nt
tip
move
occur
earli
polic
escort
transport
mph
use
move
tank
locat
tank
reloc
product
thaw
evalu
sign
breakag
transport
product
remain
intact
subsequ
tank
move
patient
product
without
incid
prior
move
actual
product
empti
valid
backup
tank
preposit
offsit
locat
precaut
repres
sampl
product
examin
tank
ensur
integr
conclus
precaut
taken
plan
prove
safe
effect
way
transport
full
tank
cryopreserv
product
success
transfer
full
tank
storag
facil
allow
laboratori
continu
meet
patient
need
store
product
indefinit
backgroundcas
studi
autolog
hematopoiet
progenitor
cell
hpc
transplant
requir
mobil
hpc
peripher
blood
mobil
perform
administr
alon
g
associ
chemotherapi
gct
hpc
product
obtain
two
method
present
differ
cell
content
could
result
differ
clinic
outcom
hematolog
recoveri
advers
reaction
ar
product
infus
retrospect
studi
aim
evalu
rate
ar
product
infus
accord
type
cell
mobil
alon
associ
chemotherapi
studi
designmethod
total
patient
lymphoma
multipl
myeloma
mm
underw
mobil
harvest
hpc
autolog
transplant
last
year
g
gct
underw
transplant
institut
apheresi
procedur
result
bag
ml
cryopreserv
dmso
kept
liquid
nitrogen
contain
thaw
infus
evalu
ar
nauseavomit
diarrhea
arrhythmia
dyspnea
neurolog
abnorm
cephalea
encephalopathi
possibl
ar
patient
cell
infus
complet
resultsfind
median
rang
age
year
group
g
gct
respect
p
peak
g
gct
group
respect
p
g
product
contain
higher
number
granulocyt
x
vs
p
platelet
x
vs
p
g
group
receiv
higher
dose
dmso
gkg
vs
p
inferior
dose
cell
x
vs
p
hematolog
recoveri
neutrophil
occur
day
g
gct
group
respect
p
ar
occur
patient
group
g
gct
respect
p
howev
number
reaction
possibl
possibl
g
gct
group
respect
p
patient
receiv
bag
hpc
similar
dose
dmso
observ
higher
number
ar
g
group
vs
p
femal
gender
associ
higher
rate
nauseavomit
vs
p
conclus
mobil
hpc
alon
mani
advantag
although
result
higher
number
unwant
cell
granulocyt
platelet
less
cell
final
product
explain
least
part
higher
rate
advers
reaction
cell
infus
observ
final
mobil
alon
result
fewer
cell
transplant
protract
hematolog
recoveri
backgroundcas
studi
peripher
blood
stem
cell
pbsc
becom
predomin
graft
sourc
adult
allogen
hematopoiet
stem
cell
transplant
hsct
recent
year
granulocyt
coloni
stimul
factor
standard
agent
pbsc
mobil
poorli
mobil
autolog
donor
plerixafor
often
ad
improv
collect
outcom
allogen
donor
mobil
poorli
studi
review
experi
use
plerixafor
rescu
agent
poorli
mobil
allogen
donor
studi
designmethod
retrospect
examin
allogen
pbsc
collect
januari
march
center
donor
receiv
mcgkg
daili
four
day
undergo
apheresi
collect
day
collect
perform
mnc
protocol
cobe
spectra
optia
amicu
apheresi
instrument
liter
blood
process
hour
goal
collect
cellskg
recipi
weight
plerixafor
ad
base
poor
cell
collect
yield
first
second
collect
day
resultsfind
allogen
donor
receiv
one
dose
plerixafor
addit
first
second
day
collect
due
poor
collect
yield
plerixafor
well
toler
donor
without
signific
advers
reaction
cell
yield
plerixafor
rang
median
cellskg
recipi
weight
plerixafor
median
increas
yield
previou
day
collect
total
rang
median
cellskg
recipi
weight
median
rang
total
cell
collect
due
plerixafor
conclus
poorli
mobil
allogen
donor
plerixafor
ad
effect
rescu
agent
achiev
collect
goal
may
decreas
number
donat
day
backgroundcas
studi
minimum
dose
cell
desir
autolog
hematopoiet
stem
cell
hpc
transplant
treat
hematopoiet
malign
yield
cell
obtain
apheresi
collect
larg
predict
peripher
blood
concentr
therefor
common
standard
proceed
apheresi
determin
flow
cytometri
flow
criteria
autolog
hpc
transplant
candid
may
disqualifi
basi
poor
anticip
collect
yield
goal
studi
determin
altern
treatment
option
avail
low
report
patient
still
proceed
apheresi
collect
transplant
name
minimum
dose
cell
obtain
mani
collect
requir
addit
numer
number
collect
neg
impact
engraft
studi
designmethod
patient
low
accur
report
flow
initi
cutoff
chang
use
intern
societi
hematotherapi
graft
engin
protocol
includ
studi
retrospect
review
apheresi
laboratori
electron
medic
record
perform
collect
data
includ
diagnosi
number
patient
proceed
transplant
mobil
regimen
number
collect
attempt
number
apheresi
procedur
apheresi
method
dose
collect
infus
neutrophil
platelet
engraft
resultsfind
patient
diagnosi
includ
lymphoma
diffus
larg
lymphoma
multipl
myeloma
hodgkin
lymphoma
amyloidosi
mantl
cell
lymphoma
plasma
cell
leukemia
burkitt
lymphoma
peripher
lymphoma
primit
neuroectoderm
tumor
germ
cell
tumor
almost
patient
mobil
neupogen
plerixafor
np
spectra
use
collect
process
blood
volum
patient
patient
proceed
transplant
transplant
minimum
dose
cell
could
collect
patient
mobil
np
attempt
collect
rest
made
case
patient
underw
mean
apheresi
procedur
rang
collect
mean
cell
rang
patient
proceed
transplant
requir
collect
attempt
mean
apheresi
procedur
rang
requir
collect
cell
mean
dose
collect
rang
mean
dose
infus
rang
incid
delay
neutrophil
engraft
day
one
patient
demonstr
delay
platelet
engraft
day
one
patient
fail
engraft
platelet
conclus
despit
low
report
flow
patient
abl
collect
cell
mean
apheresi
collect
proceed
transplant
case
delay
neutrophil
engraft
infrequ
case
delay
fail
platelet
engraft
therefor
disqualifi
patient
treatment
option
hpc
transplant
base
low
alon
may
deni
patient
life
prolong
lifesav
therapi
backgroundcas
studi
mani
transplant
center
still
process
fix
number
liter
total
blood
volum
hematopoiet
progenitor
cell
collect
predict
algorithm
achiev
target
dose
valid
primarili
autolog
donor
wide
adopt
perhap
due
eas
use
thu
valid
allogen
donor
simpl
predict
algorithm
base
percentil
collect
effici
ce
directli
calcul
number
liter
achiev
target
ce
report
lower
allogen
versu
autolog
donor
also
test
whether
use
cobe
spectra
cfr
tool
base
mnc
count
result
higher
ce
compar
histor
control
collect
standard
mlmin
studi
designmethod
retrospect
analysi
analyz
allogen
donor
nmdp
relat
collect
cobe
spectra
mnc
spectra
optia
cmnc
procedur
jan
feb
peripher
blood
count
drawn
hr
use
calcul
liter
process
follow
total
target
product
per
ul
actualpredict
liter
process
vari
median
mean
actual
dose
collect
adjust
follow
actual
total
product
actual
volum
processedpredict
volum
process
ce
use
cobe
cfr
tool
compar
nmdp
histor
control
collect
cobe
spectra
mnc
procedur
fix
cfr
mlmin
resultsfind
adjust
dose
achiev
target
goal
patient
process
median
donor
tbv
rang
adjust
dose
median
rang
mean
sd
time
predict
dose
correl
adjust
target
total
due
variat
ce
evid
correl
ce
adjustedtarget
ratio
tabl
show
data
weak
correl
cfr
product
granulocyt
platelet
seen
mean
similar
previous
report
allogen
donor
mean
tbv
process
cancela
ja
transfus
conclus
easi
use
predict
algorithm
use
conserv
ce
volum
process
may
achiev
higher
percent
collect
reach
target
dose
compar
predict
algorithm
base
regress
analysi
leberfing
transfus
use
rather
fix
cfr
may
increas
ce
backgroundcas
studi
continu
mononuclear
cell
collect
cnmc
method
peripher
blood
stem
cell
pbsc
collect
use
spectra
optia
terumo
bct
shown
result
compar
slightli
improv
collect
effici
ce
smaller
product
volum
compar
mnc
collect
method
optia
adult
popul
howev
cmnc
method
well
studi
smaller
pediatr
patient
studi
aim
review
institut
pbsc
collect
experi
pediatr
patient
use
cmnc
method
studi
designmethod
retrospect
review
data
autolog
collect
procedur
perform
patient
pediatr
hospit
april
march
use
cmnc
protocol
examin
patient
demograph
data
mobil
characterist
laboratori
valu
procedur
detail
pbsc
product
characterist
advers
reaction
hypocalcemia
access
complic
hypotensionhypertens
transfus
reaction
includ
review
resultsfind
autolog
collect
perform
patient
mean
weight
rang
kg
neuroblastoma
nbl
central
nervou
system
cn
neoplasm
nbl
cn
patient
mobil
daili
mcgkg
gscf
follow
chemotherapi
plerixafor
administ
hour
prior
collect
procedur
lab
valu
mean
hct
rang
rang
mean
count
rang
count
rang
mean
rang
rang
eighteen
patient
receiv
red
blood
cell
prime
mean
ac
infus
rate
collect
mlmintbv
rang
mean
inlet
rate
mlmin
rang
whole
blood
wb
ac
ratio
mean
collect
flow
rate
mlmin
rang
mean
procedur
length
min
rang
blood
volum
process
rang
four
patient
nbl
cn
requir
collect
day
mean
rang
rang
respect
three
procedur
collect
flow
rate
mlmin
procedur
associ
miss
gcsf
dose
day
prior
collect
mean
final
product
count
rang
hct
rang
volum
ml
rang
target
dose
achiev
patient
procedur
toler
report
asymptomat
hypocalcemia
resolv
titrat
iv
calcium
cvl
access
complic
conclus
cmnc
method
effici
safe
method
pbsc
collect
pediatr
popul
kg
backgroundcas
studi
regen
potenti
cord
blood
unit
cbu
must
determin
repres
sampl
cryopreserv
product
releas
transplant
center
cord
blood
bank
measur
potenc
use
unit
cultur
method
cfu
delay
releas
cbu
day
acceler
distribut
process
cbu
develop
rapid
method
base
measur
respons
cell
test
base
flow
cytometri
measur
phosphoryl
within
cell
test
compar
cfu
method
current
consid
gold
standard
well
aldehyd
dehydrogenas
aldh
assay
studi
designmethod
ten
cryopreserv
cbu
aliquot
tube
thaw
follow
standard
oper
procedur
sop
analyz
content
viabl
cell
use
ishag
protocol
eclon
ratio
cbu
number
cell
number
proport
aldhbright
cell
respons
cell
test
determin
cbu
use
sampl
store
hour
room
temperatur
rt
simul
extrem
warm
case
scenario
well
milder
warm
event
store
sampl
day
thaw
also
compar
potenc
segment
tube
bag
five
cbu
use
cfu
test
resultsfind
test
accur
analyz
sampl
handl
follow
sop
subject
rt
warm
event
tabl
base
result
establish
accept
threshold
respons
cell
test
sensit
identifi
cbu
subject
warm
event
identifi
seven
ten
sampl
store
sampl
subject
rt
storag
perform
reproduc
cv
segment
tube
show
mean
differ
respect
respect
bag
differ
deem
signific
inferior
precis
conclus
new
method
determin
cbu
potenc
rapid
unbias
robust
clone
test
perform
better
aldh
viabil
test
identifi
sampl
subject
warm
event
test
sensit
accur
moreov
eas
gate
cell
respons
asset
routin
qualif
cbu
test
describ
herein
fulfil
requir
valid
intend
implement
method
cord
blood
bank
facil
backgroundcas
studi
cord
blood
unit
cbu
meet
criteria
clinic
use
valuabl
larg
number
basic
research
applic
studi
designmethod
public
cord
blood
bank
cbb
clinic
inventori
current
cbu
distribut
clinic
graft
transplant
worldwid
addit
cbb
provid
research
cbu
academ
institut
research
laboratori
industri
case
research
cbu
provid
without
identifi
mother
consent
exchang
scientif
technic
logist
inform
investig
cbb
manag
predominantli
via
email
howev
approach
parti
may
associ
unnecessari
delay
improv
commun
expedit
acquisit
cbu
specif
characterist
requir
variou
laboratori
studi
cbb
establish
effici
applic
webresearch
support
distribut
research
cbu
resultsfind
cbb
webresearch
facilit
transact
order
research
cbu
provid
automat
real
time
email
confirmationsnotif
upload
ship
document
check
order
statu
track
ship
inform
allow
user
search
previou
order
use
variou
field
printupload
report
order
etc
bidirect
flow
commun
cbu
provid
research
fresh
unprocess
grade
unit
within
hour
collect
limit
inform
infecti
diseas
test
b
frozen
cbu
undergon
cryopreserv
storag
liquid
nitrogen
meet
criteria
clinic
use
array
data
may
avail
blood
count
flow
cytometri
data
bacteriolog
result
hemoglobin
phenotyp
hla
type
matern
infecti
diseas
marker
blood
group
type
sinc
implement
august
new
research
account
open
current
total
particip
laboratori
affili
worldwid
academ
commerci
transact
record
result
distribut
cbu
fresh
frozen
unit
opportun
receiv
use
basic
research
develop
project
trial
stem
cell
expans
studi
valid
procedur
gmp
monitor
system
interact
expand
includ
addit
function
user
request
conclus
cbb
webresearch
enabl
investig
request
suitabl
cbu
specif
laboratori
studi
offer
effici
interfac
streamlin
order
distribut
research
cbu
backgroundcas
studi
frontier
transfus
medicin
transplant
field
cellular
therapi
ct
emerg
novel
ct
product
produc
investig
clear
standard
across
cell
process
center
across
institut
manufactur
protocol
may
vari
depend
type
ct
product
purpos
studi
uncov
variat
manufactur
practic
similar
ct
product
across
differ
cellular
process
laboratori
institut
worldwid
studi
designmethod
exploratori
survey
identifi
variat
manufactur
practic
novel
ct
product
design
sent
cellular
process
laboratori
director
worldwid
questionnair
focus
first
process
method
use
regard
type
ct
process
also
five
stage
process
event
collect
purif
vitro
expans
freez
storag
thaw
wash
secondli
questionnair
focus
level
environment
monitor
em
use
ct
product
resultsfind
respond
survey
cellular
process
laboratori
process
product
investig
label
either
phase
iii
phase
iii
clinic
trial
hpc
product
peripher
blood
pb
bone
marrow
bm
cord
blood
cb
commonli
process
respond
lymphocyt
l
commonli
product
handl
five
process
stage
ie
facil
similarli
facil
handl
dendrit
cell
dc
natur
killer
nk
cell
andor
mesenchym
stromal
cell
msc
process
product
five
process
stage
minor
center
process
pancreat
islet
cell
neural
cell
ipsc
purif
method
vari
type
product
institut
n
tabl
em
use
ct
product
shown
tabl
conclus
exploratori
survey
show
wide
variat
ct
manufactur
practic
across
differ
cellular
process
laboratori
better
understand
effect
variat
qualiti
ct
product
import
novel
ct
develop
backgroundcas
studi
determin
effect
temperatur
time
total
cell
viabil
hematopoiet
stem
cell
hsc
product
cryopreserv
dmso
thaw
studi
designmethod
hsc
product
qualiti
control
qc
vial
deceas
autolog
donor
whose
hsc
product
cryopreserv
dmso
obtain
thaw
demograph
inform
includ
age
donat
gender
diagnosi
viabil
length
cryopreserv
collect
one
vial
donor
store
room
temperatur
rt
hour
thaw
total
cell
viabil
measur
use
trypan
blue
dye
exclus
assay
hour
thaw
repeat
measur
anova
bonferroni
posttest
perform
use
graphpad
prism
determin
effect
temperatur
time
viabil
hsc
resultsfind
mean
age
hsc
collect
year
donor
femal
mean
product
cryopreserv
durat
year
eighteen
vial
donor
vialsdonor
thaw
pair
viabil
measur
rt
hour
interact
temperatur
time
statist
signific
indic
time
effect
total
cell
viabil
temperatur
time
p
temperatur
found
significantli
affect
total
cell
viabil
mean
viabil
cell
store
rt
declin
time
tabl
match
effect
statist
signific
p
statist
signific
differ
found
mean
viabil
cell
time
point
mean
immedi
hour
cell
viabil
rt
vs
p
met
accept
criteria
viabil
cell
store
hour
retain
viabil
greater
accept
criteria
cell
store
rt
hour
viabil
conclus
total
cell
viabil
hsc
product
decreas
time
thaw
store
rt
rapid
declin
rt
storag
one
hour
recommend
patient
infus
delay
backgroundcas
studi
one
major
challeng
laboratori
medicin
address
evolv
need
patient
serv
need
increasingli
met
limit
resourc
hematopoiet
progenitor
stem
cell
transplant
patient
hpsct
popul
mobil
regimen
drug
increas
avail
stem
cell
apheresi
evolv
subject
felt
use
new
mobil
regimen
result
increas
requir
number
collect
per
patient
result
increas
technologist
effort
increas
usag
flow
cytometri
specif
donor
apheresi
product
quantif
increas
process
reagent
requir
purpos
studi
provid
object
data
regard
impact
evolv
mobil
regimen
blood
transfus
servic
resourc
studi
designmethod
review
patient
medic
record
blood
transfus
servic
record
includ
apheresi
process
flow
cytometri
record
document
mobil
regimen
requir
number
collect
total
cell
per
collect
total
cell
per
kilogram
bodi
weight
concentr
cell
per
microlit
posit
cell
data
patient
collect
three
year
n
n
n
cost
analysi
perform
simpli
extrapol
cost
technologist
time
process
suppli
cost
flow
cytometri
cost
cost
analysi
includ
intang
potenti
technologist
overtim
potenti
greater
requir
storag
space
etc
resultsfind
mobil
regimen
vari
patient
neupogen
alon
patient
neupogenmozobil
patient
zarixomozobil
patient
alon
patient
unknown
patient
patient
rice
alon
patient
mozobil
alon
patient
granix
alon
patient
patient
zarixo
alon
patient
use
neupogen
alon
combin
steadili
increas
averag
number
collect
clinic
determin
total
cell
collect
posit
cell
collect
per
patient
gradual
increas
cost
analysi
compar
suggest
follow
increas
cost
personnel
cost
n
patient
per
hpsct
patient
flow
cytometri
cost
per
hpsct
patient
process
reagent
cost
per
hpsct
patient
total
averag
increas
per
hpsct
patient
conclus
evolv
mobil
regimen
one
mani
exampl
chang
standard
care
impact
upon
increasingli
limit
laboratori
resourc
hpsct
patient
increas
number
collect
per
patient
parallel
increas
use
neupogen
isol
combin
everi
addit
collect
requir
addit
technologist
time
flow
cytometri
usag
process
suppli
resourc
object
conserv
includ
intag
cost
estim
increas
cost
total
averag
per
hpsct
patient
relat
evolv
mobil
regimen
use
data
justifi
increas
hospit
administr
support
backgroundcas
studi
address
assumpt
one
devic
reach
collect
target
quickli
perform
comparison
hematopoiet
hpc
collect
optia
amicu
similar
multipl
myeloma
patient
studi
designmethod
number
collect
reach
target
lymphocyt
lym
yield
lym
collect
effici
wbc
granulocyt
gran
rbc
plt
content
citrat
toxic
compar
mobil
consist
g
plerixafor
gpl
mobil
consecut
procedur
examin
pre
count
avail
cmnc
techniqu
use
collect
endpoint
hour
anticoagul
use
possibl
start
inlet
flow
rate
mlmin
chi
squar
test
use
statist
comparison
p
consid
signific
resultsfind
collect
patient
collect
patient
first
collect
collect
target
oa
three
six
nine
signific
differ
mean
inlet
rate
oa
mlmin
whole
blood
process
l
anticoagul
use
ml
signific
differ
pre
count
oa
lym
plt
hct
see
tabl
collectionstarget
consid
median
yieldscollect
signific
differ
lym
wbc
yield
oa
respect
signific
differ
lym
gran
plt
rbc
content
calcium
dose
oa
ml
dose
respect
conclus
collect
achiev
target
one
collect
time
vs
collect
time
vs
time
lym
wbc
yield
equival
better
lym
rbc
gran
content
significantli
higher
plt
loss
citrat
toxic
optia
superior
amicu
hpc
collect
multipl
myeloma
patient
center
backgroundcas
studi
autolog
hematopoiet
progenitor
cell
hpc
transplant
indic
patient
sever
autoimmun
diseas
aid
unrespons
convent
therapi
treatment
aim
ablat
clone
b
cell
allow
regener
new
toler
immun
system
mobil
harvest
hpc
peripher
blood
essenti
part
therapi
hpc
mobil
includ
administr
granulocyt
factor
alon
combin
chemotherapi
aim
harvest
least
cellskg
retrospect
studi
purpos
analyz
mobil
characterist
accord
specif
aid
studi
designmethod
total
patient
enrol
multipl
sclerosi
ms
system
sclerosi
ssc
system
lupu
erythematosu
sle
cell
mobil
cyclophosphamid
cy
associ
median
rang
dose
initi
day
follow
cy
administr
continu
daili
cell
harvest
autoimmun
diseas
group
differ
dose
harvest
initi
peripher
blood
cell
count
reach
minimum
one
patient
sle
fail
mobil
apheres
perform
use
cell
separ
cobe
spectra
caridian
lakewood
co
usa
collect
hpc
product
cryopreserv
solut
dimethyl
sulphoxid
cell
bag
place
metal
rack
insert
freezer
kept
thaw
infus
one
three
month
later
resultsfind
result
given
median
rang
harvest
peripher
blood
ms
ssc
sle
respect
p
ms
vs
sle
total
amount
cell
collect
ms
ssc
sle
respect
p
ms
vs
sle
neutrophil
recoveri
took
place
day
ms
ssc
sle
respect
p
ms
vs
ssc
ms
vs
sle
hpc
harvest
day
mobil
ms
ssc
sle
respect
p
ms
vs
sle
ssc
vs
sle
blood
volum
process
differ
aid
group
patient
underw
singl
session
apheresi
howev
sle
ms
ssc
patient
requir
day
ms
vs
sle
p
ssc
vs
sle
p
conclus
patient
aid
effici
hpc
mobil
plu
cyclophosphamid
regimen
patient
sle
yield
lower
number
mobil
hpc
thu
lower
number
collect
cell
ms
ssc
despit
higher
day
apheresi
backgroundcas
studi
exposur
potenti
transient
warm
event
cryogen
storag
cord
blood
unit
cbu
minim
avoid
advers
impact
unit
qualiti
retriev
cbu
manual
liquid
nitrogen
dewar
shipment
cell
therapi
center
involv
exposur
neighbor
unit
rack
ambient
air
temperatur
sought
investig
impact
remov
cbu
storag
neighbor
unit
evalu
unit
viabil
ptuv
cbu
releas
dewar
rack
differ
length
storag
studi
designmethod
retrospect
analysi
conduct
use
data
cbu
releas
privat
cord
blood
bank
control
varieti
method
determin
viabil
cbu
avail
ptuv
data
obtain
trypan
blue
includ
cbu
classifi
either
first
subsequ
releas
dewar
rack
group
respect
randomli
select
cbu
releas
dewar
group
differ
rack
cbu
select
random
differ
dewar
serv
control
group
respect
wilcoxon
rank
sum
test
use
examin
differ
consid
signific
data
analys
perform
use
stata
softwar
stata
corp
lp
resultsfind
unit
releas
ptuv
base
trypan
blue
stain
cbu
group
includ
final
analysi
unit
repres
pair
releas
dewar
rack
signific
differ
unit
viabil
group
group
respect
signific
differ
ptuv
primari
secondari
cbu
releas
dewar
rack
ptuv
group
group
similarli
compar
conclus
studi
base
actual
use
scenario
limit
small
sampl
size
pair
unit
releas
dewar
rack
howev
result
consist
previou
studi
suggest
remov
cord
blood
unit
convent
dewar
control
valid
procedur
affect
viabil
neighbor
unit
convent
dewar
procedur
manual
retriev
consist
regulatori
guidelin
standard
establish
prevent
loss
product
qualiti
normal
lifecycl
cryopreserv
product
backgroundcas
studi
abo
incompat
bone
marrow
product
often
requir
manipul
reduc
red
blood
cell
volum
infus
addit
pediatr
popul
often
necessari
reduc
overal
product
volum
patient
low
bodi
weight
spectra
optia
bmp
platform
provid
reliabl
method
bone
marrow
process
yield
safe
infus
product
studi
designmethod
concurr
valid
perform
product
infus
patient
undergo
allogen
bone
marrow
transplant
abo
incompat
donor
product
process
spectra
optia
per
manufactur
recommend
evalu
tnc
mnc
recoveri
residu
red
cell
volum
second
phase
valid
perform
goal
improv
mnc
recoveri
institut
specif
accept
paramet
mnc
recoveri
tnc
recoveri
incompat
rbc
volum
mlkg
recipi
bodi
weight
resultsfind
valid
result
summar
tabl
phase
product
mnc
recoveri
phase
ii
mnc
recoveri
exceed
desir
paramet
sampl
accept
tnc
recoveri
product
red
cell
reduct
overal
volum
reduct
approxim
final
incompat
rbc
volum
infus
product
within
institut
specif
guidelin
patient
exhibit
advers
event
infus
patient
report
hypertens
exhibit
fever
within
hour
infus
conclus
spectra
optia
bmp
platform
provid
safe
effect
consist
method
process
abo
incompat
bone
marrow
product
autom
interfac
manag
aim
system
allow
less
oper
variabl
ensur
optim
cell
recoveri
pediatr
popul
method
result
product
manag
volum
infus
incompat
rbc
volum
well
allow
excel
cell
recoveri
patient
toler
infus
advers
event
smaller
infus
volum
easili
manag
nurs
staff
backgroundcas
studi
preterm
birth
complic
one
lead
caus
death
among
children
year
age
despit
advanc
medic
care
mani
survivor
face
lifetim
disabl
includ
mental
physic
retard
chronic
lung
diseas
recent
allogen
autogen
cord
blood
cell
appli
treatment
neonat
condit
encephalopathi
hie
bronchopulmonari
dysplasia
bpd
studi
assess
safeti
autolog
red
blood
cell
rbc
umbil
cord
blood
ucb
cell
infus
preterm
infant
studi
designmethod
studi
phase
singl
center
trial
evalu
safeti
autolog
ucb
cell
infus
preterm
infant
week
gestat
age
ucb
cell
characterist
infus
vital
sign
record
clinic
data
includ
mortal
rate
preterm
complic
record
resultsfind
process
ml
cell
volum
cell
number
form
cell
vital
infus
preterm
infant
within
hour
birth
advers
effect
notic
treatment
fifteen
patient
receiv
ucb
infus
surviv
durat
hospit
rang
day
regard
preterm
complic
bpd
hie
retinopathi
prematur
rop
observ
infant
intraventricular
hemorrhag
ivh
infant
pneumonia
conclus
collect
prepar
infus
fresh
autolog
ucb
cell
preterm
infant
feasibl
safe
adequ
power
random
control
studi
need
backgroundcas
studi
patient
undergo
hematopoiet
stem
cell
transplant
hsct
major
abo
incompat
increas
risk
delay
red
blood
cell
rbc
engraft
prolong
rbc
transfus
depend
patient
evalu
report
serolog
abo
discrep
forward
type
ft
revers
type
rt
may
clarifi
statu
rbc
engraft
goal
studi
compar
abo
ft
rt
discrep
patient
major
abo
incompat
hsct
use
two
differ
serolog
techniqu
correl
transfus
rate
studi
designmethod
review
compar
ft
rt
abo
serolog
type
result
rbc
transfus
need
blood
sampl
drawn
patient
major
abo
incompat
hsct
either
day
day
use
either
autom
gel
gt
versu
manual
tube
mt
method
rt
perform
use
mt
immedi
spin
addit
min
room
temperatur
incub
data
evalu
includ
hsct
donor
abo
ft
rt
strength
reaction
grade
w
number
rbc
unit
transfus
within
week
prior
abo
type
differ
ft
rt
grade
determin
gt
grade
minu
mt
grade
group
compar
use
student
resultsfind
sampl
drawn
day
day
day
day
post
transplant
day
signific
differ
observ
reactiv
hsct
donor
abo
ft
use
gel
compar
mt
method
differ
observ
reactiv
rt
either
anti
anti
b
hsct
donor
sampl
stronger
reaction
use
mt
method
p
furthermor
signific
increas
detect
either
w
anti
hsct
donor
abo
sampl
test
mt
method
minut
incub
compar
reactiv
detect
gel
method
day
transfus
rate
mean
rbc
unit
versu
day
rbc
unit
importantli
case
hsct
donor
antibodi
detect
manual
tube
test
minut
incub
transfus
rate
rbc
unit
conclus
abo
ft
result
patient
follow
major
abo
incompat
hsct
similar
use
either
gel
mt
method
wherea
rt
perform
mt
min
incub
sensit
method
detect
hsct
donor
abo
antibodi
correl
higher
rbc
transfus
requir
indic
possibl
delay
rbc
engraft
backgroundcas
studi
cellular
therapi
ipsc
tcr
becom
commonli
util
treatment
option
patient
tradit
therapi
may
option
mani
cellular
therapi
develop
patient
cell
allogen
cellular
therapi
may
also
option
patient
allogen
cellular
therapi
requir
healthi
donor
will
abl
provid
start
materi
order
produc
final
cellular
therapi
consist
donor
experi
collect
critic
cellular
therapi
manufactur
donor
util
extens
experi
cell
sourc
donor
manag
cell
collect
donor
volunt
registri
contact
consent
provid
start
materi
research
clinic
andor
commerci
use
strong
emphasi
provid
posit
donat
experi
volunt
donor
studi
designmethod
sinc
volunt
donor
contact
consent
donat
mononuclear
cell
product
collect
apheresi
mnc
therapi
allogen
hematopoiet
stem
cell
transplant
effort
result
mnc
collect
thu
far
order
donat
mnc
product
consent
donor
ask
complet
multipl
phone
call
well
appoint
prior
collect
order
assess
medic
fit
donat
well
determin
elig
statu
purpos
mandatori
donor
meet
elig
requir
domest
regulatori
agenc
certain
intern
regulatori
agenc
donor
proceed
collect
week
follow
donat
donor
sent
electron
satisfact
survey
complet
donor
ask
rate
satisfact
donat
process
thirteen
key
metric
area
rang
flexibl
schedul
educ
materi
explan
risk
feel
appreci
care
resultsfind
nearli
donor
donat
mnc
octob
decemb
complet
survey
respons
perform
goal
met
exceed
time
area
scale
averag
overal
donor
satisfact
experi
rate
conclus
whole
donor
report
donat
experi
posit
suggest
rich
histori
process
support
donor
stem
cell
donat
translat
favor
donor
experi
donat
type
start
materi
cellular
therapi
market
backgroundcas
studi
clinic
blood
recipi
often
accompani
inflamm
mainli
caus
infect
sepsi
immun
statu
recipi
may
influenc
effect
blood
transfus
guidelin
blood
transfus
condit
discuss
lot
fact
clinician
china
give
blood
transfus
patient
bodi
temperatur
mainli
caus
inflamm
except
urgent
situat
research
demonstr
viral
mimic
polyinosin
polycytidyl
acid
poli
c
synthet
rna
molecul
induc
robust
antibodi
product
mous
model
blood
transfus
report
viral
disord
demonstr
trend
toward
increas
risk
rbc
alloimmun
human
studi
investig
transfus
mice
simul
bacteri
infect
could
boost
stronger
immun
respons
underli
mechan
studi
designmethod
inject
mice
bacteria
mimic
lipoteicho
acid
lta
bacteria
mimic
lipopolysaccharid
lp
transfus
mice
human
red
blood
cell
induc
antibodi
simul
experiment
system
studi
effect
infect
rbc
immun
mice
divid
normal
control
group
human
rbc
transfus
posit
control
group
receiv
human
rbc
intraven
experiment
group
receiv
lp
four
hour
human
rbc
transfus
experiment
group
receiv
lta
four
hour
human
rbc
transfus
assess
rbc
immun
perform
measur
serum
immunoglobulin
g
igg
immunoglobulin
igm
human
rbc
weekli
two
week
lymphocyt
chang
spleen
also
monitor
flow
cytometri
resultsfind
found
bacteri
mimic
includ
lp
lta
increas
serum
igg
second
week
igm
first
week
significantli
flow
cytometri
similar
result
observ
tradit
method
tube
test
gel
test
util
lp
treat
group
concomit
reduct
regulatori
cell
spleen
mesenter
lymph
node
conclus
result
demonstr
bacteri
mimic
includ
lp
lta
could
increas
rbc
immun
mice
indic
infect
could
enhanc
rbc
immun
conclus
need
evalu
human
studi
backgroundcas
studi
success
hematopoiet
stem
cell
transplant
relat
hla
match
unrel
transplant
present
genotyp
includ
routin
test
donor
select
studi
shown
mismatch
increas
risk
gvhd
match
reduc
overal
risk
hematopoiet
stem
cell
transplant
studi
retrospect
analyz
associ
match
short
tandem
repeat
str
result
unrel
hematopoiet
stem
cell
transplant
studi
designmethod
individu
pair
unrel
underw
unrel
allogen
hsct
hla
allel
match
donor
zhejiang
provinc
collect
retrospect
analysi
genotyp
sampl
perform
method
accord
previou
report
correl
match
short
tandem
repeat
str
result
sampl
pair
unrel
transplant
analyz
str
loci
sexual
locu
detect
everi
donor
recipi
genescan
method
commerci
powerplex
fusion
system
result
str
collect
three
time
includ
one
month
three
month
six
month
transplant
resultsfind
pair
studi
str
result
recipi
show
success
hematopoiet
stem
cell
implant
without
relaps
remain
recipi
show
chimer
statu
studi
associ
match
str
result
implement
group
chimer
group
divid
three
subgroup
accord
result
genotyp
shown
tabl
match
effect
statu
hematopoiet
stem
cell
implant
accord
result
test
p
conclus
match
relat
result
short
tandem
repeat
str
unrel
hematopoiet
stem
cell
transplant
backgroundcas
studi
one
threat
viabil
cord
blood
product
clot
coagul
normal
physiolog
process
bodi
prevent
blood
loss
initi
vascular
repair
anticoagul
routin
use
collect
cord
blood
prevent
clot
citrat
phosphat
dextros
cpd
common
studi
directli
look
ratio
cpd
cb
volum
effect
viabil
cord
blood
collect
volum
vari
greatli
studi
aim
address
effect
ratio
studi
designmethod
umbil
cord
blood
unit
obtain
consent
irb
approv
cb
unit
mix
aliquot
conic
tube
contain
fix
amount
cpd
final
volum
condit
viabil
total
nucleat
cell
count
tnc
determin
time
hour
hour
hour
unit
kept
gentl
agit
room
temperatur
viabil
determin
flow
cytometri
util
run
beckman
coulter
ishag
analysi
protocol
tnc
obtain
autom
cell
counter
use
acridin
orang
percent
loss
viabil
time
calcul
obtain
differ
origin
viabil
day
viabil
subsequ
day
day
day
day
statist
analys
anova
carri
graphpad
prism
excel
resultsfind
loss
viabil
time
directli
affect
concentr
cpd
p
larger
ratio
cpd
cb
show
increas
loss
viabil
compar
lower
dilut
p
regard
loss
tnc
statist
signific
differ
dilut
group
p
signific
differ
time
point
within
group
p
tabl
show
progress
loss
viabil
time
conclus
previou
data
review
investig
suggest
low
cb
volum
lose
viabil
faster
data
suggest
cpd
may
play
signific
role
loss
viabil
time
regard
high
volum
cpd
relat
small
volum
cord
blood
higher
volum
cb
cpd
appear
show
indic
abnorm
viabil
loss
conclus
everi
cord
blood
bank
continu
strive
maxim
volum
cord
blood
collect
process
within
short
time
frame
possibl
ensur
highest
qualiti
cell
product
possibl
institut
andor
client
backgroundcas
studi
hematopoiet
stem
cell
transplant
complex
procedur
requir
optim
coordin
clinic
transplant
servic
apheresi
process
team
infus
cryopreserv
product
necessit
optim
qualiti
control
ensur
stabl
engraft
cryopreserv
stem
cell
mobil
vari
consider
among
patient
especi
patient
underli
hematolog
diseas
extens
prior
therapi
current
paradigm
posit
cell
per
kilogram
recipi
weight
ensur
engraft
ablat
marrow
repres
calcul
surplu
pluripot
stem
cell
home
marrow
mani
variabl
may
impact
collect
qualiti
final
product
empir
observ
postul
invers
correl
yield
cell
subsequ
viabil
cell
cryopreserv
product
studi
designmethod
order
evalu
possibl
invers
correl
data
gather
autolog
stem
cell
collect
paramet
collect
tabul
data
pars
ensur
standard
apheresi
protocol
respect
techniqu
collect
paramet
evalu
relationship
viabil
cd
cell
yield
collect
procedur
linear
regress
trendlin
analysi
resultsfind
data
sequenti
hpc
collect
incorpor
yield
autolog
stem
cell
transplant
candid
tabul
cd
cell
yield
rang
cell
per
patient
kg
weight
statist
mean
cd
cell
yield
collect
cell
per
patient
kg
weight
viabil
collect
rang
statist
mean
viabil
compris
one
four
apheresi
collect
per
patient
patient
receiv
product
infus
engraft
graphic
scatter
plot
analysi
demonstr
mark
variabl
respect
cell
yield
vs
viabil
regress
trendlin
analysi
relationship
cd
cell
yield
function
viabil
demonstr
consist
neg
slope
conclus
base
preliminari
analysi
viabil
autolog
stem
cell
collect
product
show
appar
invers
relationship
procedur
yield
cell
howev
mani
variabl
deserv
focus
analysi
improv
qualiti
mobil
peripher
hematopoiet
stem
cell
yield
backgroundcas
studi
studi
done
retrospect
hpc
product
process
stem
cell
cord
blood
bank
center
calcul
microbi
contamin
rate
compar
center
contamin
rate
qualiti
indic
blood
cultur
taken
stem
cell
product
investig
percentag
posit
blood
cultur
preprocess
post
process
pre
thaw
year
respect
contamin
rate
gram
posit
bacilli
propionibacterium
speci
predomin
isol
surfac
contamin
rate
contamin
rel
low
compar
center
rate
studi
designmethod
year
year
product
investig
percentag
posit
blood
cultur
preprocess
post
process
pre
thaw
cryopreserv
fresh
product
respect
posit
cultur
rate
calcul
posit
cultur
rate
cryopreserv
product
per
yearposit
cultur
rate
fresh
product
per
yearposit
cultur
rate
total
hpc
product
per
year
resultsfind
see
tabl
conclus
calcul
method
yearli
contamin
rate
show
low
percentag
year
respect
comparison
center
experi
still
aim
minim
rate
new
pi
project
plan
propionibacterium
predomin
isol
surfac
contamin
backgroundcas
studi
acut
traumat
coagulopathi
atc
lead
high
morbid
mortal
trauma
manifest
prolong
prothrombin
time
pt
decreas
platelet
function
clot
firm
increas
fibrinolyt
activ
myxoma
viru
protein
member
serin
proteas
inhibitor
superfamili
shown
inhibit
fibrinolyt
serum
proteas
includ
plasmin
tissueor
urokinas
plasminogen
activ
tpa
upa
well
exert
activ
variou
anim
model
studi
administ
preclin
use
rat
polytrauma
hemorrhag
shock
hypothes
improv
outcom
atc
studi
designmethod
isofluran
anesthet
rat
underw
polytrauma
within
minut
follow
hemorrhag
rat
resuscit
shed
volum
fresh
whole
blood
fwb
anesthet
donor
rat
trauma
vehicl
given
intraven
prior
trauma
pt
measur
baselin
trauma
lung
wetdri
weight
measur
end
experi
addit
whole
blood
healthi
human
donor
treat
determin
direct
effect
hemostasi
rotat
thromboelastogram
platelet
function
imped
aggregomet
use
adenosin
diphosph
collagen
resultsfind
prior
trauma
modestli
delay
rise
pt
immedi
trauma
trauma
compar
vehicl
percent
chang
pt
baselin
trauma
vehicl
limit
resuscit
fwb
led
signific
rise
wetdri
weight
ratio
lung
significantli
attenu
treatment
vs
vehicl
p
significantli
decreas
clot
time
vs
vehicl
p
increas
maximum
clot
firm
vs
vehicl
p
effect
platelet
aggreg
stimul
agonist
conclus
directli
potenti
clot
format
measur
assess
administr
rat
atc
delay
develop
atc
temporarili
attenu
pt
elev
immedi
trauma
may
also
reduc
acut
lung
injuri
trauma
activ
attenu
vascular
permeabl
addit
attenu
trauma
induc
coagulopathi
preliminari
studi
suggest
potenti
benefit
use
sever
trauma
investig
optim
dose
time
strategi
indic
backgroundcas
studi
viscoelast
test
rotat
thromboelastometri
vt
implement
hospit
blood
bank
guid
transfus
manag
bleed
patient
obtain
order
privileg
vt
clinic
provid
must
complet
initi
train
cours
pass
initi
compet
assess
aim
studi
determin
user
perceiv
vt
result
practic
chang
assess
ongo
user
knowledg
compet
vt
studi
designmethod
brief
onlin
questionnair
includ
annual
compet
assess
mandatori
question
educ
administ
week
compet
question
basic
level
valid
vt
expert
provid
requir
complet
survey
pass
compet
assess
score
maintain
vt
order
privileg
addit
educ
offer
fail
provid
incomplet
survey
analyz
result
compar
clinicallaboratori
data
collect
blood
bank
vt
qualiti
inform
databas
qidb
resultsfind
respons
rate
respond
demograph
order
practic
report
tabl
common
indic
vt
order
includ
trauma
cardiovascular
cv
gastrointestin
gi
hemorrhag
howev
common
indic
qidb
cv
gi
postpartum
hemorrhag
half
respond
order
interpret
vt
report
order
least
investig
possibl
hyperfibrinolysi
minor
respond
report
order
vt
patient
commonli
baselin
coagulopath
patient
decid
treat
bleed
patient
vt
order
respond
wait
result
vt
treat
base
recent
standard
lab
avail
use
vt
confirm
decis
remaind
base
treatment
decis
clinic
stabil
sever
bleed
qidb
vt
repeat
ensur
defect
improv
intervent
wherea
respond
report
almost
alway
order
repeat
vt
mean
compet
assess
question
respond
perform
best
low
fibrinogen
hyperfibrinolysi
case
scenario
provid
repeatedli
order
vt
clinic
practic
like
pass
compet
assess
conclus
vt
perceiv
clinic
use
manag
bleed
patient
often
chang
transfus
practic
confirm
clinic
decis
make
ongo
educ
clinic
experi
vt
critic
maintain
user
profici
backgroundcas
studi
coagulopath
bleed
seriou
complic
cardiac
surgeri
key
contributor
acquir
hypofibrinogenaemia
plasma
fibrinogen
gl
standard
treatment
cryoprecipit
purifi
fibrinogen
concentr
also
use
compar
data
exist
randomis
trial
need
primari
object
fibrinogen
replenish
surgeri
fibr
studi
demonstr
new
fibrinogen
concentr
octafibrinfibryga
octapharma
cryoprecipit
studi
designmethod
pragmat
randomis
phase
trial
adult
cardiac
surgic
patient
clinic
signific
bleed
due
acquir
hypofibrinogenaemia
patient
undergo
cardiopulmonari
bypass
cpb
fibrinogen
supplement
order
within
hour
randomis
receiv
g
fibrinogen
concentr
unit
cryoprecipit
dose
equival
research
personnel
obtain
outcom
assess
blind
treatment
alloc
randomis
patient
receiv
fibrinogen
supplement
accord
clinic
need
patient
consent
randomis
waiv
written
inform
consent
obtain
soon
possibl
theraft
primari
outcom
combin
red
cell
platelet
plasma
transfus
within
hour
cpb
secondari
outcom
includ
blood
product
use
within
day
major
bleed
within
hour
fibrinogen
level
advers
event
enrol
patient
provid
power
demonstr
base
margin
patientsgroup
rate
safeti
review
dsmb
perform
everi
patient
interim
analysi
perform
patient
stop
rule
futil
overwhelm
efficaci
pragmat
design
treatment
algorithm
align
standard
practic
aid
adher
generaliz
resultsfind
largest
randomis
studi
fibrinogen
concentr
versu
cryoprecipit
adult
cardiac
surgic
patient
conduct
canadian
center
expect
complet
late
result
avail
earli
patient
random
april
safeti
issu
far
assess
dsmb
conclus
new
fibrinogen
concentr
compar
cryoprecipit
would
support
use
cardiac
surgic
patient
experienc
signific
bleed
due
hypofibrinogenaemia
yet
bleed
popul
backgroundcas
studi
mani
individu
cancer
chronic
hematolog
disord
receiv
red
cell
rbc
transfus
tx
outpati
rbc
unit
thought
increas
recipi
hemoglobin
hgb
gdl
smaller
increment
may
occur
set
better
understand
recipi
factor
affect
hgb
increment
could
help
provid
better
manag
patient
studi
designmethod
data
collect
part
red
cell
outpati
transfus
outcom
retro
studi
prospect
observ
studi
outpati
rbc
tx
inclus
criteria
age
ambulatori
least
prior
rbc
tx
within
month
subject
report
activ
bleed
time
tx
exclud
hgb
measur
minut
tx
multivari
linear
regress
chang
hemoglobin
minut
week
perform
use
backward
elimin
identifi
signific
clinic
variabl
resultsfind
total
subject
complet
studi
includ
analysi
mean
age
sd
year
patient
receiv
rbc
unit
transfus
episod
baselin
hgb
measur
subject
receiv
addit
rbc
unit
part
patient
care
subject
includ
week
increment
assess
mean
chang
hgb
gdlunit
sd
minut
gdlunit
sd
one
week
hgb
increment
minut
decreas
larger
patient
blood
volum
nadler
higher
patient
baselin
hgb
increas
rbc
compon
volum
transfus
hgb
chang
one
week
increas
chang
hgb
minut
decreas
subject
blood
volum
nadler
lower
patient
hospit
hgb
measur
subject
age
gender
volum
transfus
total
rbc
dose
week
analysi
chemotherapi
use
week
studi
transfus
elimin
backward
elimin
conclus
cohort
patient
hgb
increment
less
gdlunit
tx
two
factor
influenc
hgb
increment
minut
patient
diseas
statu
associ
hgb
respons
one
week
factor
captur
studi
may
also
impact
hgb
increment
data
suggest
recipi
factor
help
predict
provid
account
recipi
circul
blood
volum
hgb
addit
expect
increment
per
rbc
unit
achiev
tx
goal
backgroundcas
studi
platelet
morpholog
activ
believ
import
success
prophylact
platelet
transfus
thrombocytopen
patient
develop
kunicki
morpholog
score
km
evalu
qualiti
platelet
undergo
morpholog
transform
due
condit
storag
temperatur
age
higher
percentag
platelet
believ
predict
poor
platelet
recoveri
surviv
transfus
recent
year
flow
cytometri
emerg
prefer
tool
quantif
platelet
activ
surfac
express
put
platelet
activ
marker
studi
attempt
find
correl
km
express
store
platelet
explor
possibl
use
km
altern
flow
cytometri
platelet
activ
quantif
studi
designmethod
apheresi
platelet
ap
collect
donor
ml
mini
platelet
storag
bag
either
agit
rt
without
agit
sampl
assess
day
storag
km
use
phase
contrast
microscopi
one
hundr
free
float
platelet
assign
arbitrari
grade
base
morpholog
km
calcul
sum
grade
superior
morpholog
disc
equal
assess
surfac
express
ap
stain
antibodi
analyz
fac
canto
data
report
km
express
data
analyz
pearson
correl
coeffici
r
use
anova
signific
set
p
resultsfind
high
km
observ
day
platelet
platelet
morpholog
highli
preserv
rt
storag
condit
similar
kmss
subsequ
day
day
day
platelet
store
increas
amoeboid
morpholog
decreas
kmss
day
day
rt
sampl
show
margin
increas
express
day
day
day
wherea
signific
increas
observ
sampl
day
day
km
express
strong
neg
correl
r
p
expect
percentag
morpholog
display
strong
posit
correl
express
r
p
conclus
result
studi
suggest
km
compar
express
measur
via
flow
cytometri
good
indic
platelet
activ
phenotyp
store
sampl
therefor
kunicki
morpholog
score
quick
econom
altern
flow
cytometri
platelet
assess
backgroundcas
studi
approv
prothrombin
complex
concentr
kcentra
revers
vitamin
k
bleed
us
becom
rel
common
practic
use
fashion
correct
coagulopathi
caus
direct
oral
anticoagul
doac
inhibitor
howev
efficaci
safeti
scenario
studi
designmethod
perform
retrospect
observ
studi
use
revers
bleed
level
one
trauma
center
novemb
februari
follow
data
collect
patient
age
gender
weight
indic
dosag
inr
hemoglobin
hgb
prior
post
administr
clinic
outcom
acut
chronic
thromboembol
event
within
hour
day
administr
respect
addit
thromboembol
event
document
primari
team
post
infus
subsequ
evalu
author
determin
potenti
contribut
resultsfind
identifi
patient
doac
receiv
center
studi
time
frame
common
indic
receiv
intracrani
hemorrhag
ich
gastrointestin
gi
bleed
dosag
rang
ukg
patient
doac
show
signific
decreas
inr
averag
averag
howev
clinic
appear
effect
stop
hemorrhag
patient
patient
show
improv
hemorrhag
demonstr
stabil
intracrani
hemorrhag
size
andor
steadi
hgb
concentr
averag
hb
differ
administr
mgdl
notabl
five
patient
die
within
one
week
administr
four
due
irrevers
brain
damag
associ
initi
intracrani
bleed
one
due
inoper
gi
bleed
find
thromboembol
event
within
hour
administr
howev
four
patient
thromboembol
event
day
receiv
includ
stroke
myocardi
infarct
atrial
thrombi
ij
tube
thrombi
conclus
data
show
rel
effici
aid
revers
doac
patient
sever
hemorrhag
notic
patient
experienc
form
thromboembol
event
administr
although
imput
process
versu
underli
diseas
difficult
pars
addit
prospect
studi
would
warrant
evalu
safeti
indic
backgroundcas
studi
supratherapeut
inr
major
bleed
secondari
warfarin
therapi
occur
approxim
patient
chronic
anticoagul
atrial
fibril
avail
treatment
option
revers
anticoagul
includ
withhold
warfarin
administ
oral
intraven
vitamin
k
fresh
frozen
plasma
ffp
prothrombin
complex
concentr
pcc
use
pcc
recommend
sever
bleed
sever
organ
respect
consensu
guidelin
includ
accp
transfus
servic
laboratori
bed
health
system
recent
recogn
warfarin
revers
transfus
indic
plasma
transfus
occur
furthermor
plasma
order
unit
recommend
dose
plasma
unit
adult
retrospect
analysi
plasma
transfus
indic
order
deem
appropri
warfarin
revers
account
inappropri
order
multidisciplinari
team
assembl
address
inappropri
use
plasma
within
health
system
studi
designmethod
team
evalu
current
practic
examin
avail
literatur
review
standard
transfus
guidelin
indic
relat
polici
well
provid
educ
key
stakehold
group
intern
anticoagul
revers
guidelin
updat
recommend
use
ppc
emerg
revers
warfarin
recommend
use
vitamin
k
patient
warfarin
revers
remov
transfus
indic
order
plasma
addit
clinic
decis
tool
creat
incorpor
electron
medic
record
calcul
recommend
quantiti
plasma
base
predefin
algorithm
six
month
period
follow
intervent
individu
provid
receiv
time
feedback
regard
inappropri
use
plasma
resultsfind
six
month
immedi
follow
educ
effort
percentag
plasma
order
deem
appropri
due
warfarin
revers
decreas
number
unit
plasma
order
decreas
review
also
indic
mani
provid
modifi
number
plasma
unit
recommend
clinic
decis
support
tool
suggest
need
intervent
conclus
intern
review
plasma
util
bed
health
system
identifi
concern
order
indic
well
dose
provid
educ
time
feedback
appear
posit
impact
appropri
use
plasma
transfus
provid
educ
like
need
reinforc
messag
influenc
plasma
dose
practic
backgroundcas
studi
prophylact
platelet
transfus
wide
use
chemotherapi
induc
thrombocytopenia
cit
howev
platelet
count
alon
poor
predictor
bleedingfor
adequ
hemostasi
format
sustain
stabl
clot
essenti
bleed
event
cit
patient
similar
platelet
count
might
influenc
chang
clot
lysi
potenti
patient
hypothes
bleed
risk
cit
similar
platelet
count
might
influenc
chang
clot
lysi
potenti
investig
clot
strength
suscept
tpa
induc
clot
lysi
measur
design
whole
blood
rotat
thromboelastometri
assay
design
assess
clot
firm
stabil
studi
designmethod
result
cit
compar
result
healthi
individu
paramet
wereclot
time
ct
clot
format
time
cft
maximum
clot
firm
mcf
lot
lt
delta
ls
multivari
linear
regress
use
identifi
independ
determin
outcom
variabl
includ
fibrinogen
fii
fvii
fxiii
plasminogen
tpa
tafi
hemoglobin
platelet
leucocyt
count
also
result
cit
hour
hour
transfus
compar
resultsfind
consecut
cit
patient
healthi
individu
includ
patient
hour
posttransfus
hour
posttransfus
result
cit
patient
low
tafi
level
express
high
fviii
fibrinogen
vwf
activ
compar
healthi
individu
ct
cft
significantli
longer
mcf
significantli
lower
cit
lot
lt
shorter
cit
patient
delta
ls
min
significantli
differ
combin
lotlt
result
show
hyperfibrinolysi
platelet
transfus
patient
delta
lysi
speed
normal
patient
multivari
analysi
higher
plasminogen
level
significantli
associ
shorter
lotlt
higher
leukocyt
fxiii
fii
significantli
associ
prolong
lotlt
higher
fibrinogen
associ
decreas
lysi
speed
patient
receiv
platelet
hour
cft
significantli
shorter
mcf
significantli
higher
compar
valu
although
signific
increas
cft
decreas
mcf
notic
hour
outcom
still
improv
compar
lotlt
significantli
prolong
hour
hour
posttransfus
lotlt
result
transfus
indic
reduct
number
patient
hyperfibrinolysi
conclus
outcom
determin
agreement
expect
chang
associ
hyperfibrinolysi
cit
patient
slower
clot
format
form
weaker
clot
less
resist
fibrinolysi
signific
proport
cit
patient
hyperfibrinolysi
accord
lotlt
valu
platelet
transfus
significantli
improv
resist
fibrinolysi
especi
hour
transfus
patient
tpa
rotem
chang
hyperfibrinolyt
profil
less
hyperfibrinolyt
normal
profil
platelet
transfus
backgroundcas
studi
neonat
coagul
differ
adult
first
sever
day
life
due
incomplet
liver
develop
result
clot
factor
level
less
adult
applic
adult
coagul
standard
may
affect
abnorm
clot
assess
neonat
patient
premis
manag
clot
newborn
understand
normal
clot
interv
newborn
accur
determin
coagul
anomali
conduc
effici
treatmentscompar
adult
teg
report
less
frequent
pediatr
especi
neonatolog
even
less
patholog
neonat
establish
teg
paramet
interv
healthi
peopl
differ
age
conduc
expans
teg
applic
studi
designmethod
test
rang
normal
neonat
thromboelastographi
teg
valu
chines
popul
evalu
coagul
statu
newborn
patholog
pregnanc
total
neonat
enrol
studi
follow
healthi
neonat
neonat
gravida
gestat
hypertens
neonat
anem
gravida
neonat
diabet
gravida
preterm
newborn
test
compar
analys
base
cord
blood
teg
blood
coagul
blood
function
test
resultsfind
normal
neonat
teg
particip
differ
adult
clot
reaction
time
r
valu
min
lower
adult
clot
kinet
k
valu
min
adult
angl
valu
similar
adult
maximum
amplitud
valu
mm
equival
lower
limit
adult
coagul
index
ci
valu
compar
adult
neonat
teg
paramet
hypertens
anemia
significantli
differ
normal
neonat
statist
teg
differ
r
k
angl
valu
newborn
diabet
gravida
newborn
healthi
gravida
statist
teg
differ
r
angl
valu
prematur
neonat
conclus
neonat
teg
paramet
differ
interv
adult
analysi
result
also
differ
tradit
coagul
test
need
backgroundcas
studi
coagulopathi
trauma
extens
studi
last
decad
valu
viscoelastometri
guid
manag
patient
well
document
notabl
studi
coagulopathi
burn
patient
scarc
sever
studi
shown
burn
patient
hypercoagu
howev
studi
done
use
sampl
collect
patient
resuscit
upon
admiss
icu
addit
although
burn
patient
typic
normal
slightli
elev
platelet
platelet
function
question
sever
studi
studi
designmethod
conduct
prospect
observ
studi
burn
patient
year
present
level
trauma
center
teg
order
burn
team
variou
patient
done
part
studi
citrat
sampl
collect
patient
present
whole
blood
aggreg
studi
perform
immedi
remain
sampl
process
immedi
plasma
kept
frozen
test
addit
sampl
collect
day
sampl
studi
microparticl
number
ident
microrna
cytokinechemokin
concentr
coagul
factor
fviii
fix
fx
fv
fvii
ps
pc
von
willebrand
factor
antigen
activ
valu
resultsfind
date
patient
enrol
studi
still
ongo
major
patient
thermal
burn
caus
flame
exposur
mean
sd
age
patient
rang
year
male
mean
total
bodi
surfac
area
burn
tbsa
rang
mean
number
rbc
transfus
rang
unit
patient
receiv
plasma
platelet
transfus
none
die
teg
trace
normal
shorten
r
time
mean
platelet
count
within
refer
rang
time
point
figur
patient
abnorm
whole
blood
aggreg
respons
adp
collagen
arachidon
acid
obviou
even
patient
littl
tbsa
burn
patient
abnorm
platelet
activ
platelet
inhibitor
therapi
conclus
reason
decreas
platelet
activ
unclear
studi
ongo
one
theori
platelet
may
degranul
respons
acut
phase
reaction
may
produc
higher
percentag
platelet
microparticl
contribut
hypercoagu
state
observ
other
teg
studi
backgroundcas
studi
rigor
donor
screen
blood
product
test
reduc
transmiss
rate
infecti
organ
blood
transfus
risk
transmiss
emerg
pathogen
persist
pathogen
reduct
method
steril
blood
product
result
decreas
pathogen
load
previou
studi
demonstr
alter
coagul
factor
level
pathogen
reduc
cryoprecipit
assess
procoagul
microparticl
mp
activ
pathogen
reduct
scarc
cryoprecipit
purpos
studi
compar
mp
prothrombinas
activ
sampl
wb
aph
cryoprecipit
without
pathogen
reduct
studi
designmethod
studi
donor
plasma
group
donor
pool
split
produc
six
ident
aph
six
ident
wb
cryoprecipit
unit
pr
treatment
perform
three
aph
three
wb
unit
accord
manufactur
recommend
amotosalen
uva
light
remain
three
aph
three
wb
unit
serv
control
procoagul
mp
activ
assess
use
function
prothrombinas
assay
accord
manufactur
instruct
level
thrombin
report
phosphatidylserin
ps
equival
comparison
pr
group
perform
use
independ
sampl
signific
result
declar
p
resultsfind
signific
decreas
prothrombinas
activ
note
wb
compar
wb
signific
differ
measur
aph
pr
tabl
conclus
find
small
studi
suggest
pathogen
reduct
may
decreas
prothrombinas
activ
cryoprecipit
could
potenti
explain
sequestr
mp
amotosalen
adsorpt
devic
pathogen
reduct
quantit
thrombin
gener
assay
function
assess
thromboelastometri
evalu
hemostat
equival
warrant
backgroundcas
studi
taco
cardiogen
pulmonari
edema
trigger
transfus
patient
chronic
heart
failur
high
risk
taco
systol
heart
failur
risk
factor
diastol
failur
might
import
lieberman
l
et
al
tmr
studi
designmethod
herein
report
two
case
taco
diastol
heart
failur
relat
transfus
iron
overload
could
first
hit
resultsfind
case
year
old
sickl
cell
patient
die
hour
liver
transplant
indic
haemochromatosi
hepat
cirrhosi
child
pugh
diabet
cardiac
involv
major
iron
overload
sign
ventricular
hypertrophi
ekg
systol
eject
fraction
major
relax
disord
associ
diseas
deferroxamin
deferasirox
introduc
sever
time
stop
side
effect
deferripron
well
toler
introduc
late
patient
die
intract
hemorrhag
cardiogen
shock
vascular
fill
previous
grade
taco
grade
risk
factor
diastol
heart
failur
relat
hemosiderosi
case
year
old
chronic
transfus
myelodysplasia
patient
receiv
pack
red
cell
prc
year
refer
hospit
impair
gener
condit
fever
upon
arriv
hb
gdl
show
hepatosplenomegali
two
prc
transfus
slowli
seven
hour
complet
experienc
dyspnea
arteri
desatur
hypertens
bilater
crackl
increas
bnp
pgml
iv
furosemid
isosorbid
dinitr
immedi
administ
patient
die
congest
heart
multipl
organ
failur
discrep
sever
heart
failur
known
cardiac
histori
serum
ferritin
assay
retrospect
perform
show
level
ngml
conclus
cardiac
hemochromatosi
character
diastol
dysfunct
arrhythmia
late
stage
dilat
cardiomyopathi
retrospect
studi
among
consecut
taco
case
eject
fraction
wherea
show
evid
diastol
dysfunct
lieberman
l
et
al
analog
transfus
relat
acut
lung
injuri
propos
model
red
blood
cell
transfus
could
respons
first
step
caus
heart
iron
overload
consequ
diastol
dysfunct
second
step
transfus
fluid
volum
remain
intravascular
hypothesi
could
result
consid
iron
chelat
prevent
measur
prevent
taco
chronic
transfus
patient
backgroundcas
studi
wide
accept
point
care
whole
blood
coagul
test
devic
use
detect
coagulopathi
real
time
manner
massiv
bleed
situat
major
cardiac
surgeri
howev
implement
still
limit
japan
cost
lack
public
insur
support
studi
designmethod
fifti
consecut
case
elect
cardiac
surgeri
cardiopulmonari
bypass
analyz
studi
blood
sampl
collect
three
point
ie
surgeri
termin
cardiopulmonari
bypass
protamin
administr
surgeri
respect
laboratori
data
measur
two
point
care
devic
sonoclot
routin
coagul
blood
count
test
collect
blood
sampl
case
data
obtain
point
care
devic
provid
clinician
consequ
use
determin
transfus
indic
case
first
evalu
linear
correl
laboratori
examin
data
pearson
test
next
theoret
total
blood
loss
calcul
hemoglobin
content
total
amount
periop
rbc
transfus
also
record
thorough
clinic
data
collect
patient
electron
record
final
tri
establish
linear
regress
model
predict
periop
bleed
rbc
transfus
amount
measur
laboratori
data
collect
clinic
paramet
resultsfind
case
includ
studi
case
receiv
type
transfus
ie
case
rbc
transfus
case
plasma
transfus
case
platelet
transfus
respect
averag
amount
rbc
transfus
japanes
unit
approxim
us
unit
measur
paramet
routin
laboratori
platelet
count
fibrinogen
valu
strongli
correl
contrari
act
valu
routin
coagul
test
correl
sonoclot
paramet
regress
analysi
fail
establish
ration
comprehens
linear
regress
model
although
oper
time
act
valu
termin
cardiopulmonari
bypass
strongli
associ
periop
bleed
amount
rbc
transfus
extract
explanatori
variabl
paradox
exhibit
invers
correl
bleed
tendenc
plateletcoagul
function
suggest
hidden
confound
factor
studi
popul
limit
studi
design
signific
point
care
test
explanatori
variabl
sonoclot
pf
valu
termin
cardiopulmonari
bypass
correl
platelet
transfus
volum
well
oper
time
preoper
platelet
count
conclus
act
valu
termin
cardiopulmonari
bypass
use
predictor
periop
bleed
major
cardiac
surgeri
although
measur
paramet
may
use
independ
paramet
convent
act
test
intervent
studi
requir
determin
use
major
cardiac
surgeri
japanes
popul
backgroundcas
studi
histor
rbc
order
place
use
transfus
indic
blood
bank
perform
prospect
audit
order
contain
lab
valu
part
indic
although
mani
instanc
patient
satisfi
specif
approv
transfus
indic
order
provid
select
bypass
prospect
audit
process
remov
indic
cpoe
system
physician
need
place
order
outsid
approv
criteria
hesh
would
need
call
blood
bank
explain
rbc
transfus
requir
document
reason
patient
emr
remov
indic
made
process
order
potenti
medic
unnecessari
rbc
harder
sought
determin
impact
chang
total
number
blood
product
patient
transfus
studi
designmethod
quarterli
transfus
statist
includ
number
rbc
sdp
plasma
patient
transfus
compar
post
data
test
statist
signific
use
student
hospit
cmi
data
evalu
determin
chang
might
contribut
decreas
increas
need
transfus
resultsfind
fiscal
year
cmi
increas
studi
period
quarterli
averag
number
rbc
transfus
patient
transfus
follow
remov
quarterli
averag
number
rbc
transfus
patient
transfus
platelet
transfus
rate
remain
stabl
pre
post
plasma
transfus
rate
vari
wide
rang
pre
post
larg
base
number
patient
undergo
tpe
although
decreas
number
rbc
transfus
statist
signific
decreas
number
patient
transfus
per
quarter
howev
statist
signific
conclus
elimin
option
select
transfus
indic
result
fewer
total
rbc
unit
transfus
fewer
patient
transfus
despit
increas
cmi
current
rbc
acquisit
cost
approxim
per
unit
elimin
medic
unnecessari
rbc
save
roughli
per
quarter
annual
backgroundcas
studi
comprehens
patient
blood
manag
pbm
program
common
metric
promot
desir
transfus
practic
includ
rbc
platelet
transfus
cours
concurr
blood
util
audit
part
institut
pbm
program
surpris
number
plasma
transfus
identifi
transfus
event
basi
current
studi
studi
designmethod
data
plasma
transfus
academ
tertiari
care
hospit
obtain
interrog
electron
health
record
system
plasma
transfus
identifi
proxim
inr
valu
serv
basi
divid
studi
popul
two
group
patient
inr
valu
patient
inr
valu
subgroup
patient
inr
valu
primari
focu
studi
addit
studi
data
group
includ
transfus
clinic
servic
inr
valu
obtain
within
hour
transfus
avail
probabl
indic
transfus
adult
patient
includ
studi
patient
transfus
either
oper
room
care
unit
exclud
distinct
made
type
plasma
product
transfus
ie
ffp
versu
resultsfind
total
unit
plasma
transfus
singl
unit
met
inclus
criteria
review
follow
inr
valu
rang
mean
median
transfus
associ
inr
valu
exceed
associ
inr
valu
less
latter
group
high
probabl
inappropri
transfus
underw
studi
group
mean
median
inr
respect
major
unit
transfus
attribut
surgic
subspecialti
emerg
medicin
inr
avail
transfus
event
demonstr
signific
chang
baselin
final
common
indic
transfus
could
discern
includ
hypovolemia
bleed
ie
plasma
transfus
red
blood
cell
conclus
daili
audit
plasma
transfus
reveal
transfus
event
rel
common
includ
transfus
patient
normal
coagul
valu
surgic
subspecialti
emerg
medicin
account
major
transfus
like
repres
inappropri
transfus
opportun
improv
practic
institut
though
red
cell
platelet
transfus
repres
desir
practic
plasma
transfus
undesir
qualiti
improv
metric
backgroundcas
studi
hyperkalemia
rare
complic
rbc
transfus
store
rbc
leak
intracellular
potassium
k
due
inhibit
membran
atp
pump
gamma
irradi
potenti
k
leak
rbc
transfus
administ
slowli
shown
littl
effect
serum
k
concentr
howev
massiv
rapid
transfus
may
caus
tempor
hyperkalemia
especi
patient
total
blood
volum
small
serum
k
transfus
product
high
mani
case
report
occurr
transfus
associ
hyperkalemia
tah
characterist
patient
implic
blood
product
studi
systemat
studi
tah
conduct
aabb
pediatr
subcommitte
data
two
facil
report
studi
designmethod
studi
period
medic
record
patient
age
year
old
k
level
refer
rang
within
hour
rbc
transfus
review
patient
demograph
medic
histori
symptom
treatment
hyperkalemia
well
age
volum
modif
transfus
rbc
unit
resultsfind
total
patient
receiv
total
rbc
transfus
hyperkalemia
within
hour
rbc
transfus
found
patient
receiv
rbc
transfus
irradi
median
k
increas
previou
k
level
hyperkalemia
mmoll
patient
median
age
weight
time
transfus
year
old
kg
respect
patient
seriou
includ
prematur
patient
cardiac
dysfunct
renal
diseas
sepsi
brain
lesion
patient
high
volum
rbc
use
extracorpor
membran
oxygen
ecmo
patient
associ
mortal
mortal
occur
patient
within
day
hyperkalemia
occurr
among
patient
decreas
k
hyperkalemia
occurr
treat
hyperkalemia
patient
die
soon
hyperkalemia
note
transfus
patient
transfus
patient
estim
total
blood
volum
irradi
rbc
within
hour
hyperkalemia
occurr
overal
patient
receiv
median
estim
total
blood
volum
within
hour
hyperkalemia
occurr
median
age
rbc
unit
transfus
day
old
conclus
fourteen
patient
experienc
hyperkalemia
within
hour
rbc
transfus
patient
hyperkalemia
time
death
possibl
attribut
rbc
transfus
patient
median
age
weight
time
hyperkalemia
transfus
year
old
kg
respect
cardiac
dysfunct
common
risk
factor
possibl
tah
prematur
renal
dysfunct
ecmo
associ
massiv
rbc
transfus
also
associ
higher
risk
tah
addit
data
facil
pend
backgroundcas
studi
tranexam
acid
txa
inexpens
wide
avail
agent
known
reduc
red
blood
cell
rbc
transfus
cardiac
surgeri
select
orthoped
surgeri
use
cardiac
surgeri
routin
use
effect
surgeri
compar
rate
bleed
transfus
uncertain
object
studi
evalu
txa
util
pattern
surgeri
high
risk
transfus
studi
designmethod
accur
character
txa
use
surgeri
high
risk
periop
rbc
transfus
complet
retrospect
cohort
studi
evalu
patient
year
age
undergo
surgeri
five
hospit
two
citi
januari
decemb
identifi
procedur
high
risk
transfus
use
standard
canadian
classif
health
intervent
cci
procedur
code
contain
within
hospit
discharg
abstract
databas
dad
link
dad
transfus
databas
laboratori
databas
obtain
supplementari
transfus
laboratori
data
evalu
contemporari
txa
util
pattern
identifi
cohort
procedur
perform
chart
review
chart
databas
queri
describ
proport
patient
receiv
intraop
txa
also
describ
detail
txa
dose
resultsfind
citi
identifi
open
surgeri
associ
transfus
rate
cohort
tranexam
acid
use
surgeri
rang
txa
usag
highest
orthoped
spine
surgeri
includ
total
hip
arthroplasti
femur
osteotomi
pelvic
osteoplastyosteotomi
vertebrectomi
vertebr
fusion
exclud
orthoped
spine
surgeri
txa
use
limit
open
surgeri
mean
time
oper
start
time
txa
administr
minut
minut
txa
administ
bolu
infus
mean
txa
dose
mg
mg
conclus
tranexam
acid
routin
use
cardiac
orthoped
spine
surgeri
yet
util
surgic
domain
high
risk
periop
red
blood
cell
transfus
remain
low
backgroundcas
studi
massiv
transfus
protocol
associ
decreas
mortal
improv
hemostasi
adult
trauma
patient
year
greater
death
injuri
attribut
firearm
unit
state
howev
transfus
requir
patient
well
understood
studi
sought
determin
blood
util
mortal
differ
victim
gun
violenc
versu
victim
relat
trauma
patient
requir
transfus
trauma
center
urban
set
also
assess
cost
transfus
patient
studi
designmethod
state
trauma
registri
review
trauma
patient
present
tertiari
care
facil
januari
june
studi
popul
limit
patient
receiv
blood
product
hospit
cours
patient
categor
base
mechan
injuri
gunshot
wound
gsw
trauma
number
type
blood
product
assess
primari
outcom
mortal
blood
util
cost
transfus
cost
assess
two
method
blood
acquisit
cost
cost
total
cost
transfus
includ
overhead
resultsfind
data
shown
tabl
gsw
patient
younger
like
male
higher
injuri
sever
score
among
trauma
patient
requir
blood
product
administr
victim
gun
violenc
mortal
emerg
depart
ed
time
higher
overal
mortal
time
higher
gsw
cohort
compar
cohort
gsw
patient
requir
transfus
demonstr
approxim
ed
mortal
overal
mortal
gsw
patient
receiv
averag
time
amount
blood
product
per
patient
compar
patient
includ
prbc
ffp
platelet
cryoprecipit
transfus
gsw
patient
million
went
transfus
cost
averag
transfus
cost
per
patient
time
higher
gsw
victim
versu
trauma
patient
conclus
compar
traumat
injuri
injuri
associ
substanti
greater
mortal
well
greater
blood
util
cost
transfus
gsw
patient
select
group
sinc
previou
report
institut
includ
gsw
victim
transfus
report
mortal
rate
report
backgroundcas
studi
prior
one
type
blood
salvag
devic
avail
surgic
case
institut
medtron
salvag
devic
util
discontinu
fix
volum
bowl
requir
minimum
ml
rbc
produc
unit
creat
limit
pediatr
case
freseniu
continu
auto
transfus
cat
salvag
devic
util
chamber
continu
wash
low
volum
blood
requir
minimum
ml
rbc
produc
unit
earli
cat
implement
accommod
low
blood
volum
loss
case
studi
evalu
pre
post
implement
cat
devic
pediatr
cardiac
case
studi
designmethod
process
blood
recoveri
volum
patient
kilogram
kg
compar
devic
addit
key
factor
includ
patient
weight
age
case
recov
salvag
blood
reinfus
netp
also
compar
two
devic
resultsfind
januari
septemb
pediatr
cardiac
case
request
intraop
blood
salvag
util
octob
decemb
pediatr
cardiac
case
util
devic
intraop
blood
salvag
mean
standard
deviat
p
valu
shown
tabl
conclus
compar
blood
recoveri
devic
process
similar
blood
volum
devic
recov
statist
significantli
blood
volum
patient
smaller
weight
younger
age
autolog
overal
approxim
pediatr
cardiac
case
netp
use
case
netp
post
implement
allow
greater
blood
volum
recoveri
pediatr
cardiac
case
backgroundcas
studi
patient
admit
medic
intens
care
unit
micu
frequent
blood
collect
laboratori
test
also
often
transfus
correct
anemia
goal
studi
understand
laboratori
phlebotomi
caus
anemia
subsequ
transfus
within
micu
facil
specif
aim
investig
investig
patient
anemia
statu
quantit
volum
blood
lost
diagnost
phlebotomi
identifi
relat
laboratori
phlebotomi
transfus
determin
clinician
follow
transfus
trigger
guidelin
facil
studi
designmethod
prospect
retrospect
studi
investig
micu
patient
transfus
transfus
januari
june
studi
util
facil
laboratori
inform
system
electron
medic
record
system
identifi
patient
demograph
diagnosi
anemia
statu
specifi
undetermin
hemoglobin
hgb
track
admiss
transfus
trigger
laboratori
phlebotomi
perform
number
rbc
unit
transfus
chi
squar
use
analyz
data
resultsfind
studi
popul
investig
undetermin
anemia
statu
identifi
major
transfus
untransfus
patient
mean
total
phlebotomi
blood
loss
transfus
patient
ml
phlebotomi
blood
loss
untransfus
patient
ml
p
transfus
patient
receiv
unit
rbc
admiss
chang
hgb
admiss
discharg
interpret
confid
determin
hgb
valu
chang
gdl
group
overal
chang
hgb
signific
group
transfus
trigger
initi
clinician
mean
hgb
valu
gdl
median
hgb
gdl
conclus
evid
suggest
iatrogen
anemia
caus
transfus
micu
popul
facil
though
transfus
popul
admit
lower
hgb
level
discharg
hgb
level
lower
studi
control
group
higher
hgb
level
control
group
possibl
mitig
need
transfus
intervent
also
undetermin
anemia
classif
identifi
highest
frequenc
studi
popul
data
may
relat
diagnost
phlebotomi
iatrogen
anemia
within
transfus
popul
mani
patient
receiv
unit
rbc
averag
volum
ml
admiss
correspond
averag
total
blood
loss
base
transfus
trigger
data
guidelin
facil
clinician
unnecessarili
transfus
patient
micu
patient
popul
backgroundcas
studi
import
determin
optim
platelet
dose
thrombocytopen
patient
judici
use
scarc
resourc
achiev
transfus
platelet
differ
dose
compar
post
transfus
respons
indic
studi
designmethod
prospect
studi
perform
compar
efficaci
low
high
dose
standard
dose
singl
donor
apheresi
platelet
sdap
transfus
term
platelet
transfus
respons
indic
correct
count
increment
cci
percent
platelet
recoveri
ppr
correl
patient
clinic
profil
total
stabl
patient
enrol
studi
fulfil
inclus
criteria
studi
approv
institut
ethic
committe
patient
receiv
apheresi
platelet
low
dose
unit
medium
dose
plateletsunit
high
dose
differ
time
point
sequenc
standard
low
high
dose
request
receiv
base
hisher
pre
transfus
platelet
count
clinic
profil
post
transfus
count
assess
hour
transfus
post
transfus
respons
indic
calcul
term
platelet
increment
correct
count
increment
cci
percent
platelet
recoveri
ppr
transfus
free
interv
bleed
event
also
record
differ
dose
resultsfind
post
transfus
respons
indic
cci
ppr
compar
standard
dose
low
dose
post
transfus
increment
compar
standard
high
dose
howev
cci
ppr
better
standard
dose
statist
signific
higher
post
transfus
increment
observ
high
dose
compar
low
dose
howev
cci
ppr
better
low
dose
statist
signific
transfus
free
interv
standard
dose
low
dose
high
dose
day
day
day
respect
howev
differ
statist
signific
donor
exposur
patient
significantli
reduc
owe
split
platelet
product
form
custom
dose
transfus
conclus
standard
dose
apheresi
platelet
best
choic
adequ
post
transfus
respons
patient
howev
possibl
low
dose
altern
standard
consid
stabl
thrombocytopen
patient
owe
compar
post
transfus
respons
indic
cci
ppr
two
group
backgroundcas
studi
target
base
transfus
strategi
aim
provid
enough
blood
achiev
select
target
hgbhct
due
signific
variabl
respons
transfus
transfus
depend
patient
blood
usual
order
empir
rather
achiev
specif
goal
hgb
transfus
schedul
patient
dose
red
cell
transfus
degre
red
cell
product
influenc
long
given
transfus
may
keep
specif
patient
desir
target
hgb
individu
model
guid
transfus
could
improv
precis
order
reduc
unnecessari
visit
well
unit
transfus
base
develop
comput
algorithm
decis
support
capabl
individu
transfus
recommend
transfus
depend
patient
studi
designmethod
hematolog
blood
util
calcul
heme
buc
predict
individu
patient
respons
transfus
base
data
past
transfus
calcul
pull
inform
electron
medic
record
calcul
transfus
prior
transfus
use
predict
respons
futur
transfus
given
patient
current
hgb
weight
option
present
order
provid
select
transfus
dose
unit
determin
time
patient
expect
stay
select
target
hgb
perform
prospect
pilot
heme
buc
patient
transfus
depend
anemia
primari
outcom
percentag
patient
return
schedul
hgb
within
select
target
intent
treat
fashion
resultsfind
nine
month
transfus
order
use
heme
buc
complet
data
analysi
target
hgb
select
case
percent
transfus
singl
unit
two
unit
repres
signific
increas
singl
unit
transfus
histor
order
mean
predict
time
return
transfus
day
patient
within
day
select
buc
return
time
overal
transfus
patient
return
hgb
target
conclus
provid
flexibl
individu
transfus
recommend
transfus
depend
patient
use
adapt
mathemat
algorithm
learn
patient
person
experi
rbc
transfus
within
option
present
patient
remain
target
hemoglobin
select
order
provid
studi
expand
role
adaptivelearn
decis
support
technolog
ongo
backgroundcas
studi
heavi
uterin
bleed
hub
report
caus
iron
defici
anemia
affect
women
hub
carri
import
clinic
problem
also
emot
social
issu
limit
normal
activ
affect
significantli
qualiti
life
anemia
due
hub
potenti
treat
iron
therapi
object
evalu
efficaci
intraven
administr
ferric
carboxymaltos
correct
iron
defici
anemia
due
heavi
uterin
bleed
use
real
life
data
terciari
centerhospit
daycar
hospit
dedic
patient
blood
manag
pbm
studi
designmethod
retrospect
studi
select
women
refer
immunohemotherapi
daycar
hospit
gynecologyobstetr
depart
medic
appoint
januari
april
diagnos
anemia
secondari
hub
due
caus
collect
laboratori
data
includ
hemoglobin
concentr
ferritin
level
transferrin
satur
previou
administr
intraven
ferric
carboxymaltos
compar
valu
week
therapi
observ
effect
iron
therapi
anemia
bodi
iron
store
subset
anem
patient
resultsfind
medium
age
women
refer
gynecolog
appoint
diagnos
anemia
manag
immunohemotherapi
daycar
hospit
select
studi
year
previou
therapi
medium
hemoglobin
concentr
gdl
ferritin
medium
valu
ngml
medium
transferrin
satur
laboratori
reevalu
intraven
iron
therapi
rise
hemoglobin
concentr
medium
gdl
increas
gdl
also
ferritin
increas
ngml
medium
ngml
improv
transferrin
satur
increas
obtain
medium
valu
women
treat
first
visit
nt
need
addit
intraven
iron
therapi
reevalu
also
report
improv
clinic
symptom
qualiti
life
conclus
women
hub
commonli
iron
defici
anemia
therefor
import
assess
iron
bodi
store
patient
appropri
initi
adequ
treatment
also
import
establish
good
commun
differ
medic
specialti
provid
assess
treatment
particular
subset
popul
protocol
gynecologyobstetr
depart
immunohemotherapi
daycar
hospit
essenti
better
manag
anemia
patient
facilit
referr
procedur
reduc
time
proper
treatment
intraven
iron
safe
effect
therapi
quick
replenish
bodi
iron
store
correct
anemia
administr
therefor
therapeut
choic
particular
clinic
entiti
pbm
program
facilit
interdisciplinari
manag
anemia
reduc
blood
transfus
whether
medic
set
well
periop
set
continu
implement
backgroundcas
studi
patient
blood
manag
pbm
principl
highli
applic
surgic
practic
ideal
pbm
approach
multifacet
multidisciplinari
design
implement
execut
goal
investig
assess
chang
transfus
behavior
implement
robust
pbm
program
larg
tertiari
care
surgic
center
studi
designmethod
singl
center
observ
studi
pbm
implement
larg
divers
surgic
practic
formal
multidisciplinari
pbm
effort
initi
earli
consist
multipl
simultan
intervent
includ
educ
present
onlin
train
modul
standard
transfus
guidelin
electron
clinic
decis
support
cd
rule
transfus
order
advanc
transfus
analyt
provid
specif
transfus
report
transfus
data
deriv
use
baselin
inform
major
pbm
effort
initi
earli
subsequ
year
compris
cohort
outcom
includ
annual
blood
product
transfus
total
percentag
surgic
patient
receiv
least
one
unit
allogen
rbc
frequenc
percentag
patient
discharg
hospit
hemoglobin
valu
gdl
also
assess
resultsfind
total
surgic
patient
admiss
includ
annual
surgic
volum
increas
p
percentag
surgic
patient
transfus
one
unit
allogen
rbc
decreas
studi
period
p
percentag
patient
receiv
plasma
decreas
p
rel
stabil
platelet
cryoprecipit
util
patient
receiv
rbc
number
patient
discharg
hemoglobin
valu
gdl
decreas
p
conclus
pbm
implement
effort
larg
surgic
practic
associ
substanti
reduct
rbc
plasma
transfus
minim
effect
util
platelet
cryoprecipit
addit
patient
receiv
rbc
like
discharg
hemoglobin
valu
gdl
suggest
increas
toler
postop
anemia
effort
underway
assess
relationship
chang
transfus
pattern
patient
center
outcom
backgroundcas
studi
transfus
red
blood
cell
rbc
essenti
hematopoiet
stem
cell
transplant
hct
risk
transfus
reaction
tr
cost
blood
led
effort
reduc
blood
use
patient
blood
manag
pbm
recommend
includ
transfus
rather
unit
rbc
need
chang
inpati
practic
transfus
instead
unit
red
blood
cell
rbc
hct
patient
hemoglobin
hypothesi
would
reduc
rbc
util
describ
impact
chang
rbc
util
preval
transfus
reaction
nurs
staff
workflow
studi
designmethod
includ
patient
year
receiv
allogen
hct
chang
practic
transfus
instead
unit
red
blood
cell
rbc
hemoglobin
compar
rbc
util
patient
receiv
allogen
hct
month
control
arm
implement
new
practic
intervent
arm
use
regress
model
estim
independ
effect
transfus
practic
vs
unitsepisod
length
hospit
condit
regimen
donor
type
patient
receiv
least
rbc
unit
outcom
variabl
total
number
inpati
transfus
addit
survey
assess
impact
resultsfind
patient
includ
analysi
control
group
intervent
arm
cohort
match
age
primari
diagnosi
graft
sourc
condit
regimen
median
number
rbc
unit
transfusedpati
ident
arm
interquartil
rang
unitspati
mean
number
rbc
transfus
vs
howev
differ
attribut
highli
transfus
patient
use
regress
model
length
stay
rel
increas
unitsday
ci
independ
predictor
number
rbc
unit
patient
receiv
data
patient
day
control
arm
receiv
unit
vs
intervent
arm
receiv
unit
result
reduct
unit
trpatient
standard
deviat
sd
control
arm
vs
reactionspati
sd
intervent
arm
survey
rn
show
felt
posit
affect
workflow
neutral
rn
felt
advers
impact
conclus
found
signific
differ
median
number
rbc
unit
transfus
number
transfus
reaction
per
patient
compar
histor
control
modest
reduct
rbc
util
base
unit
addit
posit
impact
rn
workflow
backgroundcas
studi
assess
whole
blood
blood
compon
util
compris
vital
piec
inform
promot
optim
safe
blood
suppli
manag
clinic
guidelin
develop
blood
compon
use
past
decad
practic
impact
guidelin
uncertain
aim
studi
assess
preval
whole
blood
blood
compon
transfus
biolog
effect
safeti
best
initi
studi
designmethod
use
electron
health
record
health
claim
databas
best
initi
center
biolog
evalu
research
cber
sentinel
program
compon
three
data
partner
particip
provid
record
approxim
million
patient
transfus
event
captur
use
medic
bill
reimburs
data
includ
intern
classif
diseas
clinic
modif
ninth
tenth
revis
current
procedur
terminolog
cpt
healthcar
common
procedur
code
system
hcpc
code
code
categor
identifi
transfus
event
whole
blood
red
blood
cell
rbc
platelet
plasma
event
defin
occurr
compon
specif
code
per
person
regardless
number
unit
transfus
resultsfind
tabl
show
transfus
whole
blood
blood
compon
total
transfus
event
period
rbc
compris
transfus
compon
platelet
plasma
whole
blood
account
respect
period
overal
transfus
event
whole
blood
decreas
transfus
plasma
platelet
slightli
fluctuat
wherea
rbc
transfus
slight
increas
show
declin
conclus
studi
demonstr
medic
bill
reimburs
data
medic
record
captur
blood
transfus
provid
addit
capabl
cber
hemovigil
system
observ
overal
declin
whole
blood
rbc
transfus
sentinel
best
initi
hemovigil
activ
includ
whole
blood
blood
compon
util
trend
inform
encourag
implement
transfus
guidelin
manag
blood
resourc
unit
state
backgroundcas
studi
computer
provid
order
entri
alert
cpoe
clinic
decis
support
reduc
inappropri
transfus
goal
determin
alert
truli
decreas
inappropri
transfus
delay
red
blood
cell
rbc
transfus
goal
determin
effect
cpoe
alert
system
lower
rbc
transfus
rate
determin
patient
popul
receiv
addit
rbc
unit
alert
studi
designmethod
retrospect
data
cpoe
alert
aim
restrict
strategi
promot
transfus
order
practic
rbc
transfus
collect
june
novemb
alert
fire
base
specif
criteria
effort
avoid
alert
fatigu
provid
transfus
review
appropri
base
upon
aabb
rbc
transfus
guidelin
patient
popul
consist
inpati
exclud
intraop
transfus
massiv
transfus
outpati
transfus
patient
receiv
addit
unit
within
hour
alert
review
appropri
hemoglobin
level
demograph
list
indic
transfus
clinic
scenario
resultsfind
initi
order
alert
fire
time
initi
order
cancel
time
chang
time
continu
time
patient
receiv
unit
patient
receiv
addit
rbc
unit
patient
receiv
addit
rbc
unit
within
hour
initi
alert
cpoe
alert
rbc
unit
save
period
result
product
acquisit
cost
save
nearli
alert
result
reduct
number
rbc
unit
transfus
popul
clinic
set
addit
unit
popul
includ
gastrointestin
gi
bleed
sepsi
surgic
patient
oncolog
diagnosi
activ
bleed
trauma
final
initi
order
met
aabb
guidelin
addit
unit
meet
criteria
averag
age
patient
receiv
addit
unit
male
femal
ratio
conclus
cpoe
alert
system
clinic
decis
support
effect
reduc
inappropri
rbc
transfus
common
set
addit
transfus
gi
bleed
continu
blood
loss
vast
major
patient
receiv
rbc
unit
follow
alert
clinic
situat
meet
guidelin
therefor
alert
effect
promot
restrict
transfus
strategi
rbc
order
without
delay
transfus
need
backgroundcas
studi
plasma
routin
transfus
indic
expos
patient
risk
includ
circulatori
overload
alloimmun
hemolyt
transfus
reaction
clinic
order
plasma
transfus
academ
medic
institut
occur
comput
provid
order
entri
system
cpoe
filter
patient
recent
lab
evid
base
transfus
guidelin
order
meet
guidelin
trigger
request
inform
provid
choos
indic
menu
eg
dic
inr
andor
add
comment
laboratori
data
select
indic
comment
collect
retrospect
review
studi
designmethod
plasma
overrid
order
januari
decemb
review
determin
prefix
indic
recent
inr
comment
attend
servicedepart
order
assign
one
follow
code
indic
base
institut
aabb
guidelin
inform
indic
comment
comment
assign
code
tabul
analyz
resultsfind
common
word
free
text
indic
includ
bleed
bleed
hemorrhag
time
inr
time
transplant
time
servic
commonli
order
transfus
intern
medicin
alli
health
neurosurgeri
transplant
vascular
servic
rare
trigger
ni
overrid
total
ni
respect
servic
commonli
order
plasma
deem
ni
orthoped
surgeri
neurolog
respect
servic
least
frequent
order
plasma
deem
ni
emerg
medicin
gener
surgeri
conclus
institut
plasma
frequent
order
reason
expos
patient
unnecessari
risk
clear
trend
ni
order
note
among
traine
differ
academ
year
suggest
medic
servic
cultur
may
affect
order
entri
level
academ
train
data
identifi
servic
commonli
order
product
illustr
area
could
target
focus
educ
improv
backgroundcas
studi
anemia
defici
total
amount
red
blood
cell
rbc
hemoglobin
hgb
concentr
affect
oxygen
carri
capac
preval
hospit
patient
appropri
treatment
vari
base
etiolog
iron
defici
common
caus
anemia
independ
risk
factor
hospit
readmiss
prolong
length
stay
diminish
qualiti
life
increas
risk
morbid
mortal
newli
develop
laboratori
anemia
panel
provid
effici
assess
anemia
screen
one
simplifi
order
algorithm
studi
designmethod
reflex
algorithm
anemia
panel
establish
lab
june
medic
record
adult
patient
screen
anemia
use
reflex
panel
retrospect
review
month
period
patient
characterist
treatment
modal
collect
along
clinic
laboratori
data
includ
iron
studi
resultsfind
total
patient
found
anem
common
diagnosi
iron
defici
anemia
signific
improv
post
treatment
hgb
observ
compar
screen
hgb
vs
p
similar
improv
also
detect
mcv
rdw
indic
improv
rbc
hgb
product
tabl
averag
treatment
durat
day
oral
iron
replac
therapi
common
intervent
two
patient
treat
iv
iron
one
patient
treat
folic
acid
signific
reaction
complic
report
conclus
newli
develop
reflex
algorithm
anemia
screen
panel
provid
time
diagnosi
earlier
initi
manag
util
laboratori
resourc
effici
patient
studi
cohort
show
signific
increas
hgb
indic
success
manag
follow
anemia
tabl
screen
post
treatment
hemoglobin
mcv
rdw
level
data
shown
mean
standard
deviat
median
rang
backgroundcas
studi
problemat
compar
blood
usag
institut
variou
size
complex
larg
tertiari
care
hospit
use
blood
compon
small
commun
hospit
mean
usag
either
hospit
appropri
otherwis
three
hospit
hospit
system
hospit
tertiari
care
teach
hospit
licens
bed
hospit
b
teach
hospit
hospit
c
small
commun
hospit
bed
sinc
absolut
number
red
cell
transfus
per
hospit
differ
substanti
like
relat
patient
volum
acuiti
adjust
red
cell
usag
variabl
could
allow
valid
comparison
usag
studi
designmethod
data
collect
period
three
hospit
includ
total
red
cell
usag
number
discharg
mean
case
mix
index
cmi
cmi
valu
repres
clinic
complex
case
divers
patient
gener
cmi
vari
per
discharg
patient
complex
medic
problem
complic
surgeri
higher
cmi
thu
cmi
use
calcul
surrog
acuiti
higher
cmi
correl
greater
blood
usag
comparison
perform
first
calcul
usag
red
cell
per
discharg
correct
patient
volum
second
calcul
divid
usag
per
discharg
cmi
correct
patient
acuiti
resultsfind
result
shown
tabl
first
three
row
show
data
gross
usag
discharg
cmi
fourth
row
adjust
patient
volum
final
row
adjust
volum
acuiti
use
calcul
clear
hospit
c
small
commun
hospit
higher
adjust
rate
transfus
target
educ
intervent
conclus
blood
manag
focus
red
blood
cell
usag
per
discharg
metric
appropri
usag
take
account
complex
case
propos
calcul
may
give
greater
insight
appropri
usag
identifi
hospit
would
benefit
intervent
chang
transfus
practic
backgroundcas
studi
despit
acknowledg
benefit
patient
blood
manag
pbm
implement
effect
program
remain
challeng
especi
healthcar
system
serv
multipl
state
larg
healthcar
system
hospit
state
total
electron
medic
record
platform
initi
blood
acquisit
expenditur
blood
spend
annual
form
interdisciplinari
partnership
expedit
comprehens
pbm
program
less
year
studi
designmethod
implement
plan
develop
support
first
year
goal
establish
pbm
infrastructur
develop
state
scienc
transfus
guidelin
order
set
dissemin
educ
provid
system
provid
level
data
team
develop
priorit
matrix
formula
consist
hospit
size
data
avail
transfus
volum
guid
effici
workflow
strong
emphasi
place
phase
maxim
behavior
modif
effect
system
level
pbm
steer
committe
form
individu
pbm
task
forc
throughout
hospit
carri
strateg
plan
hospit
implement
guidelin
cpoe
blood
order
set
committe
launch
awar
campaign
across
hospit
deliv
cme
ce
educ
program
largest
hospit
transfus
data
report
develop
hospit
util
one
system
largest
inform
technolog
platform
site
key
perform
indic
see
form
basi
evalu
program
resultsfind
period
aggress
oversight
rbc
util
declin
system
overal
despit
patient
volum
increas
decreas
transfus
volum
site
data
report
implement
overal
rbc
transfus
hemoglobin
hgb
declin
rbc
transfus
hgb
increas
singl
unit
order
increas
first
month
healthcar
organ
blood
acquisit
cost
declin
averag
patient
day
fell
vs
baselin
year
conclus
creat
comprehens
pbm
program
expans
healthcar
structur
requir
innov
strategi
success
scale
key
programmat
compon
direct
regular
access
key
decis
maker
along
streamlin
process
provid
educ
cpoe
data
analyt
key
driver
success
find
show
signific
reduct
red
blood
cell
util
possibl
across
larg
system
time
frame
backgroundcas
studi
allerg
transfus
reaction
common
advers
reaction
blood
product
wide
rang
sever
reaction
usual
mild
occur
within
hour
transfus
present
cutan
manifest
local
urticari
lesion
pruritu
presum
mechan
mast
cell
degranul
histamin
releas
diphenhydramin
invers
agonist
histamin
receptor
commonli
use
medic
allevi
symptom
proven
prevent
allerg
reaction
although
recommend
premed
patient
histori
allergi
blood
transfus
studi
designmethod
conduct
retrospect
analysi
blood
bank
softwar
transfus
mediwar
lenexa
ks
find
case
access
reaction
workup
narrow
allerg
reaction
june
august
review
pathologist
interpret
report
reaction
outcom
categor
accord
implic
blood
product
volum
transfus
partialincomplet
complet
premed
attempt
repeat
transfus
within
hour
report
reaction
sever
sever
definit
sever
complianc
center
diseas
control
prevent
cdc
nation
healthcar
safeti
network
biovigil
compon
hemovigil
modul
surveil
protocol
publish
aug
resultsfind
review
total
allerg
transfus
reaction
patient
patient
two
reaction
analysi
purpos
total
number
round
mild
allerg
reaction
report
case
sever
reaction
seen
major
mild
reaction
associ
rbc
major
sever
reaction
associ
platelet
premed
mild
reaction
case
incomplet
transfus
seen
case
associ
red
blood
cell
thirti
three
percent
patient
mild
reaction
incompleteparti
transfus
transfus
within
hour
reaction
repres
allerg
reaction
conclus
incomplet
transfus
occur
mani
mild
allerg
transfus
reaction
major
reaction
resolv
treatment
could
theori
complet
henc
repres
signific
wast
blood
product
result
present
opportun
qualiti
improv
regard
manag
mild
allerg
transfus
reaction
make
patient
safeti
first
prioriti
opportun
minim
avoid
blood
product
wastag
mani
reaction
backgroundcas
studi
estim
approxim
million
red
blood
cell
rbc
transfus
unit
state
although
transfus
decreas
recent
year
still
consid
one
five
overus
procedur
hospit
blood
transfus
harm
shown
increas
risk
hospit
acquir
bacteri
infect
length
hospit
stay
well
expos
patient
transfus
reaction
alloimmun
addit
cost
blood
compon
one
greatest
hospit
expens
personnel
estim
larg
percentag
estim
blood
transfus
perform
without
valid
clinic
indic
andor
potenti
clinic
benefit
patient
blood
manag
program
aim
reduc
unnecessari
transfus
studi
designmethod
initi
launch
goal
decreas
blood
util
missouri
baptist
medic
center
mbmc
commun
hospit
st
loui
blood
util
committe
form
novemb
compris
laboratori
blood
bank
personnel
well
chief
medic
offic
cmo
cmo
person
invit
clinic
champion
oncolog
cardiothorac
surgeri
critic
care
transfus
trigger
establish
transfus
servic
educ
outreach
program
present
physician
depart
chief
quarterli
staff
meet
grand
round
present
clinic
champion
oncolog
video
made
avail
hospit
intranet
site
employe
tableau
dashboard
creat
track
transfus
accord
hemoglobin
valu
patient
care
area
physician
implement
clinic
decis
support
tool
ongo
hospit
system
transit
epic
electron
medic
record
phase
resultsfind
mbmc
reduc
rbc
transfus
unit
reduct
reduc
transfus
improv
patient
safeti
reduc
risk
transfus
reaction
similar
degre
blood
transfus
rate
remain
flat
sinc
despit
increas
case
mix
index
cmi
transfus
per
cmi
adjust
discharg
decreas
blood
cost
decreas
reduct
sinc
incept
blood
util
program
save
million
blood
compon
expens
conclus
robust
pbm
program
reduc
transfus
rate
reduc
advers
event
save
money
commun
hospit
set
sustain
reduct
possibl
physician
engag
prospect
review
transfus
request
transfus
data
employ
clinic
decis
support
tool
backgroundcas
studi
periop
bleed
major
indic
allogen
red
blood
cell
rbc
transfus
era
widespread
blood
conserv
initi
transfus
rate
major
surgeri
poorli
quantifi
outdat
reflect
interv
effort
minim
periop
transfus
current
assess
transfus
pattern
surgeri
need
object
studi
describ
contemporari
transfus
practic
patient
undergo
major
surgeri
studi
designmethod
complet
retrospect
cohort
studi
evalu
patient
year
age
undergo
surgeri
five
hospit
two
citi
januari
decemb
use
standard
canadian
classif
health
intervent
cci
procedur
code
contain
within
hospit
discharg
abstract
databas
dad
link
dad
transfus
databas
laboratori
databas
obtain
supplementari
transfus
laboratori
data
exclud
uncommon
procedur
transfus
rate
procedur
remain
procedur
character
proport
patient
transfus
mean
number
rbc
unit
transfus
number
rbc
unit
transfus
annual
resultsfind
centr
identifi
patient
admiss
surgic
procedur
main
oper
room
identifi
open
surgeri
associ
transfus
rate
procedur
baselin
transfus
rate
rang
receiv
rbc
unit
receiv
rbc
unit
transfus
unit
transfus
mean
number
rbc
transfus
unit
unit
ten
procedur
highest
transfus
rate
abdomin
aortic
aneurysm
repair
abdomin
aortic
aneurysm
bypass
vertebrectomi
knee
amput
knee
amput
femur
open
reduct
intern
fixat
cystectomi
gastrectomi
colon
repair
procedur
highest
annual
number
rbc
unit
transfus
includ
total
hip
arthroplasti
procedur
rbc
unit
hysterectomi
procedur
rbc
unit
vertebr
fusion
procedur
rbc
unit
conclus
era
blood
conserv
describ
transfus
practic
major
procedur
high
risk
transfus
implic
patient
consent
plan
blood
bank
util
backgroundcas
studi
blood
transfus
activ
often
overus
benchmark
may
use
aim
studi
defin
blood
use
across
entireti
inpati
hospit
stay
use
diagnosi
relat
group
drg
studi
designmethod
adult
inpati
hospit
stay
larg
academ
center
analyz
descript
statist
blood
usag
medicar
sever
ms
patient
relat
apr
variabl
captur
entir
hospit
stay
resultsfind
hospit
stay
evalu
tabl
burn
cardiac
surgeri
trauma
surgic
icu
show
highest
correl
rbc
use
drg
weight
spearman
rho
rang
hematolog
cardiothorac
surgeri
gastroenterolog
transplant
surgeri
show
highest
correl
platelet
use
drg
weight
spearman
rho
rang
rbc
platelet
except
coupl
servic
perform
transfus
conclus
blood
use
servic
greatest
number
blood
compon
per
hospit
stay
correl
strongli
drg
numer
weight
across
entir
inpati
hospit
stay
util
could
use
benchmark
within
hospit
backgroundcas
studi
alloimmun
human
red
cell
antigen
play
import
role
manag
patient
sickl
cell
diseas
scd
pediatr
center
support
larg
popul
scd
patient
includ
mani
chronic
transfus
protocol
order
reduc
risk
alloimmun
sinc
select
red
cell
donor
match
rh
c
e
kell
k
phenotyp
recipi
purpos
studi
evalu
state
alloimmun
patient
popul
assess
benefit
approach
studi
designmethod
chronic
transfus
patient
everi
donor
unit
transfus
trace
back
patient
electron
record
compar
donor
antigen
profil
record
blood
collect
facil
use
method
develop
independ
data
analysi
group
review
patient
transfus
histori
compris
median
rang
month
transfus
data
determin
often
mismatch
result
format
alloantibodi
compar
alloimmun
state
patient
refer
popul
studi
prior
adopt
c
e
k
match
gener
distribut
popul
resultsfind
program
achiev
signific
reduct
incid
alloimmun
c
e
k
popul
limit
prolifer
antibodi
often
observ
chronic
transfus
patient
thu
distribut
popul
studi
castro
colleagu
extend
mani
antibodi
per
patient
limit
nevertheless
patient
receiv
dozen
transfus
made
least
one
includ
antibodi
js
fy
v
kp
e
along
c
e
interestingli
observ
instanc
includ
antibodi
form
repeat
exposur
fy
red
cell
conclus
data
obtain
patient
cohort
consist
predict
castro
colleagu
conclus
subsequ
studi
eg
http
name
overal
reduct
sensit
possibl
care
select
donor
whose
antigen
profil
match
recipi
implement
novel
algorithm
select
donor
unit
larg
set
antigen
quantit
consider
immunogen
individu
antigen
determin
believ
achiev
improv
prevent
alloimmun
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
first
describ
provid
guidanc
surgeon
much
blood
order
phase
goal
cut
unnecessari
type
cross
order
make
sure
appropri
quantiti
blood
avail
surgeri
like
requir
transfus
concept
recent
emphasi
patient
blood
manag
newer
surgic
techniqu
contribut
decreas
util
blood
product
unnecessari
crossmatch
one
unintend
consequ
polici
might
underutil
type
screen
oper
requir
blood
transfus
routin
yet
unexpect
complic
aris
oper
lack
type
screen
neg
consequ
emerg
releas
blood
need
studi
designmethod
evalu
schedul
oper
institut
week
period
procedur
identifi
patient
type
screen
file
within
day
oper
within
day
cardiac
procedur
result
compar
publish
msbo
guidelin
recommend
procedur
type
screen
resultsfind
total
schedul
procedur
identifi
type
screen
file
averag
procedur
day
type
screen
order
urolog
cardiovascular
gastrointestin
surgeri
type
screen
recommend
publish
msbo
type
screen
rate
institut
procedur
recommend
type
screen
vari
rate
complianc
includ
open
hysterectomi
ovarian
surgeri
spinal
fusion
laminectomi
hip
replac
knee
replac
open
shoulder
neck
dissect
inconsist
amongst
differ
surgeon
frequenc
order
type
screen
procedur
also
inconsist
surgeon
differ
day
conclus
mani
surgeon
abl
complet
oper
minim
blood
loss
littl
need
transfus
mani
procedur
also
perform
without
type
screen
file
procedur
need
blood
orthoped
gynecolog
ent
surgeri
potenti
high
blood
loss
due
unexpect
complic
unusu
anatomi
patient
alreadi
alloantibodi
unidentifi
emerg
releas
neg
blood
could
lead
hemolyt
transfus
reaction
variabl
across
hospit
demonstr
lack
unifi
approach
util
type
screen
show
push
decreas
overutil
blood
product
possibl
swung
pendulum
toward
underutil
backgroundcas
studi
implement
patient
blood
manag
pbm
program
requir
multidisciplinari
approach
coordin
support
healthcar
provid
nurs
knowledg
pbm
empir
play
major
role
administ
blood
product
knowledg
nurs
exhibit
confid
question
conduct
contribut
process
particip
knowledg
transfer
action
enhanc
nurs
knowledg
pbm
dissemin
schedul
meet
educ
session
purpos
nurs
emb
practic
learn
pbm
influenc
provid
practic
educ
patient
studi
designmethod
studi
adopt
qualit
research
approach
employ
direct
applic
knowledg
chang
understand
influenc
think
behavior
nurs
toward
transfus
purpos
sampl
nurs
select
base
inclus
criteria
nurs
previou
knowledg
pbm
work
clinic
area
blood
product
administ
data
collect
via
interview
question
via
email
need
resultsfind
theme
gener
data
analysi
reveal
increas
knowledg
relat
associ
risk
factor
advers
reaction
blood
transfus
compet
convey
perform
expertli
act
independ
confid
voic
becom
inquisit
make
decis
educ
colleagu
motiv
spread
knowledg
educ
nurs
provid
particip
initi
action
plan
share
knowledg
spread
awar
provid
support
clinic
unit
exploit
present
learn
modul
creat
refer
page
pbm
feel
empower
mutual
among
particip
enthusiast
inform
other
risk
associ
transfus
ensur
safe
appropri
use
blood
product
encourag
patient
make
educ
decis
transfus
particip
report
empow
extent
challeng
inappropri
order
blood
product
conclus
educ
nurs
pbm
standard
construct
vest
nurs
empow
inform
pbm
awar
advers
risk
transfus
evid
improv
outcom
particip
person
knowledg
transfer
action
benefit
nurs
provid
patient
backgroundcas
studi
alemtuzumab
ale
recombin
human
kappa
monoclon
antibodi
specif
indic
patient
pt
relaps
form
multipl
sclerosi
ms
infus
reaction
malign
autoimmun
eg
immun
thrombocytopenia
itp
may
occur
date
ttp
report
pt
treatment
ale
report
pt
itp
subsequ
develop
autoimmun
thyroid
storm
ttp
studi
designmethod
case
report
year
old
male
ms
diagnos
year
prior
admiss
pta
receiv
ale
last
dose
month
pta
develop
itp
surveil
month
pta
five
day
pta
due
dark
urin
platelet
count
refer
local
hospit
evalu
admiss
diagnosi
itp
exacerb
made
treat
intraven
immunoglobulin
ivig
prednisolon
hematuria
continu
due
sever
anemia
hemoglobin
hgb
gdl
receiv
multipl
rbc
transfus
due
worsen
statu
refractori
hemotherapi
studi
perform
show
mgdl
total
mgdl
ldh
peripher
blood
smear
inspect
show
schistocytesspherocyt
emerg
transfer
hospit
therapeut
plasma
exchang
tpe
presum
ttp
resultsfind
upon
admiss
laboratori
studi
reveal
gdl
platelet
count
studi
inhibitor
level
collect
subsequ
measur
confirm
ttp
bu
respect
despit
multipl
rbcffp
transfus
prior
tpe
initi
experienc
gener
tonic
clonic
seizur
admit
critic
care
unit
addit
test
tsh
miuml
free
ngdl
mmol
support
diagnosi
thyroid
storm
autoimmun
etiolog
base
subsequ
studi
tpe
plasma
volum
use
ffp
replac
begun
underw
total
tpe
procedur
dose
cycl
rituximab
normal
platelet
hgb
ldh
level
mental
statusneurolog
function
return
baselin
post
stabil
sodium
level
conclus
ale
may
caus
sever
life
threaten
autoimmun
disord
although
itp
report
major
autoimmun
cytopenia
pt
develop
ttp
need
consid
earli
recognitiontreat
tpe
drug
induc
autoimmun
disord
necessit
clinic
hyperawar
post
therapi
surveil
period
risk
pt
popul
studi
regard
risk
etiolog
ttp
set
warrant
backgroundcas
studi
antibodi
mediat
diffus
alveolar
hemorrhag
dah
vasculitid
acut
often
condit
high
dose
immunosuppress
therapi
paramount
control
condit
plasma
exchang
often
prove
critic
import
studi
designmethod
review
medic
record
patient
pt
diagnos
dah
refer
immunotherapi
evalu
treatment
pt
anca
antineutrophil
cytoplasm
antibodi
basement
membran
antibodi
renal
vascul
rv
sever
sle
system
lupu
erythematosu
treat
adjunct
plasma
exchang
period
pt
diagnos
dah
pt
myeloperoxidas
posit
anca
rv
pt
posit
anca
rv
pt
rv
pt
sever
sle
pt
defin
dah
pt
progress
hemoptysi
andor
evid
dah
bronchoscopi
median
pt
age
year
year
old
pt
femal
major
pt
present
cough
dypsnea
hemoptysi
hypoxemia
diffus
bilater
alveolar
opac
pt
underw
bronchoscopi
pt
intub
hospit
pt
receiv
follow
regimen
high
dose
corticosteroid
cs
therapi
plasma
exchang
tpe
cyclophosphamid
cp
rituximab
rtm
pt
receiv
puls
cs
methylprednisolon
mg
iv
x
day
follow
prolong
prednison
taper
initi
mgkgday
cp
iv
everi
week
mgday
po
month
rtm
weekli
x
week
altern
protocol
x
infus
pt
receiv
daili
tpe
treatment
plasma
volum
fresh
frozen
plasma
ffp
replac
albumin
follow
ffp
plasma
volum
dah
resolv
tpe
treatment
tx
initi
within
hour
referr
resultsfind
pt
experienc
resolut
dah
day
start
regimen
resolut
dah
defin
complet
near
complet
resolut
alveolar
bleed
hemoptysi
improv
oxygen
decreas
requir
andor
increas
without
improv
chest
find
mean
number
tpe
tx
tx
intub
pt
extub
pt
signific
improv
oxygen
pt
decreas
pulmonari
infiltr
pt
die
complic
pneumonia
sepsi
pt
experienc
recurr
dah
median
month
month
studi
limit
includ
retrospect
case
seri
histor
control
group
conclus
diffus
alveolar
hemorrhag
uncommon
potenti
complic
vasculitid
includ
sle
high
dose
corticosteroid
cyclophosphamid
rituximab
plasma
exchang
use
treatment
modal
initi
promptli
appear
highli
effect
provid
rapid
resolut
antibodi
mediat
alveolar
hemorrhag
backgroundcas
studi
refractori
platelet
concentr
pc
transfus
advers
affect
conduct
comprehens
therapi
hematolog
patient
individu
select
pc
recommend
case
individu
pc
select
complic
high
degre
alloimmun
due
format
antibodi
hlahpa
plasmapheresi
procedur
pp
includ
treatment
program
aim
studi
assess
effect
transfus
individu
select
pc
patient
refractori
use
pp
second
line
therapi
studi
designmethod
septemb
decemb
hematolog
patient
pc
transfus
show
refractori
enrol
studi
enrol
patient
receiv
pc
transfus
individu
select
use
immucor
solid
phase
technolog
patient
individu
pc
select
unsuccess
pp
use
second
line
therapi
patient
receiv
pp
median
age
year
pp
perform
averag
patient
patient
pp
procedur
immedi
receiv
transfus
individu
select
pc
efficaci
pc
transfus
assess
api
cci
hemorrhag
syndrom
relief
resultsfind
patient
refractori
pc
transfus
absenc
compat
donor
platelet
pp
combin
subsequ
transfus
individu
select
pc
promot
relief
hemorrhag
syndrom
chang
api
cci
pp
combin
individu
select
pc
allow
reduc
degre
alloimmun
ratio
incompat
pair
pc
select
patient
aa
md
aml
patient
high
degre
alloimmun
pp
select
compat
platelet
unsuccess
therefor
pc
transfus
ineffect
api
hemorrhag
syndrom
complet
manag
although
sever
reduc
conclus
develop
refractori
pc
transfus
unsuccess
individu
select
platelet
one
hematolog
patient
call
pp
second
line
therapi
pp
combin
individu
select
pc
decreas
degre
alloimmun
therefor
increas
compat
clinic
efficaci
pc
transfus
pp
combin
individu
select
pc
ineffect
necessari
seek
syndrom
increas
consumpt
mechan
develop
refractori
backgroundcas
studi
therapeut
plasma
exchang
tpe
procedur
use
remov
patholog
substanc
plasma
howev
procedur
also
deplet
plasma
coagul
factor
lead
major
bleed
goal
studi
evalu
perform
mathemat
model
predict
coagul
factor
level
cohort
hospit
patient
smartphon
app
base
model
creat
determin
much
plasma
replac
need
achiev
target
factor
level
studi
designmethod
model
util
patient
weight
hematocrit
coagul
factor
level
well
volum
plasma
process
plasma
replac
model
accuraci
assess
compar
predict
versu
measur
fibrinogen
antithrombin
level
inpati
tpe
procedur
occur
larg
academ
medic
center
upon
model
valid
smartphon
app
develop
io
android
devic
resultsfind
minor
advers
event
occur
patient
resolv
spontan
manag
bleed
thrombot
complic
occur
mean
differ
predict
measur
fibrinogen
concentr
mgdl
sd
rang
percent
differ
measur
predict
fibrinogen
concentr
sd
rang
mean
differ
predict
measur
antithrombin
concentr
activ
sd
rang
mean
percent
differ
predict
measur
antithrombin
percent
activ
sd
rang
conclus
model
reliabl
predict
fibrinogen
antithrombin
concentr
within
measur
valu
mainten
critic
factor
level
essenti
clinician
consid
target
coagul
factor
higher
project
app
plexfactor
greatli
simplifi
calcul
plasma
replac
need
achiev
target
factor
level
avail
free
io
android
backgroundcas
studi
mechan
action
extracorpor
photopheresi
ecp
fulli
elucid
sever
theori
ascrib
key
role
ecp
treat
lymphocyt
start
point
immunolog
cascad
follow
vivo
numer
studi
shown
lymphocyt
particularli
suscept
ecp
major
becom
apoptot
hour
post
treatment
report
effect
ecp
monocyt
mix
short
term
studi
show
monocyt
resist
apoptosi
longer
term
studi
show
monocyt
viabil
ultim
impact
ecp
addit
studi
monocyt
dendrit
cell
dc
matur
post
ecp
suggest
monocyt
treat
lower
dose
ultraviolet
uva
light
differenti
matur
dc
treat
larger
dose
uva
becom
immatur
dc
light
report
investig
undertaken
evalu
impact
nomin
high
uva
dose
ecp
monocyt
apoptosi
differenti
dc
studi
designmethod
mononuclear
cell
obtain
healthi
subject
use
leukapheresi
dilut
plasma
salin
transfer
polyolefin
treatment
contain
ad
ngml
cell
treat
either
nomin
high
uva
light
constant
agit
hz
use
standalon
photoactiv
devic
ecp
treat
cell
leukapheresi
control
purifi
use
densiti
gradient
separ
cultur
day
human
serum
plasma
rpmi
mm
glutamin
ga
permeabl
contain
flow
cytometr
analys
includ
lymphocyt
monocyt
apoptosi
la
respect
monocytedc
subset
enumer
cytokin
induc
dc
prepar
posit
control
healthi
subject
monocyt
resultsfind
la
level
higher
ecp
arm
compar
control
throughout
storag
level
converg
ecp
arm
day
vs
control
n
per
arm
level
day
similar
control
nomin
uva
vs
lower
high
uva
p
day
level
nomin
uva
increas
control
approach
level
high
uva
day
vs
compar
control
p
approxim
monocyt
differenti
matur
dc
overnight
nomin
uva
control
compar
high
uva
p
storag
matur
dc
level
declin
rapidli
ecp
treat
arm
immatur
dc
level
remain
low
less
averag
storag
arm
conclus
ecp
treatment
promot
monocyt
apoptosi
reduc
number
matur
dc
vitro
cultur
ecp
high
uva
dose
led
rapid
declin
monocyt
viabil
promot
monocyt
differenti
immatur
dc
implic
find
respect
ecp
mechan
action
remain
determin
backgroundcas
studi
util
data
pediatr
apheresi
unclear
american
societi
apheresi
publish
recommend
asfa
guidelin
mani
children
diseas
treat
apheresi
may
includ
thu
need
exist
definit
assess
impress
apheresi
physician
treat
pediatr
patient
actual
apheresi
procedur
perform
data
studi
designmethod
descript
pilot
investig
consist
survey
retrospect
analysi
member
asfa
pediatr
subcommitte
list
diseas
indic
believ
import
condit
apheresi
perform
children
list
base
particip
medic
judgmentsexperi
restrict
sourc
materi
member
collect
pediatr
apheresi
procedur
data
respect
center
calendar
year
keep
analys
consist
asfa
guidelin
use
current
version
avail
studi
period
resultsfind
top
condit
respond
felt
apheresi
therapi
perform
children
humor
reject
variou
solid
organ
transplant
thrombot
thrombocytopen
purpura
acut
sickl
cell
diseas
crisi
graft
versu
host
diseas
sickl
cell
diseas
mainten
therapi
myasthenia
gravi
syndrom
focal
segment
glomerulosclerosi
recurr
abo
incompat
liver
transplant
desensit
acut
dissemin
encephalomyel
famili
hypercholesterolemia
rapidli
progress
glomerulonephr
neuromyel
optica
receptor
enceph
multiorgan
failuresepsi
fulmin
wilson
diseas
retrospect
procedur
analysi
children
treat
apheresi
diagnos
top
condit
treat
patient
treat
condit
top
includ
leukapheresi
acut
leukemia
cold
agglutinin
diseas
meconium
aspir
hemolysi
atyp
hemolyt
urem
syndrom
patient
diffus
alveolar
hemorrhag
system
lupu
erythematosi
brochiol
obliteran
syndrom
malaria
hypereosinophilia
major
abo
incompat
stem
cell
transplant
condit
except
receptor
enceph
meconium
aspir
hemolysi
hypereosinophilia
list
asfa
guidelin
conclus
heterogen
consid
import
condit
treat
pediatr
patient
apheresi
profession
uncommon
condit
neither
list
import
asfa
guidelin
treat
apheresi
find
provid
asfa
pediatr
subcommitte
justif
perform
multicent
analysi
help
clarifi
issu
backgroundcas
studi
urgent
red
blood
cell
rbc
exchang
requir
sickl
cell
patient
sever
complic
acut
chest
syndrom
stroke
consensu
recommend
time
request
initi
rbc
exchang
patient
studi
designmethod
retrospect
review
electron
medic
record
blood
bank
record
conduct
identifi
patient
complic
sickl
cell
diseas
requir
urgent
rbc
exchang
procedur
three
hospit
servic
central
hemapheresi
center
demograph
clinic
featur
laboratori
paramet
hemoglobinhematocrit
hemoglobin
fraction
result
histori
rbc
alloantibodi
tempor
paramet
includ
time
procedur
request
line
placement
nurs
equip
arriv
time
rbc
issu
start
procedur
well
outcom
data
record
resultsfind
patient
femal
male
mean
age
year
receiv
total
rbc
exchang
stroke
tia
acut
chest
syndrom
thirti
patient
ss
diseas
patient
sc
diseas
patient
thalassemia
patient
arab
diseas
nine
patient
currenthistor
rbc
antibodi
procedur
perform
use
central
venou
access
two
procedur
perform
use
peripher
access
tempor
data
major
step
process
shown
tabl
presenc
current
histor
rbc
alloantibodi
result
significantli
longer
time
initi
rbc
exchang
independ
sampl
procedur
success
reach
target
hematocrit
fraction
cell
remain
death
conclus
major
delay
initi
urgent
rbc
exchang
due
find
compat
rbc
product
rh
kell
match
honor
allo
rbc
antibodi
obtain
central
venou
access
benchmark
step
urgent
rbc
exchang
sickl
cell
patient
facilit
qualiti
improv
process
establish
local
nation
guidelin
patient
sever
complic
sickl
cell
diseas
backgroundcas
studi
investig
clinic
effici
plasma
exchang
pe
patient
inflammatori
dilat
cardiomyopathi
idcm
due
myocard
comparison
group
without
pe
studi
designmethod
idcm
patient
due
myocard
treatment
group
male
mean
age
year
left
ventricular
diamet
lvedd
cm
left
ventricular
eject
fraction
lvef
nyha
function
class
idcm
patient
male
mean
age
lvedd
cm
lvef
nyha
function
class
follow
without
pe
treatment
group
patient
underw
singl
volum
therapeut
pe
patient
two
fold
increas
least
two
antibodi
aha
level
cardiac
nuclear
antigen
endotheli
cardiomyocyt
conduct
smooth
muscl
cell
antigen
underw
endomyocardi
biopsi
emb
cardiac
ct
mri
myocardi
perfus
scan
coronari
angiographi
diagnos
myocard
patient
treat
either
immunosuppress
drug
without
echocardiograph
paramet
aha
level
detect
assess
baselin
two
fu
visit
month
group
also
evalu
walk
test
distanc
treatment
group
resultsfind
aha
level
significantli
decreas
pe
fu
treatment
group
p
treatment
group
patient
signific
improv
lvef
first
second
fu
vs
control
group
p
lvedd
left
right
atrial
volum
significantli
decreas
well
chang
fu
comparison
group
pe
group
patient
signific
improv
distanc
period
seven
pe
group
patient
absolut
lvef
improv
classifi
respond
vs
respond
control
group
respond
studi
group
character
initi
higher
systol
pap
vs
p
six
treatment
group
patient
control
group
patient
got
methylprednisolon
p
mean
dose
mg
per
day
respect
p
conclus
pe
improv
cardiac
function
daili
activ
patient
idcm
studi
group
respond
systol
pap
mmhg
higher
good
outcom
predictor
pe
effici
pe
help
avoid
use
immunosuppress
medic
reduc
high
dose
backgroundcas
studi
erythropoiet
protoporphyria
epp
disord
heme
synthesi
caus
abnorm
termin
enzym
ferrochelatas
protoporphyirin
ppix
accumul
within
red
cell
deposit
skin
liver
manifest
photosensit
less
commonli
liver
diseas
hematopoiet
stem
cell
transplant
hsct
correct
enzymat
abnorm
patient
may
also
requir
orthotop
liver
transplant
olt
period
multipl
therapi
employ
reduc
plasma
ppix
level
simpl
transfus
hemin
infus
reduc
ppix
product
therapeut
plasma
exchang
tpe
red
blood
cell
exchang
rbcx
shown
transient
improv
laboratori
valu
histolog
find
fail
prevent
progress
liver
diseas
edit
american
societi
apheresi
guidelin
categor
epp
categori
iii
indic
apheresi
herein
present
pediatr
patient
epp
underw
olt
bridg
sct
manag
simpl
transfus
tpe
rbcx
studi
designmethod
present
male
epp
recurr
hepat
porphyria
crise
patient
present
right
upper
quadrant
pain
transamin
anemia
hemoglobin
mgdl
hematocrit
start
hemin
panhematin
recordati
rare
diseas
inc
lebanon
brunswick
new
jersey
daili
tpe
undergo
evalu
olt
olt
start
rbcx
everi
week
underw
total
rbcx
procedur
tpe
gradual
wean
daili
week
total
tpe
procedur
perform
addit
patient
hemoglobin
threshold
rais
mgdl
suppress
erythropoiesi
resultsfind
month
follow
olt
patient
mean
hemoglobin
hematocrit
mgdl
patient
continu
elev
ppix
normal
total
plasma
porphyrin
normal
associ
diffus
axon
polyneuropathi
addit
continu
elev
liver
enzym
liver
biopsi
show
increas
iron
deposit
mix
inflamm
increas
fibrosi
patient
also
develop
hypogammaglobulinemia
associ
chronic
tpe
patient
ultim
transfer
due
high
acuiti
care
prepar
hsct
conclus
tpe
rbcx
often
employ
manag
epp
patient
despit
asfa
categori
iii
indic
experi
ppix
total
porphyrin
remain
elev
patient
continu
liver
injuri
chronic
red
cell
transfus
maintain
hematocrit
shown
improv
symptom
patient
congenit
erythropoiet
porphyria
suppress
erythropoiesi
howev
patient
transfus
level
interest
wane
hypertransfus
patient
success
manag
hemin
infus
lower
iron
burden
though
treatment
also
inadequ
patient
stand
apheresi
remain
insuffici
impact
effect
epp
hypertransfus
remain
incomplet
explor
backgroundcas
studi
globulin
atg
potent
agent
kidney
allograft
recipi
serum
sick
ss
immun
complex
mediat
condit
occur
kidney
transplant
patient
receiv
rabbit
atg
ratg
prior
rabbit
exposur
consid
risk
factor
ss
develop
patient
classic
manifest
high
fever
polyarthr
arthralgia
rash
lymphadenopathi
renal
failur
rare
rapidli
progress
paralysi
treatment
includ
corticosteroid
antihistamin
symptomat
therapi
case
seri
suggest
effect
therapeut
plasma
exchang
tpe
procedur
manag
rapidli
evolv
serum
sick
report
case
ss
renal
transplant
patient
improv
singl
plasma
exchang
treatment
studi
designmethod
case
report
literatur
review
resultsfind
year
old
femal
end
stage
renal
diseas
secondari
antibodi
goodpastur
diseas
present
ten
day
deceas
donor
kidney
transplant
debilit
polyarticular
arthralgia
pleomorph
rash
sever
allodynia
rapidli
progress
upper
limb
weak
receiv
total
mg
ratg
induct
therapi
transplant
present
sever
joint
tender
upper
lower
extrem
swell
proxim
bilater
upper
extrem
paresi
ambul
normal
even
prior
admiss
imag
brain
spinal
cord
unremark
hypercoagul
caus
neuropathi
rule
complement
level
low
patient
undergon
cours
tpe
earli
cours
suspect
reject
later
exclud
prior
exposur
rabbit
howev
past
medic
histori
signific
exposur
ratg
prior
renal
transplant
past
histori
serum
sick
due
sever
symptom
lack
respons
corticosteroid
plasma
exchang
use
albumin
replac
initi
follow
procedur
patient
notic
impress
reduct
pain
next
day
rash
wane
swell
subsid
regain
upper
extrem
function
abl
ambul
walker
point
discharg
week
later
addit
apheresi
treatment
perform
conclus
earli
plasma
exchang
highli
effect
revers
symptom
serum
sick
especi
patient
rapidli
progress
neuropathi
weak
sever
pain
refractori
corticosteroid
current
apheresi
guidelin
list
ss
indic
tpe
report
review
literatur
support
inclus
tpe
serum
sick
categori
iii
indic
grade
level
evid
futur
practic
guidelin
backgroundcas
studi
present
case
neg
femal
histori
uncompl
term
pregnanc
appropri
receiv
rh
immun
globulin
spite
antibodi
screen
becam
posit
pattern
pregnanc
unfortun
end
intrauterin
fetal
demis
week
present
institut
prenat
care
pregnanc
week
day
gestat
husband
homozyg
dd
studi
designmethod
refer
lab
test
reveal
presenc
antibodi
neg
titer
titer
initi
see
tabl
week
day
patient
underw
three
day
cours
plasmapheresi
third
day
plasmapheresi
also
ivig
administr
weekli
antibodi
titer
follow
clinic
patient
manag
weekli
ivig
administr
intrauterin
transfus
iut
possibl
week
day
gestat
patient
underw
iut
middl
cerebr
arteri
peak
systol
veloc
greater
mom
doppler
ultrasonographi
total
iut
everi
week
deliveri
tabl
resultsfind
patient
deliv
lb
oz
male
infant
week
gestat
deliveri
hemoglobin
mgdl
hematocrit
total
bilirubin
mgdl
hospit
manag
ivig
seven
day
phototherapi
one
pack
red
blood
cell
transfus
hematocrit
nadir
administ
day
life
infant
discharg
day
life
stabl
hematocrit
receiv
two
prbc
transfus
cours
three
month
hemoglobin
hematocrit
stabil
conclus
present
case
sever
hemolyt
diseas
fetu
newborn
set
suspect
rh
immunoglobulin
failur
success
manag
plasmapheresi
iv
ig
intrauterin
transfus
backgroundcas
studi
gener
apheresi
perform
aid
formula
consid
safe
advers
effect
caus
princip
physiolog
effect
hypocalcemia
prevent
oral
intraven
calcium
supplement
seriou
side
effect
anaphylaxi
rare
case
unfraction
heparin
ufh
serv
anticoagul
apheresi
howev
guidelin
ufh
dose
apheresi
avail
report
patient
develop
anaphylaxi
plasmapheresi
success
use
ufh
anticoagul
studi
designmethod
man
chronic
kidney
diseas
caus
focal
segment
glomerulosclerosi
present
nephrolog
clinic
third
kidney
transplant
first
second
transplant
perform
age
year
avail
kidney
donor
wife
incompat
patient
blood
type
wife
b
admiss
plasmapheresi
commenc
deplet
antibodi
precondit
protocol
plasma
exchang
featur
anticoagul
spectra
optia
terumo
bct
lakewood
co
usa
plan
everi
day
replac
fluid
ab
fresh
frozen
plasma
ffp
first
plasmapheresi
session
patient
develop
gener
itch
min
commenc
second
session
develop
urticaria
follow
dyspnea
hypotens
loss
conscious
plasmapheresi
stop
immedi
intraven
dexamethason
chlorpheniramin
maleat
administ
symptom
disappear
h
thereaft
skin
prick
intraderm
citrat
test
yield
strongli
posit
result
thu
use
ufh
anticoagul
plasmapheresi
elimin
replac
fluid
chang
ffp
albumin
ffp
contain
citrat
ufh
infus
continu
plasmapheresi
whole
blood
ufh
ratio
held
plasma
exchang
perform
everi
plasmapheresi
session
resultsfind
success
perform
five
plasmapheresi
session
use
ufh
sole
anticoagul
two
session
schedul
preoper
deplet
antibodi
three
postop
remov
class
ii
antibodi
patient
underw
success
kidney
transplant
maintain
good
graft
function
month
conclus
patient
develop
allerg
reaction
citrat
plasmapheresi
ufh
use
safe
anticoagul
backgroundcas
studi
therapeut
phlebotomi
tp
standard
treatment
patient
blood
disord
result
excess
red
cell
product
doubl
red
blood
cell
drbc
procedur
offer
altern
therapeut
phlebotomi
option
potenti
effici
mean
deplet
excess
red
cell
tp
male
present
hospit
emerg
room
alter
mental
statu
symptom
patient
past
medic
histori
notabl
hypertens
hypothyroid
possibl
hemochromatosi
physic
examin
confus
tachycard
plethor
initi
laboratori
result
show
elev
hemoglobin
hgb
hematocrit
hct
gdl
respect
laboratori
result
white
blood
cell
platelet
count
within
normal
rang
studi
designmethod
perform
emerg
drbc
procedur
patient
given
rapid
clinic
deterior
monitor
patient
cbc
cours
drbc
procedur
tabl
resultsfind
complet
two
consecut
drbc
procedur
patient
total
hgb
hct
level
decreas
respect
first
drbc
collect
minut
durat
remov
ml
red
blood
cell
rbc
second
drbc
collect
minut
addit
remov
ml
rbc
albumin
administ
procedur
replac
fluid
instead
isoton
salin
maintain
appropri
intravascular
oncot
pressur
advers
event
note
procedur
patient
toler
without
difficulti
conclus
util
autom
doubl
red
cell
collect
allow
donor
apheresi
instrument
use
therapeut
treat
patient
testosteron
induc
polycythemia
patient
return
baselin
cognit
function
drbc
collect
avoid
prolong
hospit
due
secondari
polycythemia
backgroundcas
studi
erythrocytapheresi
autom
rbc
exchang
transfus
rbcx
increasingli
use
treatment
sickl
cell
diseas
benefit
simpl
transfus
includ
abil
limit
iron
load
erythrocytapheresi
practic
initi
finland
februari
singl
center
blood
product
finland
provid
singl
blood
bank
allow
monitor
use
phenotyp
rbc
unit
erythrocytopheresi
practic
consequ
adequaci
suppli
phenotyp
blood
studi
designmethod
data
rbc
unit
provid
blood
bank
erythrocytapheresi
center
collect
patient
genotyp
well
advanc
start
treatment
use
id
core
xt
kit
rbc
unit
use
erythrocytapheresi
alway
match
rhce
k
jk
fy
ss
whenev
unit
avail
stock
fy
patient
match
fya
fyb
start
begin
patient
transfus
unit
unmatch
certain
antigen
particular
antigen
match
futur
transfus
phenotyp
match
unit
reserv
patient
start
one
week
procedur
blood
group
determin
antibodi
screen
crossmatch
done
blood
bank
day
procedur
crossmatch
unit
sent
treatment
center
resultsfind
eleven
patient
age
year
receiv
rbcx
studi
period
month
number
rbc
unit
use
vari
per
rbcx
per
patient
four
patient
receiv
fulli
phenotyp
match
unit
unit
transfus
seven
patient
unmatch
one
antigen
jkb
antigen
often
match
jkb
posit
unit
transfer
five
jkb
neg
patient
addit
posit
unit
transfer
neg
patient
fyb
posit
unit
one
fy
patient
fya
posit
unit
four
fy
patient
order
match
dce
phenotyp
common
peopl
african
ancestri
rare
european
rhd
neg
unit
transfer
rhd
posit
patient
none
patient
alloimmun
studi
period
conclus
erythrocytapheresi
practic
requir
care
plan
close
collabor
blood
bank
laboratori
treatment
center
erythrocytapheresi
phenotyp
match
rbc
unit
pose
challeng
suppli
phenotyp
blood
larg
number
unit
requir
furthermor
due
differ
ethnic
donor
patient
popul
necessit
review
donor
phenotyp
strategi
highlight
import
recruit
blood
donor
repres
ethnic
minor
backgroundcas
studi
multipl
clinic
studi
shown
effect
chlorhexidin
glucon
chg
reduc
infect
common
complic
tunnel
cathet
central
line
associ
bloodstream
relat
infect
clabsi
strongli
contribut
patient
morbid
loss
vascular
access
patient
requir
use
central
venou
cathet
cvc
access
either
hemodialysi
apheresi
other
found
increas
risk
clabsi
cdc
issu
guidelin
reduc
clabsi
august
process
reduc
clabsi
implement
apheresi
depart
prior
march
sever
recommend
antisept
agent
chg
tinctur
iodin
iodophor
alcohol
ad
cvc
dress
chang
apheresi
patient
pt
studi
designmethod
data
collect
retrospect
march
new
process
implement
reduc
clabsi
patient
either
month
week
use
cvc
cvc
site
disinfect
betadin
swab
follow
occlus
dress
cvc
dress
chang
everi
hour
march
skin
adjac
cvc
antisept
cleans
dress
chang
chg
appli
frequenc
cvc
infect
calcul
chg
cation
biquanid
broad
spectrum
antimicrobi
activ
shown
activ
pathogen
use
cathet
report
resist
pattern
chg
pure
topic
agent
minim
absorpt
skin
without
report
toxic
effect
hydrophil
foam
impregn
chg
design
deliv
larg
amount
first
day
follow
steadi
releas
next
day
antisept
dress
shown
decreas
skin
microbi
colon
exit
site
thu
reduc
cathet
tip
colon
resultsfind
prior
implement
chg
cvc
line
dress
rate
cvc
line
relat
infect
infect
rate
significantli
declin
januari
septemb
thereaft
annual
rate
rate
absenc
cvc
relat
infect
achiev
maintain
late
earli
data
remain
similar
conclus
chg
along
decreas
incid
cvc
line
infect
patient
undergo
apheresi
procedur
inova
fairfax
medic
campu
apheresi
depart
applic
significantli
decreas
incid
exit
site
infect
refer
http
wwwethiconcomnaproductsvascularaccessinfectioncontrolvascularaccessinfectioncontrolbiopatchprotectivediskchg
http
wwwbdcomenusofferingsbrandschloraprep
backgroundcas
studi
patient
undergo
seri
therapeut
plasma
exchang
tpe
often
receiv
steroid
part
treatment
underli
disord
use
albumin
replac
fluid
fibrinogen
often
follow
assess
need
fresh
frozen
plasma
ffp
part
replac
fluid
steroid
affect
mani
laboratori
paramet
hypothes
use
steroid
may
affect
fibrinogen
level
tpe
seri
studi
evalu
whether
steroid
use
seri
tpe
predict
need
use
ffp
part
replac
fluid
due
hypofibrinogenemia
studi
designmethod
retrospect
review
consecut
patient
academ
medic
center
underw
tpe
seri
albumin
initi
replac
fluid
patient
diagnos
ffp
indic
replac
fluid
exclud
indic
tpe
concurr
use
oral
intraven
steroid
trend
fibrinogen
whether
ffp
ever
use
replac
fluid
due
hypofibrinogenemia
note
statist
analysi
perform
use
fisher
exact
test
unpair
graphpad
statist
signific
defin
p
resultsfind
total
patient
identifi
exclud
due
lack
baselin
fibrinogen
tpe
one
patient
underw
two
separ
seri
tpe
tpe
initi
neurolog
disord
patient
disord
patient
disord
patient
tpe
seri
includ
seri
patient
receiv
steroid
seri
patient
receiv
steroid
patient
take
steroid
requir
ffp
requir
ffp
point
tpe
seri
patient
take
steroid
requir
ffp
requir
ffp
point
tpe
seri
patient
steroid
like
patient
steroid
requir
ffp
point
tpe
seri
fibrinogen
recoveri
last
tpe
procedur
compar
patient
receiv
albumin
mean
fibrinogen
patient
steroid
baselin
mean
fibrinogen
patient
steroid
conclus
steroid
use
associ
higher
risk
use
ffp
time
tpe
seri
patient
receiv
albumin
tpe
seri
fibrinogen
recoveri
differ
patient
steroid
steroid
small
sampl
steroid
effect
fibrinogen
patient
receiv
albumin
tpe
backgroundcas
studi
bacteri
contamin
recov
tissu
allograft
pose
seriou
threat
transplant
recipi
antibiot
disinfect
standard
practic
util
cardiac
valv
cv
allograft
treatment
effort
reduc
risk
bacteri
contamin
howev
composit
antibiot
cocktail
well
incub
condit
vari
wide
depend
tissu
bank
chang
antibiot
avail
recent
revis
canadian
health
standard
result
requir
quantit
valid
tissu
allograft
bioburden
reduct
purpos
studi
investig
efficaci
revis
antibiot
cocktail
intent
contamin
cv
allograft
order
quantit
bioburden
reduct
defin
optim
incub
temperatur
disinfect
process
studi
designmethod
disinfect
solut
compos
vancomycin
tobramycin
cefoxitin
rpmi
inocul
cfuml
five
challeng
organ
consid
medic
signific
tissu
bank
follow
hour
incub
remain
cfu
count
log
reduct
calcul
evalu
appropri
disinfect
incub
rang
hour
hour
four
cv
bisect
inocul
cfu
challeng
organ
place
disinfect
solut
time
point
one
half
allograft
remov
wash
lactat
ringer
solut
recov
remain
bacteria
steril
salin
sonic
mechan
shake
final
recoveri
solut
filter
quantifi
bacteri
growth
resultsfind
recoveri
effici
sonic
cv
allograft
higher
aerob
vs
anaerob
cultur
microorgan
vs
maxim
inhibitori
dilut
mid
updat
antibiot
cocktail
util
throughout
valid
studi
demonstr
work
concentr
antibiot
suffici
inhibit
growth
five
challeng
microorgan
sensit
organ
staphylococcu
aureu
streptococcu
pyogen
inhibit
dilut
follow
escherichia
coli
clostridium
sporogen
pseudomona
aeruginosa
absenc
antibiot
challeng
organ
growth
remain
rel
stationari
aerob
anaerob
cultur
respect
incub
antibiot
temperatur
result
reduct
growth
aerob
anaerob
incub
temperatur
increas
greater
increas
bacteri
growth
hour
aerob
anaerob
bioburden
reduct
increas
incub
temperatur
aerob
anaerob
conclus
studi
demonstr
cardiac
valv
optim
decontamin
propos
disinfect
solut
cocktail
incub
temperatur
increas
disinfect
protocol
shown
reduc
bacteri
bioburden
greater
aerob
anaerob
challeng
organ
backgroundcas
studi
blood
donor
screen
west
nile
viru
wnv
infect
use
mp
individu
donor
id
nucleic
acid
test
nat
reduc
risk
transfus
transmit
wnv
report
relat
donat
test
neg
describ
case
fatal
like
repres
neg
undetect
wnv
donor
infect
knowledg
report
studi
designmethod
wnv
posit
unit
apheresi
platelet
prompt
lookback
investig
prior
donat
includ
wnv
neg
apheresi
platelet
unit
transfus
heart
transplant
recipi
subsequ
develop
wnv
neuroinvas
diseas
expir
sampl
organ
donor
recipi
neg
wnv
investig
includ
notif
blood
supplier
possibl
test
suspect
platelet
donor
review
blood
compon
relat
incid
resultsfind
patient
receiv
blood
compon
prepar
donor
periop
period
patientsuspect
platelet
donor
event
summar
tabl
donor
contact
lookback
investig
deni
symptom
wnv
month
donat
neg
serolog
result
also
obtain
donor
corrobor
neg
symptom
report
remain
lost
conclus
describ
case
fatal
neuroinvas
wnv
diseas
heart
transplant
recipi
presum
acquir
wnv
neg
platelet
transfus
identifi
lookback
investig
low
sco
posit
donat
like
repres
tail
end
donor
virem
period
suspect
neg
donat
day
earlier
suggest
donor
initi
phase
wnv
infect
viral
load
reliabl
detect
small
residu
risk
viral
load
level
detect
may
best
address
pathogen
reduct
technolog
well
robust
mosquito
surveil
control
measur
backgroundcas
studi
mma
test
use
predict
clinic
signific
alloantibodi
often
use
assess
antibodi
direct
high
preval
antigen
howev
may
also
use
assess
common
antibodi
specif
find
blood
patient
antigen
requir
mma
result
greater
reactiv
result
transfus
recommend
antigen
neg
blood
neg
refer
rang
mma
laboratori
studi
designmethod
mma
data
present
review
data
updat
previou
data
incorpor
use
result
assay
perform
previous
describ
transfus
test
perform
fresh
complement
c
without
fresh
complement
nc
ad
test
system
resultsfind
follow
tabl
contain
mma
result
serum
sampl
test
antibodi
report
vari
degre
signific
other
test
insuffici
blood
product
avail
support
transfus
need
conclus
continu
test
specif
sampl
yield
posit
result
common
specif
test
one
exampl
demonstr
reactiv
exampl
yield
posit
result
emphas
import
test
without
c
sera
posit
fresh
c
ad
posit
c
present
mma
result
indic
continu
need
evalu
red
cell
transfus
patient
antibodi
specif
alon
backgroundcas
studi
circulatori
overload
taco
acut
lung
injuri
trali
import
pulmonari
complic
blood
transfus
hypothes
natriuret
peptid
marker
cardiac
stress
could
use
conjunct
clinic
risk
factor
improv
identif
classif
patient
pulmonari
transfus
reaction
studi
designmethod
case
control
studi
risk
factor
pulmonari
transfus
reaction
four
academ
hospit
util
activ
surveil
enrol
case
well
transfus
control
without
pulmonari
edema
diagnos
taco
trali
deriv
criteria
use
nation
healthcar
safeti
network
surveil
definit
case
design
possibl
trali
acut
respiratori
distress
syndrom
risk
factor
present
case
design
tacotrali
two
diagnos
could
distinguish
level
measur
prior
follow
transfus
wilcoxon
test
test
use
compar
ntprobnp
result
group
trali
taco
tacotrali
possibl
trali
control
patient
resultsfind
prior
follow
transfus
level
significantli
elev
patient
taco
possibl
trali
compar
trali
tacotrali
control
p
overal
comparison
significantli
higher
possibl
trali
case
compar
taco
case
neither
differ
delta
ratio
differ
case
taco
compar
possibl
trali
howev
ratio
pre
significantli
differ
taco
trali
case
level
higher
case
taco
iqr
compar
control
iqr
subject
without
histori
congest
heart
failur
kidney
diseas
p
level
correl
sever
pulmonari
edema
measur
degre
hypoxemia
p
hospit
mortal
p
conclus
level
use
differenti
case
taco
possibl
trali
trali
tacotrali
thu
cardiac
stress
may
major
contribut
factor
pathogenesi
taco
possibl
trali
rel
trali
furthermor
level
correl
sever
pulmonari
edema
mortal
prospect
studi
need
test
predict
util
test
identifi
patient
risk
taco
prior
transfus
backgroundcas
studi
anaphylaxi
tra
seriou
acut
transfus
complic
occur
within
minut
follow
transfus
result
pruritu
urticaria
dyspnea
hypotens
shock
death
studi
object
assess
tra
occurr
potenti
risk
factor
among
inpati
us
elderli
age
older
studi
period
studi
designmethod
retrospect
studi
util
larg
medicar
databas
januari
coordin
center
medicar
medicaid
servic
transfus
identifi
record
procedur
revenu
center
code
tra
ascertain
via
diagnosi
code
studi
evalu
tra
rate
per
inpati
transfus
stay
among
elderli
overal
calendar
year
age
gender
race
number
unit
blood
compon
transfus
fisher
exact
test
perform
compar
tra
rate
test
use
ascertain
tra
occurr
trend
calendar
year
age
transfus
volum
resultsfind
among
inpati
transfus
stay
elderli
beneficiari
tra
diagnosi
code
record
overal
rate
per
stay
tra
rate
per
vari
calendar
year
blood
compon
number
unit
transfus
well
age
sex
race
annual
tra
rate
p
tra
rate
blood
compon
group
rbc
plasma
platelet
platelet
plasma
rbc
plasma
rbc
platelet
rbc
plasma
platelet
tra
rate
age
respect
p
femal
male
tra
rate
respect
white
tra
rate
respect
tra
rate
number
unit
transfus
unit
unit
unit
unit
p
conclus
studi
among
us
elderli
suggest
declin
tra
occurr
time
find
show
substanti
higher
tra
rate
plasma
andor
platelet
transfus
compar
rbc
studi
also
identifi
significantli
increas
tra
rate
greater
number
unit
transfus
reduc
tra
risk
advanc
age
investig
suggest
increas
tra
risk
male
versu
femal
white
versu
need
investig
studi
base
claim
data
thu
limit
includ
potenti
transfus
procedur
unit
diagnosi
code
well
lack
clinic
detail
valid
record
tra
backgroundcas
studi
purpura
ptp
seriou
transfus
complic
result
thrombocytopenia
mucou
membran
hemorrhag
epistaxi
gastrointestin
urinari
tract
bleed
ptp
may
caus
substanti
morbid
prolong
hospit
death
studi
object
assess
ptp
occurr
potenti
risk
factor
among
inpati
elderli
medicar
beneficiari
age
older
studi
designmethod
retrospect
studi
util
larg
medicar
databas
januari
april
coordin
center
medicar
medicaid
servic
blood
transfus
identifi
record
procedur
revenu
center
code
ptp
ascertain
via
diagnosi
code
studi
evalu
ptp
rate
per
inpati
transfus
stay
among
elderli
medicar
beneficiari
overal
calendar
year
age
sex
race
number
unit
blood
compon
transfus
fisher
exact
test
perform
compar
ptp
rate
test
use
ascertain
ptp
occurr
trend
calendar
year
age
number
unit
transfus
resultsfind
among
inpati
transfus
stay
elderli
beneficiari
ptp
diagnosi
code
record
overal
rate
per
stay
ptp
rate
per
vari
calendar
year
age
blood
compon
number
unit
transfus
annual
ptp
rate
p
ptp
rate
blood
compon
group
rbc
plasma
platelet
platelet
plasma
rbc
plasma
rbc
platelet
rbc
plasma
platelet
ptp
rate
age
categori
respect
p
ptp
rate
number
unit
transfus
unit
unit
unit
unit
p
conclus
studi
show
significantli
increas
ptp
risk
time
greater
number
unit
transfus
studi
also
identifi
substanti
higher
ptp
rate
platelet
transfus
either
alon
combin
rbc
andor
plasma
investig
suggest
declin
ptp
risk
advanc
age
risk
differ
race
gender
need
investig
studi
base
claim
data
thu
limit
includ
potenti
diagnosi
code
transfus
procedur
unit
transfus
well
lack
clinic
detail
valid
record
ptp
diagnosi
backgroundcas
studi
patient
thrombocytopenia
platelet
transfus
standard
care
prevent
treat
bleed
mitig
risk
infect
transit
platelet
inventori
conv
platelet
pr
platelet
decemb
march
maintain
dual
inventori
due
suppli
constraint
blood
supplier
pr
platelet
conv
platelet
analyz
bacteri
detect
assay
consid
standard
care
dispens
avail
per
blood
bank
polici
concern
remain
relat
hemostat
efficaci
product
sinc
platelet
recoveri
shown
lower
seen
conv
platelet
assess
use
efficaci
product
analyz
platelet
red
cell
util
transit
period
studi
designmethod
transfus
adult
age
year
older
assess
platelet
use
receiv
pr
conv
platelet
indic
hemostat
efficaci
also
assess
red
blood
cell
rbc
util
patient
period
follow
platelet
transfus
number
shown
signific
p
resultsfind
period
transfus
given
adult
patient
receiv
pr
conv
platelet
patient
receiv
transfus
conv
platelet
transfusionspati
addit
patient
receiv
pr
platelet
transfus
transfusionspati
similar
conv
group
patient
receiv
conv
platelet
studi
interv
also
receiv
rbc
averag
rbc
transfusionspati
similarli
receiv
pr
platelet
receiv
rbc
averag
rbc
transfusionspati
also
assess
rbc
util
first
hour
platelet
transfus
proxi
hemostat
efficaci
found
rbc
util
similar
averag
rbc
unitspati
within
hour
receipt
platelet
transfus
receiv
conv
platelet
averag
rbc
unitspati
receiv
pr
platelet
conclus
period
dual
inventori
determin
platelet
usag
pattern
similar
patient
receiv
conv
pr
platelet
product
direct
measur
product
efficaci
addit
evid
show
similar
rbc
util
pattern
group
suggest
hemostat
efficaci
pr
platelet
compar
conv
platelet
product
backgroundcas
studi
preoper
autolog
blood
donat
pabd
declin
use
may
consid
patient
undergo
elect
surgeri
signific
blood
loss
likelihood
transfus
exce
howev
pabd
rare
clear
indic
known
increas
risk
periop
anemia
compensatori
erythropoiesi
requir
least
three
week
associ
gender
report
periop
anemia
data
gender
differ
compensatori
erythropoiesi
transfus
associ
pabd
program
institut
studi
designmethod
retrospect
studi
pabd
program
institut
period
januari
decemb
follow
data
collect
patient
medic
record
patient
characterist
hemoglobin
valu
date
autolog
blood
donat
transfus
blood
product
hemoglobin
decreas
femal
male
calcul
compar
statist
analysi
perform
use
stata
statacorp
lp
texa
usa
resultsfind
patient
underw
pabd
donat
total
autolog
rbc
unit
femal
mean
age
rang
donat
one
unit
wherea
rest
donat
unit
review
transfus
medicin
physician
show
none
autolog
unit
indic
mean
number
day
pabd
date
surgeri
day
baselin
hemoglobin
hgb
prior
autolog
blood
donat
patient
gdl
gdl
femal
gdl
male
p
hgb
level
measur
autolog
donat
prior
surgeri
gdl
gdl
femal
gdl
male
p
mean
hgb
decreas
donat
gdl
gdl
femal
gdl
gdl
femal
patient
receiv
autolog
transfus
compar
male
patient
differ
reach
statist
signific
unit
wast
patient
patient
transfus
autolog
unit
patient
receiv
allogen
blood
product
addit
autolog
unit
patient
hgb
gdl
conclus
indic
pabd
clear
contrast
male
femal
patient
becam
anem
show
compensatori
erythropoiesi
interv
donat
surgeri
addit
femal
patient
transfus
compar
male
although
differ
reach
statist
signific
may
reflect
physiolog
differ
transfus
autolog
unit
also
justifi
patient
hgb
valu
major
patient
subset
backgroundcas
studi
american
colleg
surgeon
ac
defin
resourc
need
provid
optim
care
injur
patient
ac
trauma
qualiti
improv
program
tqip
introduc
massiv
transfus
protocol
mtp
guidelin
level
one
trauma
center
requir
mtp
program
receiv
initi
ac
verif
trauma
center
septemb
success
summar
necessari
blood
bank
bb
resourc
implement
ensur
success
ac
trauma
center
studi
designmethod
begin
year
initi
verif
visit
divis
trauma
bb
collabor
meet
mtp
requirementsa
minimum
posit
prbc
aba
thaw
plasma
platelet
made
avail
timesa
complet
reviewupd
mtp
written
polici
establish
time
standard
deliveri
blood
minut
min
mtp
pack
prbc
plasma
platelet
prbcplasmaplatelet
transfus
ratio
best
practicesa
mtp
flow
chart
place
oper
roomsan
present
creat
mtp
part
trauma
center
intern
educ
process
emerg
medicin
neurosurgeri
orthoped
trauma
surgeon
requir
review
presentationan
mtp
worksheet
design
bb
personnel
document
commun
time
issu
mtp
pack
retrospect
monitor
perform
transfus
safeti
officeran
electron
databas
mtp
creat
mtp
perform
improv
committe
form
collabor
bb
divis
traumameet
held
monthli
assess
perform
indic
outcom
analysi
necessari
chang
process
resultsfind
number
mtp
averag
turnaround
time
tat
complianc
min
tat
averag
number
unit
prbc
plasma
platelet
averag
prbc
plasma
ratio
year
illustr
mtp
qualiti
audit
includ
review
mtp
worksheet
video
trauma
team
activ
averag
tat
min
demonstr
deliveri
first
mtp
pack
evalu
process
indic
minimum
staff
requir
ensur
uninterrupt
mtp
servic
frequenc
perceiv
tat
issu
lack
appropri
notif
order
confus
wastag
remain
minim
conclus
mtp
process
qualiti
review
system
collabor
creat
bb
divis
trauma
robust
center
ensur
prospect
agre
upon
standard
high
level
complianc
min
tat
mtp
pack
low
prbc
plasma
ratio
attain
close
collabor
bb
divis
trauma
imper
success
plan
implement
ongo
review
mtp
process
backgroundcas
studi
earli
balanc
administr
platelet
benefici
bleed
patient
rapid
infus
system
fluid
warmer
commonli
use
periop
massiv
transfus
order
keep
pace
bleed
prevent
hypothermia
unit
state
devic
approv
platelet
administr
due
lack
data
mani
physician
reluct
use
avoid
devic
lead
delay
reduc
platelet
transfus
associ
mortal
bleed
patient
sought
determin
effect
clinic
rapid
infus
system
fluid
warmer
function
store
apheresi
platelet
studi
designmethod
studi
approv
univers
wisconsin
institut
review
board
unit
apheresi
platelet
less
hour
past
clinic
expiri
date
suppli
hospit
blood
bank
mix
sampl
steril
obtain
unit
remain
volum
run
commerci
avail
rapid
infus
system
belmont
rapid
infus
belmont
instrument
corpor
billerica
rate
mlmin
warm
entir
unit
infus
second
sampl
drawn
proxim
port
outflow
line
platelet
count
maximum
amplitud
thromboelastogram
haemonet
braintre
measur
sampl
estim
test
unit
would
give
us
greater
power
detect
differ
mm
use
pair
consid
signific
studi
repeat
parallel
sampl
protocol
use
platelet
aliquot
incub
minut
fluid
warmer
corp
minneapoli
mn
resultsfind
unit
reach
goal
infus
rate
mlmin
infus
circuit
malfunct
clot
observ
averag
temperatur
rang
statist
signific
chang
mean
mm
ci
p
minimum
maximum
differ
mm
respect
statist
signific
increas
platelet
count
mean
ci
p
equival
chang
baselin
platelet
count
similar
result
seen
fluid
warmer
tabl
conclus
studi
unabl
detect
signific
effect
rapid
infus
warm
function
store
apheresi
platelet
statist
signific
increas
platelet
count
probabl
result
disaggreg
small
platelet
aggreg
lead
higher
number
autom
cell
counter
result
strongli
suggest
rapid
infus
warm
apheresi
platelet
safe
backgroundcas
studi
platelet
plt
transfus
essenti
part
support
care
patient
undergo
hematopoiet
stem
cell
transplant
hsct
prophylact
therapeut
reason
evid
base
guidelin
platelet
product
select
set
abo
incompat
hsct
isoagglutinin
donor
origin
antibodi
may
target
engraft
erythroid
precursor
recipi
type
bind
transfus
platelet
decreas
post
transfus
count
avail
guidelin
recommend
transfus
donor
recipi
plasma
compat
platelet
howev
platelet
suspend
addit
solut
due
lower
plasma
content
respect
cell
abo
compat
seem
reason
approach
order
optim
post
transfus
platelet
count
object
compar
two
differ
strategi
platelet
select
abo
incompat
hsct
studi
designmethod
review
data
two
differ
platelet
transfus
protocol
use
patient
undergo
abo
incompat
hsct
hospit
protocol
platelet
transfus
plasma
compat
donor
recipi
abo
donor
group
major
incompat
abo
recipi
group
minor
incompat
protocol
b
platelet
transfus
abo
group
red
blood
cell
concentr
abo
recipi
group
major
incompat
abo
donor
group
minor
incompat
protocol
follow
specif
abo
platelet
avail
pack
rbc
rbcc
transfus
hemoglobin
level
patient
gdl
prophylact
pool
plt
transfus
plt
count
plt
transfus
independ
defin
last
plt
transfus
plt
transfus
follow
day
rbc
transfus
independ
defin
last
transfus
rbc
transfus
follow
day
record
transfus
requir
day
hsct
spss
softwar
v
use
perform
statist
analys
resultsfind
review
data
umbil
cord
blood
transplant
ucbt
peripher
blood
stem
cell
transplant
pbsct
women
men
median
age
year
rang
myeloabl
condit
regimen
use
case
result
show
tabl
express
median
rang
conclus
statist
differ
two
differ
platelet
transfus
protocol
abo
plasma
versu
abo
cell
compat
patient
undergo
abo
incompat
hematopoiet
stem
cell
transplant
backgroundcas
studi
blood
bank
storag
pack
red
blood
cell
prbc
undergo
alter
cell
metabol
increas
oxid
stress
membran
damag
amount
signific
number
biochem
structur
alter
storag
lesion
suppos
affect
safeti
senesc
prbc
still
debat
whether
transfus
senesc
prbc
increas
risk
recurr
diseas
surgeri
cancer
studi
designmethod
patient
identifi
prospect
maintain
tumor
bank
ovarian
cancer
databas
patient
elig
underw
surgic
tumor
debulk
due
primari
ovarian
cancer
complet
cytoreduct
surgeri
receiv
transfus
allogen
prbc
hospit
stay
prbc
storag
data
avail
accord
oldest
unit
prbc
transfus
patient
assign
prbc
storag
group
storag
day
primari
endpoint
surviv
df
propens
score
match
psm
use
remov
effect
confound
outcom
ethic
approv
obtain
ethic
committe
berlin
resultsfind
total
patient
median
month
confid
interv
ci
elig
analysi
inhomogen
patient
characterist
includ
cancer
stage
surgic
complex
transfus
requir
prbc
storag
group
unadjust
analysi
patient
transfus
prbc
store
well
day
higher
risk
cancer
recurr
death
compar
patient
transfus
prbc
store
day
hazard
ratio
df
ci
p
hr
p
hr
p
psm
adjust
analysi
patient
characterist
well
balanc
confirm
prbc
storag
affect
surviv
ovarian
cancer
surgeri
conclus
transfus
senesc
prbc
even
store
prcb
day
relat
wors
oncolog
outcom
patient
without
macroscop
tumor
residu
ovarian
cancer
surgeri
receiv
periop
rbct
hospit
backgroundcas
studi
massachusett
depart
public
health
mdph
first
state
health
depart
requir
report
blood
product
transfus
advers
reaction
ar
follow
transfus
via
nation
healthcar
safeti
network
hemovigil
modul
hm
demonstr
feasibl
measur
blood
bank
activ
way
summar
three
year
data
studi
designmethod
blood
bank
report
transfus
ar
facil
data
accord
hm
surveil
protocol
analyt
dataset
data
type
extract
analyz
sa
complet
report
month
defin
month
facil
report
transfus
data
presenc
absenc
ar
includ
analysi
ar
fail
meet
imput
case
criteria
requir
unknown
allerg
ar
exclud
ar
rate
number
ar
attribut
particular
group
product
divid
number
transfus
group
facil
categor
three
bed
size
group
accord
number
total
bed
licens
resultsfind
total
report
month
facil
analyz
period
blood
product
transfus
annual
transfus
volum
decreas
year
product
product
discard
product
total
also
decreas
year
total
ar
report
ten
defin
type
ar
increas
year
ar
rate
product
type
period
ar
per
rbc
unit
transfus
ar
per
platelet
unit
transfus
ar
per
plasma
unit
transfus
platelet
ar
rate
increas
averag
ar
per
platelet
unit
transfus
per
quarter
ar
rate
facil
rang
per
total
product
transfus
conclus
decreas
transfus
consist
trend
report
elsewher
increas
ar
may
due
increas
incid
increas
user
familiar
hm
within
bed
size
group
facil
outli
ar
rate
clear
limit
includ
lack
data
valid
possibl
inconsist
case
definit
interpret
applic
could
lead
ar
mdph
collabor
cdc
improv
hm
includ
clarifi
report
discard
product
test
autom
case
definit
analys
allow
detect
trend
usag
ar
incid
provid
action
data
futur
work
assess
impact
surveil
attempt
detect
anomal
rate
associ
specif
product
wider
use
hm
allow
repres
surveil
ultim
safer
transfus
medicin
practic
backgroundcas
studi
finnish
red
cross
blood
servic
frc
bs
respons
suppli
blood
product
finland
countri
popul
million
accord
eu
blood
direct
seriou
advers
reaction
ar
event
ae
may
affect
qualiti
safeti
blood
compon
must
immedi
report
blood
safeti
offic
frc
bs
mild
advers
reaction
incorrect
blood
compon
transfus
ibct
near
miss
event
report
annual
studi
designmethod
ae
report
analyz
classifi
advers
reaction
ar
ibct
near
miss
event
accord
isbt
standard
definit
resultsfind
total
number
blood
compon
nat
screen
leukodeplet
plasma
sd
treat
pool
plasma
distribut
frcb
hospit
product
steadi
declin
use
seen
total
ar
ibct
abo
incompat
report
number
remain
steadi
studi
period
incid
ar
per
compon
issu
rate
seriou
ar
per
sever
ar
relat
allergyanaphylaxi
hemolyt
transfus
reaction
ahtr
dhtr
circulatori
overload
taco
acut
lung
injuri
trali
transfus
associ
dyspnea
tad
infect
extrem
rare
bacteri
infect
confirm
case
per
report
transmiss
hiv
hbv
hcv
transfus
perform
report
death
per
five
relat
ahtr
includ
two
abo
incompat
ibct
two
trali
one
case
bacteri
infect
taco
conclus
studi
period
despit
signific
declin
use
blood
product
number
report
ae
remain
steadi
reflect
increas
knowledg
hemovigil
despit
high
qualiti
blood
product
seriou
advers
event
occur
human
error
account
mani
exampl
case
sever
dyspnea
especi
taco
doctor
unabl
recogn
caus
possibl
prevent
likewis
yet
see
improv
number
ahtr
result
blood
compon
intend
anoth
person
reflect
seriou
deviat
sop
patient
identif
futur
need
focu
improv
unsaf
practic
throughout
entir
blood
chain
especi
bed
side
procedur
checklist
ensur
patient
identif
risk
assess
taco
revis
report
criteria
joint
taco
task
forc
welcom
backgroundcas
studi
hereditari
hemorrhag
telangiectasia
hht
rare
autosom
domin
disord
result
format
abnorm
blood
vessel
patient
develop
recurr
spontan
mucocutan
bleed
may
requir
rbc
transfus
previous
suggest
hht
patient
increas
risk
rbc
alloimmun
transfus
individu
develop
rbc
alloantibodi
thu
may
benefit
rbc
antigen
match
polici
zheng
et
al
current
provid
extend
antigen
match
rbc
hht
patient
sought
character
rbc
alloimmun
individu
studi
designmethod
prospect
maintain
hht
patient
registri
institut
queri
perform
type
screen
rbc
transfus
includ
number
unit
rbc
alloantibodi
format
find
compar
previous
collect
data
rbc
alloimmun
simpl
transfus
sickl
cell
diseas
scd
condit
necessit
extend
rbc
antigen
match
rhkell
compat
unit
institut
resultsfind
hht
patient
transfus
rbc
rbc
alloantibodi
five
patient
one
one
patient
one
rbc
alloantibodi
patient
transfus
rbc
unit
median
rang
compar
develop
rbc
alloantibodi
hht
patient
develop
alloantibodi
transfus
significantli
fewer
rbc
unit
median
rang
p
associ
alloimmun
abo
group
rbc
alloimmun
hht
patient
markedli
greater
compar
scd
patient
develop
rbc
alloantibodi
simpl
transfus
desai
pc
et
al
interest
hht
patient
type
screen
perform
conclus
rate
alloimmun
transfus
hht
patient
high
institut
greater
transfus
scd
patient
hht
patient
transfus
mani
rbc
unit
institut
appear
high
rate
rbc
alloimmun
compar
hht
patient
receiv
fewer
unit
unclear
patient
transfus
factor
predispos
certain
hht
individu
develop
rbc
alloantibodi
condit
may
result
bleed
requir
rbc
transfus
recommend
type
screen
perform
hht
patient
particularli
sinc
valid
assess
recommend
prior
issu
blood
compon
given
rariti
hht
multicent
studi
need
determin
whether
antigen
match
strategi
appropri
subset
patient
backgroundcas
studi
append
common
caus
acut
abdomin
pain
typic
manag
either
antibiot
alon
combin
surgic
intervent
hematolog
malign
treatment
caus
pancytopenia
increas
risk
surgeri
complic
neutropen
patient
howev
may
suffici
immun
respons
clear
local
infect
even
appropri
antibiot
granulocyt
transfus
previous
evalu
treatment
neutropen
patient
refractori
bacteri
fungal
infect
extens
report
medic
manag
acut
append
studi
designmethod
case
seri
adult
patient
hematolog
malign
undergo
chemotherapi
develop
acut
append
manag
medic
antibiot
granulocyt
transfus
granulocyt
obtain
via
granulocyt
factor
dexamethason
stimul
volunt
donor
apheresi
hydroxyethyl
starch
goal
dose
granulocyt
per
transfus
absolut
neutrophil
count
determin
prior
within
hour
administr
granulocyt
vital
sign
oxygen
satur
measur
transfus
resultsfind
time
granulocyt
infus
patient
initi
sever
neutropen
undetect
neutrophil
count
deem
surgic
candid
granulocyt
transfus
gener
well
toler
one
patient
two
report
episod
fever
chill
patient
receiv
granulocyt
transfus
rang
day
evid
clinic
radiolog
improv
patient
show
immedi
increas
measur
absolut
neutrophil
count
increas
highli
variabl
mean
increas
rang
thousand
neutrophil
per
microlit
tabl
one
day
follow
granulocyt
transfus
patient
frequent
develop
either
fever
increas
abdomin
pain
like
relat
increas
appendic
inflamm
respons
granulocyt
imag
studi
case
gradual
improv
show
resolut
inflammatori
find
reduct
appendic
distent
conclus
three
adult
neutropen
patient
hematolog
malign
radiolog
confirm
acut
append
manag
granulocyt
transfus
antibiot
resolut
acut
append
investig
necessari
determin
granulocyt
infus
provid
therapeut
benefit
treatment
local
infect
neutropen
patient
backgroundcas
studi
critic
bleed
cb
result
massiv
transfus
mt
often
unexpect
guidelin
recommend
transfus
blood
group
oneg
red
blood
cell
rbc
patient
blood
group
known
due
low
frequenc
oneg
blood
group
suppli
may
exhaust
limit
data
exist
use
oneg
rbc
mt
particularli
patient
pt
admit
cb
compar
mt
onset
surgeri
australian
new
zealand
massiv
transfus
registri
captur
clinic
laboratori
data
pt
receiv
mt
rbc
period
type
cb
hospit
admiss
adm
aim
studi
compar
oneg
rbc
use
pt
whose
mt
began
within
adm
group
adm
group
mt
manag
oneg
pt
studi
designmethod
mt
case
requir
data
assign
group
variabl
includ
blood
group
pt
transfus
tx
rbc
number
tx
rbc
rbc
rel
mt
onset
patient
demograph
cb
context
data
rbc
tx
mt
post
mt
includ
resultsfind
data
mt
case
hospit
avail
group
group
tabl
mt
due
nonsurg
cb
ie
trauma
gastrointestin
hemorrhag
occur
group
group
p
group
pt
tx
significantli
rbc
group
pt
median
interquartil
iqr
vs
respect
p
rbc
tx
oneg
group
group
p
higher
proport
oneg
pt
group
tx
exclus
oneg
rbc
compar
group
vs
respect
p
one
femal
oneg
pt
yr
receiv
opo
rbc
group
surgic
pt
metastat
cancer
age
tx
oneg
opo
rbc
conclus
cohort
rbc
tx
earli
mt
onset
group
oneg
rbc
compar
later
mt
onset
group
femal
oneg
pt
yr
one
transfus
opo
rbc
find
suggest
transfus
laboratori
inventori
larg
met
mt
requir
oneg
rbc
backgroundcas
studi
evid
indic
use
massiv
transfus
protocol
mtp
improv
outcom
patient
traumat
injuri
mani
institut
adopt
mtp
use
clinic
set
though
evid
support
improv
outcom
hemorrhag
lack
goal
studi
describ
type
mtp
avail
particip
institut
clinic
indic
lead
mtp
activ
studi
designmethod
survey
distribut
transfus
medicin
specialist
assess
type
content
avail
mtp
particip
invit
submit
data
indic
clinic
indic
consecut
adult
pediatr
mtp
activ
least
six
month
resultsfind
survey
receiv
respons
rate
survey
incomplet
duplic
exclud
leav
respons
analysi
site
provid
one
mtp
bleed
emerg
adult
patient
site
provid
one
mtp
provid
mtp
specif
bleed
obstetr
ob
case
specif
trauma
specif
gastrointestin
bleed
one
site
provid
mtp
site
treat
pediatr
patient
site
provid
mtp
includ
least
one
pool
cryoprecipit
round
one
mtp
compar
site
one
mtp
center
provid
data
mtp
indic
total
adult
pediatr
activ
tabl
major
adult
pediatr
activ
respect
indic
indic
includ
gastrointestin
bleed
adult
ecmo
relat
bleed
pediatr
popul
conclus
major
center
use
mtp
manag
hemorrhag
multipl
clinic
set
among
particip
site
major
indic
mtp
activ
set
despit
lack
support
clinic
evid
patient
popul
find
warrant
need
studi
determin
optim
approach
massiv
transfus
support
injur
patient
backgroundcas
studi
transfus
pack
red
blood
cell
prbc
use
treat
anemia
reflect
low
hemoglobin
hb
level
improv
oxygen
deliveri
hb
finit
oxygen
carri
capac
tissu
suppli
oxygen
depend
suffici
hb
oxygen
content
variabl
affin
hb
oxygen
impact
releas
oxygen
within
patient
tissu
due
decreas
dpg
prbc
storag
period
transfus
prbc
hb
high
affin
object
studi
evalu
effect
prbc
transfus
oxygen
satur
deliveri
model
oxygen
consumpt
extract
describ
previous
srinivasan
studi
designmethod
hemodynam
stabl
cancer
patient
year
old
requir
unit
prbc
transfus
set
enrol
studi
patient
medic
condit
diagnosi
comorbid
vital
sign
transfus
transfus
complic
oxygen
deliveri
chang
outcom
relat
chang
medic
condit
within
hour
transfus
collect
analyz
oxygen
dissoci
curv
hemox
analyz
tc
scientif
prepar
blood
sampl
pre
prbc
unit
analyz
model
patient
resultsfind
hemodynam
stabl
cancer
patient
age
year
enrol
receiv
transfus
prbc
unit
storag
age
day
transfus
increas
hemoglobin
significantli
gdl
p
left
shift
oxygen
dissoci
curv
five
six
patient
averag
mmhg
p
chang
transfus
tabl
model
increas
averag
respect
decreas
transfus
store
prbc
conclus
expect
prbc
transfus
increas
patient
hb
hemodynam
stabl
cancer
patient
howev
main
aim
prbc
transfus
patient
improv
oxygen
ie
increas
oxygen
dissoci
curv
result
decreas
chang
detect
increas
hb
due
transfus
offset
dissoci
curv
increas
rbc
mass
modest
decreas
observ
hemodynam
stabl
popul
critic
ill
surgic
patient
requir
larger
transfus
volum
may
advers
affect
reduct
oxygen
extract
ratio
backgroundcas
studi
lack
data
regard
natur
histori
human
leukocyt
antigen
hla
antibodi
impact
transfus
support
patient
hla
alloimmun
platelet
refractori
allopr
current
manag
strategi
commonli
involv
use
crossmatch
xm
platelet
plt
understand
natur
histori
may
enabl
optim
donor
product
select
studi
designmethod
retrospect
identifi
patient
allopr
support
academ
medic
center
allopr
diagnos
upon
repeat
poor
correct
count
increment
cci
practic
count
increment
random
apheresi
donor
plt
detect
hla
antibodi
singl
antigen
bead
array
patient
receiv
plt
product
includ
grade
bu
xm
plt
cci
use
monitor
respons
repeat
test
gener
perform
patient
lack
donor
increas
allosensit
suspect
order
improv
donor
select
chang
calcul
panel
reactiv
antibodi
cpra
repres
broad
antibodi
repertoir
determin
patient
one
test
hla
compat
plt
primarili
suppli
one
blood
vendor
resultsfind
period
patient
femal
met
criteria
allopr
primari
diagnos
time
refractori
includ
hematolog
diseas
malign
bleed
obstetr
major
patient
concomit
splenomegali
fever
sepsi
andor
consumpt
process
allopr
detect
poor
increment
suspici
transfus
reaction
prior
diagnosi
allopr
patient
receiv
median
unselect
plt
rang
median
day
rang
interv
suspicion
allopr
first
plt
transfus
median
day
rang
possibl
plt
categor
xm
upon
provis
plt
patient
cci
plt
signific
differ
proport
plt
result
cci
patient
support
median
day
rang
repeat
test
patient
occur
median
day
rang
cpra
either
increas
decreas
unchang
time
conclus
size
academ
hospit
approxim
allopr
patient
annual
receiv
transfus
support
major
plt
patient
ultim
diagnos
allopr
often
present
plausibl
medic
caus
platelet
refractori
splenomegali
sepsi
howev
demonstr
present
studi
find
exclud
evalu
allopr
furthermor
antibodi
may
fluctuat
repeat
test
may
critic
guid
futur
transfus
support
strategi
backgroundcas
studi
febril
transfus
reaction
fnhtr
acut
transfus
complic
result
fever
chill
headach
nausea
andor
vomit
fnhtr
may
lead
prolong
hospit
increas
morbid
mortal
studi
object
assess
fnhtr
occurr
potenti
risk
factor
among
inpati
elderli
medicar
beneficiari
age
older
transfus
studi
designmethod
retrospect
studi
util
larg
medicar
databas
studi
period
januari
coordin
center
medicar
medicaid
servic
transfus
blood
compon
identifi
record
procedur
revenu
center
code
fnhtr
ascertain
via
diagnosi
code
studi
ascertain
fnhtr
rate
per
inpati
transfus
stay
among
elderli
overal
calendar
year
age
sex
race
blood
compon
number
unit
transfus
fisher
exact
test
perform
compar
fnhtr
rate
test
evalu
trend
calendar
year
age
transfus
volum
resultsfind
among
inpati
transfus
stay
elderli
beneficiari
studi
period
fnhtr
diagnosi
code
record
overal
rate
per
stay
fnhtr
rate
per
vari
calendar
year
blood
compon
number
unit
transfus
well
age
sex
annual
fnhtr
rate
fnhtr
rate
blood
compon
group
follow
plasma
platelet
rbc
platelet
plasma
rbc
plasma
rbc
platelet
rbc
plasma
platelet
fnhtr
rate
age
categori
respect
p
femal
male
fnhtr
rate
respect
fnhtr
rate
number
unit
transfus
unit
unit
unit
unit
p
conclus
studi
fnhtr
among
us
elderli
suggest
declin
fnhtr
occurr
studi
period
studi
also
identifi
signific
increas
fnhtr
occurr
greater
number
unit
transfus
suggest
declin
fnhtr
occurr
older
age
find
show
highest
fnhtr
rate
stay
rbc
platelet
transfus
suggest
lowest
risk
plasma
autolog
transfus
studi
suggest
higher
fnhtr
risk
femal
like
due
prior
alloimmun
ie
pregnanc
need
investig
studi
base
claim
data
thu
limit
includ
potenti
fnhtr
diagnosi
code
transfus
procedur
unit
transfus
well
lack
clinic
detail
valid
record
fnhtr
diagnosi
backgroundcas
studi
transfus
associ
circulatori
overload
taco
potenti
advers
transfus
reaction
associ
high
morbid
mortal
underdiagnos
underreport
diagnost
criteria
risk
factor
well
establish
pediatr
popul
aim
assess
util
patient
data
potenti
futur
risk
stratif
vital
sign
data
indic
investig
taco
studi
designmethod
retrospect
observ
case
review
seri
pediatr
patient
experienc
taco
hospit
admiss
acut
care
floor
larg
pediatr
hospit
septemb
march
abnorm
vital
sign
defin
use
patient
control
compar
pre
within
hour
post
within
hr
transfus
data
taco
case
defin
trali
rule
accord
nation
health
safeti
network
case
definit
resultsfind
six
patient
age
yo
met
studi
design
criteria
data
collect
admiss
diagnosi
oncolog
diseas
activ
infect
posit
fluid
balanc
note
patient
neg
balanc
howev
input
assess
due
breastfeed
five
patient
requir
oxygen
therapi
one
patient
oxygen
satur
assess
three
requir
escal
care
pediatr
intens
care
unit
patient
post
transfus
chest
sign
fluid
overload
two
patient
origin
diagnos
medic
team
experienc
allerg
reaction
four
six
patient
report
blood
bank
possibl
transfus
reaction
conclus
due
close
follow
transfus
recipi
transfus
safeti
offic
expect
number
patient
taco
found
pediatr
patient
uniqu
risk
factor
diagnost
featur
data
suggest
oncolog
diagnos
comorbid
posit
fluid
balanc
receipt
multipl
transfus
potenti
risk
factor
respiratori
rate
oxygen
satur
essenti
assess
tool
chang
either
indic
need
investig
taco
backgroundcas
studi
platelet
transfus
standard
approach
prevent
treat
bleed
thrombocytopen
patient
due
implement
improv
donor
histori
questionnair
donor
test
protocol
risk
transfus
transmit
infect
decreas
year
sepsi
bacteri
contamin
platelet
howev
still
remain
concern
mitig
risk
institut
migrat
platelet
inventori
conv
platelet
fda
licens
pr
platelet
product
patient
suppli
constraint
transit
howev
necessit
mainten
dual
inventori
conv
pr
platelet
analyz
incid
transfus
reaction
two
product
adult
patient
convers
period
studi
designmethod
decemb
march
platelet
transfus
reaction
report
adult
age
year
older
evalu
consid
conv
platelet
analyz
bacteri
detect
assay
safeti
measur
pr
platelet
repres
standard
care
institut
accordingli
platelet
request
either
product
dispens
blood
bank
per
usual
blood
bank
inventori
manag
polici
studi
analyz
type
platelet
transfus
categori
transfus
reaction
patient
demograph
patient
receiv
pr
conv
platelet
reaction
ascrib
appropri
product
base
time
reaction
proxim
transfus
natur
reaction
use
nation
hemovigil
network
guidelin
resultsfind
total
transfus
reaction
identifi
follow
platelet
transfus
episod
tabl
result
includ
adult
patient
regardless
admit
diagnosi
without
stratif
mean
age
conv
group
patient
year
pr
group
mean
patient
age
year
conv
group
reaction
record
transfus
episod
pr
group
total
reaction
identifi
transfus
statist
signific
taken
p
use
fisher
exact
test
rate
type
reaction
similar
two
group
allerg
reaction
frequent
report
categori
report
trali
septic
reaction
transfus
transmit
infect
note
either
group
conclus
adult
recipi
studi
differ
rate
type
transfus
reaction
pr
conv
platelet
base
data
pr
platelet
safe
transfus
without
increas
rate
type
transfus
reaction
note
backgroundcas
studi
colombia
made
progress
haemovigil
program
led
coordin
nation
network
blood
bank
transfus
servic
nation
institut
health
aim
work
describ
find
offici
onlin
implement
haemovigil
inform
system
sihevi
nation
level
regard
notif
advers
transfus
reaction
atr
classifi
accord
intern
societi
blood
transfus
studi
designmethod
sihevi
softwar
develop
connect
blood
bank
hospit
servic
countri
modul
includ
softwar
verifi
nation
level
background
atr
patient
prior
new
transfus
retrospect
analysi
made
januari
march
record
provid
sihevi
current
receiv
notif
hospit
institut
transfus
made
countri
resultsfind
accord
report
blood
compon
frequent
transfus
red
blood
cell
fresh
frozen
plasma
averag
unit
transfus
per
patient
rat
patient
receiv
hemocompon
patient
everi
transfus
consid
activ
notif
atr
hospit
institut
rate
atr
compon
transfus
estim
present
highest
proport
case
associ
platelet
everi
unit
transfus
follow
fresh
frozen
plasma
ffp
transfus
unit
tabl
atr
report
allerg
patient
atr
identifi
underw
one
transfus
patient
found
shortest
interv
notif
atr
anoth
one
month
patient
type
atr
notifi
interv
month
transfus
two
differ
institut
report
allergi
meet
degre
probabl
definit
addit
case
taco
trali
one
caus
death
taco
conclus
although
haemovigil
program
focu
mainli
notif
sever
atr
individu
monitor
patient
report
consid
relev
safeti
identifi
transfus
histori
order
mitig
appear
new
atr
backgroundcas
studi
cryoprecipit
cryo
sourc
weight
plasma
protein
includ
factor
viii
von
willebrand
factor
factor
xiii
fibrinogen
fibronectin
produc
cold
insolubl
fraction
ffp
dose
indic
cryo
today
cryo
larg
given
replac
fibrinogen
random
control
trial
exist
evalu
indic
limit
inform
pattern
cryo
use
neonat
studi
designmethod
data
retrospect
collect
neonat
admit
nicu
transfus
cryo
may
includ
clinic
scenario
indic
dose
fibrinogen
level
compon
transfus
day
cryo
institut
recommend
cryo
dose
pediatr
patient
singl
unit
per
approxim
aabb
recommend
maximum
unit
volum
resultsfind
neonat
transfus
dose
cryo
year
median
age
recipi
first
cryo
transfus
day
rang
day
five
patient
transfus
prophylact
remaind
transfus
set
bleed
surgeri
common
indic
cryo
transfus
set
bleed
open
heart
surgeri
bypass
repair
congenit
heart
diseas
remain
patient
transfus
context
dic
intraop
exploratori
laparotomi
coagulopathi
prolong
pt
aptt
meet
clinic
criteria
dic
one
patient
hemophagocyt
lymphohistiocytosi
renal
failur
receiv
dose
cryo
urem
bleed
month
durat
cryo
often
transfus
bleed
fibrinogen
level
assess
respect
viscoelast
test
util
median
dose
cryo
transfus
iqr
exclud
patient
receiv
dose
median
dose
iqr
compon
transfus
concurr
includ
platelet
rbc
plasma
transfus
reaction
report
follow
cryo
conclus
major
neonat
cryo
transfus
set
bleed
surgeri
common
cardiac
surgeri
dic
fibrinogen
level
routin
assess
median
cryo
dose
administ
higher
institut
aabb
guidelin
studi
cryo
util
dose
associ
outcom
warrant
neonat
especi
cardiac
surgeri
case
standard
transfus
dose
decis
backgroundcas
studi
storag
platelet
unit
encourag
bacteri
growth
increas
risk
septic
transfus
reaction
str
concern
str
led
aabb
standard
result
univers
screen
platelet
plt
use
method
aabb
also
issu
criteria
cultur
plt
implic
advers
event
identifi
str
aabb
bulletin
accord
aabb
criteria
signssymptom
suggest
str
includ
fever
rise
plu
follow
rigor
hypotens
shock
tachycardia
dyspnea
andor
nauseavomit
isol
hypotens
estim
risk
str
apheresi
plt
per
unit
compar
estim
risk
str
red
blood
cell
rbc
per
unit
nonetheless
seriou
str
caus
rbc
includ
two
death
seri
involv
yersinia
enterocolitica
goal
project
analyz
larg
databas
transfus
reaction
data
calcul
sensit
specif
aabb
criteria
cultur
suspect
str
plt
compar
rbc
studi
designsmethod
collect
retrospect
data
transfus
reaction
adult
year
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
cultur
result
enrich
dataset
posit
result
limit
analysi
reaction
singl
plt
rbc
implic
reaction
involv
plasma
cryoprecipit
multipl
product
includ
analyz
aabb
cultur
criteria
assess
sensit
specif
detect
posit
residu
product
cultur
plt
compar
rbc
definit
str
defin
reaction
concord
bacteri
speci
isol
implic
unit
affect
patient
possibl
str
unit
cultur
posit
patient
cultur
either
neg
discord
patient
cultur
resultsfind
institut
submit
complet
reaction
data
reaction
cultur
residu
implic
plt
rbc
involv
plt
rbc
among
plt
posit
cultur
result
definit
str
possibl
str
among
rbc
posit
cultur
result
definit
str
possibl
str
comparison
specif
sensit
aabb
criteria
detect
posit
cultur
plt
compar
rbc
shown
tabl
conclus
result
indic
sensit
aabb
criteria
detect
posit
cultur
residu
product
poor
although
criteria
design
plt
criteria
perform
equal
poorli
reaction
involv
rbc
backgroundcas
studi
repetit
transfus
pack
red
blood
cell
prbc
import
compon
support
treatment
patient
sickl
cell
diseas
scd
alloimmun
red
cell
antigen
major
obstacl
transfus
therapi
may
lead
complic
acut
hemolyt
transfus
reaction
htr
delay
htr
rare
seriou
hyperhemolyt
syndrom
addit
complic
laboratori
work
need
identifi
antibodi
find
compat
prbc
unit
incid
significantli
higher
scd
patient
rang
compar
gener
popul
polytransfus
popul
rang
date
report
incid
rate
pediatr
scd
patient
costa
rica
purpos
studi
determin
incid
rate
cohort
sickl
cell
diseas
patient
transfus
protocol
extend
compat
rhccee
k
antigen
nation
pediatr
hospit
costa
rica
studi
designmethod
retrospect
analysi
immunohematolog
transfus
histori
juli
june
scd
patient
age
year
transfus
nation
pediatr
hospit
conduct
descript
statist
report
percentag
median
rang
iqr
rate
report
antibodi
per
prbc
transfus
comparison
alloimmun
patient
made
use
fisher
exact
test
u
test
appropri
spss
ibm
corp
armonk
ny
usa
resultsfind
incid
rate
antibodi
per
prbc
transfus
age
number
prbc
transfus
significantli
higher
alloimmun
group
refer
group
median
year
iqr
year
vs
year
iqr
year
p
median
prbc
transfus
iqr
prbc
transfus
vs
prbc
transfus
iqr
prbc
transfus
p
respect
gender
distribut
similar
group
femal
patient
alloimmun
vs
frequenc
rhdce
phenotyp
patient
dccee
patient
antibodi
found
direct
k
fya
e
f
k
e
prbc
unit
transfus
antigen
neg
patient
rural
center
conclus
first
report
rate
pediatr
scd
patient
costa
rica
incid
rate
studi
cohort
similar
report
less
heterogen
popul
donor
patient
frequenc
rhce
phenotyp
found
studi
differ
commonli
report
scd
patient
report
strengthen
recommend
develop
countri
establish
transfus
program
includ
extend
phenotyp
compat
least
rhccee
k
even
absenc
molecular
extend
type
patient
donor
gener
commun
mechan
refer
transfus
center
rural
peripher
transfus
center
minim
risk
expos
patient
differ
rhccee
k
phenotyp
develop
backgroundcas
studi
acut
hemolyt
transfus
ahtr
reaction
rare
recogn
complic
transfus
abo
incompat
platelet
common
scenario
involv
singl
donor
platelet
sdp
unit
obtain
type
donor
high
titer
transfus
type
recipi
ahtr
follow
transfus
abo
incompat
prepool
pp
platelet
less
common
pp
platelet
pool
togeth
sever
donor
high
titer
one
donor
dilut
report
case
ahtr
follow
transfus
abo
incompat
pp
platelet
unit
studi
designmethod
evalu
transfus
reaction
type
patient
myelodysplast
syndrom
receiv
type
pp
platelet
unit
thrombocytopenia
pulmonari
hemorrhag
resultsfind
shortli
transfus
initi
patient
develop
rigor
hypoxia
gross
hematuria
transfus
stop
transfus
reaction
report
diphenhydramin
acetaminophen
meperidin
given
within
hour
patient
becam
febril
laboratori
test
reveal
drop
hemoglobin
gdl
gdl
new
indirect
hyperbilirubinemia
mgdl
newli
elev
lactat
dehydrogenas
iul
undetect
haptoglobin
mgdl
cleric
error
identifi
patient
aborh
type
visual
inspect
plasma
neg
hemolysi
antibodi
screen
repeat
found
neg
direct
antiglobulin
test
dat
posit
identifi
eluat
titer
pp
platelet
unit
blood
supplier
notifi
test
reveal
donor
titer
immedi
spin
fifth
titer
tabl
conclus
transfus
medicin
servic
blood
supplier
agre
patient
experienc
ahtr
due
high
titer
donor
pp
platelet
unit
fortun
patient
recov
less
hour
discharg
week
later
may
tempt
think
pp
platelet
unit
dilut
high
titer
antibodi
case
serv
remind
group
transfus
platelet
pool
otherwis
potenti
caus
ahtr
backgroundcas
studi
passeng
lymphocyt
syndrom
pl
seriou
potenti
fatal
complic
abo
hematopoiet
stem
cell
transplant
hsct
pl
donor
b
lymphocyt
graft
mount
immun
respons
recipi
rbc
antigen
potenti
result
sever
intravascular
hemolysi
typic
within
day
hsct
sign
symptom
pl
may
mistaken
complic
hsct
possibl
delay
appropri
care
fatal
associ
unrecogn
pl
implement
preemptiv
process
monitor
patient
risk
pl
studi
designmethod
patient
undergo
allogen
hsct
requir
assess
donorrecipi
abo
clinic
servic
hsct
team
inform
transfus
medicin
tm
upcom
patient
tm
enter
safeti
alert
note
laboratori
inform
system
electron
medic
record
emr
tm
clinic
personnel
awar
potenti
pl
case
folder
creat
patient
track
abo
forward
revers
type
direct
antiglobulin
test
dat
blood
count
transfus
requir
hsct
team
order
requir
test
minimum
everi
day
patient
hous
everi
outpati
visit
tm
resid
collect
review
result
tm
attend
morn
tm
round
new
posit
dat
detect
donor
isohemagglutinin
trigger
addit
investig
includ
indic
eluat
hsct
physician
servic
directli
notifi
posit
find
tm
resid
note
describ
identif
antibodi
interpret
support
serolog
evid
pl
place
patient
emr
tm
attend
staff
resultsfind
irb
approv
record
adult
patient
undergo
abo
hsct
januari
decemb
assess
adher
protocol
peripher
blood
human
progenitor
cell
marrow
graft
equal
repres
cohort
patient
detect
posit
dat
monitor
period
fifteen
demonstr
antibodi
eluat
antibodi
identifi
case
one
patient
serolog
pl
clinic
hemolysi
manag
transfus
support
requir
urgent
red
blood
cell
exchang
direct
therapi
death
among
transplant
patient
risk
pl
surveil
period
patient
abo
evid
monitor
tm
servic
day
post
hsct
seven
patient
found
safeti
alert
note
found
emr
one
patient
suboptim
adher
sop
dat
never
order
clinic
team
clinic
team
notif
occur
everi
patient
serolog
evid
pl
conclus
failur
identifi
monitor
patient
risk
pl
transfus
medicin
servic
collabor
process
preemptiv
surveil
patient
detect
serolog
hemolyt
case
pl
allow
appropri
escal
manag
support
care
follow
mortal
associ
pl
patient
detect
serolog
evid
pl
backgroundcas
studi
one
hospit
site
recent
implement
platelet
test
verax
biomed
observ
posit
rate
sinc
yet
get
cultur
confirm
posit
result
verax
posit
unit
question
whether
repres
fals
posit
result
whether
cultur
method
lack
sensit
confirm
verax
posit
result
studi
designmethod
patient
specimen
upon
receipt
microbiolog
laboratori
platelet
unit
gram
stain
ml
specimen
inocul
bactalert
fa
plu
aerob
bottl
fn
plu
anaerob
bottl
biomerieux
durham
nc
bottl
also
get
ml
fild
enrich
medium
remel
lenexa
ks
place
bactalert
autom
blood
cultur
system
flag
posit
neg
bottl
remov
system
discard
five
day
posit
bottl
gram
stain
identif
use
vitek
ms
system
biomerieux
spike
studi
serial
dilut
staphylococcu
aureu
atcc
pseudomona
aeruginosa
atcc
prepar
steril
salin
surrog
specimen
prepar
combin
dilut
ml
apheresi
platelet
leukocyt
reduc
less
day
beyond
expir
date
final
concentr
bacteria
surrog
specimen
rang
cfuml
ml
specimen
inocul
bactalert
fa
plu
aerob
bottl
along
ml
fild
enrich
media
cultur
load
bactalert
system
incub
flag
posit
bottl
remain
neg
five
day
incub
call
neg
discard
resultsfind
accord
packag
insert
verax
test
limit
detect
paeruginosa
aureu
cfuml
platelet
fall
right
middl
rang
test
spike
specimen
limit
detect
cultur
method
reach
studi
indic
sensit
less
lowest
dilut
test
cfuml
aureu
p
aeruginosa
bottl
spike
lowest
concentr
nearli
fold
concentr
requir
give
posit
verax
result
still
went
posit
less
day
conclus
date
platelet
unit
test
posit
result
neg
subsequ
cultur
fals
posit
rate
within
fals
posit
rate
claim
packag
insert
addit
studi
demonstr
cultur
methodolog
suffici
sensit
detect
true
verax
posit
specimen
verax
posit
date
like
repres
fals
posit
backgroundcas
studi
select
iga
defici
sigad
common
primari
immunodefici
pi
frequenc
estim
vari
ethnic
sever
anaphylact
allerg
reaction
may
occur
blood
transfus
patient
sigad
screen
test
usual
identifi
mild
defici
mgdl
howev
secondari
test
necessari
identifi
true
defici
iga
mgdl
demonstr
presenc
antibodi
iga
present
data
surveil
program
sigad
effort
identifi
patient
risk
possibl
sever
transfus
reaction
studi
designmethod
autom
weekli
report
low
iga
result
base
data
result
immunolog
depart
analyz
transfus
medicin
servic
retrospect
review
electron
medic
record
emr
assess
patient
sigad
develop
algorithm
approach
identifi
patient
presumpt
discuss
patient
clinic
team
make
addit
test
recommend
true
iga
defici
document
concern
possibl
transfus
reaction
delay
blood
product
emr
goal
categor
patient
sigad
least
low
iga
true
iga
defici
assess
iga
antibodi
resultsfind
low
iga
test
result
patient
new
diagnosi
sigad
made
patient
five
unexpect
base
clinic
impress
time
test
nine
patient
known
diagnosi
sigad
also
identifi
diagnosi
histori
alreadi
note
emr
case
three
patient
true
iga
defici
antibodi
test
perform
one
new
two
known
case
three
patient
low
iga
igm
remain
patient
least
one
number
diagnos
explain
low
iga
result
new
diagnosi
sigad
order
physician
contact
fax
email
page
phone
recommend
addit
test
includ
high
sensit
iga
level
elisa
document
possibl
issu
relat
transfus
ivig
administr
emr
identifi
case
sever
allerg
transfus
reaction
low
iga
defici
patient
conclus
retrospect
chart
review
identifi
new
case
sigad
patient
popul
includ
five
patient
sigad
immunodefici
iga
unexpect
find
review
allow
us
make
test
recommend
work
discuss
case
provid
new
case
one
patient
identifi
true
iga
defici
antibodi
test
nine
patient
complet
studi
highlight
import
commun
transfus
medicin
servic
clinic
colleagu
interdisciplinari
effort
need
help
avoid
possibl
patient
harm
backgroundcas
studi
fresh
frozen
plasma
ffp
success
normal
intern
normal
ratio
inr
patient
elev
inr
due
warfarin
overdos
howev
ffp
often
request
patient
take
warfarin
mildli
elev
inr
invas
procedur
patient
inr
fail
normal
transfus
medicin
servic
frequent
ask
inr
ffp
literatur
search
fail
provid
inform
purpos
studi
assess
coagul
profil
ffp
includ
prothrombin
time
pt
inr
activ
partial
thromboplastin
time
aptt
studi
designmethod
fifti
unit
ffp
collect
blood
donor
center
identifi
plasma
frozen
within
hour
collect
thaw
plasma
liquid
plasma
cryopoor
plasma
test
abo
type
day
sinc
initi
freez
record
unit
segment
unit
obtain
unit
thaw
patient
aliquot
aliquot
time
pt
inr
aptt
test
stago
evolut
coagul
analyz
anova
tukey
hsd
test
vassarstat
use
compar
mean
inr
abo
type
statist
signific
defin
p
resultsfind
averag
day
sinc
initi
freez
day
rang
day
averag
time
thaw
aliquot
day
overal
averag
pt
averag
inr
averag
aptt
tabl
pt
inr
unit
within
normal
limit
inr
rang
compar
inr
unit
differ
abo
type
mean
significantli
differ
type
b
type
ffp
eleven
unit
aptt
upper
limit
normal
maximum
eleven
unit
thaw
averag
day
prior
conclus
perhap
surprisingli
inr
ffp
within
normal
limit
differ
inr
type
b
ffp
statist
signific
clinic
trivial
vs
respect
unit
test
averag
day
sinc
initi
thaw
typic
timefram
within
ffp
would
transfus
failur
normal
patient
mildli
elev
inr
ffp
transfus
like
due
transfus
inadequ
dose
patient
may
benefit
administr
vitamin
k
entir
avoid
ffp
transfus
backgroundcas
studi
group
ab
plasma
limit
avail
emerg
transfus
lead
increas
util
group
plasma
emerg
releas
transfus
ert
abo
incompat
plasma
transfus
becom
accept
practic
minim
risk
hemolysi
often
accredit
protect
dilut
effect
studi
perform
determin
increas
volum
incompat
plasma
transfus
associ
increas
risk
transfus
relat
complic
mortal
studi
designmethod
retrospect
studi
perform
evalu
incid
complic
mortal
hemolyt
transfus
reaction
group
b
ab
patient
receiv
plasma
contain
blood
compon
decemb
januari
ert
larg
level
trauma
center
abo
blood
type
volum
blood
compon
transfus
review
conjunct
clinic
chart
review
resultsfind
group
b
ab
patient
receiv
group
andor
group
plasma
compon
ert
day
patient
surviv
die
death
occur
within
hour
ert
secondari
underli
medic
condit
tabl
none
death
associ
transfus
complic
unexplain
drop
hemoglobin
hgb
level
gdl
averag
day
follow
ert
experienc
surviv
patient
associ
chang
hgb
level
amount
incompat
plasma
volum
transfus
establish
higher
mortal
rate
present
patient
receiv
blood
volum
replac
incompat
plasma
compar
lesser
percentag
tabl
conclus
incompat
abo
plasma
transfus
ert
safe
strategi
associ
increas
transfus
relat
advers
event
incompat
plasma
transfus
account
blood
volum
associ
increas
mortal
compar
lesser
percentag
howev
overal
sever
injuri
rule
confound
factor
lead
increas
mortal
high
risk
group
backgroundcas
studi
massiv
transfus
event
time
requir
issu
larg
quantiti
blood
product
transport
patient
problemat
clinician
often
stockpil
blood
product
bedsid
better
avail
prompt
move
new
build
blood
bank
far
oper
room
implement
use
hemoroam
mobil
blood
storag
refriger
mbr
roemer
industri
sante
ca
univers
health
system
includ
hospit
level
trauma
center
obstetr
servic
liver
transplant
servic
inpati
bed
transfus
volum
red
cell
unit
annual
new
massiv
transfus
protocol
mtp
util
rotat
mbr
keep
blood
product
continu
avail
bedsid
studi
designmethod
approv
fund
obtain
hospit
administr
mbr
purchas
valid
new
standard
oper
procedur
sop
mbr
implement
blood
issu
sop
updat
previous
issu
process
involv
courier
read
product
inform
technologist
new
process
one
technologist
issu
product
comput
system
second
technologist
check
product
mbr
print
report
first
mbr
stock
unit
red
cell
plasma
drawer
contain
apheresi
platelet
order
cryoprecipit
first
mbr
issu
second
prepar
second
mbr
issu
third
prepar
third
mbr
issu
upon
return
first
cycl
continu
long
mtp
activ
mbr
pilot
liver
transplant
program
usag
subsequ
expand
entir
health
system
includ
mtp
transfus
event
upon
request
issu
time
usag
trend
evalu
resultsfind
new
mbr
system
use
time
institut
august
march
massiv
transfus
liver
transplant
trauma
includ
obstetr
critic
care
evalu
demonstr
minimum
usag
octob
protocol
per
day
maximum
januari
protocol
per
day
overal
averag
protocol
per
day
time
issu
blood
product
use
old
sop
minut
secondsunit
issu
time
use
new
sop
minut
secondsunit
decreas
conclus
rotat
mbr
mtp
event
facilit
constant
suppli
blood
patient
bedsid
decreas
blood
issu
time
clinician
embrac
strategi
transfus
servic
receiv
posit
feedback
backgroundcas
studi
normal
salin
ns
fluid
choic
resuscit
rehydr
fluid
replac
therapeut
red
blood
cell
rbc
exchang
patient
sickl
cell
anemia
increas
concern
ns
renal
toxic
data
demonstr
greater
vitro
hemolysi
normal
rbc
ns
buffer
solut
pla
studi
designmethod
investig
degre
hemolysi
normal
rbc
sickl
rbc
vitro
incub
either
ns
pla
also
analyz
rbc
indic
includ
mean
corpuscular
volum
mcv
assess
biophys
effect
short
term
hour
storag
solut
resultsfind
sickl
rbc
experienc
significantli
greater
hemolysi
p
normal
rbc
crystalloid
solut
tabl
ns
caus
increas
hemolysi
compar
pla
sickl
rbc
hour
exposur
p
tabl
patient
sampl
contain
increas
quantiti
hemoglobin
red
cell
increas
hemoglobin
associ
increas
hemolysi
ns
spearman
correl
coeffici
similar
smaller
effect
seen
pla
hour
exposur
sickl
rbc
increas
mcv
f
ns
vs
f
pla
mcv
normal
rbc
increas
fl
ns
pla
conclus
vitro
model
demonstr
short
term
exposur
sickl
rbc
crystalloid
lead
greater
hemolysi
normal
rbc
effect
significantli
greater
ns
pla
whether
use
ns
caus
increas
hemolysi
vivo
unknown
given
recent
evid
ns
increas
renal
failur
mortal
critic
ill
patient
investig
well
justifi
studi
conduct
patient
sickl
cell
anemia
may
benefit
rehydr
resuscit
pla
similar
buffer
solut
given
exist
evid
advers
effect
low
level
hemolysi
backgroundcas
studi
order
receiv
transfus
unit
platelet
plt
year
old
neutropen
patient
acut
lymphoblast
leukemia
outpati
set
two
apheresi
plt
alloc
issu
transfus
within
next
hour
sign
transfus
reaction
note
immedi
transfus
approxim
minut
complet
outpati
visit
patient
return
emerg
depart
ed
fever
chill
blood
cultur
collect
patient
admit
hospit
initi
thought
patient
central
line
port
contamin
follow
even
septic
symptom
link
transfus
transfus
reaction
report
transfus
servic
ts
studi
designmethod
blood
supplier
notifi
transfus
reaction
origin
plt
contain
longer
avail
cultur
unit
transfus
concurr
plasma
avail
second
plt
contain
collect
transfus
patient
anoth
hospit
facil
without
report
advers
reaction
unit
transfus
part
tripl
collect
contain
return
blood
supplier
due
presenc
clot
day
collect
plt
contain
unit
transfus
transfus
marrow
transplant
patient
day
transfus
contain
sign
symptom
transfus
reaction
cultur
concurr
plasma
unit
transfus
neg
cultur
clot
plt
unit
transfus
posit
identifi
staphylococcu
aureu
blood
cultur
septic
patient
also
grew
staphylococcu
aureu
resultsfind
initi
cultur
perform
parent
plt
product
blood
center
sampl
hour
collect
neg
day
incub
instrument
addit
initi
sampl
subsequ
plate
notif
transfus
reaction
found
neg
plt
contain
suspect
collect
test
hospit
use
point
issu
bacteri
test
verax
platelet
test
midnight
day
day
found
neg
presenc
bacteria
aureu
patient
blood
cultur
posit
plt
contain
sent
genotyp
found
ident
indic
patient
septic
reaction
caus
transfus
plt
product
conclus
although
point
issu
bacteri
screen
perform
appear
level
bacteria
limit
detect
may
result
fals
neg
result
clinic
side
even
symptom
reaction
present
initi
assumpt
patient
central
blood
stream
infect
clabsi
discuss
clinic
staff
show
current
clabsi
investig
process
includ
check
see
blood
product
recent
given
may
caus
patient
septic
lesson
learn
ts
realiz
clot
found
one
contain
might
indic
presenc
bacteria
remov
inventori
backgroundcas
studi
admixtur
fetal
blood
matern
circul
common
massiv
hemorrhag
mfmh
may
caus
sever
fetal
morbiditymort
although
exact
blood
volum
bv
defin
mfmh
typic
involv
bv
ml
mfmh
ml
estim
occur
deliveri
mfmh
ml
estim
deliveri
previous
report
case
mostli
without
matern
rh
sensit
statu
describ
case
mfmh
ml
consequ
regard
fetal
outcom
matern
rhd
alloimmun
statu
studi
designmethod
case
report
year
old
femal
rh
neg
given
rh
immunoglobulin
rh
ig
week
gestat
age
ga
present
week
day
ga
schedul
biophys
profil
post
due
date
evalu
patient
rememb
last
time
felt
fetal
movement
deni
vagin
bleed
trauma
fluid
leakag
contract
ultrasonographi
reveal
absent
fetal
heart
rate
two
week
prior
normal
fetal
heart
sound
present
underw
induct
labor
deliv
gram
stillborn
femal
fetu
fetal
autopsi
reveal
chronic
placent
abrupt
like
result
mfmh
resultsfind
test
kbt
perform
deliveri
show
result
seven
hour
later
kbt
repeat
base
find
calcul
matern
bv
ml
calcul
fetal
matern
hemorrhag
fmh
estim
ml
ml
approach
total
fetal
bv
calcul
ml
given
vial
intramuscular
rhig
microgramsvi
vial
intraven
rhig
day
period
observ
clinic
advers
sequela
serolog
investig
si
month
postpartum
consult
reveal
antibodi
titer
order
si
test
month
postpartum
inconclus
rhd
antigen
posit
weakli
react
month
postpartum
antibodi
detect
week
pregnant
time
si
treat
intramuscular
rhig
mcgvial
deliv
healthi
rhd
posit
neonat
term
fetal
blood
screen
neg
deliveri
conclus
mfmh
ml
describ
rare
case
report
indic
matern
sensit
statu
case
mfmh
along
matern
serial
si
indic
adequ
dose
rhig
achiev
patient
prevent
isoimmun
support
current
guidelin
regard
dose
rhig
mfmh
high
dose
rhig
given
si
may
posit
sever
month
may
necessarili
indic
matern
alloimmun
backgroundcas
studi
identif
septic
transfus
reaction
str
reli
recognit
sign
symptom
prompt
report
suspect
transfus
reaction
clinic
sign
symptom
associ
possibl
str
includ
fever
hypotens
tachycardia
current
aabb
criteria
defin
fever
rise
howev
hypotens
tachycardia
undefin
goal
studi
compar
subject
report
symptom
object
record
vital
sign
analyz
larg
databas
transfus
reaction
report
adult
year
studi
designsmethod
collect
retrospect
data
transfus
reaction
result
cultur
residu
product
calendar
year
also
collect
data
reaction
posit
residu
product
cultur
result
enrich
dataset
posit
result
vital
sign
chang
defin
follow
fever
increas
hypotens
systol
blood
pressur
sbp
mmhg
andor
diastol
blood
pressur
dbp
mmhg
decreas
baselin
tachycardia
hr
increas
baselin
report
subject
observ
object
vital
sign
compar
precis
accuraci
report
resultsfind
reaction
vital
sign
data
adult
transfus
reaction
report
analyz
fever
report
reaction
meet
aabb
criteria
wherea
reaction
fever
report
fever
meet
aabb
criteria
hypotens
report
reaction
meet
definit
hypotens
wherea
reaction
hypotens
report
hypotens
tachycardia
report
reaction
meet
definit
tachycardia
wherea
reaction
tachycardia
report
tachycardia
comparison
precis
accuraci
subject
report
compar
defin
criteria
shown
tabl
conclus
studi
result
indic
accuraci
report
fever
hypotens
tachycardia
blood
transfus
adult
patient
high
greater
could
improv
inde
subject
report
associ
high
fals
posit
rate
greater
despit
high
neg
predict
valu
greater
mean
transfus
associ
vital
sign
chang
tend
backgroundcas
studi
present
relationship
test
usual
perform
detect
str
loci
use
capillari
electrophoresi
technolog
power
discrimin
obtain
relationship
may
confid
enough
determin
distant
relationship
genet
marker
need
distant
relationship
massiv
parallel
sequenc
mp
also
known
next
gener
sequenc
ng
offer
possibl
analyz
multipl
type
marker
singl
reaction
studi
evalu
perform
signatur
system
novel
type
system
base
ng
platform
pairwis
kinship
analysi
studi
designmethod
individu
two
famili
analyz
explor
efficaci
signatur
system
pairwis
kinship
analysi
amelogenin
autosom
str
ident
inform
snp
analyz
simutan
one
reaction
type
pairwis
relationship
includ
full
sibl
niec
first
cousin
select
two
famili
correspond
likelihood
ratio
lr
calcul
use
either
sequenc
length
genotyp
data
ie
lrsequenc
lrlength
addit
system
power
str
snp
panel
also
estim
simul
resultsfind
addit
allel
observ
base
sequenc
autosom
str
respect
compar
base
length
novel
allel
identifi
mutat
found
str
mutat
observ
snp
autosom
str
loci
lr
increas
patern
index
pi
full
sibl
index
fsi
index
gi
index
uni
first
cousin
index
fci
respect
pi
valu
snp
separ
str
two
individu
rel
simul
studi
effect
relationship
threshold
full
sibl
threshold
low
error
rate
rel
pair
could
determin
threshold
effect
rel
high
error
rate
conclus
str
type
accord
sequenc
inform
polymorph
increas
discrimin
power
kinship
test
compar
str
marker
snp
marker
panel
advantag
patern
test
especi
mutat
str
involv
rel
alleg
parent
panel
power
enough
resolv
patern
test
full
sibl
test
second
degre
relationship
test
low
error
rate
marker
still
need
test
backgroundcas
studi
blood
transfus
occur
frequent
inpati
neonat
pediatr
patient
current
rang
red
blood
cell
rbc
prepar
process
patient
larg
unknown
studi
designmethod
member
aabb
pediatr
transfus
medicin
subsect
committe
ptmscc
develop
question
survey
assess
nation
neonat
pediatr
blood
bank
practic
april
januari
survey
sent
center
us
center
survey
includ
aabb
member
institut
transfus
prepar
blood
compon
neonat
andor
pediatr
patient
result
evalu
use
descript
statist
includ
frequenc
percentag
resultsfind
thirti
five
center
complet
survey
respons
rate
center
transfus
neonat
pediatr
patient
tertiaryquaternari
academ
pediatr
hospit
respons
neonat
pediatr
intens
care
unit
site
defin
neonat
month
except
one
defin
neonat
less
day
use
addit
contain
rbc
common
small
volum
mlkg
larg
volum
mlkg
transfus
neonat
pediatr
patient
major
center
polici
storag
age
rbc
small
larg
volum
neonat
transfus
although
definit
shorter
storag
variabl
convers
center
polici
regard
storag
age
threshold
larg
small
volum
pediatr
transfus
nearli
center
provid
leukocyt
reduc
rbc
neonat
pediatr
patient
alway
provid
cytomegaloviru
cmv
seroneg
rbc
neonat
pediatr
patient
center
alway
irradi
rbc
neonat
patient
pediatr
patient
approxim
center
polici
limit
storag
age
irradi
rbc
transfus
neonat
major
limit
hour
sometim
wash
rbc
unit
neonat
pediatr
patient
respect
commonli
cite
indic
wash
rbc
unit
patient
risk
hyperkalemia
histori
transfus
reaction
major
never
volum
reduc
rbc
transfus
neonat
pediatr
patient
conclus
rbc
prepar
process
neonat
pediatr
patient
transfus
vari
among
center
irradi
transfus
cmv
seroneg
rbc
commonli
perform
neonat
compar
pediatr
patient
center
also
like
storag
age
threshold
neonat
transfus
specif
recommend
expert
group
andor
clinic
studi
may
aid
standard
practic
backgroundcas
studi
minor
label
error
pretransfus
sampl
associ
high
rate
seriou
wrong
blood
tube
wbit
error
lead
abo
mistransfus
mani
transfus
servic
reject
sampl
label
error
regardless
minor
data
support
practic
limit
studi
evalu
wbit
rate
mislabel
sampl
era
heighten
attent
patient
identif
studi
designmethod
particip
transfus
servic
blood
cord
blood
sampl
reject
reason
per
local
polici
test
abo
rhd
result
report
clinic
servic
aborhd
result
mislabel
sampl
compar
histor
aborhd
result
determin
wbit
error
occur
mislabel
sampl
resultsfind
institut
particip
total
mislabel
sampl
identifi
mislabel
sampl
collect
ward
emerg
depart
intens
care
unit
icu
main
reason
reject
sampl
phlebotomist
identif
properli
document
miss
sampl
label
unaccept
test
affix
tube
blood
provid
etc
patient
name
incomplet
misspel
total
ci
wbit
error
detect
amongst
mislabel
sampl
overal
median
iqr
rate
wbit
error
amongst
mislabel
sampl
institut
institut
rate
wbit
error
amongst
mislabel
sampl
rang
sampl
wbit
tend
found
sampl
phlebotomist
identif
properli
document
miss
sampl
unaccept
label
patient
name
incomplet
misspel
patient
medic
record
number
miss
incorrect
sampl
wbit
mostli
collect
ward
icu
emerg
depart
wbit
sampl
identifi
discrep
current
histor
sampl
abo
type
follow
discrep
abo
rhd
type
discrep
rhd
type
alon
conclus
data
support
continu
reject
sampl
meet
local
patient
phlebotomist
identif
criteria
furthermor
data
support
perform
abo
rhd
type
sampl
collect
verifi
fidel
initi
abo
rhd
type
patient
without
histor
abo
rhd
type
file
backgroundcas
studi
direct
antiglobulin
test
dat
detect
igg
attach
red
cell
membran
commonli
use
part
workup
patient
posit
indirect
antiglobulin
test
iat
transfus
servic
polici
includ
perform
dat
reflex
posit
autocontrol
switch
polici
igg
dat
would
perform
posit
iat
autocontrol
dat
test
polyspecif
ps
reagent
longer
routin
perform
part
workup
studi
designmethod
data
regard
number
posit
iat
autocontrol
dat
obtain
record
antibodi
workup
perform
number
dat
dat
perform
transfus
reaction
deriv
blood
bank
record
exclud
cost
calcul
base
supplyreag
cost
averag
hourli
rate
technic
staff
averag
staff
time
perform
test
resultsfind
cost
save
one
year
associ
switch
dat
part
posit
iat
workup
approxim
staff
time
save
approxim
hour
percentag
new
antibodi
identifi
tabl
suggest
new
polici
provid
equal
opportun
evalu
patient
may
risk
clinic
hemolysi
associ
rbc
antibodi
format
conclus
perform
igg
dat
instead
autocontrol
reflex
dat
posit
iat
result
simplifi
workup
workflow
improv
resourc
util
technic
staff
demonstr
least
equal
efficaci
backgroundcas
studi
riboflavin
ultraviolet
light
ruv
pathogen
reduct
system
ce
mark
extracorpor
treatment
whole
blood
wb
system
design
reduc
pathogen
load
inactiv
wbc
wb
transfus
recent
clinic
trial
demonstr
ruv
treatment
significantli
reduc
transfus
transmiss
plasmodium
spp
parasit
caus
malaria
system
initi
releas
treatment
ruv
limit
wb
collect
cpd
commonli
use
wb
transfus
thu
seri
studi
perform
qualifi
system
perform
treat
wb
studi
designmethod
system
perform
assess
via
photochemistri
pc
pathogen
reduct
pr
cell
qualiti
cq
wbc
inactiv
hemostat
function
pc
analysi
pair
unit
wb
cpd
simul
cpda
cpda
treat
analyz
riboflavin
lumichrom
content
liquid
chromatographi
liquid
mass
spectrometri
assess
pr
use
bacterium
yersinia
enterocolitica
cq
test
includ
cbc
blood
gase
electrolyt
measur
follow
collect
treatment
day
storag
hemolysi
evalu
per
council
europ
coe
criterion
limit
dilut
assay
lda
evalu
wbc
inactiv
comparison
gamma
irradi
hemostat
function
assess
rotem
resultsfind
pc
analysi
demonstr
differ
photoconvers
riboflavin
lumichrom
wb
unit
cpda
compar
wb
unit
cpd
enterocolitica
log
reduct
rang
cpd
rang
cq
test
mean
hemolysi
wb
unit
rang
day
storag
meet
coe
criterion
log
reduct
frequenc
prolifer
wbc
log
log
ruv
gamma
irradi
respect
mean
valu
clot
time
maximum
clot
firm
measur
rotem
within
normal
refer
rang
day
storag
conclus
extens
batteri
vitro
test
shown
accept
perform
ruv
system
treat
wb
photochemistri
remain
statist
signific
differ
pr
compar
wb
cpd
cq
met
coe
criterion
ruv
inactiv
wbc
effect
gamma
irradi
hemostat
function
preserv
ruv
pathogen
reduct
system
use
treat
wb
clinic
use
backgroundcas
studi
cardiovascular
surgeri
cv
infant
month
age
expos
larg
volum
transfus
evid
support
use
rbc
larg
volum
transfus
well
establish
blood
bank
institut
perform
volum
reduct
rbc
infant
month
age
undergo
cv
labor
intens
process
decis
made
switch
wash
rbc
use
catsmart
cell
saver
freseniu
kabi
purpos
studi
establish
chang
process
volum
reduct
wash
rbc
catsmart
cell
saver
prior
place
patient
cardiopulmonari
bypass
provid
safe
consist
result
studi
designmethod
first
analyz
laboratori
characterist
rbc
unit
pre
post
volum
reduct
pre
post
cellwash
use
catsmart
cell
saver
tabl
includ
abstract
second
sampl
obtain
four
time
point
includ
sampl
unmanipul
red
cell
pre
cellsav
sampl
post
cellsav
wash
sampl
pump
bypass
prime
sampl
collect
minut
patient
bypass
blood
sampl
analyz
analyt
consid
clinic
signific
outsid
normal
rang
blood
sampl
collect
seven
case
time
cv
infant
month
age
test
perform
gem
blood
ga
analyz
osmol
perform
advanc
instrument
particular
test
part
standard
electrolyt
panel
test
time
surgeri
thu
omit
last
bypass
time
point
resultsfind
pre
post
red
cell
wash
conclus
potassium
glucos
concentr
high
rbc
unit
prior
manipul
concentr
significantli
decreas
wash
increas
stay
volum
reduct
plasma
free
hemoglobin
slightli
elev
prior
manipul
increas
manipul
rbc
unit
volum
reduct
wash
osmol
mildli
elev
prior
manipul
volum
reduct
decreas
wash
lactic
acid
elev
rbc
unit
prior
wash
significantli
decreas
wash
summari
wash
red
cell
use
catsmart
cell
saver
freseniu
kabi
prior
major
cv
infant
month
age
safe
shown
studywash
might
somewhat
better
volum
reduct
provid
final
red
cell
product
electrolyt
concentr
close
normal
physiolog
valu
backgroundcas
studi
hepat
transplant
first
perform
result
death
patient
due
exsanguin
sinc
time
massiv
advanc
made
surgic
techniqu
anesthesia
transfus
medicin
coagul
test
includ
use
thromboelastographi
teg
juli
institut
teg
move
standalon
test
run
oper
room
staff
paper
result
laboratori
result
avail
onlin
real
time
drastic
increas
use
teg
result
examin
intraop
transfus
practic
hepat
transplant
period
teg
rare
use
compar
period
teg
consist
use
studi
designmethod
transfus
data
obtain
product
util
adult
hepat
hepat
combin
transplant
six
month
teg
move
laboratori
real
time
result
product
util
broken
compon
type
pack
red
cell
plasma
platelet
cryoprecipit
usag
compon
compar
usag
unequ
varianc
welch
test
resultsfind
signific
differ
time
teg
usag
pack
red
cell
p
plasma
p
platelet
p
signific
differ
usag
cryoprecipit
p
mean
unit
cryoprecipit
use
time
teg
mean
unit
real
time
teg
util
surgeri
use
cryoprecipit
also
signific
differ
ratio
unit
pack
red
cell
plasma
use
p
conclus
signific
differ
usag
pack
red
cell
plasma
platelet
trend
decreas
usag
product
cryoprecipit
use
significantli
reduc
ratio
unit
pack
red
cell
plasma
use
trend
support
theori
clinician
use
real
time
teg
better
guid
product
select
fact
p
valu
pack
red
cell
plasma
platelet
close
signific
lead
us
consid
expand
data
set
futur
qualiti
purpos
backgroundcas
studi
evid
restrict
transfus
threshold
prompt
recommend
order
one
red
blood
cell
rbc
unit
time
audit
may
facilit
practic
improv
patient
safeti
rbc
util
encourag
avoid
unnecessari
transfus
retrospect
audit
reli
chang
physician
practic
fact
thu
sought
perform
prospect
audit
without
interf
transfus
practic
subsequ
perform
retrospect
audit
follow
transfus
refin
appropri
screen
criteria
transfus
studi
designmethod
screen
criteria
prospect
audit
develop
patient
transfus
episod
meet
criteria
adjud
appropri
inappropri
train
deleg
sm
time
transfus
clinic
inform
includ
indic
transfus
collect
chart
review
case
insuffici
inform
adjud
retrospect
chart
review
perform
appropri
adjud
three
physician
jt
kr
rbc
transfus
academ
tertiari
care
center
juli
occur
oper
room
intens
care
unit
emerg
room
bone
marrow
transplant
ward
enrol
resultsfind
patient
enrol
transfus
medic
surgic
ward
encompass
transfus
respect
inappropri
transfus
observ
respect
signific
number
transfus
major
deem
inappropri
retrospect
chart
review
influenc
adjud
often
bleed
patient
tabl
transfus
upcom
procedur
gener
appropri
singl
unit
order
hemoglobin
level
gdl
conclus
criteria
prospect
screen
larg
consid
suitabl
even
detail
gather
retrospect
review
potenti
except
bleed
patient
propos
prospect
screen
rbc
transfus
like
otherwis
appropri
medicalsurg
ward
may
initi
target
intervent
backgroundcas
studi
hemolyt
diseas
fetu
newborn
hdfn
caus
certain
matern
igg
antibodi
infant
red
blood
cell
rbc
antigen
well
recogn
typic
manag
effect
phototherapi
ivig
transfus
andor
exchang
transfus
report
case
prolong
hdn
possibl
inhibit
hematopoiesi
despit
intens
phototherapi
ivig
multipl
transfus
infant
eventu
respond
erythropoietin
treatment
studi
designmethod
test
perform
routin
tube
method
use
peg
liss
salin
use
igg
gel
card
acid
elut
acid
treatment
ega
rbc
also
perform
identif
andor
matern
plasmawer
perform
differenti
adsorptionelut
use
r
r
adsorb
cell
titrat
andor
mother
infant
plasma
perform
use
r
r
indic
cell
rhd
genotyp
newborn
perform
use
target
exon
intron
rhd
pseudogen
rhesu
box
ident
region
initi
evalu
sanger
sequenc
rhd
rhce
exon
also
done
determin
underli
rh
genotyp
resultsfind
mother
histori
hepat
drug
use
middl
cerebr
arteri
peak
systol
veloc
antibodi
titer
perform
throughout
pregnanc
indic
hdfn
fetal
hydrop
blood
type
neg
identifi
differenti
adsorptionelut
method
last
antibodi
titer
perform
day
prior
deliveri
use
cell
plasma
reactiv
dilut
titer
use
r
r
cell
full
term
male
infant
visibl
jaundic
hydrop
total
bili
mgdl
direct
bili
mgdl
hct
elev
retic
count
birth
peripher
blood
smear
show
mark
polychromasia
increas
nucleat
rbc
breast
fed
right
birth
poor
feed
mani
day
infant
blood
type
posit
antigen
type
predict
genom
test
due
serolog
block
antigen
cord
cell
dat
genet
sequenc
rhd
gene
reveal
nucleotid
substitut
associ
rhd
allel
acid
eluat
prepar
infant
rbc
demonstr
note
whole
blood
exchang
perform
due
venou
access
care
issu
fact
bilirubin
mildli
elev
newborn
anemia
prolong
almost
week
birth
sever
decreas
reticulocyt
count
observ
week
birth
interest
note
mild
initi
present
hdfn
prolong
clinic
cours
well
drastic
decreas
retic
count
rapid
respons
erythropoietin
treatment
conclus
report
clinic
present
prolong
hdfn
due
andor
low
retic
count
posit
dat
reticulocyt
possibl
inhibit
hematopoiesi
passiv
transfer
matern
antibodi
suspect
sever
low
reticulocyt
count
observ
week
birth
therefor
also
hypothes
coat
may
protect
sever
hemolysi
inhibit
hematopoiesi
birth
backgroundcas
studi
transfus
servic
issu
red
blood
cell
rbc
unit
year
ten
percent
group
neg
novemb
revis
implement
emerg
releas
polici
reflect
situat
accept
give
rh
posit
blood
rh
neg
patient
januari
process
improv
pi
initi
result
region
blood
shortag
implement
process
track
neg
rbc
util
order
ensur
appropri
usag
keep
inventori
accept
level
studi
designmethod
follow
process
establish
emerg
releas
patient
age
femal
age
histor
type
rh
posit
give
rh
patient
age
femal
age
histor
type
rh
neg
switch
rh
posit
unit
patient
age
femal
age
histor
type
give
posit
unit
patient
age
femal
age
histor
type
give
day
technic
specialist
review
present
follow
discuss
manag
neg
rbc
neg
rbc
issu
previou
issu
neg
patient
special
instruct
give
neg
issu
non
neg
patient
investig
technologist
counsel
neg
rbc
crossmatch
crossmatch
non
neg
patient
special
instruct
remov
crossmatch
statu
technologist
neg
util
data
record
monitor
track
trend
reason
issu
neg
unit
neg
patient
unit
save
issu
resultsfind
conclus
dynam
process
monitor
neg
usag
result
reduct
overal
neg
transfus
well
decreas
neg
rbc
issu
non
neg
patient
reduct
order
blood
supplier
improv
inventori
manag
overal
effici
transfus
servic
backgroundcas
studi
birth
conjoin
twin
constitut
rare
congenit
malform
estim
incid
birth
conjoin
twin
usual
present
complex
anatom
conjunct
multipl
congenit
anomali
vari
degre
conjoin
circul
pose
multipl
challeng
transfus
anesthet
manag
case
seri
aim
summar
experi
transfus
manag
three
set
conjoin
twin
undergo
separ
surgeri
singl
institut
studi
designmethod
medic
record
conjoin
twin
admit
hospit
surgic
separ
retrospect
review
three
set
conjoin
twin
underw
surgic
separ
gener
anesthesia
preoper
evalu
perform
determin
extent
anatom
conjunct
associ
anomali
anesthesia
simultan
induc
conjoin
twin
blood
usag
track
anesthesia
record
transfus
servic
laboratori
inform
system
resultsfind
set
femal
twin
identifi
set
twin
set
twin
multidisciplinari
approach
use
oper
plan
involv
anesthesia
pediatr
surgeri
plastic
surgeri
radiolog
transfus
medicin
oper
room
staff
biomed
engin
nurs
staff
clinic
care
unit
intradepartment
plan
meet
involv
director
transfus
servic
senior
junior
transfus
medicin
attend
physician
fellow
resid
laboratori
manag
staff
supervisor
base
meet
special
need
blood
compon
typic
pediatr
transfus
modif
base
hemodynam
consider
potenti
massiv
transfus
ie
leukoreduc
fresh
etc
conjoin
twin
success
separ
estim
blood
loss
rang
ml
ml
separ
reconstruct
red
blood
cell
transfus
rang
mlkg
mlkg
conclus
complex
anatomi
relat
risk
bleed
conjoin
twin
separ
manifest
commonli
commun
vasculatur
across
twin
specif
fuse
organ
unclear
anatom
structur
imag
besid
implic
anesthesia
administr
degre
share
circul
pose
inher
risk
mutual
exsanguin
signific
bleed
aris
transfus
servic
consult
earli
preoper
period
optim
safest
blood
product
time
blood
deliveri
complex
oper
mutchinick
om
et
al
conjoin
twin
worldwid
collabor
epidemiolog
studi
intern
clearinghous
birth
defect
surveil
research
j
med
genet
c
semin
med
genet
backgroundcas
studi
patient
receiv
drug
therapi
demonstr
panreact
serolog
test
requir
test
dithiothreitol
dtt
increas
use
therapi
requir
maintain
dtt
pretreat
red
blood
cell
rbc
avail
expedit
test
previou
studi
demonstr
storag
dtt
pretreat
rbc
nine
day
lalli
et
al
transfus
studi
look
extend
shelf
life
store
pretreat
rbc
alserv
solut
studi
designmethod
reagent
screen
rbc
treat
dtt
ratio
rbc
incub
degre
celsiu
minut
wash
three
time
normal
salin
subsequ
rbc
wash
one
time
alsev
solut
final
wash
rbc
resuspend
alsev
solut
k
posit
cell
test
use
k
antisera
ensur
dtt
treatment
effect
baselin
test
rbc
includ
test
c
e
c
e
jka
jkb
fya
fyb
antigen
examin
hemolysi
test
posit
plasma
ensur
expect
lack
reactiv
control
consist
untreat
screen
rbc
maintain
parallel
test
hemolysi
grade
use
predefin
hemolysi
tabl
rang
antigen
test
observ
hemolysi
test
posit
plasma
repeat
everi
four
day
storag
end
point
determin
antigen
decreas
reactiv
two
grade
hemolysi
reach
plasma
demonstr
posit
reactiv
resultsfind
antigen
test
day
maintain
reaction
strength
within
one
grade
test
day
slight
hemolysi
first
note
day
howev
reach
cut
valu
studi
control
rbc
demonstr
similar
increas
hemolysi
treat
rbc
test
posit
plasma
also
remain
consist
studi
conclud
day
due
insuffici
quantiti
reagent
rbc
test
conclus
studi
demonstr
alsev
solut
preserv
integr
red
cell
affect
reactiv
rbc
vitro
studi
conclud
dtt
treat
rbc
suspend
alsev
solut
prepar
store
degre
celsiu
least
two
week
without
degrad
treat
screen
rbc
readili
avail
decreas
turnaround
time
antibodi
identif
backgroundcas
studi
aabb
neonat
pediatr
blood
bank
practic
survey
develop
aabb
pediatr
transfus
medicin
subsect
committe
ptmscc
captur
nation
variabl
neonat
pediatr
blood
bank
practic
report
result
analysi
question
pertain
prepar
process
compon
studi
designmethod
survey
questionnair
releas
survey
platform
http
wwwsurveymonkeycom
skip
logic
util
captur
platelet
plasma
prepar
process
practic
neonat
pediatr
patient
respons
complet
april
januari
analyz
descript
statist
includ
frequenc
percentag
use
evalu
overal
differ
practic
among
neonat
pediatr
patient
resultsfind
thirti
five
center
complet
survey
respons
rate
see
tabl
platelet
special
process
result
twenti
nine
percent
center
allow
abo
incompat
aboi
platelet
transfus
neonat
pediatr
patient
respect
hospit
provid
aboi
platelet
neonat
pediatr
patient
titer
abo
isoagglutinin
level
use
tube
method
salin
without
enhanc
hospit
titer
platelet
product
pediatr
patient
hospit
defin
high
titer
two
use
two
use
group
apheresi
platelet
unit
repres
major
platelet
product
titter
neonat
pediatr
patient
group
ab
plasma
select
transfus
neonat
center
pediatr
patient
center
transfus
one
hospit
report
permit
aboi
plasma
transfus
neonat
two
hospit
report
aboi
plasma
transfus
pediatr
patient
hospit
provid
aboi
plasma
neonat
andor
pediatr
patient
perform
titer
abo
isoagglutinin
use
tube
method
salin
without
enhanc
use
high
titer
definit
conclus
prepar
process
practic
neonat
pediatr
patient
transfus
platelet
plasma
vari
wide
hospit
specif
recommend
expert
group
andor
clinic
studi
may
aid
standard
practic
backgroundcas
studi
regulatori
standard
requir
transport
blood
product
stay
within
studi
demonstr
product
remov
refriger
storag
maintain
transport
standard
greater
minut
averag
sever
limit
time
unit
issu
receiv
back
inventori
purpos
studi
determin
long
insul
bio
transport
bag
would
maintain
product
transport
temperatur
allow
product
return
inventori
studi
designmethod
process
valid
design
use
rbc
ffp
determin
time
transport
paramet
bio
transport
bag
rbc
ffp
unit
remov
refriger
storag
probe
record
length
time
product
stay
within
simul
actual
product
transport
condit
unit
taken
patient
room
sent
pneumat
tube
system
multipl
locat
left
place
valid
trial
valid
trial
rbc
product
run
least
minut
ffp
product
least
minut
ambient
temperatur
locat
also
record
temperatur
record
set
read
temperatur
measur
interv
resultsfind
tabl
report
estim
bio
transport
bag
paramet
rbc
median
rang
time
unit
stay
within
minut
transport
median
rang
high
ambient
temperatur
ffp
minut
remov
refriger
median
rang
product
temperatur
median
rang
high
ambient
temperatur
studi
conclus
find
demonstr
bio
transport
bag
prolong
product
viabil
conclud
use
bio
transport
bag
rbc
ffp
could
return
inventori
return
time
minut
less
unit
return
time
limit
temperatur
unit
taken
determin
accept
return
inventori
backgroundcas
studi
red
blood
cell
rbc
import
issu
blood
transfus
specif
clinic
signific
antibodi
report
fung
mk
et
al
howev
frequenc
sever
transfus
relat
advers
reaction
caus
receiv
antigen
ag
rbc
well
elucid
studi
designmethod
survey
item
includ
back
ground
patient
ag
includ
rbc
transfus
total
unit
rbc
transfus
result
screen
direct
test
dat
specif
antibodi
advers
reaction
efficaci
rbc
ag
analyz
japanes
red
cross
societi
antibodi
survey
regardless
clinic
signific
protocol
review
approv
institut
review
board
univers
particip
institut
resultsfind
novemb
march
unit
rbc
transfus
case
institut
japan
unit
rbc
transfus
case
male
femal
determin
tabl
frequent
reason
rbc
transfus
neg
indirect
test
iat
follow
detect
lack
time
prepar
rbc
tabl
clinic
appar
hemolysi
observ
case
two
posit
one
case
without
advers
effect
clinic
signific
antibodi
conclus
first
collabor
studi
background
reaction
outcom
rbc
transfus
data
help
patient
irregular
antibodi
rbc
antigen
backgroundcas
studi
massiv
transfus
protocol
mtp
essenti
process
level
trauma
center
sinc
implement
model
consist
pack
red
blood
cell
rbc
fresh
frozen
plasma
ffp
platelet
plt
cryoprecipit
cryo
upon
request
differ
issu
option
base
clinic
situat
period
review
identifi
area
improv
led
two
distinct
process
chang
initi
chang
may
requir
first
pack
uncrossmatch
product
neg
rbc
ffp
rh
neg
plt
issu
prepar
backup
issu
form
backup
pack
evolv
pack
previous
use
code
second
chang
septemb
reduc
mtp
pack
size
servic
rbc
ffp
plt
rbc
ffp
plt
respons
review
mtp
show
case
use
equival
pack
within
hour
studi
designmethod
excel
use
analyz
data
collect
laboratori
inform
system
li
backup
issu
form
septemb
march
start
time
first
record
order
issu
first
pack
whichev
came
first
product
transfus
count
classifi
base
pack
need
provid
number
rbc
ffp
transfus
within
hour
addit
concurr
manual
record
use
tech
process
chang
confirm
neg
rbc
inventori
mtp
event
resultsfind
backup
pack
caus
expect
declin
neg
rbc
inventori
well
suitabl
product
ie
irradi
result
increas
donor
collect
time
tat
lab
essenti
elimin
first
pack
increas
total
number
product
use
reduc
pack
size
rather
slightli
differ
distribut
pattern
usag
time
see
tabl
major
still
use
pack
less
addit
reduc
tat
uncrossmatch
statu
first
round
led
product
discuss
lab
technologist
resid
physician
physician
prefer
wait
rather
take
uncrossmatch
allow
time
discuss
suitabl
protocol
conclus
conclus
review
process
put
place
level
trauma
center
allow
propos
monitor
two
effect
mtp
protocol
chang
main
effect
backup
pack
implement
rbc
inventori
lab
tat
product
discuss
number
mtp
use
pack
reduct
pack
size
overal
pictur
differ
greater
half
mtp
use
initi
pack
whether
pack
larg
small
greatest
effect
lab
increas
avail
product
mtp
backgroundcas
studi
implement
bloodtrack
ondemand
haemobank
smart
blood
dispens
devic
haemonet
braintre
improv
overal
process
manag
blood
suppli
oper
room
suit
increas
blood
avail
reduc
risk
decreas
wast
studi
designmethod
assess
current
blood
suppli
chain
reveal
complex
process
anywher
step
get
blood
blood
bank
patient
suit
sever
area
handoff
failur
typic
transport
time
minut
long
minut
instanc
blood
unit
receiv
need
immedi
transfus
store
unlock
refriger
core
unit
multipl
patient
store
refriger
unit
patient
longer
mechan
barrier
place
prevent
remov
wrong
unit
addit
effect
way
control
access
refriger
monitor
temperatur
maintain
traceabl
resultsfind
went
live
juli
bloodtrack
ondemand
use
haemobank
devic
care
unit
pacu
cardiovascular
recoveri
room
cvrr
tabl
summar
result
suppli
chain
complex
reduc
elimin
step
blood
avail
procedur
room
faster
deliveri
time
requir
staff
leav
inner
core
blood
wastag
previous
unit
issu
decreas
save
approxim
annual
effici
enabl
blood
bank
reposit
staff
elimin
blood
bank
workload
relat
prepar
packag
transport
blood
product
track
miss
delay
unit
significantli
reduc
second
haemobank
instal
new
cvrricu
unit
addit
averag
number
unit
dispens
control
remot
dispens
devic
increas
total
red
cell
usag
lastli
importantli
patient
safeti
bloodtrack
electron
captur
record
blood
product
movement
verifi
right
blood
remov
right
patient
conclus
implement
bloodtrack
ondemand
haemobank
devic
manag
blood
product
alloc
hospit
pacu
cvrr
significantli
streamlin
hospit
process
elimin
risk
improv
avail
reduc
cost
backgroundcas
studi
pathogen
reduct
devic
use
riboflavin
ultraviolet
light
ruv
reduc
potenti
infecti
pathogen
load
inactiv
white
blood
cell
wbc
whole
blood
wb
product
intend
transfus
develop
sever
substanc
shown
interfer
abo
blood
group
test
due
patient
sera
reactiv
group
agglutinin
acriflavin
dye
use
type
serum
neomycin
antibiot
monoclon
antibodi
daratumumab
use
immunotherapi
name
one
step
develop
process
ruv
leukoreduc
red
blood
cell
ruv
ensur
riboflavin
element
treatment
process
would
alter
otherwis
interfer
blood
type
antigen
test
variou
manual
autom
blood
group
type
method
employ
us
one
common
method
autom
manual
gel
column
agglutin
gca
method
studi
evalu
use
gca
test
blood
type
rh
factor
rbc
untreat
wb
ruv
treat
wb
ruv
wb
ruv
studi
designmethod
ten
unit
wb
variou
blood
type
b
ab
collect
citrat
phosphat
dextros
cpd
anticoagul
ml
collect
set
treat
ruv
sampl
taken
unit
prior
ruv
treatment
untreat
wb
follow
treatment
ruv
wb
compon
separ
ruv
confirm
blood
type
use
type
gel
column
agglutin
technolog
abd
monoclon
revers
group
card
sampl
test
blood
type
addit
unit
character
via
cell
qualiti
measur
resultsfind
day
process
unit
blood
type
rh
factor
match
record
collect
blood
center
chang
observ
ruv
light
treatment
ruv
cell
qualiti
paramet
expect
rang
wb
base
histor
data
key
paramet
ph
well
hemolysi
well
requir
valu
respect
conclus
pathogen
reduct
use
ruv
light
interfer
b
ab
blood
type
rh
factor
rbc
treat
wb
ruv
test
common
gca
test
system
backgroundcas
studi
septic
transfus
reaction
occur
patient
transfus
contamin
blood
product
howev
patient
expos
contamin
unit
exhibit
sign
reaction
other
reaction
sever
overal
clinic
circumst
patient
expos
contamin
unit
may
affect
likelihood
reaction
studi
assess
incid
patient
diagnos
presenc
neutropenia
septic
transfus
reaction
case
studi
designmethod
review
highli
probablydefinit
septic
transfus
reaction
report
american
red
cross
januari
decemb
clinic
diagnos
patient
record
patient
categor
follow
hematolog
malign
includ
transplant
aplast
anemiapancytopenia
includ
transplant
solid
organ
transplant
hematolog
condit
cancer
cardiaccardiovascular
condit
infect
obstetricgynecolog
condit
accidenttrauma
renal
failur
patient
neutrophil
count
status
record
definit
like
specif
record
like
given
clinic
factor
patient
historyrecord
possibl
base
clinic
diagnosi
resultsfind
case
report
occur
patient
hematolog
malign
case
aplast
anemia
case
neutropenia
present
definit
like
possibl
case
respect
percent
incid
definitelik
neutropenia
definitelikelyposs
neutropenia
case
respect
case
definit
neutropenia
hematolog
malign
aplast
anemia
combin
categori
combin
categori
case
patient
neutropenia
combin
group
definitelik
neutropenia
present
case
definitelikelyposs
neutropenia
present
case
conclus
among
report
septic
transfus
reaction
case
patient
hematolog
malign
aplast
anemia
common
diagnos
neutropenia
risk
neutropenia
also
common
group
septic
transfus
reaction
find
may
due
frequenc
blood
product
transfus
group
caus
may
present
clinic
assess
warrant
backgroundcas
studi
emerg
neonat
transfus
fraught
challeng
blood
bank
bb
neonatolog
servic
must
provid
blood
time
manner
simultan
adher
proper
blood
bank
standard
navig
hospit
process
inform
system
occur
outsid
control
set
neonat
icu
neonat
transfus
immedi
follow
birth
pose
uniqu
challeng
describ
institut
experi
develop
protocol
particularli
difficult
scenario
studi
designmethod
need
protocol
address
red
blood
cell
rbc
transfus
recogn
specif
set
deliveri
room
oper
room
emerg
depart
key
stakehold
includ
bb
neonatolog
nurs
emerg
hospit
admissionregistr
laboratori
inform
system
inform
technolog
servic
challeng
address
involv
uniqu
identif
unborn
patient
document
transfus
said
patient
immedi
period
effici
commun
bb
rapid
provis
unmodifi
rbc
unit
adher
regul
standard
set
forth
fda
accredit
agenc
multipl
meet
protocol
draft
defin
respect
role
bb
neonatolog
servic
resultsfind
sever
revis
protocol
outlin
neonatolog
creat
pend
neonat
admiss
profil
electron
medic
record
two
uniqu
identifi
assign
transfus
deem
necessari
neonatolog
telephon
blood
bank
code
babi
blood
unambigu
prompt
emerg
bb
given
neonat
uniqu
identifi
request
rbc
emerg
releas
read
back
bb
issu
one
whole
unit
addit
solut
pack
rbc
group
leukoreduc
hemoglobin
neg
freshest
yet
perform
bb
perform
matern
type
screen
posit
screen
prompt
immedi
test
issu
unit
two
time
simul
conduct
identifi
area
improv
first
complet
minut
second
minut
conclus
thought
protocol
neonat
transfus
help
streamlin
effort
decreas
confus
among
caregiv
situat
experi
reflect
one
possibl
approach
within
physic
logist
limit
institut
futur
effort
dissemin
knowledg
protocol
caregiv
within
hospit
backgroundcas
studi
select
compat
red
blood
cell
rbc
unit
includ
match
donor
sex
systemat
review
aim
summar
evid
examin
impact
rbc
transfus
recipi
mortal
studi
designmethod
ovid
medlin
ovid
embas
cinahl
pubm
web
scienc
cochran
databas
systemat
review
search
januari
identifi
random
control
trial
rct
observ
studi
examin
impact
donor
sex
recipi
outcom
conduct
elig
studi
gener
pool
hazard
ratio
hr
use
model
model
appli
emphas
unknown
depend
among
effect
size
prespecifi
analysi
done
subgroup
cardiac
surgeri
patient
studi
qualiti
duplic
use
robin
tool
certainti
evid
outcom
assess
use
grade
resultsfind
five
retrospect
observ
studi
n
includ
rct
found
rbc
transfus
associ
higher
risk
death
compar
transfus
pool
hazard
ratio
hr
confid
interv
ci
see
figur
subgroup
cardiovascular
surgeri
n
signific
increas
mortal
transfus
pool
hr
ci
data
prone
confound
select
bia
report
bia
certainti
evid
low
figur
compar
recipi
mortal
outcom
patient
transfus
compar
red
blood
cell
transfus
across
differ
studi
follow
period
conclus
rbc
transfus
associ
increas
risk
death
pool
analysi
howev
certainti
evid
low
observ
studi
press
need
studi
impact
donor
sex
potenti
widespread
impact
backgroundcas
studi
role
immatur
platelet
transfus
increment
elucid
immatur
platelet
singl
donor
platelet
sdp
greater
longev
biolog
activ
matur
counterpart
use
diagnost
marker
thrombocytopen
patient
studi
look
absolut
immatur
platelet
count
sdp
unit
given
neonat
patient
receiv
multipl
transfus
determin
affect
platelet
recoveryincr
studi
designmethod
sdp
unit
neonat
patient
identifi
time
aliquot
prepar
total
sdp
transfus
patient
sdppatient
identifi
period
ml
sampl
measur
collect
unit
time
aliquot
prepar
sampl
analyz
use
autom
hematolog
analyz
complet
blood
count
cbc
percent
immatur
platelet
fraction
obtain
multipli
platelet
count
time
percent
platelet
recoveri
ppr
obtain
formula
platelet
count
platelet
count
unit
platelet
count
splenic
factor
total
blood
volum
tbv
splenic
factor
tbv
bodi
weight
time
mlkg
week
estim
gestat
age
ega
mlkg
week
cbc
obtain
within
hour
resultsfind
sdp
transfus
patient
sdp
platelet
count
ppr
shown
tabl
appear
correl
platelet
increment
instead
indic
lead
approxim
improv
platelet
count
higher
appear
provid
addit
benefit
could
secondari
reduct
physiolog
capac
higher
number
immatur
platelet
irradi
tabl
comparison
ppr
sdp
aliquot
transfus
neonat
patient
valu
except
note
mean
sd
sd
standard
deviat
ega
estim
gestat
age
sdp
singl
donor
platelet
percent
immatur
platelet
fraction
absolut
immatur
platelet
count
ppr
percent
platelet
recoveri
conclus
may
trend
toward
higher
count
recoveri
presenc
higher
higher
number
patient
determin
trend
becom
statist
signific
potenti
benefit
higher
content
unit
affect
irradi
sdp
unit
destin
neonat
transfus
backgroundcas
studi
rh
prophylaxi
led
signific
reduct
incid
rh
hemolyt
diseas
fetu
newborn
mani
facil
perform
acid
elut
kb
test
assess
fetomatern
hemorrhag
fmh
determin
dose
rh
immun
globulin
rhig
overestim
fmh
known
limit
kb
test
describ
case
woman
significantli
elev
kb
test
result
led
administr
larg
amount
rhig
inappropri
case
illustr
import
care
clinic
evalu
correl
laboratori
test
result
order
provid
best
care
obstetr
patient
studi
designmethod
year
old
group
woman
pregnanc
receiv
dose
rhig
week
gestat
gave
birth
healthi
group
male
babi
via
normal
spontan
vagin
deliveri
week
gestat
follow
unev
pregnanc
eight
vial
rhig
administ
mother
postpartum
kb
test
reveal
fetal
erythrocyt
matern
blood
correspond
estim
fmh
ml
kb
test
result
rhig
requir
evalu
daili
manag
meet
determin
perform
investig
resultsfind
neonat
clinic
statu
review
indic
evid
neonat
distress
lack
correl
clinic
pictur
lab
result
trigger
laboratori
investig
although
repeat
kb
test
persist
elev
neg
rosett
test
subsequ
confirm
dispar
calcul
fmh
suggest
possibl
secondari
caus
elev
hbf
matern
serum
hgb
electrophoresi
reveal
hbf
deliveri
suggest
elev
matern
f
cell
pregnanc
hereditari
persist
fetal
hemoglobin
hpfh
hematolog
paramet
normal
make
probabl
matern
thalassemia
minor
hemoglobinopathi
less
like
conclus
case
highlight
need
real
time
clinic
correl
patient
posit
kb
test
result
especi
import
patient
high
volum
estim
fmh
base
result
kb
test
clinic
pictur
consist
high
volum
fmh
addit
investig
must
perform
order
prevent
unnecessari
rhig
administr
backgroundcas
studi
time
deliveri
blood
emerg
crucial
effort
despit
turnaround
time
tat
key
perform
indic
transfus
servic
establish
benchmark
aim
describ
impact
intervent
request
urgent
rbc
urbc
improv
tat
studi
designmethod
monitor
tat
urbc
transfus
prospect
dec
tat
target
min
defin
time
taken
urgent
request
urbc
issu
includ
unmatch
ux
rx
ro
rbc
patient
requir
ahg
crossmatch
xm
andor
rbc
standbi
exclud
case
prolong
tat
investig
reason
delay
document
intervent
implement
feb
includ
new
standardis
protocol
order
urgent
blood
via
telephon
poster
aid
clear
simpl
instruct
remind
relay
urgenc
request
use
keyword
like
urgent
creat
dedic
extens
line
urgent
order
initi
request
singl
doctor
nurs
emerg
emd
oto
g
one
time
prevent
confus
prior
blood
bank
would
receiv
request
urgenc
indic
andor
multipl
call
receiv
singl
patient
resultsfind
year
rbc
issu
respons
request
urbc
transfus
ot
emd
icu
ward
paediatr
locat
mean
tat
ux
rx
ro
urbc
min
min
min
respect
pend
like
receipt
type
screen
sampl
prior
xm
contribut
overal
longer
tat
rx
urbc
mean
tat
less
min
except
ro
urbc
tat
ro
urbc
significantli
shorten
henc
faster
urbc
deliveri
intervent
ux
rx
ro
urbc
met
target
tat
target
achiev
rate
ux
maintain
rx
greatli
improv
ro
urbc
test
p
improv
overal
tat
urbc
issu
like
result
greater
awar
familiar
new
workflow
among
laboratori
clinic
staff
despit
effort
delay
courier
collect
remain
main
reason
delay
lee
other
includ
invalid
sampl
rx
urbc
request
issu
like
manpow
shortag
ramanathan
conclus
workflow
intern
benchmark
demonstr
improv
effici
target
tat
complianc
rx
ro
urbc
respect
continu
monitor
evalu
help
improv
maintain
good
minim
tat
urbc
issuanc
backgroundcas
studi
electron
issu
ei
shown
improv
effici
hospit
blood
bank
provid
abil
blood
bank
respond
quickli
urgent
request
patient
known
blood
group
recent
neg
antibodi
screen
studi
evalu
extens
ei
allow
releas
blood
way
away
blood
bank
close
patient
util
electron
remot
blood
issu
erbi
network
electron
remot
blood
releas
system
blood
bank
staff
issu
blood
use
erbi
process
blood
refriger
blood
bank
studi
designmethod
studi
site
uk
usa
site
perform
erbi
blood
refriger
remot
blood
bank
blood
refriger
blood
bank
retrospect
data
collect
erbi
softwar
databas
blood
bank
laboratori
inform
system
li
prospect
time
motion
studi
data
collect
method
use
determin
blood
bank
clinic
staff
time
step
blood
issu
process
unit
red
blood
cell
resultsfind
erbi
remot
blood
refriger
tabl
time
taken
blood
unit
reach
clinic
area
reduc
hospit
use
erbi
remot
blood
refriger
blood
bank
staff
time
increas
erbi
blood
blood
bank
effici
improv
issu
transfus
ratio
lower
blood
unit
obtain
erbi
refriger
compar
ei
blood
bank
staff
cost
perform
erbi
reduc
compar
site
median
reduct
rang
per
unit
erbi
blood
refriger
blood
bank
tabl
time
taken
clinic
staff
obtain
blood
reduc
erbi
blood
refriger
blood
bank
blood
bank
staff
time
perform
erbi
reduc
compar
ei
perform
blood
bank
median
rang
secondsunit
mean
increas
cost
per
blood
unit
erbi
clinic
staff
refriger
rang
per
blood
unit
conclus
erbi
remot
refriger
improv
effici
transfus
reduc
time
taken
blood
unit
reach
patient
clinic
blood
bank
staff
time
cost
benefit
realiz
erbi
blood
refriger
blood
bank
except
time
involv
shift
blood
bank
clinic
staff
collect
blood
backgroundcas
studi
major
hemorrhag
protocol
mhp
provid
time
coordin
deliveri
blood
product
bleed
patient
evid
militari
civilian
trauma
studi
advoc
ratio
base
transfus
protocol
approach
wide
adopt
hospit
treat
patient
divers
bleed
etiolog
studi
investig
success
mhp
tertiari
univers
hospit
achiev
aim
includ
blood
product
wastag
sole
plasma
product
frozen
solvent
deterg
sd
plasma
studi
designmethod
retrospect
analysi
mhp
activ
year
perform
data
collect
use
hospit
laboratori
inform
system
electron
patient
record
databas
determin
number
locat
clinic
indic
mhp
activ
evid
blood
product
wastag
resultsfind
one
hundr
forti
one
mhp
activ
male
occur
seventi
two
occur
emerg
room
er
oper
room
intens
care
trauma
account
activ
gastrointestin
common
follow
vascular
surgic
bleed
event
case
emerg
group
rhd
neg
red
cell
use
prior
mhp
activ
mhp
activ
blood
pack
request
rather
individu
compon
case
median
red
cell
plasma
ratio
transfus
post
activ
deliveri
time
product
vari
product
type
red
cell
plasma
median
deliveri
time
minut
respect
blood
product
wastag
significantli
higher
plasma
compar
red
cell
mhp
activ
analysi
reveal
plasma
wastag
activ
major
occur
er
plasma
wastag
also
major
mhp
activ
wastag
case
death
occur
prior
transfus
unit
red
cell
transfus
plasma
wast
case
conclus
studi
demonstr
trauma
common
caus
mhp
tertiari
center
activ
rel
high
red
cell
plasma
ratio
achiev
plasma
wastag
high
reflect
limit
post
thaw
shelf
life
non
protocol
mhp
activ
plasma
wastag
occur
low
red
cell
transfus
event
indic
need
continu
educ
staff
involv
mhp
activ
futur
effort
reduc
plasma
wastag
would
necessit
increas
post
thaw
shelf
life
would
requir
chang
licensur
manufactur
altern
plasma
product
region
backgroundcas
studi
accord
colleg
american
pathologist
cap
approxim
advers
event
occur
us
hospit
annual
due
specimen
identif
error
id
error
result
label
error
mislabel
specimen
associ
almost
actual
patient
safeti
event
pose
seriou
concern
blood
bank
bb
cord
blood
specimen
label
error
identifi
either
mislabel
unlabel
organ
implement
second
independ
sampl
requir
abo
blood
group
verif
collect
process
improv
outcom
type
screen
specimen
cord
blood
specimen
collect
labor
deliveri
l
unit
continu
demonstr
inconsist
label
practic
perform
improv
initi
identifi
bb
transfus
stewardship
offic
studi
designmethod
standard
practic
obstetr
unit
cord
blood
sampl
collect
newborn
deliveri
group
andor
rh
neg
mother
l
uniqu
environ
pregnant
patient
deliv
newborn
patient
present
one
hospit
room
increas
risk
specimen
label
error
attempt
improv
collect
label
process
cord
blood
collect
kit
pilot
june
prepar
collect
kit
kept
patient
room
contain
clear
storag
bag
specimen
tube
neon
green
advisori
label
cord
blood
use
red
bag
deliveri
resultsfind
cord
blood
collect
kit
pilot
day
june
inpati
room
l
trial
result
decreas
cord
blood
specimen
label
error
base
outcom
l
leadership
agre
offici
adopt
prepar
collect
kit
best
practic
purpos
period
demonstr
almost
reduct
cord
blood
specimen
label
error
conclus
prior
implement
prepar
collect
kit
cord
blood
specimen
collect
label
practic
within
l
inconsist
evidenc
incid
report
month
prepar
collect
kit
usag
l
leadership
recogn
mark
decreas
specimen
collect
error
eas
use
prepar
kit
low
cost
intervent
element
togeth
contribut
ongo
success
within
depart
improv
cord
blood
specimen
collect
label
practic
use
prepar
collect
kit
cord
blood
specimen
outcom
posit
last
impact
collect
complianc
improv
patient
safeti
among
vulner
patient
popul
newborn
infant
backgroundcas
studi
patient
await
heart
transplant
receiv
transfus
risk
develop
leukocyt
antigen
hla
antibodi
may
impact
compat
futur
organ
ventricular
assist
devic
vad
use
bridg
transplant
known
associ
increas
hla
antibodi
product
patient
receiv
transfus
may
also
risk
develop
red
blood
cell
rbc
alloantibodi
complic
find
compat
blood
prior
surgeri
case
describ
patient
de
novo
develop
red
blood
cell
antibodi
heartwar
continu
flow
vad
devic
commonli
use
adult
older
pediatr
patient
studi
designmethod
year
old
male
histori
dilat
cardiomyopathi
left
ventricular
heart
failur
place
heartwar
hvad
may
bridg
cardiac
transplant
patient
sever
routin
type
screen
neg
last
date
transfus
prior
patient
activ
transplant
new
find
warm
autoantibodi
report
patient
admit
hospit
sinc
transfus
outsid
hospit
caus
absorpt
studi
neg
underli
alloantibodi
type
screen
routin
perform
month
anticip
futur
transplant
new
antibodi
identifi
second
antibodi
identifi
absenc
recent
transfus
resultsfind
time
demonstr
warm
autoantibodi
evid
patient
serum
patient
neg
fya
antigen
conclus
patient
transplant
transfus
fya
antigen
neg
rbc
develop
new
alloantibodi
outsid
expect
window
alloimmun
rais
mani
question
regard
vad
associ
increas
express
rbc
antibodi
may
occur
addit
hla
antibodi
rbc
sensit
pattern
orthotop
heart
transplant
candid
use
bridg
devic
transplant
requir
studi
backgroundcas
studi
red
blood
cell
rbc
transfus
increas
hemoglobin
concentr
gdl
per
unit
typic
adult
increas
attenu
presenc
ongo
hemolysi
activ
blood
loss
occasion
low
red
cell
volum
unit
transfus
recipi
larg
intravascular
blood
volum
may
show
unexpectedli
small
increas
rare
situat
howev
etiolog
greatli
attenu
respons
perplex
studi
designmethod
case
report
resultsfind
patient
male
myelodysplasticmyeloprolif
neoplasm
mdsmpn
massiv
splenomegali
patient
blood
group
rh
posit
neg
direct
indirect
antiglobulin
test
transfus
unit
rbc
increas
hemoglobin
evid
bleed
hemolysi
laboratori
test
show
ldh
iul
n
iul
haptoglobin
mgdl
n
mgdl
total
bilirubin
mgdl
n
reticulocyt
count
peripher
blood
smear
reveal
schistocyt
polychromasia
spherocytosi
hemoglobin
concentr
remain
essenti
unchang
throughout
rest
stay
patient
discharg
patient
readmit
one
week
later
hemoglobin
without
activ
bleed
hemolysi
addit
unit
rbc
result
increas
gdl
gdl
patient
type
fya
neg
account
rh
neg
rr
neg
unit
transfus
order
serial
monitor
allogen
cell
demonstr
shorten
surviv
rhd
neg
cell
partial
splenectomi
perform
use
embol
splenic
arteri
result
stabil
hemoglobin
around
base
appar
stabil
hemoglobin
splenic
arteri
embol
surgic
splenectomi
perform
result
hemoglobin
increas
gdl
patient
remain
transfus
free
day
conclus
sever
refractori
rbc
transfus
rare
event
although
spleen
like
culprit
organ
report
outcom
splenectomi
frequent
reluct
perform
splenectomi
patient
case
illustr
splenic
arteri
embol
may
use
initi
approach
potenti
predictor
util
subsequ
surgic
splenectomi
backgroundcas
studi
year
old
femal
histori
sickl
cell
anemia
present
institut
acut
sickl
cell
crisi
hemoglobin
arriv
gdl
decreas
gdl
hospit
admiss
day
given
patient
long
histori
transfus
multipl
known
antibodi
warm
alloantibodi
recent
identifi
cold
react
previou
delay
hemolyt
transfus
reaction
unidentifi
alloantibodi
red
blood
cell
transfus
avoid
due
continu
downtrend
hemoglobin
given
one
compat
unit
c
e
jkb
k
n
pack
red
blood
cell
studi
designmethod
transfus
reaction
request
clinic
team
due
progress
decreas
hemoglobin
gdl
gdl
follow
rbc
transfus
c
e
jkb
k
n
given
n
antibodi
typic
igm
cold
react
transfus
unit
n
direct
polyclon
coomb
dat
perform
sampl
base
posit
post
transfus
dat
neg
dat
antibodi
screen
test
perform
resultsfind
patient
dat
neg
howev
polyclon
igg
dat
posit
neg
complement
antibodi
screen
also
gel
liss
screen
subsequ
red
cell
panel
initi
elut
also
adsorpt
perform
rr
cell
result
eluat
consist
igg
red
cell
genotyp
show
patient
n
c
e
k
jkb
doa
antibodi
identif
show
reactiv
ahg
igg
nonreact
previou
unidentifi
antibodi
found
doa
patient
subsequ
transfus
crossmatch
compat
unitssh
good
respons
increas
repeat
hemolyt
reaction
patient
recov
treatment
reactiv
warm
autoimmun
hemolyt
anemia
medic
support
patient
ultim
discharg
home
conclus
usual
natur
occur
igmigg
stimul
antibodi
act
agglutinin
test
perform
temperatur
howev
case
warm
react
describ
presenc
warm
react
eluat
combin
patient
sever
anemia
day
follow
n
red
cell
transfus
result
delay
hemolyt
transfus
reaction
secondari
warm
alloantibodi
conclus
presenc
new
onset
patient
recurr
red
cell
transfus
may
merit
administr
n
red
cell
backgroundcas
studi
clinic
implic
immatur
platelet
content
platelet
unit
remain
uncertain
known
viabl
longer
throughout
shelf
life
singl
donor
platelet
sdp
unit
use
diagnost
gaug
thrombocytopen
present
howev
ascertain
stabil
immatur
platelet
count
affect
time
test
analyz
time
absolut
immatur
platelet
count
measur
chang
test
defin
time
point
unit
releas
neonat
patient
transfus
studi
designmethod
sdp
unit
neonat
patient
identifi
time
aliquot
prepar
unit
collect
healthi
donor
store
room
temperatur
gentli
agit
total
sdp
identifi
period
ml
sampl
collect
unit
time
aliquot
prepar
patient
transfus
sampl
analyz
use
autom
hematolog
analyz
complet
blood
count
cbc
percent
immatur
platelet
fraction
obtain
multipli
platelet
count
time
sampl
separ
group
depend
time
elaps
aliquot
issu
sampl
run
time
hour
hour
hour
sampl
analyz
hour
result
report
mean
standard
deviat
sd
unless
otherwis
indic
resultsfind
aliquot
identifi
uniqu
unit
uniqu
patient
unit
platelet
count
rang
rang
see
tabl
statist
differ
mean
platelet
count
separ
hour
hour
hour
tabl
analysi
platelet
sampl
obtain
tandem
neonat
aliquot
sd
standard
deviat
ci
confid
interv
percent
immatur
platelet
fraction
absolut
immatur
platelet
count
conclus
accur
measur
beyond
hour
aliquot
obtain
neonat
transfus
light
studi
aim
look
role
immatur
platelet
transfus
need
limit
hour
sampl
still
provid
valuabl
inform
establish
role
content
recipi
platelet
count
backgroundcas
studi
sickl
cell
complic
repres
clinic
challeng
patient
present
crisi
laboratori
result
potenti
complic
treatment
option
acut
present
specif
case
result
indic
patient
unexplain
decreas
hemoglobin
hgb
respons
blood
transfus
set
increas
lactat
dehydrogenas
ldh
bilirubin
lead
clinic
suspicion
hemolyt
process
studi
designmethod
year
old
male
sickl
cell
diseas
hgb
ss
diagnos
age
month
complic
episod
acut
chest
syndrom
vasoocclus
crise
pulmonari
hypertens
baselin
hgb
gdl
patient
manag
hydroxyurea
red
cell
transfus
acut
fall
hemoglobin
note
transfus
red
cell
unit
hgb
decreas
ldh
ul
bilirubin
mgdl
delay
hemolyt
transfus
reaction
dhtr
suspect
patient
receiv
neg
sickl
neg
blood
blood
type
po
resultsfind
three
sampl
sent
blood
bank
test
neg
direct
antiglobulin
test
dat
poli
igg
antibodi
screen
panel
neg
sampl
regardless
test
mediaenhanc
use
retest
unit
transfus
show
crossmatch
compat
bilirubin
unchang
sampl
sent
refer
laboratori
found
presenc
alloantibodi
autoantibodi
addit
test
antibodi
low
frequenc
antigen
v
vs
kpa
jsa
cw
lua
cob
dia
wra
ytb
gpmur
also
neg
genotyp
rh
variant
show
probabl
rhd
genotyp
rhd
probabl
rhce
ce
rhce
predict
phenotyp
patient
found
gata
mutat
result
loss
fyb
express
red
blood
cell
tissu
endothelium
henc
patient
expect
make
alloantibodi
fyb
antigen
patient
start
high
dose
steroid
led
slow
steadi
increas
hgb
subsequ
improv
ldh
bilirubin
conclus
sickl
cell
present
hemolyt
respons
could
transfus
howev
may
distinct
present
inher
patient
mediat
antibodi
red
blood
cell
therefor
qualifi
delay
hemolyt
respons
hemolyt
present
improv
strong
immunosuppress
hold
transfus
strictli
necessari
backgroundcas
studi
albumin
commonli
prescrib
fraction
blood
product
mani
indic
support
strong
clinic
evid
altern
albumin
includ
crystalloid
fluid
colloid
fluid
howev
recent
studi
suggest
possibl
harm
associ
use
hydroxyethyl
starch
altern
colloid
solut
may
impact
use
albumin
studi
describ
use
albumin
tertiari
academ
centr
period
studi
designmethod
retrospect
cohort
studi
larg
tertiari
care
hospit
ontario
canada
ottawa
hospit
data
warehous
queri
inpati
outpati
encount
albumin
transfus
januari
decemb
albumin
use
studi
period
report
includ
number
hospit
encount
total
amount
albumin
administ
normal
concentr
albumin
concentr
albumin
attend
medicalservic
patient
encount
associ
albumin
transfus
compar
randomli
select
cohort
patient
receiv
albumin
resultsfind
ottawa
hospit
patient
receiv
albumin
encount
albumin
transfus
albumin
administ
inpati
administ
outpati
overal
annual
number
patient
receiv
albumin
doubl
period
studi
total
amount
albumin
transfus
increas
gram
number
patient
encount
albumin
infus
total
amount
albumin
transfus
stabl
increas
dramat
largest
patient
group
receiv
albumin
cardiac
surgeri
intern
medicin
intens
care
hematolog
patient
encount
albumin
transfus
increas
proport
cardiac
surgeri
patient
intens
care
patient
greatest
compar
patient
encount
albumin
transfus
conclus
number
patient
receiv
albumin
total
amount
albumin
transfus
ottawa
hospit
increas
increas
mostli
seen
may
relat
clinic
studi
demonstr
possibl
harm
associ
use
altern
colloid
fluid
analysi
perform
understand
chang
indic
use
albumin
well
differ
clinic
outcom
among
patient
receiv
albumin
backgroundcas
studi
acut
traumat
coagulopathi
associ
increas
mortal
studi
shown
prompt
administr
plasma
product
high
plasma
red
cell
ratio
trauma
set
improv
outcom
prior
april
transfus
medicin
tm
suppli
thaw
plasma
tp
trauma
patient
initi
massiv
transfus
protocol
mtp
type
ab
tp
typic
weekday
type
ab
typic
weekend
first
round
mtp
consist
tp
often
plasma
thaw
fulfil
first
round
delay
product
minimum
minut
respons
request
trauma
servic
effort
improv
plasma
suppli
time
tm
start
suppli
liquid
plasma
lp
april
first
round
mtp
plasma
product
requir
thaw
tm
label
dispens
practic
also
modifi
attempt
decreas
time
suppli
plasma
product
studi
perform
determin
switch
lp
modif
tm
labelingdispens
procedur
result
signific
decreas
time
provid
plasma
first
round
mtp
studi
designmethod
retrospect
studi
time
initi
mtp
dispens
time
plasma
first
round
gather
determin
dispens
time
tm
provis
lp
label
dispens
procedur
modif
respect
mean
dispens
time
calcul
time
period
test
perform
evalu
two
period
mean
differ
signific
resultsfind
total
record
retriev
record
exclud
plasma
product
transfus
thu
unabl
determin
dispens
time
mean
procedur
modif
time
dispens
minut
n
sd
mean
procedur
modif
minut
n
sd
differ
mean
signific
p
differenti
shift
also
show
reduct
mean
dispens
time
follow
result
day
shift
minut
n
sd
minut
n
sd
even
shift
minut
n
sd
minut
n
sd
late
night
shift
minut
n
sd
minut
n
sd
result
signific
even
shift
p
late
night
shift
p
day
shift
p
conclus
switch
lp
tp
first
round
mtp
modifi
label
dispens
procedur
tm
abl
significantli
reduc
time
requir
suppli
plasma
mtp
backgroundcas
studi
studi
transfus
recipi
weak
type
shown
alloimmun
thu
blood
product
may
safe
administ
allow
better
manag
limit
inventori
serolog
type
rhd
variabl
result
depend
specif
reagent
methodolog
use
easili
distinguish
weak
partial
rhd
variant
studi
aim
evalu
impact
rhd
genotyp
inventori
rhd
neg
blood
product
singl
tertiari
care
pediatr
hospit
studi
designmethod
transfus
histori
march
march
initi
aborhd
type
review
pediatr
patient
less
year
age
time
recent
aborhd
type
document
serolog
weak
posit
test
initi
aborhd
type
institut
includ
gel
column
technolog
diagnost
raritan
nj
tube
test
use
monoclon
igm
blend
polyclon
igg
bioclon
ortho
serolog
weak
test
perform
result
weak
discrep
eg
reagent
gel
show
tube
neg
weak
incid
alloimmun
blood
product
exposur
gender
evalu
number
rhd
neg
unit
could
replac
rhd
posit
unit
rhd
genotyp
perform
determin
base
estim
preval
weak
type
ethnic
mix
us
popul
local
transfus
practic
give
rhd
posit
blood
product
male
weak
rhd
phenotyp
rhd
neg
blood
product
femal
weak
rhd
phenotyp
resultsfind
patient
less
year
old
abo
type
femal
male
identifi
serolog
weak
rbc
platelet
transfus
weak
patient
rbc
platelet
femal
rbc
platelet
male
weak
patient
receiv
rbc
platelet
transfus
transfus
go
five
patient
alloimmun
detect
estim
rbc
platelet
transfus
could
replac
rhd
posit
product
year
time
period
rhd
genotyp
perform
conclus
given
variabl
rate
transfus
weak
patient
decis
perform
rhd
genotyp
take
consider
likelihood
transfus
although
report
popul
predominantli
caucasian
limit
number
transfus
limit
remain
particularli
import
prevent
alloimmun
pediatr
popul
greater
lifetim
risk
associ
morbid
maxim
benefit
rhd
genotyp
better
mechan
need
develop
inform
access
across
institut
optim
care
prevent
repeat
test
backgroundcas
studi
correct
classif
abo
blood
type
imper
success
transfus
practic
allel
inherit
abo
subtyp
gene
mutat
abo
gene
caus
quantit
qualit
differ
antigen
express
patient
may
therefor
express
variant
classic
b
antigen
red
blood
cell
rbc
react
readili
standard
reagent
antisera
weak
reaction
imped
identif
patient
phenotyp
caus
potenti
transfus
incompat
blood
product
consequ
advers
reaction
may
result
due
immunogen
abo
blood
group
system
subgroup
vari
degre
rariti
b
antigen
express
less
frequent
group
b
subgroup
includ
bx
bw
bm
bel
found
greater
incid
asian
popul
exhibit
weak
hemagglutin
reaction
due
antigen
varianc
typic
mix
field
reaction
occur
forward
type
rbc
express
although
pattern
exclus
studi
designmethod
aborh
type
perform
via
column
agglutin
technolog
method
gel
matrix
contain
microbead
allow
small
unagglutin
rbc
pass
bottom
centrifug
sampl
contain
antigen
correspond
reagent
antisera
hemagglutin
occur
form
immun
complex
larg
pass
column
posit
reaction
indic
agglutin
remain
top
suspend
throughout
gel
matrix
neg
reaction
show
singl
button
cell
bottom
column
mix
field
reactiv
exhibit
two
popul
cell
show
separ
reaction
microtub
resultsfind
rare
case
detect
neonat
asian
descent
abo
forward
type
patient
rbc
cord
blood
sampl
react
weakli
reagent
antisera
caus
question
specimen
integr
venou
sampl
request
confirmatori
test
yield
equal
weak
reaction
tabl
although
mix
field
present
specimen
sent
genotyp
result
abo
abo
predict
phenotyp
none
common
mutat
caus
detect
patient
genotyp
profil
conclus
genotyp
essenti
accur
identifi
patient
express
subgroup
rare
alway
react
characterist
patient
phenotyp
gener
transfus
group
rbc
group
ab
plasma
although
transfus
indic
vari
institut
backgroundcas
studi
hemorrhag
remain
major
caus
potenti
prevent
death
rapid
effect
respons
vital
success
outcom
major
blood
loss
institut
transfus
servic
respond
massiv
hemorrhag
follow
previous
develop
massiv
transfus
protocol
mtp
howev
time
took
issu
blood
product
long
clinic
feedback
unsatisfactori
recent
multipl
chang
made
mtp
improv
effici
transfus
servic
respond
clinic
set
studi
designmethod
base
root
caus
analysi
clinic
issu
follow
chang
made
redesign
paperwork
safeti
check
logist
mtp
pack
optimizedcentr
equip
arrang
blood
bank
work
space
staff
train
evalu
effect
chang
length
time
blood
bank
notif
ie
activ
mtp
protocol
issuanc
blood
product
record
compar
previou
case
pair
use
statist
analysi
resultsfind
averag
time
spent
receipt
call
issuanc
product
implement
chang
minut
chang
time
spent
dramat
reduc
nearli
minut
p
incid
report
conclus
studi
demonstr
work
effici
blood
bank
emerg
condit
significantli
improv
strateg
rearrang
order
work
flow
eg
blood
product
instead
assembl
blood
product
activ
mtp
extrem
time
sensit
task
optim
equip
spatial
arrang
reduc
staff
walk
distanc
redesign
set
paperwork
relev
personnel
train
contribut
improv
transfus
servic
effici
without
compromis
patient
safeti
backgroundcas
studi
platelet
plt
transfus
second
red
blood
cell
transfus
pediatr
patient
pt
make
approxim
transfus
pediatr
hospit
order
practic
pediatr
plt
transfus
well
character
literatur
addit
plt
transfus
indic
larg
base
studi
among
adult
popul
may
requir
adjust
pediatr
pt
studi
designmethod
irb
approv
retrospect
studi
plt
order
obtain
hospit
qualiti
center
electron
medic
record
blood
audit
report
pediatr
pt
perform
pt
met
follow
inclus
criteria
inpati
age
year
minimum
plt
order
admiss
neonat
intens
care
unit
pt
exclud
paramet
total
number
plt
order
indic
clinic
servic
order
plt
plt
transfus
order
indic
procedur
associ
plt
order
plt
count
within
hour
order
minimummaximum
plt
order
per
pt
analyz
descript
statist
use
summar
result
resultsfind
nineti
three
pt
includ
fourteen
clinic
servic
place
plt
order
total
accompani
indic
mean
plt
count
median
see
tabl
servic
frequent
order
plt
bone
marrow
transplant
follow
hematolog
oncolog
order
associ
procedur
invas
procedur
indic
select
mean
plt
count
pt
whose
indic
prophylaxi
spontan
hemorrhag
sixti
six
percent
n
pt
multipl
plt
order
mean
median
rang
pt
multipl
plt
order
order
associ
one
indic
wherea
pt
order
one
indic
conclus
plt
transfus
order
common
among
pediatr
patient
institut
major
pt
receiv
one
order
studi
requir
character
order
pattern
indic
pediatr
plt
transfus
backgroundcas
studi
g
antigen
rh
antigen
found
red
blood
cell
also
express
either
c
antigen
difficult
distinguish
antibodi
panel
may
confus
plu
sinc
commonli
found
alloantibodi
mixtur
andor
contribut
solitari
alloantibodi
caus
hemolyt
diseas
fetu
newborn
hdfn
unclear
two
prior
case
report
isol
pregnanc
demonstr
evid
hemolyt
diseas
one
infant
moder
hemolyt
diseas
requir
prolong
phototherapi
second
dc
infant
studi
designmethod
neg
woman
refer
medicin
servic
week
gestat
hypertens
alloimmun
alloantibodi
alloantibodi
first
identifi
year
ago
ectop
pregnanc
time
receiv
prophylact
rhig
transfus
neg
red
blood
cell
current
pregnanc
follow
serial
antibodi
titer
middl
cerebr
arteri
mca
doppler
ultrasound
refer
hospit
although
titer
elev
threshold
mca
doppler
show
evid
fetal
anemia
receiv
prophylact
rhig
pregnanc
due
previou
diagnosi
alloantibodi
upon
arriv
hospit
g
differenti
test
perform
reveal
presenc
plu
alloantibodi
resultsfind
posit
infant
deliv
week
due
matern
hypertens
neonat
dat
posit
eluat
react
c
cell
consist
neonat
rbc
first
day
life
infant
develop
elev
bilirubin
level
requir
day
phototherapi
treatment
hdfn
hematocrit
remain
stabl
transfus
given
conclus
presenc
absenc
establish
rhig
prophylaxi
administ
mother
postpartum
suspect
pregnant
woman
appear
simultan
antibodi
panel
prophylact
rhig
administ
present
g
differenti
studi
case
matern
alloantibodi
infant
neg
c
antigen
case
demonstr
develop
mild
hdfn
attribut
isol
alloantibodi
backgroundcas
studi
nation
univers
hospit
singapor
bed
tertiari
hospit
issu
almost
unit
blood
compon
annual
audit
transfus
appropri
sinc
despit
clear
guidelin
inappropri
usag
still
persist
studi
designmethod
retrospect
audit
perform
januari
decemb
use
blood
bank
regist
patient
electron
medic
record
appropri
red
blood
cell
rbc
use
determin
use
singapor
ministri
health
guidelin
platelet
plt
concord
aabb
bsh
guidelin
fresh
frozen
plasma
ffp
cap
guidelin
appropri
indic
rbc
haemoglobin
hb
level
less
prophylact
plt
plt
count
less
ffp
revers
warfarin
inr
request
inappropri
indic
meet
criteria
resultsfind
total
transfus
episod
rbc
plt
ffp
audit
disciplin
paediatr
obstetr
medicin
surgeri
cardiac
orthopaed
liver
transplant
use
rbc
plt
ffp
cardiac
total
transfus
deem
appropri
disciplin
signific
differ
rbc
appropri
greater
variabl
appropri
usag
plt
ffp
ffp
appropri
obstetr
paediatr
lowest
appropri
use
surgeri
reflect
variat
ration
ffp
usag
across
disciplin
high
overal
percentag
appropri
rbc
plt
transfus
reflect
good
transfus
practic
clinician
main
indic
inappropri
transfus
attribut
low
hb
rbc
bleed
prevent
plt
given
among
blood
compon
ffp
lowest
appropri
usag
inappropri
ffp
use
associ
surgic
procedur
like
due
difficulti
assess
bleed
patient
due
correct
coagulopathi
patient
persist
low
inr
revers
warfarin
unlik
rbc
plt
exist
ffp
guidelin
lack
clear
evid
base
indic
patient
ptaptt
poor
predictor
substanti
prophylact
ffp
usag
conclus
rate
appropri
transfus
institut
determin
rbc
plt
ffp
studi
reflect
overal
higher
rate
appropri
compon
use
compar
intern
metz
local
ffp
chng
continu
educ
better
blood
manag
necessari
improv
appropri
use
blood
amidst
increas
demand
blood
grow
age
local
popul
backgroundcas
studi
massiv
transfus
greater
unit
rbc
hour
well
describ
increasingli
uncommon
event
previou
report
massiv
transfus
protocol
mtp
activ
met
old
unit
criteria
understand
episod
high
review
year
blood
use
high
acuiti
hospit
episod
met
critic
administr
definit
three
blood
compon
administ
one
hour
studi
designmethod
year
worth
blood
use
bed
urban
counti
hospit
review
episod
occur
outsid
mtp
descript
statist
patient
episod
assembl
tabl
graph
use
microcomput
spreadsheet
softwar
resultsfind
hospit
admit
patient
administ
blood
compon
mtp
activ
trauma
episod
episod
occur
secondari
surgeri
trauma
patient
episod
bleed
relat
surgeri
patient
sever
gi
bleed
low
surgic
bleed
situat
higher
gi
bleed
conclus
apart
convent
massiv
transfus
situat
smaller
episod
use
occur
frequent
acut
care
hospit
rapid
correct
low
mortal
transfus
servic
need
abl
support
situat
rapid
respons
hemostat
product
backgroundcas
studi
acut
manag
intracerebr
hemorrhag
ich
priorit
factor
reduct
hematoma
expans
risk
signific
care
patient
neurolog
dysfunct
secondari
expans
intracerebr
pressur
greatli
reduc
qualiti
life
current
literatur
benefit
platelet
transfus
ich
inconclus
tier
platelet
protocol
hospit
implement
june
improv
clinic
outcom
reduc
tat
data
collect
electron
medic
record
two
one
prior
tier
platelet
one
follow
implement
studi
designmethod
platelet
data
collect
septemb
septemb
may
respect
emerg
room
neurolog
intens
care
unit
consid
depart
manag
major
ich
patient
undergo
standard
protocol
request
blood
product
standard
protocol
platelet
requir
initi
review
clinician
order
lab
personnel
verifi
patient
confirm
blood
type
current
platelet
count
within
hr
number
previou
platelet
transfus
within
order
two
adult
dose
platelet
unit
platelet
concern
requir
audit
blood
bank
patholog
resid
fellow
count
exceed
cellsmcl
unit
cellsmcl
activ
bleed
patient
requir
determin
clinic
need
suspect
brain
bleed
clinic
goal
maintain
platelet
count
cellsmcl
thu
major
platelet
request
patient
undergo
standard
protocol
basi
platelet
count
alon
addit
absenc
confirm
blood
type
may
present
delay
requir
blood
draw
test
prior
releas
platelet
transfus
three
tat
defin
time
admiss
symptom
present
transfus
time
platelet
request
issu
blood
time
platelet
issu
transfus
resultsfind
initi
yield
signific
result
reduc
tat
ed
patient
blood
bank
depend
tat
also
reduc
tat
patient
group
data
pertain
tat
show
overal
reduct
without
signific
tabl
preliminari
data
clinic
outcom
indic
hematoma
reduct
follow
tier
platelet
implement
tabl
conclus
tier
platelet
tat
reduct
limit
blood
bank
practic
investig
requir
determin
factor
affect
transfus
start
time
product
receiv
respect
hospit
unit
effect
tier
platelet
trauma
protocol
anoth
area
investig
trauma
protocol
also
bypass
product
audit
measur
clinic
outcom
limit
notat
ct
scan
enter
electron
medic
record
within
hour
period
standard
measur
clinic
benefit
use
combin
ct
scan
lab
follow
platelet
transfus
would
provid
clearer
insight
backgroundcas
studi
japan
autolog
blood
donat
pad
transfus
still
play
role
elimin
risk
relat
allogen
blood
transfus
especi
diseas
object
studi
determin
rate
advers
reaction
pad
transfus
singl
institut
period
studi
designmethod
januari
decemb
investig
advers
reaction
pad
transfus
compar
allogen
blood
transfus
hospit
advers
reaction
categor
accord
definit
propos
intern
societi
blood
transfus
isbt
work
parti
haemovigil
resultsfind
total
blood
compon
transfus
studi
period
pad
transfus
number
wherea
allogen
blood
transfus
number
number
rate
advers
reaction
pad
transfus
wherea
allogen
blood
transfus
respect
latter
signific
p
among
advers
reaction
pad
transfus
common
febril
transfus
reaction
fnhtr
follow
allerg
reaction
sever
advers
reaction
pad
transfus
grade
case
regard
blood
compon
type
advers
reaction
involv
case
whole
blood
pad
frozen
pad
autolog
plasma
advers
reaction
caus
autolog
blood
conserv
observ
periop
autolog
cell
salvag
acut
normovolem
hemodilut
studi
conclus
advers
reaction
observ
pad
transfus
rate
institut
backgroundcas
studi
transfus
medicin
examin
tmise
offer
onlin
fall
spring
transfus
medicin
tm
fellow
first
offer
exam
repres
cooper
american
societi
clinic
patholog
ascp
aabb
consist
approxim
item
previou
studi
found
senior
patholog
resid
examin
rise
score
correl
outcom
american
board
patholog
abp
primari
certifi
examin
hypothes
tmise
score
correl
outcom
abp
tm
subspecialti
certifi
examin
tm
board
studi
designmethod
tm
fellowship
program
director
coordin
identifi
via
accredit
council
graduat
medic
educ
acgm
websit
email
excel
spreadsheet
captur
anonym
data
tm
fellow
onward
field
includ
fellow
primari
specialti
whether
clinic
hematologyoncolog
subspecialti
train
fellowship
graduat
year
season
year
tmise
prior
graduat
whether
tmise
proctor
fellow
tmise
percentil
score
year
outcom
tm
board
attempt
averag
tmise
score
compar
use
unpair
test
sigmaplot
p
defin
statist
signific
resultsfind
tm
fellowship
program
contact
respond
least
data
total
fellow
tmise
result
score
andor
percentil
outcom
first
attempt
tm
board
provid
fellow
averag
tmise
score
fellow
pass
tm
board
attempt
averag
score
fellow
fail
tm
board
attempt
fellow
score
first
quartil
tmise
first
time
tm
board
pass
rate
second
quartil
pass
rate
third
quartil
pass
rate
quartil
pass
rate
tabl
conclus
averag
score
fellow
pass
tm
board
attempt
significantli
higher
fellow
fail
tmise
quartil
appear
predict
tm
board
outcom
may
due
prolong
interv
tmise
tm
board
administr
fellow
score
quartil
lower
risk
fail
tm
board
backgroundcas
studi
continu
educ
ce
train
clinic
laboratori
personnel
critic
maintain
knowledg
profici
skill
transfus
medicin
laboratori
certif
agenc
well
employ
requir
averag
ce
credit
annual
order
maintain
profession
certif
howev
laboratori
medic
staff
face
increas
challeng
find
opportun
meet
requir
studi
designmethod
anonym
survey
develop
identifi
challeng
laboratori
profession
face
order
access
ce
train
survey
compris
question
cover
educ
background
institut
requir
fund
staf
constraint
survey
distribut
electron
past
attende
grifol
academi
immunohematolog
transfus
scienc
educ
cours
tsec
resultsfind
total
transfus
medicin
laboratori
profession
invit
take
survey
respons
receiv
major
respond
mtmlscl
follow
sbbbbsh
approxim
half
respond
greater
year
experi
clinic
laboratori
among
respond
employ
hospit
transfus
servic
laboratori
immunohematolog
refer
laboratori
almost
respond
certifi
american
societi
clinic
patholog
ascp
case
respond
indic
ce
hour
requir
maintain
certif
requir
employ
overal
respond
attend
ce
event
within
last
year
common
reason
attend
ce
includ
staff
shortag
fund
travel
necess
use
vacat
time
lack
opportun
cover
topic
interest
requir
cost
associ
event
registr
travel
accommod
expens
paid
individu
employ
case
respect
conclus
certif
agenc
employ
requir
ce
proof
profession
compet
laboratori
face
financi
staf
constraint
affect
capac
staff
access
ce
train
innov
ce
train
model
need
take
challeng
account
order
ensur
effect
backgroundcas
studi
anecdot
mani
transfus
medicin
tm
fellowship
program
face
scarciti
applic
purpos
studi
identifi
trend
tm
fellowship
posit
avail
fill
well
survey
formerli
accredit
program
insight
experi
factor
led
withdraw
accredit
studi
designmethod
nation
graduat
medic
educ
gme
censu
review
identifi
number
tm
fellowship
posit
avail
fill
academ
year
american
colleg
graduat
medic
educ
acgm
websit
search
identifi
tm
fellowship
program
current
formerli
accredit
formerli
accredit
fellowship
program
former
fellowship
program
director
pd
andor
coordin
list
acgm
websit
email
anonym
survey
creat
googl
form
pd
ask
identifi
factor
led
fellowship
program
withdraw
whether
plan
reopen
fellowship
program
futur
question
addit
thought
resultsfind
decemb
nation
gme
censu
report
number
accredit
tm
fellowship
program
stabl
academ
year
number
avail
tm
fellowship
posit
rose
period
averag
rang
tm
fellowship
posit
unfil
year
decemb
acgm
report
tm
fellowship
program
ever
receiv
accredit
withdrawn
accredit
last
year
tabl
three
formerli
accredit
fellowship
program
merg
singl
program
two
other
subsequ
reopen
respect
remain
formerli
accredit
program
respond
survey
program
cite
sever
year
lack
applic
signific
acgm
administr
requir
maintain
accredit
primari
reason
withdraw
april
two
addit
tm
fellowship
program
accredit
open
juli
one
posit
conclus
number
tm
fellowship
program
remain
steadi
sinc
number
avail
posit
increas
tm
fellowship
posit
unfil
annual
give
credenc
anecdot
difficulti
secur
fellow
year
futur
studi
investig
traine
motiv
pursu
tm
fellowship
could
yield
valuabl
inform
backgroundcas
studi
booklet
continu
educ
pediatr
apheresi
seri
third
instal
tackl
issu
surround
hematopoiet
stem
cell
collect
apheresi
hematopoiet
stem
cell
transplant
hsct
occur
annual
unit
state
patient
age
twenti
twenti
percent
transplant
util
autolog
allogen
product
increas
recent
year
invas
medic
procedur
hematopoiet
stem
cell
collect
apheresi
psycholog
upset
pediatr
popul
caus
fear
pain
feel
helpless
feel
manifest
anger
aggress
anxieti
lead
increas
procedur
time
treatment
delay
long
term
psycholog
trauma
studi
show
educ
pediatr
patient
famili
expect
well
hospit
staff
expect
reduc
feel
anxieti
help
patient
feel
empow
reduc
emot
trauma
previou
project
reveal
lack
age
appropri
literatur
apheresi
procedur
gener
includ
topic
cover
first
two
booklet
seri
therapeut
plasma
exchang
red
blood
cell
exchang
studi
designmethod
storyboard
develop
collabor
pediatr
apheresi
physician
accompani
artwork
produc
conjunct
medic
illustr
enhanc
stori
pediatr
audienc
resultsfind
stori
discuss
apheresi
stem
cell
collect
perform
detail
step
lead
procedur
review
occur
day
collect
includ
strategi
cope
well
brief
mention
expect
futur
child
return
transplant
storyboard
directli
address
procedur
standpoint
autolog
donat
booklet
may
also
help
allogen
pediatr
donor
prepar
collect
booklet
made
avail
hospit
websit
patient
use
conclus
instal
pediatr
apheresi
seri
provid
educ
materi
age
appropri
level
help
prepar
reduc
stress
experienc
children
caregiv
stem
cell
collect
materi
serv
anticipatori
guidanc
vulner
sensit
popul
ultim
design
promot
cope
strategi
empower
reduc
fear
unknown
smallest
patient
prepar
complex
invas
procedur
backgroundcas
studi
purpos
studi
gain
evid
effect
microlearn
video
donor
collect
oper
video
favor
accept
individu
organ
hypothesi
peopl
drawn
respond
video
much
inform
transmit
brain
visual
visual
aid
found
improv
learn
video
learn
advantag
engag
visual
auditori
channel
brain
assert
microlearn
video
help
knowledg
retent
video
spread
cognit
load
learner
auditori
visual
learn
channel
ten
microlearn
video
creat
one
year
learner
abl
access
video
demand
organ
intern
websit
banner
creat
homepag
organ
intern
websit
team
member
would
easili
abl
click
banner
access
quick
tip
video
librari
studi
designmethod
video
develop
partnership
market
commun
depart
train
depart
video
film
organ
orlando
locat
multimedia
studio
video
also
film
organ
simul
lab
script
develop
train
depart
review
approv
director
process
improv
repres
qualiti
assur
attend
film
ensur
video
accur
repres
current
step
sop
topic
follow
video
creat
studi
efficaci
microlearn
video
pack
apheresi
blood
productsminor
consentshand
washingdonor
contact
informationfil
sampl
tubescons
sensedonor
arm
preparationneedl
guardadvers
reactionslook
offlin
sop
resultsfind
unit
event
data
obtain
regard
insuffici
quantiti
sampl
tube
minor
consent
form
report
indic
improv
respect
base
three
month
event
data
obtain
video
present
survey
data
obtain
three
month
prior
submiss
abstract
date
team
member
complet
survey
question
ask
survey
respons
follow
find
video
receiv
email
ask
view
manag
found
intern
websit
mani
quick
tip
video
view
complet
survey
averag
number
microlearn
video
view
four
total
number
video
view
respond
easi
find
quick
tip
video
scale
one
easi
find
five
easi
find
weight
averag
quick
tip
help
job
scale
one
help
five
help
job
weight
averag
enjoy
short
video
format
train
scale
one
realli
five
ye
love
weight
averag
click
count
data
obtain
video
titl
look
offlin
sop
releas
video
receiv
hit
uniqu
user
conclus
found
organiz
microlearn
video
favor
receiv
posit
impact
team
member
daili
work
therefor
quick
tip
microlearn
video
program
continu
backgroundcas
studi
although
blood
transfus
remain
common
procedur
perform
hospit
deficit
transfus
medicin
knowledg
exist
amongst
physician
improp
unnecessari
transfus
may
advers
affect
patient
follow
initi
accredit
council
graduat
medic
educ
strategi
clinic
patholog
cp
resid
institut
taken
activ
role
improv
patient
safeti
healthcar
qualiti
directli
engag
clinician
prospect
audit
pa
guidelin
transfus
order
studi
assess
whether
patholog
resid
program
across
unit
state
us
util
pa
way
improv
transfus
medicin
tm
educ
ultim
patient
outcom
studi
designmethod
questionnair
distribut
amongst
patholog
program
director
pd
evalu
whether
cp
resid
particip
pa
transfus
request
learn
structur
resid
program
resultsfind
survey
accredit
patholog
program
respond
questionnair
percent
pd
state
cp
resid
perform
pa
red
blood
cell
rbc
transfus
meet
hospit
guidelin
percent
program
without
pa
system
report
monitor
guidelin
rbc
transfus
method
less
half
survey
pd
held
posit
tm
director
associ
pd
hold
respons
conclus
cp
resid
involv
pa
compon
patient
blood
manag
program
significantli
improv
transfus
practic
reduc
unnecessari
transfus
assess
us
patholog
resid
program
reveal
miss
opportun
close
half
survey
institut
directli
involv
resid
relev
patient
improv
program
resid
engag
initi
enhanc
medic
knowledg
ultim
improv
patient
safeti
backgroundcas
studi
good
bedsid
transfus
practic
critic
element
transfus
chain
depend
compet
physician
base
knowledg
regard
standard
blood
transfus
guidelin
applic
practic
patient
care
present
studi
aim
assess
basic
knowledg
clinic
resid
institut
regard
blood
transfus
guidelin
bedsid
transfus
practic
set
accordingli
intervent
strategi
plan
execut
assess
perform
understand
impact
intervent
studi
designmethod
studi
divid
three
phase
phase
blood
transfus
practic
assess
clinic
area
observ
transfus
episod
step
occur
patient
bedsid
assess
includ
inform
consent
physician
order
blood
requisit
bedsid
check
start
transfus
monitor
document
use
proforma
assess
knowledg
clinic
resid
subject
questionnair
base
institut
blood
transfus
guidelin
fill
gap
knowledg
practic
clinic
resid
regard
blood
transfus
practic
educ
strategi
includ
interact
seminar
clinic
specialti
regular
messag
alert
regularli
sensit
intervent
phase
implement
phase
clinic
area
assess
blood
transfus
practic
resultsfind
averag
score
knowledg
regard
bedsid
transfus
practic
studi
found
gain
resid
word
mouth
senior
colleagu
clinic
experi
stay
hospit
first
year
resid
correct
respons
rate
questionnair
increas
year
howev
actual
good
bedsid
transfus
practic
follow
less
observ
improp
bedsid
storag
blood
compon
major
concern
lead
deterior
qualiti
blood
compon
best
sampl
label
practic
follow
less
observ
inform
consent
record
found
less
observ
despit
fact
knowledg
regard
knowledg
assess
educ
intervent
slight
improv
practic
like
blood
transfus
consent
physician
order
document
patient
ident
check
file
improp
storag
compon
ward
refriger
improv
statist
signific
multitask
patient
bedsid
without
help
nurs
staff
blood
activ
major
reason
conclus
present
studi
gave
us
insight
lot
scope
improv
bedsid
transfus
practic
hospit
achiev
continu
educ
effort
follow
effect
assess
gap
analysi
backgroundcas
studi
japan
intern
cooper
agenc
jica
fund
project
support
hemovigil
hv
program
overseen
nation
blood
servic
ghana
nbsg
collabor
terumo
bct
inc
tbct
object
project
improv
current
transfus
practic
train
medic
staff
hv
establish
system
monitor
evalu
safeti
blood
transfus
compar
acut
advers
reaction
trar
patient
receiv
transfus
whole
blood
wb
treat
use
mirasol
pathogen
reduct
technolog
prt
system
patient
receiv
convent
wb
transfus
korl
bu
teach
hospit
accra
komfo
anoky
teach
hospit
kumasi
select
site
studi
designmethod
hv
train
plan
design
aabb
consult
servic
aabbc
assess
exist
practic
nbsg
aim
develop
practic
train
materi
creat
hv
awar
increas
transfus
medicin
knowledg
among
traine
hospit
nbsg
staff
train
program
incorpor
lectur
practic
session
ward
develop
use
ghanaian
aabb
expertis
aabbc
engag
dovel
technolog
llc
develop
hv
infrastructur
data
repositori
portal
electron
data
captur
manag
analysi
transfus
trar
hv
train
includ
follow
topic
qualiti
system
defin
africa
societi
blood
transfus
standard
trar
base
isbt
definit
transfus
reaction
near
miss
follow
hv
form
complet
report
write
databas
develop
use
portal
analysi
tbct
provid
train
oper
process
includ
manufactur
issu
mirasol
administr
blood
product
resultsfind
nbsg
current
monitor
project
collabor
lead
two
hospit
sinc
launch
project
earli
june
transfus
record
report
portal
audit
conduct
five
month
demonstr
increas
level
knowledg
enthusiasm
hv
better
complianc
oper
process
addit
principl
behind
train
train
trainer
realiz
hv
knowledg
mirasol
experi
share
amongst
staff
conclus
establish
effect
hv
infrastructur
undertak
hv
train
strengthen
qualiti
requir
transfus
practic
better
monitor
report
transfus
trar
lesson
learn
assist
expans
similar
train
program
hv
infrastructur
site
goal
establish
nation
hv
system
ghana
backgroundcas
studi
requir
individu
must
achiev
elig
donat
blood
student
may
find
difficult
learn
requir
lectur
present
topic
may
dri
typic
unengag
blood
bank
professor
medic
laboratori
scienc
program
northeast
want
find
new
method
teach
subject
matter
program
gener
senior
level
student
instruct
senior
year
design
block
student
spend
certain
number
day
content
area
immunohematolog
section
consist
day
includ
lectur
laboratori
experi
compress
schedul
one
day
dedic
donat
process
effort
creat
interact
learn
experi
fit
schedul
provid
student
qualiti
content
workshop
develop
role
play
aid
student
learn
requir
studi
designmethod
pilot
workshop
design
student
role
play
donor
interview
process
aid
learn
variou
reason
deferr
lectur
present
prior
workshop
introduc
student
interview
process
donor
elig
student
work
pair
given
donor
binder
serv
guid
workshop
binder
contain
inform
regard
medic
deferr
travel
restrict
two
predetermin
scenario
contain
donor
inform
use
inform
one
student
complet
interview
questionnair
student
interview
given
inform
regard
hemoglobin
hematocrit
weight
donor
platelet
count
applic
mini
physic
interview
review
questionnair
well
mini
physic
card
ask
follow
question
applic
interview
complet
worksheet
answer
question
whether
donor
elig
reason
inelig
role
switch
student
opportun
play
role
resultsfind
workshop
execut
januari
shown
initi
success
student
describ
workshop
help
engag
process
averag
exam
score
donor
elig
exam
averag
anecdot
evid
show
increas
understand
content
conclus
although
elig
criteria
donor
complex
ever
chang
inform
present
way
maxim
learner
engag
understand
potenti
workshop
adapt
train
healthcar
profession
donat
facil
compet
assess
tool
keep
mind
time
constraint
facil
backgroundcas
studi
august
fda
approv
ortho
blood
bank
analyz
employ
column
agglutin
gel
technolog
june
two
transfus
servic
within
bed
commun
hospit
system
implement
routin
use
ortho
test
menu
fulli
evalu
includ
antibodi
titrat
valid
studi
clearli
demonstr
increas
sensit
autom
antibodi
titrat
result
increas
titer
averag
tradit
tube
techniqu
titer
result
howev
unknown
whether
age
reagent
red
blood
cell
factor
sensit
autom
assay
studi
designmethod
retrospect
analysi
conduct
compar
autom
titrat
result
time
minimum
three
separ
patient
sera
contain
antibodi
follow
blood
group
system
studi
rh
kell
duffi
kidd
sampl
frozen
multipl
aliquot
facilit
studi
time
autom
antibodi
titrat
perform
upon
receipt
fresh
lot
ortho
panel
b
titrat
studi
repeat
week
use
exact
reagent
red
cell
reagent
expir
panel
one
addit
titrat
studi
perform
sampl
use
next
fresh
lot
ortho
panel
cell
differ
reagent
red
cell
donor
attempt
fulli
evalu
autom
titrat
consist
time
resultsfind
total
sera
evalu
studi
result
titer
result
differ
throughout
entir
studi
period
includ
across
lot
number
ortho
panel
two
outlier
one
sampl
demonstr
increas
titer
upon
test
fresh
reagent
red
cell
differ
lot
sampl
demonstr
increas
titer
upon
test
fresh
reagent
red
cell
differ
lot
note
serolog
phenotyp
target
antigenallel
reagent
red
cell
select
titrat
studi
ident
across
lot
number
conclus
provid
standard
methodolog
conduct
titrat
studi
high
degre
reproduc
autom
titer
result
vari
differ
time
upon
use
consist
reagent
red
cell
antigen
sourc
even
antigen
sourc
inconsist
titer
result
chang
origin
result
data
suggest
age
reagent
red
cell
signific
impact
autom
titrat
result
howev
random
differ
individu
reagent
red
cell
may
affect
titer
result
differ
backgroundcas
studi
hospit
transfus
servic
use
us
fda
approv
dna
genotyp
system
predict
extend
rbc
phenotyp
donor
patient
aim
studi
evalu
oper
characterist
research
use
genotyp
platform
idcor
xt
grifol
diagnost
solut
inc
ca
studi
designmethod
dna
extract
edta
whole
blood
sampl
test
use
idcor
xt
current
system
turnaround
time
tat
dna
extract
final
result
receipt
technologist
time
compar
differ
batch
size
end
studi
questionnair
administ
oper
evalu
eas
perform
key
procedur
step
system
use
scale
easiest
resultsfind
total
sampl
test
system
tat
method
comparison
associ
oper
survey
result
present
tabl
idcor
xt
show
reduct
mean
tat
time
respect
compar
current
system
oper
perform
mean
idcor
xt
run
mean
overal
oper
rate
idcor
xt
current
system
key
featur
respect
conclus
compar
oper
characterist
idcor
xt
system
offer
certain
advantag
includ
abil
effici
test
smaller
number
sampl
without
wastag
less
technologist
time
faster
tat
increas
autom
process
includ
reagent
track
qc
monitor
plate
layout
associ
idcor
xt
system
requir
slightli
time
daili
mainten
backgroundcas
studi
purpos
studi
prospect
evalu
perform
analyz
autom
blood
group
laboratori
inc
hercul
ca
academ
hospit
transfus
servic
perform
approxim
type
screen
test
annual
analyz
evalu
concord
platform
immucor
inc
norcross
ga
current
use
well
tube
test
blood
supplier
label
studi
designmethod
test
aborh
forward
revers
antibodi
screen
ab
aborh
donor
unit
confirm
crossmatch
compat
igg
perform
use
gel
card
compar
control
method
use
edta
sampl
edta
cord
blood
sampl
test
card
compar
addit
sampl
test
correl
tube
test
dat
antigen
type
c
c
e
e
k
compar
tube
test
use
commerci
reagent
blood
supplier
label
concord
rate
calcul
togeth
compar
control
method
use
assay
resultsfind
concord
control
abo
group
assay
abo
rh
donor
confirm
rh
kell
antigen
type
assay
well
crossmatch
newborn
test
card
tabl
regard
dat
concord
increas
sensit
reflect
gel
methodolog
tube
test
conclus
autom
immunohematolog
system
essenti
support
test
volum
larg
hospit
transfus
servic
environ
perform
type
screen
aborh
unit
confirm
rh
kell
antigen
type
antibodi
identif
studi
demonstr
analyz
gel
card
equival
immunohematolog
analyz
tube
test
use
sampl
concord
rare
exampl
identifi
system
accept
lower
concord
comparison
dat
tube
test
attribut
known
increas
sensit
gel
base
antiglobulin
test
backgroundcas
studi
autom
blood
bank
test
platform
allow
staff
multitask
reduc
turnaround
time
improv
antibodi
detect
autom
instrument
meet
perform
expect
histor
state
util
immucor
galileo
instrument
perform
type
screen
test
antibodi
identif
solid
phase
methodolog
staff
encount
increas
posit
antibodi
reactiv
appear
gold
standard
method
peg
led
increas
turnaround
time
critic
patient
temporari
elimin
autom
antibodi
panel
test
workflow
studi
designmethod
addit
autom
instrument
platform
immucor
echo
immucor
assess
compar
current
instrument
eas
use
turnaround
time
method
comparison
focus
antibodi
posit
rate
staff
train
use
new
instrument
compar
day
day
oper
exist
instrument
eas
use
workflow
capabl
turnaround
time
compar
instrument
type
screen
sampl
run
specimen
well
concurr
load
sampl
size
run
method
comparison
perform
twenti
sampl
one
month
period
three
instrument
sampl
util
test
antibodi
screen
posit
exist
neg
peg
antibodi
screen
repeat
echo
assess
reactiv
resultsfind
staff
determin
echo
instrument
similar
use
compar
exist
instrument
would
difficult
implement
lab
compar
turnaround
time
instrument
type
screen
test
determin
shorter
turnaround
time
sampl
run
shorter
turnaround
time
larger
concurr
run
turnaround
time
reduc
minut
reduct
increas
run
size
becam
larger
abl
provid
aborh
result
minut
faster
sampl
initi
test
antibodi
screen
posit
galileo
sampl
repeat
neg
echo
sampl
repeat
neg
overal
antibodi
posit
rate
found
antibodi
posit
rate
found
echo
conclus
complet
instrument
assess
determin
immucor
echo
immucor
would
accept
instrument
altern
exist
instrument
factor
lead
conclus
includ
reduct
turnaround
time
type
screen
aborh
test
eas
use
echo
staff
reduct
antibodi
posit
rate
echo
instrument
reduct
could
lead
decreas
manual
test
requir
abil
use
autom
antibodi
panel
test
complet
complex
workup
without
neg
affect
workflow
creat
unnecessari
reagent
util
backgroundcas
studi
cord
blood
unit
cbu
must
test
hemoglobinopathi
prior
releas
allogen
transplant
test
previous
outsourc
lab
use
isoelectr
focus
ief
test
use
capillari
electrophoresi
ce
evalu
compar
studi
designmethod
sebia
capillari
ii
flex
pierc
instrument
use
phoresi
softwar
evalu
accuraci
precis
instrument
eight
capillari
capabl
run
eight
sampl
simultan
accuraci
examin
test
sebia
qualiti
control
sampl
multipl
time
compar
result
packag
insert
expect
result
precis
evalu
run
hemoglobin
hb
f
control
time
singl
run
rack
sampl
precis
evalu
run
one
normal
two
abnorm
cbu
sampl
multipl
day
use
eight
capillari
parallel
test
extern
lab
new
instrument
conduct
determin
correl
method
resultsfind
accuraci
result
within
rang
manufactur
specif
hb
afsc
normal
patholog
af
control
precis
data
tabl
use
refer
lab
result
includ
percentag
bart
hb
total
process
unit
histor
exclud
clinic
use
due
abnorm
hb
result
phoresi
softwar
determin
percent
bart
hb
present
allow
medic
director
determin
clinic
signific
hemoglobinopathi
potenti
approv
cbu
clinic
use
would
formerli
otherwis
discard
first
month
employ
ce
cbu
save
exclus
due
hemoglobinopathi
conclus
evalu
ce
instrument
met
exceed
requir
turn
around
time
shorten
approxim
week
cost
compar
ief
ce
sensit
previou
method
help
save
potenti
lifesav
unit
reason
ce
method
chosen
replac
refer
lab
backgroundcas
studi
blood
product
intend
inventori
must
maintain
temperatur
defin
feder
regul
evalu
thermomet
lincolnshir
il
possibl
enhanc
exist
blood
product
return
process
similar
scale
appear
take
temperatur
blood
product
read
outsid
bag
sit
devic
temperatur
report
integ
unsur
measur
outsid
bag
would
compar
gold
standard
use
previou
temperatur
valid
temperatur
probe
insert
center
unit
accord
manufactur
materi
sold
calibr
certif
state
accur
within
one
degre
celsiu
error
rang
standard
deviat
confid
interv
provid
latter
particular
concern
establish
product
return
accept
studi
designmethod
two
rbc
two
plasma
unit
remov
refriger
allow
warm
toward
room
temperatur
multipl
pair
temperatur
read
perform
devic
establish
gold
standard
institut
logtag
record
logtag
record
auckland
new
zealand
total
sixti
pair
read
taken
total
data
point
use
linear
regress
softwar
packag
r
r
foundat
statist
comput
found
mean
measur
error
variabl
independ
true
temperatur
error
approxim
normal
distribut
around
true
temperatur
inform
establish
possibl
estim
rang
possibl
true
temperatur
normal
distribut
mean
equal
observ
temperatur
minu
expect
error
standard
deviat
sd
equal
measur
error
sd
resultsfind
estim
measur
error
mean
sd
rel
true
temperatur
thu
detect
downward
bia
within
manufactur
state
accuraci
rang
observ
distribut
calcul
probabl
gold
standard
true
temperatur
given
read
see
tabl
conclus
probabl
read
actual
less
cutoff
unaccept
institut
chose
read
reason
certain
indic
unit
true
temperatur
less
conclus
advertis
accuraci
devic
found
true
averag
error
around
read
upper
limit
need
establish
order
reason
confid
unit
accept
return
inventori
backgroundcas
studi
goal
set
transfus
servic
ts
stat
type
screen
ta
order
emerg
depart
ed
labor
deliveri
l
complet
within
minut
sampl
order
receipt
sampl
posit
antibodi
screen
consid
outlier
includ
tat
tat
monitor
data
often
requir
design
special
clinic
area
trauma
neonat
intens
care
studi
designmethod
ts
collect
data
begin
data
collect
includ
date
time
receipt
complet
test
issu
blood
product
comput
system
data
show
combin
ed
l
goal
met
bare
met
met
note
increas
ta
volum
instrument
use
ortho
provu
could
handl
volum
test
stat
priorit
capabl
new
instrument
approv
purchas
end
ortho
vision
max
receiv
valid
put
use
ortho
vision
instrument
also
approv
purchas
valid
put
use
resultsfind
first
quarter
end
accept
tat
see
tabl
monthli
data
show
steadi
improv
sinc
new
instrument
implement
decreas
number
ta
receiv
actual
increas
number
ta
quarter
compar
quarter
conclus
sever
thing
contribut
failur
meet
minut
tat
provu
could
handl
volum
test
provu
true
stat
capabl
ta
test
time
minut
test
volum
continu
increas
evalu
data
enabl
new
instrument
purchas
faster
reliabl
ta
test
complet
minut
vision
vision
max
stat
priorit
capabl
addit
improv
tat
also
huge
decreas
amount
reagent
use
three
month
implement
instrument
monthli
stand
order
reagent
red
cell
abl
cut
cost
save
backgroundcas
studi
million
donor
apheresi
platelet
unit
transfus
yearli
unit
state
cost
billion
unit
shelf
life
five
day
deriv
exclus
volunt
donor
combin
factor
result
platelet
shortag
vitro
manufactur
platelet
overcom
issu
suppli
provid
readi
sourc
independ
avail
donor
bioreactor
system
design
recreat
key
vivo
characterist
nativ
hematopoiet
stem
cell
hsc
nich
modifi
cellular
environ
cgmp
grade
reagent
procedur
util
throughout
entir
process
eventu
clinic
grade
manufactur
mind
studi
designmethod
bioreactor
system
consist
peristalt
pump
cell
cultur
bioreactor
fresh
media
reservoir
wast
media
contain
platelet
collect
vessel
tube
strateg
placement
valv
connect
compon
creat
system
compon
exclud
pump
design
dispos
move
process
toward
cgmp
bioreactor
consist
unit
separ
porou
membran
capabl
allow
cellular
product
move
chamber
cord
blood
mononuclear
hsc
seed
bioreactor
differenti
matur
megakaryocyt
mk
media
platelet
particl
harvest
matur
mk
extend
proplatelet
proplt
porou
membran
increas
shear
rate
chamber
resultsfind
shear
flow
play
import
role
system
increas
percentag
mk
form
proplt
acceler
rate
proplt
extens
physiolog
relev
mechanostimulatori
interstiti
fluid
flow
bone
marrow
sinusoid
shear
stress
pa
gener
within
respect
chamber
bioreactor
via
programm
peristalt
pump
capabl
pulsatil
continu
flow
within
bioreactor
chamber
hsc
differenti
matur
mk
rate
n
extend
proplt
respons
flow
platelet
shed
respons
shear
forc
analyz
flow
cytometri
use
hematolog
analyz
matur
mk
count
analyz
flow
cytometri
mk
assess
count
cell
seed
plate
conclus
use
novel
bioreactor
system
design
recapitul
bone
marrow
microenviron
physiolog
relev
shear
forc
improv
mk
differenti
platelet
product
vitro
deriv
mk
repres
signific
step
road
produc
transfus
platelet
unit
backgroundcas
studi
despit
recent
advanc
biostabil
clinic
blood
suppli
still
experi
shortag
storag
limit
red
blood
cell
rbc
yet
suffici
address
promis
new
avenu
cell
stabil
includ
biomimet
approach
base
intracellular
condit
found
anim
abil
maintain
viabl
cell
tissu
frozen
desicc
state
cryptobiosi
approach
address
storag
limit
lyophil
human
rbc
powder
could
theoret
store
sever
year
rehydr
need
transfus
process
involv
sugar
trehalos
compound
cytoprotect
properti
cryptobiot
anim
howev
trehalos
imperm
mammalian
cell
hamper
progress
use
promis
biomolecul
rbc
preserv
approach
util
sonopor
sugar
load
rbc
sonopor
process
transient
pore
induc
cell
membran
oscil
ga
microbubbl
object
studi
verifi
efficaci
trehalos
load
stabil
function
preserv
blood
unit
studi
designmethod
human
red
blood
cell
obtain
inform
consent
donor
rbc
resuspend
dilut
load
buffer
contain
trehalos
immedi
prior
treatment
microbubbl
ad
sampl
ultrasound
puls
appli
use
ultrasound
imag
system
trehalos
uptak
rbc
confirm
enzymat
rbc
cool
rate
follow
dri
rbc
store
ambient
temperatur
resuspend
deioniz
water
cell
recoveri
measur
use
autom
cell
count
cell
viabil
assess
stain
resultsfind
trehalos
load
minim
toxic
rbc
recov
treatment
rbc
show
recoveri
viabil
storag
wherea
significantli
reduc
recoveri
observ
without
treatment
n
p
recoveri
lyophil
rbc
rehydr
cell
viabil
cell
popul
n
without
trehalos
load
viabl
rbc
recov
rehydr
conclus
result
demonstr
sonopor
enhanc
deliveri
trehalos
rbc
dramat
increas
recoveri
intact
rbc
follow
freezingthaw
dryingrehydr
although
test
need
evalu
rbc
function
vivo
dri
preserv
approach
offer
signific
potenti
help
stabil
clinic
blood
suppli
increas
access
blood
transfus
futur
backgroundcas
studi
cold
store
platelet
concentr
pc
receiv
renew
attent
therapeut
product
treat
sever
hemorrhag
due
superior
hemostat
effect
fewer
inflammatori
mediat
compar
room
temperatur
rt
store
pc
blood
bank
perspect
clinic
use
cold
store
pc
develop
would
requir
product
manag
dual
inventori
rt
store
pc
cold
store
pc
recent
studi
wood
et
al
explor
opportun
transform
rt
store
pc
cold
store
pc
day
rt
storag
analyz
impact
rt
storag
time
prior
move
cold
storag
platelet
plt
qualiti
extend
storag
time
studi
designmethod
aliquot
plasma
suspend
pc
store
small
prepar
bag
mimic
storag
featur
common
plt
bag
six
bag
fill
day
product
five
place
storag
continu
agit
per
current
practic
one
place
storag
without
agit
follow
five
day
one
rt
store
bag
move
cold
storag
aliquot
analyz
metabol
activ
ph
glucos
lactat
plt
activ
respons
adp
bind
exposur
bind
supernat
microvesicl
count
stain
clot
format
evalu
use
rotat
thromboelastometri
rotem
resultsfind
increas
delay
transfer
storag
ph
drop
trend
mirror
increas
glucos
consumpt
increas
lactat
product
plt
activ
chang
first
three
cold
storag
delay
time
thereaft
increas
plt
effect
also
reflect
alter
respons
adp
decreas
high
two
shortest
cold
storag
delay
time
almost
respons
longer
delay
time
bind
increas
releas
microvesicl
increas
two
shortest
cold
storag
delay
time
longer
delay
time
increas
cold
storag
delay
result
increas
clot
time
second
measur
rotem
profil
howev
chang
clot
firm
detect
indic
similar
alpha
valu
aliquot
conclus
plt
qualiti
day
storag
deterior
increas
time
pc
held
rt
move
cold
storag
studi
suggest
may
possibl
produc
cold
store
pc
inventori
suffici
qualiti
transfer
rt
store
pc
cold
storag
prior
expiri
studi
requir
verifi
result
backgroundcas
studi
autom
cryopreserv
platelet
product
procedur
develop
implement
transfus
medicin
depart
cryobank
moscow
sklifosovski
research
institut
emerg
medicin
patent
ru
ru
ru
autom
techniqu
implement
vladimir
region
blood
bank
tyumen
region
blood
bank
purpos
compar
qualiti
clinic
effect
cpc
produc
sever
blood
bank
studi
designmethod
apheresi
platelet
concentr
pc
collect
trima
accel
system
blood
bank
platelet
cryopreserv
close
system
patent
ru
autom
techniqu
patent
ru
combin
cryoprotect
use
pc
cryopreserv
defrost
platelet
also
process
close
system
patent
ru
defrost
pc
store
continu
gentl
stir
longer
hour
transfus
patient
given
therapeut
cpc
transfus
correct
thrombocytopenia
control
acut
bleed
cpc
transfus
effect
clinic
evid
control
hemorrhag
posttransfus
correct
count
increment
platelet
cci
respect
resultsfind
pc
frozen
cryobank
moscow
sklifosovski
research
institut
emerg
medicin
cpc
dose
store
yet
therapeut
dose
thaw
transfus
patient
pc
frozen
vladimir
region
blood
bank
februari
april
cpc
dose
thaw
transfus
patient
pc
frozen
tyumen
region
blood
bank
august
april
cpc
dose
thaw
transfus
patient
recoveri
platelet
origin
popul
blood
bank
defrost
cpc
show
platelet
cellsdos
moscow
sklifosovski
institut
emerg
medicin
cellsdos
vladimir
region
blood
bank
cellsdos
tyumen
region
blood
bank
surgic
surgeri
patient
neurosurg
patient
patient
organ
transplant
moscow
sklifosovski
institut
emerg
medicin
oncolog
haematolog
patient
neurosurg
patient
surgic
patient
vladimir
region
blood
bank
haematolog
patient
surgic
patient
surgeri
patient
tyumen
region
blood
bank
receiv
therapeut
cpc
transfus
hemorrhag
stop
subject
given
cpc
transfus
complic
seen
medic
center
posttransfus
cci
respect
moscow
sklifosovski
institut
emerg
medicin
respect
vladimir
region
blood
bank
posttransfus
cci
tyumen
region
blood
bank
cci
high
h
would
suggest
donor
platelet
still
circul
recipi
blood
within
hour
complet
transfus
conclus
cpc
demonstr
highli
effect
blood
bank
mark
clinic
effect
due
high
perform
cpc
backgroundcas
studi
previous
pathway
volum
reduc
sourc
antibodi
interest
use
expens
andor
labori
tradit
method
eg
ultrafiltr
membran
dialysi
fraction
precipit
mani
antibodi
specif
avail
commerci
must
obtain
plasma
donor
patient
sourc
found
typic
contain
addit
antibodi
sinc
routin
screen
detect
antibodi
low
preval
antigen
antisera
ideal
remov
antibodi
includ
isoagglutinin
larger
volum
sourc
materi
harder
manipul
may
requir
multipl
freez
thaw
cycl
obtain
aliquot
could
affect
product
stabil
requir
storag
space
method
sought
volum
reduc
sourc
materi
addit
antibodi
could
easili
remov
studi
designmethod
plastic
separ
devic
made
printer
creat
two
compart
insert
ml
tube
allow
ml
caviti
tube
base
sourc
materi
ad
tube
immedi
invert
frozen
min
hour
creat
ice
column
ic
cap
separ
devic
tube
remov
freezer
immedi
centrifug
swing
bucket
rotor
minut
separ
devic
prevent
ic
enter
tube
base
yet
allow
solut
separ
ic
flow
tube
base
ic
decant
concentr
solut
cs
extract
separ
devic
insert
syring
blunt
needl
total
protein
measur
via
bradford
assay
resultsfind
sampl
test
ic
mean
mass
initi
plasma
mass
yet
contain
mean
total
protein
tabl
cs
mean
mass
initi
plasma
mass
recov
mean
total
protein
conclus
describ
new
method
ice
use
reduc
mass
sourc
materi
concentr
protein
backgroundcas
studi
coagulopathi
trauma
result
increas
mortal
sinc
death
caus
condit
occur
within
first
hour
rapid
detect
aggress
correct
significantli
improv
patient
outcom
fibrinogen
play
crucial
role
vulner
coagul
factor
hemorrhag
reach
critic
low
level
earlier
factor
fibrinogen
deficit
strong
predictor
tic
independ
predictor
mortal
fibrinogen
replac
improv
surviv
howev
blanket
administr
feasibl
due
potenti
complic
high
cost
limit
suppli
cryoprecipit
fibrinogen
concentr
result
prompt
measur
replac
fibrinogen
part
current
european
guidelin
manag
hemorrhag
coagulopathi
increasingli
advoc
us
unfortun
rapid
poc
test
current
exist
fibrinogen
standard
clauss
method
typic
slow
turnaround
time
min
miss
golden
hour
current
fibrinogen
test
suffici
simpl
rapid
robust
perform
prehospit
set
studi
designmethod
address
need
develop
first
poc
fibrinogen
sensor
sensor
exploit
novel
aptam
fibrinogen
microfluid
electrochem
architectur
analog
glucos
test
strip
aptam
poc
given
chemic
thermal
stabil
eas
synthesi
high
consist
aptam
probe
enabl
reagentless
detect
greatli
reduc
assay
time
complex
sensor
electrod
function
aptam
bind
yield
chang
redox
current
correspond
concentr
sensor
character
buffer
plasma
whole
blood
sampl
use
fibrinogen
standard
demonstr
proof
concept
resultsfind
novel
fibrinogen
aptam
exhibit
kd
nm
minim
cross
reactiv
protein
includ
fibrinogen
degrad
product
prototyp
sensor
quantit
fibrinogen
accur
rapidli
across
clinic
rang
mgml
lod
mgml
cv
min
develop
handheld
reader
integr
smartphon
portabl
potentiostat
interrog
sensor
data
display
analyz
smartphon
via
custom
app
conclus
demonstr
prototyp
sensor
enabl
measur
fibrinogen
directli
plasma
whole
blood
min
outcom
support
product
develop
success
sensor
could
ultim
deploy
ambul
ed
periop
environ
improv
patient
outcom
backgroundcas
studi
abo
blood
group
system
cognat
antibodi
foundat
transfus
transplant
medicin
serolog
test
method
remain
essenti
unchang
year
reli
visual
interpret
agglutin
increas
rate
abo
incompat
aboi
hematopoiet
stem
cell
hsct
solid
organ
transplant
new
test
modal
necessari
aboi
hsct
patient
requir
extens
monitor
morbid
includ
graft
reject
passeng
lymphocyt
syndrom
pl
aim
develop
novel
serolog
test
antibodi
use
set
aboi
transplant
studi
designmethod
biolay
interferometri
bli
optic
assay
measur
interfer
pattern
light
reflect
two
surfac
develop
assay
measur
abo
antibodi
human
plasma
sampl
determin
lower
limit
detect
serial
dilut
monoclon
antibodi
ab
plasma
valid
assay
volunt
blood
donor
plasma
sampl
lastli
assay
plasma
sampl
patient
undergo
aboi
hsct
resultsfind
serial
dilut
monoclon
antibodi
ab
plasma
determin
lower
limit
detect
ngul
peak
absorb
valu
posit
strongli
correl
antibodi
concentr
valid
bli
blood
donor
abo
blood
group
show
vari
level
antibodi
bind
among
differ
individu
highest
level
group
donor
lastli
acquir
longitudin
sampl
hsct
patient
abo
compat
aboi
identifi
three
aboi
minor
mismatch
donor
patient
hsct
patient
one
patient
show
clinic
evid
pl
day
increas
titer
bli
detect
rise
antibodi
patient
day
one
day
clinic
laboratori
evid
hemolysi
two
aboi
hsct
patient
demonstr
plshemolysi
although
patient
posit
dat
bli
neg
antibodi
indic
bli
specif
clinic
signific
hemolysi
conclus
increas
aboi
transplant
innov
method
detect
clinic
relev
abo
antibodi
high
sensit
specif
critic
demonstr
bli
offer
technolog
platform
capabl
sensit
detect
clinic
relev
antibodi
furthermor
bli
expand
use
detect
interact
limit
abo
blood
group
system
potenti
detect
clinic
relev
antibodi
help
direct
appropri
clinic
care
earlier
accomplish
current
test
modal
backgroundcas
studi
alloimmun
one
main
side
effect
blood
transfus
could
sever
complic
red
blood
cell
transfus
especi
patient
diseas
requir
multipl
transfus
convent
blood
group
phenotyp
hemagglutin
assay
carri
unsuit
certain
clinic
situat
molecular
type
offer
altern
method
allow
deduct
blood
group
phenotyp
genotyp
howev
current
method
requir
long
turnaround
time
perform
limit
applic
emerg
situat
rapid
decis
need
test
perform
near
advantag
studi
designmethod
work
report
develop
novel
rapid
multiplex
molecular
method
visual
identif
seven
allel
three
clinic
relev
blood
group
system
fy
fy
fy
gypb
gypb
jk
jk
assay
design
carri
unitari
test
specif
clinic
situat
test
patient
serolog
method
fail
emerg
situat
test
use
later
flow
biosensor
handl
dna
procedur
includ
multiplex
late
amplif
perform
directli
whole
blood
amplicon
migrat
nucleic
acid
dipstick
gold
nanoparticl
use
report
permit
detect
blood
group
snp
gener
red
dot
visibl
nake
eye
assay
paramet
optim
test
valid
blood
donor
sampl
known
phenotyp
resultsfind
optim
assay
includ
multiplex
paramet
primer
concentr
cycl
number
later
flow
paramet
migrationhybrid
temperatur
buffer
composit
final
protocol
enabl
determin
deduc
phenotyp
total
process
time
one
hour
receiv
blood
sampl
valid
show
concord
rate
deduc
phenotyp
standard
serolog
phenotyp
allel
investig
conclus
technolog
protect
patent
allow
accur
determin
deduc
phenotyp
antigen
owe
simpl
handl
assay
oper
profession
propos
assay
offer
potenti
develop
relev
snp
panel
immunohematolog
new
applic
test
infecti
diseas
near
futur
backgroundcas
studi
decemb
fda
approv
use
psoralen
treat
platelet
prepar
blood
system
march
fda
issu
revis
draft
guidanc
bacteri
risk
control
platelet
four
day
old
local
blood
supplier
initi
manufactur
distribut
psoralen
treat
platelet
march
transfus
servic
bed
commun
hospit
system
immedi
initi
util
psoralen
treat
platelet
begin
march
transfus
servic
maintain
dual
inventori
psoralen
treat
pa
platelet
addit
solut
treat
plateletpheresi
product
clinician
provid
option
electron
order
psoralen
treat
product
transfus
rather
order
fulfil
platelet
manag
exclus
transfus
servic
laboratori
staff
base
primarili
product
expir
date
patient
blood
type
compat
studi
designmethod
retrospect
analysi
conduct
compar
incid
transfus
reaction
involv
platelet
versu
transfus
reaction
involv
treat
platelet
march
februari
resultsfind
two
year
studi
period
total
transfus
perform
across
system
patient
includ
exactli
plateletpheresi
transfus
total
plateletpheresi
transfus
period
psoralen
treat
plateletpheresi
product
treat
plateletpheresi
product
studi
period
total
transfus
reaction
associ
psoralen
treat
platelet
transfus
result
incid
rate
studi
period
total
transfus
reaction
associ
treat
platelet
transfus
result
incid
rate
conclus
psoralen
treat
platelet
success
introduc
bed
commun
hospit
system
march
subsequ
two
year
psoralen
treat
treat
platelet
util
rate
rel
equival
clinic
signific
differ
p
incid
transfus
reaction
psoralen
treat
versu
treat
platelet
product
patient
experienc
sever
transfus
reaction
platelet
product
report
bacteri
contamin
associ
platelet
transfus
entir
evalu
period
thu
introduct
psoralen
treat
platelet
within
hospit
system
impact
overal
incid
transfus
reaction
platelet
backgroundcas
studi
trima
accel
system
apheresi
devic
use
continu
flow
centrifug
take
blood
donor
separ
transfus
compon
red
blood
cell
platelet
plasma
blood
compon
collect
return
donor
trima
accel
design
meet
need
blood
center
global
stage
purpos
studi
evalu
yield
leukoreduct
perform
trima
accel
platelet
store
platelet
addit
solut
pa
plasma
studi
designmethod
prospect
open
label
multicent
control
studi
evalu
yield
leukoreduct
platelet
collect
trima
accel
terumo
bct
lakewood
co
store
freseniu
kabi
bad
homburg
germani
plasma
healthi
adult
volunt
donor
consent
donat
either
singl
doubl
tripl
platelet
product
trima
accel
donat
system
conduct
immedi
addit
intersol
solut
product
store
per
standard
blood
bank
condit
day
collect
platelet
product
assess
residu
white
blood
cell
wbc
content
final
platelet
yield
resultsfind
two
hundr
particip
donat
evalu
singl
doubl
tripl
platelet
product
mean
sd
residu
wbc
count
singl
doubl
tripl
platelet
product
respect
breakdown
platelet
product
show
singl
platelet
unit
wbc
count
less
million
doubl
platelet
unit
wbc
content
lower
million
tripl
platelet
unit
wbc
content
lower
million
determin
confid
singl
doubl
tripl
platelet
product
accept
residu
wbc
level
therefor
meet
unit
state
fda
accept
criteria
singl
doubl
tripl
platelet
product
mean
sd
platelet
yield
respect
singl
platelet
product
platelet
yield
none
doubl
tripl
platelet
product
platelet
yield
respect
conclus
singl
doubl
tripl
platelet
product
collect
trima
accel
store
pa
met
accept
criteria
residu
wbc
level
platelet
yield
backgroundcas
studi
despit
introduct
leukodeplet
blood
compon
shown
donor
leukocyt
engraft
microchimer
tam
remain
consequ
red
blood
cell
rbc
transfus
patient
group
mechan
donor
leukocyt
surviv
follow
blood
transfus
unclear
specul
genet
factor
may
one
possibl
reason
studi
conduct
determin
whether
associ
individu
genet
profil
establish
tam
blood
transfus
recipi
studi
designmethod
australian
trauma
patient
n
transfus
rbc
unit
injuri
sever
score
greater
recruit
twelv
patient
found
tam
date
whole
exom
sequenc
conduct
four
patient
tam
four
patient
without
tam
align
exom
data
human
genom
refer
sequenc
assembl
conduct
analysi
differenti
genet
variat
carri
variat
uniqu
least
patient
group
investig
primari
focu
gene
associ
immun
regul
resultsfind
preliminari
analysi
perform
mani
chang
found
four
patient
tam
present
highli
heterogen
gene
includ
zinc
finger
protein
gene
human
leukocyt
antigen
gene
interest
chang
found
gene
unknown
function
variant
addit
chang
found
follow
gene
gene
variant
id
role
regul
prolifer
gene
chr
variant
id
chemokin
contribut
tumor
associ
leukocyt
remov
conclus
next
gener
whole
exom
sequenc
technolog
allow
explor
genet
variat
across
differ
popul
group
provid
clue
potenti
indic
mechan
tam
may
establish
certain
patient
preliminari
analysi
provid
potenti
genet
chang
could
involv
gene
role
regul
prolifer
expect
analysi
expand
patient
number
allow
genom
data
explor
detail
australian
govern
fund
australian
red
cross
blood
servic
provid
blood
blood
product
servic
australian
commun
backgroundcas
studi
apheresi
platelet
store
either
plasma
portion
plasma
replac
platelet
addit
solut
pa
platelet
store
pa
may
reduc
risk
sever
advers
transfus
reaction
allerg
reaction
immun
reaction
trigger
cellular
mediat
plasma
potenti
acut
lung
injuri
trali
object
studi
quantifi
vivo
radiolabel
recoveri
surviv
apheresi
platelet
collect
trima
accel
system
terumo
bct
lakewood
co
store
day
solut
freseniu
kabi
bad
homburg
germani
studi
designmethod
prospect
multicent
studi
involv
healthi
adult
particip
donat
singl
hyperconcentr
platelet
product
trima
accel
system
product
dilut
pa
immedi
collect
via
autopa
meter
attain
plasma
carryov
intersol
store
day
standard
condit
day
whole
blood
wb
drawn
prepar
fresh
control
platelet
test
control
platelet
label
either
randomli
assign
particip
simultan
infus
autolog
radiolabel
platelet
per
biomed
excel
safer
transfus
best
method
venou
wb
sampl
collect
day
infus
follow
day
recoveri
surviv
test
control
platelet
calcul
use
multipl
hit
model
cost
softwar
resultsfind
evalu
data
point
includ
analysi
day
evalu
test
product
platelet
concentr
platelet
yield
evalu
test
product
neg
bacteri
test
test
per
site
standard
practic
confirm
day
day
product
ph
shown
tabl
recoveri
test
platelet
greater
control
surviv
greater
control
confid
limit
conclus
hyperconcentr
platelet
collect
trima
accel
system
store
intersol
day
met
unit
state
fda
accept
criteria
platelet
recoveri
surviv
compar
fresh
control
backgroundcas
studi
fresh
whole
blood
fwb
often
use
militari
medic
limit
access
blood
compon
disadvantag
fwb
current
polici
us
mani
countri
call
specif
sinc
contain
rbc
plasma
significantli
constrain
pool
elig
donor
similarli
plasma
type
ab
donor
key
resourc
trauma
resuscit
requir
specif
howev
donor
pool
limit
remov
antibodi
would
significantli
increas
suppli
univers
plasma
match
fwb
walk
donor
thu
greatli
simplifi
transfus
logist
object
research
program
develop
filter
specif
remov
b
antibodi
fwb
plasma
sourc
studi
designmethod
human
whole
blood
plasma
unit
collect
cpd
obtain
region
blood
donor
center
human
whole
blood
assess
within
day
collect
plasma
obtain
frozen
thaw
prior
use
whole
blood
plasma
pass
porou
polym
bead
contain
novel
modif
design
remov
blood
group
antibodi
plasmablood
polym
ratio
sampl
collect
pre
analyz
remov
blood
group
antibodi
blood
type
reagent
red
cell
standard
agglutin
assay
ortho
clinic
effect
coagul
hemostat
activ
measur
aptt
pt
assay
stat
coagul
analyz
diagnostica
stago
teg
analyz
haemonet
inc
respect
complet
blood
cell
count
cbc
measur
hemavet
hematolog
analyz
drew
scientif
antibodi
remov
effici
calcul
lowest
dilut
agglutin
reagent
red
cell
start
donor
titer
rang
resultsfind
treatment
plasma
function
b
polym
reduc
antibodi
titer
mean
sd
respect
control
polym
display
titer
reduct
antibodi
respect
treatment
whole
blood
function
b
polym
reduc
antibodi
titer
respect
control
polym
display
titer
reduct
antibodi
respect
conclus
data
indic
surfac
modif
significantli
select
remov
antibodi
fwb
plasma
research
develop
filter
warrant
backgroundcas
studi
platelet
concentr
pc
store
plastic
bag
constant
agit
condit
result
progress
declin
platelet
qualiti
due
ongo
metabol
activ
platelet
activ
current
platelet
storag
bag
compos
either
polyvinylchlorid
pvc
polyolefin
optimis
provid
adequ
howev
platelet
adher
surfac
may
promot
platelet
activ
new
materi
coat
support
platelet
respir
whilst
prevent
platelet
adhes
activ
may
enabl
platelet
storag
beyond
day
studi
examin
impact
store
platelet
pvc
bag
coat
recombin
serglycin
intracellular
proteoglycan
express
hematopoiet
endotheli
cell
human
serum
albumin
molecul
chosen
properti
differenti
glycosyl
profil
studi
designmethod
deriv
platelet
ssp
split
pvc
platelet
storag
bag
macopharma
either
uncoat
coat
serglycin
albumin
albumex
solut
serglycin
recombinantli
express
cell
purifi
condit
medium
via
anion
exchang
chromatographi
platelet
concentr
store
day
agit
platelet
metabol
activ
function
test
day
use
vitro
assay
resultsfind
platelet
concentr
ph
glucos
lactat
valu
similar
group
storag
express
platelet
glycoprotein
gpiib
gpiiia
unaffect
bag
coat
activ
profil
platelet
store
coat
uncoat
bag
similar
determin
bind
platelet
function
assess
viscoelast
test
teg
compar
group
storag
microscop
examin
inner
plastic
surfac
bag
day
demonstr
significantli
reduc
platelet
adhes
serglycin
albumin
coat
bag
compar
uncoat
pvc
bag
whilst
morpholog
adher
platelet
similar
conclus
storag
platelet
pvc
bag
coat
serglycin
albumin
support
platelet
metabol
advers
affect
platelet
phenotyp
function
extend
period
day
although
protein
test
reduc
platelet
activ
initi
find
provid
develop
next
gener
platelet
storag
bag
biomimet
focu
backgroundcas
studi
apheresi
platelet
store
either
plasma
portion
plasma
replac
platelet
addit
solut
pa
common
practic
europ
platelet
store
pa
may
reduc
risk
sever
advers
transfus
reaction
allerg
reaction
immun
reaction
trigger
cellular
mediat
plasma
potenti
acut
lung
injuri
trali
addit
pa
allow
plasma
use
applic
object
studi
demonstr
vitro
qualiti
platelet
collect
trima
accel
system
terumo
bct
lakewood
co
store
day
solut
freseniu
kabi
bad
homburg
germani
studi
designmethod
prospect
pair
open
label
multicent
studi
particip
donat
separ
platelet
product
test
control
trima
accel
system
test
product
singl
hyperconcentr
platelet
product
dilut
pa
immedi
collect
via
autopa
meter
attain
plasma
carryov
intersol
wherea
control
product
singl
standard
platelet
product
collect
plasma
test
control
product
test
day
day
day
ph
surfac
express
platelet
activ
extent
shape
chang
esc
hypoton
shock
respons
hsr
morpholog
score
resultsfind
sixti
evalu
pair
platelet
product
collect
test
site
test
product
day
day
assur
product
ph
confid
confid
limit
test
product
control
morpholog
score
day
storag
tabl
differ
test
control
confid
interv
expect
base
previou
find
diedrich
et
al
vassallo
et
al
test
platelet
esc
hsr
score
decreas
express
increas
compar
control
conclus
vitro
data
demonstr
platelet
collect
trima
accel
system
store
intersol
day
accept
vitro
platelet
qualiti
backgroundcas
studi
blood
center
nation
institut
neoplast
diseas
upgrad
trima
accel
softwar
support
demand
platelet
transfus
autoflow
new
featur
trima
accel
intend
reduc
access
relat
alert
make
autom
adjust
flow
rate
base
access
flow
system
pressur
issu
detect
trima
accel
devic
trima
accel
use
accessori
pressur
cuff
design
encourag
donor
squeez
ensur
pressur
mmhg
donor
vein
combin
autoflow
minim
oper
intervent
improv
donor
experi
studi
designmethod
retrospect
studi
consist
donat
novemb
februari
trima
accel
control
compar
donat
februari
april
trima
accel
test
trima
accel
procedur
data
captur
use
cadenc
system
terumo
bct
lakewood
co
venou
access
alert
donor
inform
analyz
test
control
group
measur
differ
resultsfind
statist
signific
differ
averag
number
access
alert
measur
trima
accel
trima
accel
averag
number
access
alert
drop
per
procedur
control
period
wherea
test
period
averag
number
access
alert
per
procedur
p
valu
twice
mani
donat
complet
success
without
access
relat
alert
compar
test
period
softwar
control
period
softwar
p
valu
donat
greater
alert
singl
donat
trima
period
compar
control
period
frequent
access
alert
singl
donat
p
valu
donat
access
relat
alert
per
procedur
decreas
control
period
test
access
relat
alert
per
procedur
decreas
control
period
test
test
control
group
compar
total
blood
volum
versu
platelet
count
versu
conclus
trima
accel
reduc
number
access
relat
oper
alert
per
donat
reduc
oper
intervent
enabl
staff
spend
time
donor
complet
addit
duti
donor
room
floor
backgroundcas
studi
prophylact
platelet
concentr
pc
transfus
first
line
therapi
patient
hemorrhag
syndrom
puriti
function
transfus
pc
cornerston
effici
treatment
obtain
pc
whole
blood
sampl
blood
bank
current
use
hard
spin
centrifug
method
lead
poor
rest
platelet
yield
prolong
storag
also
issu
blood
bank
platelet
storag
lesion
order
improv
platelet
qualiti
preserv
therapeut
aim
develop
fraction
devic
isol
human
platelet
whole
blood
bag
alreadi
shown
acoust
platelet
separ
effici
method
fraction
blood
low
shear
stress
environ
puriti
yield
lead
minim
platelet
activ
preserv
platelet
respons
agonist
function
aim
studi
impact
acoust
fraction
platelet
storag
compar
qualiti
platelet
rich
plasma
prp
produc
acoustophoresi
soft
spin
centrifug
studi
designmethod
prp
obtain
soft
spin
centrifug
acoust
fraction
store
day
constant
agit
platelet
analyz
rest
condit
stimul
common
platelet
agonist
use
flow
cytometri
monitor
express
activ
marker
annexin
v
phosphatidylserin
check
morpholog
metabol
characterist
platelet
day
storag
resultsfind
prp
obtain
soft
spin
acoust
fraction
show
compar
storag
respons
surfac
express
phosphatidylserin
increas
upon
storag
type
prp
differ
surfac
level
platelet
activ
marker
two
type
prp
interestingli
platelet
prepar
acoustophoresi
retain
slightli
increas
respons
collagen
storag
compar
platelet
prepar
soft
spin
centrifug
metabolit
concentr
increas
platelet
storag
prp
ph
simultan
decreas
compar
variou
public
metabol
chang
within
standard
therapeut
transfus
conclus
preliminari
result
show
compar
platelet
age
prp
prepar
soft
spin
acoust
fraction
data
suggest
side
effect
platelet
storag
acoust
fraction
platelet
storag
lesion
result
metabol
activ
platelet
shown
revers
upon
transfus
qualiti
function
platelet
obtain
acoust
fraction
appear
match
blood
bank
standard
therapeut
transfus
plan
larger
trial
collabor
ef
french
blood
bank
confirm
result
valid
devic
backgroundcas
studi
respons
platelet
transfus
vari
depend
patient
product
specif
factor
platelet
microparticl
pmp
may
play
role
efficaci
platelet
transfus
pmp
deriv
platelet
bleb
respons
stressor
hypothes
reflect
platelet
activ
activ
platelet
may
remov
circul
rapidli
lead
increas
platelet
transfus
observ
studi
investig
hypothesi
select
transfus
unit
low
pmp
content
hematologyoncolog
hemeonc
inpati
would
result
decreas
platelet
usag
studi
designmethod
baselin
platelet
transfus
per
patient
per
month
ppm
determin
period
hospit
hemeonc
patient
studi
period
platelet
unit
test
pmp
content
thrombolux
dynam
light
scatter
measur
lightintegra
technolog
vancouv
bc
canada
unit
less
pmp
content
label
low
pmp
per
manufactur
recommend
hemeonc
inpati
receiv
platelet
unit
low
pmp
ppm
calcul
three
month
follow
studi
period
platelet
unit
issu
without
measur
select
pmp
ppm
calcul
individu
patient
characterist
respons
platelet
transfus
captur
resultsfind
ppm
averag
hemeonc
inpati
baselin
studi
period
report
tabl
conclus
averag
ppm
hemeonc
inpati
lowest
studi
period
select
transfus
platelet
low
pmp
content
observ
differ
ppm
studi
period
baselin
period
statist
signific
studi
limit
use
averag
ppm
overal
assess
platelet
usag
may
account
patient
factor
known
contribut
platelet
transfus
requir
futur
studi
may
benefit
evalu
impact
pmp
individu
platelet
transfus
respons
clinic
outcom
backgroundcas
studi
mechan
onset
vvr
platelet
apheresi
difficult
elucid
withdraw
return
flow
affect
donor
complexli
therefor
monitor
indic
reflect
physiolog
chang
donor
effect
mean
observ
occurr
studi
use
laser
doppler
flowmetri
continu
monitor
blood
flow
puls
rate
heart
rate
platelet
collect
analyz
process
vvr
studi
designmethod
retrospect
studi
includ
high
risk
donor
vvr
vvr
case
experienc
percent
decreas
blood
flow
dbf
percent
decreas
heart
rate
dhr
calcul
physiolog
posit
certain
time
apheresi
plot
use
valu
dbf
x
use
valu
dhr
motion
dot
everi
second
observ
platelet
apheresi
field
divid
area
central
changeless
area
n
increas
flow
decreas
heart
rate
dh
area
increas
heart
rate
ih
area
b
decreas
flow
df
ih
area
c
df
dh
area
posit
chang
abl
paint
give
color
area
pixel
exhibit
second
stay
posit
total
occup
rate
area
calcul
certain
period
apheresi
resultsfind
occup
rate
n
area
vvr
rate
area
vvr
signific
p
valu
rate
area
gradual
increas
minut
onset
vvr
delay
vvr
case
posit
area
continu
donor
releas
bed
conclus
physiolog
condit
donor
abl
observ
introduc
laser
doppler
flowmetri
platelet
apheresi
suitabl
analysi
inform
may
give
us
effect
clue
prevent
delay
vvr
backgroundcas
studi
trima
accel
system
apheresi
devic
use
continu
flow
centrifug
take
blood
donor
separ
transfus
compon
red
blood
cell
platelet
plasma
blood
compon
collect
return
donor
trima
accel
design
meet
need
blood
center
global
stage
purpos
studi
evalu
yield
leukoreduct
perform
trima
accel
platelet
store
plasma
studi
designmethod
prospect
open
label
multicent
control
studi
evalu
yield
leukoreduct
platelet
collect
trima
accel
terumo
bct
lakewood
co
store
plasma
healthi
adult
volunt
donor
consent
donat
either
singl
doubl
tripl
platelet
product
trima
accel
donat
product
store
per
standard
blood
bank
condit
day
collect
platelet
product
assess
residu
white
blood
cell
wbc
content
final
platelet
yield
resultsfind
two
hundr
particip
donat
evalu
singl
doubl
tripl
platelet
product
mean
sd
residu
wbc
count
singl
doubl
tripl
platelet
product
respect
breakdown
platelet
product
show
singl
platelet
unit
wbc
count
less
million
doubl
platelet
unit
wbc
content
lower
million
tripl
platelet
unit
wbc
content
lower
million
determin
confid
singl
doubl
tripl
platelet
product
accept
residu
wbc
level
failur
collect
therefor
meet
unit
state
fda
accept
criteria
singl
doubl
tripl
platelet
product
mean
sd
platelet
yield
respect
singl
platelet
product
residu
platelet
yield
none
doubl
tripl
platelet
product
platelet
yield
respect
conclus
singl
doubl
tripl
platelet
product
collect
trima
accel
store
plasma
met
accept
criteria
residu
wbc
level
platelet
yield
backgroundcas
studi
platelet
microparticl
known
indic
platelet
activ
earli
marker
inflammatori
autoimmun
condit
known
certain
donor
demograph
associ
platelet
activ
whether
repeat
donor
consist
activ
platelet
studi
aim
understand
platelet
activ
statu
plateletpheresi
donor
quantifi
chang
platelet
activ
statu
across
multipl
donat
two
collect
technolog
import
activ
platelet
andor
microparticl
fragment
could
affect
immun
hemostat
properti
platelet
transfus
studi
designmethod
studi
conduct
vienna
gener
hospit
depart
transfus
medicin
start
januari
microparticl
mp
content
thrombolux
lightintegra
technolog
inc
canada
measur
plasma
prp
uniqu
donor
prior
donat
determin
platelet
activ
statu
platelet
collect
either
amicu
trima
accel
cell
separ
store
intersol
microparticl
content
also
test
final
product
resultsfind
averag
age
donor
year
male
platelet
count
platelet
activ
statu
donor
mp
content
mp
consid
mp
consid
activ
uniqu
donor
mp
threshold
specif
sensit
posit
predict
valu
ppv
neg
predict
valu
npv
predict
prp
platelet
activ
repeat
donor
prp
mp
first
donat
consist
consecut
result
within
month
case
chang
significantli
day
mp
content
donor
prp
product
sampl
show
signific
posit
correl
residu
mp
donat
pc
trima
amicu
significantli
differ
vs
level
signific
even
though
donor
popul
conclus
platelet
activ
statu
determin
mp
content
donor
prp
vari
significantli
donor
regardless
sex
age
often
chang
month
activ
statu
platelet
donat
product
consequ
platelet
activ
donor
howev
type
cell
separ
affect
level
residu
mp
studi
need
determin
effect
platelet
activ
statu
clinic
outcom
backgroundcas
studi
genet
modif
porcin
consider
potenti
suppli
almost
unlimit
function
red
blood
cell
rbc
resolv
worldwid
shortag
human
rbc
clinic
transfus
three
major
xenoantigen
present
porcin
galactosea
galactos
agal
acid
glycan
product
transferas
human
variabl
level
antibodi
agal
sda
epitop
recent
cmah
tripl
tko
pig
mediat
gene
target
success
produc
lab
aim
present
studi
evalu
immunogen
rbc
tko
pig
human
antibodi
studi
designmethod
pig
blood
collect
heparin
vacuum
tube
tko
wild
type
ie
unmodifi
wt
pig
flow
cytometri
analysi
perform
rbc
collect
tko
pig
wt
pig
human
blood
group
type
assess
agal
antigen
express
rbc
tko
pig
wt
pig
voluntari
blood
donor
incub
human
ab
serum
analyz
immunoglobulin
ig
g
igm
bind
character
flow
cytometri
total
antibodi
bind
evalu
hemagglutin
resultsfind
rbc
tko
piglet
human
blood
group
type
neg
agal
antigen
express
rbc
wt
pig
posit
three
antigen
vitro
bind
human
igmigg
tko
pig
rbc
significantli
lower
compar
wt
pig
rbc
hemagglutinaion
tko
pig
rbc
human
serum
much
weaker
compar
wt
pig
rbc
conclus
result
indic
tko
pig
rbc
express
significantli
reduc
xenoantigen
compar
wt
pig
rbc
data
also
suggest
tko
erythrocyt
may
sourc
human
transfus
backgroundcas
studi
taiwan
qualiti
monitor
blood
product
key
issu
ratio
lr
product
increas
prevent
seriou
transfus
reaction
febril
transfus
reaction
fnhtr
current
manual
count
residu
wbc
rwbc
enumer
time
consum
requir
technic
skill
taiwan
blood
suppli
account
red
blood
cell
goal
full
achiev
autom
import
opportun
feasibl
studi
sysmex
new
blood
bank
applic
develop
qualiti
monitor
blood
product
report
basic
perform
applic
rwbc
use
routin
manufactur
lr
red
cell
concentr
studi
evalu
feasibl
sysmex
analysi
rwbc
sampl
studi
designmethod
evalu
three
item
repeat
stabil
correl
manual
countflow
cytometri
fcm
method
repeat
test
rwbc
use
sampl
stabil
test
stabil
sampl
pack
rwbc
use
sampl
sampl
run
correl
test
correl
manual
count
fcm
bd
use
sampl
resultsfind
repeat
rwbc
cv
rwbc
cv
stabil
confirm
rwbc
show
good
stabil
hour
correl
result
correl
formula
manual
count
fcm
respect
conclus
show
good
consist
manual
count
fcm
result
higher
count
may
due
gate
area
fcm
includ
rain
dot
refer
damag
cell
gate
exclud
suspect
artefact
damag
cell
exclud
manual
count
routin
possibl
perform
routin
residu
wbc
test
hematolog
analyz
platform
near
futur
believ
improv
workflow
qualiti
monitor
blood
product
shorten
tat
minutessampl
rais
qc
sampl
rate
rcc
pack
reduc
total
test
cost
includ
labor
charg
backgroundcas
studi
trima
accel
use
collect
platelet
pa
goal
collect
minimum
two
platelet
product
per
collect
collect
time
often
dictat
select
devic
use
product
collect
januari
center
began
use
newest
version
trima
accel
accessori
terumo
bct
lakewood
co
trima
accel
design
meet
need
blood
center
access
manag
autoflow
featur
trima
accel
design
reduc
access
relat
alert
make
autom
adjust
flow
rate
base
donor
access
flow
system
pressur
issu
detect
trima
accel
devic
accessori
pressur
cuff
design
encourag
donor
squeez
ensur
pressur
mmhg
donor
arm
addit
trima
accel
design
enhanc
platelet
collect
product
modif
platelet
collect
algorithm
improv
procedur
manag
studi
designmethod
trima
accel
devic
upgrad
version
softwar
januari
util
cadenc
system
terumobct
lakewood
co
procedur
data
captur
donat
march
test
addit
procedur
data
donat
collect
control
period
trima
accel
novemb
januari
comparison
platelet
product
yield
procedur
time
venou
access
alert
donor
inform
analyz
test
control
group
resultsfind
follow
softwar
instal
trima
accel
overal
platelet
collect
effici
increas
platelet
yield
note
test
procedur
versu
control
procedur
p
averag
procedur
time
drop
test
control
group
approxim
min
min
vs
min
p
improv
report
collect
yield
vs
p
statist
signific
differ
also
shown
averag
number
access
alert
donat
trima
accel
trima
accel
averag
number
access
alert
drop
per
procedur
control
period
per
procedur
test
period
p
valu
twice
mani
donat
complet
success
without
access
relat
alert
compar
test
period
control
period
p
valu
zero
donat
greater
alert
singl
donat
trima
period
compar
control
period
frequent
access
alert
singl
donat
p
valu
test
control
group
compar
total
blood
volum
versu
platelet
count
versu
conclus
trima
accel
increas
platelet
collect
product
compar
current
trima
accel
trima
accel
also
dramat
reduc
number
access
relat
oper
alert
per
donat
implement
softwar
enabl
center
collect
platelet
compon
per
procedur
contribut
improv
cost
effect
mainten
adequ
inventori
backgroundcas
studi
hemanext
develop
technolog
long
term
storag
red
blood
cell
rbc
storag
condit
storag
rbc
condit
shown
improv
qualiti
cell
transfus
white
blood
cell
wbc
rbc
transfus
may
respons
caus
transfus
associ
graft
versu
host
diseas
immunocompromis
patient
gamma
irradi
blood
product
transfus
current
use
prevent
seriou
advers
effect
blood
transfus
unknown
effect
gamma
irradi
wbc
abrog
affect
reduc
oxygen
content
hemanext
rbc
therefor
present
studi
design
determin
effect
hemanext
rbc
storag
condit
qualiti
red
blood
cell
growth
prolifer
follow
gamma
irradi
studi
designmethod
two
unit
fresh
leukocyt
reduc
red
cell
concentr
obtain
rhode
island
blood
center
ribc
two
unit
pool
togeth
creat
homogen
pool
peripher
blood
mononuclear
cell
pbmnc
isol
one
two
unit
abo
match
red
cell
concentr
use
ficol
gradient
antibodi
coat
magnet
bead
per
manufactur
instruct
use
pbmnc
isol
aliquot
blood
ad
back
pool
final
concentr
equal
aliquot
pool
unit
ad
convent
pvc
red
cell
storag
bag
hour
room
temperatur
hemanext
red
cell
process
system
transfer
hemanext
bag
storag
day
vitro
metric
atp
hemolysi
etc
red
cell
qualiti
measur
process
storag
storag
day
ml
remov
bag
rbc
remain
bag
expos
gy
gamma
irradi
per
standard
protocol
ribc
pbmnc
isol
irradi
sampl
test
abil
respond
mitogen
limit
dilut
assay
resultsfind
percent
oxygen
satur
hemoglobin
hemanext
rbc
sampl
reduc
hemolysi
sampl
day
gamma
irradi
control
hemanext
result
show
signific
growth
prolifer
differ
level
control
hemanext
rbc
growth
prolifer
inhibit
least
reduct
frequenc
respond
cell
follow
gamma
irradi
pbmnc
rcc
store
normal
convent
hemanext
rbc
storag
bag
conclus
result
indic
prolifer
wbc
present
rbc
process
hemanext
red
cell
process
system
store
hemanext
storag
bag
suscept
gamma
irradi
similar
fashion
store
current
convent
storag
condit
backgroundcas
studi
platelet
transfus
use
treatment
prophylaxi
bleed
associ
major
trauma
surgeri
individu
thrombocytopen
platelet
dysfunct
platelet
transfus
unit
state
collect
apheresi
challeng
platelet
collect
apheresi
calcul
accur
estim
donor
platelet
count
maxim
number
platelet
collect
without
jeopard
safeti
donor
studi
designmethod
prospect
open
label
multicent
studi
evalu
safeti
efficaci
trima
accel
system
modifi
postcount
algorithm
softwar
healthi
adult
volunt
donor
consent
donat
either
singl
doubl
platelet
product
trima
accel
system
modifi
platelet
postcount
algorithm
softwar
particip
platelet
count
measur
confirm
collect
product
assess
residu
white
blood
cell
wbc
content
ph
resultsfind
one
hundr
twenti
particip
donat
evalu
singl
doubl
platelet
product
singl
doubl
platelet
collect
result
postcount
lower
confid
interv
singl
doubl
platelet
product
calcul
mean
differ
measur
postcount
trima
accel
predict
postcount
singl
doubl
collect
respect
thu
trima
predict
platelet
postcount
averag
lower
actual
measur
postcount
regard
collect
platelet
qualiti
evalu
platelet
unit
residu
wbc
specif
singl
platelet
unit
mean
residu
wbc
doubl
platelet
unit
mean
residu
wbc
platelet
ph
assess
day
collect
depend
site
standard
practic
product
ph
singl
doubl
final
advers
event
ae
report
particip
ae
rate
consist
prospect
clinic
studi
previou
version
trima
accel
postcount
algorithm
total
ae
total
particip
conclus
collect
singl
doubl
platelet
product
trima
accel
system
modifi
platelet
postcount
algorithm
softwar
safe
maintain
particip
post
procedur
platelet
count
backgroundcas
studi
human
serum
eye
drop
sed
use
treatment
dri
eye
syndrom
hypothesi
activ
compon
serum
growth
factor
activ
effect
dri
eye
adhes
cell
cell
layer
eye
strengthen
therebi
improv
barrier
function
howev
vitro
model
test
effect
sed
develop
standard
vitro
system
test
heal
effect
sed
human
endotheli
epitheli
cell
repres
cell
layer
eye
also
investig
concentr
serum
heal
effect
optim
studi
designmethod
two
serum
pool
test
cell
layer
human
umbil
vein
endotheli
cell
human
lung
epitheli
cell
measur
resist
across
cell
layer
caus
adhes
cell
carri
triplic
serum
pool
electr
imped
sens
eci
array
cell
per
well
format
cell
monolay
serum
pipet
per
well
duplic
final
concentr
serum
control
growth
medium
result
calcul
normal
time
serum
addit
measur
hour
resultsfind
reproduc
result
obtain
variou
cell
line
serum
pool
endotheli
cell
highest
differ
resist
measur
serum
indic
strengthen
barrier
function
cell
layer
improv
adhes
cell
effect
variou
concentr
almost
maintain
full
hour
epitheli
cell
highest
resist
differ
measur
serum
relationship
serum
long
activ
measur
lower
percentag
serum
return
level
serum
initi
effect
within
hour
measur
conclus
eci
reproduc
vitro
model
develop
test
serum
pool
use
endotheli
epitheli
cell
direct
reproduc
activ
measur
dilut
endotheli
cell
improv
adhes
cell
remain
concentr
full
measur
time
epitheli
cell
case
serum
eci
suitabl
research
wound
appli
cell
layer
order
determin
maximum
heal
effect
sed
backgroundcas
studi
decad
notion
transfus
medicin
would
holi
grail
find
vitro
assay
could
tell
happen
vivo
despit
great
effort
put
develop
assay
flow
cytometr
assess
express
morpholog
score
microscopi
hypoton
shock
respons
hsr
extent
shape
chang
esc
other
none
routin
use
hospit
blood
bank
platelet
plt
inventori
manag
recent
detect
plt
microparticl
mp
introduc
assess
plt
activ
statu
clinic
valid
associ
high
mp
poor
outcom
still
progress
studi
compar
mp
content
morpholog
score
clinic
outcom
goal
reveal
challeng
inform
futur
studi
studi
designmethod
clinic
studi
conduct
vancouv
gener
hospit
canada
enrol
hematologyoncolog
patient
patient
baselin
data
includ
plt
count
plt
transfus
characterist
includ
plt
activ
statu
prospect
collect
plt
activ
statu
measur
mp
content
mp
dynam
light
scatter
thrombolux
lightintegra
technolog
inc
canada
morpholog
score
obtain
phase
contrast
microscopi
nikon
japan
object
small
sampl
mp
singl
donor
plt
sdp
suspend
plasma
compar
morpholog
score
clinic
respons
measur
correct
count
increment
cci
resultsfind
patient
receiv
total
transfus
sdp
patient
male
year
age
diagnos
allaml
cmv
posit
test
posit
antibodi
baselin
plt
count
bleed
rare
sensit
analysi
reveal
major
abo
mismatch
complex
case
multipl
transfus
short
success
patient
test
posit
antibodi
patient
older
year
confound
factor
activ
statu
measur
mp
sdp
transfus
impact
confound
factor
n
show
moder
correl
cci
cmv
posit
patient
diagnos
aml
p
activ
plt
mp
morpholog
score
sdp
show
moder
invers
correl
p
correl
platelet
due
difficulti
differenti
platelet
accur
visual
inspect
conclus
contrast
rel
qualiti
control
paramet
express
mp
content
morpholog
score
reflect
entir
histori
plt
donor
plt
unit
data
suggest
refin
question
might
lead
solut
rather
aim
predict
outcom
goal
might
predict
worst
outcom
plt
transfus
mp
low
morpholog
score
high
probabl
insuffici
increas
cci
cmv
aml
patient
thu
practic
approach
improv
overal
clinic
outcom
may
avoid
activ
plt
transfus
prophylaxi
backgroundcas
studi
improv
platelet
apheresi
product
enabl
blood
center
maintain
adequ
inventori
short
shelf
life
product
improv
oper
cost
effect
trima
accel
terumo
bct
lakewood
co
design
enhanc
platelet
collect
product
modif
platelet
collect
algorithm
improv
procedur
manag
studi
designmethod
retrospect
studi
consist
donat
januari
juli
trima
accel
control
compar
donat
juli
march
trima
accel
test
trima
accel
procedur
data
captur
use
cadenc
system
terumo
bct
lakewood
co
platelet
product
yield
procedur
time
donor
inform
analyz
test
control
group
measur
differ
resultsfind
statist
signific
differ
platelet
collect
product
measur
trima
accel
trima
accel
averag
procedur
time
drop
test
control
group
approxim
min
vs
min
p
improv
report
collect
yield
vs
p
normal
donat
time
trima
accel
produc
increas
platelet
yield
hour
averag
versu
control
procedur
p
test
control
group
compar
total
blood
volum
platelet
count
despit
statist
signific
differ
favor
larger
tbv
versu
p
higher
platelet
count
versu
p
control
group
conclus
trima
accel
result
statist
signific
increas
platelet
collect
product
compar
current
trima
accel
trima
accel
may
enabl
blood
center
collect
platelet
compon
per
procedur
contribut
improv
blood
center
cost
effect
mainten
adequ
inventori
backgroundcas
studi
bacteri
contamin
platelet
one
major
threat
blood
safeti
approx
platelet
unit
potenti
contamin
risk
may
even
higher
sinc
evalu
conduct
cultur
base
method
known
high
fals
neg
rate
even
receiv
contamin
unit
necessarili
caus
bacteri
sepsi
recipi
platelet
transfus
often
immunocompromis
critic
ill
bacteri
contamin
may
problemat
consequ
health
statu
pathogen
inactiv
technolog
develop
reduc
risk
infect
nation
hemovigil
data
sever
franc
belgium
switzerland
well
sever
hemovigil
studi
show
effici
prevent
bacteri
sepsi
aim
evalu
amotosalenuva
pathogen
inactiv
technolog
mitig
risk
bacteri
contamin
platelet
use
organ
play
import
role
bacteri
sepsi
studi
designmethod
three
therapeut
apheresi
platelet
unit
plateletsunit
plasma
collect
h
post
collect
two
unit
spike
approx
cfu
per
bag
saureau
atcc
ecoli
atcc
respect
third
unit
serv
control
day
post
collect
h
post
spike
sampl
test
taken
follow
pathogen
inactiv
unit
intercept
blood
system
ceru
corpor
usa
use
larg
volum
process
kit
platelet
post
inactiv
unit
incub
day
take
sampl
analysi
day
day
bacteri
growth
detect
bactalert
autom
blood
cultur
system
biomerieux
franc
platelet
count
platelet
volum
ph
assess
day
day
day
standard
procedur
resultsfind
averag
ph
day
drop
day
day
drop
day
ph
unit
never
drop
cours
storag
platelet
count
per
bag
chang
significantli
storag
averag
volum
loss
neglig
day
day
bacteri
growth
detect
day
pathogen
inactiv
ecoli
saureau
unit
control
unit
day
storag
bacteri
growth
detect
blood
cultur
unit
show
steril
unit
formerli
spike
bacteria
conclus
unit
spike
ecoli
saureu
success
inactiv
amotosalenuva
pathogen
inactiv
stay
steril
day
storag
post
inactiv
qualiti
paramet
unit
within
specif
recogn
signific
drop
ph
day
day
storag
backgroundcas
studi
venou
access
manag
crucial
donor
experi
oper
effici
apheresi
devic
terumo
bct
develop
trima
accel
terumo
bct
lakewood
co
improv
donat
experi
reduc
venou
access
alert
via
autoflow
featur
autoflow
intend
reduc
access
relat
alert
make
autom
adjust
flow
rate
base
access
flow
system
pressur
issu
detect
trima
accel
devic
addit
accessori
pressur
cuff
design
encourag
donor
squeez
ensur
pressur
mmhg
donor
vein
combin
autoflow
accessori
reduc
venou
access
alert
minim
oper
intervent
improv
donor
experi
studi
designmethod
retrospect
studi
consist
analysi
donat
januari
juli
trima
accel
control
compar
procedur
juli
march
trima
accel
cuff
test
trima
accel
procedur
data
captur
use
cadenc
system
terumo
bct
lakewood
co
analyz
access
alert
resultsfind
control
period
averag
number
access
alert
per
procedur
wherea
test
period
averag
number
access
alert
per
procedur
p
valu
twice
mani
donat
complet
success
without
access
relat
alert
compar
test
period
softwar
control
period
softwar
p
valu
furthermor
rate
donat
access
alert
singl
donat
reduc
factor
test
period
donat
access
relat
alert
compar
control
period
approxim
donat
greater
access
alert
p
valu
conclus
trima
accel
result
signific
reduct
venou
access
alert
result
less
oper
intervent
reduc
oper
intervent
enabl
staff
spend
time
donor
complet
addit
duti
donor
room
floor
backgroundcas
studi
dri
plasma
provid
valuabl
function
fresh
frozen
plasma
ffp
hemostat
resuscit
includ
replac
volum
buffer
shock
provid
coagul
factor
dri
plasma
offer
advantag
simpler
storag
dri
plasma
studi
two
year
stabil
versu
ffp
frozen
addit
dri
plasma
rehydr
min
much
quickli
thaw
ffp
french
lyophil
plasma
flyp
import
us
special
oper
command
fda
investig
new
drug
protocol
recent
flyp
shipment
experienc
unplan
transit
temperatur
excurs
hour
max
function
test
perform
flyp
determin
usabl
studi
designmethod
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
factor
level
fibrinogen
labil
factor
v
viii
measur
rehydr
flyp
exflyp
coagul
paramet
measur
rotat
thromboelastometri
rotem
thrombin
fiia
gener
quantifi
thrombogram
histor
flyp
data
use
refer
comparison
also
made
vs
pool
ffp
fresh
plasma
ppp
fresh
ffp
resultsfind
pt
ptt
exflyp
prolong
fibrinogen
fv
fviii
level
exflyp
decreas
compar
control
similarli
clot
time
rotem
longer
exflyp
angl
rate
clot
max
amplitud
clot
strength
similar
control
thrombogram
chang
lagtim
seen
exflyp
vs
ffpppp
peak
fiia
exogen
thrombin
potenti
etp
significantli
diminish
exflyp
histor
thrombogram
rotem
data
flyp
avail
tabl
show
exflyp
unit
vs
ffpppp
tabl
compar
exflyp
mean
vs
histor
flyp
mean
conclus
histor
flyp
normal
fviii
fv
rel
unchang
exflyp
fviii
deplet
consequ
limit
clot
initi
delay
pt
rotem
ct
decreas
fiia
peak
etp
consist
shelf
life
reduct
prior
studi
rotem
data
compar
current
use
plasma
product
backgroundcas
studi
review
test
packet
end
test
add
time
process
client
need
result
hour
sampl
receipt
everi
minut
import
qualiti
control
staff
separ
process
caus
issu
identifi
occur
result
addit
delay
rework
addit
physic
separ
depart
hinder
commun
faster
method
provid
qualiti
control
check
laboratori
test
need
laboratori
place
staff
within
test
lab
perform
qualiti
check
process
effect
around
time
assess
studi
designmethod
first
laboratori
area
select
studi
viral
marker
test
includ
antibodi
test
hiv
htlv
iii
hcv
hbsag
hbc
chaga
team
assembl
review
identifi
critic
check
point
need
within
process
critic
check
point
assess
determin
could
perform
comput
autom
could
perform
check
team
identifi
sampl
accept
extern
control
critic
check
perform
work
station
place
within
laboratori
test
area
qualiti
staff
perform
check
procedur
train
develop
addit
laboratori
inform
system
configur
algorithm
allow
automat
approv
test
result
critic
check
accept
resultsfind
batch
viral
marker
test
check
take
minut
compar
minut
check
end
test
except
review
qualiti
control
staff
prior
result
releas
process
chang
result
improv
averag
time
detail
tabl
specif
averag
viral
marker
test
decreas
atlanta
laboratori
san
antonio
laboratori
conclus
implement
qualiti
control
review
reduc
time
result
releas
time
maintain
high
qualiti
review
result
releas
estim
implement
addit
area
reduc
time
hour
reduct
review
time
allow
qualiti
control
staff
perform
detail
qualiti
verif
area
outsid
test
process
includ
facil
cleanli
appropri
label
storag
materi
train
safeti
backgroundcas
studi
patient
safeti
remain
critic
issu
health
care
nation
patient
safeti
foundat
recent
declar
prevent
medic
harm
public
health
crisi
studi
estim
patient
mortal
medic
error
death
annual
makari
daniel
bmj
medic
error
estim
fold
common
jame
jt
journal
patient
safeti
aim
studi
evalu
patient
safeti
event
relat
transfus
blood
compon
studi
designmethod
descript
studi
patient
safeti
incid
relat
blood
transfus
report
aabb
center
patient
safeti
cp
medic
center
januari
septemb
data
aggreg
children
hospit
adult
hospit
report
patient
safeti
event
pediatr
adult
patient
involv
transfus
blood
compon
analyz
report
categor
use
code
center
diseas
control
hemovigil
modul
denomin
pediatr
adult
total
transfus
per
year
descript
statist
use
rate
calcul
per
compon
transfus
pearson
chi
squar
comparison
p
signific
resultsfind
report
transfus
report
pediatr
transfus
report
adult
transfus
calcul
report
rate
per
compon
pediatr
adult
report
p
among
pediatr
report
common
incid
code
tabl
transfus
protocol
follow
among
adult
report
common
incid
code
product
administ
conclus
total
incid
report
rate
pediatr
vs
adult
patient
significantli
differ
higher
rate
associ
pediatr
transfus
pediatr
patient
higher
number
protocol
follow
report
adult
patient
higher
number
administ
report
understand
patient
safeti
event
relat
blood
transfus
help
target
hemovigil
educ
intervent
appropri
patient
popul
backgroundcas
studi
softwar
electron
posit
patient
identif
eppid
blood
transfus
implement
novemb
inpati
ambulatori
transfus
hospit
technolog
util
barcod
wristband
barcod
print
blood
compon
label
implement
embrac
nurs
remov
manual
process
two
licens
independ
practition
verifi
patient
identif
mppid
blood
compon
transfus
intraop
intraop
transfus
exclud
initi
scope
studi
designmethod
multidisciplinari
committe
assembl
identifi
feasibl
util
eppid
intraop
transfus
address
remov
mppid
decreas
blood
compon
wastag
improv
complianc
blood
administr
document
pilot
design
eppid
instal
cardiac
surgeri
oper
room
or
train
includ
video
interact
session
led
clinic
informat
superus
total
anesthesiologist
provid
train
pilot
includ
case
ran
week
onlin
survey
creat
solicit
feedback
provid
pilot
complet
januari
committe
recommend
expans
remain
or
provid
train
expans
complet
decemb
data
includ
pilot
number
n
case
use
eppid
blood
compon
n
scan
return
blood
bank
patient
safeti
risk
post
expans
transfus
n
use
eppid
compar
mppid
overal
complianc
day
massiv
transfus
event
exclud
resultsfind
pilot
case
complet
provid
transfus
use
eppid
unit
scan
return
onlin
survey
convey
provid
felt
eppid
improv
patient
safeti
decreas
blood
wastag
desir
use
eppid
transfus
follow
expans
transfus
audit
tabl
show
due
user
error
eppid
softwar
post
expans
show
eppid
complianc
increas
compar
mppid
previou
audit
day
post
expans
use
mppid
transfus
decreas
later
audit
conclus
pilot
studi
show
feasibl
provid
accept
eppid
intraop
transfus
creat
momentum
expans
eppid
or
strong
collabor
stakehold
combin
step
implement
pilot
follow
expans
eppid
bar
scan
technolog
allow
increas
patient
safeti
workflow
effici
intraop
suit
backgroundcas
studi
appropri
util
blood
compon
crucial
patient
safeti
improv
outcom
base
multipl
random
control
trial
hemoglobin
hgb
threshold
prophylact
rbc
transfus
lower
gdl
howev
guidelin
emphas
use
hgb
level
sole
criterion
make
transfus
decis
institut
current
threshold
coincid
hgb
critic
valu
gdl
critic
valu
defin
life
threaten
laboratori
valu
requir
time
provid
notif
prompt
clinician
take
action
avoid
signific
morbid
mortal
hypothesi
critic
valu
notif
affect
provid
decis
transfus
alert
hgb
level
gdl
aim
determin
critic
valu
low
hgb
valu
threshold
prophylact
transfus
lead
rbc
transfus
studi
designmethod
total
case
adult
age
year
review
receiv
rbc
transfus
hgb
gdl
institut
pediatr
patient
patient
massiv
transfus
surgic
patient
exclud
data
collect
regard
demograph
vital
sign
diagnosi
symptom
anemia
hgb
presenc
activ
bleed
length
stay
number
rbc
unit
transfus
transfus
reaction
criteria
justif
transfus
base
presenc
follow
unstabl
vital
sign
b
cardiac
diseas
c
activ
bleed
symptom
anemia
absenc
criteria
transfus
categor
justifi
descript
analyt
tool
use
data
analysi
resultsfind
total
case
analyz
median
age
year
rang
f
ratio
twenti
one
percent
patient
symptom
anemia
evid
bleed
group
patient
hgb
level
patient
gdl
sixteen
patient
cardiac
diseas
base
retrospect
review
case
transfus
decis
made
provid
alert
hgb
critic
valu
averag
rbc
unit
transfus
patient
transfus
reaction
report
conclus
studi
show
overutil
rbc
transfus
due
critic
valu
notif
gdl
hgb
level
lower
critic
valu
transfus
threshold
gdl
base
literatur
review
reduc
institut
backgroundcas
studi
blood
bank
high
volum
laboratori
process
approxim
specimen
per
year
blood
bank
specimen
unaccept
unlabel
unsign
miss
necessari
patient
identifi
document
case
new
specimen
request
drawn
per
protocol
attempt
decreas
number
unaccept
specimen
immedi
notif
nurs
manag
nm
prompt
debrief
process
staff
initi
june
decreas
number
unaccept
specimen
implement
addit
qualiti
improv
process
studi
designmethod
april
new
patient
safeti
initi
establish
facil
wide
multidisciplinari
effort
includ
nurs
educ
hospit
qualiti
laboratori
medicin
includ
awar
campaign
mind
draw
patient
specimen
mind
accur
patient
id
begin
two
slogan
use
print
worn
project
champion
blood
bank
also
redesign
specimen
requisit
form
reflect
initi
new
requisit
form
includ
remind
import
step
patient
identif
id
specimen
collect
process
stop
sign
use
anchor
form
along
slogan
instruct
includ
prompt
bring
label
requisit
form
patient
bedsid
minim
disrupt
ie
close
curtain
check
patient
identifi
document
label
tube
bedsid
two
staff
remain
patient
room
procedur
complet
two
independ
patient
id
resultsfind
chart
repres
unaccept
specimen
averag
monthli
unaccept
specimen
identifi
blood
bank
half
data
prior
half
first
quarter
upon
review
unaccept
specimen
sinc
januari
implement
new
initi
led
decreas
averag
number
unaccept
specimen
per
month
sinc
april
conclus
mind
initi
awar
campaign
led
signific
decreas
number
unaccept
specimen
identifi
blood
bank
step
map
remind
polici
relat
specimen
collect
patient
id
heighten
awar
correct
patient
specimen
label
improv
patient
safeti
patient
experi
backgroundcas
studi
aabb
standard
commun
concern
introduc
edit
standard
blood
bank
transfus
servic
fulfil
requir
suggest
box
establish
process
personnel
anonym
commun
concern
qualiti
safeti
purpos
retrospect
studi
evalu
effect
suggest
box
contribut
qualiti
system
larg
academ
hospit
transfus
servic
studi
designmethod
lock
suggest
box
locat
staff
locker
area
allow
personnel
privat
enter
comment
medic
director
md
inform
staff
provid
anonym
concern
recommend
qualiti
safeti
access
suggest
box
limit
md
ensur
mechan
feedback
could
involv
senior
peer
manag
submit
suggest
acknowledg
receiv
email
weekli
basi
submiss
distribut
account
member
execut
manag
team
discuss
monthli
execut
manag
qualiti
meet
determin
action
implement
chang
commun
staff
monthli
meet
md
staff
engag
work
option
optim
resolut
work
flow
chang
equip
select
retrospect
review
submiss
sinc
perform
categor
base
qualiti
system
essenti
qse
use
aabb
standard
item
align
qse
categor
work
cultur
percent
result
chang
calcul
overal
categori
resultsfind
total
suggest
receiv
ten
valid
qualiti
safeti
concern
categor
qse
summar
tabl
recurr
item
includ
tabl
data
one
concern
ibst
bar
code
scanner
cross
coverag
schedul
item
classifi
work
cultur
includ
employe
recognit
holiday
staf
recycl
suggest
primari
reason
entri
result
chang
includ
cost
altern
solut
suggest
refer
supplier
custom
conclus
ad
suggest
box
becom
product
compon
facil
qualiti
system
provid
feedback
across
qse
overal
suggest
result
meaning
chang
addit
includ
work
cultur
enhanc
find
indic
success
suggest
box
employe
engag
continu
qualiti
improv
backgroundcas
studi
integr
compon
periop
qualiti
program
consist
monitor
routin
qualiti
control
result
salvag
blood
process
devic
institut
defin
qualiti
control
qc
paramet
schedul
perform
qc
two
hospit
salvag
devic
test
monthli
hematocrit
hct
residu
heparin
hep
autotransfus
team
evalu
rbc
concentr
washout
perform
prior
result
per
total
number
test
report
qualiti
indic
recogn
method
captur
specif
salvag
devic
perform
purpos
studi
use
six
sigma
box
plot
monitor
variabl
qc
result
evalu
perform
salvag
devic
quarterli
basi
one
year
studi
designmethod
box
plot
templat
hct
hep
develop
blood
salvag
devic
qc
result
input
month
test
perform
box
plot
includ
follow
qc
result
mean
median
quartil
quartil
minimummaximum
outlier
threshold
line
ad
hct
chart
indic
result
met
accept
criteria
determin
threshold
line
ad
hep
chart
indic
result
uml
met
accept
criteria
quarter
box
plot
review
prior
quarter
result
track
trend
perform
devic
resultsfind
quarterli
data
show
devic
produc
mean
qc
result
met
accept
criteria
identifi
outlier
meet
accept
criteria
investig
qc
repeat
accept
result
review
quarter
end
identifi
two
salvag
devic
box
plot
significantli
wider
quartil
devic
result
review
two
devic
remov
servic
due
wide
variabl
qc
result
conclus
util
box
plot
monitor
qc
result
effect
manag
multipl
piec
equip
multipl
locat
display
accept
unaccept
result
manner
creat
accur
pictur
multipl
salvag
devic
perform
time
backgroundcas
studi
inventori
manag
depart
imd
blood
center
distribut
roughli
unit
annual
found
six
distribut
hub
standard
oper
depart
qualiti
error
investig
increas
percent
two
year
cost
depart
estim
labor
identifi
trend
depart
began
investig
use
leansix
sigma
methodolog
defin
process
base
valu
ad
step
outcom
decreas
error
qualiti
studi
designmethod
imd
identifi
increas
process
investig
result
high
potenti
loss
product
revenu
imd
implement
leansix
sigma
methodolog
reevalu
procedur
find
defect
process
begin
repres
blood
center
six
distribut
hub
map
process
complet
current
imd
util
qualiti
improv
tool
publish
tool
time
healthcar
langford
intern
inc
team
began
system
analysi
identifi
process
defect
impact
custom
upon
conclus
discoveri
workshop
found
six
hub
oper
manner
slight
varianc
process
creat
opportun
error
team
use
process
benchmark
tool
identifi
distribut
hub
oper
differ
upon
complet
activ
determin
standard
oper
procedur
need
updat
includ
specif
step
elimin
document
resultsfind
seventeen
distribut
depart
standard
oper
procedur
rewritten
inclus
hub
includ
definit
direct
process
team
identifi
execut
across
organ
result
depart
saw
decreas
product
qualiti
investig
almost
two
year
total
cost
save
nearli
conclus
inventori
manag
depart
dedic
continu
improv
plan
motiv
posit
result
seen
calendar
year
distribut
depart
plan
continu
evalu
procedur
base
leansix
sigma
methodolog
backgroundcas
studi
standard
oper
procedur
sop
critic
standard
laboratori
test
result
blood
bank
per
aabb
standard
except
polici
process
procedur
must
warrant
clinic
situat
requir
justif
medic
director
gener
uncommon
event
individu
may
rais
concern
system
action
issu
order
better
understand
incid
context
deviat
identifi
potenti
area
improv
educ
compon
ongo
qualiti
assur
control
qaqc
sought
review
institut
prior
occurr
sop
deviat
studi
designmethod
retrospect
studi
undertaken
review
categor
document
reason
sop
deviat
institut
occurr
year
period
year
review
analyz
resultsfind
year
studi
period
sop
deviat
identifi
averag
deviat
per
year
document
reason
deviat
categor
occurr
tabul
shown
tabl
issu
surround
specimen
labelingaccess
greatest
aggreg
caus
howev
second
singl
caus
deviat
result
extend
valid
test
specimen
issu
test
form
thu
great
major
deviat
relat
sop
conclus
consid
number
activ
defin
blood
bank
sop
deviat
rare
retrospect
review
uncov
sever
key
categori
definit
area
target
improv
pattern
may
remain
larg
unnot
without
retrospect
review
henc
period
review
frequenc
reason
deviat
qualiti
monitor
provid
opportun
sop
improv
andor
refin
staff
educ
backgroundcas
studi
rare
occas
symptom
hypotens
lead
transfus
reaction
tr
occur
receiv
salvag
autolog
blood
autotransfus
team
process
investig
possibl
reason
reaction
due
infrequ
tr
workup
procedur
sop
lack
organ
continu
work
flow
hinder
confid
staff
biennial
sop
review
recogn
rare
use
process
revis
five
year
earli
appli
lean
tool
improv
process
increas
effici
studi
designmethod
three
trainer
appli
lean
techniqu
month
sort
set
order
shine
standard
sustain
framework
elimin
obsolet
excess
document
sop
improv
locat
number
suppli
need
complet
workup
educ
tool
creat
practic
team
assist
trainer
revis
sop
implement
compet
assess
perform
employe
event
monitor
chang
implement
survey
present
employe
measur
satisfact
revis
resultsfind
new
step
practic
wet
lab
employe
garner
opinion
comfort
level
practic
scenario
trainer
gather
question
team
includ
train
modul
futur
employe
sop
written
recip
format
action
step
result
three
page
step
elimin
sop
time
perform
process
drop
four
hour
two
hour
sever
time
measur
made
tr
kit
elimin
reduc
wast
suppli
kept
organ
locat
access
compet
assess
pass
employe
five
event
relat
miss
step
process
implement
new
sop
zero
event
report
satisfact
survey
show
prior
implement
scale
highest
averag
employe
comfort
level
four
revis
process
took
effect
employe
rate
chang
seven
scale
conclus
util
techniqu
reduc
wast
decreas
time
need
complet
work
intraop
tr
increas
staff
comfort
level
new
process
zero
event
report
implement
new
sop
recogn
streamlin
result
increas
compet
gaug
employe
comfort
level
import
factor
determin
chang
process
increas
accuraci
confid
level
among
staff
backgroundcas
studi
larg
teach
hospit
identifi
need
improv
complianc
aabb
standard
cap
checklist
item
relat
transfus
document
electron
medic
record
emr
group
set
goal
decreas
number
transfus
document
nonconform
tdn
patient
transfus
emerg
depart
ed
current
chart
system
includ
manual
entri
unit
number
product
code
baselin
tdn
rate
show
patient
prior
intervent
least
one
incorrect
incomplet
portion
transfus
record
educ
role
definit
nurs
perform
transfus
tdn
rate
lower
patient
impact
end
interdisciplinari
group
nurs
transfus
medicin
personnel
process
engin
continu
meet
determin
option
scan
blood
isbt
barcod
emr
rather
manual
type
inform
emr
develop
addit
scope
project
includ
trauma
center
record
transfus
inform
trauma
visit
hand
paper
document
form
later
scan
patient
emr
studi
designmethod
ed
emr
programm
creat
field
would
accept
data
entri
via
barcod
scanner
transfus
chart
intent
ed
patient
trauma
center
patient
would
transfus
chart
manner
barcod
scanner
ed
transfus
nurs
ivtx
mobil
comput
cart
configur
read
isbt
barcod
label
scanner
test
nurs
practic
scan
train
unit
valid
environ
emr
scanner
went
use
quarter
two
nurs
work
unit
transfus
blood
ed
ed
nurs
ivtx
work
unit
complianc
transfus
document
track
resultsfind
data
quarter
prior
implement
transfus
chart
via
scan
compar
first
quarter
implement
follow
inform
observ
initi
tdn
increas
scan
unit
number
product
code
emr
main
sourc
tdn
unit
transfus
chart
conclus
interdisciplinari
group
continu
monitor
tdn
ed
next
two
year
number
patient
impact
quarter
tdn
decreas
eventu
number
patient
impact
per
quarter
track
stop
may
process
determin
control
initi
challeng
chart
transfus
emr
use
scanner
includ
ensur
unit
document
address
addit
educ
practic
anoth
sourc
error
emerg
scanner
would
randomli
drop
digit
unit
number
product
code
resourc
abl
address
root
sourc
error
tdn
rate
remain
lower
prior
scanner
implement
backgroundcas
studi
per
fda
guidelin
lr
compon
must
contain
fewer
residu
wbc
method
determin
residu
wbc
rwbc
content
platelet
compon
includ
manual
count
nageott
method
expens
sought
determin
valid
use
hematolog
analyz
screen
rwbc
content
studi
designmethod
sampl
singl
donor
platelet
whole
blood
platelet
concentr
cbc
test
within
hour
collect
use
hematolog
analyz
valu
greater
consid
posit
confirmatori
test
perform
use
beckman
fc
resultsfind
tabl
summar
valid
result
singl
donor
platelet
sdp
whole
platelet
pspp
wbpc
conclus
cbc
power
discrimin
produc
offici
count
wbc
level
requir
certifi
unit
yet
rapid
reliabl
test
method
higher
rang
easi
use
find
effect
tool
screen
apheresi
platelet
rwbc
content
excess
allow
limit
screen
pspp
wbpc
less
effici
due
frequenc
fals
posit
futur
use
cbc
screen
method
sdp
part
sequenti
qualiti
control
plan
warrant
consider
backgroundcas
studi
proper
storag
vapor
phase
nitrogen
freezer
vpnf
liquid
phase
nitrogen
freezer
lpnf
essenti
ensur
qualiti
cryopreserv
hematopoiet
stem
cell
product
aabb
fact
accredit
progenitor
cell
process
lab
defici
incid
cryostorag
process
respons
recent
cryostorag
failur
want
determin
product
truli
safe
previous
believ
studi
designmethod
oper
qualiti
medic
staff
critic
review
equip
monitor
system
process
procedur
perform
failur
mode
effect
analysi
fmea
determin
cryostorag
system
could
fail
resultsfind
vpnf
lpnf
reli
proper
vacuum
insul
lid
seal
maintain
level
temperatur
proper
function
solenoid
valv
enabl
vpnf
automat
fill
current
process
control
detect
insul
lid
solenoid
malfunct
includ
temperatur
oxygen
level
monitor
redund
alarm
check
detect
freezer
integr
failur
manufactur
prevent
mainten
recommend
intend
prevent
failur
eg
biannual
solenoid
replac
follow
manual
level
measur
manual
fill
assur
adequ
level
autom
failur
lpnf
accumul
sludg
frost
make
manual
level
measur
difficult
could
lead
failur
detect
chang
consumpt
indic
compromis
freezer
integr
procedur
includ
standard
instruct
level
measur
condit
current
process
control
ensur
ampl
suppli
includ
stand
order
manifold
connect
freezer
multipl
tank
monitor
tank
level
critic
reexamin
disast
plan
suppli
reveal
extern
access
therefor
readili
avail
lastli
failur
respond
alarm
addit
potenti
failur
mode
use
electron
monitor
system
contact
design
personnel
respons
obtain
addit
procedur
clearli
delin
parti
respons
respond
alarm
select
staff
enhanc
secur
clearanc
may
inhibit
alarm
longer
minut
therefor
confid
alarm
would
trigger
appropri
action
conclus
fmea
allow
us
conclud
product
safe
store
risk
unrecogn
temperatur
excurs
well
manag
opportun
improv
would
enhanc
safeti
product
provid
addit
peac
mind
success
identifi
backgroundcas
studi
qualiti
umbil
cord
blood
ucb
cryopreserv
monitor
continu
ensur
qualiti
thaw
ucb
suitabl
clinic
transplant
object
retrospect
studi
use
fresh
ucb
cryopreserv
ucb
qualiti
control
sampl
qc
vial
assess
qualiti
process
cord
blood
bank
studi
designmethod
total
ucb
sampl
collect
march
march
sampl
process
cryopreserv
accord
valid
standard
oper
procedur
sop
total
nucleat
cell
count
cell
viabil
qc
vial
measur
record
total
nucleat
cell
tnc
cell
viabil
determin
cell
counter
beckman
coulter
manual
count
method
trypan
blue
respect
final
product
ucb
freez
medium
contain
dmso
cryopreserv
liquid
phase
liquid
nitrogen
tank
qc
vial
thaw
test
differ
durat
cryopreserv
year
accord
sop
accept
criteria
qualiti
check
point
determin
tnc
recoveri
cell
viabil
thaw
ucb
qc
vial
storag
period
cryopreserv
ucb
deriv
five
group
less
year
year
year
year
year
tukey
honest
signific
test
use
evalu
effect
differ
time
storag
tnc
recoveri
rate
thaw
cell
viabil
resultsfind
mean
tnc
recoveri
rate
mean
cell
viabil
thaw
ucb
qc
thaw
tnc
cell
viabil
affect
durat
storag
p
valu
qualiti
cryopreserv
ucb
stabl
year
qc
vial
well
within
predetermin
accept
criteria
conclus
object
data
gener
thaw
qc
vial
demonstr
stabil
store
ucb
product
time
thu
process
cryopreserv
well
maintain
cord
blood
bank
prospect
valid
ucb
product
stabil
carri
find
longer
storag
durat
cryopreserv
ucb
liquid
phase
liquid
nitrogen
tank
backgroundcas
studi
healthcar
imper
provid
optim
care
without
wast
resourc
crossmatch
follow
rbc
transfus
tx
within
hour
repres
potenti
area
resourc
optim
concurr
antibodi
screen
unexpectedli
convert
tx
request
may
result
potenti
avoid
delay
patient
care
assess
issu
institut
perform
audit
antibodi
screen
crossmatch
order
determin
whether
follow
tx
within
hour
studi
designmethod
antibodi
screen
crossmatch
order
sampl
receiv
institut
blood
bank
review
one
month
period
depart
dpt
order
provid
obtain
via
electron
record
tx
record
patient
correspond
order
referenc
determin
patient
receiv
tx
within
hour
screen
crossmatch
order
effici
ratio
efr
calcul
divid
either
number
crossmatch
order
number
tx
event
result
order
number
antibodi
screen
order
number
event
follow
order
ratio
consid
optim
resultsfind
total
crossmatch
order
antibodi
screen
evalu
crossmatch
order
result
tx
within
hour
efr
antibodi
screen
order
follow
tx
order
efr
order
effici
differ
depart
emerg
medicin
em
worst
efr
crossmatch
order
intern
medicin
im
worst
efr
antibodi
screen
order
tabl
conclus
audit
crossmatch
order
lead
tx
common
antibodi
screen
order
follow
unplan
tx
suggest
former
might
signific
issu
focus
qualiti
improv
depart
requir
intervent
obgyn
hemeonc
dpt
provid
demonstr
highli
effici
order
practic
futur
work
includ
evalu
factor
em
surgeri
dpt
protocol
standard
order
set
may
contribut
rel
ineffici
screen
crossmatch
order
practic
observ
backgroundcas
studi
facil
recent
implement
new
blood
donor
comput
system
collect
manufactur
valid
convert
data
donor
legaci
system
ls
new
system
ns
recommend
fda
guidanc
industri
blood
establish
comput
system
valid
user
facil
april
team
develop
convers
valid
plan
execut
use
dream
coder
excel
power
queri
pq
screen
print
comparison
convers
plan
includ
risk
assess
softwar
tabl
donor
data
dd
element
establish
number
screen
print
verifi
data
ls
ns
dream
coder
use
popul
inform
convert
data
ls
ns
use
vendor
provid
convers
file
studi
designmethod
tabl
provid
tabl
convers
process
sixteen
tabl
use
data
convers
tabl
use
ls
tabl
load
valid
environ
verifi
copi
product
environ
pq
develop
use
ls
ns
databas
take
account
convers
data
element
ls
ns
pq
use
ensur
dd
come
ls
match
migrat
ns
pq
use
compar
dd
databas
pq
consist
ls
ns
merg
queri
merg
queri
filter
match
record
identifi
discrep
data
two
system
screen
print
review
confirm
convert
dd
popul
correct
field
ns
ls
data
migrat
per
week
ns
reject
file
pq
issu
review
inform
technolog
group
resolv
data
migrat
issu
file
review
vendor
could
resolv
issu
determin
data
migrat
script
need
chang
vendor
adjust
import
script
dd
migrat
resultsfind
six
import
script
need
correctionaft
final
dd
migrat
three
reject
file
three
differ
import
scriptspq
identifi
two
addit
dd
discrep
conclus
decad
worth
dd
move
ensur
data
correctli
convert
requir
deploy
new
comput
system
perform
data
extract
migrat
multipl
time
review
data
pq
abl
identifi
data
element
transfer
correctli
correct
import
script
discrep
resolv
prior
go
live
end
confid
dd
accur
convert
migrat
allow
high
degre
certainti
continu
provid
safest
blood
patient
protect
valuabl
blood
donor
backgroundcas
studi
number
platelet
obtain
apheresi
depend
type
cell
separ
characterist
donor
fda
note
product
obtain
need
valid
separ
ensur
desir
therapeut
dose
platelet
compli
qualiti
control
requir
necessari
quantifi
amount
harvest
platelet
obtain
apheresi
procedur
object
verifi
complianc
schedul
obtain
amicu
cell
separ
studi
designmethod
two
devic
amicu
separ
system
evalu
prior
verif
technic
support
servic
made
adjust
separ
platelet
yield
adjust
pya
effect
adjust
assess
verifi
perform
separ
amicu
simpl
schedul
harvest
correl
platelet
program
obtain
qualiti
control
verifi
base
criteria
establish
manufactur
expect
bia
carri
statist
analysi
establish
protocol
clsi
document
platelet
count
qualiti
control
carri
use
analyt
control
iso
accredit
regulatori
requir
mexico
harvest
platelet
singl
product
plateletsunit
unit
test
decid
make
comparison
demand
requir
aabb
plateletsunit
unit
test
evalu
distribut
obtain
averag
bia
percentag
requir
establish
obtain
account
resultsfind
perform
singl
procedur
procedur
averag
valu
harvest
platelet
respect
minimum
valu
maximum
averag
bia
separ
kurtosi
valu
valu
total
bia
process
accord
protocol
fulfil
comparison
schedul
harvest
harvest
obtain
measur
cell
counter
process
perform
separ
fulfil
criteria
establish
aabb
platelet
harvest
occur
process
analyz
separ
conclus
data
show
wide
variabl
program
platelet
harvest
obtain
complianc
although
confus
variabl
relat
donor
analyz
differ
could
relat
platelet
collect
system
well
fact
apheresi
system
estim
platelet
collect
measur
platelet
obtain
carri
devic
analyt
control
would
explain
distribut
data
obtain
separ
would
question
use
protocol
employ
quantit
test
howev
separ
meet
requir
establish
aabb
respect
valid
perform
devic
singl
platelet
harvest
backgroundcas
studi
octob
larg
transfus
laboratori
switch
manual
test
methodolog
laboratori
tube
test
previou
year
prepar
chang
autom
platform
decis
made
convert
manual
test
first
gel
thought
standard
stabil
test
platform
test
error
would
decreas
howev
case
particular
manual
aborh
test
studi
designmethod
control
chart
maintain
display
event
test
perform
laboratori
includ
aborh
antibodi
screen
direct
antiglobulin
test
antibodi
identif
antigen
type
control
chart
set
upper
warn
limit
sd
control
limit
sd
upper
warn
limit
reach
indic
review
event
need
done
octob
limit
reach
aborh
test
analysi
event
perform
resultsfind
comparison
number
event
occur
octob
octob
doubl
per
aborh
test
upon
investig
half
event
pre
gel
implement
half
post
howev
look
closer
post
implement
event
impact
twice
number
patient
involv
two
patient
compar
pre
post
event
pre
implement
event
rang
forget
add
miss
mix
field
problem
test
equip
would
solv
gel
technolog
post
implement
event
occur
technologist
perform
aborh
multipl
patient
card
interchang
read
enter
reaction
laboratori
inform
system
label
card
left
tech
prefer
minimum
need
two
patient
identifi
tech
train
verifi
specimen
label
prior
result
entri
use
process
pre
implement
special
emphasi
given
tech
verifi
gel
card
well
three
post
implement
event
two
identifi
test
tech
enter
result
third
caught
due
mismatch
autom
instrument
conclus
switch
gel
test
elimin
rang
defect
creat
new
one
rare
seen
tube
test
uptick
specif
type
event
lab
standard
tech
label
gel
card
requir
card
label
minimum
patient
initi
full
medic
record
number
addit
tech
requir
open
result
grid
card
rather
sampl
card
set
reason
card
must
prior
result
sinc
standard
implement
similar
event
occur
time
public
backgroundcas
studi
process
ensur
administr
prophylact
rh
immun
globulin
rhig
import
manag
women
complianc
aabb
standard
determin
postpartum
rhig
prophylaxi
particularli
challeng
entail
test
mother
babi
result
evalu
togeth
clinic
decis
make
includ
reflex
test
addit
laboratori
studi
miss
test
deviat
test
procedur
result
failur
provid
appropri
adequ
dose
rhig
studi
designmethod
examin
error
deviat
relat
immunohematolog
test
rhig
prophylaxi
hospit
error
aris
provid
side
includ
failur
use
electron
order
set
result
omiss
fetal
bleed
screen
test
rhig
order
blood
bank
error
includ
failur
perform
reflex
test
weak
test
cord
blood
assay
posit
invalid
fetal
bleed
screen
error
includ
perform
weak
indic
babi
born
mother
report
babi
type
report
invalid
posit
weak
result
initi
gener
daili
laboratori
inform
system
report
retrospect
audit
identifi
case
weak
test
miss
subsequ
order
prevent
miss
weak
test
also
address
addit
failur
point
system
design
implement
cord
blood
worksheet
technologist
complet
worksheet
cord
blood
test
use
algorithm
checklist
approach
perform
complet
requir
test
sampl
babi
mother
worksheet
also
captur
document
relat
time
order
provid
issu
rhig
blood
bank
resultsfind
sinc
implement
cord
blood
worksheet
note
error
relat
blood
bank
test
appropri
administr
postpartum
rhig
prophylaxi
worksheet
made
workflow
safer
help
ensur
facil
complianc
aabb
standard
cord
blood
worksheet
also
serv
valuabl
educ
tool
traine
graduat
medic
educ
program
conclus
util
cord
blood
worksheet
simpl
yet
effect
way
guid
accur
immunohematolog
test
prompt
provid
place
appropri
order
postpartum
rhig
prophylaxi
ensur
rhig
issu
blood
bank
time
manner
backgroundcas
studi
oper
excel
oe
applic
far
reach
benefit
organ
includ
reduc
signific
wast
empow
staff
becom
problem
solver
cost
save
despit
mani
benefit
oe
initi
struggl
roadblock
incorpor
oper
excel
oe
exist
busi
cultur
requir
effect
strateg
plan
studi
explor
strategi
use
success
incorpor
oper
excel
busi
cultur
studi
designmethod
oe
steer
committe
formul
member
variou
function
depart
develop
evalu
metric
track
gemba
walk
oe
huddl
effect
ascertain
oe
success
deploy
throughout
organ
metric
target
track
weekli
determin
gap
overcom
resultsfind
initi
train
particip
manag
low
function
depart
report
gemba
walk
given
month
addit
manag
perform
requir
number
gemba
walk
per
month
oe
huddl
score
oe
huddl
effect
post
assess
score
contribut
lack
staff
particip
roadblock
discuss
key
busi
metric
display
huddl
year
oe
signific
improv
made
function
depart
report
gemba
walk
manag
perform
requir
gemba
walk
per
month
addit
oe
huddl
score
due
increas
staff
particip
effect
busi
metric
huddl
group
began
review
roadblock
respect
countermeasur
conclus
particip
low
begin
variou
critic
oe
activ
low
particip
due
busi
prioriti
challeng
forc
oe
background
addit
manag
get
offic
observ
work
perform
manag
perform
gemba
walk
understand
principl
behind
final
natur
work
team
indic
train
understand
basic
principl
conduct
oe
huddl
cours
year
busi
start
incorpor
oe
cultur
success
contribut
coach
workshop
frequent
report
metric
encourag
improv
recognit
success
also
staff
better
understand
appli
oe
workplac
motiv
start
use
problem
solv
tool
pdsa
backgroundcas
studi
electron
medic
record
emr
computer
physician
order
entri
cpoe
facilit
laboratori
test
medic
imag
order
revolution
healthcar
across
countri
past
decad
advantag
includ
signific
decreas
drug
expenditur
improv
effici
diagnost
upgrad
record
report
bill
servic
decreas
bill
error
howev
cpoe
may
also
unexpect
neg
impact
laboratori
includ
blood
bank
bb
affect
test
volum
time
tat
qualiti
metric
institut
stat
request
emerg
depart
ed
complet
within
minut
averag
implement
emr
averag
drop
significantli
mandat
analysi
identifi
caus
possibl
solut
improv
studi
designmethod
retrospect
review
number
stat
request
type
screen
ts
receiv
ed
prior
execut
emr
sampl
ed
patient
record
stat
order
nonconsecut
month
assess
clinic
justif
patient
present
complaint
requir
stat
ts
b
whether
patient
transfus
resultsfind
emr
bb
receiv
monthli
averag
hand
written
stat
ts
order
ed
execut
emr
averag
monthli
stat
order
increas
target
tat
met
order
review
patient
record
present
complaint
justifi
stat
ts
account
includ
acut
neurolog
cardiovascular
symptom
gi
obgyn
bleed
anemia
within
categori
major
patient
anemia
receiv
transfus
other
transfus
clinic
unjustifi
group
includ
patient
complaint
urolog
pain
dermatolog
symptom
local
infect
intox
none
transfus
investig
show
ts
order
ed
includ
default
order
set
default
stat
conclus
although
implement
emr
cpoe
facilit
appropri
priorit
effici
ts
order
come
without
pitfal
autom
preselect
menu
option
may
result
unnecessari
request
exponenti
increas
workload
could
lead
error
delay
result
issu
blood
product
disrupt
qualiti
program
close
monitor
educ
commun
clinic
team
develop
order
set
judici
use
default
set
use
best
practic
alert
bpa
may
help
earli
identif
mitig
undesir
impact
emr
implement
backgroundcas
studi
blood
draw
laboratori
test
lead
iatrogen
anemia
morbid
risk
factor
pediatr
critic
ill
popul
calcul
minimum
volum
need
test
requir
laboratori
assist
typic
impract
clinician
goal
project
develop
smartphon
app
perform
calcul
bedsid
reduc
number
tube
volum
blood
drawn
patient
studi
designmethod
smartphon
app
io
android
devic
develop
user
input
desir
test
select
larg
academ
medic
center
test
menu
app
output
mani
type
blood
collect
tube
need
well
minimum
blood
volum
requir
within
tube
instrument
dead
volum
hematocrit
correct
taken
account
test
may
optim
perform
blood
specimen
combin
calcul
interfac
frequent
order
test
present
resultsfind
app
incorpor
test
panel
encompass
central
laboratori
instrument
system
collect
tube
type
specimen
type
hous
staff
nurs
pediatr
intens
care
unit
picu
integr
app
critic
care
workflow
usag
user
feedback
specimen
collect
pattern
patient
outcom
follow
report
preliminari
feedback
picu
central
laboratori
use
overwhelmingli
posit
conclus
app
tinyblood
greatli
simplifi
calcul
minimum
blood
volum
need
laboratori
test
receiv
overwhelmingli
posit
feedback
avail
free
io
android
backgroundcas
studi
hawaii
donor
rh
neg
lead
shortag
rbc
collect
wide
use
increas
avail
univers
rbc
implement
program
often
prolong
difficult
journey
variabl
degre
success
effect
use
leadership
principl
avoid
project
pitfal
studi
describ
success
launch
program
use
strateg
phase
team
select
multidisciplinari
collabor
exceed
product
right
type
mix
rtm
goal
studi
designmethod
project
divid
phase
valid
steadi
state
growth
distinct
prioriti
approach
valid
phase
focus
quickli
accumul
requir
collect
meet
qualiti
paramet
therefor
approach
includ
care
select
donor
known
pool
commit
wb
donor
staff
technic
train
vendor
educ
onsit
support
phase
priorit
wb
donor
convers
approach
reli
core
team
select
train
staff
perform
manag
therefor
base
convers
rather
total
wb
procedur
rtm
goal
foster
collabor
remov
conflict
interest
recruit
collect
staff
group
receiv
credit
collect
regardless
procedur
type
steadi
state
would
priorit
donor
pool
manag
new
donor
convers
procedur
net
success
rtm
key
perform
indic
kpi
core
collect
team
select
wb
apheresi
pool
basi
technic
skill
also
posit
attitud
abil
commun
motiv
influenc
other
donor
team
member
train
includ
signific
vendor
support
encompass
technic
aspect
also
approach
donor
handl
respons
includ
scenario
prior
collect
date
team
member
identifi
good
candid
collect
base
blood
type
size
preview
elig
notifi
everi
member
collect
staff
everi
staff
member
make
touchpoint
donor
particip
onsit
convers
daili
result
celebr
obstacl
face
collabor
resultsfind
valid
complet
half
time
allot
tabl
show
unit
collect
collect
goal
steadi
state
conclus
strateg
principl
enabl
success
execut
program
complet
valid
ramp
month
ahead
schedul
build
result
similar
leadership
skill
appli
throughout
organ
facilit
project
backgroundcas
studi
industri
includ
blood
donor
center
experienc
challeng
dissemin
inform
time
effect
manner
maintain
minim
disrupt
oper
one
solut
mitig
commun
issu
team
huddl
prior
implement
weekli
huddl
monthli
meet
primari
mean
commun
howev
meet
attend
low
blood
collect
reduc
staff
survey
result
indic
commun
within
work
unit
need
improv
intent
weekli
huddl
posit
impact
commun
reach
staff
minim
disrupt
work
flow
commun
discuss
updat
issu
time
manner
provid
forum
staff
bring
forth
concern
ask
question
studi
designmethod
weekli
huddl
implement
late
two
minut
huddl
held
week
central
locat
within
work
area
blood
collect
reduc
huddl
follow
specif
agenda
templat
cover
updat
donor
appoint
schedul
mobil
schedul
train
equip
procedur
staff
recognit
addit
gener
updat
remind
discuss
staff
encourag
ask
question
bring
forth
concern
april
survey
sent
current
staff
gain
insight
perceiv
impact
weekli
huddl
well
commun
prefer
attend
record
monthli
meet
weekli
huddl
also
compar
resultsfind
survey
respons
rate
result
show
prefer
commun
method
follow
close
weekli
huddl
individu
tie
second
commun
method
commun
method
includ
monthli
meet
signagejob
aid
offic
commun
huddl
improv
commun
within
work
unit
accord
survey
respond
indic
inform
share
huddl
keep
chang
occur
within
work
unit
addit
agre
huddl
provid
venu
bring
forth
concern
ask
question
overal
respond
feel
huddl
worthwhil
use
time
staff
attend
weekli
huddl
shown
increas
monthli
meet
attend
conclus
frequenc
effect
huddl
improv
commun
well
negat
need
tradit
monthli
staff
meet
focu
monthli
meet
shift
educ
opportun
recent
manag
staff
attend
educ
event
team
huddl
learn
new
tactic
incorpor
huddl
includ
huddl
board
display
inform
dashboard
share
relev
statist
schedul
huddl
throughout
week
reach
staff
improv
timeli
inform
deliveri
backgroundcas
studi
organ
undergon
dramat
chang
recent
year
evolv
care
center
greater
bed
becom
headquart
bed
system
keep
institut
push
unifi
process
achiev
better
patient
outcom
conserv
limit
resourc
evalu
exist
arrang
within
clinic
laboratori
blood
product
test
medicaladministr
oversight
transfus
servic
current
provid
region
blood
center
contractu
arrang
began
mani
year
ago
facil
function
small
commun
hospit
evolut
medic
center
network
necessit
explor
develop
implement
insourc
transfus
servic
describ
process
involv
studi
designmethod
sought
develop
expand
global
vision
insourc
central
transfus
servic
serv
patient
need
main
hospit
across
network
gap
analysi
project
budget
gantt
chart
util
determin
minimum
necessari
requir
associ
expens
recur
timelin
deliver
resultsfind
gap
analysi
entail
assess
exist
infrastructur
softwar
system
personnel
laboratori
equip
adequaci
tandem
regulatori
personnel
equip
infrastructur
requir
necessari
safe
support
high
volum
transfus
servic
item
step
necessari
bridg
gap
catalog
budget
accordingli
propos
show
favor
return
invest
within
five
year
approv
hospit
administr
develop
gantt
chart
organ
deliver
coordin
task
timelin
make
apprais
appropri
window
task
complet
provid
aid
formul
evalu
deadlin
respect
task
requir
one
year
prior
continu
post
hold
weekli
meet
formal
minut
ensur
adher
schedul
prompt
attent
problem
mani
aspect
project
move
parallel
requir
care
choreograph
serial
approach
necessit
map
event
order
avoid
pitfal
unforeseen
hurdl
hire
procur
effort
briefli
stall
administr
confront
possibl
significantli
reduc
financi
alloc
state
conclus
care
plan
research
implement
new
transfus
servic
could
achiev
one
year
timelin
timefram
month
would
enabl
adequ
buffer
account
unforeseen
fund
regulatori
impedi
state
feder
level
backgroundcas
studi
draft
guidanc
bpac
fda
propos
method
mitig
risk
bacteri
contamin
platelet
extent
method
impact
platelet
avail
product
cost
must
evalu
herein
attempt
categor
product
financi
impact
associ
bacteri
detect
cultur
bd
per
donat
delay
larg
volum
cultur
per
split
unit
dlvc
bd
per
donat
well
combin
pathogen
reduct
pr
elig
donat
one
aforement
strategi
remaind
studi
designmethod
model
built
assess
product
econom
impact
bacteri
safeti
method
describ
background
blood
center
bc
hospit
abstract
bc
impact
discuss
month
platelet
collect
data
one
bc
analyz
determin
split
rate
sr
total
result
apheresi
platelet
compon
bacteri
safeti
method
method
collect
optim
ensur
maximum
platelet
compon
product
maximum
unit
elig
pr
without
impact
sr
also
calcul
permut
direct
indirect
cost
incur
collect
compon
process
test
releas
assess
static
indirect
cost
eg
administr
includ
revenu
base
sell
price
bd
pr
compon
bc
applic
upcharg
cmv
irradi
averag
direct
cost
associ
dlvc
bd
ad
upcharg
resultsfind
conclus
implement
bacteri
safeti
measur
impact
platelet
avail
day
usabl
shelf
life
product
cost
perform
pr
product
feasibl
bc
without
impact
avail
sr
pr
may
offset
financi
loss
associ
bacteri
safeti
measur
higher
valu
pr
gener
tie
broad
safeti
profil
replac
cmv
irradi
bc
must
select
product
method
consider
hospit
custom
need
willingness
perform
poi
test
bd
backgroundcas
studi
well
document
laboratori
workforc
shrink
due
diminish
influx
medic
technolog
mt
medic
laboratori
technician
mlt
graduat
immin
retir
babi
boomer
competit
new
graduat
fierc
applic
experienc
mtmlt
immunohematolog
refer
laboratori
irl
job
larg
metropolitan
area
rare
workload
referr
lab
increas
hospit
outsourc
antibodi
work
workload
staf
larg
irl
increas
respect
staff
retent
rate
sinc
multipl
complianc
risk
factor
prompt
intens
execut
leadership
scrutini
oversight
deep
dive
caus
complianc
risk
identifi
need
stratifi
workforc
map
task
appropri
job
posit
studi
designmethod
complex
task
time
exercis
perform
return
staff
util
figur
irl
respect
optim
staff
util
target
indic
staff
stretch
beyond
maximum
capac
data
exercis
staff
tabl
organ
review
three
largest
irl
two
high
complianc
risk
individu
staff
interview
observ
perform
independ
parti
familiar
laboratori
process
procedur
resultsfind
two
irl
b
c
higher
complianc
risk
spent
twice
much
time
task
train
compet
assess
equip
qualif
test
task
number
virtual
ident
irl
good
stand
irl
good
stand
three
four
time
staff
support
role
two
irl
higher
complianc
risk
data
analysi
recommend
independ
review
result
addit
two
lab
assist
two
oper
support
specialist
technic
trainer
administr
assist
assum
task
increas
supervisori
presenc
lab
cultur
qualiti
focus
first
time
right
implement
allow
laboratori
quickli
reach
regulatori
complianc
sustain
month
count
conclus
time
studi
coupl
map
task
job
descript
essenti
exercis
maxim
product
certifi
technic
staff
ad
staff
lower
compens
rate
effect
increas
manpow
product
without
ad
expens
abil
certifi
technic
staff
focu
test
task
increas
supervisori
oversight
enhanc
regulatori
complianc
rais
moral
staff
backgroundcas
studi
intraop
cell
salvag
periop
autotransfus
servic
util
either
machin
wall
suction
vacuum
regul
collect
blood
surgic
field
exist
regul
requir
costli
annual
prevent
mainten
pm
outsid
vendor
addit
function
verif
tech
regul
sent
annual
pm
unavail
sever
week
inoper
return
requir
replac
altern
vacuum
regul
lower
cost
less
time
pm
identifi
evalu
exist
regul
studi
designmethod
vacuum
regul
design
cell
salvag
new
vacuum
regul
nvr
obtain
trial
compar
exist
gener
use
vacuum
regul
current
vacuum
regul
cvr
guidelin
avail
perform
comparison
attempt
simul
condit
daili
use
one
regul
model
attach
hospit
wall
vacuum
system
set
aspir
normal
salin
basin
initi
set
use
one
aspirationanticoagul
set
ana
set
yankauer
suction
tip
time
long
took
entir
aspir
content
basin
sinc
surgic
team
commonli
request
two
ana
set
util
one
aspir
field
process
repeat
two
ana
set
one
line
use
aspir
content
basin
left
open
atmospher
resultsfind
use
one
ana
set
regul
model
clear
salin
basin
second
use
two
ana
set
one
line
use
second
open
atmospher
cvr
model
aspir
salin
second
nvr
model
clear
basin
second
find
reproduc
repeat
test
acquisit
cost
nvr
model
higher
cvr
model
howev
cost
analysi
prove
replac
cvr
nvr
would
yield
return
invest
sinc
nvr
model
warranti
annual
pm
requir
given
oper
test
result
high
rate
eas
use
tech
anticip
time
labor
save
favor
cost
analysi
exist
cvr
model
replac
nvr
implement
new
nvr
signific
decreas
complaint
surgeon
weak
suction
reduc
need
troubleshoot
case
chang
note
cell
salvag
qualiti
control
paramet
switch
conclus
switch
current
vacuum
regul
new
vacuum
regul
elimin
time
labor
cost
pm
unexpect
bonu
new
nvr
model
perform
better
use
surgeon
prefer
two
ana
set
setup
result
greater
surgeon
satisfact
backgroundcas
studi
improv
commun
known
posit
affect
healthcar
oper
patient
safeti
blood
bank
bb
oper
significantli
impact
interrupt
due
phone
call
neg
impact
laboratori
workflow
potenti
affect
patient
care
report
experi
newli
form
oper
taskforc
improv
intern
workflow
interdepartment
commun
studi
designmethod
aim
studi
improv
commun
nurs
personnel
outpati
infus
center
institut
specif
reduc
number
phone
call
unit
time
spent
bb
staff
address
concern
oper
taskforc
blood
bank
ambassador
assembl
bridg
commun
gap
clarifi
workflow
nurs
personnel
group
form
supervisor
specialist
medic
director
intervent
strategi
includ
establish
platform
safe
share
idea
identifi
champion
chang
side
outlin
address
signific
concern
team
clarifi
common
goal
ownership
establish
baselin
metric
initi
meet
held
blood
bank
ambassador
nurs
team
compos
nurs
manag
qualiti
improv
personnel
bedsid
nurs
inform
technolog
specialist
follow
addit
clarif
regular
commun
via
email
metric
number
call
bb
estim
time
spent
bb
staff
clarifi
issu
concern
rais
nurs
personnel
resultsfind
baselin
data
show
averag
call
per
month
octob
made
nurs
infus
center
serv
outpati
hematolog
oncolog
servic
institut
approxim
hour
per
month
spent
clarifi
issu
relat
bb
workflow
nurs
unit
common
issu
discuss
transfus
requir
requisit
agre
patient
file
transfus
guidelin
specimen
problem
request
addit
specimen
test
blood
product
avail
duplic
order
first
interdepartment
meet
follow
addit
clarif
via
email
call
number
reduc
per
month
decreas
averag
call
per
month
four
consecut
month
januari
april
repres
reduct
baselin
call
number
estim
time
spent
phone
call
conclus
blood
bank
ambassador
significantli
improv
interdepartment
commun
assert
common
leadership
goal
intern
workflow
posit
affect
dramat
reduct
phone
call
time
spent
clarifi
concern
experi
team
may
reveal
key
factor
success
implement
organiz
chang
backgroundcas
studi
acquir
hemophilia
aha
due
spontan
format
autoantibodi
factor
viii
acquir
bleed
disord
signific
morbid
mortal
therapi
includ
immunosuppress
bleed
control
erad
inhibitor
treatment
underli
condit
bleed
patient
inhibitor
bypass
medic
recombin
activ
factor
vii
rfviia
activ
prothrombin
complex
concentr
apcc
initi
promptli
treatment
advantag
disadvantag
exampl
rfviia
recombin
product
thu
theoret
less
risk
infect
known
unknown
agent
compar
human
product
apcc
howev
cost
rfviia
significantli
higher
thu
develop
econom
model
rigor
examin
cost
effect
rfviia
apcc
scenario
studi
designmethod
markov
decis
analyt
model
develop
simul
hypothet
cohort
adult
patient
bleed
due
aha
treat
either
rfviia
apcc
day
regardless
treatment
model
develop
patient
transit
differ
health
state
continu
bleed
thrombosi
stop
bleed
death
patient
model
bleed
initi
thu
enter
model
stage
depend
probabl
treatment
efficaci
advers
event
subsequ
day
patient
either
remain
state
enter
state
model
absorb
state
mean
patient
transit
state
enter
one
state
patient
experienc
thrombot
event
assum
event
sever
addit
rfviia
apcc
given
also
assum
event
cohort
model
paramet
includ
probabl
health
util
index
cost
gather
medic
literatur
except
cost
apcc
rfviia
obtain
institut
data
resultsfind
period
treatment
cost
rfviia
substanti
cost
apcc
vs
averag
qualiti
adjust
life
day
qald
gain
rfviia
slightli
lower
compar
apcc
vs
overal
apcc
prevail
rfviia
suggest
increment
ratio
sensit
analysi
also
confirm
robust
model
across
test
rang
input
variabl
conclus
aha
patient
bleed
apcc
compar
rfviia
thu
apcc
use
patient
avail
contraind
clinic
backgroundcas
studi
work
fast
pace
surgic
set
make
difficult
establish
reliabl
staf
level
unpredict
hour
lead
larg
amount
overtim
callback
time
extra
hour
work
put
stress
employe
also
sourc
high
burnout
rate
januari
autotransfus
team
implement
multipl
staf
tool
accommod
high
pace
surgic
environ
creat
improv
balanc
twelv
technician
studi
designmethod
team
collect
data
case
perform
blood
salvag
procedur
determin
potenti
chang
staf
model
data
includ
averag
length
time
patient
oper
room
hour
averag
number
surgic
case
period
case
data
analysi
defend
follow
addit
schedul
five
hour
shift
convert
hour
shift
third
technician
two
design
late
shift
cover
potenti
overtim
addit
schedul
chang
implement
commun
sbar
sheet
assist
determin
staf
shift
chang
august
day
current
surgic
case
assign
point
translat
mani
staff
need
end
schedul
shift
eg
one
one
point
process
withdrew
emot
determin
staff
requir
stay
overtim
resultsfind
slight
increas
case
overtim
decreas
hour
increas
howev
minim
increas
hour
per
posit
tabl
data
indic
end
first
shift
approxim
eight
point
assign
schedul
surgic
case
number
point
specifi
averag
four
technician
need
staff
day
prior
implement
tool
number
technician
need
staff
vari
decid
even
shift
technician
conclus
introduc
staf
workload
tool
abl
make
chang
staf
model
improv
staf
model
result
decreas
overtim
less
hour
per
shift
posit
balanc
backgroundcas
studi
blood
center
bc
transit
tradit
model
therapeut
phlebotomi
tb
perform
donor
servic
creation
medic
group
oper
licens
medic
clinic
mc
associ
hospit
allow
perform
bill
profession
nurs
physician
consult
servic
associ
tb
mc
serv
whose
diagnos
allow
crossov
phlebotom
product
allogen
inventori
summar
oper
financi
regulatori
process
studi
designmethod
project
champion
chief
medic
offic
cmo
support
bc
senior
execut
manag
sec
multidisciplinari
work
group
establish
includ
bc
project
manag
physician
train
procedur
writer
therapeut
apheresi
nurs
tan
market
financ
qualiti
assur
inform
technolog
facil
extern
consult
bill
credenti
specialist
attorney
credenti
mc
physician
center
medicar
medicaid
servic
contract
privat
carrier
need
complet
payment
mc
need
inspect
licens
agenc
health
care
administr
procedur
written
accord
appropri
law
regul
new
electron
medic
record
emr
creat
allow
patient
inform
enter
one
tablet
sync
across
devic
method
collect
insur
copay
creat
allow
credit
card
process
cash
check
accept
pilot
program
launch
use
exist
bc
space
modif
reconfigur
recept
area
ensur
emr
visibl
patient
bc
physician
tan
staf
mc
account
receiv
ar
review
resultsfind
workflow
follow
prior
patient
schedul
appoint
accept
insur
prescript
verifi
confirm
day
present
copay
health
screen
includ
vital
perform
tan
physician
complet
histori
physic
patient
clear
tb
occur
clinic
open
patient
present
mean
payment
charg
recov
mc
credenti
medicar
medicaid
contract
privat
carrier
final
sever
carrier
allow
bill
ar
current
day
day
day
day
conclus
creation
medic
group
oper
licens
mc
tb
servic
perform
success
implement
support
sec
cmo
multidisciplinari
team
need
patient
experi
optim
challeng
includ
obtain
contract
payment
carrier
backgroundcas
studi
us
presid
emerg
plan
aid
relief
pepfar
program
integr
blood
safeti
activ
key
strategi
countri
high
preval
hiv
weak
blood
safeti
system
goal
strengthen
blood
transfus
servic
decreas
hiv
infect
tti
provid
univers
access
safe
blood
standard
screen
program
implement
countri
nation
region
blood
center
encompass
questionnair
screen
behavior
exclud
potenti
blood
donor
univers
laboratori
test
hiv
tti
current
major
gap
quantifi
impact
pepfar
hiv
transmiss
risk
blood
donat
studi
designmethod
world
health
organ
global
databas
blood
safeti
data
analyz
select
countri
africa
asia
caribbean
statist
analysi
perform
use
aim
aid
impact
model
goal
modul
spectrum
softwar
version
laboratori
qualiti
hiv
test
assum
sensit
specif
incid
rate
hiv
calcul
preval
rate
hiv
infect
transmit
blood
transfus
infect
blood
donat
time
impact
laboratori
test
program
blood
donat
hiv
transmiss
risk
blood
transfus
determin
estim
number
new
hiv
infect
avert
sinc
implement
pepfar
program
resultsfind
result
indic
hiv
incid
rate
blood
donat
show
decreas
trend
african
countri
cambodia
haiti
follow
pattern
observ
wide
trend
ghana
lesotho
guyana
revers
ethiopia
invert
wide
tajikistan
increas
trend
angola
kazakhstan
kyrgyz
republ
predict
new
hiv
infect
blood
transfus
avert
laboratori
test
increas
time
particip
countri
sum
total
hiv
infect
avert
estim
africa
rang
south
sudan
mozambiqu
caribbean
guyana
haiti
asia
tajikistan
kyrgyz
republ
conclus
mathemat
model
hiv
preval
rate
blood
donat
provid
evid
posit
impact
year
pepfar
support
univers
hiv
test
donat
blood
reduc
risk
hiv
transmiss
blood
transfus
africa
asia
caribbean
countri
sustain
univers
laboratori
test
donat
blood
hiv
number
avert
new
hiv
infect
safe
blood
transfus
expect
increas
backgroundcas
studi
detail
inform
transfus
whole
blood
blood
compon
electron
health
record
ehr
record
inform
standard
blood
transplant
isbt
code
system
unit
state
us
code
system
add
sensit
granular
blood
surveil
code
system
bill
reimburs
code
may
lack
us
food
drug
administr
fda
center
biolog
effect
research
cber
recent
establish
biolog
effect
safeti
best
initi
part
cber
sentinel
program
aim
studi
character
preval
whole
blood
blood
compon
transfus
use
code
particip
data
partner
best
initi
studi
designmethod
explor
approxim
million
patient
record
three
ehr
databas
columbia
univers
stanford
univers
regenstrief
institut
along
librari
code
assess
transfus
whole
blood
blood
compon
red
blood
cell
plasma
cryoprecipit
platelet
resultsfind
transfus
trend
blood
compon
vari
total
transfus
event
red
blood
cell
rbc
account
half
event
platelet
plasma
cryoprecipit
whole
blood
compris
remain
event
observ
increas
rbc
transfus
event
suggest
increas
administr
cryoprecipit
rel
consist
use
plasma
overal
downward
trend
administr
platelet
whole
blood
usag
minim
becam
obsolet
studi
period
conclus
demonstr
use
code
system
feasibl
within
best
ehr
databas
incorpor
code
cber
blood
surveil
system
enhanc
hemovigil
activ
afford
fda
abil
activ
monitor
blood
compon
util
advers
event
backgroundcas
studi
incid
rate
ir
alway
number
case
divid
total
pt
risk
popul
question
incid
method
im
way
case
determin
pt
calcul
repeat
blood
donor
often
vari
investig
recent
paper
model
differ
im
hiv
use
simul
donat
infect
data
found
im
use
investig
sinc
elm
extend
lookback
method
result
bias
estim
differ
im
cm
convent
method
prefer
ir
estim
brambilla
transfus
assess
im
perform
actual
donor
data
calcul
hiv
hcv
ir
five
estim
interv
ei
organ
studi
designmethod
cm
repeat
rpt
donor
consid
incid
contribut
pt
least
donat
exist
within
ei
rpt
donor
lack
prior
donat
within
ei
censor
elm
histori
rpt
donor
within
ei
trace
back
length
time
ei
look
prior
neg
donat
donor
previou
neg
ei
cm
donor
censor
ir
calcul
case
divid
total
time
risk
repeat
donor
express
per
resultsfind
number
hiv
hcv
posit
rpt
donor
use
cm
elm
im
correspond
ir
ei
provid
see
tabl
cm
ir
usual
doubl
ir
elm
correspond
pt
million
million
method
respect
pattern
gener
seen
hcv
except
year
cm
elm
ir
closer
conclus
contrast
analysi
use
simul
data
cm
popul
actual
rpt
donor
produc
consist
higher
ir
compar
elm
advantag
elm
posit
donor
identifi
ei
util
concern
correspond
increas
pt
entir
popul
compens
find
elm
identifi
incid
donor
cm
elm
pt
usual
pt
cm
number
incid
donor
captur
elm
greater
larger
denomin
without
equal
increas
numer
result
lower
elm
ir
simul
attempt
model
differ
condit
chang
donat
frequenc
number
posit
donat
may
match
actual
chang
donor
popul
observ
given
rapid
shift
donor
collect
recent
year
differ
method
difficult
model
thu
incid
method
like
continu
use
backgroundcas
studi
transfus
servic
essenti
compon
everi
system
support
intervent
howev
blood
product
avail
limit
mani
patient
throughout
world
order
improv
access
blood
product
crucial
provid
countri
enough
detail
transfus
need
enabl
target
invest
determin
need
transfus
servic
countri
level
diseas
preval
inform
well
diseas
specif
transfus
rate
requir
diseas
preval
estim
avail
global
burden
diseas
gbd
studi
countri
sex
age
time
propos
use
administr
data
determin
transfus
rate
gbd
caus
appli
rate
gbd
preval
estim
order
determin
blood
product
need
countri
time
studi
designmethod
initi
step
analysi
use
truven
analyt
marketscan
databas
hcup
nationwid
inpati
sampl
determin
pack
red
blood
prbc
platelet
transfus
proport
diseas
categori
inpati
encount
diseas
categori
defin
base
global
burden
diseas
caus
list
inpati
encount
princip
diagnosi
use
determin
like
indic
transfus
transfus
event
defin
least
one
pack
red
blood
cell
platelet
transfus
procedur
code
code
per
inpati
encount
resultsfind
common
inpati
encount
least
one
prbc
platelet
transfus
cancer
relat
anemia
inpati
encount
acut
blood
loss
anemia
hereditari
nutrit
hemolyt
bone
marrow
failur
anemia
bleed
event
chronic
liver
diseas
among
cancer
relat
anemia
leukemia
multipl
myeloma
highest
proport
admiss
least
one
transfus
conclus
popul
level
requir
blood
product
depend
locat
specif
epidemiolog
diseas
profil
use
administr
dataset
indic
transfus
determin
next
step
analysi
determin
diseas
specif
transfus
rate
appli
transfus
rate
diseas
preval
estim
global
burden
diseas
studi
countri
estim
number
need
blood
transfus
contrast
current
transfus
avail
report
global
databas
blood
safeti
backgroundcas
studi
atrial
fibril
af
common
cardiac
arrhythmia
affect
individu
develop
world
year
age
af
like
underdiagnos
result
therapeut
delay
increas
complic
risk
pilot
program
screen
af
mobil
electrocardiogram
ecg
applic
institut
commun
blood
center
benefit
donor
alert
possibl
af
seek
medic
evalu
studi
designmethod
follow
blood
collect
donor
age
older
invit
volunt
screen
af
give
inform
consent
complet
anonym
demograph
medic
histori
form
af
screen
ecg
applic
load
onto
tablet
devic
use
assess
heart
rhythm
result
normal
unclassifi
unread
possibl
af
record
subject
possibl
af
result
reciev
copi
heart
trace
advis
consult
health
provid
particip
also
complet
evalu
incorpor
likert
scale
unfavor
favor
resultsfind
total
donor
averag
age
screen
major
femal
caucasian
allogen
donor
health
provid
minor
subject
report
previou
af
evalu
interpret
normal
two
plu
one
unsur
previou
af
diagnosi
deni
current
af
thirti
plu
one
unsur
report
irregular
puls
histori
possibl
af
result
total
seven
none
previous
evalu
af
though
two
report
irregular
puls
histori
averag
age
possibl
af
less
normal
screen
refer
tabl
cohort
character
user
report
interest
opportun
likert
scale
found
result
usefulhelp
thought
devic
easi
use
like
major
recommend
continu
offer
screen
conclus
pilot
af
screen
program
commun
blood
center
well
receiv
donor
particip
gener
possibl
af
result
studi
older
donor
popul
screen
af
prior
qualifi
blood
collect
warrant
also
correl
diagnost
outcom
possibl
af
screen
would
valuabl
backgroundcas
studi
peripher
blood
hematopoiet
progenitor
cell
hpc
transplant
common
product
hpc
transplant
peripher
blood
hpc
donor
receiv
recombin
human
granulocyt
factor
stimul
product
releas
hpc
peripher
blood
apheresi
collect
among
concern
lactat
peripher
blood
hpc
donor
unknown
potenti
harm
child
via
ingest
potent
growth
factor
nurs
two
studi
previous
describ
excret
human
milk
leav
transplant
commun
limit
inform
make
appropri
safeti
recommend
nurs
hpc
donor
studi
level
measur
lactat
hpc
donor
studi
designmethod
serial
plasma
milk
sampl
collect
volunt
peripher
blood
hpc
donor
concentr
sampl
measur
use
immunoassay
elisa
resultsfind
peak
concentr
donor
milk
hour
first
dose
given
remain
detect
donor
milk
hour
final
dose
conclus
compar
previou
report
higher
peak
concentr
donor
breast
milk
mobil
identifi
addit
still
detect
breast
milk
day
last
dose
time
even
conserv
guidelin
would
allow
donor
resum
breastfeed
underscor
need
cautious
counsel
lactat
hpc
donor
regard
presenc
breast
milk
unknown
risk
pose
nurs
infant
backgroundcas
studi
understand
usag
red
blood
cell
rbc
componentscan
facilit
demand
plan
clinic
suppli
period
review
audit
blood
util
first
step
patient
blood
manag
futurein
studi
aim
nationwid
analysi
red
cell
transfus
clinic
indic
studi
designmethod
nation
health
insur
nhi
program
place
taiwan
sinc
rbc
identifi
diseas
diagnos
surgic
procedur
retriev
nhi
databas
compris
inform
blood
transfus
countri
resultsfind
total
person
transfus
red
cell
unit
adjust
ml
whole
rbc
equival
unit
medic
center
metropolitan
hospit
commun
hospit
clinic
rbc
transfus
medic
center
transfus
metropolitan
commun
hospit
transfus
clinic
total
rbc
unit
transfus
medic
indic
transfus
surgic
indic
obstetr
gynecolog
compar
rbc
transfus
transfus
unit
medic
obstetricsgynecolog
remain
steadi
year
transfus
unit
surgic
procedur
decreas
breakdown
data
show
hematolog
oncolog
disord
account
rbc
transfus
respect
gastrointestin
vascular
cardiothorac
surgeri
also
common
indic
rbc
transfus
rbc
usag
vari
hospit
approxim
rbc
unit
transfus
cancer
patient
medic
center
less
cancer
patient
metropolitan
commun
hospit
hand
significantli
higher
percentag
rbc
usag
gastrointestin
surgeri
respiratori
diseas
observ
metropolitan
commun
hospit
compar
medic
center
intern
medic
procedur
number
rbc
unit
transfus
per
hospit
similar
hospit
howev
signific
variat
observ
surgic
procedur
hospit
conclus
first
comprehens
analysi
rbc
usag
taiwan
studi
identifi
clinic
area
red
cell
unit
transfus
countri
data
import
futur
plan
provid
inform
realiz
patient
blood
manag
backgroundcas
studi
rare
blood
group
rh
encod
differ
allel
also
encod
partial
e
call
phenotyp
often
segreg
allel
encod
partial
thu
subject
like
develop
alloantibodi
respons
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
unit
scarc
donor
test
reagent
procedur
accur
screen
antigen
weaken
commonli
seen
report
case
pregnant
women
differ
antibodi
profil
least
incompat
unit
select
studi
designmethod
standard
hemagglutin
genom
techniqu
use
resultsfind
patient
week
pregnanc
fetal
distress
report
rhd
darrhc
cear
homozyg
immun
reactiv
titer
unit
propos
iut
high
risk
immun
ten
day
later
due
sever
renal
failur
patient
fetu
die
cover
hemorrhag
two
option
possibl
rr
unit
would
incompat
iat
unit
would
incompat
without
prevent
immun
best
scenario
would
r
r
unit
avail
deliv
patient
rhd
darrhc
cear
homozyg
immun
deliveri
respect
titer
rr
unit
consid
reactiv
use
r
r
unit
bare
reactiv
passiv
antibodi
found
newborn
babi
harbor
partial
discov
hbss
rh
unit
reactiv
even
though
r
r
unit
order
prevent
immun
unit
consid
best
option
easier
collect
unit
patient
normal
deliveri
pregnanc
titrat
weakli
reactiv
untreat
rbc
unit
select
mother
mother
blood
propos
newborn
luckili
transfus
need
two
year
later
new
pregnanc
month
emerg
deliveri
perform
fetal
distress
titer
birth
hemoglobin
emerg
transfus
done
fresh
unit
follow
exchang
transfus
use
phenotyp
patient
normal
antibodi
titer
perform
rr
rbc
respect
lost
first
newborn
month
week
could
carri
last
pregnanc
term
unit
rhnull
suitabl
transfus
conclus
transfus
immun
individu
unit
avail
follow
phenotyp
test
rr
r
r
rhnull
depend
antibodi
strength
clinic
histori
avail
unit
best
altern
decid
close
cooper
clinic
team
essenti
set
earliest
stage
pregnanc
case
illustr
urgent
need
implement
effici
procedur
donor
test
pick
unit
well
donor
recruit
campaign
target
individu
backgroundcas
studi
organ
procur
transplant
network
optn
recommend
routin
subtyp
group
kidney
donor
donor
express
lower
amount
antigen
use
recipi
blood
type
b
despit
guidanc
kidney
transplant
sinc
decemb
subtyp
quarter
organ
procur
organ
opo
report
issu
subtyp
serolog
base
abo
type
subtyp
blood
type
may
inform
patient
receiv
transfus
advent
next
gener
sequenc
ng
technolog
allow
rapid
scalabl
method
molecular
determin
abo
blood
type
subtyp
may
address
limit
serolog
method
enabl
widespread
adopt
subtyp
kidney
transplant
studi
designmethod
develop
ng
base
method
specif
amplifi
enrich
sequenc
exon
abo
gene
follow
short
read
sequenc
use
either
miseq
platform
illumina
inc
raw
sequenc
data
process
use
custom
bioinformat
pipelin
allow
infer
abo
blood
type
subtyp
combin
sequenc
inform
popul
base
frequenc
variou
allel
concord
observ
abo
genotyp
serolog
determin
use
data
individu
match
abo
genotypeserolog
inform
concord
subtyp
determin
use
data
individu
match
subtyp
genotypeserolog
inform
resultsfind
exon
complet
sequenc
use
custom
ng
base
assay
observ
concord
abo
genotyp
correspond
serolog
individu
unambigu
genotyp
subtyp
avail
case
case
allel
could
unambigu
distinguish
allel
eight
case
serotyp
one
case
serotyp
combin
sequenc
data
inform
public
databas
allow
us
success
infer
genotyp
case
concord
among
patient
unambigu
subtyp
four
discrep
case
two
case
patient
allel
identifi
serolog
two
case
serolog
indic
subtyp
allel
identifi
genotyp
conclus
studi
demonstr
feasibl
use
molecular
techniqu
routin
subtyp
donor
patient
await
renal
transplant
understand
reason
observ
discrep
genotyp
serolog
improv
genotyp
determin
may
need
routin
implement
abo
genotyp
clinic
laboratori
backgroundcas
studi
deleteri
variant
affect
cybb
gene
region
associ
loss
nicotinamid
adenin
dinucleotid
nadph
function
chronic
granulomat
diseas
cgd
directli
upstream
cybb
gene
xk
gene
encod
kx
transmembran
protein
red
blood
cell
loss
kx
protein
greatli
reduc
express
kell
system
antigen
refer
mcleod
mld
phenotyp
mld
neuroacanthocytosi
syndrom
includ
chronic
anemia
late
onset
neuromuscular
complic
mld
syndrom
cgd
rare
describ
patient
delet
affect
cybb
xk
two
black
male
age
present
separ
brother
hospit
multifoc
lung
consolid
year
old
receiv
four
granulocyt
transfus
cgd
therapi
hospit
chronic
right
lung
fungal
pneumonia
produc
year
old
brother
receiv
three
red
blood
cell
unit
anemia
produc
antibodi
perform
serolog
dna
studi
individu
illustr
fuller
pictur
red
cell
phenotyp
identifi
caus
genet
variant
studi
designmethod
pool
human
sera
region
tile
genom
pcr
strategi
use
detect
larg
region
x
chromosom
delet
publish
primer
gassner
et
al
use
amplifi
genom
pcr
target
span
mbp
region
contain
cybb
xk
gene
follow
use
custom
primer
strategi
resultsfind
brother
red
blood
cell
found
weakli
reactiv
cellano
kpb
antisera
contigu
pcr
amplicon
fail
amplifi
consist
larg
delet
fine
map
stepwis
pcr
strategi
identifi
approxim
delet
affect
gene
xk
cybb
conclus
studi
mld
phenotyp
cgd
identifi
previous
unreport
delet
affect
least
function
gene
includ
xk
cybb
evalu
patient
either
cgd
mld
syndrom
consid
evalu
syndrom
syndrom
suspect
genet
studi
includ
method
capabl
detect
type
loss
function
variat
identifi
extent
delet
transfus
exposur
minim
whenev
possibl
case
due
risk
provok
respons
backgroundcas
studi
appropri
classif
rhd
phenotyp
crucial
correct
indic
immunoglobulin
rhig
pregnant
women
serolog
distinct
weak
partial
phenotyp
often
doubt
make
genet
analysi
rhd
gene
highli
recommend
pregnant
women
addit
properli
defin
rhd
phenotyp
one
import
aspect
matern
medicin
predict
whether
rhd
variant
alloimmun
pregnant
woman
order
indic
appropri
use
rhig
base
analyz
rhd
gene
cohort
pregnant
women
popul
southeast
brazil
serolog
weak
phenotyp
evalu
implic
variant
found
alloimmun
studi
designmethod
select
total
prenat
patient
sampl
sampl
show
weak
reactiv
type
routin
antigen
express
evalu
tube
gel
hemagglutin
four
monoclon
reagent
dna
test
ldt
rhd
beadchip
bioarray
solut
immucor
sequenc
use
identifi
rhd
allel
resultsfind
standard
serolog
reactiv
identifi
could
predict
type
variant
would
identifi
agglutin
vari
molecular
analys
show
pregnant
women
rhd
weak
type
potenti
risk
rhd
weak
type
risk
patient
previous
gestat
ig
prophylaxi
patient
show
neg
antibodi
screen
follow
conclus
result
show
weak
type
far
frequent
type
variant
select
prenat
patient
popul
serolog
weak
phenotyp
accord
literatur
obstetr
patient
risk
candid
rhig
accord
result
use
rhd
genotyp
could
prevent
unnecessari
inject
rhig
pregnant
women
serolog
weak
phenotyp
howev
immun
observ
cohort
pregnant
women
weak
type
even
use
rhig
previou
gestat
backgroundcas
studi
knowledg
preval
rh
variant
support
develop
strategi
match
rh
avoid
rh
alloimmun
risk
hemolyt
transfus
reaction
andor
poor
transfus
outcom
molecular
rh
type
perform
identifi
rh
alter
allel
play
import
role
expand
match
scd
patient
donor
rh
system
studi
examin
transfus
request
donor
unit
compar
rhce
allel
scd
patient
rh
allel
frequenc
donor
popul
addit
number
potenti
compat
donor
assess
per
request
aim
identifi
rh
genotyp
lack
insuffici
donor
cohort
studi
designmethod
request
rh
genotyp
match
donor
januari
januari
evalu
patient
donor
rhd
rhce
allel
determin
laboratori
develop
test
ldt
rhd
rhce
sequenc
use
determin
genotyp
among
patient
african
brazilian
blood
donor
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
evalu
number
potenti
compat
donor
resultsfind
evalu
transfus
request
patient
two
also
rh
alloantibodi
found
differ
combin
rhce
variant
allel
predict
partial
antigen
lack
high
preval
antigen
patient
frequent
allel
rhce
rhce
c
ce
sand
rhce
cear
although
rh
allel
also
found
donor
number
donor
homozyg
rh
genotyp
insuffici
fulfil
transfus
request
conclus
although
common
c
ce
allel
associ
rh
genotyp
match
request
uncommon
donor
abil
identifi
unit
fill
transfus
request
challeng
fill
request
unit
special
challeng
phenotyp
much
less
frequent
donor
develop
strategi
screen
donor
optim
identif
donor
rh
variant
allel
critic
support
scd
patient
rh
genotyp
match
unit
backgroundcas
studi
novel
drug
use
treatment
multipl
myeloma
daratumumab
dara
interfer
diagnost
screen
identif
unexpect
antibodi
caus
reagent
red
blood
cell
rrbc
complic
detect
underli
potenti
clinic
relev
moment
strategi
overcom
problem
howev
sever
drawback
aim
studi
evalu
diagnost
use
novel
recombin
particular
emphasi
dilut
effect
solubl
detect
unexpect
antibodi
studi
designmethod
fusion
protein
contain
extracellular
domain
express
mammalian
cell
purifi
evalu
diagnost
function
spike
donor
plasma
contain
mix
vari
volumesconcentr
pb
control
incub
minut
antibodi
detect
perform
indirect
antiglobulin
test
iat
convent
tube
techniqu
dg
gel
techniqu
resultsfind
ratio
recombin
nomin
concentr
per
plasma
allow
complet
inhibit
respect
inhibit
spike
bare
detect
amount
donor
plasma
could
readili
detect
sampl
contrast
demonstr
dg
gel
techniqu
incub
dilut
prepar
respect
simul
dara
plasma
spike
antibodi
could
still
detect
conclus
present
result
show
inhibit
therapeut
plasma
concentr
daratumumab
use
novel
small
volum
without
interfer
alloantibodi
detect
addit
data
confirm
success
neutral
subsequ
antibodi
detect
requir
highli
concentr
neutral
plasma
screen
avail
routin
techniqu
tube
gel
techniqu
enabl
complet
inhibit
minim
dilut
plasma
highli
concentr
present
work
may
provid
combin
iat
rapid
accur
screen
identif
method
even
weakli
react
mask
backgroundcas
studi
mn
blood
group
antigen
present
extracellular
domain
glycophorin
gpa
glycophorin
b
gpb
mn
antigen
express
gpa
ss
antigen
express
gpb
hand
glycophorin
e
gpe
express
erythrocyt
membran
glycophorin
famili
gene
call
gypa
gypb
gype
locat
chromosom
high
homolog
normal
antigen
sensit
proteas
antigen
prm
identifi
sta
gpzan
en
uk
kikuchi
uchikawa
et
al
report
novel
prm
low
molecular
weight
studi
perform
immunochem
serolog
molecular
genet
analysi
novel
prm
antigen
confirm
prm
present
gp
hybrid
molecul
studi
designmethod
prm
screen
blood
donor
perform
japanes
red
cross
kanto
koshinetsu
block
blood
center
june
novemb
mn
blood
type
determin
autom
blood
group
machin
monoclon
red
blood
cell
rbc
suspend
bromelin
solut
posit
reaction
observ
n
antigen
examin
standard
tube
method
rbc
membran
protein
analyz
immunoblot
flow
cytometr
analysi
ss
antigen
rbc
perform
polyclon
identifi
molecular
mechan
novel
prm
antigen
reticulocyt
mrna
genom
dna
donor
analyz
pcr
clone
follow
sequenc
genom
fragment
span
sequenc
exon
downstream
exon
upstream
exon
downstream
exon
amplifi
gdna
pcr
sequenc
resultsfind
rbc
among
investig
individu
agglutin
even
bromelin
treatment
immunoblot
individu
show
strong
abnorm
band
molecular
weight
approxim
kda
lower
gpb
band
react
antibodi
recogn
extracellular
cytoplasm
domain
gpa
among
individu
type
mn
none
individu
ss
five
individu
individu
howev
antigen
densiti
rbc
almost
half
compar
control
rbc
rbc
respect
flow
cytometr
analysi
among
individu
express
low
incid
antigen
miltenberg
sta
observ
clone
sequenc
analysi
use
cdna
reveal
individu
prm
compris
exon
specif
sequenc
fuse
exon
pcr
amplifi
larg
fragment
gypb
gdna
show
replac
gyp
hybrid
allel
junction
occur
bp
upstream
exon
conclus
prm
predict
encod
gyp
hybrid
gene
primari
structur
polypeptid
encod
hybrid
gene
compris
amino
acid
residu
gpe
fuse
residu
gpb
polypeptid
express
antigen
ss
antigen
backgroundcas
studi
abo
type
recipi
donor
import
optim
transfus
transplant
outcom
although
serolog
abo
type
highli
reliabl
limit
discord
forward
revers
type
addit
live
solid
organ
stem
cell
donor
evalu
often
involv
buccal
swab
prevent
upfront
serolog
abo
type
combin
dna
base
genotyp
solut
use
help
resolv
serolog
abo
discord
well
screen
transplant
donor
abo
method
requir
interpret
subject
matter
expert
sought
develop
target
abo
next
gener
sequenc
ng
assay
along
companion
interpret
softwar
autom
data
process
abo
type
known
abo
allel
studi
designmethod
target
long
rang
pcr
base
dna
enrich
abo
gene
achiev
evalu
seri
pcr
primer
combin
use
blood
buccal
swab
isol
dna
pcr
product
run
agaros
gel
agil
bioanalyz
determin
product
size
qualiti
promis
pcr
product
underw
illumina
trusight
ng
librari
prepar
sequenc
use
illumina
miseq
investig
previous
creat
curat
allel
databas
http
bloodantigenscom
custom
bloodtyp
interpret
softwar
determin
blood
group
whole
genom
sequenc
data
previou
effort
improv
upon
curat
abo
allel
ad
ng
sequenc
read
base
cistran
phase
bloodtyp
softwar
determin
full
abo
allel
haplotyp
resultsfind
pcr
primer
evalu
show
reproduc
pcr
product
span
abo
exon
blood
sampl
buccal
swab
yield
good
qualiti
ng
data
exon
encod
major
abo
specif
includ
abo
subtyp
ax
weak
antigen
aw
ael
hybrid
allel
cisab
b
verifi
abo
ng
assay
combin
blood
buccal
swab
sampl
test
found
concord
serolog
abo
type
sanger
sequenc
weak
subtyp
hybrid
allel
sampl
found
case
target
abo
ng
result
could
fulli
resolv
cistran
phase
genotyp
allow
unambigu
allel
determin
interpret
softwar
conclus
target
abo
ng
base
assay
develop
optim
blood
buccal
swab
isol
dna
companion
interpret
softwar
autom
ng
abo
analysi
develop
correctli
determin
abo
type
compar
serolog
sanger
sequenc
assay
softwar
interpret
repres
new
improv
standard
dna
base
abo
test
allow
abo
type
blood
sampl
avail
resolut
weak
subtyp
hybrid
abo
allel
backgroundcas
studi
recombin
blood
group
protein
rbgp
solubl
protein
deriv
eukaryot
express
system
mimic
red
cell
blood
group
antigen
studi
evalu
rbgp
potenti
use
red
cell
immunohaematolog
rci
laboratori
elucid
complex
antibodi
antenat
test
current
laboratori
method
use
resolv
complex
case
multipl
antibodi
antibodi
high
frequenc
antigen
antibodi
high
titr
low
avid
htla
natur
cumbersom
investig
requir
great
deal
oper
expertis
may
lead
delay
provis
suitabl
red
cell
unit
transfus
previou
studi
involv
rbgp
shown
signific
potenti
reduc
turnaround
time
antibodi
investig
subsequ
provis
red
cell
unit
patient
complex
antibodi
studi
evalu
use
rbgp
rci
laboratori
studi
designmethod
sampl
contain
complex
antibodi
test
use
appropri
rbgp
imusyn
inhibit
assay
use
per
manufactur
instruct
plasma
incub
rbgp
inhibit
specif
antibodi
cognat
blood
group
antigen
follow
indirect
antiglobulin
test
biorad
gel
card
method
resultsfind
sampl
test
contain
htla
type
antibodi
success
inhibit
use
rbgp
sampl
contain
antibodi
high
frequenc
antigen
success
inhibit
lower
frequenc
antibodi
also
test
use
rbgp
result
includ
tabl
conclus
recombin
blood
group
protein
novel
effect
way
manag
sampl
antenat
test
inhibit
assay
quick
straightforward
method
facilit
fast
antibodi
identif
allow
rapid
effect
provis
suitabl
unit
patient
requir
transfus
also
stratif
risk
due
antibodi
implic
hdfn
two
notabl
case
observ
wherebi
rbgp
allow
prompt
identif
specif
includ
antibodi
thu
facilit
provis
suitabl
unit
expedi
note
high
percentag
htla
type
antibodi
inhibit
success
howev
note
accur
assign
specif
ambigu
type
antibodi
backgroundcas
studi
blood
transfus
therapi
standard
care
manag
anemia
thalassemia
patient
mani
recipi
lead
accumul
excess
iron
hemochromatosi
inherit
iron
storag
disord
increas
risk
develop
iron
overload
mutat
hfe
gene
impair
molecular
mechan
remov
excess
iron
thalassemia
patient
routin
character
mutat
hbb
gene
encod
screen
hfe
mutat
current
part
explor
preval
hfe
mutat
chronic
transfus
pediatr
adolesc
thalassemia
patient
pakistan
evalu
dna
profil
hbb
hfe
gene
mutat
object
improv
thalassemia
patient
manag
studi
designmethod
pediatr
adolesc
patient
treat
afzal
memori
thalassemia
foundat
amtf
hospit
screen
singl
assay
use
novel
leansequenc
process
develop
biomolecular
analyt
panel
includ
set
thalassemia
bp
delet
cd
g
g
g
g
c
ttct
c
c
g
g
sickl
cell
hb
c
e
hemochromatosi
hfe
mutat
duplic
barcod
buccal
swab
sampl
collect
crude
extract
prepar
without
dna
purif
patel
et
al
crude
extract
amplifi
multiplex
pcr
reaction
hbb
hfe
gene
analyz
leansequenc
also
analyz
group
patient
extend
set
red
blood
cell
antigen
present
data
elsewher
proceed
resultsfind
patient
homozyg
heterozyg
hfe
mutat
normal
hbb
g
c
common
mutat
group
homozyg
compound
heterozyg
mostli
codon
g
ivsi
g
hb
e
also
common
codon
g
homozyg
compound
heterozyg
g
c
g
ttct
patient
identifi
bp
delet
homozyg
heterozyg
ttct
patient
compound
het
hb
e
sickl
cell
mutat
patient
normal
hb
hb
c
mutat
conclus
hfe
gene
mutat
uncommon
pakistani
thalassemia
patient
routin
screen
mutat
would
provid
addit
input
design
individu
proactiv
transfus
therapi
especi
pediatr
patient
name
routin
provid
cell
select
accord
patient
extend
rbc
antigen
profil
minim
risk
alloimmun
reduc
preval
condit
report
increas
frequenc
transfus
likewis
reduc
risk
iron
overload
leansequenc
mutat
panel
describ
potenti
facilit
routin
assess
patient
also
may
prove
benefici
thalassemia
carrier
screen
backgroundcas
studi
discrep
test
method
whether
autom
versu
tube
serolog
versu
dna
led
identif
novel
jk
allel
thirti
allel
code
alter
silenc
express
jk
multipl
ethnic
known
investig
jk
donor
jkb
serolog
discord
current
histor
type
patient
jk
phenotyp
differ
jk
predict
dna
studi
designmethod
rbc
type
perform
standard
tube
method
monoclon
clone
clone
genom
dna
isol
wbc
hea
precisetyp
perform
patient
jk
code
exon
amplifi
sequenc
resultsfind
sampl
south
asian
male
donor
rbc
current
donat
type
jk
b
histor
record
indic
jk
tube
test
rbc
weakli
reactiv
immucor
seraclon
rbc
also
jk
sequenc
result
sampl
heterozyg
predict
jk
ab
addit
novel
chang
c
encod
identifi
chang
exom
aggreg
consortium
exac
rare
frequenc
sampl
year
old
caucasian
femal
patient
rbc
type
jk
hea
precisetyp
predict
jk
addit
test
found
rbc
immucor
seraclon
rbc
also
type
jk
b
jk
sequenc
exon
confirm
jk
b
also
reveal
novel
chang
found
dbsnp
exac
databas
sequenc
primer
link
new
chang
jk
conclus
report
two
new
jk
allel
jk
b
c
jk
c
previous
report
similar
chang
encod
differ
amino
acid
chang
conjunct
c
silent
report
two
swiss
donor
jkb
detect
adsorptionelut
henni
et
al
vox
sang
chang
predict
locat
close
membran
protein
ramsey
et
al
transfus
known
encod
partial
jkb
jk
identifi
patient
whose
rbc
type
jk
multipl
reagent
predict
locat
transmembran
ramsey
et
al
transfus
impact
protein
express
difficult
predict
sampl
insuffici
adsorptionelut
studi
determin
allel
encod
jka
null
phenotyp
low
level
jka
antigen
number
discord
identifi
serolog
dna
studi
show
combin
power
serolog
molecular
type
test
patient
donor
backgroundcas
studi
identif
group
solid
organ
evalu
red
blood
cell
rbc
allow
abo
incompat
aboi
transplant
group
b
recipi
classif
determin
use
lectin
manufactur
extract
dolicho
biflori
seed
dilut
differenti
human
group
rbc
subgroup
weak
reactiv
observ
rbc
use
either
two
reagent
manufactur
reagent
state
weak
reaction
occur
rbc
understand
implic
weak
lectin
rbc
type
subgroup
classif
evalu
incid
weak
hemagglutin
two
licens
lectin
reagent
associ
abo
allel
use
genom
dna
sequenc
exon
studi
designmethod
lectin
type
perform
use
two
licens
reagent
accord
manufactur
protocol
valid
use
known
reagent
rbc
weak
reactiv
defin
hemagglutin
either
lectin
reagent
sampl
abo
group
use
standard
licens
antisera
b
rbc
genom
dna
extract
subject
abo
exon
sequenc
use
intron
flank
primer
exon
two
overlap
fragment
exon
standard
sanger
dideoxi
sequenc
perform
use
bigdy
termin
cycl
sequenc
kit
sequenc
data
align
resultsfind
incid
weak
lectin
reactiv
approxim
among
blood
donor
sixteen
group
blood
donor
identifi
along
one
group
live
kidney
donor
live
donor
histori
deem
purpos
aboi
transplant
kidney
acut
reject
day
group
recipi
rbc
live
kidney
donor
reactiv
lectin
donor
heterozyg
abo
c
suggest
inherit
one
abo
allel
sixteen
heterozyg
abo
c
live
kidney
donor
homozyg
abo
oc
abo
pair
abo
could
rule
given
none
sampl
weakli
reactiv
licens
thu
three
abo
allel
could
assign
sequenc
data
abo
one
abo
one
abo
abo
allel
pair
abo
one
abo
abo
one
abo
one
abo
one
abo
three
unassign
abo
allel
control
consist
three
group
donor
rbc
hemagglutin
along
two
group
donor
one
ab
donor
rbc
nonreact
test
use
lectin
sequenc
control
sampl
reveal
three
consensu
abo
three
abo
one
abo
conclus
weak
equivoc
result
lectin
rel
common
among
donor
analysi
abo
exon
sequenc
data
reveal
abo
common
allel
reveal
nucleotid
chang
associ
weak
lectin
reactiv
weak
reactiv
lectin
link
abo
allel
name
abo
abo
small
survey
express
group
carbohydr
chain
among
abo
allel
systemat
evalu
acut
reject
abo
kidney
aboi
recipi
suggest
addit
biochem
studi
warrant
backgroundcas
studi
human
platelet
antigen
hpa
implic
fetomatern
alloimmun
thrombocytopenia
fmait
platelet
plt
refractori
post
transfus
purpura
until
type
hpa
identifi
approxim
half
hpa
report
caus
gene
mutat
three
mutat
gene
identifi
lab
caus
substitut
respect
mutat
heterozyg
three
individu
unabl
determin
effect
point
mutat
hpa
antigen
directli
studi
recombin
express
plasmid
gpiiia
three
variant
construct
vitro
recombin
protein
extract
coupl
luminex
bead
test
platelet
antibodi
use
luminex
xmap
technolog
determin
whether
three
point
mutat
effect
hpa
antigen
studi
designmethod
cdna
amplifi
ligat
vector
ligat
plasmid
transfect
chines
hamster
ovari
cell
cho
respect
stabli
express
cell
select
screen
protein
extract
confirm
western
blot
use
tag
antibodi
protein
coupl
micro
bead
respect
coupl
bead
valid
anti
human
igg
serum
sampl
test
use
coupl
bead
bead
react
serum
sampl
respect
complex
subject
flow
cytometr
analysi
standard
serum
use
posit
control
three
neg
sera
without
hpa
antibodi
prepar
ab
type
blood
donor
use
neg
control
resultsfind
western
blot
analysi
reveal
establish
cell
line
express
gpiiia
molecul
molecular
weight
wt
similarli
protein
identifi
cell
prematur
stop
mutat
luminex
mfi
show
three
bead
coupl
gpiiia
protein
wt
respect
exhibit
similar
result
react
sarum
impli
new
mutat
affect
antigen
hpa
serum
sampl
one
posit
consist
result
measur
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
conclus
report
recombin
express
four
gpiiia
molecular
found
mutat
affect
express
protein
luminex
bead
use
coupl
recombin
protein
detect
hpa
antibodi
show
mutat
effect
antigen
hpa
compar
wild
type
result
consist
maipa
assay
work
sponsor
nation
natur
scienc
foundat
china
scienc
research
foundat
zhejiang
healthi
bureau
backgroundcas
studi
inconclus
reactiv
solid
phase
sprca
antibodi
screen
identif
led
develop
follow
workflow
effici
manag
pretransfus
sampl
larg
academ
tertiari
care
center
autom
sprca
screen
panreact
screen
cell
sampl
antibodi
screen
absc
repeat
polyethylen
glycol
peg
tube
patient
histori
antibodi
peg
absc
neg
absc
interpret
neg
patient
may
elig
comput
crossmatch
compat
blood
risk
move
peg
tube
test
failur
identifi
antibodi
reactiv
sprca
studi
quantifi
often
workflow
use
antibodi
detect
failur
consequ
studi
designmethod
retrospect
review
absc
result
perform
januari
decemb
sprca
perform
immucor
readi
screen
norcross
ga
usa
result
correct
neg
peg
absc
identifi
review
antibodi
identif
ab
id
subsequ
antibodi
screen
clinic
insignific
autoantibodi
exclud
detail
immunohematolog
workup
collect
includ
transfus
reaction
direct
antiglobulin
test
dat
acid
eluat
test
tube
peg
tube
method
respect
resultsfind
absc
perform
neg
peg
absc
identifi
new
antibodi
found
sampl
peg
absc
twenti
seven
patient
new
signific
alloantibodi
peg
absc
identifi
jka
commonli
detect
antibodi
tabl
antibodi
detect
within
week
initi
correct
peg
absc
eleven
patient
receiv
rbc
transfus
correct
result
new
ab
id
time
ab
id
dat
result
posit
acid
eluat
neg
posit
dat
one
delay
transfus
reaction
identifi
patient
howev
transfus
preced
posit
sprca
screen
conclus
workflow
defer
peg
absc
miss
clinic
signific
alloantibodi
serolog
clinic
consequ
rare
transfus
infrequ
initi
correct
screen
detect
alloantibodi
benefit
workflow
labor
suppli
save
posit
spcra
screen
signific
antibodi
identifi
address
concern
miss
antibodi
threshold
move
peg
absc
adjust
result
cell
sampl
sprca
screen
backgroundcas
studi
delay
hemolyt
transfus
reaction
dhtr
due
rbc
rbc
lysi
descript
sever
dhtr
cell
diseas
scd
patient
scarc
dhtr
nearli
untransfus
patient
pt
associ
novel
clinic
import
high
incid
hi
antibodi
dombrock
system
describ
studi
designmethod
yo
posit
woman
without
scd
prior
surgeri
multipl
rbc
alloantibodi
e
fya
jkb
lea
jsa
possibl
leb
fyb
neg
dat
admit
nstemi
percutan
coronari
intervent
treatment
aspirin
enoxaparin
ticagrelor
hgb
drop
hematemesi
hypotens
neg
rbc
emerg
transfus
day
despit
posit
antibodi
screen
upper
gi
bleed
gib
confirm
endoscop
appear
resolv
hgb
rose
epo
iv
iron
ad
gib
recur
day
requir
gastrectomi
hgb
drop
dat
posit
unidentifi
hi
antibodi
system
becam
serolog
appar
monocyt
monolay
assay
test
hi
antibodi
reveal
reactiv
monocyt
normal
suggest
acceler
clearanc
hi
rbc
addit
salin
compat
least
incompat
rbc
unit
transfus
day
due
hemolysi
surgic
loss
lab
icter
serum
reveal
total
bilirubin
ldh
ul
haptoglobin
creatinin
treatment
ivig
eculizumab
rituximab
began
day
day
without
transfus
day
discharg
hgb
resultsfind
hi
antibodi
holley
hy
rbc
howev
anomal
antigen
suspect
pt
heterozyg
variant
respons
hy
antigen
express
genom
sequenc
exon
reveal
heterozygos
nonsynonym
snp
variant
report
well
snp
characterist
domr
identifi
phase
variant
identifi
yet
determin
variant
may
alter
hy
antigen
could
explain
serolog
find
conclus
sever
dhtr
pt
unusu
recognit
treatment
nearli
untransfus
pt
requir
daili
clinic
commun
first
exampl
highli
antibodi
pt
variant
like
modifi
hy
strength
perhap
respons
novel
hi
antibodi
backgroundcas
studi
abo
antibodi
detect
blood
type
lung
transplant
patient
occasion
frequenc
time
detect
persist
descript
clinic
outcom
presenc
antibodi
report
studi
designmethod
singl
center
retrospect
review
lung
transplant
recipi
antibodi
januari
decemb
perform
avail
relev
clinic
patholog
transfus
serolog
data
collect
electron
medic
record
resultsfind
four
recipi
identifi
among
total
lung
transplant
descript
patient
procedur
characterist
four
recipi
seen
tabl
lung
alloc
score
rang
recipi
abo
type
rhd
one
addit
cold
agglutinin
lung
donor
abo
type
present
transplant
transplant
recipi
persist
strength
recipi
vari
greatli
tabl
intraop
transfus
support
minim
three
patient
total
product
fourth
requir
massiv
resuscit
product
two
patient
treat
suspect
humor
reject
one
new
hla
antibodi
one
empir
base
radiolog
spirometr
find
length
stay
rang
transbronchi
biopsi
two
patient
acut
cellular
reject
acr
singl
biopsi
one
one
one
patient
two
biopsi
one
patient
acr
rang
mo
patient
live
graft
viabl
conclus
lung
transplant
across
blood
group
mismatch
occur
occas
appear
antibodi
prior
transplant
appear
correl
graft
dysfunct
cellular
reject
case
seri
patient
strongest
persist
antibodi
titer
requir
massiv
transfus
also
cold
agglutinin
activ
infect
longer
larger
multicent
trial
need
better
understand
outcom
titer
confirm
backgroundcas
studi
en
rbc
complet
nearli
complet
absenc
glycophorin
gpa
two
en
mn
blood
group
variant
describ
finnish
type
delet
gypa
exon
en
fin
mweak
uk
type
gp
hybrid
short
gpa
segment
en
uk
en
rbc
decreas
sialic
acid
loss
wrb
express
caus
hemolysi
allogen
rbc
en
donor
extrem
rare
worldwid
addit
genet
inform
highli
desir
studi
designmethod
serolog
test
perform
routin
method
blood
group
phenotyp
employ
hea
immucor
norcross
ga
gypa
analyz
amplif
sequenc
exon
resultsfind
woman
evalu
histori
broad
rbc
incompat
age
cholecystectomi
age
uterin
hemorrhag
miscarriag
pregnanc
never
transfus
born
lahor
pakistan
parent
remot
cousin
allahabad
india
group
b
plasma
polyethylen
glycol
salin
solut
method
direct
antiglobulin
test
neg
rbc
phenotyp
en
wr
reactiv
glycin
soja
lectin
indic
reduc
sialic
acid
plasma
nonreact
en
rbc
consist
en
literatur
us
patient
report
immunohematol
demograph
serolog
extend
rbc
phenotyp
publish
histori
patient
discuss
confirm
subject
report
rbc
gpa
detect
human
monoclon
antisera
immunoblot
time
genet
done
test
hea
interrog
gypa
exon
c
predict
phenotyp
genet
analysi
confirm
gypa
mm
background
homozygos
insert
nucleotid
g
posit
exon
insert
predict
caus
frameshift
region
code
transmembran
helic
domain
stop
codon
amino
acid
downstream
genbank
propos
term
en
ind
india
novel
variant
conclus
en
ind
insert
gypa
variant
first
new
genet
basi
en
phenotyp
year
undetect
commonli
use
probe
ethnic
northeast
india
previous
unknown
set
rare
phenotyp
backgroundcas
studi
abo
subgroup
express
b
antigen
weakli
rbc
due
inherit
alter
abo
gene
affect
either
efficaci
specif
concentr
ab
glycosyltransferas
report
investig
abo
patient
ukrain
show
suspect
appear
dual
popul
rbc
upon
test
routin
serolog
studi
designmethod
flow
cytometr
analysi
routin
abo
genotyp
includ
analysi
upstream
enhanc
region
involv
determin
transcript
rate
certain
tissu
carri
genet
analysi
perform
dna
sequenc
abo
exon
includ
base
pair
adjac
intron
proxim
promot
resultsfind
dna
analysi
show
patient
genotyp
abo
normal
consist
group
b
sequenc
analysi
abo
exon
reveal
unexpect
chang
code
sequenc
explain
weak
phenotyp
pcr
analysi
upstream
enhanc
region
show
homozygos
expect
four
repeat
consist
genotyp
howev
sequenc
abo
promot
unravel
substitut
g
posit
flow
cytometr
analysi
show
express
normal
h
antigen
level
biphas
pattern
observ
although
cell
intermedi
level
antigen
express
also
present
type
pattern
previous
report
subgroup
caus
mutat
regulatori
region
locat
intron
investig
parent
dna
show
mother
abo
ab
express
rbc
father
abo
g
promot
well
display
characterist
flow
cytometr
pattern
taken
togeth
famili
investig
confirm
occur
b
allel
conclus
found
previous
unreport
mutat
locat
area
abo
promot
three
previous
describ
substitut
g
give
rise
phenotyp
well
c
result
phenotyp
takahashi
et
al
vox
sanguini
isa
et
al
vox
sanguini
confirm
luciferas
assay
c
mutat
reduc
promot
activ
vitro
thu
unlik
act
via
similar
mechan
caus
downregul
b
transcript
therebi
decreas
express
b
antigen
rbc
fact
mutat
posit
close
site
absenc
deviat
consensu
b
sequenc
propos
explain
phenotyp
famili
backgroundcas
studi
order
provid
highli
match
blood
treatment
chronic
transfus
patient
scd
implement
molecular
match
level
rh
k
match
extend
match
rh
kel
fy
jk
mn
di
extend
match
includ
rhd
rhce
variant
allel
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
compat
donor
fulfil
need
patient
level
match
patient
level
consid
rh
variant
much
difficult
find
compat
donor
patient
scd
besid
challeng
fulfil
request
multipl
neg
antigen
rh
match
unit
cost
effect
practic
minim
risk
alloimmun
remain
controversi
partli
patient
develop
alloantibodi
despit
extens
exposur
donor
rbc
antigen
order
optim
use
unit
patient
genotyp
patient
genet
marker
could
potenti
help
classif
respond
scd
patient
studi
evalu
abil
practic
avoid
product
rbc
antibodi
neg
consequ
alloimmun
follow
year
studi
designmethod
total
patient
scd
homozyg
hb
receiv
rang
rbc
unit
enrol
studi
nine
patient
cytokin
gene
polymorph
previous
associ
risk
alloimmun
transfus
extend
match
rbc
unit
level
match
patient
rhag
gene
polymorph
previous
associ
risk
rh
aloimmun
patient
genet
risk
factor
associ
rbc
alloimmun
transfus
rh
k
match
unit
level
match
patient
clinic
relev
genotyp
gene
polymorph
associ
risk
rh
alloimmun
transfus
extend
match
rbc
unit
includ
rh
variant
allel
level
match
resultsfind
nine
patient
receiv
transfus
level
match
patient
develop
patient
develop
patient
receiv
transfus
level
match
alloantibodi
form
patient
receiv
transfus
level
match
one
patient
genotyp
fy
develop
conclus
although
patient
develop
antibodi
low
preval
antigen
one
patient
develop
practic
improv
abil
find
compon
transfus
support
patient
benefit
patient
observ
lack
develop
common
alloantibodi
transfus
follow
two
year
show
transfus
strategi
effici
keep
patient
hb
baselin
level
backgroundcas
studi
year
old
e
asian
man
recent
transfus
present
chronic
anemia
dyspnea
antibodi
react
panel
cell
jk
rbc
autolog
control
rbc
type
jk
plasma
contain
appar
test
done
investig
plasma
reactiv
determin
jk
genotyp
studi
designmethod
antibodi
identif
antigen
type
perform
standard
method
licens
reagent
eluat
made
gamma
ii
immucor
genom
dna
isol
wbc
hea
precisetyp
perform
jk
code
exon
amplifi
sequenc
resultsfind
patient
rbc
neg
dat
type
jk
jk
immucor
ortho
monoclon
jk
polyclon
jk
ab
predict
hea
precisetyp
plasma
react
peg
iat
papain
iat
jk
andor
jk
b
panel
cell
jk
sequenc
confirm
jk
genotyp
reveal
heterozygos
new
jk
allel
g
tran
known
silenc
null
jk
new
jk
similar
jk
associ
weaken
jka
express
dna
result
prompt
serolog
investig
patient
rbc
incub
polyclon
eluat
made
weakli
reactiv
peg
iat
elut
indic
patient
rbc
express
jka
confirm
lack
jkb
patient
plasma
adsorb
jk
rbc
contain
plasma
adsorb
jk
rbc
contain
eluat
made
first
set
rbc
use
adsorpt
react
jk
jk
b
rbc
thu
contain
appar
surprisingli
jk
rbc
donor
homozyg
jk
jk
weakli
incompat
patient
plasma
peg
iat
conclus
describ
patient
partial
jka
detect
adsorptionelut
encod
novel
jk
tran
silenc
jkb
encod
jk
initi
plasma
reactiv
consist
adsorpt
shown
contain
separ
base
eluat
result
third
antibodi
specif
jk
rbc
patient
rbc
express
low
level
jka
suggest
antibodi
incompat
patient
plasma
rbc
donor
express
jka
encod
jk
show
recogniz
differ
protein
encod
allel
new
jk
encod
show
avail
jk
genotyp
rbc
enabl
precis
determin
antibodi
specif
inform
transfus
practic
backgroundcas
studi
abo
arguabl
import
blood
group
system
transfus
medicin
laboratori
typic
use
serolog
method
perform
abo
type
howev
serolog
signific
limit
includ
recent
transfus
patient
may
exhibit
mix
field
agglutin
wherein
patient
recent
donor
antigen
detect
ii
forward
revers
type
must
perform
may
yield
discord
result
limit
problemat
phenotyp
involv
weakli
express
antigen
laboratori
overcom
drawback
combin
genotyp
solut
ssp
sequenc
etc
method
requir
interpret
subject
matter
expert
aim
studi
evalu
altern
abo
pcr
base
genotyp
solut
recent
introduc
thermo
fisher
scientif
studi
designmethod
thermo
fisher
scientif
solut
base
pcr
technolog
develop
year
ago
genotyp
complex
human
leukocyt
antigen
hla
system
abo
analyz
reaction
identifi
multipl
relev
snp
locat
within
abo
gene
evalu
solut
analyz
archiv
dna
sampl
includ
blood
blank
sampl
serotyp
fail
produc
discord
result
sampl
deceas
solid
organ
donor
resultsfind
genotyp
result
gener
concord
type
obtain
tradit
methodolog
sever
case
serolog
provid
conclus
result
includ
five
discord
serolog
six
indermin
lectin
reaction
case
abl
provid
conclus
result
agreement
sanger
sequenc
result
avail
overcom
major
challeng
molecular
type
provid
robust
autom
approach
increas
laboratori
product
reduc
time
less
minut
oper
intervent
reagent
softwar
fulli
autom
analysi
deliv
genotyp
predict
phenotyp
result
approxim
minut
conclus
conclud
provid
simpl
effect
robust
method
abo
type
includ
accur
subgroup
backgroundcas
studi
human
monoclon
antibodi
target
treatment
lymphoma
solid
tumor
marker
identifi
broadli
express
cell
surfac
protein
regul
phagocytosi
studi
designmethod
patient
year
old
femal
histori
lymphoma
statu
post
allogen
peripher
blood
stem
cell
transplant
octob
admit
hospit
gdl
hemoglobin
patient
previou
histori
cold
warm
autoantibodi
panagglutinin
use
gel
technolog
detect
hospit
sampl
sent
immunohematolog
refer
laboratori
complet
workup
transfus
histori
medic
initi
avail
initi
test
gel
show
revers
abo
discrep
panagglutinin
neg
dat
tube
test
use
peg
liss
enzym
select
continu
identif
strong
agglutin
strength
seen
agt
use
reagent
patient
plasma
test
cell
treat
ficin
dtt
glycin
cord
cell
age
cell
batteri
rare
cell
base
patient
race
antibodi
reactiv
reaction
cell
test
though
dat
neg
eluat
perform
identifi
autoantibodi
demonstr
panagglutinin
titrat
plasma
versu
phenotyp
match
cell
show
reactiv
greater
alloabsorpt
use
human
stroma
perform
panagglutinin
remov
resolv
abo
discrep
four
coldalloabsorpt
remov
reactiv
reactiv
remain
test
addit
alloabsorpt
perform
remov
remain
reactiv
test
igg
coomb
resultsfind
result
suggest
potent
antibodi
high
frequenc
antigen
mind
sever
test
perform
use
cell
rare
phenotyp
complet
histori
obtain
found
patient
clinic
trial
monoclon
antibodi
therapi
target
literatur
review
antibodi
identifi
specif
igg
coomb
sera
clone
requir
resolv
reactiv
clone
lack
use
gamma
clone
monoclon
cell
previous
react
clone
contain
longer
react
antibodi
test
success
complet
use
gamma
clone
sera
agt
omit
phase
abo
test
complet
cold
alloabsorb
stroma
conclus
addit
monoclon
therapi
continu
emerg
case
highlight
need
extens
commun
blood
bank
clinic
servic
regard
use
treatment
backgroundcas
studi
thalassemia
common
inherit
disord
pakistan
overal
carrier
frequenc
approxim
children
diagnos
year
disord
patient
receiv
transfus
support
manag
symptom
anemia
develop
antibodi
red
blood
cell
rbc
antigen
lead
increas
transfus
frequenc
zaidi
design
program
manag
transfus
therapi
patient
object
reduc
risk
alloimmun
therebi
ultim
lower
util
transfus
benefit
routin
use
rbc
genotyp
determin
extend
antigen
profil
patient
well
donor
studi
designmethod
thalassemia
patient
support
amtf
hospit
major
ethnic
pathan
sindhi
punjabi
baluchi
urdu
screen
determin
rbc
antigen
mn
rhce
lu
kel
fy
jk
di
yt
co
along
rhce
allel
describ
hashmi
et
al
duplic
barcod
buccal
swab
sampl
collect
crude
extract
prepar
patel
et
al
sampl
analyz
novel
leansequenc
process
biomolecular
analyt
achiev
scalabl
simultan
determin
multipl
variant
multipl
sampl
use
pcr
capillari
electrophoresi
genotyp
determin
phenotyp
predict
use
proprietari
softwar
resultsfind
patient
neg
k
ytb
e
n
fyb
includ
instanc
gata
silenc
mutat
jkb
doa
dob
fya
c
jka
c
e
k
yta
none
patient
variant
rhce
allel
encod
partial
phenotyp
also
character
patient
set
thalassemia
hemochromatosi
mutat
report
mutat
frequenc
separ
abstract
conclus
first
comprehens
genotyp
analysi
pakistani
thalassemia
patient
show
allel
divers
group
limit
small
number
gene
encod
princip
rbc
antigen
phenotyp
frequenc
e
c
k
jkb
similar
report
asian
fyb
jka
c
closer
frequenc
report
african
frequenc
antigen
includ
n
fyb
appear
differ
report
major
ethnic
group
rel
limit
allel
divers
compar
say
individu
african
heritag
bode
well
program
proactiv
provid
transfus
support
design
minim
sensit
risk
leansequenc
streamlin
protocol
use
crude
extract
buccal
swab
sampl
facilit
rapid
character
transfus
recipi
well
donor
need
support
object
backgroundcas
studi
studi
red
blood
cell
rbc
alloimmun
reveal
increas
risk
alloantibodi
product
patient
chronic
inflamm
remain
howev
littl
understand
inflammatori
pathway
promot
product
alloantibodi
patient
recent
studi
demonstr
specif
group
inflammatori
cytokin
type
interferon
ifn
promot
differenti
rbc
alloantibodi
develop
mice
given
hepat
c
viru
hcv
infect
diseas
manag
ifn
therapi
hypothes
patient
hcv
may
elev
rate
rbc
alloimmun
thu
undertook
retrospect
examin
alloimmun
amongst
patient
hcv
studi
designmethod
alloimmun
subject
extract
databas
subject
queri
electron
medic
record
histori
hcv
infect
histori
report
follow
subsequ
collect
evid
ifn
therapi
rbc
antibodi
specif
sex
parallel
rbc
transfus
patient
extract
gener
databas
establish
rate
hcv
infect
well
ifn
therapi
amongst
control
group
test
yate
correct
continu
fisher
exact
test
use
statist
comparison
consid
signific
resultsfind
total
alloimmun
subject
histori
hcv
infect
major
individu
male
form
singl
alloantibodi
common
specif
comparison
patient
transfus
rbc
histori
hcv
proport
alloimmun
subject
histori
hcv
significantli
higher
proport
control
transfus
patient
hcv
vs
addit
proport
alloimmun
subject
receiv
ifn
therapi
significantli
differ
transfus
control
hcv
conclus
substanti
portion
alloimmun
patient
cohort
histori
hcv
neither
hcv
infect
receipt
type
ifn
therapi
associ
increas
rate
rbc
alloimmun
larger
scale
studi
may
help
rigor
investig
whether
type
ifn
therapi
hcv
infect
diseas
may
impact
likelihood
alloimmun
follow
rbc
transfus
backgroundcas
studi
fetal
neonat
alloimmun
thrombocytopenia
fnait
platelet
counterpart
hemolyt
diseas
fetu
newborn
common
usual
sever
case
fnait
caus
neg
women
give
birth
posit
child
risk
becom
women
posit
higher
risk
compar
women
lack
hla
allel
aim
studi
estim
risk
posit
neg
women
give
birth
posit
child
studi
designmethod
literatur
search
conduct
identifi
prospect
fnait
studi
risk
becom
postpartum
calcul
use
bay
theorem
singl
trial
contain
need
inform
data
also
use
prevfnait
studi
recent
complet
larg
prospect
fnait
studi
poland
result
type
european
caucasian
nation
marrow
donor
program
use
estim
frequenc
allel
gener
popul
resultsfind
women
posit
risk
deliveri
posit
child
estim
confid
interv
ci
contrast
estim
immun
risk
ci
women
neg
neg
conclus
women
neg
posit
risk
ci
deliveri
posit
child
time
higher
women
neg
thu
risk
posit
women
rang
risk
rhd
neg
women
deliveri
rhd
posit
child
mother
receiv
rhd
prophylaxi
backgroundcas
studi
serolog
weak
test
patient
option
howev
work
group
colleg
american
pathologist
aabb
recommend
rhd
genotyp
perform
discord
serolog
rhd
type
result
encount
andor
serolog
weak
identifi
goal
identif
true
candid
rhig
inject
andor
rhd
neg
rbc
institut
adopt
test
process
rhd
test
perform
two
method
gel
tube
identifi
serolog
discrep
henc
candid
previous
conclud
process
posit
predict
valu
detect
variant
howev
yet
establish
sought
evalu
cost
efficaci
molecular
institut
studi
designmethod
result
perform
retrospect
review
patient
age
gender
race
clinic
present
use
rhig
inject
transfus
also
review
cost
analysi
perform
resultsfind
analyz
period
type
screen
perform
blood
bank
sampl
includ
studi
sent
due
serolog
discrep
initi
result
rhd
neg
major
patient
type
partial
type
kept
rhd
neg
remain
type
weak
variant
chang
rhd
posit
patient
transfus
subsequ
twenti
patient
pregnant
receiv
rhig
cost
see
tabl
demograph
patient
receiv
rhig
unnecessari
weak
would
save
approxim
assum
least
vialspati
cost
molecular
sendout
approxim
total
cost
patient
includ
studi
cost
rhd
neg
posit
prbc
unit
supplier
conclus
phase
daili
transfus
medicin
practic
remain
advanc
challeng
topic
patient
popul
major
serolog
type
discrep
identifi
method
attribut
partial
variant
patient
treat
rhd
neg
thu
cost
effect
molecular
question
probabl
reserv
specif
clinic
situat
patient
popul
backgroundcas
studi
mcleod
syndrom
genet
disord
male
associ
late
onset
clinic
subclin
myopathi
neurodegener
neuroacanthocytosi
central
nervou
system
cn
manifest
associ
elev
cpk
level
weak
undetect
kell
system
antigen
absenc
kx
antigen
rbc
approxim
differ
xk
gene
mutat
report
appear
grow
awar
syndrom
investig
xk
four
male
patient
three
diagnos
acanthocythosi
one
fever
infect
present
studi
designmethod
rbc
type
perform
standard
tube
method
licens
unlicens
reagent
genom
dna
isol
wbc
xk
gene
amplifi
sequenc
resultsfind
proband
summar
tabl
rbc
four
show
depress
kell
system
antigen
kp
rbc
type
rbc
also
type
identifi
patient
plasma
albumin
papain
peg
iat
evalu
involuntari
jerk
movement
blood
film
show
acanthocyt
red
cell
neg
test
xk
gene
sequenc
reveal
novel
allel
proband
nucleotid
delet
posit
result
frameshift
prematur
stop
codon
sampl
intron
g
splice
site
mutat
predict
associ
altern
splice
nonsens
mutat
posit
result
prematur
stop
codon
missens
mutat
posit
result
amino
acid
chang
conclus
report
molecular
genet
basi
mcleod
phenotyp
four
proband
result
nucleotid
delet
caus
prematur
stop
splice
site
mutat
nonsens
mutat
missens
mutat
three
proband
includ
patient
missens
mutat
diagnos
acanthocytosi
also
neurolog
symptom
consist
mcleod
syndrom
howev
proband
splice
site
mutat
indic
mcleod
syndrom
emphas
differ
xk
gene
mutat
may
differ
clinic
effect
may
account
variabl
mcleod
phenotyp
proband
previous
transfus
identifi
plasma
autolog
donat
recommend
individu
mcleod
phenotyp
backgroundcas
studi
transfus
support
major
part
therapi
patient
sickl
cell
anemia
sca
hemoglobinopathi
allel
divers
within
predominantli
black
sca
popul
especi
rhce
locu
make
desir
routin
queri
rhce
allel
predict
extend
antigen
phenotyp
effort
reduc
labor
turnaround
time
identifi
rhce
allel
interest
test
novel
platform
studi
designmethod
leansequenc
rbc
genotyp
hashmi
et
al
aabb
abstract
permit
analysi
sampl
pool
rbc
antigen
blood
group
mn
rh
lu
kel
fy
jk
di
yt
co
includ
rhce
antigen
ccee
v
vs
hrb
hr
cw
cx
crawford
jal
stem
mar
cest
ceag
cevf
celo
encod
allel
protocol
analyt
step
singl
multiplex
pcr
barcod
amplicon
amplif
label
pool
amplicon
capillari
sequenc
protocol
use
analyz
genom
dna
blind
sampl
previous
genotyp
extend
rbc
antigen
set
licens
method
data
analyz
phenotyp
predict
use
novel
algorithm
rhce
allel
determin
resultsfind
sampl
found
express
partial
c
c
partial
e
e
name
c
singl
c
allel
pair
ce
allel
e
singl
e
encod
allel
pair
ce
allel
predict
weak
phenotyp
u
v
gata
silenc
fyb
uncommon
antigen
neg
u
e
yta
jsb
ceag
hrb
pair
ce
allel
rhce
allel
pair
previous
determin
name
rhce
ceag
homozyg
rhce
ceag
pair
ce
ce
ce
cemo
ceti
rhce
cesceti
five
discrep
note
one
predict
vv
comparison
assay
leansequenc
detect
rhce
cear
detect
refer
assay
four
discrep
lua
c
mn
n
due
threshold
set
leansequenc
softwar
adjust
conclus
leansequenc
result
highli
concord
marker
test
method
predict
rbc
phenotyp
challeng
sampl
lean
workflow
includ
parallel
format
comprehens
imput
rhce
allel
novel
algorithm
offer
rapid
determin
extend
patient
donor
rbc
antigen
profil
facilit
manag
chronic
transfus
patient
backgroundcas
studi
human
monoclon
antibodi
known
interfer
serolog
blood
bank
test
previous
report
success
globulin
ahg
adsorpt
allogen
rr
rbc
alway
reproduc
increas
enrol
patient
clinic
trial
solid
tumor
lymphoma
reliabl
effici
solut
need
human
platelet
concentr
hpc
use
adsorb
hla
antibodi
present
platelet
report
novel
use
hpc
adsorb
studi
designmethod
sampl
receiv
novemb
day
march
day
april
day
femal
relaps
lymphoma
enrol
phase
ib
clinic
trial
rituximab
histor
blood
type
posit
neg
antibodi
screen
pregnanc
transfus
sampl
screen
commerci
reagent
cell
immedi
spin
ahg
liss
ahg
peg
ahg
salin
incub
except
reaction
compon
prewarm
minut
mix
follow
hpc
direct
insert
procedur
use
avail
plasma
sampl
perform
sequenti
adsorpt
evalu
reactiv
prewarm
peg
ahg
patient
sampl
spike
jka
antiserum
hpc
adsorb
verifi
expect
alloantibodi
reactiv
resultsfind
first
sampl
forward
type
posit
consist
histor
data
revers
type
b
cell
autocontrol
ac
direct
test
dat
neg
antibodi
screen
reactiv
neg
ahg
use
serolog
phenotyp
obtain
second
sampl
show
similar
abo
dat
ac
result
screen
reactiv
liss
w
peg
ahg
despit
use
ahg
three
hpc
adsorpt
success
remov
reactiv
ahg
third
sampl
abo
dat
ac
result
test
diminish
reactiv
remov
hpc
adsorpt
patient
specimen
spike
show
expect
reactiv
conclus
adsorpt
hpc
effici
remov
reactiv
ahg
previous
report
rbc
reduc
reactiv
note
fewer
adsorpt
requir
blood
drawn
drug
dose
use
hpc
adsorpt
knowledg
time
may
offer
improv
effici
test
ahg
phase
blood
type
phenotyp
prior
initi
drug
dose
well
blood
remain
critic
optim
test
patient
backgroundcas
studi
one
manifest
worldwid
genet
variat
divers
ethnic
distribut
blood
group
antigen
lead
uniqu
challeng
transfus
support
popul
although
genom
project
yield
import
insight
global
red
blood
cell
rbc
antigen
distribut
middl
east
popul
remain
underrepres
current
worldwid
sequenc
databas
genet
structur
qatari
popul
profoundli
impact
ancestr
popul
high
level
consanguin
migratori
flow
present
fantast
exampl
genet
divers
middl
east
north
africa
mena
region
describ
first
time
predict
extend
rbc
platelet
phenotyp
whole
genom
next
gener
sequenc
wg
qatari
individu
studi
designmethod
wg
perform
qatari
nation
particip
larger
studi
align
data
analyz
use
rylan
red
cell
leukocyt
antigen
predict
ng
queri
known
singl
nucleotid
indel
variant
red
blood
cell
rbc
platelet
antigen
gene
resultsfind
highest
variant
nucleotid
frequenc
observ
fyafyb
doadob
loci
respect
follow
promot
silenc
variant
fifteen
particip
carri
hbb
predict
kpa
jsa
antigen
also
present
among
other
analysi
also
reveal
one
lu
yt
co
ab
jr
instanc
heterozygos
null
kidd
allel
total
particip
carri
differ
weak
kidd
antigen
variant
includ
homozyg
state
select
region
bcam
gene
fail
qualiti
filter
less
sampl
antigen
frequenc
allel
compar
european
countri
frequenc
variant
compar
africa
identifi
detect
platelet
bw
antigen
conclus
wg
data
analysi
reveal
uniqu
combin
blood
group
platelet
antigen
qatari
popul
distinct
continent
blood
group
distribut
extract
genom
project
qatari
popul
possess
highest
frequenc
fy
variant
outsid
africa
suggest
natur
select
resist
malaria
clinic
high
preval
alloimmun
observ
qatar
might
relat
high
frequenc
polymorph
weak
kidd
antigen
latter
possibl
lead
discord
serolog
result
qatar
popul
compos
expatri
qatari
nation
circumst
rbc
antigen
discrep
donor
recipi
differ
genet
background
lead
alloimmun
rare
blood
group
frequent
found
qatar
studi
genom
data
stratifi
qatari
popul
ancestri
popul
bedouin
persian
arab
help
refin
knowledg
blood
group
divers
mena
region
gener
qatar
particular
import
step
toward
optim
precis
transfus
strategi
region
backgroundcas
studi
genet
variat
also
known
darc
associ
fy
blood
group
system
well
appreci
promot
variant
destroy
bind
site
erythroid
transcript
factor
though
report
fy
allel
typic
inherit
fy
allel
silenc
express
fyb
two
singl
nucleotid
polymorph
snp
locat
exon
associ
weaken
antigen
express
fy
typic
found
fy
weaken
fyb
term
fyx
gata
variant
common
individu
african
descent
fyx
variant
often
found
individu
caucasian
descent
though
found
fy
fy
allel
found
ci
report
blood
donor
gata
fyx
variant
inherit
ci
studi
designmethod
peripher
blood
old
african
american
male
blood
donor
test
panel
blood
group
antigen
variant
use
precisetyp
hea
molecular
beadchip
immucor
part
routin
test
panel
found
donor
homozyg
heterozyg
softwar
result
donor
possibl
variant
pv
fya
fyb
donor
histori
serolog
type
fy
genom
dna
reextract
peripher
blood
mononuclear
cell
sanger
sequenc
exon
perform
result
sequenc
align
consensu
variant
compar
allel
tabl
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
resultsfind
sanger
sequenc
confirm
genotyp
identifi
heterozygos
synonym
snp
conclus
rbc
genotyp
panel
use
algorithm
integr
genotyp
result
multipl
snp
popul
frequenc
predict
antigen
phenotyp
sinc
snp
associ
fyx
promot
snp
destroy
gata
bind
site
immucor
softwar
result
donor
phenotyp
pv
fya
fyb
sanger
sequenc
confirm
donor
carri
one
fy
allel
along
novel
allel
encod
fyx
silenc
gata
variant
case
illustr
screen
blood
donor
follow
serolog
confirm
uncov
new
blood
group
allel
serolog
import
backgroundcas
studi
partial
weak
antigen
weak
discrep
reaction
serolog
test
despit
use
fda
approv
reagent
technolog
addit
test
distinguish
partial
weak
follow
clinic
manag
practic
current
variabl
gener
prenat
patient
discrep
reaction
categor
manag
rh
neg
addit
patient
test
rh
posit
actual
partial
phenotyp
recogn
possibl
risk
need
rhig
prophylaxi
elmhurst
memori
hospit
blood
bank
discrep
type
sampl
evalu
molecular
test
help
blood
bank
identifi
patient
despit
type
rh
posit
elig
rhig
immunoprophylaxi
studi
designmethod
period
fourteen
month
januari
april
seven
prenat
patient
sampl
reaction
strength
discrep
autom
gel
methodolog
manual
tube
method
antigen
addit
subject
rhd
genotyp
screen
weakparti
autom
gel
methodolog
erytra
analyz
grifol
diagnost
use
primari
type
tube
test
includ
immedi
spin
ahg
phase
perform
commerci
avail
panel
monoclon
seraclon
monoclon
blend
biorad
medic
diagnost
use
forward
type
perform
retyp
genom
dna
evalu
grifol
immunohematolog
tx
resultsfind
seven
prenat
patient
identifi
reaction
strength
discrep
autom
gel
test
manual
tube
test
subject
rhd
genotyp
patient
found
weak
type
patient
found
partial
one
patient
demonstr
partial
type
cs
previous
type
rh
neg
differ
laboratori
second
patient
identifi
partial
type
viii
previous
type
rh
posit
differ
facil
patient
deliv
rh
posit
infant
patient
partial
type
cs
receiv
rhig
week
gestat
patient
partial
type
viii
receiv
rhig
week
neg
antibodi
screen
time
deliveri
physician
advis
genet
test
find
recommend
made
rhig
prophylaxi
rhig
prophylaxi
indic
weak
subtyp
conclus
rhd
complex
serolog
profil
depend
express
antigen
red
cell
surfac
technic
condit
test
result
type
discrep
autom
technolog
manual
monoclon
reagent
use
serolog
type
combin
genotyp
result
optim
rhig
prophylaxi
patient
popul
might
otherwis
receiv
prophylaxi
prevent
backgroundcas
studi
serolog
phenotyp
test
express
surfac
rbc
antigen
wherea
molecular
genotyp
test
inherit
dna
allel
laboratori
may
util
techniqu
help
resolv
discrep
indic
need
test
jk
phenotyp
extrem
rare
common
among
polynesian
studi
designmethod
complex
antibodi
identif
workup
perform
use
patient
plasma
rbc
standard
tube
pegliss
gel
methodolog
inform
obtain
urea
lysi
test
compar
serolog
phenotyp
molecular
genotyp
result
resultsfind
sampl
plasma
red
cell
receiv
year
old
femal
diagnos
ovarian
cancer
report
transfus
histori
direct
antiglobulin
test
dat
show
polyspecif
globulin
ahg
includ
neg
albumin
control
gel
antibodi
screenpanel
eluat
reactiv
cell
test
tube
test
screen
cell
potenti
peg
liss
also
panreact
patient
rbc
treat
edtaglycin
acid
ega
obtain
dat
neg
cell
cell
subsequ
test
patient
serum
react
peg
iat
indic
autoantibodi
serolog
phenotyp
jk
confirm
use
multipl
manufactur
antisera
phenotyp
similar
jk
null
rbc
nonreact
tube
peg
eluat
initi
suggest
probabl
rare
frozen
unlicens
antisera
unexpectedli
test
patient
rbc
contradict
jk
null
serolog
phenotyp
serolog
phenotyp
also
contradict
lysi
patient
rbc
urea
jk
null
rbc
resist
urea
lysi
due
discrep
serolog
result
molecular
genotyp
test
perform
molecular
result
jk
jk
b
predict
phenotyp
jk
ab
kidd
gene
dna
sequenc
perform
jk
exon
reveal
known
polymorph
explain
serolog
phenotyp
product
patient
transfus
three
unit
jk
rbc
without
report
incid
conclus
case
illustr
molecular
genotyp
benefit
patient
discrep
serolog
test
result
predict
molecular
phenotyp
allud
possibl
suppress
antigen
express
compar
molecular
genotyp
result
serolog
phenotyp
result
rare
clinic
present
reveal
blood
util
optim
wast
rare
neg
blood
product
backgroundcas
studi
organ
blood
group
genet
variant
allel
enabl
interpret
red
blood
cell
rbc
genotyp
accur
predict
rbc
antigen
phenotyp
blood
group
allel
defin
one
multipl
genet
variant
commonli
singl
nucleotid
variant
snv
formerli
snp
multipl
heterozyg
variant
identifi
establish
variant
phase
cistran
posit
requir
allel
interpret
phase
inform
limit
genotyp
technolog
andor
physic
distanc
variant
use
next
gener
sequenc
ng
coupl
physic
phase
annot
resolv
snv
gene
defin
new
jk
allel
previous
design
two
jk
allel
studi
designmethod
eighteen
dna
sampl
obtain
fda
genotyp
repositori
aabb
sequenc
use
bloodseq
custom
blood
group
gene
target
ng
panel
read
illumina
miseq
raw
sequenc
data
align
human
refer
genom
snv
indel
assess
use
vcf
gatk
haplotypecal
annot
physic
phase
inform
gatk
readbackedphas
allel
determin
variant
isbt
jk
tabl
literatur
design
jk
allel
cdna
posit
rel
transcript
resultsfind
use
isbt
nomenclatur
found
four
snv
indic
five
publish
jk
allel
jk
refer
allel
jk
g
jk
jk
jk
two
sampl
contain
variant
current
defin
jk
jk
ci
configur
one
sampl
homozyg
variant
delet
rule
copi
number
analys
one
sampl
heterozyg
variant
phase
annot
indic
also
present
ci
thu
dataset
three
jk
c
allel
observ
allel
frequenc
gnomad
show
variant
preval
individu
african
ancestri
frequenc
respect
conclus
ng
analys
sampl
unexpectedli
found
two
snv
present
ci
previous
defin
distinct
jk
allel
variant
similarli
common
individu
african
ancestri
ng
approach
provid
addit
genom
inform
confirm
phase
snv
propos
determin
phase
perform
possibl
accur
annot
allel
backgroundcas
studi
promot
antibodi
product
promot
b
cell
helper
capabl
cell
inhibit
gener
regulatori
cell
risk
alloimmun
low
patient
hematolog
diseas
platelet
transfus
aim
studi
investig
factor
influenc
platelet
antibodi
product
platelet
transfus
recipi
studi
designmethod
thirti
platelet
recipi
platelet
antibodi
respond
platelet
recipi
without
platelet
antibodi
randomli
select
c
g
singl
nucleotid
polymorph
snp
promot
region
gene
genotyp
polymeras
chain
reaction
pcr
fragment
length
polymorph
rflp
method
antiplatelet
antibodi
test
perform
use
solid
phase
red
cell
adher
assay
techniqu
maspat
kit
sanquin
amsterdam
netherland
data
includ
age
sex
diseas
benign
vs
malign
hematolog
vs
amount
platelet
transfus
gc
polymorph
gene
posit
platelet
antibodi
product
analyz
resultsfind
age
sex
percentag
patient
benign
diseas
percentag
patient
homozygot
c
allel
posit
gene
similar
respond
also
similar
patient
hematolog
diseas
patient
diseas
percentag
patient
hematolog
diseas
respond
lower
vs
p
although
amount
platelet
pheresi
transfus
patient
hematolog
diseas
higher
diseas
vs
p
detect
rate
platelet
antibodi
lower
patient
hematolog
diseas
patient
diseas
vs
p
compar
patient
hematolog
diseas
patient
diseas
ci
fold
rel
risk
platelet
antibodi
product
conclus
studi
found
associ
gene
polymorph
platelet
antibodi
product
patient
hematolog
diseas
lower
risk
platelet
antibodi
product
patient
diseas
backgroundcas
studi
human
gene
encod
glycoprotein
express
duffi
blood
group
antigen
fy
duffi
protein
act
receptor
distinct
cytokin
malaria
parasit
p
vivax
p
knowlesi
aim
identifi
long
rang
allel
gene
possibl
includ
regulatori
element
without
ambigu
autochthon
popul
malaria
endem
area
studi
designmethod
collect
blood
sampl
healthi
volunt
ethiopia
southwestern
low
altitud
tropic
region
assay
devis
amplifi
gene
singl
amplicon
determin
genom
sequenc
haplotyp
resolv
nucleotid
cover
code
sequenc
cd
gene
includ
untransl
region
utr
intron
flank
region
comput
phase
genotyp
data
ethiopian
individu
individu
genom
project
use
input
markov
haplotyp
mach
resultsfind
ethiopian
analyz
singl
nucleotid
polymorph
snp
distinct
genotyp
pattern
observ
except
gata
box
mutat
snp
encod
mutat
found
physic
evid
amplif
sequenc
fragment
analysi
allow
us
discern
allel
chromosom
analyz
allel
detect
carri
snp
found
common
fy
b
phenotyp
clinic
relev
fy
allel
african
consist
allel
allel
repres
fy
allel
fy
b
fy
allel
fy
bw
phenotyp
respect
snp
found
comput
model
indic
chang
neutral
physic
confirm
allel
allel
correctli
predict
mach
softwar
allel
miss
anoth
haplotyp
actual
occur
among
ethiopian
cohort
predict
mach
singl
occurr
dataset
snp
list
gene
mach
predict
haplotyp
present
ethiopian
cohort
conclus
describ
distinct
allel
autochthon
popul
high
frequenc
fy
allel
studi
similar
studi
conduct
african
region
adjunct
human
refer
genom
assembl
gold
standard
refer
comprehens
popul
specif
data
allel
use
templat
sequenc
allel
call
sequenc
precis
medicin
approach
backgroundcas
studi
mani
larg
blood
donor
center
use
genotyp
red
blood
cell
rbc
donor
predict
multipl
blood
group
antigen
subsequ
confirm
serolog
increas
rbc
genotyp
come
identif
sampl
phenotyp
found
discord
serolog
type
report
case
littl
c
type
discrep
identifi
novel
null
rhce
ce
allel
blood
donor
predict
type
littl
c
antigen
posit
rbc
genotyp
donor
histori
list
donor
rbc
littl
c
antigen
neg
investig
use
higher
resolut
rhce
genotyp
identifi
nucleotid
variant
previous
associ
null
rhce
ce
allel
studi
designmethod
peripher
blood
male
blood
donor
test
panel
blood
group
antigen
variant
use
hemoid
dq
agena
bioscienc
part
routin
test
rhce
c
result
predict
donor
type
c
current
donat
type
serolog
use
multipl
sourc
genom
dna
reextract
peripher
blood
mononuclear
cell
rhce
beadchip
immucor
test
sanger
sequenc
rhce
exon
perform
result
sequenc
align
consensu
variant
compar
allel
tabl
isbt
work
parti
blood
group
allel
nomenclatur
immunogenet
resultsfind
rhce
beadchip
predict
donor
type
c
e
c
consist
initi
test
use
hemoid
dq
higher
resolut
test
employ
sanger
sequenc
rhce
exon
variant
detect
exon
exon
reveal
heterozygos
rhce
conclus
donor
carri
one
rhce
ce
one
rhce
ce
allel
one
variant
detect
third
interven
sequenc
g
variant
report
context
rhce
ce
null
allel
donor
report
base
serolog
reason
conclud
variant
associ
rhce
ce
allel
variant
dbsnp
databas
exom
aggreg
consortium
exac
found
variant
quit
rare
frequenc
case
illustr
high
throughput
screen
blood
donor
follow
serolog
confirm
uncov
new
blood
group
allel
serolog
import
backgroundcas
studi
abo
type
import
compon
pretransfus
test
amino
acid
substitut
caus
abo
gene
mutat
usual
predict
impact
glycosyltransferas
function
may
caus
abo
blood
group
discrep
identifi
two
novel
mutat
exon
b
glycosyltransferas
gene
respons
weak
b
variant
howev
influenc
two
mutat
unclear
studi
effect
substitut
catalyt
activ
region
b
glycosyltransferas
caus
novel
mutat
gtb
express
explor
vitro
system
import
recogn
abo
subtyp
molecular
method
studi
designmethod
abo
antigen
serum
antibodi
proband
detect
serolog
method
sequenc
abo
gene
amplifi
pcr
sequenc
bidirect
cdna
abo
mutant
b
allel
obtain
gene
synthesi
clone
vector
topo
ta
eukaryot
express
construct
recombin
plasmid
recombin
plasmid
transfect
hela
cell
lipofectamin
stabl
express
cell
harvest
use
select
stabl
express
cell
stimul
sodium
butyr
induc
erythroid
differenti
flow
cytometri
perform
use
phycoerythrin
pe
murin
antibodi
hela
cell
transfect
agglutin
test
stabl
express
cell
also
examin
resultsfind
one
proband
identifi
bw
phenotyp
proband
identifi
b
phenotyp
heterozyg
site
code
region
abo
gene
identifi
directli
sequenc
analysi
haplotyp
analysi
show
proband
b
phenotyp
carri
novel
b
allel
c
p
proband
bw
phenotyp
carri
anoth
novel
b
allel
g
substitut
posit
two
novel
mutat
locat
catalyt
activ
region
blood
group
enzym
eukaryot
express
vector
abo
two
mutat
success
construct
confirm
clone
sequenc
stabl
express
hela
cell
also
obtain
recombin
plasmid
transfect
select
compar
cell
averag
fluoresc
intens
g
flow
fluoresc
result
reveal
larg
amount
b
antigen
expressd
surfac
cell
small
amount
b
antigen
c
g
cell
agglutin
test
show
cell
strong
agglutin
cell
weak
agglutin
conclus
studi
demonstr
mutat
c
g
caus
substitut
catalyt
activ
region
blood
group
enzym
contribut
b
antigen
express
work
support
scienc
research
foundat
zhejiang
provinc
medic
scienc
research
foundat
zhejiang
provinc
backgroundcas
studi
encod
multipass
transmembran
protein
express
kidd
blood
group
antigen
signific
genet
variat
also
known
jk
includ
multipl
variant
jk
jk
allel
result
weak
null
jka
jkb
antigen
express
respect
report
jk
allel
includ
snp
exon
appear
silenc
express
jka
studi
designmethod
peripher
blood
old
african
american
femal
blood
donor
test
panel
blood
group
antigen
variant
use
agena
hemoid
dq
agena
bioscienc
part
routin
test
panel
found
donor
heterozyg
thu
predict
donor
type
jk
ab
donor
histori
serolog
type
jk
genom
dna
reextract
peripher
blood
mononuclear
cell
total
rna
extract
rbc
primer
ssp
perform
exon
sequenc
base
known
null
mutat
gene
region
exon
cdna
pcr
product
subject
sanger
sequenc
analysi
result
sequenc
align
consensu
sequenc
variant
compar
allel
tabl
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
resultsfind
rule
jk
allel
associ
weaken
antigen
express
chang
consensu
found
exon
donor
found
heterozyg
exon
cdna
pcr
product
confirm
heterozygos
well
synonym
snp
conclus
snp
exon
identifi
jk
allel
donor
whose
rbc
type
jk
snp
list
jk
allel
tabl
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
snp
report
allel
frequenc
esp
cohort
http
espgswashingtonedu
two
null
allel
report
involv
singl
nucleotid
delet
dela
neighbor
jk
jk
g
variant
report
result
threonin
arginin
chang
amino
acid
residu
snp
result
substitut
threonin
neutral
polar
side
chang
arginin
polar
side
chain
given
serolog
phenotyp
donor
allel
like
associ
weak
null
express
donor
heterozyg
carri
jk
allel
express
jkb
would
interest
determin
rbc
homozyg
jk
variant
identifi
donor
would
resist
urea
lysi
report
rbc
associ
jk
null
phenotyp
backgroundcas
studi
rh
locu
compos
two
highli
homolog
gene
rhd
rhce
compos
exon
distribut
opposit
orient
facilit
macro
micro
gene
convers
lead
absenc
high
frequenc
antigen
creat
hybrid
protein
encod
low
frequenc
antigen
creat
partial
antigen
current
rh
blood
group
system
compris
antigen
gene
convers
encod
variant
protein
partial
phenotyp
numer
partial
phenotyp
usual
identifi
posit
person
make
describ
partial
common
peopl
african
descent
report
case
caucasian
pregnant
woman
harbor
rhd
diiib
variant
allel
complex
antibodi
mixtur
studi
designmethod
standard
hemagglutin
techniqu
includ
allogen
autolog
adsorpt
rhdrhce
genom
dna
sequenc
exon
hous
techniqu
perform
antibodi
titrat
done
techniqu
rhd
type
perform
diaclon
aborh
use
instrument
resultsfind
patient
chechnya
admit
hospit
deliv
third
child
proper
done
pregnanc
inform
avail
previou
pregnanc
type
group
ab
fy
ab
jk
ab
rhd
weaken
notic
reaction
antibodi
screen
show
complex
mixtur
alloantibodi
titer
respect
autoantibodi
high
frequenc
antigen
rbc
also
identifi
molecular
work
undertaken
confirm
suspicion
partial
genom
test
found
patient
harbor
variant
allel
rhd
diiib
rhd
homozyg
like
hemizyg
state
sequenc
rhce
gene
show
alter
confirm
patient
rhce
ce
homozyg
state
type
g
neg
individu
group
r
r
unit
found
compat
urgent
call
made
collect
fresh
unit
newborn
type
group
ab
dcece
k
birth
dat
elut
show
panagglutin
investig
due
small
amount
sampl
receiv
level
hemoglobin
gdl
total
bilirubin
day
hemoglobin
drop
gdl
bilirubin
treat
phototherapi
day
discharg
hospit
outpati
follow
stop
month
babi
hemoglobin
gdl
conclus
report
case
pregnant
woman
harbor
rhd
diiib
variant
allel
develop
complex
mixtur
luckili
despit
numer
incompat
clinic
pictur
newborn
mild
mother
among
exampl
individu
harbor
rare
rhd
diiib
variant
allel
defin
convers
exon
rhce
gene
rhd
gene
serolog
investig
need
better
character
variant
claim
confus
origin
diiib
associ
diii
type
variant
backgroundcas
studi
blood
group
compat
patient
donor
key
safe
transfus
standard
red
blood
cell
rbc
type
perform
serolog
mean
method
come
limit
case
exist
alloantibodi
inaccur
result
due
certain
antigen
variant
molecular
rbc
type
circumv
problem
due
analysi
dna
sequenc
code
antigen
studi
analyz
serolog
sampl
two
rapid
molecular
method
studi
designmethod
dna
sampl
individu
blood
group
serotyp
serotyp
abo
rhd
rhce
kk
jk
fy
mn
ss
done
standard
techniqu
genotyp
rhd
rhce
kel
jk
fy
gypab
lu
yt
di
vel
co
kn
combin
base
taqman
probe
well
assay
veryfi
extend
diagnostik
gmbh
kit
detect
blood
group
specif
includ
rhd
del
weak
neg
categori
partial
ds
sampl
also
type
abo
abo
basic
diagnostik
gmbh
sampl
analyz
two
method
end
point
fluoresc
pcr
result
automat
evalu
softwar
resultsfind
respect
antigen
pair
encod
blood
group
system
jk
fy
mn
ss
zygos
test
mention
sampl
includ
sampl
rare
antigen
kk
kp
ab
yt
ab
kn
ab
co
ab
analyz
sampl
reveal
concord
serolog
molecular
type
done
studi
molecular
method
end
point
pcr
pcr
agre
conclus
studi
show
molecular
rbc
type
method
repres
suitabl
addit
serolog
term
assay
time
well
resolut
case
two
assay
requir
parallel
molecular
test
abo
rhd
rhce
kell
kidd
duffi
mn
dombrock
lutheran
cartwright
diego
vel
colton
knop
low
manual
fulli
autom
result
evalu
assay
time
minut
end
point
pcr
minut
pcr
provid
benefici
opportun
molecular
blood
group
test
backgroundcas
studi
goa
antigen
low
frequenc
antigen
rh
system
associ
partial
antigen
categori
diva
report
found
approxim
black
individu
immunohematolog
refer
lab
encount
number
patient
alloantibodi
direct
antigen
unexpect
number
donor
either
confirm
suspect
goa
posit
decid
screen
donor
ro
phenotyp
posit
antigen
neg
c
e
determin
group
higher
preval
goa
antigen
studi
designmethod
period
week
segment
remov
red
blood
cell
rbc
unit
previous
found
neg
c
e
antigen
initi
ro
donor
test
without
consid
ethnic
later
decid
check
donor
record
identifi
african
american
aa
ethnic
group
donor
test
gel
techniqu
use
unlicens
antisera
shown
reactiv
differ
reagent
cell
posit
goa
nonreact
cell
posit
jsa
v
vs
stem
antigen
group
b
donor
test
gel
techniqu
eluat
prepar
cell
use
adsorb
plasma
contain
eluat
also
shown
reactiv
cell
posit
goa
nonreact
cell
antisera
well
cell
posit
b
antigen
goa
posit
donor
confirm
neg
direct
antiglobulin
test
dat
gel
resultsfind
pleas
refer
follow
tabl
conclus
result
show
aa
donor
ro
phenotyp
higher
expect
preval
goa
antigen
statist
analysi
indic
suffici
evid
support
hypothesi
signific
level
expect
goa
antigen
found
aa
donor
unexpect
find
larg
number
caucasian
ro
donor
caucasian
expect
ro
phenotyp
ro
donor
test
caucasian
like
reflect
predomin
caucasian
blood
donor
continu
underrepresent
minor
donor
base
effort
recruit
black
ro
donor
transfus
patient
sickl
cell
diseas
becom
success
may
see
increas
patient
develop
antibodi
low
frequenc
antigen
found
black
popul
studi
may
warrant
establish
preval
low
frequenc
antigen
ro
rbc
preferenti
transfus
patient
popul
backgroundcas
studi
abo
subgroup
allel
name
isbt
work
parti
serolog
studi
distinguish
four
main
abo
subgroup
subgroup
b
subgroup
cisab
b
even
though
subgroup
may
produc
unexpect
abo
antibodi
risk
differ
abo
allel
report
studi
summar
data
collect
span
ten
year
correl
abo
allel
antibodi
format
chines
blood
center
studi
designmethod
sampl
discrep
red
cell
serum
group
categor
specif
subgroup
standard
serolog
method
unexpect
serum
identifi
use
b
red
cell
abo
genotyp
perform
polymeras
chain
reaction
type
analysi
region
includ
exon
flank
sequenc
express
regulatori
element
intron
abo
gene
resultsfind
total
sampl
confirm
follow
abo
subgroup
subgroup
b
subgroup
cisab
b
variant
allel
includ
isbt
name
unnam
allel
identifi
sampl
allel
found
subgroup
sampl
allel
unexpect
antibodi
serum
allel
form
similarli
b
variant
allel
found
unexpect
antibodi
serum
remain
allel
made
cisab
variant
found
allel
b
variant
found
b
allel
found
serum
see
tabl
conclus
allel
produc
unexpect
abo
antibodi
abo
allel
therefor
understand
differ
risk
unexpect
abo
antibodi
format
variant
abo
allel
essenti
safe
transfus
work
support
two
scienc
foundat
china
zhejiang
innov
health
talent
backgroundcas
studi
patient
depend
platelet
plt
transfus
support
becom
refractori
platelet
refractori
attribut
alloimmun
primarili
hla
antibodi
mediat
consecut
correct
count
increment
cci
accord
current
clinic
practic
refractori
patient
may
receiv
plt
howev
transfus
result
adequ
count
increment
retrospect
analysi
investig
possibl
platelet
activ
statu
affect
success
hla
match
plt
studi
designmethod
clinic
studi
conduct
vancouv
gener
hospit
canada
enrol
hematologyoncolog
patient
patient
baselin
data
includ
human
leukocyt
antibodi
hla
statu
plt
count
well
plt
transfus
characterist
includ
plt
activ
statu
prospect
collect
platelet
activ
statu
measur
microparticl
mp
content
thrombolux
lightintegra
technolog
inc
canada
optim
threshold
predict
plt
activ
singl
donor
platelet
sdp
suspend
plasma
previous
determin
specif
sensit
clinic
respons
activ
sdp
compar
studi
patient
resultsfind
twenti
one
patient
test
posit
antibodi
becam
refractori
insuffici
cci
follow
two
consecut
random
plt
transfus
patient
show
insuffici
cci
baselin
data
patient
compar
patient
male
year
age
diagnos
aml
cml
md
baselin
platelet
count
bleed
rare
howev
averag
length
stay
patient
compar
day
patient
patient
respond
plt
transfus
significantli
lower
platelet
recoveri
cci
patient
vs
signific
level
one
patient
yr
old
male
aml
receiv
plt
character
plt
activ
statu
first
treatment
day
patient
receiv
plt
transfus
increasingli
insuffici
cci
two
hla
match
transfus
unsuccess
plt
success
increas
cci
see
tabl
conclus
select
random
plt
transfus
patient
achiev
suffici
high
cci
patient
howev
hla
match
plt
restor
cci
one
alloimmun
patient
addit
studi
need
determin
whether
platelet
could
improv
success
rate
transfus
backgroundcas
studi
abo
one
genet
divers
blood
group
system
abo
allel
describ
abo
refer
allel
encod
abo
glycosyltranferas
produc
common
phenotyp
dna
variat
abo
gene
vari
abo
enzym
specif
ie
vs
b
andor
impact
abo
express
activ
major
abo
allel
weak
null
weak
phenotyp
sometim
confound
serolog
case
abo
unexpect
discrep
result
abo
gene
sequenc
inform
report
case
donor
test
group
gel
phase
autom
tube
test
group
abo
sequenc
implic
abo
allel
caus
discrep
studi
designmethod
sampl
healthi
volunt
blood
donor
submit
routin
test
abo
test
perform
autom
gel
test
lectin
diagnost
nj
lewi
blood
group
albaclon
uk
test
perform
tube
test
abo
genotyp
perform
use
custom
long
rang
abo
pcr
span
exon
follow
clone
neb
pcr
clone
kit
sanger
dna
sequenc
annot
referenc
isbt
tabl
abo
transcript
resultsfind
gel
sampl
display
neg
forward
reaction
revers
show
agglutin
b
cell
tube
donor
cell
exhibit
mix
field
b
react
test
repeat
multipl
sampl
collect
result
donor
also
neg
dba
lectin
posit
neg
clone
sequenc
abo
exon
permit
simultan
sequenc
data
physic
phase
accur
annot
abo
allel
donor
predict
weak
phenotyp
due
heterozygos
abo
abo
c
abo
abo
c
g
g
c
c
delg
g
g
c
g
conclus
describ
discord
abo
gel
tube
forward
test
result
donor
hemizyg
weak
allel
abo
allel
determin
phase
inform
assign
heterozyg
dna
variant
specif
allel
inform
accur
red
blood
cell
genotyp
conclud
abo
associ
fals
neg
result
use
gel
card
method
whenev
possibl
abo
blood
group
type
includ
two
differ
forward
method
consid
revers
type
detect
unusu
abo
subtyp
discrep
resolv
dna
sequenc
backgroundcas
studi
multipli
transfus
patient
risk
alloimmun
consequ
hemolyt
transfus
reaction
extend
blood
group
type
rbc
effect
tool
reduc
occurr
reaction
howev
molecular
genotyp
valuabl
option
phenotyp
reagent
unavail
recent
transfus
obfusc
true
phenotyp
moreov
genotyp
make
possibl
creation
extens
character
donor
repositori
would
impract
use
tradit
serolog
method
pauciti
refer
panel
barrier
develop
standard
qualiti
control
genotyp
technolog
sinc
manufactur
user
genotyp
kit
reli
clinic
materi
refer
aim
develop
valid
renew
dna
refer
panel
standard
blood
group
genotyp
studi
designmethod
blood
donor
screen
collabor
blood
establish
donor
select
base
result
rbc
phenotyp
andor
genotyp
sampl
analyz
sanger
sequenc
taqman
assay
character
blood
group
polymorph
peripher
blood
mononuclear
cell
isol
subject
ebv
transform
gener
immort
cell
line
bulk
genom
dna
extract
cell
line
lyophil
produc
refer
panel
encompass
genet
variant
polymorph
interest
intern
collabor
studi
involv
differ
laboratori
coordin
valid
panel
stabil
acceler
degrad
studi
perform
year
time
point
resultsfind
particip
collabor
studi
use
wide
varieti
methodolog
collect
perform
genotyp
test
produc
result
analysi
genotyp
result
show
overal
agreement
expect
outcom
highest
level
discord
observ
kn
crom
c
ok
polymorph
limit
valu
panel
antigen
result
stabil
acceler
degrad
studi
show
stabl
concentr
dna
degrad
materi
test
time
point
conclus
develop
valid
renew
dna
refer
panel
blood
group
genotyp
mean
intern
collabor
studi
panel
aid
develop
new
genotyp
technolog
assay
improv
qualiti
control
current
avail
kit
promot
better
clinic
outcom
transfus
patient
panel
avail
upon
request
made
devic
develop
user
backgroundcas
studi
rh
system
polymorph
blood
group
system
human
second
immunogen
next
abo
system
rhd
polymorph
show
substanti
ethnic
variabl
partial
allel
divers
includ
dau
allel
evid
molecular
level
rhd
allel
rare
partial
variant
report
type
discrep
femal
blood
donor
initi
type
rh
neg
previou
donat
year
ago
studi
designmethod
type
perform
use
three
differ
fda
licens
reagent
fda
k
clear
devic
three
differ
manufactur
method
includ
micropl
hemagglutin
column
agglutin
techniqu
gel
test
tube
rhd
exon
perform
use
sanger
dna
sequenc
analysi
resultsfind
previou
type
use
micropl
hemagglutin
weak
test
use
tube
method
neg
subsequ
donat
micropl
hemagglutin
gave
posit
result
weak
test
addit
test
use
column
agglutin
method
neg
result
reveal
presenc
rhd
exon
characterist
dau
cluster
two
modif
found
respect
rhd
exon
exon
presenc
mutat
characterist
presenc
rhd
predict
partial
weak
phenotyp
conclus
amino
acid
chang
locat
inner
boundari
red
blood
cell
rbc
membran
chang
affect
antigen
integr
proper
express
drastic
decreas
antigen
densiti
individu
react
differ
test
variou
monoclon
antibodi
access
referr
laboratori
genom
test
import
time
identif
variant
backgroundcas
studi
demand
red
blood
cell
rbc
antigen
neg
product
continu
rise
trigger
studi
suggest
rbc
close
match
patient
may
decreas
likelihood
alloimmun
creat
need
blood
center
employ
screen
method
addit
demand
antigen
neg
rbc
must
match
need
sever
method
appli
standard
tube
autom
serolog
micropl
mcp
molecular
hea
beadchip
hbc
hbc
strength
abil
test
mani
antigen
simultan
shortcom
includ
cost
limit
detect
mani
null
phenotyp
especi
rh
k
jk
system
detect
serolog
immunohematolog
refer
lab
reli
screen
serolog
mcp
initi
chosen
capabl
focu
screen
common
antigen
cece
k
fyafyb
jkajkb
ss
algorithm
expand
includ
direct
test
base
ethnic
broad
test
antigen
base
antisera
avail
newli
encount
antigen
neg
donor
sent
test
hbc
studi
designmethod
rbc
unit
sort
base
three
ethnic
african
american
hispan
caucasian
unit
test
cece
k
kpb
detect
donor
unit
neg
two
four
rh
k
antigen
test
fyafyb
jkajkb
ss
unit
k
regardless
rhce
type
test
k
mcp
unit
meet
criteria
test
african
american
hispan
ethnic
jsa
dia
also
test
unit
type
js
di
test
jsb
dib
respect
found
js
di
hbc
request
addit
unit
type
submit
hbc
resultsfind
rbc
unit
screen
either
rr
unit
test
fyafyb
jkajkb
ss
addit
antigen
test
found
follow
dia
dib
kpa
k
kpb
andor
n
yta
lub
jsb
total
antigen
test
mcp
screen
method
sever
unit
neg
antigen
k
jsb
u
discov
find
unit
null
phenotpy
rh
k
jk
system
conclus
use
combin
serolog
mcp
molecular
hbc
algorithm
allow
us
nimbl
adapt
specif
need
base
chang
patient
popul
mcp
method
instrument
support
antigen
neg
unit
requir
low
resolut
molecular
screen
method
strength
increasingli
commonplac
serolog
screen
permit
detect
rare
donor
could
miss
molecular
method
provid
inexpens
screen
larg
number
donor
unit
number
like
prove
mcp
true
stalwart
method
backgroundcas
studi
mma
use
predict
clinic
signific
alloantibodi
antibodi
bind
sensit
rbc
determin
perform
indirect
antiglobulin
test
might
expect
strong
antibodi
would
like
result
posit
mma
weakli
reactiv
antibodi
would
like
result
neg
mma
studi
designmethod
mma
perform
use
antigen
posit
antigen
neg
red
blood
cell
case
known
antibodi
specif
select
rbc
incub
patient
serum
without
sourc
fresh
complement
present
red
blood
cell
test
also
incub
salin
salin
control
control
increas
reactiv
might
present
rbc
alon
rbc
sensit
perform
incub
tube
water
bath
one
hour
intermitt
mix
antiglobulin
test
perform
red
cell
sampl
use
includ
salin
control
studi
focus
compar
reactiv
antibodi
coat
rbc
mma
result
posit
mma
defin
reactiv
monocyt
neg
reactiv
monocyt
neg
mma
result
recommend
patient
receiv
antigen
posit
unit
clinic
reaction
expect
mma
result
referr
review
resultsfind
sampl
indirect
antiglobulin
test
posit
cutoff
howev
demonstr
reactiv
includ
exampl
also
noteworthi
sampl
indirect
antiglobulin
result
less
demonstr
signific
reactiv
includ
one
neg
antiglobulin
test
conclus
clinic
signific
antibodi
assum
base
antibodi
specif
strength
reactiv
mma
result
show
two
characterist
necessarili
correl
clinic
signific
might
expect
import
evalu
patient
result
basi
use
mma
valu
assess
clinic
relev
specif
patient
antibodi
backgroundcas
studi
gene
chromosom
encod
kidd
jk
glycoprotein
carri
blood
group
system
antigen
jka
jkb
protein
encod
gene
membran
transport
mediat
urea
transport
erythrocyt
jk
glycoprotein
consist
intramembran
domain
extracellular
loop
jka
jkb
antigen
express
result
singl
nucleotid
polymorph
exon
antigen
locat
extracellular
loop
sever
mutat
identifi
exon
intron
respons
weaken
express
jk
antigen
report
novel
silenc
mutat
discov
due
discord
serolog
predict
molecular
jka
phenotyp
red
cell
donor
white
hispan
studi
designmethod
genom
dna
extract
edta
whole
blood
sampl
use
autom
magnet
particl
nucleic
acid
purif
method
dna
test
multiplex
hea
molecular
beadchip
test
immucor
bioarray
solut
nj
usa
nucleotid
associ
jka
jkb
polymorph
present
predict
jk
ab
phenotyp
histor
serolog
phenotyp
two
separ
donat
show
phenotyp
jk
third
serolog
type
new
sampl
use
monoclon
confirm
previou
jk
phenotyp
subsequ
sequenc
studi
perform
appli
biosystem
dna
analyz
use
termin
sequenc
kit
life
technolog
co
ca
usa
dna
analyz
use
geneiou
pro
biomatt
auckland
nz
bioinformat
softwar
platform
obtain
nucleotid
base
sequenc
compar
ncbi
refer
sequenc
resultsfind
sequenc
analysi
reveal
delet
exon
impact
downstream
nucleotid
sequenc
mutat
jk
exon
nb
locat
implic
presenc
aberr
weak
jka
antigen
may
may
detect
serolog
method
novel
mutat
produc
abnorm
jk
extracellular
loop
result
lack
express
jka
antigen
final
protein
conclus
novel
mutat
ensu
delet
discov
investig
jka
antigen
type
discrep
predict
molecular
phenotyp
serolog
express
phenotyp
mutat
shown
silenc
jka
antigen
express
test
need
better
understand
mechan
underli
aberr
effect
mutat
antigen
express
signific
backgroundcas
studi
year
pregnant
kuwaiti
patient
prior
histori
transfus
second
babi
die
hour
sever
hemolysi
hyperbilirubinemia
current
antenat
screen
reveal
antibodi
plasma
close
fetal
monitor
recommend
famili
studi
initi
one
brother
jra
neg
howev
week
gestat
age
ultrasound
reveal
cardiomyopathi
ascit
intrauterin
growth
retard
sign
fetal
anemia
thu
urgent
intrauterin
transfus
iut
request
fetal
hemoglobin
gmdl
howev
jra
neg
rbc
transfus
intrauterin
due
fetal
tachycardia
immedi
caesarian
section
perform
babi
born
prematur
kg
hydrop
fetali
ascit
pleural
effus
laboratori
investig
show
reticulocytosi
high
indirect
bilirubin
normoblastemia
spherocytosi
blood
film
hemoglobin
level
gmdl
babi
ventil
receiv
dose
intraven
immunoglobulin
requir
exchang
transfus
babi
improv
day
hemoglobin
level
maintain
gmdl
receiv
jra
neg
rbc
time
studi
designmethod
antibodi
identif
perform
mother
serum
pregnanc
use
liss
indirect
antiglobulin
test
addit
allogen
adsorpt
use
donor
red
cell
extend
phenotyp
patient
resultsfind
patient
antibodi
high
preval
antigen
could
identifi
thu
sampl
refer
refer
laboratori
indic
patient
type
jra
neg
antibodi
react
moder
strength
liss
indirect
antiglobulin
test
untreat
papain
treat
cell
upon
deliveri
babi
direct
antigobulin
test
eluat
neg
plasma
react
posit
indirect
antiglobulin
test
show
antibodi
conclus
sinc
phenotyp
jra
neg
rare
clinic
signific
antibodi
either
case
jra
incompat
transfus
rbc
abil
caus
hemolyt
diseas
fetu
newborn
hdfn
describ
case
literatur
hdfn
occur
occur
intens
mild
moder
often
requir
treatment
beyond
phototherapi
howev
two
fatal
case
report
thu
case
highlight
need
prevent
manag
close
fetal
monitor
especi
mother
high
antibodi
titer
sinc
jra
neg
rbc
unit
difficult
obtain
measur
must
taken
ensur
avail
appropri
blood
type
autolog
donat
alway
consid
addit
sibl
also
potenti
donor
jra
neg
rbc
backgroundcas
studi
daratumumab
dara
human
monoclon
antibodi
treatment
multipl
myeloma
mm
dara
bind
rbc
interfer
detect
rbc
alloantibodi
goal
studi
evalu
risk
rbc
alloimmun
mm
patient
treat
dara
studi
designmethod
retrospect
studi
serolog
profil
transfus
histori
mm
patient
treat
dara
juli
march
undertaken
case
posit
ab
screen
treat
dtt
identifi
rbc
alloantibodi
patient
divid
two
group
patient
transfus
patient
rbc
transfus
histori
monitor
first
dara
dose
last
patient
neg
ab
screen
extend
first
neg
ab
screen
last
dara
dose
ab
screen
ever
posit
number
rbc
unit
transfus
degre
rbc
ag
match
compat
phenotyp
match
also
record
resultsfind
transfus
group
none
patient
posit
ab
screen
prior
first
dara
treatment
patient
develop
posit
ab
screen
treatment
patient
ab
screen
remain
neg
durat
ab
screen
posit
vari
markedli
rang
day
month
last
dose
total
ab
screen
done
patient
none
show
detect
alloantibodi
dtt
treatment
among
patient
transfus
compat
rbc
averag
phenotyp
match
averag
unit
patient
receiv
compat
averag
unit
patient
receiv
unit
group
patient
ab
screen
perform
patient
posit
screen
dtt
treatment
patient
found
cold
autoantibodi
month
last
dose
dara
undetect
month
later
patient
serolog
histori
year
first
dara
dose
alloantibodi
never
reoccur
treatment
conclus
knowledg
first
studi
incid
rbc
alloimmun
patient
treat
dara
result
indic
risk
form
new
rbc
alloantibodi
treatment
low
probabl
due
dara
mediat
immunosuppress
differ
risk
rbc
alloimmun
follow
transfus
either
compat
phenotyp
match
rbc
unit
backgroundcas
studi
preval
specif
red
blood
cell
antibodi
rbca
vari
wide
among
differ
area
race
diseas
method
studi
data
avail
pediatr
popul
rbca
direct
antigen
express
rbc
membran
respons
hemolyt
transfus
reaction
complic
appropri
screen
rbca
essenti
ensur
transfus
compat
clinic
signific
antibodi
detect
patient
requir
transfus
transfus
servic
must
find
administ
rbc
lack
correspond
antigen
much
time
effort
spent
detect
identifi
rbca
omiss
pretransfus
test
pt
inabl
recogn
danger
evalu
preval
rbca
pediatr
hospit
studi
designmethod
retrospect
transvers
studi
record
patient
n
perform
pt
analyz
present
posit
rbca
detect
select
blood
sampl
type
abod
gel
method
diam
grifol
screen
rbca
use
select
cell
set
reagent
rbc
also
gel
antibodi
identif
accomplish
commerci
panel
cell
set
similar
method
addit
techniqu
eg
peg
enzym
whenev
need
resultsfind
irregular
rbca
detect
pediatr
patient
screen
femal
male
patient
least
one
rbc
transfus
hospit
anoth
center
antibodi
detect
autoantibodi
panaglutinin
femal
alloantibodi
identifi
alloantibodi
one
rbca
two
three
frequenc
identifi
alloantibodi
antim
anti
antik
antid
antilea
antijka
antilua
antileb
anti
antikpa
antic
anti
antijkb
conclus
show
overal
preval
antibodi
pediatr
popul
alloantibodi
clinic
import
irregular
antibodi
identifi
rh
kell
duffi
kidd
ss
system
high
frequenc
correl
age
present
antibodi
mainli
children
mostli
natur
extens
rbc
antigen
match
includ
rh
kell
system
consid
politransfus
patient
regardless
basal
diseas
order
avoid
alloimmun
hemolyt
transfus
reaction
backgroundcas
studi
weak
fyb
antigen
miss
commerci
antisera
individu
fy
x
allel
show
pronounc
reduct
fyb
antigen
howev
amount
fyb
antigen
present
red
cell
individu
suffici
induc
product
potenti
hemolyt
transfus
reaction
report
result
new
monoclon
human
igm
clone
detect
fyb
antigen
weak
fyb
antigen
express
fy
x
individu
studi
designmethod
random
sampl
blood
donor
patient
test
duplic
use
new
reagent
five
major
clinic
site
across
usa
follow
irb
approv
blood
center
immunohematolog
refer
laboratori
hospit
transfus
servic
laboratori
fyb
test
perform
use
tube
methodimmedi
spin
result
compar
result
use
predic
method
fda
licens
reagent
fda
k
clear
devic
addit
sampl
previous
character
fy
x
molecular
method
test
fyb
antigen
sampl
wilcoxon
test
perform
evalu
differ
strength
reactiv
use
new
reagent
predic
method
resultsfind
total
sampl
test
fyb
antigen
express
serolog
use
predic
sampl
strength
reactiv
compar
new
reagent
show
strength
reactiv
least
grade
stronger
sampl
compar
type
result
use
predic
moreov
sampl
show
reaction
strength
least
grade
stronger
new
antisera
compar
predic
vs
vs
vs
overal
stronger
reactiv
new
statist
signific
compar
result
sampl
p
fy
x
sampl
fyb
type
neg
use
predic
test
new
sampl
show
w
reaction
one
sampl
react
sampl
type
fy
predic
new
investig
refere
show
discrep
due
cleric
error
conclus
human
igm
monoclon
clone
show
stronger
reactiv
fyb
antigen
compar
fda
approv
reagent
monoclon
reagent
effect
routin
fyb
antigen
type
detect
weak
fyb
antigen
express
fy
x
individu
backgroundcas
studi
children
transfus
depend
anemia
sickl
cell
diseas
scd
thalassemia
increas
risk
develop
red
blood
cell
rbc
alloantibodi
due
lifelong
need
transfus
therapi
advent
genotyp
extend
rbc
antigen
panel
success
incorpor
chronic
transfus
therapi
program
cttp
precis
match
blood
popul
patient
studi
designmethod
key
member
transfus
servic
ts
immunohematolog
refer
laboratori
irl
hematolog
clinic
hc
care
children
sickl
cell
diseas
thalassemia
hemoglobinopathi
met
develop
chronic
transfus
therapi
program
benefit
patient
help
minim
risk
red
cell
alloimmun
children
enrol
baselin
genotyp
perform
includ
rbc
antigen
well
detect
fy
bgata
mutat
possibl
signific
mutat
rh
system
form
develop
assist
commun
hc
ts
irl
transfus
interv
volum
patient
estim
obtain
freshest
less
week
blood
avail
match
rh
kell
system
neg
antibodi
screen
doubl
rbc
unit
collect
possibl
patient
requir
unit
singl
transfus
episod
patient
develop
rbc
alloantibodi
switch
phenotyp
match
rbc
prevent
develop
addit
antibodi
base
profil
resultsfind
sinc
incept
program
june
patient
follow
disord
enrol
scd
thalassemia
disord
enrol
rbc
alloantibodi
includ
scd
patient
previous
receiv
phenotyp
match
blood
found
variant
e
antigen
genotyp
children
without
alloantibodi
enrol
develop
antibodi
follow
provis
rbc
match
rh
kell
system
antibodi
receiv
unit
none
develop
addit
alloantibodi
conclus
genotyp
success
incorpor
cttp
provid
precis
match
blood
reduc
risk
rbc
alloantibodi
develop
much
inform
provid
genotyp
compar
tradit
serolog
phenotyp
without
expens
cell
separ
techniqu
recent
transfus
patient
prevent
rbc
antigen
sensit
help
avoid
costli
serolog
prevent
delay
hemolyt
transfus
reaction
improv
blood
manag
addit
benefit
includ
improv
avail
blood
patient
otherwis
rare
blood
type
particularli
gata
mutat
present
backgroundcas
studi
indian
blood
group
system
isbt
compris
antigen
ina
antigen
inb
infi
inja
inra
antigen
locat
glycoprotein
encod
gene
short
arm
chromosom
glycoprotein
function
leukocyt
home
receptor
cellular
adhes
molecul
present
studi
design
identifi
frequenc
allel
encod
inra
neg
phenotyp
first
observ
year
old
femal
muslim
gujarat
inform
us
probabl
find
donor
assess
risk
antibodi
format
transfus
recipi
studi
designmethod
buffi
coat
extract
whole
blood
sampl
collect
consent
random
blood
donor
lok
samarpan
raktadan
kendra
surat
gujarat
india
buffi
coat
pool
batch
ship
dept
transfus
medicin
nih
clinic
center
dna
extract
molecular
analysi
pcr
base
assay
devis
use
primer
gcgggcctctctcccagctattgttaacca
attctcctttctggacatagcggg
genotyp
singl
nucleotid
polymorph
snp
exon
gene
assay
appli
genom
dna
posit
control
heterozyg
homozyg
well
neg
homozyg
templat
control
molecular
grade
water
includ
test
plate
resultsfind
test
random
blood
donor
pool
allel
frequenc
pool
observ
posit
allel
allel
frequenc
estim
rang
less
allel
popul
confid
interv
poisson
distribut
vast
major
donor
came
hindu
commun
conclus
genom
aggreg
databas
gnomad
list
allel
frequenc
among
individu
posit
individu
found
east
asian
south
asian
finnish
popul
howev
snp
detect
among
random
blood
donor
state
gujarat
western
india
inra
neg
phenotyp
first
observ
muslim
patient
mutat
may
either
restrict
index
case
famili
common
muslim
commun
studi
local
may
provid
inform
frequenc
mutat
immunogen
transfus
recipi
occur
among
blood
donor
backgroundcas
studi
gold
standard
compat
test
histor
base
upon
serolog
test
tube
gel
solid
phase
methodolog
detect
red
cell
agglutin
sever
condit
howev
serolog
reli
upon
determin
safest
blood
transfus
molecular
test
human
blood
group
antigen
provid
reliabl
method
accur
predict
phenotyp
transfus
recipi
without
extens
serolog
test
addit
ad
insight
variant
blood
group
antigen
creat
new
arena
match
blood
donor
patient
transfus
abstract
describ
molecular
test
incorpor
blood
collect
facil
influenc
chang
immunohematolog
laboratori
practic
studi
designmethod
sixti
donor
record
multipl
donat
without
full
phenotyp
molecular
genotyp
select
week
test
outsid
contract
laboratori
molecular
result
electron
transfer
blood
establish
comput
system
bec
staff
immunohematolog
refer
laboratori
irl
valid
result
transmit
rare
unit
uniqu
antigen
ad
frozen
blood
inventori
report
american
rare
donor
program
ardp
resultsfind
end
year
fulli
phenotyp
donor
databas
expand
includ
fulli
test
donor
addit
identifi
rare
donor
recruit
add
rare
frozen
unit
report
ardp
see
tabl
discuss
addit
donor
perform
molecular
test
patient
improv
medic
care
major
patient
sickl
cell
diseas
scd
area
molecular
genotyp
perform
enabl
irl
provid
phenotyp
similar
rbc
unit
effort
prevent
alloimmun
irl
also
select
patient
molecular
genotyp
autoimmun
hemolyt
anemia
drug
interfer
ie
daratumumab
multipl
transfus
phenotyp
match
prevent
alloimmun
simplifi
process
provid
best
match
blood
avail
patient
irl
also
provid
blood
collect
rare
donor
identifi
molecular
genotyp
blood
center
patient
need
rare
blood
conclus
unlik
genotyp
fulli
replac
serolog
test
prove
complementari
adjunct
immunohematolog
servic
hemovigil
focu
mani
associ
manag
care
patient
transfus
molecular
genotyp
aid
provid
blood
scd
patient
signific
autoimmun
diseas
medic
condit
molecular
genotyp
enorm
potenti
revolution
practic
blood
center
establish
larg
donor
pool
fulli
type
donor
well
identifi
mani
donor
rare
blood
group
backgroundcas
studi
incid
hdfn
caus
rh
antigen
reduc
markedli
low
level
develop
countri
still
pose
challeng
health
care
system
develop
countri
present
convent
test
tube
ctt
method
recommend
perform
titrat
antibodi
antenat
case
ctt
increasingli
replac
gel
microcolumn
agglutin
gma
system
offer
mani
advantag
transfus
laboratori
studi
topic
clear
guidelin
establish
precis
method
titrat
antenat
case
gma
studi
designmethod
sampl
rh
neg
antenat
femal
evalu
period
yearsthes
initi
subject
indirect
agglutin
test
iat
ctt
use
polyspecif
ahg
well
gma
cell
antibodi
screen
panel
posit
sampl
subject
identif
antibodi
use
cell
antibodi
identif
panelpres
antibodi
rule
use
doubl
adsorpt
methodthey
subject
titrat
ctt
gma
igg
rabbit
prepar
rbc
singl
donor
use
titrationtitr
ctt
carri
use
liss
incub
time
min
well
normal
salin
incub
time
min
make
rbc
suspens
similarli
titrat
gma
carri
use
liss
incub
time
min
well
normal
salin
incub
time
min
recommend
earlier
studi
better
correl
two
method
titer
correl
clinic
context
recent
histori
administr
intervent
like
iut
perform
outcom
pregnanc
resultsfind
antenat
case
test
posit
ict
gma
case
also
test
posit
tube
method
test
posit
gma
histori
antibodi
identifi
case
combin
case
titrat
tube
method
use
liss
gave
posit
result
titrat
gma
use
normal
salin
ns
result
mix
field
reaction
two
method
includ
analysi
titer
obtain
ctt
use
ns
gma
use
liss
includ
analysi
titrat
perform
total
differ
sampl
obtain
antenat
case
valu
evalu
karl
pearson
coeffici
correl
evalu
valu
sampl
includ
suggest
moder
correl
case
involv
singl
antibodi
evalu
p
suggest
strong
correl
case
undergon
iut
case
report
iufd
titer
valu
patient
note
least
ctt
gma
conclus
gma
highli
sensit
precis
method
titrat
antenat
case
prospect
report
titer
gma
along
ctt
evalu
treat
clinician
made
awar
result
two
method
ctt
gma
better
correl
singl
antibodi
present
titer
gma
igg
mostli
correspond
valu
ctt
good
correl
clinic
outcom
data
studi
requir
establish
critic
titer
gma
backgroundcas
studi
abo
type
two
caucasian
patient
sampl
yield
discrep
result
sampl
forward
type
revers
type
sampl
forward
type
revers
type
ab
genotyp
sampl
bagen
yield
inconclus
result
studi
designmethod
serolog
perform
routin
tube
test
method
follow
phase
reactiv
immedi
spin
incub
rt
incub
reagent
forward
type
albaclon
monoclon
b
quotient
bioclon
monoclon
diagnost
group
polyclon
b
revers
type
perform
type
b
reagent
rbc
quotient
extend
test
done
rbc
quotient
genotyp
genom
dna
gdna
extract
blood
qiaamp
affin
column
qiagen
abo
intron
enhanc
region
exon
sequenc
sanger
dideoxi
method
pcr
product
includ
abo
exon
clone
zyppi
plasmid
miniprep
kit
zymo
research
sequenc
resultsfind
sampl
forward
type
quotient
reagent
neg
phase
w
rt
rbc
forward
type
ortho
reagent
w
w
rt
forward
b
type
neg
phase
reagent
condit
forward
type
monoclon
polyclon
b
w
rt
revers
type
rbc
neg
w
rt
w
neg
phase
rbc
w
rt
b
rbc
sequenc
gdna
clone
abo
exon
product
detect
allel
abo
abo
sampl
sequenc
gdna
clone
abo
exon
product
show
presenc
allel
abo
abo
conclus
best
knowledg
variant
allel
abo
previous
report
variant
commonli
found
allel
encod
phenotyp
variant
allel
encod
cisab
phenotyp
eg
abo
basi
serolog
molecular
result
combin
conclud
allel
abo
encod
weak
phenotyp
backgroundcas
studi
monoclon
antibodi
mab
highli
specif
reagent
produc
hybridoma
cell
known
show
variabl
reactiv
potenti
impact
red
blood
cell
rbc
antigen
type
identif
antibodi
crossmatch
implement
routin
test
import
evalu
perform
accuraci
mab
studi
describ
result
perform
evalu
new
monoclon
blood
group
reagent
bgr
globulin
ahg
serolog
test
studi
designmethod
random
sampl
blood
donor
patient
test
duplic
five
major
clinic
site
across
usa
follow
irb
approv
blood
center
immunohematolog
refer
laboratori
hospit
transfus
servic
laboratori
specif
new
mab
reagent
includ
igm
igmigg
igg
result
use
mab
reagent
evalu
compar
result
use
predic
fda
licens
reagent
fda
k
clear
devic
predic
method
includ
test
tube
micropl
molecular
genotyp
differ
manufactur
posit
neg
percentag
agreement
ppa
npa
calcul
lower
confid
bound
estim
set
confid
interv
ci
least
concord
level
test
perform
resultsfind
total
data
point
gener
sampl
aborh
antisera
percent
agreement
ppa
npa
met
except
npa
valu
respect
ci
ci
result
concord
predic
three
discrep
found
two
due
cleric
error
one
resolv
favor
new
mab
blood
group
system
antigen
type
met
desir
npa
ppa
fya
jkb
leb
k
type
concord
predic
also
concord
predic
ppa
npa
found
antibodi
screen
identif
crossmatch
use
total
discrep
initi
report
repres
investig
repeat
refere
show
one
true
discrep
found
one
patient
recent
histori
bone
marrow
transplant
conclus
new
bgr
ahg
mab
reagent
yield
result
substanti
equival
current
fda
licens
reagent
fda
k
clear
devic
new
reagent
accur
effect
rbc
antigen
type
antibodi
screen
antibodi
identif
crossmatch
test
backgroundcas
studi
immun
hemolyt
anemia
diiha
report
incid
approxim
million
piperacillin
third
commonli
implic
drug
diiha
behind
cefotetan
ceftriaxon
serolog
result
diiha
caus
piperacillin
usual
includ
posit
direct
antiglobulin
test
dat
eluat
react
rbc
presenc
solubl
piperacillin
present
patient
develop
piperacillin
induc
sever
hemolyt
anemia
due
igg
alon
studi
designmethod
retrospect
electron
medic
record
review
util
case
present
primari
consult
servic
involv
case
gener
surgeri
hematolog
critic
care
nephrolog
piperacillin
antibodi
test
sent
new
york
blood
center
resultsfind
year
old
man
extens
cardiac
past
medic
histori
present
acut
append
refus
surgeri
treat
antibiot
day
piperacillintazobactam
follow
ten
day
ampicillinclavulan
acid
return
er
day
discharg
ruptur
appendix
underw
urgent
surgeri
treat
empir
piperacillintazobactam
admiss
hour
hb
fell
gdl
gdl
accompani
marker
acut
hemolysi
ldh
ul
haptoglobin
gdl
indirect
bilirubin
mgdl
indirect
coomb
test
reveal
panagglutinin
dat
posit
igg
eluat
neg
strong
suspicion
diiha
piperacillintazobactam
held
sampl
blood
sent
new
york
blood
center
reveal
antibodi
piperacillin
detect
immun
complex
method
addit
specif
observ
weakli
reactiv
peg
iat
igg
gel
test
panel
rbc
interestingli
patient
posit
e
antigen
phenotyp
patient
develop
acut
renal
failur
oliguria
requir
dialysi
subsequ
went
acut
respiratori
failur
requir
mechan
ventil
repeat
dat
neg
day
initi
dat
check
clinic
condit
improv
day
hematocrit
improv
back
baselin
howev
patient
dialysi
depend
month
prior
improv
renal
function
conclus
unlik
penicillin
cephalosporin
piperacillin
induc
hemolyt
anemia
typic
complement
mediat
induc
brisk
sever
hemolysi
dat
test
usual
posit
due
complement
igg
case
demonstr
piperacillin
induc
brisk
sever
hemolyt
anemia
absenc
detect
complement
rapid
withdraw
piperacillin
essenti
recoveri
end
organ
damag
may
delay
recoveri
backgroundcas
studi
posit
donor
identif
accur
linkag
current
donat
previou
donor
record
crucial
label
rbc
antigen
type
base
histor
test
studi
investig
conduct
upon
detect
antigen
type
discrep
current
previou
donat
process
improv
implement
time
impact
frequenc
type
discrep
evalu
studi
designmethod
blood
establish
comput
system
bec
provid
correl
current
test
result
previou
result
retrospect
review
donor
antigen
type
discrep
flag
bec
complet
discrep
flag
hous
prior
label
classifi
intern
discrep
antigen
type
repeat
hospit
custom
report
discrep
classifi
extern
discrep
discrep
investig
determin
caus
identifi
discrep
process
chang
evalu
resultsfind
period
discrep
detect
involv
genet
rh
variat
fyx
associ
weak
blood
group
antigen
type
detect
commerci
fda
licens
reagent
investig
reveal
process
failur
multipl
depart
also
contribut
donor
antigen
type
discrep
includ
collect
data
entri
technic
procedur
inform
system
key
process
improv
includ
implement
donor
health
histori
identif
point
develop
job
aid
investig
duplic
donor
test
procedur
revis
includ
process
obtain
segment
unit
test
incub
maximum
time
recommend
manufactur
requir
confirm
second
manufactur
reagent
e
neg
antigen
type
genotyp
perform
sampl
type
discrep
key
identifi
genet
variat
level
antigen
express
result
process
chang
antigen
type
discrep
decreas
approxim
collect
collect
year
period
conclus
donor
type
discrep
frequenc
reduc
implement
process
improv
across
multipl
depart
system
inform
system
function
compar
current
previou
test
critic
featur
label
histor
antigen
genet
variant
frequent
caus
test
discrep
warrant
investig
investig
discrep
recogn
sourc
error
respond
process
improv
crucial
implement
robust
system
label
histor
blood
group
antigen
backgroundcas
studi
antigen
pr
seri
associ
sialic
acid
residu
glycophorin
also
report
specif
determin
resid
side
chain
attach
mn
sialoglycoprotein
major
pr
specif
antibodi
gener
cold
agglutinin
react
optim
lower
temperatur
rare
igg
iga
biphas
properti
case
caus
sever
hemolyt
anemia
report
case
report
patient
gammaglobulinemia
high
titertherm
amplitud
show
obviou
evid
hemolysi
studi
designmethod
test
perform
routin
tube
method
use
peg
liss
salin
untreat
ficin
cell
acid
eluat
prepar
test
reagent
red
cell
iat
method
heat
eluat
prepar
cold
adsorb
plasma
use
cell
heat
eluat
test
red
cell
also
test
untreat
cell
autolog
cell
test
patient
plasma
hour
salin
settl
method
obtain
thermal
capac
plasma
treat
dtt
also
test
reagent
red
cell
differenti
igm
igg
resultsfind
patient
hemoglobin
gdl
hematocrit
total
bilirubin
mgdl
within
normal
rang
laboratori
test
ldh
haptoglobin
retic
count
perform
hemolysi
suspect
clinic
transfus
need
admiss
igm
detect
serum
protein
electrophoresi
spep
pleas
see
tabl
reaction
plasma
eluat
differ
cell
dat
weakli
posit
autocontrol
strongli
posit
room
temperatur
rt
iat
antibodi
titer
follow
rt
indic
cell
indic
cell
plasma
still
strongli
reactiv
cell
titer
indic
cell
antibodi
react
hour
salin
settl
method
plasma
treat
dtt
conclus
reactiv
dtt
treat
plasma
spep
result
consist
eluat
autolog
control
patient
antigen
type
indic
autoantibodi
high
titer
high
thermal
amplitud
indic
antibodi
potenti
caus
hemolysi
obviou
sign
hemolysi
possibl
patient
hemolysi
trigger
transfus
need
although
sever
hemolyt
anemia
due
high
titer
interest
note
obviou
clinic
hemolysi
need
transfus
patient
high
titer
thermal
amplitud
auto
backgroundcas
studi
kidd
blood
group
antibodi
caus
seriou
hemolyt
reaction
patient
type
alloreact
natur
antibodi
establish
patient
type
alloantibodi
exclud
antibodi
associ
variant
jk
antigen
although
uncommon
known
occur
definit
identif
variant
jk
antigen
requir
molecular
test
year
refer
case
associ
statu
molecular
test
purpos
studi
determin
presenc
clinic
signific
jk
variant
refer
case
formul
transfus
manag
strategi
variant
test
absent
pend
studi
designmethod
case
refer
variant
jk
test
identifi
laboratori
log
serolog
molecular
result
case
review
resultsfind
august
march
case
refer
variant
jk
test
base
serolog
andor
predict
molecular
type
patient
jkb
patient
jka
patient
race
white
black
multiraci
result
jk
sequenc
clinic
signific
variant
patient
jk
ab
jka
exon
associ
weak
variant
express
jkapotenti
signific
variant
patient
jk
ab
jkb
exon
silent
could
associ
aberr
splice
jk
b
clinic
signific
variant
patient
jk
ab
jk
includ
jka
exon
patient
without
risk
jka
alloantibodi
accompani
convent
jka
allel
conclus
keep
rariti
jk
variant
yield
clinic
signific
variant
seri
highli
select
case
rel
low
patient
jk
ab
patient
antibodi
associ
suspect
variant
jk
jk
phenotyp
guid
select
unit
rbc
transfus
patient
heterozyg
phenotyp
unit
match
antibodi
may
given
concern
alloimmun
antithet
jk
antigen
patient
homozyg
phenotyp
jk
jk
transfus
defer
like
presenc
least
one
convent
allel
risk
exposur
antithet
foreign
antigen
conclud
real
valu
molecular
test
lie
identifi
patient
without
clinic
signific
variant
unnecessari
restrict
rbc
unit
select
lift
especi
patient
multipl
alloantibodi
backgroundcas
studi
reagent
red
blood
cell
rbc
known
igg
sensit
rbc
coomb
control
cell
prepar
pool
group
rho
posit
rbc
sensit
igg
antibodi
tube
test
hemagglutin
rbc
reagent
use
confirm
valid
neg
globulin
ahg
test
result
indirect
antiglobulin
test
iat
direct
antiglobulin
test
dat
qualiti
control
purpos
reagent
rbc
verifi
ahg
ad
tube
adequ
wash
ensur
ahg
nt
inactiv
unbound
protein
manufactur
quotient
laboratori
indic
interpret
section
packag
insert
agglutin
reagent
rbc
indic
posit
reaction
strength
reactiv
indic
aabb
technic
manual
provid
criteria
read
grade
tube
agglutin
provid
uniform
reproduc
colleg
american
pathologist
requir
written
polici
defin
criteria
agglutin
eg
cap
trm
studi
designmethod
valid
rbc
quotient
perform
parallel
rbc
data
collect
period
two
differ
lot
number
manufactur
reagent
test
patient
antibodi
screen
use
iat
method
igg
extend
crossmatch
qualiti
control
result
record
day
use
time
new
vial
reagent
open
aabb
grade
criteria
use
standard
purpos
resultsfind
total
patient
sampl
test
igg
crossmatch
perform
manufactur
reaction
specimen
strong
reaction
quotient
reaction
seen
sampl
specimen
use
reagent
quotient
reaction
requir
use
optic
aid
crossmatch
thirteen
agreement
reaction
fourteen
unit
decreas
reactiv
strength
quotient
three
unit
decreas
reaction
strength
qualiti
control
test
time
reaction
manufactur
occur
time
forti
one
time
quotient
reagent
weaker
reaction
five
time
quotient
reagent
decreas
reactiv
compar
conclus
transfus
servic
laboratori
challeng
provid
high
qualiti
result
time
cost
effici
due
find
valid
studi
laboratori
decid
switch
back
reagent
depend
stronger
agglutin
reaction
backgroundcas
studi
rh
complex
polymorph
human
blood
group
system
rh
antigen
encod
rh
locu
compos
two
highli
homolog
gene
rhd
rhce
number
rhce
allel
associ
silenc
rh
antigen
express
identifi
aim
studi
describ
novel
molecular
defect
correspond
silent
rhce
allel
identifi
peruvian
woman
phenotyp
second
pregnanc
studi
designmethod
phenotyp
carri
microcolumn
biovu
system
ortho
clinic
diagnost
usa
tube
agglutin
method
use
commerci
monoclon
biorad
germani
polyclon
reagent
genom
dna
extract
whole
blood
use
qiaamp
dna
blood
kit
qiagen
germani
red
cell
genotyp
perform
hea
rhce
kit
solut
warren
nj
usa
sinc
phenotyp
genotyp
result
discord
sampl
character
sequenc
ten
rhce
exon
flank
intron
region
use
sanger
sequenc
resultsfind
patient
phenotyp
refer
suspicion
alloantibodi
hea
kit
predict
phenotyp
rhce
kit
identifi
alter
allel
addit
patient
rbc
multipl
commerci
includ
includ
includ
monoclon
reagent
sequenc
analysi
rhce
gene
indic
individu
howev
patient
also
appar
homozyg
mutat
posit
exon
predict
encod
prematur
stop
codon
molecular
mechan
consist
aberr
rhce
ce
sequenc
abolish
c
e
express
rhce
allel
report
isbt
genom
databas
conclus
case
describ
novel
polymorph
exon
rhce
gene
caus
silenc
c
e
express
woman
phenotyp
although
dna
genotyp
predict
blood
group
great
valu
genotyp
alway
consist
phenotyp
mani
genet
event
may
caus
appar
discrep
result
hemagglutin
dna
genotyp
sequenc
remain
gold
standard
studi
complex
rh
molecular
variant
backgroundcas
studi
pembrolizumab
human
mous
monoclon
antibodi
lymphocyt
use
immunotherapeut
agent
group
malign
like
immun
checkpoint
inhibitor
pembrolizumab
associ
wide
varieti
includ
pneumon
coliti
hepat
endocrinopathi
among
other
rare
associ
hemolyt
anemia
present
case
autoimmun
hemolyt
anemia
unusu
antibodi
reactiv
present
approxim
week
cycl
pembrolizumab
studi
designmethod
type
screen
dat
elut
adsorpt
serolog
studi
perform
use
standard
refer
laboratori
techniqu
chart
review
perform
emr
resultsfind
patient
male
histori
recurr
metastat
melanoma
wt
braf
diagnos
year
prior
previous
treat
surgic
resect
cycl
ipiliumab
start
pembrolizumab
toler
first
two
cycl
fatigu
mild
nausea
present
clinic
day
third
cycl
complain
fatigu
dyspnea
jaundic
day
dark
urin
lab
time
show
hemoglobin
gdl
gdl
prior
cycl
reticulocytosi
bl
total
bilirubin
mgdl
direct
bilirubin
gdl
haptoglobin
undetect
ldh
iul
consist
hemolysi
type
screen
po
new
posit
antibodi
screen
initi
gel
antibodi
id
panel
show
posit
autocontrol
reactiv
destroy
ficin
polyspecif
dat
monospecif
igg
acid
eluat
strongli
reactiv
untreat
cell
weakabs
cell
cold
panel
neg
plasma
adsorb
two
differ
untreat
antigen
select
rbc
result
adsorb
plasma
show
reactiv
serum
reactiv
rbc
exclud
admit
treat
oral
prednison
mgkg
prbc
unit
admiss
cours
complic
nstemi
requir
stent
discharg
hemoglobin
gdl
discontinu
pembrolizumab
one
week
discharg
profoundli
anem
hemoglobin
gdl
total
bilirubin
mgdl
haptoglobin
undetect
receiv
prbc
unit
given
continu
anemia
slowli
taper
steroid
given
weekli
rituxan
week
sinc
time
requir
addit
transfus
hemoglobin
remain
stabl
gdl
conclus
patient
develop
autoimmun
hemolyt
anemia
third
cycl
pembrolizumab
workup
reveal
ficin
sensit
neuraminidas
resist
autoantibodi
suggest
fs
backgroundcas
studi
acquir
immun
thrombot
thrombocytopen
purpura
ittp
rare
devast
autoimmun
disord
character
gener
microvascular
thrombot
lesion
organ
failur
variabl
sever
studi
shown
product
antibodi
ittp
link
specif
hla
class
ii
suscept
protect
allel
current
studi
aim
identifi
ittp
patient
lebanon
display
similar
risk
andor
protect
allel
describ
literatur
studi
designmethod
loci
studi
genet
level
two
repres
sampl
consist
lebanes
patient
ittp
one
hand
lebanes
healthi
control
hand
extract
dna
amplifi
use
specif
primer
visual
agaros
gel
electrophoresi
fischer
test
use
statist
comparison
ittp
patient
group
healthi
lebanes
control
resultsfind
patient
typic
clinic
featur
ittp
sever
activ
associ
antibodi
three
signific
result
obtain
common
patient
n
control
n
common
control
n
patient
n
common
patient
n
control
n
allel
notabl
signific
differ
found
compar
patient
group
control
group
found
patient
vs
control
detect
patient
vs
control
found
patient
vs
control
conclus
lebanes
popul
appear
protect
factor
develop
ittp
appear
risk
factor
develop
diseas
result
consist
previou
studi
report
literatur
conduct
popul
hand
appear
risk
factor
ittp
specif
lebanes
popul
allel
previous
describ
signific
predispos
andor
protect
factor
literatur
common
lebanes
ittp
patient
healthi
control
allel
shown
frequent
hla
studi
done
healthi
lebanes
popul
may
explain
discrep
backgroundcas
studi
weak
subgroup
b
less
common
subgroup
less
clarifi
genet
level
report
result
rare
weak
b
subgroup
due
mutat
enhanc
region
gene
patient
african
american
male
admit
commun
hospit
rhode
island
abo
type
patient
show
forward
type
revers
type
b
enhanc
front
backtyp
resolv
discrep
specimen
sent
genotyp
reveal
b
subgroup
unusu
genet
variant
intron
region
abo
gene
enhanc
gene
express
serolog
test
includ
enhanc
forward
tube
type
show
weak
reaction
variou
manufactur
serolog
test
includ
perform
subgroup
abo
identifi
show
variant
enhanc
region
gene
express
intron
subgroup
describ
typic
variant
found
expressor
region
gene
studi
designmethod
abo
studi
describ
particular
genotyp
abo
studi
perform
expect
would
adsorb
elut
similar
subgroup
b
perform
use
pool
plasma
sourc
tradit
techniqu
incub
describ
aabb
technic
manual
use
assay
resultsfind
seen
elut
patient
cell
qualiti
control
perform
includ
test
cell
b
cell
last
wash
cell
test
show
expect
result
abo
type
describ
one
time
without
studi
second
case
abo
type
describ
conclus
although
b
subgroup
found
variant
enhanc
region
gene
antigen
express
success
adsorb
elut
patient
cell
similar
b
subgroup
base
serolog
reactiv
subgroup
probabl
bm
backgroundcas
studi
biochem
natur
blood
group
antigen
polysaccharid
ab
blood
group
antigen
indirect
product
gene
first
relat
gene
encod
glycosyltransferas
transferas
synthes
antigen
polysaccharid
chain
epitop
sugar
molecul
sequenc
b
glycosyltransferas
express
type
b
individu
erythrocyt
catalyz
transfer
galactos
group
molecul
h
precursor
sugar
chain
form
b
antigen
weak
b
bm
erythrocyt
agglutin
b
reagent
bm
erythrocyt
easili
detect
absorpt
elut
test
presenc
b
glycosyltransferas
serum
bm
individu
less
activ
studi
designmethod
studi
correct
effect
abnorm
blood
group
bm
subtyp
caus
new
mutat
one
case
abnorm
type
b
blood
group
identifi
use
microcolumn
gel
card
test
tube
method
determin
blood
group
respect
detect
blood
group
substanc
saliva
use
anticoagul
whole
blood
extract
dna
qiaamp
blood
kit
sequenc
invitrogen
corpor
two
gener
pedigre
investig
activ
glycosyltransferas
erythrocyt
membran
serum
measur
blood
donor
sampl
blood
sampl
transform
vitro
use
serum
normal
type
b
resultsfind
bm
subtyp
confirm
blood
group
serolog
test
genotyp
sequenc
result
new
mutat
site
mutat
exon
famili
survey
result
show
father
sister
normal
type
blood
group
mother
type
similarli
weakli
express
b
antigen
includ
mutat
exon
gac
tag
suggest
mutat
herit
mutat
led
prematur
termin
protein
code
exon
signific
decreas
activ
glycosyltransferas
serum
treatment
could
convert
bm
subtyp
blood
group
normal
type
b
blood
group
vitro
conclus
bm
subtyp
blood
group
result
new
herit
mutat
site
found
blood
group
examin
combin
normal
type
b
serum
correct
effect
bm
subtyp
blood
group
suggest
abnorm
blood
group
correct
chang
activ
glycosyltransferas
improv
safeti
blood
transfus
backgroundcas
studi
alloimmun
trigger
individu
lack
particular
antigen
expos
antigen
transfus
pregnanc
caus
format
immun
antibodi
addit
exogen
exposur
underli
inflammatori
auto
immun
condit
may
lead
format
unexpect
antibodi
studi
designmethod
herein
case
natur
occur
alloantibodi
healthi
blood
donor
rh
posit
blood
group
report
case
signifi
import
incorpor
indirect
antiglobulin
test
iat
blood
unit
routin
protocol
resultsfind
old
male
blood
group
rhd
posit
first
time
voluntari
famili
donor
without
signific
transfus
medic
drug
histori
donat
blood
depart
transfus
medicin
blood
bank
case
report
immunohematolog
ih
laboratori
iat
posit
autocontrol
donor
neg
phase
antibodi
identif
eleven
cell
panel
demonstr
presenc
antibodi
plasma
reactiv
wide
thermal
amplitud
direct
antiglobulin
test
polyspecif
ahg
antihuman
donor
neg
alloadsorpt
perform
select
cell
confirm
presenc
alloantibodi
dtt
dithiothretiol
test
demonstr
igm
igg
natur
antibodi
antibodi
show
dosag
phenomena
reactiv
decreas
enzym
papain
treatment
donor
red
cell
phenotyp
mn
system
igm
igg
antibodi
titer
antibodi
respect
gel
card
techniqu
post
dtt
treatment
igg
antibodi
titer
conclus
present
case
clinic
signific
natur
occur
antibodi
react
wide
thermal
amplitud
detect
donor
serum
publish
report
natur
occur
antibodi
healthi
donor
popul
mn
system
known
commonest
natur
occur
antibodi
igm
natur
react
salin
phase
rel
less
common
mostli
immun
natur
igg
type
reactiv
mani
small
center
especi
develop
countri
iat
done
rh
neg
blood
group
donor
order
rule
presenc
alloantibodi
primarili
due
financi
constraint
case
author
want
emphas
protocol
iat
test
blood
donor
irrespect
rh
statu
incorpor
blood
bank
improv
safeti
blood
transfus
servic
patient
altern
iat
test
pool
cell
done
donor
initi
screen
procedur
antibodi
screen
three
cell
panel
put
iat
posit
case
thu
pave
way
better
transfus
practic
reduc
risk
advers
reaction
backgroundcas
studi
explor
feasibl
rh
blood
group
antigen
detect
precis
transfus
applic
rh
antigen
detect
technolog
comput
inform
identif
technolog
laboratori
blood
group
autoanalysi
softwar
system
blood
transfus
inform
manag
softwar
system
studi
designmethod
red
blood
cell
rbc
patient
donor
detect
abo
rh
antigen
c
c
e
e
use
laboratori
blood
type
automat
analysi
system
result
upload
transfus
inform
manag
system
tim
comput
recognit
technolog
automat
chose
appropri
blood
compat
abo
rh
antigen
blood
done
polybren
microcylind
gel
card
antiglobulin
method
reduc
incid
antibodi
avoid
repeat
incompat
due
unknown
rh
system
antigen
clinic
practic
realiz
precis
blood
transfus
resultsfind
blood
transfus
precis
program
implement
recipi
could
achiev
complet
compat
transfus
abo
type
rh
antigen
transfus
reaction
occur
within
first
minut
infus
hour
infus
blood
routin
examin
blood
biochemistri
measur
hour
infus
hb
increas
averag
serum
bilirubin
signific
chang
patient
receiv
unit
red
cell
suspens
repeat
infus
ineffect
rate
red
blood
cell
transfus
rate
delay
hemolyt
reaction
advers
reaction
transfus
occur
occurr
rate
blood
group
irregular
antibodi
significantli
reduc
patient
multipl
blood
transfus
compar
patient
implement
precis
blood
transfus
program
case
irregular
antibodi
posit
proport
antibodi
rh
system
decreas
significantli
previou
period
prior
implement
precis
blood
transfus
protocol
conclus
implement
rh
blood
group
antigen
detect
technolog
achiev
clinic
precis
blood
transfus
avoid
product
rh
system
antibodi
also
reduc
occurr
advers
reaction
blood
transfus
improv
abil
solv
difficult
blood
safeti
blood
transfus
therapi
backgroundcas
studi
rbc
genotyp
use
supplement
serolog
provid
extend
match
blood
resolv
type
discrep
predict
phenotyp
recent
transfus
patient
patient
posit
direct
antiglobulin
test
hospit
transfus
servic
use
us
fda
approv
dna
genotyp
system
predict
rbc
phenotyp
donor
patient
aim
studi
evalu
perform
anoth
genotyp
platform
current
classifi
research
use
studi
designmethod
dna
extract
edta
whole
blood
sampl
collect
blood
donor
patient
sampl
test
use
system
evalu
idcor
xt
grifol
diagnost
solut
inc
ca
current
system
predict
rbc
phenotyp
follow
antigen
compar
cc
ee
v
vs
kk
kpakpb
jsajsb
jkajkb
fyafyb
mn
ss
u
diadib
doadob
hy
joa
coacob
lualub
discord
sampl
refer
dna
sequenc
resultsfind
total
blood
donor
patient
includ
evalu
result
data
point
comparison
predict
rbc
phenotyp
fulli
concord
antigen
differ
descript
predict
phenotyp
found
instanc
relat
categor
weak
partial
rh
blood
group
antigen
report
presenc
fyb
gata
allel
true
discrep
found
one
antigen
type
predict
idcor
xt
current
system
dna
sequenc
amplicon
includ
gypa
exon
identifi
two
snp
intron
region
prevent
bind
idcor
xt
forward
primer
target
site
tabl
conclus
predict
rbc
antigen
express
obtain
idcor
xt
genotyp
system
current
use
show
high
degre
concord
singl
fals
neg
antigen
report
idcor
xt
unlik
clinic
import
weak
partial
antigen
express
specifi
predict
phenotyp
report
rh
blood
group
antigen
idcor
xt
may
clinic
applic
select
patient
popul
gata
mutat
promot
region
fyb
allel
identifi
genotyp
report
system
presenc
report
predict
phenotyp
idcor
xt
may
lead
unnecessari
transfus
rbc
patient
mutat
use
predict
phenotyp
report
backgroundcas
studi
red
blood
cell
rbc
alloimmun
pregnanc
rare
still
major
problem
depend
specif
antibodi
implic
hemolyt
diseas
fetu
newborn
mild
sever
alloimmun
may
requir
need
phototherapi
transfus
neonat
rarest
case
need
utero
transfus
studi
designmethod
object
studi
present
result
global
red
blood
cell
alloimmun
pregnant
women
period
year
french
region
provenc
alp
cote
azur
cors
number
relat
number
birth
region
determin
preval
alloimmun
pregnanc
also
evalu
impact
recommend
nation
colleg
obstetrician
implement
sinc
systemat
inject
rhig
week
amennorhea
studi
incid
alloimmun
cohort
resultsfind
year
analys
pregnanc
ie
pregnant
women
antibodi
implic
hemolyt
diseas
fetu
antibodi
implic
hemolyt
diseas
newborn
antibodi
incid
pregnanc
also
evalu
effect
systemat
inject
rhig
pregnant
women
week
amennorhea
studi
incid
number
new
case
year
period
observ
signif
decreas
incid
p
year
sinc
integr
recommend
practic
incid
stabil
result
compar
countri
also
practic
routin
inject
begin
quarter
conclus
result
broad
period
year
show
differ
preval
antibodi
pregnant
women
compar
countri
inde
franc
respect
rhk
phenotyp
transfus
young
woman
decreas
number
women
system
addit
sinc
recommend
nation
colleg
obstetrician
routin
inject
rhig
week
amenorrhea
incid
alloimmun
significantli
decreas
stabil
backgroundcas
studi
therapi
eg
daratumumab
isatuximab
use
treat
multipl
myeloma
hematolog
disord
circul
drug
patient
plasma
bind
reagent
rbc
caus
interfer
test
strategi
elimin
interfer
aim
remov
denatur
rbc
pretreat
trypsin
dtt
previou
studi
shown
papain
ficin
treatment
avoid
interfer
howev
recent
report
primarili
europ
indic
papain
treat
rbc
may
effect
avoid
interfer
et
al
tran
med
report
detect
iat
use
commerci
papain
panel
suggest
method
effect
mitig
strategi
mann
isbt
abstract
advoc
use
papain
treat
panel
neutral
gel
card
test
underli
antibodi
agglutin
aim
studi
reassess
abil
papain
treat
rbc
overcom
interfer
evalu
papain
panel
use
report
batteri
patient
plasma
sampl
studi
designmethod
previous
evalu
sampl
patient
receiv
therapi
daratumumab
isatuximab
test
untreat
papain
treat
commerci
rbc
panel
quotient
test
perform
standard
tube
liss
iat
quotient
igg
gel
number
patient
sampl
select
aim
randomli
repres
variou
circul
plasma
concentr
dose
regiment
resultsfind
plasma
react
weakli
micro
cell
tube
liss
iat
untreat
papain
treat
quotient
panel
cell
reactiv
strength
unchang
untreat
papain
treat
rbc
plasma
react
igg
gel
test
untreat
cell
papain
treat
cell
panel
enhanc
reactiv
note
test
use
papain
panel
weaken
reactiv
observ
sampl
use
quotient
papain
panel
notabl
isatuximab
plasma
reactiv
markedli
enhanc
papain
treat
panel
rbc
untreat
vs
papain
treat
conclus
approv
treat
multipl
myeloma
antibodi
may
therapeut
potenti
beyond
hematolog
malign
use
predict
increas
dtt
trypsin
treatment
rbc
mitig
interfer
lack
commerci
avail
treat
rbc
major
limit
avail
commerci
solut
would
attract
previous
found
papain
protocol
treatment
rbc
overcom
interfer
test
possibl
commerci
papain
treat
rbc
includ
use
europ
might
differ
liss
tube
gel
test
reactiv
iat
elimin
reactiv
enhanc
papain
treat
rbc
igg
gel
although
use
papain
treat
rbc
would
expect
enhanc
underli
reactiv
rh
antibodi
show
reactiv
remain
iat
indic
rbc
unaffect
interfer
clinic
signific
antibodi
detect
iat
backgroundcas
studi
provid
blood
product
provinc
quebec
serv
popul
million
also
play
role
immunohematolog
refer
laboratori
irl
resolv
complex
antibodi
identif
case
refer
hospit
annual
receiv
roughli
request
hospit
blood
bank
investig
antibodi
identif
case
pregnanc
transfus
reaction
variou
discrep
among
servic
provid
within
irl
antibodi
identif
investig
exclud
pregnanc
repres
two
third
activ
softwar
haemonet
implement
manag
clinic
case
receiv
sampl
report
result
serv
electron
databas
present
studi
survey
red
blood
cell
rbc
antibodi
provid
valuabl
inform
antibodi
combin
work
frequenc
studi
designmethod
data
extract
databas
use
aggreg
serolog
investig
specif
code
june
implement
march
result
excel
file
manual
analys
resultsfind
data
exclud
pregnanc
follow
up
compil
case
receiv
averag
requestscas
consid
unev
regard
blood
unit
select
case
lack
antibodi
case
consid
reaction
cold
agglutinin
antibodi
rbc
media
antibodi
without
clinic
signific
underli
antibodi
antibodi
daratumumab
case
show
antibodi
blood
group
antigen
specif
without
clinic
signific
rhig
knop
data
regard
two
type
unexpect
rbc
antibodi
alloantibodi
autoantibodi
calcul
sampl
infer
could
make
evalu
case
addit
sole
antibodi
rh
specif
e
specif
evalu
classifi
unev
categori
whenev
autoantibodi
consid
clinic
signific
alloantibodi
total
case
show
blood
group
antigen
specif
clinic
signific
among
case
show
uniqu
antibodi
rh
specif
antibodi
found
case
case
least
one
case
antibodi
case
least
one
overal
present
frequent
case
follow
case
case
combin
observ
case
repres
frequent
rh
antibodi
combin
conclus
studi
summar
last
year
antibodi
identif
irl
exclud
pregnanc
work
up
clearli
show
remain
major
burden
patient
manag
rare
case
also
unrev
work
exampl
case
case
identifi
intend
produc
comprehens
portrait
investig
case
whole
pictur
lost
workload
urgenc
behind
request
also
serv
demonstr
relev
antibodi
work
up
order
prevent
transfus
reaction
favor
patient
outcom
backgroundcas
studi
introduct
immunoprophylaxi
rhd
neg
pregnant
women
drastic
reduc
incid
hemolyt
diseas
fetu
newborn
howev
immunoglobin
administr
risk
free
high
cost
discoveri
circul
free
fetal
dna
cffdna
prompt
introduct
fetal
rhd
genotyp
matern
plasma
approach
increasingli
adopt
sever
countri
sinc
avoid
treatment
substanti
proport
rhd
neg
woman
give
birth
rhd
neg
child
purpos
studi
valid
method
antenat
determin
fetal
rhd
statu
use
cffdna
matern
plasma
present
preliminari
data
ongo
valid
studi
designmethod
consequ
analyz
sampl
rhd
neg
pregnant
women
week
gestat
unknown
posit
rhd
partner
genom
dna
extract
matern
plasma
separ
qiaamp
circul
nucleic
acid
kit
qiagen
valencia
ca
us
use
automat
extract
qiasymphoni
order
determin
fetal
rhd
genotyp
use
taqman
primer
probe
detect
exon
rhd
gene
pcr
free
dna
fetal
kit
rhd
institut
de
biotechnolog
jacqu
boy
foster
citi
ca
intern
control
ad
maiz
dna
extract
use
primersprob
set
specif
maiz
dna
result
antenat
fetal
genotyp
compar
obtain
postnat
cord
blood
rh
phenotyp
resultsfind
sampl
rhd
posit
rhd
neg
sampl
process
avail
comparison
agreement
three
sampl
inconclus
due
miss
data
birth
conclus
fetal
rhd
genotyp
matern
plasma
promis
tool
manag
rhd
neg
pregnant
women
data
confirm
larger
seri
non
invas
approach
reduc
risk
mother
babi
reduc
unnecessari
immunoprophylaxi
backgroundcas
studi
platelet
transfus
therapi
patient
immun
platelet
transfus
refractoi
ptr
immun
thrombocytopenia
transfus
key
obtain
effect
treatment
patient
establish
known
antigen
platelet
donor
databas
could
provid
fast
conveni
way
find
donor
rel
immun
patient
hla
hpa
import
antigen
caus
platelet
alloimmun
diseas
popul
differ
area
polymorph
charact
hla
hpa
nan
import
comprehens
transport
hub
citi
locat
southwestern
china
million
peopl
aim
studi
design
establish
platelet
donor
databas
known
hla
hpa
genotyp
could
suitabl
popul
nan
area
china
provid
guarante
treatment
patient
immun
ptr
immun
thrombocytopenia
well
studi
designmethod
total
unrel
random
healthi
individu
use
popul
studi
hpa
polymorph
nan
area
china
individu
china
marrow
donor
program
use
popul
studi
polymorph
nan
area
base
data
popul
studi
optim
size
platelet
donor
databas
predict
set
goal
design
establish
platelet
donor
databas
known
hla
hpa
genotyp
nan
area
name
nan
area
platelet
donor
databas
known
hla
hpa
genotyp
genotyp
donor
databas
detect
respect
resultsfind
accord
popul
studi
hpa
polymorph
polymorph
nan
area
follow
calcul
deriv
platelet
donor
databas
size
donor
approxim
patient
could
find
genotyp
match
donor
databas
databas
size
donor
approxim
patient
could
find
creg
match
donor
databas
databas
size
donor
approxim
patient
could
find
creg
match
donor
databas
current
nan
area
platelet
donor
databas
known
hla
hpa
genotyp
establish
includ
donor
approxim
patient
could
find
genotyp
match
donor
databas
approxim
patient
could
find
creg
match
donor
databas
conclus
studi
provid
design
method
establish
platelet
donor
databas
known
platelet
antigen
andor
antigen
genotyp
suitabl
popul
nan
china
current
nan
area
platelet
donor
databas
known
hla
hpa
genotyp
includ
donor
establish
could
provid
guarante
safe
treatment
platelet
transfus
backgroundcas
studi
human
platelet
antigen
hpa
one
kind
specif
alloantigen
surfac
platelet
glycoprotein
region
ethnic
differ
hpa
immunolog
stimul
produc
antibodi
blood
transfus
pregnanc
transplant
gener
alloimmun
lead
clinic
complic
neonat
alloimmun
thrombocytopenia
purpura
platelet
transfus
refractori
establish
reliabl
hpa
genotyp
analysi
crucial
laboratori
avail
refer
dna
genom
dna
dna
panel
establish
immort
cell
line
good
way
keep
refer
dna
genom
dna
perman
especi
maintain
donor
specif
hpa
gener
studi
designmethod
screen
larg
donor
patient
rare
hpa
phenotyp
individu
guangxi
provinc
select
inform
consent
includ
hpa
phenotyp
perform
assay
flow
cytometri
monoclon
immobil
platelet
antigen
test
maipa
confirm
dna
sequenc
genotyp
previous
viru
use
transform
peripher
blood
lymphocyt
carri
rare
hpa
phenotyp
individu
genet
analysi
conduct
test
whether
gene
mutat
compar
transform
pcr
broth
cultiv
appli
qualiti
control
method
detect
whether
cell
line
contamin
mycoplasma
resultsfind
rare
hpa
gene
individu
success
establish
passag
dna
gene
mutat
test
pcr
broth
cultiv
detect
contamin
mycoplasma
posit
control
show
posit
result
isbt
platelet
immunolog
workshop
dna
extract
establish
success
use
refer
dna
conclus
dna
use
refer
dna
hpa
genotyp
perman
research
materi
preserv
studi
backgroundcas
studi
elev
level
igg
report
patient
scd
blood
irb
approv
link
studi
residu
sampl
submit
irl
analyz
immunoglobulin
ig
via
fc
consider
interest
sampl
yr
old
patient
transfus
day
prior
unit
present
thrombosi
histori
scd
transfus
request
weakli
posit
w
tube
direct
antiglobulin
test
dat
report
mix
field
reactiv
note
detect
patient
serum
eluat
fc
test
patient
rbc
show
two
rbc
popul
differ
level
igg
sensit
visual
presenc
peak
histogram
studi
designmethod
sampl
test
fc
fluorescein
isothiocyan
fitc
igg
iga
igm
life
technolog
carlsbad
ca
optim
dilut
dulbecco
pb
contain
bsa
rbc
acquir
sampl
becton
dickinson
san
jose
ca
fc
analyz
optim
set
naiv
uncoat
rbc
ig
coat
cell
test
adjust
fc
set
control
valid
normal
rang
igg
determin
test
allogen
rbc
calcul
mean
standard
deviat
see
tabl
singl
sampl
avail
subsequ
sampl
obtain
patient
could
perform
due
natur
irb
resultsfind
fc
method
detect
ig
report
percent
ig
sampl
patient
sampl
analyz
via
fc
day
note
control
sampl
igm
coat
control
cell
due
control
first
test
sampl
retest
day
interest
repeat
sampl
day
sinc
old
retest
atyp
two
cell
popul
visibl
histogram
three
fc
run
increas
sampl
age
day
day
hematocrit
data
avail
review
conclus
patient
igg
igm
low
level
iga
day
test
bound
rbc
detect
via
fc
presenc
two
peak
flow
cytometr
test
patient
rbc
use
like
due
surviv
igg
coat
transfus
rbc
observ
chang
igg
cell
coat
time
may
caus
spherocyt
rbc
lose
charg
cell
membran
harden
backgroundcas
studi
phenotyp
rare
genet
trait
character
reduc
express
b
h
antigen
red
blood
cell
two
fucosyltransferas
encod
h
secretor
gene
regul
express
phenotyp
result
nonfunct
gene
least
partli
function
gene
weakli
function
gene
nonfunct
gene
studi
designmethod
case
report
format
resultsfind
gravida
para
woman
present
prenat
care
first
time
approxim
week
gestat
prior
histori
transfus
forward
type
show
group
revers
type
indic
group
antibodi
screen
identif
panel
show
reactiv
cell
autocontrol
direct
antiglobulin
test
neg
plasma
strongli
reactiv
panel
cell
wide
thermal
rang
even
treatment
dtt
ficin
reactiv
remov
allogen
adsorpt
autolog
adsorpt
patient
plasma
react
panel
cell
neg
antigen
includ
lan
coa
sda
dib
ata
kpb
jsb
lub
vel
patient
red
cell
react
monoclon
b
nonreact
human
sourc
indic
group
aw
ah
antibodi
identifi
genet
test
reveal
compound
heterozyg
genotyp
two
rare
mutat
genotyp
predict
nonsecretor
statu
allel
former
mutat
encod
weak
h
antigen
express
allel
latter
mutat
encod
h
antigen
express
thu
genet
test
result
consist
phenotyp
rbc
defici
nonsecretor
treatment
patient
plasma
dtt
destroy
igm
elimin
absenc
residu
reactiv
would
due
igg
suggest
low
fetal
risk
sourc
blood
possibl
transfus
patient
consid
rbc
patient
sibl
group
incompat
patient
plasma
autolog
collect
american
rare
donor
program
patient
blood
need
met
healthi
newborn
deliv
conclus
report
case
pregnant
woman
phenotyp
associ
two
rare
mutat
provis
rbc
patient
phenotyp
ongo
challeng
earli
commun
obstetrician
transfus
servic
refer
laboratori
essenti
optim
transfus
manag
backgroundcas
studi
reduc
reagent
use
treat
plasma
order
distinguish
igm
igg
antibodi
remov
treat
plasma
prior
antibodi
test
common
dialyz
plasma
overnight
method
ultrafiltr
devic
use
drug
analysi
also
use
remov
day
test
method
b
studi
evalu
two
method
statist
differ
studi
designmethod
eleven
blood
sampl
alloantibodi
select
method
remov
method
use
nmwl
cellulos
dialysi
tube
method
b
use
kda
nmwl
ultrafiltr
devic
centrifre
ultrafiltr
devic
ultracel
milliporesigma
burlington
remov
specimen
method
titrat
test
igm
igg
abo
isohemaglutinin
level
manual
tube
test
confirm
previous
identifi
alloantibodi
treatment
also
perform
ensur
clinic
signific
antibodi
still
detect
method
treat
plasma
dialyz
overnight
phosphat
buffer
salin
recov
tube
method
b
treat
plasma
ad
devic
sampl
chamber
spun
fix
angl
centrifug
minut
ultrafiltr
devic
free
plasma
solut
filter
across
cellulos
membran
filter
plasma
recov
sampl
chamber
filter
doubl
dilut
perform
analyt
test
parallel
tube
method
determin
igm
abo
isohemagglutinin
level
achiev
room
temperatur
incub
igg
level
c
incub
four
time
autom
wash
globulin
endpoint
titrat
determin
last
tube
reaction
statist
analysi
titrat
concentr
normal
last
tube
dilut
reaction
differ
dialyz
filter
plasma
endpoint
use
pair
determin
signific
differ
resultsfind
signific
differ
method
igm
igg
abo
isohemaglutinin
titer
hypothes
mean
differ
reject
previous
identifi
alloantibodi
still
detect
treatment
conclus
plasma
sampl
treat
show
statist
differ
dialyz
filter
plasma
use
ultrafiltr
devic
allow
day
test
accept
remov
maintain
immunoglobulin
backgroundcas
studi
current
type
weak
antigen
identifi
molecularli
common
type
europ
north
america
type
brazil
although
weak
type
less
frequent
still
consid
common
follow
weak
type
type
weak
ds
rare
found
distinct
popul
date
three
exampl
weak
type
type
report
part
eurasian
cluster
recent
found
four
unrel
blood
donor
weak
type
type
southern
brazil
littl
known
rhd
variant
perform
serolog
molecular
studi
sampl
individu
rel
better
character
rare
phenotyp
studi
designmethod
donor
sampl
show
atyp
agglutin
reaction
type
routin
tube
gel
test
addit
serolog
test
perform
gel
clone
use
extend
partial
rhd
type
set
rhce
phenotyp
also
perform
gel
molecular
test
includ
convent
pcr
techniqu
rhd
beadchip
immucor
genom
dna
sequenc
donor
rel
request
serolog
molecular
studi
resultsfind
dna
sequenc
show
presenc
mutat
exon
rhd
gene
lead
substitut
amino
acid
arginin
tryptophan
codon
rhd
protein
associ
weak
type
dna
sampl
donor
rel
serolog
test
show
weak
express
antigen
reactiv
tube
reaction
rhd
phenotyp
gel
red
blood
cell
rbc
sampl
molecularli
character
rhd
weak
type
posit
agglutin
result
obtain
clone
use
rh
haplotyp
associ
weak
type
dcece
conclus
first
serolog
character
rhd
weak
type
show
mix
field
reactiv
individu
studi
share
rhd
weak
type
ce
haplotyp
confirm
previous
found
one
exampl
weak
type
presenc
rare
variant
four
unrel
famili
suggest
founder
effect
popul
southern
brazil
backgroundcas
studi
high
titer
antibodi
coat
cognat
antigen
rare
caus
red
blood
cell
rbc
antigen
phenotyp
event
refer
block
phenomenon
block
antigen
phenomenon
bap
hemolyt
diseas
fetu
newborn
hdfn
bap
complic
laboratori
fetal
phenotyp
help
confirm
caus
hemolysi
treat
cord
rbc
ethylen
glycin
arginin
ega
remov
bap
maintain
express
antigen
except
k
case
hdfn
bap
k
antibodi
publish
despit
report
hdfn
involv
case
chloroquin
diphosph
cdp
use
resolv
bap
effect
one
publish
comparison
elut
method
cdp
fail
remov
rbc
coat
antibodi
time
frequent
heat
elut
given
efficaci
greater
applic
ega
laboratori
longer
maintain
inventori
cdp
report
case
sever
hdfn
bap
due
use
modifi
gentl
heat
elut
remov
bap
case
report
multipar
femal
present
week
pregnanc
complic
k
antibodi
ultrasound
evid
fetal
anemia
cesarean
section
perform
emerg
neonat
exchang
transfus
sever
hdfn
test
result
neonat
blood
specimen
typic
found
hdfn
howev
initi
neonat
rbc
phenotyp
k
antigen
neg
studi
designmethod
serolog
test
done
use
standard
procedur
modifi
gentl
heat
elut
method
equal
part
pack
rbc
albumin
heat
minut
use
dissoci
suspect
block
k
antibodi
rbc
repeat
k
phenotyp
perform
room
temperatur
incub
confirmatori
genotyp
perform
refer
laboratori
use
bioarray
platform
immucor
inc
norcross
ga
resultsfind
modifi
gentl
heat
elut
procedur
result
success
remov
bap
preserv
rbc
k
antigen
type
tabl
genotyp
confirm
neonat
rbc
k
antigen
posit
conclus
although
infrequ
consid
heat
elut
use
bap
rare
situat
simpl
frequent
effect
cdp
remov
rbc
coat
antibodi
involv
readili
avail
suppli
modifi
gentl
heat
elut
mitig
decreas
antigen
express
effect
remov
bap
allow
accur
k
phenotyp
backgroundcas
studi
molecular
technolog
increasingli
use
transfus
medicin
predict
phenotyp
base
blood
group
genet
especi
tradit
serolog
assay
fail
accur
identifi
rare
complex
antigen
report
present
case
identif
antigen
dombrock
system
use
sequenc
ng
studi
designmethod
patient
clinic
symptom
laboratori
find
includ
blood
bank
laboratori
workup
studi
resultsfind
patient
year
old
male
past
medic
histori
sickl
cell
anemia
hemoglobin
sc
diseas
complic
bilater
hip
avascular
necrosi
acut
chest
syndrom
requir
full
red
blood
cell
rbc
exchang
transfus
histori
multipl
transfus
besid
sever
histor
antibodi
patient
found
antibodi
high
preval
antigen
dombrock
system
resembl
antibodi
howev
sampl
submit
red
cell
genotyp
use
id
core
xt
grifol
indic
patient
genotyp
holley
antigen
sinc
antibodi
may
induc
partial
holley
antigen
rbc
surfac
ng
perform
character
particular
antigen
mutat
detect
ng
studi
suggest
antibodi
initi
identifi
less
like
antibodi
clinic
signific
unknown
antibodi
later
assess
use
monocyt
monolay
assay
mma
result
indic
antibodi
clinic
insignific
rbc
unit
issu
accordingli
conclus
present
studi
possibl
antibodi
suggest
tradit
antibodi
panel
studi
could
confirm
rule
tradit
rbc
genotyp
method
use
ng
technolog
molecular
profil
determin
clinic
decis
abl
make
base
result
case
highlight
valu
ng
transfus
servic
offer
comprehens
evalu
genet
variat
thu
provid
person
rbc
unit
recipi
backgroundcas
studi
repeat
blood
transfus
due
differ
allogen
antigen
system
stimul
bodi
produc
type
immun
respons
antibodi
exogen
erythrocyt
result
ineffect
red
blood
cell
transfus
import
reason
inefficaci
red
blood
cell
transfus
irregular
antibodi
detect
applic
routin
pretransfus
detect
method
detect
rate
irregular
antibodi
normal
popul
posit
rate
method
sensit
studi
designmethod
case
blood
transfus
collect
male
femal
age
year
abo
rh
homolog
blood
transfus
accord
blood
transfus
indic
cross
match
blood
medic
record
compar
valu
hemoglobin
blood
transfus
nt
rise
expect
valu
within
hour
infus
red
blood
cell
prepar
elimin
blood
loss
blood
dilut
reason
clinic
sign
hemolyt
transfus
reaction
name
ineffect
blood
transfus
use
enhanc
detect
method
carri
irregular
antibodi
identif
patient
ineffect
blood
transfus
increas
antibodi
screen
cell
concentr
increas
ratio
test
serum
antibodi
screen
cell
use
enhanc
liss
increas
incub
time
globulin
method
adopt
absorptiondispers
method
resultsfind
patient
patient
ineffect
blood
transfus
account
studi
caus
inefficaci
patient
blood
transfus
show
case
irregular
antibodi
account
total
transfus
case
retrospect
analysi
sampl
blood
donor
given
patient
irregular
antibodi
found
patient
infus
red
blood
cell
incongru
antigen
result
ineffect
transfus
patient
patient
given
infus
red
blood
cell
contain
correspond
antigen
ineffect
blood
transfus
occur
conclus
presenc
irregular
antibodi
detect
blood
convent
detect
method
import
caus
ineffect
transfus
irregular
antibodi
mainli
produc
immun
stimul
blood
transfus
pregnanc
antibodi
screen
perform
patient
histori
blood
transfus
pregnanc
histori
repeat
blood
transfus
therapi
irregular
antibodi
detect
routin
method
enhanc
method
irregular
antibodi
identif
appli
backgroundcas
studi
blood
group
chimer
rare
phenomenon
occur
either
congenit
acquir
case
describ
literatur
sinc
case
present
major
clinic
manifest
usual
recogn
time
blood
group
type
agglutin
discrep
cell
type
serum
type
requir
evalu
differenti
abo
subgroup
blood
group
chimer
studi
designmethod
describ
case
femal
twin
abo
rh
antigen
chimer
detect
routin
donor
abo
type
resolv
serolog
molecular
studi
resultsfind
red
blood
cell
rbc
reaction
detect
femal
donor
type
routin
doubl
popul
gel
column
antibodi
serum
type
identifi
antibodi
ask
new
blood
collect
togeth
rel
father
mother
twin
new
blood
serum
saliv
sampl
collect
father
type
b
posit
mother
posit
none
discrep
detect
twin
blood
type
reproduc
result
initi
detect
saliv
studi
show
presenc
b
substanc
secret
abo
subgroup
hypothesi
exclud
mother
father
rh
fenotyp
show
type
twin
fenotyp
also
demonstr
howev
doubl
popul
c
antigen
detect
twenti
one
short
tandem
repeat
str
loci
evalu
extract
dna
twin
peripher
blood
confirm
blood
group
chimer
use
powerplex
fusion
pcr
amplif
kit
promega
corpor
usa
chimermark
softwar
softgenet
least
six
loci
vwa
tpox
show
one
two
addit
peak
besid
main
tall
str
peak
consist
presenc
chimer
conclus
rare
case
perman
chimer
involv
two
blood
system
presenc
separ
group
ab
c
c
rbc
character
discrep
rbc
type
achiev
str
molecular
test
despit
rare
phenomenon
diagnost
suspicion
necessari
order
resolv
type
discrep
provid
compat
blood
transfus
backgroundcas
studi
hemolyt
anemia
defin
reduc
surviv
circul
red
blood
cell
due
prematur
destruct
use
intraven
immunoglobulin
ivig
among
less
frequent
caus
sever
hemolysi
mainli
caus
presenc
antibodi
direct
erythrocyt
antigen
especi
abo
system
immunoglobulin
prepar
passiv
transfer
alloantibodi
present
blood
product
report
rare
case
sever
hemolysi
treatment
variant
syndrom
studi
designmethod
femal
patient
year
old
previous
healthi
sought
emerg
paresthesia
symmetr
paresi
hand
lower
limb
progress
worsen
accompani
pain
moder
intens
day
still
present
difficulti
walk
facial
fold
horizont
nystagmu
look
right
strength
right
hemispher
proport
hyperreflexia
glasgow
coma
scale
ecg
point
comput
tomographi
ct
skull
magnet
reson
imag
mri
perform
absenc
acut
lesion
diagnosi
guillain
syndrom
miller
fisher
subtyp
confirm
patient
histori
transfus
previou
histori
pregnanc
abort
histori
viral
infect
recent
immun
report
biolog
accid
three
year
ago
resultsfind
five
therapeut
plasmapheresi
session
perform
albumin
replac
improv
pictur
hospit
discharg
month
patient
paresthesia
lower
limb
addit
treatment
dose
ivig
indic
first
dose
blood
product
patient
present
sever
intravascular
hemolysi
mark
anemia
reticulocytosi
total
receiv
three
dose
ivig
howev
follow
two
dose
patient
mild
anemia
immunohematolog
studi
show
patient
serum
second
third
dose
ivig
auto
identifi
gel
test
liss
enzym
administ
fourth
dose
immunoglobulin
serolog
test
immunoglobulin
perform
show
presenc
titr
igg
subclass
point
treatment
immunoglobulin
suspend
conclus
case
sever
hemolysi
use
ivig
treatment
miller
fisher
variant
guillain
syndrom
passiv
transfer
young
patient
histori
viral
infect
probabl
alloimmun
c
antigen
biolog
accid
diagnosi
hereditari
suggest
associ
patholog
use
immunoglobulin
may
justifi
hemolysi
patient
backgroundcas
studi
standard
care
method
perform
antibodi
screen
patient
donor
sampl
unit
state
clearli
econom
employ
autom
method
test
vast
major
sampl
neg
howev
method
use
result
increas
detect
weak
unidentifi
uid
antibodi
reactiv
react
establish
method
antibodi
identif
liss
peg
enzym
igg
gel
card
recent
public
shown
solid
phase
sp
assay
sensit
detect
prophylact
immedi
inject
sever
month
post
inject
other
demonstr
sp
show
increas
sensit
uid
reactiv
especi
femal
diagnosi
cancer
autoimmun
diseas
mani
factor
affect
reactiv
antibodi
isotyp
concentr
antigen
densiti
fc
receptor
bind
affin
question
remain
best
method
antibodi
screen
laboratori
abstract
present
refer
laboratori
case
method
detect
antibodi
reactiv
sp
studi
designmethod
method
use
retrospect
studi
publish
procedur
solid
phase
sp
igg
gel
g
card
tube
hemagglutin
use
liss
peg
convert
igg
ahg
resultsfind
tabl
show
case
reactiv
detect
sp
case
patient
identifi
antibodi
specif
passiv
remain
case
diagnosi
warm
auto
immun
hemolyt
anemia
waiha
warm
auto
antibodi
waa
reactiv
sp
conclus
mean
adopt
sp
assay
clinic
laboratori
decis
laboratori
director
determin
method
antibodi
detect
fit
best
clinic
laboratori
set
may
choos
conserv
employ
sensit
method
sp
accept
problem
subject
detect
uid
reactiv
immunohematolog
refer
laboratori
use
mani
differ
method
detect
analyz
sampl
submit
hospit
determin
clinic
signific
antibodi
present
histor
mani
report
antibodi
detect
enzym
gel
sp
small
number
case
year
indic
need
us
implement
sp
test
order
confirm
result
obtain
hospit
blood
bank
backgroundcas
studi
maspat
base
assay
platelet
find
compat
donor
platelet
transfus
patient
serum
test
sever
donor
platelet
rapid
simpl
way
purpos
wide
use
hospit
well
blood
servic
institut
flow
cytometri
use
screen
platelet
antibodi
patient
serum
long
time
two
method
respect
advantagesw
compar
result
flow
cytometri
assay
maspat
elucid
pattern
differ
two
studi
designmethod
patient
compat
platelet
transfus
chosen
randomli
serum
patient
test
platelet
donor
respect
ie
pair
total
use
flow
cytometri
assay
result
compar
maspat
routin
use
shanghai
blood
center
flow
cytometri
assay
wash
platelet
incub
serum
room
temperatur
wash
time
follow
incub
antibodi
platelet
wash
subject
flow
cytometri
sampl
fitc
median
fluoresc
intens
mfi
platelet
gate
greater
twice
neg
control
healthi
ab
donor
serum
determin
posit
maspat
well
result
elucid
perform
accord
manufactur
manual
resultsfind
among
patient
sampl
ident
result
donor
method
term
pair
inconsist
two
method
ie
coincid
rate
neg
flow
cytometri
posit
maspat
situat
rest
contrari
posit
flow
cytometri
neg
maspat
situat
result
discrep
minor
differ
signific
differ
situat
remark
differ
despit
high
inconsist
two
method
final
choic
compat
unit
inconsist
patient
total
conclus
comparison
two
method
platelet
demonstr
maspat
result
posit
predict
probabl
due
adheres
fact
one
patient
treat
drug
situat
prove
platelet
antibodi
use
test
howev
sensit
demand
specif
choos
compat
unit
maspat
popular
due
simplic
rapid
discrep
investig
carri
elucid
method
accur
use
theoret
clinic
backgroundcas
studi
pathogen
reduct
pr
system
red
blood
cell
rbc
use
amustalin
gsh
inactiv
pathogen
virus
protozoa
bacteria
leukocyt
format
nucleic
acid
adduct
random
control
design
phase
trial
compar
safeti
efficaci
pr
rbc
convent
rbc
object
studi
qualifi
pr
process
region
blood
center
oneblood
biolog
research
laboratori
orlando
fl
support
phase
trial
studi
designmethod
cpd
leukocyt
reduc
rbc
prepar
day
collect
oneblood
st
petersburg
fl
transport
oneblood
orlando
lab
test
unit
ml
treat
mm
mm
amustalin
within
collect
control
c
unit
ml
untreat
c
rbc
store
day
sampl
c
sampl
analysi
vitro
paramet
tabl
hemoglobin
hb
hematocrit
hct
evalu
oneblood
locat
mimic
transport
clinic
transfus
site
rbc
ship
ceru
end
storag
assess
hemolysi
upon
receipt
resultsfind
post
pr
volum
hb
recoveri
g
hb
reduct
extracellular
protein
compar
c
end
storag
higher
atp
c
ph
k
lactat
lower
hct
na
glucos
similar
c
c
atp
molg
hb
indic
effect
rbc
viabil
throughout
storag
hemolysi
compar
c
shipment
hemolysi
lower
compar
c
tabl
conclus
pr
rbc
success
qualifi
region
blood
center
support
larg
phase
trial
pr
rbc
compon
met
us
criterion
hemolysi
end
storag
shipment
measur
vitro
paramet
rbc
indic
suitabl
transfus
backgroundcas
studi
human
anellovirus
smallest
particl
size
smallest
genom
size
least
complex
genet
organ
human
pathogen
establish
chronic
persist
infect
infanc
earli
childhood
produc
constantli
detect
load
plasma
thereaft
studi
suggest
ubiquit
present
human
popul
immun
surveil
requir
control
level
viru
load
studi
designmethod
use
quantit
dna
pcr
assay
recent
develop
target
conserv
region
anelloviru
genom
examin
viral
load
plasma
blood
donor
hiv
carrier
pittsburgh
pennsylvania
resultsfind
blood
donor
posit
averag
load
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
hiv
carrier
posit
averag
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
conclus
result
valid
pcr
assay
develop
confirm
detect
viral
load
around
copi
present
blood
donor
survey
addit
hiv
infect
appear
reset
anelloviru
load
averag
carrier
approxim
order
magnitud
higher
broad
rang
load
approx
copiesml
hiv
carrier
investig
correl
immun
health
statu
backgroundcas
studi
cell
dose
extend
predictor
hematopoiet
recoveri
delay
recoveri
despit
suffici
number
common
suggest
factor
play
role
kinet
process
effect
total
nucleat
cell
tnc
engraft
remain
unclear
sever
studi
shown
conflict
result
object
studi
analyz
impact
tnc
engraft
surviv
studi
designmethod
analysi
januari
decemb
includ
hematopoiet
stem
cell
transplant
hsct
procedur
autolog
allogen
patient
pt
male
femal
main
reason
hsct
acut
leukemia
allogen
hsct
multipl
myeloma
autolog
hsct
haploident
transplant
exclud
condit
regimen
prior
allogen
hsct
myeloabl
pt
nma
main
sourc
stem
cell
peripher
blood
resultsfind
median
tnc
infus
respect
autolog
hsct
found
higher
tnc
dose
correl
faster
neutrophil
engraft
p
spearman
correl
coeffici
higher
cell
dose
effect
allogen
hsct
group
higher
tnc
dose
correl
faster
platelet
engraft
p
either
nma
group
cell
dose
predict
faster
engraft
pt
receiv
tnc
observ
shorter
median
time
neutrophil
engraft
autolog
group
shorter
time
platelet
recoveri
allogen
group
tabl
statist
differ
surviv
outcom
observ
group
regard
tnc
dose
number
conclus
seri
strong
associ
higher
tnc
cell
dose
shorter
time
engraft
observ
could
demonstr
effect
cell
dose
impact
surviv
observ
regard
tnc
cell
dose
backgroundcas
studi
west
nile
viru
wnv
viru
northern
hemispher
wnv
lineag
primarili
respons
human
diseas
endem
australia
although
less
virul
wnv
kunjin
strain
endem
tropic
northern
region
australia
perform
wnv
donor
screen
potenti
tt
risk
associ
donor
return
endemicoutbreak
countri
estim
risk
develop
probabilist
model
mont
carlo
simul
appli
eu
neighbour
countri
wnv
transmiss
season
studi
designmethod
input
paramet
countri
probabl
acquir
asymptomat
wnv
infect
period
observ
deriv
number
report
wn
fever
wnf
case
countri
ratio
symptomat
asymptomat
infect
donor
visit
outbreak
countri
period
observ
deriv
proport
australian
donor
popul
visit
countri
period
observ
return
donor
donat
viraem
base
number
return
donor
donat
within
week
leav
outbreak
countri
donat
use
clinic
product
transfus
issu
clinic
product
tt
risk
express
risk
transfus
clinic
product
deriv
infecti
donat
given
return
donor
risk
estim
perform
weekli
basi
input
paramet
assum
triangular
distribut
simul
run
iter
resultsfind
countri
report
highest
wnv
tt
risk
transmiss
season
peak
weekli
risk
greec
hungari
itali
conclus
result
demonstr
low
risk
blood
safeti
australia
wnv
transmiss
season
eu
neighbour
countri
estim
risk
low
addit
risk
mitig
strategi
deferr
donor
return
countri
requir
model
allow
regular
estim
tt
risk
countri
associ
return
donor
readili
adapt
specif
countri
pathogen
howev
low
level
risk
feasibl
monitor
report
case
number
wnf
set
trigger
point
implement
risk
model
countri
backgroundcas
studi
test
platelet
plt
unit
mandat
march
implement
primari
cultur
singl
donor
platelet
sdp
collect
time
later
pool
platelet
pspp
two
method
primari
cultur
avail
bactalert
ebd
plt
supplier
use
either
bactalert
ml
test
volum
ebd
ml
test
volum
sinc
abl
compar
bacteri
contamin
septic
transfus
reaction
rate
plt
unit
test
two
method
studi
designmethod
plt
unit
transfus
institut
jan
dec
studi
sdp
pspp
unit
test
primari
cultur
supplier
use
bactalert
ebd
system
bactalert
test
biomerieux
st
loui
mo
perform
inocul
ml
sdp
collect
pspp
unit
bactalert
bpa
cultur
bottl
h
collect
ebd
haemonet
corpor
braintre
perform
inocul
ml
aliquot
sdp
collect
pspp
unit
ebd
cultur
pouch
h
collect
pouch
incub
h
oxygen
level
head
space
measur
use
ebd
oxygen
analyz
unit
releas
use
neg
method
test
hour
cultur
perform
obtain
aliquot
unit
time
releas
transfus
ml
volum
plate
onto
blood
agar
plate
plate
incub
hour
specimen
yield
bacteri
growth
cultur
quantit
record
patient
receiv
contamin
unit
review
contamin
septic
transfus
rate
calcul
method
unit
type
resultsfind
total
plt
unit
transfus
year
studi
period
test
bactalert
sdp
pspp
ebd
sdp
pspp
unit
found
bacteri
contamin
test
bactalert
sdp
pspp
sdp
pspp
ebd
contamin
rate
express
rate
per
million
plt
unit
unit
test
bactalert
vs
ebd
compar
overal
plt
unit
type
overal
vs
sdp
vs
pspp
vs
contamin
product
transfus
result
five
septic
reaction
one
unit
test
bactalert
ebd
vs
per
million
respect
conclus
despit
differ
volum
plt
test
two
method
ml
ebd
ml
bact
alert
rate
plt
bacteri
contamin
septic
reaction
transfus
contamin
plt
significantli
differ
plt
test
two
primari
test
method
use
addit
measur
need
reduc
rate
bacteri
contamin
septic
reaction
bacteri
contamin
plt
product
backgroundcas
studi
blood
system
platelet
develop
inactiv
broad
rang
pathogen
leukocyt
platelet
concentr
pc
system
util
amotosalen
uva
light
approv
us
treat
apheresi
platelet
plasma
pa
dose
rang
platelet
despit
implement
bacteri
cultur
screen
unrecogn
bacteri
contamin
may
still
result
fulmin
infect
tti
particular
anaerob
bacteria
exhibit
longer
lag
period
slowli
grow
pc
storag
condit
miss
cultur
base
bacteri
screen
result
tti
evalu
efficaci
inactiv
bacteri
two
anaerob
bacteria
clostridium
perfringen
fast
grow
anaerob
propionibacterium
acn
slow
grow
anaerob
contamin
pc
treat
store
pc
storag
condit
day
studi
designmethod
experi
pc
prepar
either
pa
plasma
final
volum
ml
dose
platelet
use
platelet
compon
divid
half
half
spike
either
c
perfringen
p
acn
prior
treatment
half
unit
one
anaerob
recombin
sampl
taken
plate
assay
pc
treat
amotosalen
uva
sampl
taken
pre
day
storag
control
arm
pc
also
spike
confirm
growth
surviv
c
perfringen
p
acn
similar
process
without
uva
pc
storag
condit
test
resultsfind
c
perfringen
cp
p
acn
pa
inactiv
summar
conclus
reproduc
inactiv
multipl
anaerob
bacteria
pc
high
level
log
cfuml
result
steril
demonstr
absenc
detect
bacteria
day
storag
control
arm
demonstr
growthsurviv
bacteria
similar
process
storag
period
backgroundcas
studi
acut
lung
injuri
trali
potenti
fatal
complic
transfus
studi
sever
clinic
studi
trali
relat
loss
product
qualiti
red
blood
cell
storag
call
storag
lesion
donor
characterist
exampl
age
genet
sex
influenc
storag
lesion
investig
relat
donor
characterist
onset
trali
hypothes
donor
sex
age
blood
type
relat
trali
incid
studi
designmethod
perform
secondari
analysi
donor
data
two
cohort
studi
combin
one
largest
cohort
trali
patient
date
first
cohort
consist
retrospect
nest
case
control
studi
icu
patient
second
cohort
consist
prospect
case
control
studi
cardiac
surgeri
patient
suspect
trali
defin
use
consensu
definit
ali
obtain
donor
sex
age
blood
type
nation
blood
bank
use
test
compar
number
transfus
product
test
compar
proport
trali
patient
transfus
control
resultsfind
retrospect
cohort
consist
patient
fulfil
diagnost
criteria
trali
male
median
age
iqr
massiv
transfus
patient
receiv
transfus
develop
trali
randomli
select
serv
control
patient
male
median
age
iqr
massiv
transfus
trali
patient
receiv
product
control
test
p
relat
trali
incid
donor
sex
chi
squar
test
p
trali
patient
transfus
control
receiv
mainli
product
donor
year
old
chi
squar
test
p
donor
age
influenc
trali
risk
chi
squar
test
p
trali
control
patient
receiv
blood
product
blood
type
p
trali
relat
blood
group
match
blood
type
compat
transfus
test
p
prospect
case
control
studi
cardiac
surgeri
patient
patient
develop
trali
male
median
age
iqr
patient
randomli
select
control
male
median
age
iqr
cohort
confirm
result
retrospect
studi
donor
blood
type
donor
sex
blood
blood
product
cohort
group
receiv
mainli
product
male
trali
patient
receiv
transfus
chi
squar
test
p
conclus
conclud
two
cohort
trali
patient
donor
blood
type
donor
age
donor
sex
transfus
blood
blood
product
associ
increas
risk
trali
backgroundcas
studi
impair
deform
red
blood
cell
rbc
relat
diseas
consequ
red
cell
concentr
rcc
storag
polydimethylsiloxan
pdm
microfluid
devic
especi
design
reproduc
rbc
circul
blood
vessel
recent
develop
assess
rbc
deform
devic
made
two
inlet
two
array
channel
uniqu
outlet
flow
rate
measur
near
channel
outlet
correl
rbc
rheolog
properti
analyt
approach
use
extern
standard
account
variat
studi
aim
valid
microbead
extern
standard
monitor
rbc
deform
storag
studi
designmethod
carboxyl
polystyren
microspher
solut
use
extern
standard
studi
stock
solut
banglab
dispers
filter
phosphat
buffer
salin
pb
glycerol
ad
match
averag
rbc
flow
rate
previous
record
microfluid
devic
fresh
rbc
multipl
hardwar
softwar
paramet
test
respect
impact
perform
analyt
method
ie
precis
accuraci
measur
rate
occurr
plug
event
valid
extern
standard
approach
three
differ
extern
standard
solut
prepar
b
c
test
use
nine
differ
chip
experi
design
evalu
reproduc
output
result
chip
side
inlet
fill
standard
side
inlet
fill
either
standard
b
c
rightleft
flow
rate
ratio
use
analyt
output
signal
rcc
sampl
differ
storag
age
analyz
use
extern
standard
approach
compar
respect
deform
resultsfind
flow
rate
record
left
right
inlet
compar
chip
coeffici
variat
cv
within
chip
lower
demonstr
high
homogen
channel
mask
use
fabric
pdm
chip
evalu
manufactur
reproduc
left
inlet
chip
fill
standard
flow
rate
compar
cv
deem
within
accept
rang
final
signific
differ
record
flow
rate
standard
b
c
overal
flow
rate
extern
standard
solut
determin
nl
cv
similar
flow
rate
observ
rcc
sampl
previou
studi
conclus
microfluid
method
believ
suitabl
precis
sensit
rbc
deform
analysi
develop
appropri
extern
standard
approach
use
address
variabl
use
carboxyl
polystyren
microspher
found
reproduc
method
backgroundcas
studi
granulocyt
transfus
use
treat
bacterialfung
infect
sever
neutropen
leukem
stem
cell
transplant
patient
inadequ
dosag
limit
usag
past
use
mobil
agent
fulli
autom
devic
improv
yield
granulocyt
concentr
lead
improv
clinic
outcom
establish
dose
transfus
granulocyt
one
import
predictor
success
granulocyt
transfus
studi
designmethod
clinic
data
januari
februari
first
time
consecut
femal
donor
rel
friend
patient
collect
bmi
calcul
donor
donor
categor
three
group
normal
bmi
bmi
overweight
bmi
obes
goal
studi
see
whether
correl
increas
bmi
first
time
femal
donor
greater
increas
wbc
mobil
filgrastim
neupogen
plu
dexamethason
donor
receiv
dose
mcg
singl
subcutan
inject
hour
prior
collect
dexamethason
mg
mg
tablet
also
prescrib
hour
prior
collect
donor
without
histori
eye
diseas
complet
blood
count
perform
prior
mobil
post
apheresi
granulocyt
concentr
allogen
blood
donor
criteria
use
qualifi
granulocyt
donor
statist
analysi
wilcoxson
test
use
compar
distribut
follow
paramet
age
weight
pre
wbcgranulocyt
platelet
count
post
wbcplatelet
count
wbcplatelet
count
donor
tbv
tbv
process
run
time
collect
prefer
granulocyt
concentr
volumetot
wbchematocritanc
collect
effici
increas
wbc
granulocyt
post
decreas
wbcplatelet
post
bmi
group
statist
analysi
perform
use
r
version
statist
test
use
signific
adjust
made
multipl
test
resultsfind
first
time
femal
donor
normal
bmi
overweight
obes
four
paramet
found
statist
signific
weight
p
donor
total
blood
volum
p
granulocyt
concentr
volum
p
wbc
content
granulocyt
concentr
hematocrit
major
granulocyt
concentr
collect
three
bmi
group
paramet
list
statist
signific
conclus
conclud
increas
bmi
correl
greater
increas
wbc
mobil
dexamethason
first
time
femal
donor
increas
bmi
correl
larger
volum
granulocyt
concentr
collect
increas
total
white
cell
content
found
fulli
autom
apheresi
machin
allow
us
minim
red
cell
contamin
optim
granulocyt
collect
data
analys
extend
male
donor
well
repeat
femalemal
donor
confirm
find
backgroundcas
studi
pandem
character
rapidli
increas
genet
diverg
ongo
monitor
molecular
divers
blood
donor
import
compon
comprehens
surveil
system
studi
subtyp
distribut
drug
resist
mutat
drm
infect
blood
donor
five
chines
region
studi
designmethod
wb
confirm
blood
sampl
collect
five
blood
center
jan
dec
hiv
pol
region
sequenc
reconstruct
phylogeni
subtyp
drm
sequenc
analyz
use
previou
publish
method
resultsfind
sequenc
success
obtain
infect
donor
subtyp
distribut
follow
circul
recombin
form
crf
b
predomin
subtyp
blood
center
vari
sampl
drm
yield
drug
resist
preval
drm
identifi
includ
proteas
inhibitor
pi
accessori
drm
pi
major
drm
nucleosid
rt
inhibitor
drm
nucleosid
rt
inhibitor
drm
tabl
conclus
subtyp
distribut
chines
donor
continu
show
abund
divers
compar
previou
result
formerli
predomin
subtyp
b
continu
decreas
first
report
subtyp
infect
donor
newli
identifi
subtyp
associ
men
sex
men
msm
find
consist
shift
predomin
mode
hiv
transmiss
illeg
drug
inject
sexual
transmiss
includ
msm
transmiss
observ
gener
chines
popul
drm
preval
increas
data
blood
center
limit
studi
rel
low
amplif
rate
result
support
need
continu
molecular
surveil
donor
better
understand
hiv
risk
factor
import
improv
blood
safeti
backgroundcas
studi
iron
deplet
pose
signific
health
risk
blood
donor
yet
much
blood
collect
donor
alreadi
iron
defici
donor
screen
includ
test
hemoglobin
best
avail
rapid
test
serv
proxi
iron
statu
fact
poor
predictor
actual
iron
store
mani
low
iron
donor
thu
deplet
donat
problem
recogn
fda
aabb
push
new
protocol
reduc
risk
donor
serum
ferritin
consid
one
best
indic
iron
store
due
technolog
limit
test
use
laboratori
machin
slow
expens
impract
use
screen
test
within
exist
blood
donat
workflow
vitascan
develop
ironscan
rapid
diagnost
test
quantit
assess
ferritin
minut
finger
stick
blood
demonstr
accuraci
compar
immulit
ferritin
assay
studi
designmethod
test
ferritin
develop
later
flow
immunassay
colorimetr
line
develop
assay
function
ferritin
protein
concentr
analyz
optic
reader
calcul
ferritin
valu
test
serum
sampl
whole
blood
sampl
compar
linear
correl
agreement
immulit
ferritin
laboratori
assay
resultsfind
serum
blood
sampl
demonstr
strong
correl
respect
use
heir
studi
design
ngml
defin
iron
defici
also
demonstr
sensit
specif
serum
sensit
specif
blood
conclus
ironscan
assay
demonstr
strong
agreement
laboratori
standard
test
blood
feasibl
implement
test
screen
donor
iron
defici
figur
ironscan
system
vitscan
reader
platform
b
test
cartridg
packag
c
vitascan
employe
use
devic
serum
data
e
blood
data
cutoff
ngml
backgroundcas
studi
bacteri
contamin
platelet
may
lead
septic
event
organ
grow
undetect
cultur
platelet
storag
organ
growth
might
influenc
milieu
platelet
suspend
studi
evalu
growth
bacteri
speci
implic
septic
event
platelet
addit
solut
pa
platelet
character
slower
grower
exhibit
lag
time
platelet
studi
designmethod
hyperconcentr
doubl
unit
aphersi
platelet
target
yield
concurr
plasma
collect
amicu
normal
consent
donor
hyperconcentr
unit
divid
equal
two
aliquot
one
aliquot
ad
yield
aliquot
equival
volum
plasma
use
prepar
platelet
ad
follow
rest
agit
aliquot
immedi
split
ml
clx
contain
inocul
cfuml
purpos
quantit
plate
assay
fresh
overnight
cultur
bacteri
isol
includ
aureu
epidermidi
e
coli
k
pneumonia
baumannii
capra
sanguini
orali
gallolyticu
warneri
b
cereu
platelet
store
agit
sampl
obtain
daili
quantit
plate
cultur
duplic
storag
depend
organ
experi
repeat
time
resultsfind
aureu
epidermidi
e
coli
k
pneumonia
sanguini
orali
gallolyticu
warneri
b
cereu
similar
growth
kinet
plasma
p
day
epidermidi
gallolyticu
trend
p
toward
slightli
greater
lesser
growth
respect
plasma
compar
pa
baumannii
day
capra
day
significantli
greater
growth
pa
compar
plasma
p
conclus
nine
organ
exhibit
similar
growth
kinet
platelet
suspend
pa
compar
plasma
two
organ
display
significantli
faster
earli
late
growth
pa
backgroundcas
studi
mani
blood
center
elect
discard
product
donor
posit
antibodi
screen
may
assign
perman
deferr
avoid
wastag
associ
futur
posit
donat
studi
sought
examin
differ
antibodi
persist
blood
donor
base
antibodi
specif
donor
age
gender
recommend
donor
manag
strategi
studi
designmethod
studi
retrospect
cohort
studi
repeat
adult
volunt
allogen
blood
donor
electron
donat
histori
larg
commun
blood
center
donor
birthdat
gender
donat
date
antibodi
screen
result
antibodi
specif
obtain
via
electron
queri
donat
occur
januari
june
antibodi
categor
persist
recurr
evanesc
base
antibodi
screen
result
histori
mean
time
antibodi
evanesc
calcul
group
mean
compar
use
anova
less
consid
signific
differ
resultsfind
signific
differ
mean
time
antibodi
evanesc
compar
donor
gender
age
number
antibodi
specif
donor
age
significantli
less
like
evanesc
antibodi
compar
younger
donor
mean
time
antibodi
evanesc
significantli
longer
antibodi
specif
kell
blood
group
system
antigen
compar
direct
rh
kidd
duffi
mn
blood
group
system
antigen
p
among
donor
antibodi
evanesc
mean
time
evanesc
day
mean
persist
day
suggest
averag
donor
antibodi
evanesc
group
becam
undetect
month
follow
initi
posit
donat
howev
twenti
percent
donor
posit
antibodi
screen
repeat
posit
donat
donor
least
two
posit
donat
mean
time
evanesc
day
conclus
result
studi
suggest
younger
donor
like
result
neg
antibodi
screen
subsequ
donat
compar
donor
year
old
data
suggest
possibl
initi
deferr
year
donor
two
consecut
posit
antibodi
screen
aggress
deferr
period
older
donor
antibodi
direct
antigen
kell
system
backgroundcas
studi
nucleic
acid
test
pool
sourc
plasma
donat
critic
qualiti
control
step
ensur
manufactur
product
safeti
new
nucleic
acid
test
multiplex
pcr
assay
multiplex
assay
recent
develop
simultan
screen
pool
sourc
plasma
donat
hepat
b
viru
hbv
hepat
c
viru
hcv
current
new
test
review
licensur
food
drug
administr
fda
studi
designmethod
period
total
individu
donat
differ
donor
donor
center
test
master
pool
contain
donat
pool
test
algorithm
use
pool
aliquot
individu
plasma
donat
subsequ
identifi
posit
donat
plasma
pool
test
parallel
multiplex
assay
individu
hcv
hbv
assay
clinic
specif
sensit
multiplex
assay
assay
compar
use
mcnemar
test
match
pair
p
valu
resultsfind
donat
confirm
neg
hcv
hbv
donat
confirm
posit
least
one
target
viru
assay
demonstr
clinic
specif
test
target
viru
number
donat
confirm
posit
viral
type
calcul
clinic
sensit
assay
type
list
follow
tabl
conclus
multiplex
assay
assay
show
similar
clinic
sensit
p
valu
detect
hbv
howev
two
assay
result
statist
differ
hcv
detect
indic
multiplex
assay
superior
assay
detect
hcv
rna
differ
hcv
result
explain
least
part
dramat
improv
analyt
sensit
iuml
versu
iuml
multiplex
assay
overal
multiplex
pcr
assay
demonstr
equival
superior
case
hcv
compar
individu
hcv
hbv
assay
backgroundcas
studi
hepat
e
viru
hev
major
caus
acut
hepat
worldwid
possibl
threat
transfus
safeti
data
europ
show
variabl
preval
hev
igg
aim
studi
assess
preval
reactiv
hev
viremia
blood
donor
geograph
area
lombardi
evalu
subgroup
donor
incid
infect
year
follow
period
addit
use
data
estim
risk
transfus
transmiss
studi
designmethod
studi
conduct
within
botia
repositori
pair
viremia
studi
nearli
sampl
collect
anonym
donat
sampl
test
nucleic
acid
test
hev
rna
use
procleix
hev
assay
limit
detect
iuml
serolog
studi
subset
donat
test
hev
igg
use
diapro
hev
elisa
kit
diagnost
bioprob
srl
milano
itali
hev
igg
igm
analyz
posit
sampl
time
donat
one
year
index
donat
furthermor
incid
studi
repeat
donor
serial
sampl
avail
botia
biorepositori
analyz
period
year
risk
receiv
infecti
blood
unit
estim
accord
two
differ
method
hev
rna
yield
serolog
incid
data
assum
durat
viremia
day
seroconvert
donor
resultsfind
nine
donor
sampl
show
hev
rna
reactiv
one
sampl
confirm
reactiv
repeat
tma
test
show
igm
igg
seroconvers
indic
primari
hev
infect
thu
hev
rna
preval
ci
seropreval
studi
proport
confirm
igg
reactiv
ci
incid
studi
median
year
show
donor
neg
baselin
seroconvert
incid
ci
estim
transfus
risk
use
hev
rna
yield
per
blood
donat
upper
bound
ci
use
incid
data
per
blood
donat
ci
conclus
result
suggest
hyperendem
hev
among
blood
donor
geograph
area
compar
european
countri
estim
transfus
risk
gave
coincid
result
use
two
independ
approach
hev
rna
yield
donor
averag
risk
blood
donat
also
suggest
risk
acquir
therefor
transmit
infect
remain
substanti
stabl
past
decad
backgroundcas
studi
safeti
blood
storag
recent
affirm
multipl
random
trial
howev
question
around
potenti
harm
store
red
blood
cell
rbc
rais
cardiac
surgeri
patient
may
especi
vulner
harm
due
high
rate
transfus
inflammatori
state
occur
bypass
studi
examin
associ
mortal
exposur
store
rbc
cardiac
surgeri
patient
popul
studi
designmethod
adult
year
receiv
least
rbc
transfus
context
cardiac
surgeri
identifi
academ
centr
assess
effect
rbc
storag
mortal
cox
proport
hazard
model
fit
patient
exposur
defin
transfus
rbc
shortest
storag
durat
analys
continu
variabl
quartil
week
storag
categori
model
day
refer
group
exclus
exposur
rbc
store
longest
durat
model
hemoglobin
creatinin
plateletplasmacryoprecipit
transfus
abo
ident
rbc
transfus
covari
age
sex
abo
blood
group
admiss
year
comorbid
adjust
analys
model
met
cox
proport
hazard
assumpt
resultsfind
patient
receiv
rbc
transfus
median
patient
age
iqr
patient
femal
median
number
rbc
unit
transfus
iqr
median
unit
age
day
overal
mortal
hazard
ratio
hr
continu
analysi
ci
p
everi
decreas
blood
storag
model
use
week
storag
show
signific
differ
refer
group
exclus
exposur
rbc
store
day
compar
exposur
rbc
store
week
tabl
similar
find
obtain
model
data
shown
conclus
patient
undergo
cardiac
surgeri
associ
mortal
exposur
store
rbc
found
regardless
whether
exposur
analys
continu
variabl
categori
storag
durat
backgroundcas
studi
intercept
blood
system
platelet
tripl
storag
ts
process
set
ce
mark
approv
pathogen
reduct
platelet
platelet
addit
solut
pa
current
fda
approv
system
util
amotosalen
uva
light
inactiv
pathogen
leukocyt
studi
evalu
vitro
function
intercept
pc
prepar
use
ts
set
day
storag
studi
designmethod
amicu
apheresi
pc
collect
plasma
input
collect
pool
two
collect
contain
dose
platelet
count
ml
treat
use
intercept
ts
set
test
untreat
control
tripl
dose
collect
dose
count
ml
pc
store
day
assess
vitro
physicalmetabol
characterist
day
resultsfind
follow
treatment
platelet
dose
recoveri
pc
contain
dose
per
compon
treat
pc
met
fda
requir
day
vitro
platelet
qualiti
day
compar
unpair
untreat
control
pc
tabl
conclus
pool
amicu
pc
treat
intercept
ts
set
store
day
retain
vitro
metabol
function
properti
consist
rang
untreat
control
pc
vivo
function
backgroundcas
studi
blood
center
observ
season
increas
hepat
b
core
antibodi
repeat
reactiv
rate
rr
use
ortho
immunosorb
assay
elisa
platform
fall
earli
winter
month
increas
especi
mark
etiolog
higher
season
rate
unclear
howev
interf
antibodi
follow
influenza
vaccin
previous
implic
studi
designmethod
rr
blood
donor
screen
elisa
assay
analyz
past
three
year
compar
rr
blood
center
bc
well
blood
center
abc
perform
test
total
assess
reactiv
rate
requir
hepat
marker
use
blood
donor
screen
includ
hepat
b
surfac
antigen
hbsag
nucleic
acid
test
hepat
b
viru
dna
also
review
donor
record
report
vaccin
within
past
week
blood
donor
well
reactiv
result
resultsfind
season
increas
rr
observ
studi
period
abc
increas
observ
assay
blood
donor
screen
test
season
increas
reactiv
rate
observ
assay
elisa
test
rr
hbv
donor
screen
test
hbsag
increas
compar
annual
averag
abc
respect
rr
month
februari
august
averag
bc
abc
rr
peak
octob
novemb
bc
respect
compar
abc
comparison
peak
rr
abc
oct
nov
oct
nov
donor
record
review
select
period
nov
reveal
donor
reactiv
result
report
vaccin
within
previou
eight
week
compar
blood
donor
time
frame
major
influenza
viru
vaccin
conclus
document
season
increas
rr
ortho
assay
use
blood
donor
screen
fall
earli
winter
month
show
exagger
increas
caus
phenomenon
unclear
possibl
donor
develop
antibodi
vaccin
assay
exclud
result
signific
loss
blood
donor
presum
hepat
b
increas
rr
observ
hepat
b
marker
use
donor
screen
fda
allow
process
donor
repeat
reactiv
test
two
separ
occas
problem
result
excess
number
defer
blood
donor
advent
nat
test
hepat
b
larger
question
address
whether
screen
test
increas
safeti
blood
suppli
backgroundcas
studi
sinc
hepat
viru
hav
outbreak
involv
predominantli
men
sex
men
msm
affect
european
countri
mainland
franc
number
report
case
increas
respect
first
month
frequenc
peak
juli
signific
number
case
appear
associ
msm
activ
deduc
proport
male
among
notifi
case
detect
outbreak
strain
analyz
case
studi
designmethod
report
hav
incid
blood
donor
hav
risk
factor
viral
load
genotyp
involv
blood
product
recipi
outcom
hav
outbreak
franc
hepat
viru
nat
screen
requir
donat
contribut
medicin
product
perform
ef
behalf
lfb
hav
test
carri
use
procleix
assay
tigri
system
blood
donat
viral
load
individu
sampl
assess
hav
kit
altona
diagnost
serial
dilut
intern
standard
hav
rna
nat
assay
quantif
curv
fragment
encompass
junction
amplifi
sequenc
strain
character
resultsfind
hepat
viru
rna
preval
blood
donat
fold
higher
period
vs
frequenc
peak
donat
time
number
case
gener
popul
still
increas
thirteen
donor
detect
vs
donor
confirm
asymptomat
time
blood
donat
genotyp
ia
msm
strain
identifi
case
detect
viral
load
hav
posit
donor
rang
iuml
differ
significantli
despit
higher
male
femal
ratio
vs
identif
outbreak
strain
infect
male
donor
msm
hav
risk
factor
food
profession
exposur
mainli
identifi
male
femal
evalu
donor
risk
factor
identifi
remain
donor
male
femal
similar
food
profession
exposur
risk
factor
identifi
blood
donor
identifi
none
found
last
case
involv
red
blood
cell
concentr
destroy
alreadi
transfus
platelet
concentr
transfus
result
made
avail
collect
plasma
destroy
haemovigil
enquiri
posit
blood
transfus
reveal
one
case
hepat
confirm
molecular
comparison
donor
recipi
viral
strain
conclus
knowledg
studi
first
estim
risk
collect
blood
donat
hepat
outbreak
hav
outbreak
franc
risk
collect
asymptomat
blood
donor
increas
remain
rare
event
nevertheless
least
one
hepat
occur
backgroundcas
studi
platelet
crossmatch
solid
phase
test
util
patient
demonstr
platelet
refractori
methodolog
detect
incompat
patient
plasma
donor
platelet
due
presenc
platelet
human
leukocyt
antigen
hla
andor
abo
antibodi
platelet
crossmatch
techniqu
show
compat
platelet
lack
antigen
patient
antibodi
case
demonstr
patient
antibodi
detect
platelet
crossmatch
test
studi
designmethod
region
immunohematolog
refer
lab
irl
receiv
patient
sampl
request
platelet
crossmatch
obtain
compat
patient
sampl
also
sent
panel
reactiv
antibodi
pra
detect
hla
antibodi
pra
result
report
use
mean
fluoresc
intens
mfi
result
equal
quantit
titer
result
pra
result
show
reactiv
mfi
result
approxim
caus
incompat
platelet
crossmatch
test
result
six
platelet
crossmatch
hla
type
posit
antigen
patient
hla
antibodi
therefor
platelet
incompat
given
high
pra
mfi
platelet
crossmatch
result
repeat
use
plasma
dilut
explor
prozon
phenomena
could
observ
resultsfind
platelet
crossmatch
result
use
plasma
dilut
yield
reactiv
platelet
one
incompat
platelet
posit
patient
mfi
antigen
approxim
respect
second
incompat
platelet
posit
mfi
approxim
respect
platelet
crossmatch
result
use
plasma
dilut
yield
reactiv
one
platelet
incompat
platelet
result
addit
dilut
posit
antigen
patient
antibodi
mfi
approxim
three
compat
platelet
use
plasma
dilut
dilut
posit
antigen
two
posit
antigen
one
posit
antigen
antibodi
mfi
result
antibodi
approxim
respect
show
antibodi
detect
normal
dilut
plasma
regardless
mfi
conclus
exampl
platelet
crossmatch
use
solid
phase
methodolog
show
low
sensit
prozon
effect
backgroundcas
studi
due
risk
hiv
transmiss
food
drug
administr
recommend
ban
blood
donat
men
sex
men
msm
revis
current
donat
restrict
limit
men
sex
man
past
year
light
advanc
hiv
screen
ban
may
repres
optim
strategi
ensur
safe
blood
suppli
studi
designmethod
use
decis
tree
compar
strategi
screen
blood
suppli
donor
current
standard
deferr
msm
follow
gener
hiv
abag
viral
load
vl
test
donat
unit
deferr
gener
abag
vl
test
donat
unit
deferr
male
donor
condomless
anal
intercours
past
month
follow
gener
abag
vl
test
donat
unit
primari
outcom
expect
number
accept
hiv
donat
per
million
unit
donat
blood
key
model
input
paramet
includ
msm
preval
hiv
test
sensit
chronic
acut
infect
fals
neg
rate
current
msm
deferr
question
screen
question
sensit
analys
assess
impact
variat
paramet
resultsfind
base
case
current
strategi
result
hiv
accept
blood
donat
per
million
test
strategi
result
hiv
accept
blood
donat
per
million
strategi
result
lowest
risk
hiv
accept
blood
donat
per
million
sensit
analys
strategi
superior
across
plausibl
rang
hiv
test
sensit
acut
chronic
hiv
infect
strategi
remain
superior
long
msm
preval
less
higher
msm
preval
current
strategi
superior
effect
screen
question
ie
fals
neg
rate
current
msm
deferr
question
screen
question
contribut
uncertainti
model
compar
current
standard
strategi
could
add
million
msm
potenti
donor
suppli
conclus
screen
question
combin
univers
gener
hiv
abag
viral
load
test
may
effect
current
strategi
includ
deferr
donat
msm
qualiti
abil
screen
question
accur
assess
risk
key
screen
strategi
backgroundcas
studi
blood
donor
invit
begin
donat
career
last
half
teen
year
hope
effect
young
donor
absorb
sens
respons
commun
blood
suppli
recent
donor
studi
point
young
donor
may
need
addit
inform
encourag
protect
iron
store
teen
donor
tend
less
store
iron
older
donor
blood
center
wish
suppli
inform
donor
help
becom
awar
maintain
iron
store
question
rais
share
inform
iron
physiolog
inform
encourag
discourag
donat
percentag
donor
qualifi
hematocrit
affect
studi
designmethod
age
appropri
materi
explain
import
maintain
healthi
store
iron
balanc
bodi
develop
teenag
school
year
fy
print
materi
describ
bodi
need
iron
possibl
effect
blood
donat
iron
store
suggest
step
maintain
iron
balanc
materi
sent
high
school
blood
drive
plan
also
sent
home
potenti
donor
address
donor
parent
along
inform
blood
drive
consent
form
sign
consent
requir
special
letter
sent
parent
packag
explain
import
iron
nutrit
teenag
nutrit
need
iron
supplement
offer
nearbi
collect
center
donor
consent
wish
pick
older
teenag
requir
letter
parent
saw
iron
inform
day
donat
iron
inform
distribut
donor
time
blood
drive
number
donor
present
number
qualifi
hematocrit
first
month
school
year
septemb
februari
fy
compar
time
previou
year
fy
resultsfind
conclus
femal
male
donor
volunt
blood
donat
young
donor
evalu
young
donor
group
provis
inform
import
iron
physiolog
need
adequ
iron
store
donor
promot
encourag
gave
increas
donor
volunt
time
period
fiscal
year
fy
fy
explan
possibl
deleteri
effect
blood
donat
suggest
mitig
effect
appear
increas
decreas
younger
donor
particip
older
group
gain
qualif
modest
number
yo
femal
donor
increas
qualifi
femal
donor
group
increas
previou
year
age
group
provis
iron
nutrit
inform
teenag
parent
associ
increas
number
young
donor
volunt
donor
present
also
qualifi
donat
improv
greatest
yo
femal
donor
backgroundcas
studi
australia
face
increas
demand
intraven
immunoglobulin
necessit
recruit
whole
blood
donor
plasma
donat
also
increas
donat
frequenc
within
regul
limit
plasma
donat
per
year
australian
red
cross
blood
servic
databas
contain
comprehens
donor
demograph
donat
test
result
present
plasma
donor
requir
total
protein
tp
albumin
igg
igm
iga
test
donor
undergo
subsequ
annual
measur
tp
albumin
igg
haematolog
marker
use
data
evalu
impact
plasmapheresi
differ
intens
donor
health
use
biochem
haematolog
marker
donor
deferr
inform
studi
designmethod
record
extract
donor
made
plasma
donat
januari
end
decemb
record
retriev
donor
made
least
one
plasma
donat
year
effect
prior
mix
donat
count
donor
age
igg
iga
igm
first
electron
captur
donor
review
examin
approxim
million
donat
record
collect
analysi
yearli
measur
igg
tp
albumin
haemoglobin
platelet
differenti
white
cell
count
reason
perman
deferr
plasma
donat
panel
discuss
resultsfind
increas
donor
age
increas
number
previou
donat
associ
small
decreas
mean
igg
tp
level
howev
effect
observ
iga
igm
albumin
level
plasma
donor
period
donor
show
small
declin
mean
igg
level
highest
donat
frequenc
associ
mean
igg
level
lower
donor
lowest
donat
frequenc
effect
greater
femal
male
chang
albumin
tp
minim
affect
higher
donat
frequenc
plasma
donat
effect
platelet
lymphocyt
neutrophil
eosinophil
regardless
donat
frequenc
donat
mix
haemoglobin
level
increas
slightli
time
plasma
donat
frequenc
common
reason
perman
deferr
plasma
donor
cardiovascular
reason
mean
age
year
rang
follow
donor
reaction
mean
age
year
rang
clonal
disord
mean
age
year
rang
conclus
review
routin
annual
biochem
haematolog
data
plasma
donor
suggest
plasmapheresi
time
per
year
safe
donor
backgroundcas
studi
panther
system
fulli
autom
platform
nucleic
acid
amplif
test
use
blood
screen
grifol
diagnost
holog
assay
eg
hiv
hcv
hbv
zikv
typic
perform
plasma
ml
volum
assay
limit
detect
lod
low
iuml
case
viral
load
plasma
blood
compart
expect
low
adequ
sampl
volum
avail
sought
determin
whether
test
multipl
ml
replic
rep
system
program
perform
automat
use
ml
input
sampl
could
enhanc
sensit
detect
studi
designmethod
proof
concept
replic
test
could
detect
low
viral
load
use
aptima
quant
assay
test
plasma
elit
control
blood
donor
individu
aptima
procleix
zika
viru
assay
test
edta
plasma
lyse
whole
blood
wb
blood
donor
follow
longitudin
year
index
donat
hiv
sampl
ml
test
rep
zikv
plasma
ml
lyse
wb
ml
sampl
test
rep
respect
resultsfind
base
statist
model
analyt
dilut
seri
test
hiv
nat
yield
plasma
sampl
lod
replic
panther
test
reduc
cml
ci
rep
ml
cml
ci
rep
ml
cml
ci
rep
ml
plasma
hiv
elit
control
ec
detect
hiv
individu
median
rep
detect
plasma
collect
individu
consist
neg
standard
vl
assay
result
detect
hiv
individu
studi
entri
use
replic
test
approach
median
rep
detect
plasma
blood
donor
detect
zikv
individu
studi
entri
median
day
donat
use
replic
test
approach
median
rep
detect
lyse
wb
avail
blood
donor
studi
entri
zikv
detect
individu
median
rep
detect
conclus
replic
test
easili
perform
panther
platform
provid
substanti
lower
lod
enhanc
detect
low
level
viral
rna
sampl
blood
donor
clinic
case
find
document
hiv
rna
high
proport
ec
patient
extend
detect
zikv
rna
plasma
wb
zikv
infect
donor
backgroundcas
studi
cryopreserv
platelet
concentr
consider
altern
storag
method
assur
patient
care
circumst
liquid
preserv
imposs
howev
cryopreserv
significantli
damag
platelet
includ
signific
ectodomain
shed
clear
inhibit
shed
caus
consequ
damag
studi
designmethod
control
platelet
compar
pair
cryopreserv
platelet
either
without
marimastat
broad
spectrum
sheddas
inhibitor
shed
monitor
flow
cytometri
western
blot
ectodomain
glycocalicin
supernat
platelet
function
investig
ristocetin
agglutin
mgml
platelet
adhes
immobil
collagen
microfluid
flow
chamber
shear
rate
resultsfind
cryopreserv
without
marimastat
caus
signific
decreas
express
flow
cytometri
mfi
median
fluoresc
intens
compar
control
p
expect
marimastat
effici
conserv
express
cryopreserv
mfi
comparison
control
glycocalicin
signal
increas
cryopreserv
platelet
without
marimastat
remain
stabl
presenc
marimastat
data
indic
marimastat
effici
inhibitor
shed
cryopreserv
howev
marimastat
could
improv
platelet
agglutin
cryopreserv
sinc
signific
differ
agglutin
amplitud
found
without
includ
marimastat
p
addit
adhes
cryopreserv
platelet
collagen
flow
significantli
lower
compar
control
p
irrespect
marimastat
addit
p
conclus
conclud
shed
consequ
platelet
cryopreserv
inhibit
shed
improv
cryoplatelet
function
agglutin
adhes
experi
backgroundcas
studi
sudden
precipit
drop
patient
blood
pressur
infus
salvag
blood
unit
defin
symptom
suspect
hypotens
reaction
coronari
arteri
bypass
graft
surgeri
papaverin
often
use
prepar
intern
mammari
arteri
act
vasodil
papaverin
enter
cell
salvag
reservoir
may
complet
wash
cell
salvag
devic
present
final
product
type
occurr
consid
contraind
may
caus
problem
patient
reinfus
earli
autotransfus
team
investig
seri
hypotens
reaction
occur
reinfus
salvag
blood
case
perform
studi
designmethod
januari
april
eight
suspect
salvag
blood
reaction
investig
per
establish
procedur
due
drop
patient
blood
pressur
eight
reaction
five
coronari
arteri
bypass
graft
surgeri
cabg
suspect
reaction
workup
studi
follow
test
perform
implic
salvag
blood
unit
hematocrit
hct
plasmalow
hemoglobin
plhb
blood
cultur
residu
papaverin
pap
test
four
eight
case
involv
use
papaverin
control
resultsfind
one
case
first
reinfus
unit
implic
suspect
hypotens
reaction
case
met
accept
workup
criteria
hct
cultur
neg
case
one
met
accept
criteria
plhb
mgdl
case
cabg
remain
three
case
consist
two
cardiac
surgeri
one
orthoped
surgeri
see
tabl
conclus
case
papaverin
use
surgic
field
residu
papaverin
detect
final
implic
salvag
rbc
unit
faulti
cell
salvag
equip
rule
caus
suspect
reaction
result
studi
residu
papaverin
test
perform
suspect
salvag
unit
reaction
drug
util
surgic
case
backgroundcas
studi
request
rare
blood
made
american
rare
donor
program
ardp
continu
basi
report
check
complet
accuraci
process
begin
octob
staff
began
check
prior
antibodi
histori
return
patient
rare
unit
request
request
review
previou
request
inform
studi
designmethod
phenotyp
current
rare
unit
request
compar
prior
request
made
patient
chang
phenotyp
note
facil
contact
determin
chang
due
differ
chang
antibodi
statu
resultsfind
record
request
rare
blood
review
involv
differ
patient
whose
prior
histori
show
chang
request
rbc
phenotyp
previou
request
chang
includ
addit
antigen
request
antigen
drop
previous
request
request
facil
request
unit
patient
contact
ask
inform
variat
request
one
facil
total
differ
request
patient
common
reason
provid
request
base
present
serolog
test
request
adjust
base
molecular
test
perform
sinc
prior
request
andor
patient
previous
seen
anoth
hospit
common
reason
provid
request
unit
lack
one
addit
antigen
due
new
antibodi
identifi
antibodi
demonstr
previous
reason
state
miss
antigen
subsequ
request
low
preval
antigen
need
could
avoid
unit
caucasian
donor
antigen
test
antigen
would
perform
request
facil
antibodi
antigen
detect
current
sampl
conclus
without
nation
antibodi
registri
patient
seen
multipl
health
care
facil
knowledg
antibodi
rbc
antigen
evanesc
import
evalu
request
rare
blood
alloimmun
patient
optim
captur
complet
antibodi
statu
month
request
rare
blood
review
prior
request
show
differ
antigen
phenotyp
request
patient
specif
gener
thought
potenti
clinic
signific
k
jka
e
cw
v
jsa
fyb
case
subsequ
request
addit
antigen
neg
specif
suggest
patient
could
alloimmun
subsequ
transfus
work
highlight
import
antibodi
statu
alloimmun
patient
share
inform
healthcar
facil
donor
center
ardp
uniqu
posit
evalu
chang
antigen
neg
rbc
request
time
backgroundcas
studi
babesia
assay
procleix
system
qualit
vitro
nucleic
acid
test
current
use
investig
new
drug
ind
protocol
assay
base
amplif
tma
design
detect
four
clinic
relev
babesia
speci
b
microti
b
divergen
b
duncani
b
venatorum
human
whole
blood
specimen
investig
test
intend
screen
blood
donat
individu
pool
donat
pool
whole
blood
sampl
lyse
pool
autom
procleix
system
investig
use
test
procleix
panther
system
report
result
multicent
studi
evalu
clinic
perform
procleix
babesia
assay
procleix
panther
system
studi
designmethod
reproduc
sensit
specif
assay
evalu
clinic
site
use
least
reagent
lot
reproduc
assay
test
neg
posit
panel
member
clinic
sensit
determin
test
b
microti
b
duncani
b
divergen
b
venatorum
whole
blood
specimen
andor
cultur
erythrocyt
lyse
test
neat
dilut
clinic
specif
determin
screen
individu
donat
concurr
screen
individu
donor
lysat
idl
pool
pool
total
screen
donat
june
februari
initi
reactiv
donat
tma
confirm
pcr
igg
immunofluoresc
assay
ifa
andor
test
resultsfind
high
reproduc
demonstr
coeffici
variat
valu
rang
analyt
signal
sco
valu
posit
panel
member
intern
control
sco
valu
neg
member
clinic
sensit
neat
dilut
sampl
specif
ci
confirm
posit
donat
identifi
tma
reactiv
pcr
ifa
two
window
period
case
ie
nat
posit
ifa
neg
identifi
one
case
new
york
confirm
test
florida
lower
risk
state
confirm
index
pcr
repeat
reactiv
idl
found
reactiv
pool
conclus
procleix
babesia
assay
procleix
panther
system
demonstr
high
clinic
specif
sensit
reproduc
detect
repeat
reactiv
idl
pool
show
effect
pool
lysat
screen
blood
donat
note
fund
provid
grifol
conduct
clinic
studi
backgroundcas
studi
laboratori
use
solid
phase
test
system
platelet
crossmatch
one
state
limit
test
system
chemic
contamin
test
materi
produc
erron
test
result
unit
use
platelet
crossmatch
pull
stock
inventori
demand
pathogen
reduc
singl
donor
platelet
sdp
increas
percentag
pathogen
reduc
unit
stock
inventori
like
increas
pathogen
inactiv
pi
process
use
involv
treatment
sdp
chemic
agent
amotosalen
want
determin
sampl
taken
pathogen
reduc
sdp
could
use
platelet
crossmatch
studi
designmethod
sampl
differ
patient
crossmatch
sdp
sampl
obtain
prior
pi
treatment
total
platelet
crossmatch
perform
use
sdp
sampl
taken
prior
pi
treatment
inclus
patient
sampl
crossmatch
repeat
use
treatment
sampl
reaction
strength
crossmatch
grade
strong
posit
w
weak
posit
neg
compar
origin
treat
sampl
post
pi
treatment
sampl
donor
unit
abo
sdp
consider
reaction
strength
crossmatch
compar
platelet
antibodi
screen
test
previous
done
patient
sampl
posit
hla
antibodi
posit
hla
platelet
antibodi
neg
serum
plasma
patient
sampl
includ
use
test
resultsfind
patient
sampl
chang
crossmatch
reactiv
sampl
show
chang
hlaplatelet
antibodi
hla
antibodi
sampl
antibodi
neg
decreas
reactiv
strength
seen
pathogen
reduc
sampl
crossmatch
reaction
becom
neg
crossmatch
reaction
increas
strength
conclus
crossmatch
reactiv
strength
platelet
sampl
decreas
result
pathogen
inactiv
treatment
amotosalen
use
solid
phase
test
system
platelet
crossmatch
perform
sdp
sampl
taken
prior
pi
treatment
accur
result
backgroundcas
studi
pathogen
reduct
pr
system
use
amustalin
glutathion
gsh
develop
inactiv
pathogen
leukocyt
red
blood
cell
rbc
compon
amustalin
form
adduct
nucleic
acid
inhibit
replic
contamin
pathogen
leukocyt
although
leukocyt
effect
inactiv
pr
rbc
clinic
trial
institut
practic
may
requir
irradi
ir
pr
site
studi
character
vitro
function
pr
control
rbc
without
ir
day
post
donat
throughout
day
storag
studi
designmethod
leukocyt
reduc
rbc
prepar
cpd
whole
blood
collect
within
hour
donat
replic
abo
match
rbc
pool
divid
test
input
compon
control
c
compon
test
input
rbc
treat
mm
mm
amustalin
c
compon
untreat
store
post
donat
c
compon
replic
ir
sampl
analysi
vitro
paramet
perform
throughout
storag
resultsfind
compon
contain
hemoglobin
hematocrit
compar
c
exhibit
lower
hemolysi
reduc
extracellular
k
increas
atp
level
ph
conserv
ph
physiolog
function
reduc
hemolysi
ph
post
rejuven
post
rejuven
oxygen
dissoci
rbc
deform
compar
howev
paramet
remain
within
function
physiolog
rang
tabl
conclus
although
ir
expect
requir
routin
use
rbc
licensur
studi
demonstr
robust
pr
treatment
combin
ir
measur
vitro
paramet
intercept
treat
rbc
includ
atp
glucos
level
conserv
within
physiolog
function
rang
backgroundcas
studi
improv
logist
blood
collect
transport
compli
temperatur
control
requir
evalu
new
thermoregul
box
system
tb
blood
product
packag
ship
long
distanc
panel
vip
phase
chang
materi
pcm
use
condit
extrem
extern
temperatur
system
success
perform
intern
test
cool
whole
blood
wb
unit
collect
maintain
intern
temperatur
extrem
summer
winter
temperatur
aabb
current
studi
tb
test
room
temperatur
ship
wb
donat
apheresi
product
blood
sampl
tube
studi
designmethod
mimic
freshli
collect
product
wb
collect
bag
reveo
lr
terumobct
fill
ml
salin
addit
apheresi
platelet
concentr
pc
plasma
bag
trima
collect
set
terumobct
blood
sampl
tube
fill
ml
ml
ml
salin
respect
monitor
probe
insert
insid
bag
record
temperatur
profil
either
one
eight
reveo
wb
unit
pack
tb
pcm
cryopak
apheresi
product
one
pc
plasma
four
donat
pc
plasma
use
minim
maxim
load
test
maxim
ship
delay
singl
blood
sampl
tube
pack
tb
repres
limit
condit
tb
configur
expos
extrem
winter
summer
condit
design
experi
resultsfind
tb
use
pcm
allow
rapid
cool
blood
product
min
maintain
intern
temperatur
one
eight
reveo
wb
donat
extrem
extern
temperatur
use
pcm
allow
minim
maxim
apheresi
donat
product
stay
within
accept
hold
temperatur
rang
expos
extrem
winter
summer
condit
respect
final
blood
tube
expos
extern
temperatur
condit
maintain
intern
temperatur
respect
conclus
vip
box
pcm
allow
thermoregul
box
system
use
extend
ship
period
extrem
temperatur
condit
increas
intern
volum
box
accept
product
expens
addit
pcm
increas
total
weight
conclus
thermoregul
box
system
design
use
combin
pcm
meet
specif
requir
regard
packag
transport
blood
product
especi
winter
condit
backgroundcas
studi
support
research
improv
erythrocyt
storag
low
oxygen
tension
haemoglobin
oxygen
satur
fresh
erythrocyt
concentr
rcc
measur
wall
rcc
bag
use
reson
raman
spectroscopi
rr
surprisingli
larg
variat
fresh
day
rcc
found
pilot
studi
analysi
find
larg
number
freshli
prepar
rcc
sanquin
blood
bank
analys
rr
devic
determin
relationship
observ
variat
donordon
variabl
use
extern
oxygen
satur
measur
rr
fresh
rcc
immedi
compon
prepar
studi
designmethod
fresh
rcc
analys
rr
devic
microvascular
oximet
pendar
medic
devic
valid
analys
rcc
comparison
measur
qualifi
blood
ga
analys
radiomet
flex
addit
investig
whether
low
high
valu
effect
shelf
life
rcc
sampl
day
blood
ga
cbc
sysmex
well
haemolysi
atp
content
resultsfind
result
measur
rr
devic
correspond
measur
blood
ga
analys
differ
data
donor
compar
donordon
data
blood
pressur
time
donat
donat
durat
well
individu
donor
characterist
weight
height
calcul
bmi
age
hb
gender
data
rcc
show
binomi
distribut
two
peak
strongli
influenc
gender
donor
men
subject
women
subject
donor
paramet
show
clear
effect
cell
count
haemolysi
day
day
atp
day
day
show
normal
expect
valu
regardless
whether
valu
high
low
conclus
measur
rr
laser
devic
correspond
measur
blood
ga
analys
use
rr
devic
advers
effect
vitro
qualiti
erythrocyt
storag
small
test
group
rcc
link
vitro
qualiti
valu
immedi
collect
mean
femal
donor
lower
male
donor
explain
basi
avail
donordon
data
research
need
explain
differ
backgroundcas
studi
concern
rais
regard
potenti
advers
effect
blood
donor
low
ferritin
level
may
exist
absenc
anemia
young
donor
premenopaus
femal
two
donor
increas
risk
therefor
particular
ethic
medic
concern
neurodevelop
donor
donor
fetu
might
advers
affect
low
ferritin
level
group
object
studi
determin
effect
deferr
rate
teenag
donor
use
one
possibl
strategi
employ
donat
interv
studi
designmethod
blood
donor
donat
type
age
year
old
met
hemoglobin
hb
accept
criteria
ferritin
test
drawn
result
obtain
ferritin
level
ngml
sent
low
ferritin
notif
letter
suggest
supplement
oral
multivitamin
contain
mg
iron
consult
physician
deferr
donat
day
upon
return
donor
hb
drawn
meet
hb
criteria
donat
underw
second
ferritin
test
donor
fail
second
ferritin
test
notifi
letter
defer
day
resultsfind
donor
met
hb
accept
criteria
defer
day
due
ferritin
level
ng
ml
donor
return
second
donat
pass
hb
criteria
drawn
donat
underw
second
ferritin
test
donor
second
ferritin
test
accept
ferritin
level
remain
donor
unaccept
ferritin
level
second
test
increas
decreas
chang
ferritin
level
compar
first
ferritin
test
year
old
donor
ferritin
test
failur
rate
blood
donor
drawn
compar
hgb
test
failur
rate
yr
old
donor
drawn
time
period
conclus
strikingli
higher
percent
teen
donor
defer
base
initi
ferritin
test
compar
hb
test
vs
ident
period
time
notif
low
ferritin
passiv
educ
iron
supplement
extend
day
deferr
period
alon
adequ
correct
ferritin
level
larg
major
low
ferritin
donor
return
rate
donor
could
adequ
assess
due
short
timefram
studi
studi
compar
return
accept
rate
hb
vs
teen
donor
need
fulli
assess
impact
blood
suppli
particular
deferr
strategi
iron
supplement
intervent
backgroundcas
studi
primari
cultur
platelet
plt
implement
singl
donor
plt
sdp
collect
later
pool
plt
pspp
use
one
two
method
bactalert
ebd
compar
bacteri
speci
load
plt
product
test
two
method
studi
designmethod
plt
unit
transfus
institut
januari
decemb
studi
bactalert
test
biomerieux
st
loui
mo
perform
inocul
ml
sdp
pspp
unit
bactalert
bpa
cultur
bottl
h
ebd
haemonet
corpor
braintre
perform
inocul
ml
aliquot
sdp
pspp
unit
ebd
cultur
pouch
h
unit
releas
neg
h
cultur
perform
obtain
aliquot
unit
time
releas
transfus
ml
volum
plate
onto
blood
agar
plate
plate
incub
hour
specimen
yield
bacteri
growth
cultur
quantit
determin
bacteri
load
transfus
reaction
monitor
patient
record
receiv
contamin
unit
review
resultsfind
total
plt
unit
transfus
year
studi
period
test
bactalert
sdp
pspp
ebd
sdp
pspp
unit
found
bacteri
contamin
test
bactalert
sdp
pspp
sdp
pspp
ebd
contamin
septic
reaction
rate
compar
overal
plt
type
p
valu
comparison
howev
bacteri
speci
differ
bacteri
speci
unit
test
bactalert
includ
one
staphylococcu
aureu
staphylococci
one
gram
neg
bacillu
acinetobact
baumannii
one
bacillu
speci
bacteri
speci
unit
test
ebd
includ
staphylococci
viridan
group
streptococci
bacteri
load
unit
test
bactalert
rang
cfuml
mean
load
unit
test
ebd
rang
mean
cfuml
transfus
contamin
unit
result
five
septic
reaction
one
unit
pretest
bactalert
aureu
cfuml
unit
pretest
ebd
staphylococci
viridan
group
streptococci
cfuml
conclus
differ
volum
plt
test
two
method
ml
ebd
ml
bact
alert
associ
differ
bacteri
contamin
rate
septic
reaction
howev
differ
rang
bacteri
speci
found
streptococci
proportion
staphylococci
present
product
test
bactalert
well
lower
bacteri
load
product
test
method
backgroundcas
studi
teen
donor
women
donor
popul
suscept
iron
deplet
differ
iron
mitig
strategi
increas
interdon
interv
iron
replac
counsel
may
implement
prevent
complex
enact
addit
donor
age
sex
increas
frequenc
red
blood
cell
rbc
donat
shown
increas
risk
iron
defici
calcul
potenti
rbc
donat
unit
loss
base
limit
annual
donat
known
donor
popul
perform
studi
designmethod
use
dataset
donor
blood
center
locat
gave
rbc
identifi
donor
associ
success
allogen
donat
within
prior
period
includ
analysi
rbc
unit
count
collect
type
wb
rbc
apheresi
collect
data
stratifi
agesex
yo
male
femal
f
yo
f
f
yo
f
center
loss
calcul
base
group
number
rbc
donat
unit
u
compar
total
number
obtain
period
resultsfind
total
contain
donat
period
rbc
unit
f
donor
restrict
donat
per
year
yr
yo
f
loss
u
loss
u
donat
frequenc
yo
f
rbc
lose
u
yo
f
allow
allow
rbc
loss
u
restrict
f
annual
donat
result
rbc
loss
u
among
u
limit
yo
femal
result
loss
u
allow
loss
reduc
u
stratifi
center
limit
rbc
donat
yo
f
show
high
variabl
across
center
rang
loss
teen
donor
loss
teen
donor
conclus
limit
donat
youngest
donor
small
impact
rbc
loss
oper
feasibl
involv
least
regulatori
legal
complex
impact
donat
unit
avail
variabl
across
center
base
upon
proport
teen
donor
backgroundcas
studi
septic
transfus
reaction
str
result
transfus
bacteri
contamin
platelet
plt
major
hazard
platelet
transfus
address
problem
test
bacteri
contamin
mandat
march
implement
cultur
singl
donor
platelet
sdp
unit
pool
platelet
pspp
studi
designmethod
blood
supplier
perform
primari
test
cultur
plt
hour
collect
releas
unit
cultur
neg
hour
incub
bacteri
contamin
str
rate
evalu
introduct
primari
test
cultur
plt
aliquot
time
issu
str
assess
evalu
patient
receiv
contamin
plt
period
jun
sdp
jun
pspp
period
mar
sdp
jan
pspp
bacteri
contamin
str
rate
compar
two
period
resultsfind
total
plt
cultur
period
sdp
pspp
period
sdp
pspp
contamin
unit
identifi
period
overal
contamin
rate
significantli
higher
compar
period
per
million
p
analysi
plt
unit
type
show
contamin
rate
significantli
lower
sdp
compar
pspp
period
vs
per
million
p
period
vs
per
million
contamin
rate
sdp
unchang
vs
per
million
pspp
decreas
consider
vs
p
contamin
product
transfus
pre
post
result
str
pre
post
str
rate
significantli
higher
vs
period
vs
per
million
p
str
rate
significantli
lower
sdp
compar
pspp
period
vs
per
million
period
vs
per
million
signific
differ
contamin
rate
vs
per
million
str
rate
vs
per
million
note
stratif
period
conclus
introduct
primari
cultur
sdp
pspp
significantli
reduc
bacteri
contamin
str
sdp
plt
pspp
find
highlight
continu
need
reduc
rate
perform
secondari
test
near
time
use
applic
pathogen
reduct
technolog
backgroundcas
studi
donor
questionnair
dhq
develop
streamlin
donor
process
question
group
timefram
optim
donor
recal
donor
pregnanc
statu
continu
includ
dhq
numer
revis
recent
dhq
modif
chang
focu
question
pregnanc
within
last
week
lifetim
pregnanc
thu
chang
placement
within
dhq
evalu
assess
whether
placement
question
impact
respons
donor
studi
designmethod
everi
blood
donor
present
complet
dhq
electron
question
dhq
determin
donor
current
pregnant
pregnant
within
last
week
femal
donor
answer
question
ask
ever
pregnant
question
pregnanc
question
reloc
question
modifi
ask
donor
ever
pregnant
respons
gather
timefram
first
date
donor
indic
pregnanc
determin
date
compar
dhq
determin
inconsist
respons
gener
estim
equat
depend
variabl
pregnanc
question
answer
correctli
independ
variabl
dhq
group
independ
variabl
assess
rate
question
answer
incorrectli
adjust
multipl
respons
per
donor
uniqu
donor
provid
respons
statist
signific
defin
resultsfind
data
show
femal
indic
pregnanc
previou
dhq
correctli
answer
pregnanc
question
subsequ
dhq
follow
reloc
pregnanc
question
femal
indic
pregnanc
previou
dhq
recogn
pregnanc
histori
subsequ
dhq
conclus
posit
question
dhq
could
factor
accuraci
donor
respons
data
show
greater
likelihood
inaccur
respons
question
move
begin
later
posit
dhq
potenti
solut
order
question
dhq
serious
risk
donorrecipi
rather
timefram
therebi
improv
likelihood
accur
respons
critic
question
enhanc
comput
support
highlight
donor
respons
answer
inconsist
visit
would
also
aid
identifi
discrep
could
reconcil
donor
backgroundcas
studi
preval
rbc
alloimmun
report
blood
recipi
littl
data
exist
preval
alloimmun
rbc
antigen
healthi
donor
posit
antibodi
ab
screen
blood
donor
often
lead
donor
deferr
although
plasma
volum
remain
rbc
unit
minim
unit
must
label
ab
specif
caus
oper
challeng
blood
center
hospit
aim
current
studi
determin
preval
specif
alloantibodi
blood
donor
year
period
quantifi
antibodi
gender
age
race
studi
designmethod
date
blood
donat
correspond
ab
screenid
result
gender
ethnic
age
obtain
collect
center
record
determin
overal
preval
alloimmun
rbc
antigen
donor
pool
search
donor
record
identifi
least
one
posit
ab
screen
resultsfind
year
period
ab
screen
perform
donor
femal
male
total
donor
posit
ab
screen
ab
id
record
constitut
femal
male
donor
test
frequent
ab
id
account
femal
male
posit
ab
screen
common
specif
identifi
detect
donor
screen
donor
identifi
specif
femal
donor
rh
posit
k
c
c
fya
jka
identifi
respect
donor
posit
ab
screen
id
record
common
ab
femal
posit
screen
vs
male
posit
screen
account
asian
african
american
hispan
multiraci
white
femal
donor
posit
screen
common
ab
specif
male
repres
specif
ab
identifi
male
frequenc
increas
age
posit
donor
respect
age
group
compar
age
group
conclus
preval
posit
rbc
ab
screen
blood
donor
blood
center
expect
time
like
femal
donor
like
femal
donor
year
identifi
male
femal
implic
pregnanc
exposur
presenc
healthi
femal
donor
post
introduct
rhig
indic
pregnanc
elimin
backgroundcas
studi
pgdprime
rapid
test
bacteria
platelet
develop
improv
platelet
test
current
use
safeti
measur
platelet
transfus
design
provid
simpler
test
procedur
compar
current
product
analyt
sensit
new
pgdprime
test
evalu
demonstr
substanti
equival
pgd
assay
detect
pgd
assay
claim
strain
studi
designmethod
blind
frozen
bacteri
test
panel
prepar
panel
compris
three
level
bacteri
speci
reconstitut
platelet
sampl
one
member
limit
detect
lod
pgd
assay
low
one
member
slightli
lod
assay
mid
one
lod
pgd
assay
high
two
neg
sampl
includ
panel
panel
member
thaw
ad
fresh
platelet
sampl
reconstitut
panel
member
test
one
lot
current
pgd
assay
six
lot
pgdprime
devic
bacteria
test
includ
b
cereu
c
perfringen
aureu
epidermidi
agalactia
e
aerogen
e
coli
k
pneumonia
p
aeruginosa
marcescen
resultsfind
shown
tabl
sampl
lod
pgd
assay
detect
pgd
assay
control
six
lot
pgdprime
devic
test
antigen
pgdprime
assay
detect
sampl
lowest
antigen
concentr
conclus
pgdprime
deliv
substanti
equival
sensit
verax
platelet
pgd
test
greatli
improv
eas
use
elimin
centrifug
step
simplifi
user
work
flow
backgroundcas
studi
need
readili
avail
sourc
fibrinogen
fb
set
acut
hemorrhag
hemorrhag
pph
moment
unfulfil
neither
fibrinogen
concentr
cryoprecipit
cp
avail
immedi
use
need
either
reconstitut
thaw
respect
tat
either
product
approxim
minut
critic
especi
pph
fb
correl
degre
bleed
outcom
previou
studi
extend
storag
thaw
cryoprecipit
tcp
perform
day
studi
designmethod
aim
studi
determin
stabil
fibrinogen
fb
feasibl
prolong
day
storag
tcp
room
temperatur
rt
refriger
rf
day
total
singl
unit
type
cp
thaw
tcp
store
undisturb
either
room
temp
refriger
day
respect
fb
tcp
measur
resultsfind
prolong
storag
tcp
rt
show
fb
accept
day
averag
calcul
amount
fb
day
rt
storag
remain
stabl
mg
per
unit
mg
mg
per
aabb
standard
note
averag
labil
factor
viii
activ
iu
iu
fda
requir
iu
contrast
rf
storag
show
fb
could
lost
day
due
precipit
observ
rt
unit
precipit
disappear
warm
cp
conclus
studi
demonstr
prolong
rf
storag
tcp
practic
precipit
led
poor
recoveri
fb
also
made
safe
transfus
product
difficult
hand
rt
storag
tcp
prove
effect
method
maintain
adequ
fb
day
rt
tcp
novel
enhanc
mean
provid
fb
replac
superior
turnaround
time
limit
wastag
backgroundcas
studi
sinc
ef
grand
est
produc
deliv
pathogen
reduc
platelet
concentr
use
photochem
treatment
pct
combin
amotosalen
ultraviolet
light
uva
ceru
uva
treatment
amotosalen
adsorb
compound
adsorpt
devic
cad
incub
time
agit
larg
volum
set
limit
specifi
french
regulatori
author
aim
studi
evalu
qualiti
process
without
presenc
residu
air
cad
step
air
remov
manual
oper
studi
designmethod
two
buffi
coat
pc
bcpc
donor
pool
split
obtain
two
ident
bcpc
treat
pr
cad
time
remov
air
bag
control
treat
pr
cad
time
presenc
residu
air
bag
test
biolog
paramet
swirl
platelet
content
residu
leukocyt
ph
lactat
glucos
ldh
solubl
residu
amotosalen
concentr
assess
resultsfind
mean
platelet
content
control
test
pct
respect
pct
unit
present
maximum
swirl
compliant
ph
residu
amotosalen
concentr
unit
pc
evolut
biolog
paramet
storag
period
similar
control
test
tabl
except
day
due
air
presenc
test
pc
conclus
qualiti
control
show
differ
cad
oper
perform
without
presenc
residu
air
bag
qualiti
preserv
studi
allow
simplifi
prt
process
pct
elimin
manual
oper
air
remov
cad
oper
thu
contribut
reduc
time
process
variabl
loss
platelet
content
backgroundcas
studi
platelet
apheresi
use
solut
pa
allow
collect
platelet
reduc
plasma
content
divers
plasma
creat
plasma
compon
transfus
addit
benefit
collect
free
plasma
compon
reduc
incid
reaction
report
literatur
howev
incid
transfus
reaction
divert
plasma
wide
report
plasma
platelet
transfus
reaction
data
tertiari
referr
health
system
present
studi
designmethod
transfus
reaction
rate
versu
convent
plasma
well
versu
convent
platelet
calcul
two
year
period
statist
analysi
perform
report
transfus
reaction
deem
blood
bank
director
unrel
transfus
exclud
resultsfind
overal
differ
transfus
reaction
rate
divert
plasma
convent
plasma
insignific
p
ci
allerg
transfus
reaction
account
report
plasma
transfus
reaction
also
two
case
circulatori
overload
trend
lower
transfus
reaction
rate
pa
platelet
versu
convent
platelet
reach
statist
signific
p
ci
allerg
transfus
reaction
account
report
platelet
transfus
reaction
also
two
case
circulatori
overload
one
febril
nonhemolyt
reaction
divert
plasma
singl
implic
pa
platelet
unit
caus
transfus
reaction
conclus
use
plasma
divert
product
pa
platelet
appear
increas
decreas
rate
reaction
plasma
transfus
use
pa
platelet
versu
convent
platelet
tend
reduc
recipi
transfus
reaction
rate
observ
risk
reduct
associ
pa
platelet
consist
literatur
reflect
benefit
decreas
recipi
exposur
donor
plasma
protein
broadli
demonstr
noninferior
divert
plasma
repres
addit
benefit
blood
collect
transfus
servic
util
cell
separ
plasma
divers
capabl
pa
platelet
collect
backgroundcas
studi
antibodi
pose
risk
acut
hemolyt
transfus
reaction
recipi
correspond
antigen
debat
continu
titer
b
antibodi
class
igm
igg
test
ensur
optim
safeti
us
militari
use
singl
titer
cutoff
igm
b
safe
recipi
resurg
whole
blood
use
civilian
trauma
elucid
preval
antibodi
differ
donor
popul
import
enhanc
donor
recruit
studi
designmethod
rh
posit
male
fix
site
donor
histori
donat
test
mitig
transfus
relat
acut
lung
injuri
maintain
robust
commit
donor
pool
igm
igm
antibodi
determin
use
singl
titer
plasma
ethylenediaminetetraacet
acid
edta
sampl
test
use
salin
diluent
dilut
plasma
mix
commerci
avail
b
cell
incub
room
temperatur
minut
centrifug
second
rpm
read
agglutin
reactiv
either
constitut
posit
donor
race
donor
retriev
blood
establish
comput
system
test
donor
resultsfind
tabl
show
result
male
rh
posit
donor
test
stratifi
race
hispan
ethnic
donor
often
separ
race
therefor
hispan
race
choic
donor
histori
questionnair
result
show
preval
antibodi
vari
race
lowest
preval
american
indian
donor
follow
caucasianwhit
asianpacif
island
blackafrican
american
hispan
undeclar
use
fisher
exact
preval
igm
antibodi
statist
higher
hispan
donor
compar
caucasianwhit
donor
race
group
number
reach
statist
signific
conclus
popul
male
rh
posit
donor
south
texa
preval
igm
antibodi
vari
race
lowest
preval
caucasianwhit
donor
data
help
target
whole
blood
collect
maxim
avail
unit
low
igm
antibodi
backgroundcas
studi
present
studi
conduct
find
preval
viral
hepat
marker
among
blood
donor
defer
basi
histori
hepat
relat
risk
factor
compar
preval
accept
blood
donor
assess
impact
deferr
blood
safeti
know
natur
histori
hbv
hcv
asymptomat
window
period
chronic
carrier
stage
genet
divers
mutant
crypticoccult
infect
potenti
transmiss
blood
transfus
remain
therefor
need
garner
data
evid
support
deferr
elicit
histori
presenc
risk
factor
relat
develop
hepat
interest
blood
safeti
realiz
studi
designmethod
observ
studi
recruit
defer
blood
donor
defer
basi
histori
hepat
relat
risk
factor
carri
serolog
hepat
b
hepat
c
obtain
written
inform
consent
histori
jaundic
tattooingbodi
pierc
surgerydent
extract
contact
person
hepat
high
risk
behavior
blood
transfusionstransplant
immunoglobulin
administr
studi
particip
voluntari
studi
protocol
approv
ethic
committe
institut
resultsfind
defer
blood
donor
reactiv
elisa
reactiv
hbsag
wherea
antibodi
initi
reactiv
discrimin
test
hbv
hcv
reactiv
hepat
b
concord
posit
hbsag
elisa
nat
wherea
one
nat
yield
one
hepat
b
reactiv
histori
jaundic
one
histori
tattoo
one
histori
high
risk
behavior
hepat
c
reactiv
concord
elisa
nat
reactiv
sero
yield
two
nat
yield
defer
donor
reactiv
hepat
c
major
histori
jaundic
follow
high
risk
behavior
total
donor
viral
marker
either
hepat
b
hepat
c
present
studi
therefor
potenti
deferr
histori
hepat
relat
risk
factor
could
interdict
hbv
andor
hcv
reactiv
blood
donor
enter
quarantin
blood
suppli
per
donor
odd
test
reactiv
elisa
ci
odd
test
reactiv
id
nat
yield
ci
respect
donor
defer
histori
hepat
relat
risk
factor
compar
select
donor
without
histori
risk
test
reactiv
hepat
b
c
significantli
higher
deferr
high
risk
behavior
compar
risk
factor
deferr
author
acknowledg
select
bia
may
possibl
could
recruit
donor
defer
basi
histori
hepat
relat
risk
factor
conclus
find
present
studi
support
deferr
histori
hepat
relat
risk
factor
first
step
toward
pursuit
safe
blood
suppli
backgroundcas
studi
introduct
compon
therapi
sagm
europ
north
america
main
addit
solut
use
red
blood
cell
concentr
rbc
main
improv
qualiti
rbc
last
part
centuri
came
introduct
leukodeplet
paggsm
gener
two
still
storag
blood
bank
result
progress
accumul
storag
lesion
character
larg
number
vitro
chang
paramet
like
hemolysi
morpholog
adenosin
triphosph
atp
content
membran
stabil
etc
storag
lesion
lea
partial
mitig
storag
novel
storag
addit
alkalin
addit
solut
sever
novel
alkalin
addit
formul
propos
metabolom
character
perform
date
studi
designmethod
perform
metabolom
analys
red
blood
cell
store
sagm
standard
addit
europ
paggsm
alkalin
addit
solx
either
end
netherland
day
resultsfind
metabol
linkag
analysi
provid
glanc
overview
metabol
rewir
across
addit
indic
strong
effect
redox
homeostasi
carboxyl
acid
fatti
acid
purin
metabol
alkalin
addit
compar
sagm
result
indic
alkalin
addit
especi
better
preserv
atp
correl
atp
dpg
poor
addit
except
suggest
rewir
shunt
specif
addit
addit
deamin
purin
hypoxanthin
predict
hemolysi
morpholog
alter
guanosin
supplement
paggsm
fuel
atp
gener
feed
pentos
phosphat
pathway
via
phosphoribolysi
decreas
urat
hypoxanthin
ratio
observ
alkalin
addit
sugget
decreas
gener
urat
purin
degrad
consequ
less
format
hydrogen
peroxid
xanthin
oxidas
activ
despit
mani
benefit
observ
purin
redox
metabol
alkalin
addit
prevent
accumul
free
fatti
acid
oxid
byproduct
open
window
futur
alkalin
formul
includ
lipophil
antioxid
conclus
alkalin
via
differ
strategi
replac
chlorid
anion
either
high
bicarbon
high
citratephosph
membran
imperm
glucon
result
differ
metabol
outcom
case
superior
current
canon
addit
result
metabol
analys
indic
superior
preserv
rbc
alkalin
addit
gener
alkalin
addit
sagm
paggsm
particular
dpg
atp
gener
mainten
well
purin
metabol
redox
homeostasi
especi
ppp
phase
byproduct
favor
alkalin
addit
comparison
sagm
paggsm
howev
observ
metabol
benefit
extend
prevent
fatti
acid
releas
lipid
oxid
result
present
studi
provid
addit
insight
metabol
benefit
alkalin
storag
addit
like
guid
formul
novel
addit
near
futur
backgroundcas
studi
intercept
blood
system
platelet
fda
approv
ex
vivo
prepar
apheresi
platelet
compon
pc
plasma
pa
platelet
addit
solut
collect
trima
amicu
devic
respect
system
util
amotosalen
uva
light
inactiv
pathogen
leukocyt
studi
evalu
vitro
function
amicu
pc
plasma
treatment
storag
day
studi
designmethod
four
singl
doubl
dose
apheresi
pc
collect
amicu
platform
plasma
input
pc
dose
platelet
count
ml
pc
intercept
treat
use
dual
storag
ds
set
store
evalu
vitro
physicalmetabol
characterist
day
resultsfind
platelet
dose
recoveri
transfus
product
dose
platelet
treat
pc
day
day
vitro
platelet
qualiti
day
consist
publish
rang
intercept
pc
plasma
collect
trima
devic
tabl
conclus
data
indic
intercept
blood
system
platelet
compat
amicu
pc
plasma
pc
treat
use
ds
set
store
day
retain
vitro
metabol
function
properti
consist
vivo
function
compar
publish
treat
trima
pc
plasma
day
fda
licens
intercept
pc
met
fda
requir
transfus
dose
ph
backgroundcas
studi
pathogen
reduct
import
platelet
platelet
store
room
temperatur
five
day
transfus
condit
optim
microorgan
growth
intercept
system
one
pathogen
inactiv
method
combin
amotosalen
uva
light
inactiv
contamin
virus
bacteria
protozoa
implement
intercept
system
institut
evalu
impact
pathogen
reduct
platelet
qualiti
metabol
paramet
studi
designmethod
platelet
collect
apheresi
suspend
autolog
plasma
process
follow
intercept
patholog
reduct
system
treatment
convent
manufactur
protocol
pathogen
reduct
platelet
mix
amotosalen
expos
uva
light
follow
overnight
incub
compound
adsorpt
devic
cad
remov
residu
amotosalen
platelet
concentr
unit
volum
ph
glucos
lactat
measur
collect
day
post
cad
incub
day
day
respect
platelet
yield
per
unit
calcul
platelet
concentr
unit
volum
data
present
mean
standard
deviat
follow
number
specimen
statist
comparison
done
use
student
consid
signific
resultsfind
pathogen
reduct
led
small
signific
loss
platelet
day
n
day
n
p
averag
platelet
retent
per
unit
decreas
yield
partial
caus
volum
loss
day
ml
day
ml
p
process
platelet
concentr
drop
well
day
day
p
addit
ph
pr
platelet
significantli
lower
five
day
storag
convent
platelet
convent
platelet
n
pr
platelet
n
p
although
ph
pr
platelet
unit
pathogen
reduct
also
result
decreas
glucos
convent
platelet
mgdl
pr
platelet
mgdl
p
increas
lactat
convent
platelet
mmoll
pr
platelet
mmoll
p
measur
day
five
could
contribut
lower
ph
seen
pr
platelet
convent
platelet
conclus
pathogen
reduct
affect
qualiti
metabol
platelet
howev
qualiti
paramet
pr
platelet
within
rang
defin
aabb
standard
backgroundcas
studi
infect
endem
countri
test
blood
donor
virus
mandatori
sinc
initi
detect
isol
htlv
research
expand
led
develop
sensit
specif
method
antibodi
detect
legisl
requir
htlv
antibodi
detect
recommend
supplement
assay
like
western
blot
wb
reactiv
case
experi
one
indetermin
ind
wb
six
htlv
reactiv
screen
donat
unfortun
reason
indetermin
pattern
remain
unclear
recent
studi
propos
use
htlv
algorithm
us
blood
donor
reduc
amount
test
number
defer
donor
transfus
concern
algorithm
might
applic
endem
countri
studi
designmethod
jan
nov
total
blood
donat
initi
screen
chemiluminesc
immunoassay
cmia
sampl
repeatedli
reactiv
cmia
total
sampl
also
test
wb
innogenet
order
evalu
dt
sampl
randomli
select
retest
anoth
test
electrochemiluminesc
immunoassay
eclia
resultsfind
among
htlv
reactiv
sampl
sampl
cmiawb
cmiawb
ind
randomli
select
cmiawb
cmiawb
ind
sampl
test
eclia
cmiawb
sampl
reactiv
respect
eclia
howev
cmiawb
ind
sampl
reactiv
eclia
subsequ
wb
analysi
cmiaecliawb
ind
sampl
show
reactiv
sampl
remain
sampl
one
reactiv
one
sampl
conclus
discord
result
observ
dt
htlv
cmiaeclia
associ
pattern
presenc
env
andor
gag
protein
might
relat
seroconvers
period
describ
case
presenc
htlv
rna
render
moment
concern
use
propos
dt
htlv
cmiaeclia
algorithm
especi
endem
countri
unfortun
sampl
test
pcr
yet
subsequ
sampl
testedavail
order
confirmrul
window
period
possibl
epidemiolog
differ
explain
wb
ind
donor
countri
compar
us
need
evalu
howev
htlv
endem
countri
consid
still
prematur
adopt
dt
htlv
algorithm
without
popul
studi
solv
unclear
question
moment
backgroundcas
studi
previous
unusu
high
number
blood
donor
reactiv
hcv
test
chemiluminesc
confirm
indetermin
immunoblot
describ
capit
citi
south
american
countri
object
work
expand
identif
frequent
pattern
band
detect
immunoblot
indetermin
posit
donor
differ
region
countri
studi
designmethod
blood
donor
chemiluminesc
read
greater
sco
architect
sampl
analyz
hcv
blot
test
mp
diagnost
ref
confirm
infect
result
confirmatori
test
consolid
three
categori
neg
indetermin
posit
accord
manufactur
instruct
chi
squar
test
unpair
perform
comparison
group
resultsfind
studi
period
unit
whole
blood
collect
correspond
nation
collect
countri
seroreact
obtain
southern
andean
zone
one
highest
preval
caribbean
area
lowest
although
bank
locat
differ
region
found
confirm
indetermin
reactiv
donor
n
band
preval
howev
statist
signific
differ
found
preval
band
caribbean
pacif
region
compar
area
countri
p
import
note
donat
caribbean
region
absent
band
tabl
hand
donat
confirm
posit
region
countri
analyz
core
band
preval
final
found
least
frequent
band
group
posit
donat
north
pacif
andean
region
two
band
pattern
present
noteworthi
caribbean
region
present
specif
pattern
four
band
conclus
caribbean
region
differ
hcv
reactiv
posit
comparison
rest
countri
forego
suggest
inform
present
implement
antigen
variant
accord
geograph
locat
screen
test
use
although
bank
locat
differ
region
found
confirm
indetermin
reactiv
donor
band
preval
backgroundcas
studi
concern
persist
whether
red
blood
cell
rbc
storag
lesion
donor
agegend
process
method
frequenc
donat
may
impact
vitro
qualiti
rbc
neg
affect
transfus
qualiti
safeti
rbc
rejuven
shown
revers
mani
physic
biochem
chang
retrospect
analysi
determin
whether
gender
impact
vitro
qualiti
measur
rbc
store
day
rejuven
wash
intend
immedi
transfus
studi
designmethod
compon
prepar
ml
whole
blood
donat
healthi
adult
age
male
femal
us
site
day
storag
unit
treat
rejuvesol
solut
citra
lab
llc
ml
incub
minut
wash
l
sodium
chlorid
dextros
solut
use
cobe
cell
processor
terumo
store
hour
fund
materi
studi
provid
zimmer
biomet
resultsfind
vitro
qualiti
measur
femal
donor
f
male
donor
report
day
collect
day
storag
rejuven
wash
pw
storag
hour
tabl
vitro
recoveri
unit
signific
differ
p
observ
atp
pw
hemolysi
maintain
howev
collect
store
pw
exhibit
significantli
higher
hemolysi
conclus
rbc
rejuven
provid
benefici
blood
compon
whether
rbc
obtain
f
indic
vitro
qualiti
measur
evalu
although
maintain
rbc
obtain
exhibit
slightli
higher
hemolysi
level
store
compar
rbc
f
analysi
rel
age
donor
need
backgroundcas
studi
reveo
autom
system
terumobct
process
whole
blood
wb
unit
two
three
compon
name
plasma
red
cell
concentr
rcc
interim
platelet
unit
ipu
initi
reveo
process
valid
done
use
blood
collect
set
concern
relat
rcc
hemolysi
end
storag
requir
compli
csa
standard
test
new
lr
blood
collect
set
made
avail
experi
specif
design
evalu
rcc
hemolysi
qualiti
criterion
product
forecast
base
smaller
sampl
size
use
predict
analyt
statist
model
vitro
qualiti
criteria
gener
product
also
monitor
studi
designmethod
reveo
lr
blood
collect
set
use
collect
wb
ml
within
fresh
protocol
h
overnight
protocol
collect
time
wb
unit
process
rcc
hemolysi
measur
follow
standard
qualiti
control
qc
procedur
data
analyz
model
fit
normal
distribut
process
use
mont
carlo
simul
calcul
expect
conform
rate
rcc
hemolysi
end
storag
consid
rccyear
product
target
approach
appli
rcc
hemolysi
rate
obtain
previou
reveo
valid
reveo
protocol
result
compar
moreov
vitro
qualiti
paramet
plasma
platelet
concentr
pc
ie
platelet
yield
ph
residu
leukocyt
fviii
etc
test
compar
resultsfind
averag
hemolysi
reveo
lr
rcc
protocol
respect
mont
carlo
simul
appli
data
complianc
rate
expect
base
yearli
product
rcc
statist
approach
appli
reveo
valid
studi
result
hemolysi
protocol
expect
complianc
rate
rcc
hemolysi
calcul
reveo
lr
plasma
pc
result
within
csa
accept
conclus
design
experi
small
sampl
size
combin
statist
model
predict
analyt
strateg
tool
blood
center
forese
perform
outcom
follow
process
chang
new
technolog
implement
canadian
standard
associ
nation
standard
canada
blood
blood
compon
csa
backgroundcas
studi
transmiss
bacteria
transfus
remain
signific
problem
transfus
medicin
disinfect
clean
venipunctur
site
hand
surfac
key
compon
success
control
hygien
blood
bank
includ
cord
blood
bank
besid
bacteri
enumer
monitor
bacteri
pathogen
perform
reduc
risk
septic
refer
hygien
standard
disinfect
hospit
china
convent
method
cultur
biochem
method
inconveni
time
experi
requir
identifi
presenc
pathogen
bacteriath
aim
studi
develop
isotherm
amplif
assay
improv
effici
bacteri
pathogen
identif
studi
designmethod
studi
design
specif
primer
fluoresc
probe
conserv
region
four
pathogen
bacteria
staphylococcu
aureu
salmonella
spp
hemolyt
streptococcu
pseudomona
aeruginosa
assay
dna
four
baceria
isol
aliquot
cultur
medium
effici
extract
method
raa
reaction
conduct
constant
temperatur
simul
vivo
dna
recombin
min
evalu
sensit
method
four
pathogen
bacteria
cultur
variou
concentr
cfuml
inocul
surfac
sampl
amplifi
detect
assay
specif
valid
use
bacteria
fungi
perform
assay
evalu
skin
surfac
sampl
taken
steril
swab
blood
collect
product
obtain
microbiolog
profil
manufactur
condit
result
compar
cultur
biochem
method
standard
resultsfind
combin
fluoresc
probe
detect
raa
assay
could
reliabl
detect
cfuml
pure
cultur
four
pathogen
bacteria
constant
temperatur
within
min
sensit
convent
method
assay
success
use
amplifi
detect
dna
sampl
taken
skin
surfac
test
bacteria
fungi
sixti
sampl
thirti
skin
sampl
surfac
sampl
respect
analyz
convent
cultur
method
assay
skin
sampl
two
sampl
taken
hand
staff
detect
staphylococcu
aureu
raa
assay
consist
convent
method
conclus
data
present
studi
indic
provid
rapid
sensit
specif
detect
pathogen
skin
surfac
sampl
without
prior
isol
character
bacteria
convent
method
assay
serv
altern
tool
cultur
biochem
method
screen
pathogen
bacteria
result
obtain
plate
count
base
cultur
method
show
environ
skin
surfac
area
blood
collect
product
potenti
contamin
pathogen
could
potenti
risk
blood
product
acknowledg
research
support
public
welfar
technolog
applic
research
project
zhejiang
provinc
backgroundcas
studi
syphili
bacteri
infect
caus
treponema
pallidum
could
transmit
sexual
contact
blood
transfus
pregnanc
mother
fetu
sinc
colombia
mandatori
screen
pallidum
blood
donat
sever
studi
demonstr
activ
syphili
infect
potenti
transmiss
hiv
relat
higher
probabl
coinfect
pathogen
potenti
transmit
blood
aim
studi
identifi
syphili
coinfect
viru
associ
sexual
transmiss
colombian
blood
donat
studi
designmethod
retrospect
analysi
blood
donat
reactiv
syphili
hiv
hcv
hbv
htlv
collect
januari
decemb
certifi
blood
bank
nation
level
made
confirmatori
test
hiv
hcv
htlv
immunoblot
complementari
test
hbv
infect
hbsag
anti
hbc
igm
syphili
infect
establish
vener
diseas
research
laboratori
vdrl
rapid
plasma
reagin
rpr
test
resultsfind
studi
period
blood
donat
screen
catalog
first
time
event
unit
reactiv
treponem
test
howev
donat
activ
infect
frequenc
coinfect
viral
marker
tabl
accord
calcul
pallidum
seroprovel
per
donat
syphili
constitut
regist
coinfect
case
one
blood
donat
syphili
coinfect
donat
came
male
donor
word
preval
ratio
pr
men
versu
women
ci
male
preval
donat
vs
femal
preval
donat
hand
syphili
reactiv
donat
came
voluntari
donat
mean
pr
ci
versu
repetit
donor
conclus
syphili
remain
public
health
problem
due
high
preval
particularli
asymptomat
person
blood
donor
despit
penicillin
effect
cure
syphili
strain
decreas
effect
treatment
coinfect
impli
challeng
health
system
complic
detect
presenc
sexual
transmit
infect
sti
countri
studi
three
four
blood
donat
come
first
time
donor
preval
infect
syphili
time
higher
donat
repetit
donor
perman
screen
infect
justifi
complementari
strategi
reduc
risk
infect
backgroundcas
studi
pauciti
data
regard
red
blood
cell
rbc
alloimmun
preval
healthi
blood
donor
despit
potenti
signific
antibodi
blood
donor
transfus
recipi
collect
center
studi
designmethod
donordon
data
sourc
us
blood
center
rbc
antibodi
screen
result
use
tube
gel
solid
phase
blood
type
donor
demograph
transfus
histori
pregnanc
histori
evalu
multivari
logist
regress
use
assess
rate
posit
antibodi
screen
differ
among
subgroup
resultsfind
uniqu
blood
donor
donat
unit
total
donat
antibodi
screen
posit
studi
period
donor
posit
antibodi
screen
least
includ
femal
male
posit
rbc
antibodi
screen
common
older
year
old
preval
younger
year
old
preval
donor
p
rhd
neg
rhd
posit
donor
p
prior
transfus
histori
strongli
associ
posit
rbc
antibodi
screen
vs
transfus
histori
odd
ratio
confid
interv
ci
p
prior
pregnanc
histori
among
femal
vs
pregnanc
histori
odd
ratio
ci
p
similar
amount
miss
data
observ
prior
transfus
prior
pregnanc
question
follow
multivari
logist
regress
analysi
age
sex
rhd
statu
prior
transfus
histori
prior
pregnanc
histori
retain
signific
independ
associ
posit
antibodi
screen
p
miss
data
omit
analysi
clinic
signific
antibodi
common
specif
includ
e
k
c
fya
c
jka
femal
clinic
signific
antibodi
detect
previous
pregnant
never
transfus
donor
detect
previous
transfus
never
pregnant
donor
conclus
find
databas
provid
largest
donor
cohort
evalu
rbc
antibodi
confirm
transfus
previou
pregnanc
key
risk
factor
data
may
implic
donor
regard
futur
rbc
transfus
pregnanc
sinc
rbc
andor
compon
made
donat
antibodi
posit
donor
may
suitabl
transfus
data
also
implic
blood
center
oper
level
backgroundcas
studi
collect
teenag
donor
compris
larg
fraction
us
blood
suppli
regulatori
oper
administr
impact
cohort
deserv
care
assess
less
appreci
subsequ
contribut
group
age
understand
size
residu
draw
also
import
polici
practic
chang
might
deflect
incom
stream
young
donor
quantifi
residu
draw
amplifi
oper
financi
signific
difficult
expens
initi
recruit
older
individu
replac
high
school
first
time
donor
ftd
studi
designmethod
donor
data
collect
central
us
region
blood
center
comput
record
data
includ
id
sex
date
locat
product
deferr
code
allogen
donor
gave
unit
first
time
age
year
includ
high
school
sourc
collect
deem
includ
unit
given
current
yo
includ
yo
ftd
cohort
yo
ftd
etc
due
substanti
growth
total
collect
last
decad
averag
annual
draw
period
provid
adjust
smaller
ftd
recruit
cohort
earlier
year
resultsfind
total
success
donat
event
record
donor
gave
first
time
yo
donat
high
school
age
year
total
donor
yo
persist
give
behavior
provid
collect
unadjust
residu
donat
yo
repres
blood
center
total
adjust
collect
growth
residu
donat
compris
except
assess
ftd
cohort
year
compris
wholli
yo
show
increas
residu
draw
expect
effect
rise
impact
time
laps
behavior
disqualifi
deferr
geograph
conclus
high
school
age
ftd
continu
suppli
signific
fraction
blood
suppli
age
twenti
analysi
clearli
underestim
full
decad
shown
yo
ftd
likewis
yo
donat
began
residu
contribut
truncat
better
model
residu
collect
includ
product
type
need
understand
latent
inventori
impact
regulatori
disrupt
intak
retent
new
teenag
donor
backgroundcas
studi
hemolysi
rate
end
storag
repres
import
qualiti
marker
red
cell
concentr
rcc
regulatori
agenc
establish
clear
standard
rcc
hemolysi
end
storag
howev
recommend
specif
methodolog
regard
supernat
hemoglobin
hb
recent
studi
signific
differ
observ
rcc
hemolysi
rate
depend
analyt
approach
use
aim
studi
compar
rcc
hemolysi
result
obtain
differ
method
studi
designmethod
first
part
studi
store
day
proceed
supernat
hb
measur
three
condit
seri
cbc
perform
hematolog
analyz
beckman
coulter
rcc
sampl
prior
centrifug
min
sampl
tube
seri
centrifug
seri
cbc
measur
omit
seri
sampl
subject
hard
spin
condit
shorter
time
min
seri
supernat
filter
hb
measur
use
hemocu
plasmalow
hb
system
follow
manufactur
recommend
second
part
studi
supernat
obtain
rcc
blood
sampl
mention
seri
harbo
method
wavelength
nm
optic
path
length
hemocu
system
use
measur
free
hb
calcul
hemolysi
rate
resultsfind
averag
hb
valu
calcul
seri
gdl
slightli
higher
seri
gdl
seri
gdl
result
averag
hemolysi
seri
compar
seri
respect
importantli
seri
rcc
would
met
canadian
standard
hemolysi
compar
seri
seri
harbo
vs
hemocu
studi
hb
averag
valu
gdl
gdl
respect
measur
averag
hemolysi
hemocu
higher
harbo
sampl
conclus
result
suggest
use
two
separ
tube
would
recommend
avoid
unfavor
bia
hemolysi
calcul
harbo
hemocu
plhb
compar
studi
suggest
signific
evid
hemocu
system
calibr
use
intern
council
standard
hematolog
refer
method
would
appropri
measur
method
free
hemoglobin
backgroundcas
studi
recent
increas
number
hepat
outbreak
unit
state
although
presenc
hav
rna
blood
donor
known
low
hav
antibodi
preval
popul
unknown
studi
designmethod
sampl
us
blood
donor
collect
primarili
midwestern
us
test
presenc
hav
igg
igm
antibodi
use
chemiluminesc
microparticl
immunoassay
architect
platform
abbott
laboratori
resultsfind
overal
preval
igg
previou
studi
use
sampl
collect
part
nation
health
nutrit
examin
survey
nhane
show
decreas
preval
howev
nhane
includ
individu
year
age
older
one
specimen
igm
posit
confirm
preval
specimen
hav
rna
neg
igg
preval
among
donor
year
drop
among
donor
age
year
increas
among
donor
age
year
high
preval
among
year
old
like
due
infant
vaccin
recommend
initi
differ
seen
sex
overal
igg
preval
male
femal
respect
among
five
state
highest
number
donor
igg
preval
missouri
significantli
higher
preval
illinoi
kentucki
p
differ
seen
igg
preval
among
individu
previous
test
posit
either
igm
igg
indic
correl
igg
statu
antibodi
statu
conclus
studi
demonstr
overal
high
rate
igg
us
blood
donor
low
risk
hav
transfus
transmiss
low
risk
support
hav
vaccin
polici
develop
sinc
backgroundcas
studi
goal
staff
american
rare
donor
program
ardp
ensur
request
rare
blood
ardp
member
fill
import
know
request
rare
blood
fill
unfil
request
rare
blood
may
delay
patient
treatment
may
result
continu
low
hemoglobin
may
put
patient
risk
process
ardp
member
request
rare
unit
ardp
staff
send
two
fax
ardp
member
regist
rare
donor
type
request
complet
success
find
unit
email
request
recruit
sent
domest
ardp
member
regist
donor
request
still
unfil
next
step
would
consult
facil
ardp
medic
director
final
meet
fda
ind
requir
intern
request
patient
physician
permiss
autolog
donat
possibl
insuffici
elig
sibl
mma
result
request
made
intern
rare
donor
panel
studi
designmethod
review
unfil
request
perform
evalu
criteria
includ
phenotyp
aborh
number
unit
request
patient
diagnosi
resultsfind
research
request
respons
unfil
request
total
request
diagnosi
patient
sickl
cell
diseas
scd
phenotyp
preval
donor
african
descent
number
unit
request
rang
unit
averag
per
order
unfil
request
cancel
within
averag
day
fourteen
request
posit
unit
five
request
rh
unit
plasma
five
unfil
order
unit
neg
multipl
antigen
thirteen
antigen
high
preval
conclus
ardp
member
collabor
effect
fill
request
rare
blood
fill
rate
request
fill
monitor
unfil
request
import
determin
reason
request
remain
unfil
patient
popul
impact
data
collect
indic
unfil
request
patient
scd
major
request
associ
cancel
order
patient
discharg
without
transfus
impact
lack
transfus
patient
live
unknown
find
prompt
ardp
take
action
develop
implement
outcom
form
collect
inform
regard
impact
unfil
order
backgroundcas
studi
treponem
test
remain
posit
life
treatment
syphili
late
transfus
transmiss
nt
revert
neg
success
treatment
mani
late
infect
need
approxim
unit
blood
day
usa
less
popul
donat
unnecessari
deferr
donor
due
persist
reactiv
remot
noninfecti
identifi
follow
nt
revers
algorithm
need
reassess
revers
algorithm
replac
tradit
diagnost
algorithm
nt
test
confirm
transfus
medicin
autom
introduct
autom
nt
method
use
tradit
algorithm
evalu
prefer
method
screen
blood
donor
reduc
deferr
individu
past
longer
infecti
studi
designmethod
serum
plasma
specimen
concord
nt
result
test
asi
evolut
autom
rpr
analyz
use
asi
rpr
carbon
antigen
sampl
sourc
blood
bank
plasma
center
sampl
also
includ
nonreact
specimen
reactiv
specimen
pregnant
women
clinic
diagnos
reactiv
specimen
treat
untreat
public
health
depart
test
rpr
establish
expect
result
reactiv
sampl
rang
reactiv
minim
titer
titer
rpr
age
patient
rang
age
year
old
includ
male
femal
resultsfind
specimen
reactiv
specimen
nonreact
rpr
asi
evolut
identifi
reactiv
specimen
reactiv
nonreact
specimen
nonreact
posit
agreement
ci
neg
agreement
ci
conclus
year
nt
standard
screen
blood
donor
nt
displac
autom
avail
autom
nt
analyz
data
present
nt
test
reevalu
primari
donor
screen
test
decreas
deferr
rate
due
noninfecti
persist
reactiv
backgroundcas
studi
flow
cytometri
unit
determin
peripher
blood
cell
count
hematopoiet
progenitor
cell
count
procedur
start
sampl
analyz
afterward
stem
cell
process
laboratori
although
use
ukneqa
stem
cell
enumer
programm
extern
qualiti
assess
past
set
assess
correl
cell
count
obtain
flow
cytometri
unit
obtain
process
laboratori
order
replac
current
extern
qualiti
assess
measur
particularli
given
process
laboratori
also
subscrib
ukneqa
stem
cell
enumer
programm
studi
designmethod
retrospect
analyz
correl
cell
count
obtain
unit
stem
cell
process
laboratori
januari
april
flow
cytomet
antibodi
erythrocyt
lysi
solut
use
unit
cxp
softwar
clone
pe
clone
beckman
coulter
pharmlys
flow
cytomet
antibodi
erythrocyt
lysi
solut
use
stem
cell
process
laboratori
facscalibur
cellquest
softwar
clone
pe
clone
quicklysistm
absolut
cell
count
unit
use
flow
count
fluorospher
process
laboratori
perfect
count
microspher
cytogno
regress
use
compar
two
laboratori
plot
use
assess
agreement
final
spearman
rank
correl
coeffici
use
determin
correl
result
obtain
flow
cytometri
unit
stem
cell
process
laboratori
resultsfind
regress
show
deviat
linear
two
laboratori
analysi
show
bia
cell
count
spearman
correl
coeffici
confid
interv
p
one
patient
cell
count
result
obtain
laboratori
conclus
correl
two
laboratori
determin
cell
count
good
plan
carri
correl
yearli
extern
qualiti
assess
backgroundcas
studi
donor
vigil
systemat
monitor
advers
event
ae
blood
donor
care
view
improv
qualiti
safeti
blood
donor
understand
donor
ae
taiwan
provid
basi
improv
blood
donat
process
donor
care
procedur
report
gener
comprehens
analysi
blood
donat
data
base
standard
surveil
complic
relat
blood
donat
issu
isbt
ihn
aabb
work
group
decemb
studi
designmethod
donor
ae
analyz
compar
includ
donat
pattern
age
gender
estim
blood
volum
ebv
rel
blood
volum
rbv
reaction
rate
calcul
reaction
per
donat
unless
state
citrat
reaction
hemolysi
air
embol
infiltr
calcul
platelet
apheresi
collect
resultsfind
donat
respect
overal
reaction
rate
four
common
ae
vasovag
reaction
vvr
citrat
reaction
infiltr
hematoma
whole
blood
donat
donor
contribut
total
donat
account
ae
reaction
rate
reaction
rate
repeat
donor
donor
age
year
account
total
donat
reaction
rate
donor
age
older
account
total
donat
reaction
rate
downtrend
overal
reaction
rate
donor
age
appar
interestingli
reaction
rate
ae
donor
age
andor
year
least
time
higher
year
andor
older
year
reaction
rate
older
age
group
age
older
compar
stabl
observ
period
vari
wide
youngest
donor
year
ae
male
less
femal
vs
p
vs
p
reaction
rate
vvr
decreas
age
male
femal
vvr
femal
higher
male
vs
p
vs
p
vvr
associ
loss
second
andor
complic
analysi
show
vvr
femal
increas
rbv
increas
rbv
analysi
limit
whole
blood
donor
conclus
first
comprehens
report
donor
ae
taiwan
accord
find
vvr
common
advers
event
young
donor
andor
donor
like
ae
compar
older
donor
andor
repeat
donor
femal
ae
male
especi
vvr
prophylact
calcium
tablet
provid
platelet
apheresi
donor
unless
refus
meantim
regular
monitor
needl
punctur
techniqu
blood
collect
site
taken
place
effort
success
decreas
reaction
rate
citrat
reaction
vs
p
infiltr
vs
p
recent
evalu
show
ae
would
deter
donor
donat
especi
vvr
happen
take
measur
reduc
occurr
vvr
would
next
prioriti
backgroundcas
studi
donor
factor
age
sex
shown
influenc
donor
hemoglobin
hb
level
also
associ
hemolysi
store
red
cell
concentr
rcc
femal
blood
donor
lower
hb
level
lower
rcc
hemolysi
level
male
blood
donor
howev
relationship
donor
hb
rcc
hemolysi
previous
investig
aim
studi
examin
hb
influenc
hemolysi
level
store
rcc
characterist
differ
donor
group
explor
data
two
larg
nation
blood
servic
use
evalu
donor
screen
practic
may
affect
qualiti
characterist
rcc
studi
designmethod
hemolysi
data
collect
routin
qualiti
control
test
june
decemb
two
larg
nation
blood
servic
merg
associ
donor
inform
age
sex
hb
frequenc
donat
rcc
unit
test
blood
servic
measur
donor
hb
use
freseniu
compolab
system
use
similar
method
autom
analyz
hemocu
low
plasma
measur
hemolysi
expiri
leukoreduc
sagm
rcc
interv
two
blood
servic
differ
australian
red
cross
blood
servic
arcb
interv
lower
hb
limit
gl
femal
gl
male
wherea
canadian
blood
servic
cb
interv
lower
limit
gl
male
femal
donor
regress
analysi
analysi
group
mean
perform
resultsfind
analysi
merg
dataset
rcc
show
donor
age
sex
influenc
hb
level
male
donor
show
signific
decreas
hb
age
time
donat
p
significantli
higher
femal
donor
everi
age
group
p
hb
level
male
femal
donor
markedli
differ
two
blood
servic
rcc
hemolysi
increas
donor
age
mark
differ
male
femal
donor
age
signific
differ
rcc
hemolysi
male
donor
observ
two
blood
servic
particularli
year
old
male
donor
arcb
cb
except
male
donor
arcb
p
relationship
donor
hb
rcc
hemolysi
conclus
data
highlight
influenc
donor
characterist
product
qualiti
characterist
differ
donor
select
criteria
amongst
blood
servic
influenc
popul
donor
elig
donat
therefor
characterist
product
avail
transfus
backgroundcas
studi
pgdprime
rapid
test
bacteria
platelet
develop
improv
test
current
use
safeti
measur
platelet
transfus
design
provid
simpler
test
procedur
compar
current
product
robust
new
test
challeng
deviat
nomin
test
procedur
simul
potenti
error
user
vari
environment
condit
studi
designmethod
suscept
test
loss
accuraci
valid
examin
test
neg
posit
sampl
creat
spike
bacteria
panel
individu
platelet
run
test
use
measur
decreas
increas
nomin
valu
sampl
reagent
volum
incub
time
time
liquid
addit
laboratori
environment
condit
stack
guardband
studi
combin
vari
volum
sampl
ad
reaction
ratio
sampl
process
reagent
volum
sampl
ad
devic
environment
chamber
use
vari
humid
condit
incub
use
control
temperatur
condit
resultsfind
pgdprime
test
yield
accur
result
neg
posit
sampl
throughout
guardband
test
conclus
pgdprime
rapid
test
robust
assay
withstand
high
level
potenti
error
user
test
use
wide
rang
environment
condit
backgroundcas
studi
bacteri
contamin
resid
within
epiderm
layer
resist
current
disinfect
practic
sourc
contamin
collect
whole
blood
blood
compon
divers
first
ml
whole
blood
establish
practic
effect
strategi
mitig
incid
skin
flora
relat
blood
product
contamin
previou
data
suggest
addit
sampl
divers
beyond
current
measur
would
reduc
bacteri
load
blood
collectionsepar
system
extens
studi
studi
sought
evalu
bacteri
content
blood
fraction
collect
contamin
sourc
inject
site
addit
ml
beyond
today
practic
divers
volum
ml
use
simpl
vitro
model
system
studi
designmethod
model
system
prepar
model
divers
line
similar
wagner
et
al
transfus
construct
use
inlet
line
doubl
needl
apheresi
platelet
collect
kit
freseniu
kabi
luer
lock
ad
place
sampl
divers
pouch
cm
past
second
test
articl
prepar
evalu
inject
site
steril
bag
contain
whole
blood
anticoagul
inocul
minimum
cfu
overnight
epidermi
cultur
upon
dri
needl
model
divers
line
insert
inocul
area
aliquot
blood
taken
via
syring
luer
posit
place
divers
pouch
ml
aliquot
sampl
line
seal
first
aliquot
drawn
second
luer
ml
aliquot
bacteria
concentr
fraction
determin
use
pour
plate
method
total
cfu
fraction
calcul
resultsfind
overal
result
total
cfu
fraction
show
continu
reduct
bacteri
load
increas
volum
collecteddivert
data
first
ml
collect
divers
line
consist
publish
wagner
et
al
show
bacteria
remov
first
fraction
collect
subsequ
fraction
show
continu
reduct
bacteri
load
result
addit
log
decreas
initi
ml
divers
conclus
studi
illustr
bacteri
load
reduct
continu
occur
past
standard
divers
volum
ml
vitro
model
divers
system
studi
requir
evalu
potenti
benefit
extend
divers
model
onlin
collect
system
practic
applic
impact
backgroundcas
studi
uncommon
power
interrupt
occur
blood
center
hospit
extrem
weather
event
backup
gener
fail
refriger
blood
warm
beyond
studi
evalu
level
sever
bacteria
refriger
leukodeplet
rbc
follow
hour
temperatur
excurs
toward
room
temperatur
studi
designmethod
two
abo
rh
ident
leukoreduc
rbc
prepar
whole
blood
collect
consent
donor
fenwal
round
lake
unit
pool
mix
inocul
day
cfuml
quantit
plate
assay
p
fluorescen
enterocolita
marcescen
liquefacien
e
coli
aureu
pool
divid
equal
two
unit
store
day
one
two
unit
test
place
laboratori
bench
hour
surfac
temperatur
record
return
storag
unit
maintain
refriger
storag
control
sampl
taken
quantit
plate
assay
day
day
pre
day
post
day
day
experi
repeat
time
per
organ
resultsfind
end
temperatur
excurs
surfac
temperatur
unit
bacteri
result
express
cfumltest
cfumlcontrol
tabl
signific
differ
observ
growth
test
control
unit
storag
p
fluorescen
e
coli
aureu
day
post
excurs
bacteri
count
test
unit
contain
enterocolitca
declin
approxim
rel
control
unit
differ
observ
timepoint
marcescen
significantli
greater
level
bacteria
observ
test
unit
rel
control
day
respect
bacteria
count
liquefacien
subject
temperatur
excurs
greater
control
unit
day
differ
attain
statist
signific
conclus
room
temperatur
excurs
rbc
affect
bacteri
count
p
fluorescen
e
coli
aureu
temporarili
decreas
level
enterocolitica
immedi
follow
temperatur
excurs
enhanc
growth
marcescen
later
storag
backgroundcas
studi
introduct
gener
hiv
combin
assay
improv
detect
acut
hiv
infect
assay
detect
presenc
antibodi
along
antigen
blood
screen
reduc
risk
transfus
relat
hiv
infect
increas
sensit
coupl
high
specif
minim
donor
deferr
provid
public
safer
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
antibodi
antigen
develop
studi
designmethod
perform
immunoassay
detect
antibodi
antigen
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
use
posit
sampl
specif
evalu
sampl
obtain
random
blood
plasmapheresi
donor
sensit
evalu
use
presum
posit
sampl
antigen
viral
isol
seroconvers
sensit
evalu
commerci
seroconvers
panel
analyt
sensit
evalu
use
intern
standard
antigen
resultsfind
imprecis
less
cv
posit
sampl
day
specif
sensit
antigen
posit
sampl
sensit
antigen
posit
viral
isol
sampl
seroconvers
sensit
better
licens
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
analyt
sensit
rang
iuml
iuml
conclus
result
indic
new
autom
alin
hiv
agab
combo
assay
provid
accept
perform
specif
sensit
precis
also
assay
provid
better
seroconvers
sensit
licens
compar
assay
backgroundcas
studi
order
provid
plasma
compon
therapi
whole
blood
goe
seri
manufactur
step
visual
inspect
accept
standard
guid
perform
visual
inspect
would
benefici
improv
consist
regulatori
standard
plasma
color
red
blood
cell
rbc
concentr
plasma
necessari
first
determin
accept
could
use
develop
visual
inspect
aid
studi
designmethod
determin
best
accept
vs
unaccept
plasma
visual
represent
creat
plasma
unit
similar
size
color
inject
rbc
increment
volum
rang
plasma
unit
laid
increas
rbc
concentr
tech
manag
inspect
plasma
unit
determin
common
visual
rbc
concentr
plasma
calcul
base
whole
blood
averag
hematocrit
rbcsml
doubl
unit
pack
rbc
determin
number
rbc
inject
unit
determin
photo
taken
plasma
unit
use
creat
visual
inspect
aid
resultsfind
visual
determin
tech
manag
fell
inject
plasma
unit
one
sourc
found
mention
limit
rbc
plasma
specif
rbcsml
packag
insert
pathogen
reduct
technolog
platelet
use
guidelin
unit
determin
concentr
rbcsml
visual
inspect
aid
produc
implement
compon
laboratori
initi
use
plasma
unit
inspect
plasma
pass
visual
inspect
aid
made
avail
two
hospit
blood
bank
sinc
initi
implement
flaw
calcul
discov
visual
determin
concentr
rbcsml
survey
indic
respond
use
inspect
aid
believ
help
determin
plasma
accept
express
opinion
aid
improv
plasma
inspect
found
use
train
give
new
tech
confid
make
inspect
decis
conclus
develop
implement
plasma
visual
inspect
aid
provid
consist
visual
inspect
across
multipl
area
handl
plasma
prior
transfus
aid
accept
simpl
use
tool
tech
manag
backgroundcas
studi
certainli
true
liquid
red
blood
cell
rbc
unit
conveni
practic
frozen
unit
longer
shelf
life
easier
ship
risk
breakag
less
resourc
intens
less
expens
howev
liquid
unit
rare
phenotyp
alway
avail
frozen
unit
reli
case
provid
lifesav
treatment
total
american
rare
donor
program
ardp
request
request
ardp
liquid
unit
outcom
request
investig
studi
designmethod
request
calendar
year
review
outcom
request
liquid
unit
determin
number
liquid
unit
found
unit
talli
aborh
type
antigen
phenotyp
resultsfind
facil
place
request
liquid
rbc
unit
rare
phenotyp
request
request
unit
requir
frozen
unit
complet
request
one
includ
antigen
high
preval
rariti
aborh
antibodi
play
factor
unit
avail
liquid
state
ten
request
group
rbc
four
request
involv
rbc
phenotyp
lack
u
rbc
lack
uvar
account
request
unit
found
liquid
state
request
unit
accept
uvar
unit
one
patient
molecular
test
result
addit
request
rbc
unit
lack
high
preval
antigen
includ
coa
lub
dib
joa
jra
ppipk
ko
even
request
rbc
ab
recipi
univers
recipi
base
aborh
unabl
fill
due
rariti
type
one
request
rhce
allel
match
rhce
conclus
request
rbc
unit
rare
type
submit
specif
liquid
unit
fill
liquid
unit
unabl
fill
liquid
unit
involv
u
antigen
addit
involv
high
preval
antigen
request
frozen
rare
unit
util
fill
gap
liquid
unit
avail
without
frozen
unit
patient
would
receiv
transfus
time
manner
potenti
delay
associ
recruit
collect
rare
donor
ardp
advis
center
request
liquid
unit
review
patient
clinic
cours
determin
transfus
emin
requir
reconsid
frozen
unit
request
backgroundcas
studi
blood
screen
laboratori
face
mani
challeng
today
chang
healthcar
environ
includ
ineffici
manual
process
shorten
time
requir
staf
shortag
budget
constraint
advanc
autom
technolog
help
allevi
challeng
aim
studi
implement
autom
laboratori
track
system
product
laboratori
test
whole
blood
sourc
plasma
donor
sampl
metric
collect
determin
effect
implement
autom
track
laboratori
system
number
sampl
process
per
shift
time
perform
process
time
sampl
test
qualiti
relat
issu
number
employe
requir
perform
test
studi
designmethod
implement
autom
product
laboratori
occur
two
phase
phase
one
integr
middlewar
across
primari
test
platform
phase
two
involv
fulli
autom
part
test
process
instal
track
autom
system
system
includ
autom
input
sampl
system
centrifug
decap
reseal
storag
sampl
tube
analyt
work
also
autom
place
chemistri
immunoassay
analyz
directli
track
system
resultsfind
tabl
show
data
track
autom
system
compar
metric
collect
track
autom
system
show
increas
number
sampl
process
per
shift
also
decreas
averag
time
process
sampl
averag
time
time
sampl
receiv
result
sent
client
decreas
two
hour
number
correct
report
gener
decreas
number
employe
requir
perform
process
sampl
decreas
conclus
autom
donor
test
product
laboratori
enabl
us
test
sampl
increas
less
peopl
decreas
abl
report
result
shorter
period
time
hour
faster
averag
remov
manual
error
prone
process
allow
reduct
correct
report
test
sampl
effici
timeli
manner
without
addit
staff
backgroundcas
studi
due
long
possibl
storag
time
frozen
plasma
one
two
year
addit
safeti
step
implement
product
process
releas
transfus
approv
quarantin
storag
includ
retest
donor
hiv
hbv
hcv
month
one
routin
use
method
least
month
delay
possibl
releas
process
opposit
pathogen
inactiv
pi
techniqu
allow
immedi
use
treat
unit
two
three
day
howev
pi
mean
addit
manipul
plasma
possibl
loss
coagul
factor
product
subsequ
storag
therefor
studi
influenc
pi
methylen
blue
intercept
factor
viii
common
use
qualiti
paramet
frozen
plasma
compar
result
untreat
store
plasma
pair
system
studi
designmethod
produc
pool
plasma
unit
split
pool
three
arm
intercept
treat
plasma
methylen
blue
mb
treat
plasma
untreat
plasma
plasma
frozen
immedi
inactiv
fibrinogen
factor
viii
analyz
month
year
year
report
find
factor
loss
differ
pi
method
pi
treat
unit
untreat
control
unit
well
stabil
coagul
factor
within
group
resultsfind
compar
pi
group
fibrinogen
content
mgdl
significantli
lower
mean
ci
vs
vs
vs
vs
mb
respect
pi
treat
arm
p
fibrinogen
content
group
slightli
higher
compar
mb
group
differ
signific
report
factor
viii
content
pi
treat
group
year
vs
vs
vs
vs
mb
respect
compar
pi
treat
group
mb
show
higher
factor
viii
level
howev
differ
also
signific
level
significantli
lower
p
stabil
factor
within
group
defin
chang
valu
month
year
freez
given
fibrinogen
p
factor
viii
p
three
arm
conclus
manipul
plasma
caus
pathogen
inactiv
techniqu
lead
signific
loss
factor
viii
compar
manipul
plasma
howev
addit
loss
frozen
state
year
similar
three
arm
therefor
increas
pi
techniqu
take
account
mean
volum
mb
treat
plasma
ml
wherea
treat
plasma
ml
total
content
factor
transfus
unit
significantli
higher
mb
group
influenc
total
number
transfus
unit
per
patient
backgroundcas
studi
rare
red
cell
concentr
rcc
frequent
cryopreserv
store
use
high
glycerol
method
slow
freez
rate
prior
transfus
thaw
unit
must
glycerol
remov
methodolog
also
appli
reagent
red
blood
cell
rbc
provid
cell
test
purpos
avoid
liquid
nitrogen
storag
howev
deglycerol
process
rcc
requir
extens
wash
step
translat
small
ml
model
labour
intens
purpos
studi
evalu
simplifi
wash
process
provid
practic
deglycerol
method
reagent
small
volum
rbc
cryopreserv
studi
designmethod
rcc
glycerol
final
concentr
supernat
reduct
pre
post
glycerol
glycerol
rbc
aliquot
ml
volum
cryovial
place
freezer
minimum
hour
prior
deglycerol
sampl
thaw
water
bath
two
deglycerol
process
perform
process
involv
four
wash
step
salin
salin
two
wash
dextros
process
involv
three
wash
step
achiev
increas
volum
wash
solut
elimin
fourth
wash
step
rbc
sampl
suspend
post
process
hemoglobin
loss
hemoglobin
recoveri
glycerol
concentr
determin
addit
sampl
deglycerol
test
rbc
hemolysi
hour
hypotherm
storag
pointprocess
resultsfind
process
yield
approxim
ml
deglycerol
rbc
hematocrit
glycerol
concentr
sampl
hemoglobin
recoveri
process
compar
process
rbc
post
deglycerol
store
hour
prepar
use
process
hemolysi
respect
process
rbc
hemolysi
time
point
compar
process
sampl
store
correspond
time
point
signific
differ
observ
hour
p
conclus
simplifi
deglycerol
method
success
deglycerol
small
volum
rbc
rbc
suspend
post
process
sampl
store
hypotherm
day
increas
util
reagent
cell
small
volum
transfus
backgroundcas
studi
walk
blood
bank
wbb
use
low
titer
group
fresh
whole
blood
fwb
effect
strategi
resuscit
hemorrhag
shock
patient
battlefield
significantli
reduc
battlefield
morbid
mortal
wbb
vital
prolong
field
care
set
evacu
higher
level
care
may
delay
hour
day
screen
potenti
wbb
donor
deploy
auster
condit
assist
mitig
transfus
transmit
diseas
risk
identif
blood
type
determin
titer
statu
studi
designmethod
donor
screen
transfus
transmit
diseas
use
requir
panel
allogen
test
accord
fda
guidelin
wbb
donor
test
perform
contract
test
laboratori
wbb
donor
test
enter
dod
oper
blood
bank
system
record
use
calcul
diseas
preval
use
number
posit
screen
test
divid
total
number
potenti
donor
screen
resultsfind
year
time
period
may
march
potenti
donor
screen
infecti
diseas
well
determin
blood
type
antibodi
screen
isohemagglutinin
titer
statu
type
donor
preval
rate
identifi
screen
test
follow
posit
antibodi
screen
case
confirm
neutral
one
case
identifi
hcv
eia
nat
hiv
eia
nat
one
case
confirm
two
case
identifi
indetermin
serolog
test
two
case
confirm
posit
us
armi
ranger
account
screen
event
roughli
us
armi
prescreen
event
ranger
regiment
elect
screen
blood
type
donor
elig
program
program
identifi
accuraci
blood
type
us
armi
ranger
us
armi
ranger
present
program
blood
type
group
conclus
screen
walk
blood
bank
donor
deploy
mitig
risk
diseas
well
provid
identif
group
donor
screen
walk
blood
bank
donor
inform
militari
medic
leader
front
line
assist
decis
regard
donor
elig
provid
fresh
whole
blood
fwb
auster
environ
use
fwb
point
injuri
poi
decreas
mortal
potenti
surviv
casualti
screen
potenti
donor
extend
avail
whole
blood
battlefield
backgroundcas
studi
project
focus
improv
whole
blood
compon
manufactur
includ
process
standard
increas
plasma
yield
reduc
wast
streamlin
workflow
introduc
compomat
product
studi
designmethod
comprehens
evalu
conduct
biolog
manufactur
team
process
includ
complet
sop
train
qualif
valid
implement
optim
equip
data
collect
use
oneblood
proprietari
bec
rsa
review
evalu
month
post
implement
plasma
volum
compar
manual
process
throughput
measur
time
oper
unload
complet
unit
reload
new
spun
wb
unit
multipl
unloadedreload
one
hour
allow
realist
full
day
labor
load
throughput
calcul
reduc
measur
data
data
evalu
month
post
implement
collect
two
site
resultsfind
custom
use
select
detector
test
bag
system
two
vendor
seven
compon
process
hardsoft
spin
sourc
leukocyt
pediatr
rbc
rbc
secondari
process
singl
cryo
singl
rdpsfsc
plasma
yield
increas
overal
compar
manual
process
yield
vari
process
type
centrifug
speed
site
use
hae
rcpl
bag
system
initi
soft
spin
secondari
hard
spin
rdp
increas
plasma
yield
achiev
use
hae
bag
system
initi
hard
spin
secondari
hard
spin
freezethaw
cryo
plasma
initi
increas
evalu
month
post
implement
site
averag
throughput
depend
averag
time
oper
unload
reload
unit
time
varianc
observ
depend
bag
system
complex
practic
number
use
two
oper
workload
produc
highest
throughput
secondari
process
singl
cryo
singl
rdp
unit
produc
per
hour
hard
spin
process
bag
type
two
oper
six
produc
unitshour
initi
soft
spin
process
rcpl
bag
system
plasma
filter
conclus
autom
whole
blood
compon
manufactur
allow
plasma
yield
standard
high
unit
throughput
increas
effici
plasma
yield
throughput
backgroundcas
studi
ef
gener
use
intercept
pathogen
reduct
pr
process
platelet
sinc
novemb
pr
process
includ
photochem
treatment
pct
amotosalen
ultraviolet
light
uva
follow
adsorpt
residu
amotosalen
compound
adsorpt
devic
cad
hour
object
evalu
effect
hour
delay
illumin
cad
step
platelet
qualiti
implement
delay
would
increas
flexibl
process
facilit
organ
product
studi
designmethod
two
ef
site
pacc
gest
prepar
pc
leukodeplet
pc
obtain
tacsi
process
terumo
bct
pool
intersol
freseniu
two
pc
pool
split
control
c
test
pc
treat
pr
larg
volum
set
ceru
illumin
immedi
transfer
cad
bag
hour
store
agit
transfer
cad
bag
vitro
paramet
platelet
wbc
content
mpv
ph
glucos
lactat
ldh
swirl
residu
amotosalen
assess
cad
step
storag
period
day
resultsfind
mean
platelet
content
ef
gest
ef
pacc
cad
oper
unit
present
maximum
swirl
storag
period
residu
amotosalen
concentr
less
mean
ph
day
differ
becam
similar
group
storag
period
sign
platelet
lysi
activ
compar
presenc
glucos
still
observ
day
group
conclus
storag
period
hour
illumin
contain
cad
treatment
nt
affect
qualiti
pc
day
delay
cad
bring
flexibl
daili
weekli
organ
pr
platelet
product
backgroundcas
studi
sinc
middl
east
respiratori
caus
case
human
infect
death
countri
saudi
arabia
affect
countri
case
local
death
rate
potenti
transmiss
clear
detect
infecti
viral
particl
genom
rna
whole
blood
serum
plasma
acut
infect
patient
make
pathogen
concern
safeti
blood
suppli
especi
endem
region
sever
line
evid
clinic
data
suggest
pathogen
reduct
amotosalen
ultraviolet
uva
light
technolog
effect
safe
treatment
blood
product
investig
efficaci
amotosalenuva
light
inactiv
human
platelet
concentr
safe
exclud
potenti
contamin
studi
designmethod
inocul
four
apheresi
platelet
unit
plasma
clinic
isol
four
differ
day
spike
unit
use
evalu
efficaci
amotosalenuva
intercept
blood
system
ceru
corpor
concord
usa
inactiv
platelet
concentr
infecti
genom
viral
titer
assess
plaqu
assay
respect
spike
treat
sampl
parallel
posit
neg
platelet
control
collect
sampl
also
inocul
vero
cell
three
consecut
passag
test
exclud
presenc
replic
inactiv
platelet
resultsfind
treatment
spike
platelet
unit
amotosalenuva
light
result
complet
inactiv
infecti
viral
titer
mean
log
reduct
pfuml
inocul
pretreat
sampl
cell
cultur
result
obviou
viral
replic
complet
cytopath
effect
cpe
within
day
similar
posit
control
viral
replic
cpe
observ
cell
inocul
inactiv
sampl
even
day
incub
three
success
passag
evalu
genom
titer
inactiv
sampl
show
almost
equival
titer
observ
pretreat
sampl
expect
conclus
amotosalen
uva
light
treatment
platelet
concentr
spike
effici
complet
inactiv
infecti
log
regulatori
label
claim
yet
suggest
treatment
platelet
amotosalen
uva
light
could
minim
risk
possibl
transmiss
endem
area
backgroundcas
studi
plateletpheresi
unit
must
store
c
maintain
viabil
storag
make
unit
suscept
bacteri
growth
could
fatal
patient
sinc
unit
collect
center
cultur
releas
identifi
unit
possibl
danger
transfus
recipi
review
process
illustr
effect
give
insight
risk
cultur
releas
process
studi
designmethod
product
record
review
june
cultur
process
initi
march
plateletpheresi
unit
held
hour
sampl
cultur
use
rapid
microbiolog
test
system
aerob
cultur
cultur
held
throughout
day
life
product
unit
avail
inventori
cultur
immedi
notif
system
fax
place
everi
custom
notif
unit
recal
need
notic
sent
immedi
sampl
becam
posit
cultur
bottl
give
posit
report
sent
nearbi
univers
microbiolog
laboratori
gram
stain
subcultur
identif
posit
evalu
probabl
sourc
gram
stain
subcultur
neg
growth
cultur
classifi
fals
posit
notif
cultur
outcom
sent
custom
ship
unit
report
transfus
resultsfind
fals
posit
unit
cultur
true
posit
total
waiv
cultur
except
releas
unit
requir
immedi
transfus
design
patient
test
unit
failur
process
discard
posit
cultur
product
trigger
action
includ
discard
blood
center
inventori
true
posit
collect
discard
process
notif
facil
receiv
posit
cultur
product
instruct
return
discard
unit
facil
notifi
regard
outcom
test
unit
report
transfus
collect
found
true
cultur
posit
alreadi
ship
five
collect
return
discard
five
posit
cultur
unit
transfus
notif
transfus
reaction
receiv
unit
conclus
notif
receiv
facil
true
posit
success
acknowledg
true
posit
like
skin
environment
contamin
group
contain
transfus
unit
signific
posit
cultur
collect
intercept
prior
shipment
remov
inventori
cultur
plateletpheresi
unit
hour
hold
conjunct
robust
commun
system
connect
facil
receiv
ship
blood
compon
effect
deterr
bacteri
contamin
advers
event
last
year
enhanc
cultur
techniqu
may
add
addit
assur
prevent
advers
event
contamin
platelet
backgroundcas
studi
new
donor
hemovigil
system
implement
octob
captur
sever
vasovag
reaction
vvr
program
donor
drink
water
eat
salt
snack
donat
implement
june
aim
studi
measur
effect
watersalt
snack
distribut
rate
vvr
without
loss
conscious
loc
studi
designmethod
pre
period
prior
implement
sep
jun
post
period
follow
implement
jun
mar
pre
donor
inform
registr
drink
water
donat
amount
mention
suppli
vari
empti
glass
donor
fill
water
tank
juic
box
water
bottl
noth
snack
offer
donat
mostli
sugari
june
program
introduc
collect
site
leaflet
poster
pictogram
inform
donor
import
drink
water
eat
salt
snack
given
water
bottl
bag
salt
pretzel
arriv
told
drink
whole
bottl
donat
eat
pretzel
check
point
monitor
consumpt
registr
interview
venipunctur
reinforc
made
check
point
bottl
empti
sever
vvr
report
standard
form
rate
vvr
calcul
per
donat
rate
compar
use
test
resultsfind
signific
reduct
number
rate
vvr
see
tabl
risk
reduct
vvr
conclus
captur
sever
vvr
allow
quick
evalu
prevent
program
whole
blood
donor
structur
program
water
salt
snack
deliveri
blood
collect
site
significantli
reduc
incid
vvr
sex
age
group
improv
donor
safeti
make
donat
experi
better
like
donor
return
backgroundcas
studi
daratumumab
darzalex
treatment
increasingli
use
therapeut
option
patient
multipl
myeloma
refractori
treatment
treatment
combin
patient
primari
diseas
lead
need
transfus
support
daratumumab
act
antibodi
unfortun
therapi
interfer
blood
bank
test
caus
panreact
due
bind
marker
rbc
membran
therefor
much
like
warm
autoantibodi
reactiv
may
mask
clinic
signific
underli
alloantibodi
dtt
treatment
remedi
interfer
howev
blood
bank
struggl
bring
protocol
instead
send
test
refer
lab
great
expens
term
cost
time
tat
purpos
studi
compar
dtt
protocol
versu
refer
lab
protocol
term
cost
time
studi
designmethod
retrospect
review
blood
bank
patient
daratumumab
therapi
februari
april
includ
patient
type
screen
perform
studi
period
collect
follow
data
age
sex
date
daratumumab
start
total
number
type
screen
locat
test
tat
test
patient
type
screen
perform
exclud
analysi
februari
decemb
type
screen
sampl
sent
refer
laboratori
test
cost
approxim
per
test
januari
current
use
valid
dtt
protocol
test
cost
approxim
dollar
per
test
includ
tech
time
reagent
cost
resultsfind
notifi
daratumumab
patient
might
requir
transfus
exclud
patient
analysi
due
lack
type
screen
order
leav
patient
analysi
sampl
sent
refer
lab
time
test
hous
time
averag
tat
refer
lab
hour
minut
compar
tat
hour
minut
equat
time
save
hour
minut
averag
total
spent
approxim
sampl
test
refer
lab
versu
test
sampl
conclus
valid
dtt
protocol
significantli
decreas
tat
type
screen
daratumumab
patient
popul
addit
experienc
signific
cost
save
bring
dtt
test
compar
send
sampl
refer
laboratori
bring
test
also
significantli
reduc
time
blood
avail
patient
popul
backgroundcas
studi
blood
donat
rel
safe
advers
event
occur
due
insert
larg
bore
needl
physiolog
respons
loss
roughli
ml
blood
andor
underli
condit
donor
common
advers
event
ae
vasovag
reaction
vvr
usual
resolv
spontan
minim
medic
intervent
loss
conscious
loc
accompani
vvr
donor
may
fall
risk
injuri
fall
result
signific
injuri
si
injuri
requir
medic
intervent
studi
designmethod
analyz
allogen
apheresi
wb
collect
month
vasovag
event
identifi
case
report
signific
injuri
base
classif
medic
director
consist
aabb
definit
report
signific
injuri
categori
includ
close
head
injuriesconcuss
dental
injuri
fractur
lacer
motor
vehicl
accid
mva
record
review
perform
report
case
close
head
injuri
includ
diagnos
concuss
rate
signific
injuri
calcul
per
ni
allogen
donat
overal
proport
loc
event
resultsfind
allogen
donat
vvr
rate
ni
includ
loc
rate
ni
reaction
si
event
donat
rate
ni
donat
loc
reaction
highest
rate
lacer
ni
concuss
ni
lowest
mva
ni
femal
suffer
injuri
male
respect
young
donor
yo
injuri
older
donor
yo
respect
p
first
time
donor
injuri
repeat
donor
respect
p
signific
differ
injuri
young
male
young
femal
donor
older
male
older
femal
donor
donor
sought
medic
intervent
injuri
except
donor
small
lacer
donor
broken
tooth
lost
conclus
signific
injuri
rare
event
associ
loc
case
record
signific
injuri
almost
alway
requir
medic
intervent
result
incur
cost
continu
donor
vigil
safeti
measur
prevent
loc
help
mitig
potenti
avoid
event
backgroundcas
studi
pgdprime
rapid
test
bacteria
platelet
develop
improv
test
current
use
safeti
measur
platelet
transfus
design
provid
simpler
test
procedur
compar
current
product
current
pgd
test
employ
intact
igg
captur
detector
antibodi
vulner
low
rate
fals
posit
result
sampl
contain
high
level
heterophil
antibodi
rheumatoid
factor
new
pgdprime
test
incorpor
intact
igg
captur
f
ab
fragment
detector
antibodi
test
line
well
stringent
sampl
prepar
regim
reduc
alreadi
low
fals
posit
fp
rate
studi
designmethod
specif
new
test
evalu
limit
studi
test
individu
platelet
unit
pool
variou
type
sampl
type
includ
apheresi
platelet
plasma
whole
blood
deriv
platelet
whole
blood
deriv
platelet
pool
lr
pool
whole
blood
deriv
platelet
pool
whole
blood
deriv
platelet
nlr
pool
apheresi
platelet
platelet
addit
solut
pa
addit
frozen
plasma
sampl
accumul
year
platelet
unit
identifi
fals
posit
user
current
pgd
test
run
new
test
determin
suscept
sampl
result
classifi
nonreact
initi
reactiv
ir
ir
sampl
retest
two
addit
devic
confirm
ir
result
devic
yield
reactiv
result
classifi
repeat
reactiv
rr
rr
sampl
consid
yield
confirm
fp
result
resultsfind
specif
test
result
platelet
unit
summar
tabl
addit
sampl
previou
fp
result
pgd
test
correctli
identifi
neg
test
use
pgdprime
test
conclus
limit
studi
show
pgdprime
specif
test
platelet
sampl
test
archiv
pgd
fals
posit
sampl
indic
pgdprime
react
vast
major
pgd
fals
posit
sampl
test
backgroundcas
studi
blood
transfus
mani
part
world
reli
serolog
screen
hepat
b
surfac
antigen
hbsag
prevent
transfus
transmit
hbv
infect
sensit
hbsag
assay
must
capabl
cope
wide
rang
mutant
without
compromis
specif
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
hbsag
develop
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
confirm
hbsag
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
sensit
evalu
use
known
posit
sampl
commerci
avail
seroconvers
panel
intern
hbsag
standard
hbsag
mutant
hbsag
genotyp
specimen
h
specif
evalu
sampl
obtain
random
blood
plasmapheresi
donor
resultsfind
within
laboratori
imprecis
less
cv
posit
sampl
day
test
overal
specif
sensit
presum
hbsag
posit
sampl
genotyp
mutant
detect
vs
licens
compar
assay
seroconvers
detect
compar
licens
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
analyt
sensit
rang
ngml
alin
hbsag
confirmatori
assay
confirm
posit
hbsag
specimen
includ
hbsag
mutant
sampl
confirm
licens
compar
hbsag
confirmatori
assay
conclus
new
autom
alin
hbsag
assay
provid
accept
perform
precis
specif
sensit
alin
assay
demonstr
gain
sensit
licens
compar
assay
detect
confirm
wider
rang
mutant
backgroundcas
studi
vasovag
sever
reaction
classifi
donor
sever
symptom
exampl
prolong
recoveri
faint
convuls
incontin
requir
medic
attent
mild
moder
reaction
accompani
injuri
also
includ
categori
donor
refer
hospit
observ
recent
year
number
sever
reaction
notic
rise
unpleas
undesir
trend
alarm
especi
advers
reaction
caus
blood
donor
injur
fall
fish
bone
diagram
use
identifi
factor
number
sever
reaction
age
gender
donat
histori
ethnic
highlight
studi
aim
analyz
preval
sever
reaction
past
year
find
differ
sever
reaction
demograph
age
donat
histori
donor
gender
malefemal
ethnic
chinesemalayindianoth
number
sever
reaction
studi
designmethod
retrospect
data
gather
hemovigil
report
whole
blood
donat
januari
octob
total
number
donat
perform
period
reaction
case
sever
reaction
requir
medic
attent
descript
analysi
inferenti
statist
use
chi
squar
use
find
differ
number
reaction
demograph
signific
threshold
set
resultsfind
incid
total
reaction
stood
number
sever
reaction
requir
medic
attent
hemovilgil
report
increas
percentag
sever
reaction
compar
vs
respect
rate
sever
reaction
higher
among
age
group
compar
age
group
vs
p
femal
experienc
sever
reaction
male
vs
p
repeat
donor
lesser
sever
reaction
donor
vs
p
indian
highest
number
sever
reaction
compar
chines
malay
ethnic
group
vs
vs
vs
respect
despit
rise
trend
demograph
variabl
found
statist
signific
number
sever
reaction
even
still
need
good
commun
import
proper
rest
hydrat
blood
donat
reinforc
proper
donor
care
staff
donor
need
address
well
conclus
donor
experienc
sever
reaction
result
blood
donat
may
rise
howev
show
differ
demograph
variabl
number
sever
reaction
nevertheless
donor
safeti
quintessenti
factor
blood
donat
optim
target
minim
rate
reaction
recogn
vulner
cohort
donor
donat
staff
take
extra
measur
commun
pre
post
donat
advic
group
staff
would
also
abl
anticip
reaction
henc
monitor
close
backgroundcas
studi
form
partnership
import
strategi
promot
blood
donat
support
donor
center
entir
commun
donor
center
strive
engag
meaning
lesbian
gay
transgend
queer
lgbtq
commun
also
compli
feder
regul
defer
male
sex
male
msm
last
month
univers
lgbtq
group
approach
donor
center
idea
host
blood
drive
highlight
current
msm
donor
regul
provid
other
opportun
voic
opinion
fda
work
group
organ
blood
drive
also
maintain
feder
regul
blood
donat
knowledg
publish
report
donor
center
support
lgbtq
sponsor
blood
drive
herein
describ
develop
partnership
evalu
merit
studi
designmethod
collabor
initi
univers
lgbtq
group
email
commun
follow
meet
plan
blood
drive
prior
drive
recruit
donor
center
medic
staff
lgbtq
group
leadership
review
criteria
donor
elig
import
product
safeti
also
divers
sensit
educ
donor
guidelin
provid
donor
collect
staff
lgbtq
group
use
flier
social
media
public
drive
member
member
subsequ
pledg
donat
elig
recruit
other
donat
person
inelig
group
provid
regulatori
materi
msm
donat
member
recruit
prior
donat
day
drive
allianc
set
tabl
outsid
donor
center
provid
inform
interest
particip
msm
regul
opportun
sign
petit
fda
resultsfind
partnership
result
success
implement
collabor
blood
drive
lgbtq
group
repeat
second
year
first
lgbtq
blood
drive
donat
collect
first
day
drive
donat
second
day
second
year
lgbtq
blood
drive
held
one
day
donat
collect
valu
compar
averag
daili
collect
donat
per
month
conclus
although
overal
donat
number
similar
blood
drive
success
build
commun
univers
lgbtq
group
meet
donor
center
lgbtq
group
goal
creat
ongo
collabor
futur
blood
drive
maintain
complianc
feder
regul
blood
drive
schedul
hope
draw
addit
donor
center
continu
support
hospit
valu
initi
care
lgbtq
commun
backgroundcas
studi
arm
servic
blood
program
asbp
establish
becam
fulli
oper
servic
organ
asbp
collect
process
store
distribut
blood
blood
product
soldier
sailor
airmen
marin
famili
worldwid
daili
basi
use
custom
servic
card
listen
need
custom
stakehold
measur
donat
experi
cadet
summer
train
blood
drive
consist
differ
regiment
blood
drive
juli
august
three
particip
asbp
donor
center
design
donor
center
donor
center
b
donor
center
c
coordin
accomplish
drive
process
ship
blood
compon
blood
must
ship
within
day
collect
oversea
locat
support
us
militari
oper
blood
drive
larg
comparison
normal
blood
drive
produc
unit
whole
blood
collect
studi
designmethod
comment
card
use
measur
cadet
donor
satisfact
length
time
took
donat
blood
comment
card
distribut
cadet
blood
donor
respons
rate
strongli
agre
data
given
score
agre
score
respons
percentag
multipli
score
determin
level
satisfact
donor
center
level
satisfact
compar
staf
model
mix
personnel
three
donor
center
use
drive
staf
model
differ
number
phlebotomist
interview
overal
personnel
resultsfind
three
staf
variabl
number
interview
seem
correl
directli
amount
satisfact
cadet
donor
amount
time
spent
donat
blood
overal
satisfact
rate
individu
donor
center
rate
rang
percent
total
staf
rang
personnel
number
phlebotomist
rang
littl
fluctuat
overal
satisfact
simpli
state
number
staff
member
perform
donor
interview
increas
donor
satisfact
increas
conclus
connect
interview
satisfact
use
plan
budget
execut
futur
cst
blood
drive
hope
asbp
might
keep
these
cadet
lifelong
donor
advoc
militari
program
backgroundcas
studi
granulocyt
factor
wide
use
prophylaxi
treatment
neutropenia
cancer
patient
also
peripher
blood
stem
cell
pbsc
mobil
collect
aim
studi
evalu
possibl
chang
platelet
surfac
antigen
inject
pbsc
donor
studi
designmethod
januari
decemb
healthi
voluntari
donor
pbsc
donat
buddhist
stem
cell
center
elig
prospect
studi
given
subcutan
day
peripher
blood
collect
complet
blood
count
platelet
surfac
antigen
sixteen
healthi
control
also
includ
comparison
multiparamet
flow
cytometri
immunophenotyp
studi
perform
resultsfind
decreas
platelet
count
found
pbsc
donor
compar
normal
subject
vs
p
platelet
size
measur
forward
scatter
fsc
also
smaller
pbsc
donor
vs
mean
fluoresc
intens
increas
pbsc
donor
vs
p
surfac
antigen
differ
pbsc
donor
healthi
control
adjust
fsc
data
mean
antigen
densiti
show
vs
p
vs
p
vs
vs
vs
respect
conclus
conclus
note
increas
densiti
platelet
surfac
antigen
mild
decreas
platelet
count
size
inject
associ
might
explain
thrombot
embol
event
inject
backgroundcas
studi
acut
lung
injuri
trali
common
caus
fatal
pathogenesi
trali
complet
understood
howev
leukocyt
antibodi
direct
human
leukocyt
antigen
hla
human
antigen
donor
plasma
implic
case
studi
shown
femal
donor
prior
pregnanc
hla
antibodi
hla
ab
reduc
risk
trali
current
standard
requir
plasma
apheresi
whole
blood
apheresi
platelet
ap
allogen
transfus
femal
histori
pregnanc
test
neg
hla
ab
understand
impact
hla
ab
test
analyz
return
rate
donor
histori
pregnanc
posit
hla
ab
test
studi
designmethod
femal
donor
posit
hla
ab
test
notifi
mail
result
ongo
elig
whole
blood
donat
donor
neg
hla
ab
recruit
ap
donat
return
rate
septemb
decemb
donor
test
hla
ab
compar
analyz
resultsfind
test
femal
histori
pregnanc
hla
ab
commun
donor
cd
direct
donor
dd
test
donor
hla
ab
posit
cd
hla
ab
posit
dd
hla
ab
posit
donor
test
test
neg
hla
ab
cd
dd
donor
test
hla
ab
posit
return
donat
whole
blood
cd
dd
overal
donor
test
neg
hla
ab
return
donat
ap
andor
whole
blood
cd
dd
hla
ab
posit
ap
cd
return
rate
wherea
hla
ab
neg
ap
cd
return
rate
tabl
conclus
result
indic
notif
posit
hla
ab
test
deter
donor
donat
futur
howev
histor
ap
donor
return
rate
similar
regardless
hla
ab
result
suggest
deter
backgroundcas
studi
algorithm
test
repeat
reactiv
rr
result
antibodi
hepat
c
chang
product
chiron
riba
hcv
sia
riba
discontinu
manufactur
riba
test
supplementalconfirmatori
test
licens
us
test
blood
donor
assay
still
avail
blood
center
test
rr
hcv
nat
neg
riba
current
test
algorithm
involv
test
sampl
found
rr
initi
test
chemiluminisc
assay
chlia
altern
screen
method
enzym
immunoassay
eia
sampl
rr
nat
hcv
posit
test
studi
designmethod
analyz
rr
rate
five
year
prior
five
year
discontinu
riba
order
see
signific
impact
donor
deferr
due
rr
nat
hcv
neg
blood
center
defer
donor
test
rr
regardless
result
supplement
confirmatori
test
current
reentri
protocol
place
howev
reentri
may
consid
six
month
indetermin
posit
riba
result
associ
hcv
lookback
posit
result
screen
method
also
associ
lookback
rr
rate
calcul
percentag
total
number
donor
per
year
result
supplementalconfirmatori
result
calcul
percentag
total
number
donor
per
year
well
percentag
rr
result
resultsfind
result
summar
tabl
conclus
discontinu
riba
major
impact
either
donor
deferr
subsequ
donor
notif
initi
lookback
hcv
percentag
rr
donor
test
posit
indetermin
riba
similar
percentag
test
posit
current
method
analysi
seem
case
previous
result
indetermin
may
fact
indic
detect
neg
rate
supplement
test
increas
riba
discontinu
conclud
certainti
sinc
sampl
test
current
method
point
view
donor
previous
notifi
indetermin
riba
result
categor
either
posit
neg
screen
test
may
lead
better
understand
hcv
test
result
backgroundcas
studi
blood
servic
group
bsg
implement
deriv
pool
platelet
buffi
coat
method
back
bsg
prepar
pool
platelet
use
convent
pool
kit
method
buffi
coat
unit
unit
plasma
centrifug
extractor
method
tediou
time
consum
signific
amount
manual
handl
march
bsg
adopt
use
tacsi
pl
kit
method
buffi
coat
unit
unit
plasma
tacsi
pl
system
pool
platelet
prepar
aim
improv
effici
platelet
prepar
process
studi
designmethod
studi
compar
qualiti
paramet
process
effici
workflow
switch
pool
platelet
prepar
process
tacsi
pl
system
qualiti
control
qc
paramet
data
year
period
convent
platelet
pool
kit
system
tacsi
pl
system
analys
qc
measur
studi
volum
ph
measur
residu
leukocyt
count
platelet
yield
steril
test
descript
statist
graphic
analysi
perform
use
microsoft
excel
total
time
number
staff
requir
process
typic
batch
unit
pool
platelet
two
differ
method
studi
workflow
space
requir
process
system
also
compar
resultsfind
qualiti
paramet
method
within
specifi
qc
criteria
signific
differ
total
process
time
batch
unit
pool
platelet
significantli
reduc
tacsi
pl
system
staf
requir
also
reduc
headcount
new
system
workflow
tacsi
pl
system
also
streamlin
fewer
step
shorter
walk
distanc
physic
pool
buffi
coat
easier
faster
method
compar
train
pool
method
previou
system
balanc
bucket
centrifug
tacsi
pl
system
longer
requir
equip
abl
space
requir
pool
platelet
process
accommod
equip
workbench
work
space
also
reduc
conclus
qualiti
indic
pool
platelet
use
tacsi
pl
system
equival
prepar
convent
pool
kit
tacsi
pl
system
streamlin
work
process
improv
significantli
oper
effici
backgroundcas
studi
donor
recruit
retent
pose
ongo
challeng
blood
bank
worldwid
intern
continu
need
new
blood
donor
meet
increas
demand
one
approach
improv
effect
donor
recruit
strategi
target
influenc
factor
studi
aim
identifi
percept
omani
youth
toward
blood
donat
order
identifi
factor
explain
intent
donat
blood
studi
designmethod
comprehens
anonym
voluntari
survey
develop
use
assess
percept
student
age
attend
sultan
qaboo
univers
squ
univers
two
year
period
analysi
perform
use
ibm
spss
statist
categor
variabl
present
number
percentag
associ
group
analyz
use
test
consid
statist
signific
resultsfind
total
student
survey
male
femal
donat
blood
previous
donor
donat
half
survey
student
thought
enough
knowledg
blood
donat
report
social
media
univers
main
sourc
knowledg
respect
educ
school
report
survey
student
influenc
parent
peer
report
respect
person
moral
altruism
report
awar
blood
bank
locat
blood
drive
report
squ
student
student
statist
signific
differ
motiv
discourag
factor
toward
blood
donat
squ
student
tabl
conclus
squ
student
report
higher
rate
motiv
lower
rate
discourag
factor
factor
toward
blood
donat
compar
student
reflect
influenc
increas
effort
improv
knowledg
blood
donat
recruit
among
student
squ
run
yearli
competit
colleg
blood
donat
need
extend
effort
societi
improv
awar
blood
donat
distinct
promot
strategi
adopt
increas
first
time
repeat
blood
donat
among
youth
backgroundcas
studi
canada
men
sex
men
defer
month
sinc
last
sexual
contact
risk
question
identifi
donor
msm
could
allow
low
risk
sexual
activ
msm
donat
individu
risk
assess
question
could
includ
donor
histori
questionnair
dhq
either
individu
identifi
donor
deferr
use
algorithm
identifi
individu
unclear
impact
altern
risk
question
would
donor
collect
survey
whole
blood
donor
determin
proport
would
answer
ye
potenti
altern
risk
question
rate
accept
ask
question
dhq
studi
designmethod
two
questionnair
develop
ask
potenti
individu
risk
question
recent
time
period
ask
donor
rate
comfort
answer
question
point
scale
week
period
januaryfebruari
whole
blood
donor
attend
collect
site
canada
invit
paper
questionnair
day
random
resultsfind
donor
attend
complet
donor
attend
complet
first
time
donor
like
answer
ye
risk
question
repeat
donor
tabl
p
although
said
use
condom
mani
donor
said
uncomfort
defin
somewhat
uncomfort
uncomfort
would
refus
donat
ask
anal
sex
dhq
uncomfort
question
conclus
risk
question
often
propos
altern
msm
histori
question
identifi
signific
proport
donor
particularli
new
donor
deferr
base
question
would
substanti
neg
impact
blood
collect
gener
particularli
recruit
new
donor
question
anal
sex
appear
sensit
backgroundcas
studi
pgdprime
test
bacteria
platelet
later
flow
assay
develop
improv
test
current
use
safeti
measur
platelet
transfus
simplifi
test
procedur
current
product
robust
sampl
matrix
variat
challeng
test
neg
posit
sampl
variou
matrix
condit
compon
level
higher
lower
expect
normal
rang
platelet
sampl
studi
designmethod
platelet
sampl
produc
potenti
interfer
level
list
tabl
test
use
blind
bacteri
spike
panel
compris
strain
bacteria
one
neg
panel
member
resultsfind
conclus
sampl
condit
test
interfer
bacteri
detect
creat
fals
posit
result
except
sampl
high
total
protein
immunoglobulin
level
produc
invalid
fals
posit
result
patient
abnorm
condit
would
infrequ
platelet
donor
backgroundcas
studi
sever
acut
respiratori
syndrom
sar
caus
zoonot
diseas
emerg
epidem
form
earli
china
spread
worldwid
month
caus
human
infect
nearli
death
novemb
septemb
although
current
confirm
report
transmiss
asymptomat
individu
recent
research
data
indic
least
theoret
possibl
studi
aim
investig
efficaci
theraflex
system
inactiv
platelet
concentr
pc
theraflex
system
macopharma
use
uvc
light
without
need
addit
photoact
compound
studi
designmethod
plasma
reduc
pc
bc
plasma
addit
solut
ssp
macopharma
spike
viru
suspens
vv
pc
ml
macotron
uv
machin
macopharma
sampl
taken
spike
load
hold
sampl
uvc
treatment
differ
dose
standard
titer
strain
frankfurt
determin
tissu
cultur
infect
dose
endpoint
titrat
vero
cell
atcc
resultsfind
result
infect
assay
demonstr
uvc
irradi
inactiv
spike
titer
bag
bag
receiv
pc
uvc
dose
higher
inactiv
detect
limit
system
result
reduct
factor
bag
bag
conclus
result
demonstr
theraflex
procedur
effect
technolog
inactiv
contamin
pc
backgroundcas
studi
pilot
studi
perform
intern
use
cell
antibodi
screen
retest
red
cell
antibodi
reactiv
rbc
unit
leukofiltr
addit
ml
use
integr
segment
data
suggest
rbc
unit
centrifug
hard
rpm
min
retest
neg
rbc
unit
centrifug
soft
rpm
min
retest
neg
base
data
institut
appli
receiv
fda
varianc
retest
rbc
unit
donor
antibodi
segment
retest
neg
rbc
unit
releas
gener
inventori
without
addit
label
antibodi
identif
benefici
local
transfus
servic
practic
dictat
limit
abil
transfus
rbc
studi
designmethod
red
cell
antibodi
test
perform
edta
sampl
use
immucor
pool
cell
reactiv
sampl
confirm
antibodi
screen
perform
use
ortho
mt
gel
plasma
product
discard
base
upon
origin
antibodi
screen
result
process
use
hard
spin
segment
obtain
rbc
unit
show
reactiv
retest
use
pool
group
cell
suspens
ortho
mt
gel
sampl
test
posit
sent
transfus
servic
routin
antibodi
id
specif
appli
tie
tag
attach
rbc
unit
sampl
retest
neg
pool
cell
screen
releas
inventori
antibodi
identif
perform
screen
reactiv
new
resultsfind
percentag
donat
retest
neg
vs
origin
studi
percentag
donat
retest
neg
vs
origin
studi
conclus
although
hard
soft
spin
process
red
cell
remov
red
cell
alloantibodi
hard
spin
effect
compar
pilot
project
cell
antibodi
screen
use
use
pool
cell
antibodi
screen
standard
current
practic
donor
test
laboratori
lead
lower
percentag
antibodi
posit
unit
practic
applic
instruct
insert
registr
record
donor
demonstr
rbc
antibodi
donat
collect
bag
set
ensur
theori
increas
composit
rate
donor
retest
neg
segment
backgroundcas
studi
weak
test
current
requir
prenat
patient
requir
blood
transfus
howev
still
requir
perform
rh
neg
babi
rh
neg
mother
assess
risk
immun
determin
rhig
candid
reagent
type
year
chang
weak
test
usual
perform
tube
method
new
technolog
gel
methodolog
may
sensit
detect
weak
phenotyp
routin
test
without
addit
incub
ahg
phase
therefor
possibl
laboratori
perform
routin
test
use
gel
methodolog
weak
tube
test
could
discontinu
even
rh
neg
babi
rh
neg
mother
enough
data
studi
designmethod
period
six
month
januari
june
cord
blood
sampl
test
three
differ
methodolog
cord
blood
found
rh
posit
rh
neg
cord
blood
test
use
autom
gel
methodolog
manual
gel
methodolog
tube
method
weak
incub
min
autom
gel
methodolog
perform
use
erytra
analyz
gel
card
manufactur
grifol
diagnost
tube
type
perform
use
seraclon
monoclon
blend
biorad
medic
diagnost
resultsfind
cord
blood
test
cord
found
rh
neg
found
rh
po
discrep
found
rh
neg
cord
blood
test
gel
tube
method
howev
rh
po
cord
blood
type
rh
neg
immedi
spin
tube
method
yield
use
gel
method
autom
manual
rh
po
cord
blood
weak
posit
ahg
phase
use
tube
method
rh
neg
cord
blood
gel
found
rh
posit
tube
method
therefor
prove
theori
weak
tube
test
requir
cord
blood
found
rh
neg
gel
method
conclus
gel
methodolog
abl
identifi
two
babi
rh
posit
without
test
howev
tube
test
primari
methodolog
test
ahg
would
still
requir
point
believ
gel
methodolog
would
detect
type
weak
partial
phenotyp
routin
test
therefor
primari
method
test
transfus
medicin
laboratori
gel
weak
tube
test
discontinu
cord
blood
test
backgroundcas
studi
singl
donor
platelet
sdp
deriv
apheresi
use
second
option
institut
due
higher
cost
pool
random
donor
platelet
concentr
pc
first
choic
reduc
patient
exposur
pc
origin
multipl
donor
associ
advers
effect
plateletpheresi
donat
subdivis
capabl
meet
annual
need
sdp
unit
establish
blood
bank
reason
sustain
product
mediat
clinic
advantag
use
sdp
pc
econom
effici
approach
also
key
factor
decis
make
regard
implement
donor
donor
borderlin
venou
access
entail
search
econom
effici
devic
adapt
wide
rang
donor
studi
designmethod
collect
effici
ce
rate
process
time
donor
adapt
exposur
anticoagul
acda
retrospect
compar
use
four
apheresi
devic
amicu
freseniu
cobe
spectra
terumo
bct
use
collect
set
well
spectra
optia
trima
terumo
bct
use
set
evalu
devic
applic
varieti
donor
categor
group
base
venou
access
group
difficult
manag
smallest
venou
diamet
resultsfind
analysi
includ
data
procedur
perform
devic
male
compris
donor
donor
averag
age
tbv
hematocrit
platelet
respect
ce
highest
spectra
optia
follow
trima
amicu
cobe
spectra
howev
trima
significantli
econom
effici
collect
yield
unit
compar
cobe
spectra
spectra
optia
amicu
respect
collect
rate
yielddur
trima
significantli
higher
devic
spectra
optia
cobe
spectra
amicu
respect
acda
volum
use
amicu
significantli
greater
system
p
spectra
optia
suitabl
sole
donor
group
donor
cobe
spectra
amicu
adapt
wider
rang
donor
group
trima
although
use
singl
needl
set
could
adapt
donor
due
abil
adjust
low
high
venou
resist
conclus
four
evalu
devic
trima
found
effici
yield
maxim
number
sdp
unit
compat
divers
donor
popul
provid
highest
collect
rate
minimum
acda
exposur
backgroundcas
studi
blood
donor
center
benefit
patient
make
blood
product
avail
routin
nation
blood
shortag
disast
hospit
base
blood
donor
center
collect
compris
apheresi
platelet
red
blood
cell
fresh
frozen
plasma
ffp
transfus
howev
platelet
expir
everi
year
due
short
life
span
day
plasma
collect
made
recov
plasma
product
less
use
less
cost
effect
product
surpass
transfus
need
hospit
process
need
improv
better
util
staff
resourc
avoid
wastag
maxim
blood
compon
product
studi
designmethod
qualiti
improv
began
octob
start
transfer
excess
product
fresh
frozen
plasma
ffp
unus
platelet
main
hospit
trauma
center
prior
expir
project
requir
obtain
larg
transport
cooler
valid
revis
standard
oper
procedur
sop
valid
ship
function
blood
bank
comput
system
creat
pack
slip
get
statist
report
revis
fda
registr
find
effici
cost
effect
way
obtain
wet
ice
red
cell
transport
dri
ice
ffp
transfer
establish
effect
commun
system
facil
reliabl
cost
effect
transport
product
final
freezer
purchas
store
ffp
collect
blood
donor
center
resultsfind
wastag
platelet
plasma
reduc
unit
platelet
ffp
product
increas
unit
save
occur
immedi
zero
save
challeng
includ
obtain
wet
ice
transport
red
blood
cell
dri
ice
ffp
reliabl
transport
effici
commun
receiv
facil
sever
innov
idea
tri
discard
final
solut
work
main
hospit
later
start
send
irradi
blood
product
transfus
servic
return
avoid
need
order
irradi
blood
product
blood
center
save
ad
extra
conclus
blood
product
transfer
initi
improv
blood
product
manag
cost
save
organ
whole
joint
initi
similar
depart
sister
institut
lead
substanti
qualiti
improv
shown
area
collabor
transfus
medicin
futur
blood
collect
therapeut
apheresi
stem
cell
collect
antibodi
identif
provis
compat
blood
product
complex
red
cell
platelet
antibodi
among
other
backgroundcas
studi
effort
mitig
incid
acut
lung
injuri
trali
aabb
recommend
measur
reduc
incid
transfus
high
plasma
volum
product
hpvp
donor
may
possess
hla
antibodi
given
multipar
women
higher
preval
hla
antibodi
major
hpvp
collect
male
donor
note
male
donor
pool
expand
decemb
fda
chang
polici
indefinit
deferr
men
sex
men
msm
deferr
last
sexual
encount
msm
elig
donat
presenc
hla
antibodi
could
implic
hpvp
donat
thu
aim
studi
determin
preval
hla
antibodi
amongst
cohort
msm
studi
designmethod
bank
serum
sampl
obtain
msm
enrol
emori
involv
studi
observ
cohort
studi
sexual
activ
msm
conduct
hla
antibodi
detect
flow
cytometri
screen
one
lambda
canoga
park
ca
result
class
class
ii
hla
antibodi
assess
entir
cohort
compar
control
resultsfind
serum
sampl
subject
test
overal
individu
posit
flowpra
screen
three
individu
class
antibodi
alon
class
ii
antibodi
alon
class
ii
antibodi
averag
pra
class
class
ii
msm
preval
hla
antibodi
similar
group
respect
among
male
class
antibodi
alon
class
ii
antibodi
group
class
antibodi
alon
class
ii
antibodi
alon
class
ii
antibodi
conclus
knowledg
first
descript
preval
hla
antibodi
among
sexual
activ
msm
found
approxim
msm
cohort
hla
antibodi
higher
previou
report
gener
male
blood
donor
popul
also
found
differ
preval
hla
antibodi
msm
indic
hla
sensit
impact
hiv
statu
data
provid
herein
may
prove
use
collect
test
practic
polici
msm
donor
particular
aabb
standard
stipul
previous
pregnant
women
donat
hpvp
provid
screen
hla
antibodi
neg
higher
preval
hla
allosensit
msm
compar
total
male
popul
warrant
consider
screen
msm
prior
hpvp
donat
backgroundcas
studi
univers
blood
screen
necessari
prevent
transfus
transmit
htlv
infect
ihtlv
ii
endem
countri
countri
select
test
may
avoid
unnecessari
deferr
donor
high
risk
return
travel
donor
born
countri
high
htlv
preval
blood
center
requir
high
throughput
ihtlv
ii
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
antibodi
htlviii
develop
studi
designmethod
perform
new
chemiluminesc
immunoassay
detect
antibodi
htlv
htlv
ii
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
use
htlv
htlv
ii
posit
sampl
specif
evalu
sampl
obtain
volunt
blood
donor
obtain
unit
state
sensit
evalu
use
preselect
ii
undifferenti
posit
specimen
sampl
individu
htlv
iii
associ
diseas
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
specimen
done
use
mp
diagnost
htlv
blot
resultsfind
imprecis
less
posit
sampl
day
test
clinic
sensit
specif
blood
donor
popul
conclus
new
autom
alin
htlv
iii
assay
provid
specif
sensit
compar
licens
compar
assay
result
indic
new
alin
autom
htlv
iii
assay
provid
accept
perform
specif
sensit
precis
backgroundcas
studi
transfus
transmit
malaria
remain
rare
seriou
complic
associ
blood
transfus
endem
countri
like
singapor
recent
evid
suggest
main
risk
introduc
malaria
blood
suppli
countri
donor
previou
resid
malaria
endem
area
donor
consid
low
level
parasitemia
asymptomat
malaria
antibodi
test
use
sever
countri
identifi
blood
donor
prevent
transfus
transmit
malaria
report
detect
malaria
dna
pcr
malaria
antibodi
donor
previou
resid
malaria
endem
area
studi
designmethod
donor
year
old
male
india
donat
time
singapor
deni
histori
malaria
infect
inform
blood
bank
last
visit
india
month
ago
donor
allow
donat
malaria
antibodi
test
pcr
perform
parallel
assess
malaria
risk
donor
resultsfind
result
show
malaria
antibodi
test
plasmodium
dna
use
pcr
detect
donor
sampl
sampl
sent
refer
laboratori
plasmodium
vivax
identifi
donor
donat
discard
immedi
contact
senior
medic
staff
inform
result
new
sampl
collect
one
week
repeat
test
show
result
donat
follow
sampl
sent
anoth
laboratori
perform
malaria
antibodi
test
show
result
use
differ
test
kit
result
investig
summar
tabl
donor
perman
defer
refer
infecti
diseas
clinic
evalu
manag
conclus
case
present
demonstr
transfus
transmit
malaria
still
occur
countri
perform
antibodi
test
screen
blood
donor
malaria
pcr
perform
parallel
antibodi
test
donat
donor
would
issu
use
may
transmit
malaria
patient
requir
blood
transfus
studi
requir
determin
incid
signific
antibodi
pcr
posit
case
especi
countri
wherein
signific
number
donor
previou
resid
malaria
endem
area
backgroundcas
studi
inventori
contain
rare
red
blood
cell
rbc
glycerol
use
meryman
manual
method
current
unit
deglycerol
use
cobe
outdat
need
replac
shortli
although
autom
cell
processor
integr
activ
glycerol
deglycerol
rbc
yet
valid
deglycerol
manual
glycerol
rbc
unit
studi
aim
optim
deglycerol
manual
glycerol
unit
use
autom
cell
processor
system
sinc
unit
still
manual
glycerol
current
oper
optim
also
includ
determin
optim
age
rbc
unit
moment
freez
studi
designmethod
twenti
manual
glycerol
rbc
unit
inventori
frozen
approxim
ten
year
thaw
water
bath
deglycerol
use
autom
cell
processor
system
acp
haemonet
suspend
separ
experi
addit
rbc
unit
manual
glycerol
day
per
group
unit
frozen
day
unit
thaw
deglycerol
acp
final
improv
recoveri
deglycerol
centrifug
step
test
compar
deglycerol
process
without
centrifug
pool
experi
test
condit
rbc
vitro
qualiti
assess
hour
deglycerol
resultsfind
deglycerol
unit
test
met
criteria
hematocrit
steril
hour
storag
hemolysi
still
lower
typic
obtain
unit
deglycerol
cobe
unit
met
criteria
hemolysi
hemoglobin
unit
howev
addit
centrifug
step
recoveri
could
improv
lower
averag
hemolysi
age
unit
time
glycerol
influenc
hemolysi
upon
deglycerol
inde
hemolysi
significantli
higher
unit
frozen
day
collect
compar
frozen
day
result
justifi
need
evalu
optim
time
unit
still
manual
glycerol
institut
set
experi
deglycerol
unit
compli
standard
hematocrit
hemoglobin
hemolysi
steril
long
glycerol
frozen
later
seven
day
conclus
rbc
unit
manual
glycerol
deglycerol
acp
autom
cell
processor
suspend
store
hour
met
vitro
qualiti
standard
steril
hematocrit
standard
hemolysi
met
everi
unit
vastli
improv
compar
routin
obtain
cobe
difficulti
reach
standard
hemoglobin
might
relat
centrifug
volum
limit
inde
centrifug
step
remov
excess
supernat
prior
deglycerol
acp
seem
improv
blood
qualiti
red
blood
cell
yield
thu
autom
cell
processor
use
deglycerol
rbc
unit
manual
glycerol
backgroundcas
studi
serolog
screen
antibodi
hepat
c
viru
hcv
often
conjunct
nucleic
acid
test
nat
use
worldwid
prevent
transfus
transmit
hcv
infect
nat
provid
improv
sensit
detect
hcv
window
serolog
test
provid
continu
detect
hcv
infect
individu
individu
resolv
infect
detect
hcv
rna
blood
plasma
center
requir
high
throughput
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safeti
blood
plasma
suppli
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
address
need
screen
assay
improv
autom
assay
detect
antibodi
hcv
develop
studi
designmethod
perform
immunoassay
detect
antibodi
hcv
evalu
next
gener
autom
platform
abbott
alin
reproduc
assess
day
use
posit
sampl
specif
evalu
sampl
obtain
volunt
blood
donor
plasmapheresi
donor
unit
state
sensit
evalu
use
preselect
posit
posit
chronic
infect
sampl
seroconvers
panel
confirm
repeatedli
reactiv
sampl
done
use
test
algorithm
consist
hcv
score
hcv
quantit
rna
assay
resultsfind
imprecis
less
cv
posit
sampl
test
day
clinic
sensit
preselect
specimen
seroconvers
sensit
better
licens
compar
evidenc
new
assay
identifi
earlier
bleed
seroconvers
panel
specif
blood
donor
plasmapheresi
sampl
conclus
result
indic
new
autom
alin
assay
provid
accept
perform
precis
specif
sensit
seroconvers
sensit
improv
relat
licens
compar
assay
backgroundcas
studi
sever
acut
respiratori
syndrom
sar
caus
zoonot
diseas
emerg
epidem
form
earli
china
spread
worldwid
month
caus
human
infect
nearli
death
novemb
septemb
although
current
confirm
report
transmiss
asymptomat
individu
recent
research
data
indic
least
theoret
possibl
studi
aim
investig
efficaci
theraflex
system
inactiv
human
plasma
theraflex
system
macopharma
use
methylen
blue
mb
combin
visibl
light
reduct
pathogen
infect
plasma
studi
designmethod
leukodeplet
plasma
prepar
whole
blood
use
standard
blood
bank
technolog
plasma
unit
spike
viru
suspens
vv
mblight
treatment
done
accord
manufactur
instruct
use
macotron
illumin
devic
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
titer
strain
frankfurt
determin
tissu
cultur
infect
dose
endpoint
titrat
vero
cell
atcc
resultsfind
spike
titer
bag
bag
receiv
plasma
unit
alreadi
lowest
test
light
dose
inactiv
detect
limit
system
result
reduct
factor
bag
bag
conclus
result
demonstr
theraflex
procedur
effect
technolog
inactiv
contamin
plasma
unit
backgroundcas
studi
establish
haemovigil
system
cover
entir
transfus
chain
import
ensur
safeti
suppli
blood
septemb
pilot
haemovigil
network
base
cloud
technic
built
oper
jiangsu
provinc
china
first
wide
area
haemovigil
network
hwan
china
studi
designmethod
hwan
softwar
standard
transfus
databas
develop
unifi
standard
collect
control
share
exchang
analyz
data
transfus
chain
mean
applic
middlewar
technolog
combin
manual
way
mechan
report
analyz
interv
transfus
advers
event
establish
oper
warn
inform
dispos
advic
issu
effici
emerg
respons
system
built
saa
servic
portal
connect
relev
particip
within
scope
hwan
resultsfind
septemb
end
march
taicang
blood
transfus
servic
issu
unit
blood
compon
unit
red
cell
unit
platelet
unit
total
ffp
unit
cryoprecipit
patient
transfus
unit
blood
compon
thu
blood
compon
pilot
site
trace
donor
recipi
vice
versa
donor
complic
among
blood
donat
patient
suffer
allerg
reaction
advers
incid
transfus
chain
report
captur
conclus
exemplari
hwan
cover
entir
transfus
chain
explor
work
perfectli
taicang
district
hv
cloud
china
first
region
hv
network
realiz
bidirect
monitor
intervent
activ
whole
blood
transfus
chain
meaning
practic
hwan
china
backgroundcas
studi
motiv
interview
effect
enhanc
blood
donor
retent
implement
may
costli
address
econom
challeng
conduct
two
studi
examin
impact
motiv
interview
content
donat
intent
deliv
onlin
survey
studi
designmethod
studi
one
respond
femal
mean
age
year
sd
year
complet
donat
commit
measur
randomli
assign
one
seven
motiv
question
control
group
studi
two
respond
femal
mean
age
year
sd
year
moder
level
donat
commit
randomli
assign
receiv
motiv
question
studi
futur
donat
intent
measur
immedi
follow
intervent
resultsfind
first
studi
reveal
signific
effect
interview
question
donat
intent
among
particip
moder
blood
donat
commit
f
p
among
low
commit
f
p
high
commit
f
p
studi
two
replic
signific
effect
interview
question
donat
intent
f
p
rel
control
condit
analys
reveal
significantli
higher
donat
intent
question
combin
p
conclus
find
provid
initi
support
survey
question
model
motiv
interview
content
may
elicit
person
reflect
posit
impact
donat
intent
particularli
among
individu
moder
level
donat
commit
backgroundcas
studi
blood
center
see
increas
amount
apheresi
platelet
product
reject
high
platelet
concentr
increas
occur
steadili
period
two
year
two
year
timefram
blood
center
discontinu
run
platelet
count
prior
platelet
pheresi
procedur
process
discontinu
order
streamlin
process
elimin
paper
reduc
laboratori
staff
interrupt
collect
day
donat
test
follow
day
averag
previou
three
platelet
count
use
program
instrument
current
donat
increas
platelet
reject
caus
decreas
amount
avail
product
loss
revenu
blood
center
studi
designmethod
team
led
qualiti
staff
develop
implement
plan
begin
obtain
day
donat
donor
pro
con
collect
lab
staff
evalu
significantli
chang
process
depart
paper
record
process
determin
would
implement
trial
period
three
month
evalu
determin
product
cost
save
resultsfind
signific
reduct
high
platelet
concentr
reject
demonstr
blood
center
reject
approxim
product
per
month
project
implement
center
realiz
reduct
product
reject
per
month
result
save
blood
center
approxim
per
month
annual
conclus
implement
obtain
day
donat
donor
platelet
count
result
decreas
reject
platelet
pheresi
product
signific
cost
save
backgroundcas
studi
apheresi
platelet
ap
collect
donor
center
limit
two
fix
collect
site
commun
blood
drive
limit
whole
blood
wb
donat
plan
commun
wb
drive
blood
center
evalu
opportun
hold
concurr
wb
ap
mobil
drive
discuss
hospit
center
first
combin
wb
ap
mobil
drive
step
maxim
effici
reduc
cost
mobil
platelet
drive
set
studi
designmethod
blood
donor
field
recruit
request
new
wb
mobil
drive
desir
region
counti
high
interest
ap
donat
day
request
oper
staff
visit
desir
mobil
collect
site
assess
space
donor
registr
donor
histori
segreg
wb
ap
collect
donor
recoveri
electr
outlet
locat
support
apheresi
machin
donor
center
leadership
set
weekli
meet
examin
feasibl
host
concurr
wb
ap
blood
drive
aspect
platelet
collect
requir
mobil
blood
drive
prerequisit
evalu
standard
oper
procedur
review
revis
includ
allow
ap
collect
mobil
drive
ap
suppli
equip
review
eas
transport
field
recruit
educ
recruit
adult
area
high
school
wb
drive
prescreen
abil
donat
multipl
product
hla
test
result
multipar
femal
donor
donat
historyr
blood
cell
loss
staf
mobil
drive
includ
wb
collect
staff
apheresi
oper
addit
oper
staff
mitig
unforese
issu
resultsfind
prescreen
donor
schedul
donat
time
slot
two
back
donor
one
backup
donor
ultim
donat
ap
donor
ap
donor
total
product
collect
includ
seven
platelet
unit
doubl
product
singl
product
wb
donat
four
six
hour
respect
platelet
unit
result
cost
save
unit
purchas
outsid
blood
supplier
platelet
collect
bolster
inventori
normal
low
collect
day
review
leadership
team
identifi
need
special
mobil
ap
collect
chair
conclus
donor
center
success
held
combin
wb
ap
mobil
drive
first
time
time
initi
plan
implement
week
approach
ap
donor
select
result
increas
ap
product
cost
effici
manner
backgroundcas
studi
obtain
fast
accur
test
result
essenti
hospit
base
donor
center
blood
product
label
avail
patient
use
sever
differ
autom
methodolog
avail
test
facil
want
compar
current
methodolog
solid
phase
autom
gel
system
studi
designmethod
compar
test
result
run
time
three
instrument
time
includ
put
sampl
rack
load
sampl
instrument
order
test
run
time
test
review
result
unload
sampl
aborh
test
includ
front
back
type
includ
weak
du
test
applic
confirm
test
forward
type
weak
du
test
applic
side
side
comparison
immucor
neo
current
methodolog
ortho
vision
perform
sever
day
ortho
vision
max
becam
avail
use
addit
run
perform
compar
turnaround
time
resultsfind
conclus
sampl
run
agreement
platform
antibodi
screen
abo
confirm
agreement
platform
aborh
test
process
time
antibodi
screen
aborh
minut
faster
vision
vision
maxx
neo
perform
confirm
test
time
took
vision
vision
maxx
institut
perform
confirm
test
test
benefici
us
remain
neo
backgroundcas
studi
consist
blood
suppli
support
transfus
reli
regular
repeat
volunt
blood
donat
studi
focus
donor
previous
defer
hb
level
better
understand
valu
suppli
educ
inform
action
donor
took
base
deferr
studi
designmethod
anonym
nation
survey
activ
inact
donat
past
month
donor
group
defer
low
hemoglobin
level
conduct
survey
question
assess
donor
action
prefer
regard
post
deferr
educ
understand
deferr
demograph
inform
analysi
perform
compar
categor
survey
result
donor
group
p
denot
statist
signific
resultsfind
survey
result
activ
inact
donor
respons
respect
activ
donor
like
recal
receiv
educ
materi
vs
take
iron
vitamin
supplement
vs
live
within
min
donor
site
vs
like
older
yr
vs
inact
donor
counterpart
activ
inact
donor
similar
p
anemia
histori
frequenc
predomin
vegan
mix
interest
receiv
inform
rais
hemoglobin
level
conclus
activ
donor
frequent
recal
receiv
educ
materi
low
hemoglobin
deferr
like
take
action
improv
hemoglobin
altern
method
recruit
consid
given
uncertain
valu
inform
compar
activ
vs
inact
donor
backgroundcas
studi
larg
commun
blood
center
ask
allogen
blood
donor
histori
pregnanc
screen
risk
acut
lung
injuri
health
histori
questionnair
almost
exclus
comput
rare
resort
manual
paper
donor
card
made
chang
word
question
pregnanc
adopt
recent
version
uniform
donor
histori
questionnair
late
studi
designmethod
answer
donor
pregnanc
question
januari
sept
review
compar
percent
women
age
answer
ye
whether
ever
pregnant
question
q
regard
pregnanc
reword
donor
screen
manual
exclud
studi
septemb
donor
ask
two
question
ever
pregnant
last
six
week
pregnant
pregnant
septemb
femal
donor
ask
one
combin
question
ever
pregnant
pregnant
look
two
subperiod
septemb
separ
singl
q
two
part
ever
pregnant
pregnant
occur
januari
resultsfind
first
studi
period
femal
donor
year
age
said
ye
ever
pregnant
second
studi
period
chang
q
number
drop
month
month
analysi
donor
respons
show
approxim
decreas
donor
answer
ye
question
ever
pregnant
follow
chang
format
question
two
separ
question
one
combin
question
pregnant
even
emphas
two
part
natur
new
q
minim
improv
observ
last
day
studi
period
femal
year
older
chang
answer
q
ye
hand
chang
answer
ye
precaut
blood
center
system
place
prevent
collect
apheresi
platelet
plasma
procedur
prevent
releas
transfus
plasma
product
return
femal
donor
previous
report
pregnant
even
answer
conclus
concern
femal
donor
either
confus
new
format
question
take
time
read
new
question
studi
could
reveal
effect
commun
strategi
relat
donor
questionnair
backgroundcas
studi
blood
shortag
holiday
especi
challeng
donor
center
transfus
servic
cogent
effort
made
minim
elect
surgeri
holiday
due
decreas
blood
donat
studi
done
analyz
differ
among
four
region
unit
state
month
septemb
decemb
regard
blood
suppli
level
blood
center
studi
designmethod
data
access
america
blood
center
databas
month
indic
number
blood
center
region
follow
west
midwest
south
east
blood
suppli
data
categor
day
day
day
n
number
day
repeat
measur
analysi
varianc
dunnett
pair
conduct
use
spss
ascertain
differ
among
four
region
studi
repeat
measur
analysi
independ
variabl
region
depend
variabl
day
blood
suppli
resultsfind
month
septemb
dunnett
test
reveal
signific
among
four
region
p
analyz
day
blood
suppli
month
decemb
dunnett
also
reveal
signific
among
four
region
p
mean
day
blood
suppli
region
east
midwest
south
west
mean
day
blood
suppli
region
east
midwest
south
west
mean
day
blood
suppli
region
east
midwest
south
west
blood
center
midwest
region
affect
short
blood
suppli
level
decemb
compar
three
region
eighteen
percent
center
day
blood
suppli
three
occas
five
occas
blood
center
west
region
highest
blood
suppli
level
report
day
day
suppli
christma
day
east
region
report
day
suppli
blood
blood
center
remain
three
region
report
blood
suppli
pair
perform
blood
shortag
categori
day
day
day
compar
month
decemb
month
septemb
signific
found
midwest
south
region
three
blood
suppli
categori
east
region
reveal
signific
day
categori
west
region
reveal
signific
differ
blood
suppli
categori
conclus
studi
compar
blood
suppli
level
holiday
month
month
across
four
region
unit
state
dunnett
determin
differ
region
day
blood
suppli
signific
pair
reveal
signific
differ
septemb
decemb
blood
suppli
level
midwest
south
east
west
region
midwest
averag
blood
center
day
blood
suppli
month
decemb
septemb
region
studi
prudent
continu
track
blood
suppli
level
donat
transfus
servic
across
countri
identifi
region
vulner
blood
shortag
backgroundcas
studi
gener
blood
donor
consid
healthi
popul
healthier
popul
part
blood
donor
screen
blood
pressur
check
qualifi
donor
blood
donat
criterion
blood
pressur
american
colleg
cardiologyamerican
heart
associ
task
forc
issu
new
blood
pressur
guidelin
new
guidelin
normal
blood
pressur
defin
mm
hg
work
tri
assess
rate
blood
donor
abnorm
blood
pressur
base
new
hypertens
guidelin
studi
designmethod
donor
inform
obtain
blood
center
donat
databas
period
januari
march
first
donat
time
use
donor
resultsfind
pleas
see
tabl
inform
blood
pressur
blood
donor
studi
period
variat
observ
differ
age
group
ethnic
background
conclus
base
snap
shot
studi
signific
number
blood
donor
abnorm
blood
pressur
base
new
hypertens
guidelin
studi
investig
need
confirm
find
assess
need
action
backgroundcas
studi
nowaday
psycholog
care
play
import
role
societi
colleg
student
major
blood
donat
popul
still
mani
easi
anxiou
advers
reaction
time
blood
donat
defici
medic
knowledg
accord
research
mental
stress
main
caus
advers
reaction
allevi
anxieti
blood
donor
among
colleg
student
becom
import
problem
research
aim
investig
influenc
psycholog
care
anxieti
medic
student
student
explor
appropri
mode
promot
educ
voluntari
blood
donat
enhanc
proport
fix
blood
donor
colleg
blood
donor
ensur
blood
suppli
meet
clinic
use
demand
studi
designmethod
student
comprehens
univers
region
citi
age
volunt
donat
blood
randomli
divid
observ
group
control
group
student
group
observ
group
medic
student
student
control
group
medic
major
student
major
student
control
group
given
routin
blood
donat
nurs
observ
group
given
psycholog
care
treatment
control
group
observ
group
score
anxieti
scale
sa
collect
case
advers
reaction
record
respect
resultsfind
observ
group
sa
score
collect
medic
student
student
significantli
decreas
donat
p
respect
control
group
sa
score
obviou
chang
donat
p
whether
medic
student
student
incid
advers
reaction
control
group
higher
observ
group
p
incid
advers
reaction
major
volunt
higher
medic
major
volunt
observ
group
control
group
respect
p
incid
advers
reaction
medic
student
control
group
higher
medic
student
observ
group
p
conclus
psycholog
care
effect
allevi
anxieti
emot
volunt
univers
especi
major
student
advers
reaction
prevent
donat
differ
method
nurs
includ
convent
care
psycholog
care
chosen
accord
actual
situat
time
effect
holist
psycholog
care
deserv
promot
allevi
anxieti
emot
incid
revers
reaction
volunt
necessari
establish
scientif
effect
mode
promot
educ
psycholog
counsel
voluntari
blood
donat
backgroundcas
studi
time
platelet
administr
drive
blood
bank
inventori
stabl
platelet
inventori
ensur
time
deliveri
blood
product
challeng
maintain
tertiari
care
center
demand
emerg
prophylact
platelet
transfus
ppt
activ
surgic
oncolog
unit
respect
high
volum
overnight
ppt
lead
earli
morn
inventori
shortag
last
hour
particularli
inventori
shipment
occur
regular
busi
hour
delay
transfus
emerg
situat
addit
overnight
ppt
increas
patient
sleep
interrupt
reason
studi
designmethod
singl
inpati
oncolog
unit
found
highest
contributor
number
overnight
platelet
transfus
prophylact
transfus
medicin
oncolog
physiciansnurs
partner
leader
patient
well
initi
explor
reason
delay
overnight
ppt
analysi
demonstr
daili
lab
drawn
overnight
led
ppt
order
abnorm
cbc
result
hour
later
solut
postpon
lab
draw
implement
statist
analysi
signific
use
test
perform
percentag
valu
resultsfind
postpon
lab
draw
inpati
oncolog
unit
led
signific
reduct
proport
overnight
platelet
transfus
ppt
also
decreas
frequenc
platelet
inventori
shortag
conclus
partnership
laboratori
clinic
staff
identifi
simpl
yet
impact
solut
reduc
overnight
ppt
postpon
laboratori
collect
time
chang
time
lab
draw
shift
time
platelet
administr
stabil
platelet
inventori
collabor
clinic
staff
oncolog
unit
well
lead
patient
well
initi
help
frame
project
goal
greater
context
project
util
clinic
multidisciplinari
approach
blood
bank
qualiti
improv
appli
hospit
unit
transfus
medicin
servic
backgroundcas
studi
larg
level
trauma
site
set
goal
blood
wastag
april
temperatur
indic
implement
red
blood
cell
rbc
year
end
wastag
correct
action
prevent
action
capa
request
hospit
qualiti
see
could
done
decreas
product
wastag
studi
designmethod
transfus
servic
ts
reach
clinic
staff
review
process
order
receiv
storag
oper
room
transfus
return
blood
product
wastag
data
evalu
servic
line
determin
product
wast
well
number
product
sent
return
resultsfind
three
area
focu
identifi
massiv
transfus
protocol
mtp
temperatur
indic
handl
blood
product
mtp
wastag
expect
cryoprecipit
cryo
discard
hospit
system
decid
updat
mtp
cycl
star
cryo
cycl
subsequ
even
cycl
rather
everi
cycl
discuss
staff
determin
inconsist
notif
ts
mtp
deactiv
result
addit
plasma
cryo
thaw
wast
nurs
unit
rbc
return
patient
immedi
abl
transfus
commun
sent
remind
nurs
staff
ensur
consent
sign
vital
taken
transfus
line
establish
prior
request
blood
also
short
delay
expect
better
keep
unit
floor
start
transfus
soon
possibl
long
complet
within
hour
post
issu
wastag
enter
error
manag
system
includ
associ
cost
product
data
collect
servic
line
show
biggest
offend
return
wast
blood
product
share
transfus
committe
meet
guilt
offend
improv
order
habit
august
unit
sent
cardiac
surgeri
return
neg
blood
remot
store
review
resuppli
process
found
unit
place
storag
time
manner
ts
began
track
notifi
replac
product
sent
via
tube
system
hold
individu
respons
time
storag
decreas
wastag
well
number
return
unit
seen
sever
month
start
septemb
conclus
although
wastag
caus
ts
correct
action
expect
led
ts
data
abl
show
clinic
staff
specif
pattern
help
drive
need
chang
understand
clinic
ts
side
transfus
key
understand
improv
need
associ
dollar
figur
wastag
way
get
clinic
staff
understand
impact
blood
product
wastag
backgroundcas
studi
platelet
product
intend
reduc
risk
bacteri
prolifer
potenti
bacteri
infect
consequ
platelet
high
rate
wastag
due
expir
problemat
valuabl
resourc
term
therapeut
benefit
cost
recent
food
drug
administr
fda
publish
second
draft
guidanc
concern
bacteri
risk
control
strategi
permit
use
rapid
bacteri
detect
devic
extend
apheresi
platelet
product
given
expect
final
regulatori
chang
object
studi
evalu
econom
impact
concern
acquisit
cost
wastag
apheresi
platelet
implement
rapid
bacteri
test
larg
academ
medic
center
studi
designmethod
conduct
retrospect
review
apheresi
platelet
acquisit
cost
wastag
due
expir
two
success
time
point
implement
rapid
bacteri
test
rbt
bacteri
test
perform
apheresi
platelet
unit
per
fda
guidelin
platelet
unit
wast
due
expir
day
owe
approv
storag
contain
exclud
studi
resultsfind
period
implement
rbt
apheresi
platelet
unit
expir
purchas
translat
expir
rate
convers
annual
data
follow
rbt
implement
result
apheresi
platelet
unit
expir
platelet
unit
purchas
translat
expir
rate
correspond
reduct
platelet
unit
wast
annual
direct
cost
rbt
equal
use
mean
apheresi
platelet
unit
cost
report
aabb
blood
survey
report
account
direct
cost
rbt
implement
rbt
correspond
project
annual
cost
save
institut
conclus
larg
academ
medic
center
introduct
rapid
bacteri
test
led
signific
reduct
apheresi
platelet
acquisit
cost
wastag
due
expir
find
suggest
rapid
bacteri
test
simultan
enhanc
safeti
apheresi
platelet
transfus
contribut
signific
cost
save
backgroundcas
studi
februari
nac
blood
blood
product
publish
statement
recommend
cmv
safe
leukoreduc
cmv
igg
seroneg
product
consid
equival
except
intrauterin
transfus
nac
recommend
canadian
blood
servic
stop
provid
cmv
seroneg
unit
hospit
develop
new
process
maintain
small
inventori
cmv
seroneg
compon
sole
purpos
intrauterin
transfus
given
municip
public
system
exclus
use
leukoreduc
product
support
organ
stem
cell
transplant
program
infrequ
preform
intrauterin
transfus
one
facil
implement
nac
recommend
might
reason
option
reduc
laboratori
cost
without
jeopard
patient
safeti
sought
evalu
potenti
cost
save
adopt
nac
cmv
recommend
studi
designmethod
annual
blood
product
order
sole
supplier
analyz
determin
number
cvm
seroneg
rbc
sdp
purchas
associ
addit
cost
cmv
enhanc
actual
cost
compar
evalu
determin
impact
longer
offer
order
provid
option
request
cmv
seroneg
addit
alreadi
cmv
safe
leukoreduc
blood
product
receiv
resultsfind
system
purchas
rbc
sdp
total
product
cmv
upcharg
rbc
sdp
system
spent
cvm
seroneg
rbc
sdp
total
wide
variat
purchas
sdp
system
mean
rang
variat
also
observ
rbc
purchas
system
mean
rang
conclus
adopt
recommend
nac
system
could
save
approxim
year
current
cmv
seroneg
upcharg
rate
per
rbc
per
sdp
without
neg
impact
patient
safeti
chang
would
howev
decreas
overal
blood
spend
backgroundcas
studi
blood
center
support
sickl
cell
diseas
scd
program
children
adult
patient
donor
patient
past
sever
year
howev
need
increas
number
donor
system
complet
phenotyp
meet
need
custom
studi
assess
nearli
year
molecular
genotyp
predict
phenotyp
nearli
blood
donor
studi
designmethod
donor
sampl
submit
molecular
genotyp
follow
common
blood
group
antigen
c
c
e
e
v
vs
k
k
kp
kp
b
js
js
b
fy
fy
b
jk
jk
b
n
u
lu
lu
b
b
jo
hy
co
co
b
di
di
b
yt
yt
b
cr
vel
molecular
genotyp
perform
outsid
vendor
use
current
unlicens
laboratori
develop
test
ldt
predict
phenotyp
base
upon
singl
nucleotid
polymorph
snp
analysi
also
test
molecular
chang
rhd
rhce
gypb
intron
fy
b
could
identifi
variant
weakli
express
antigen
result
electron
transfer
blood
establish
comput
system
bec
select
valid
data
perform
immunohematolog
refer
laboratori
irl
staff
resultsfind
tabl
show
neg
antigen
frequenc
donor
popul
compar
publish
frequenc
gener
popul
except
fy
higher
publish
antigen
frequenc
sort
donor
popul
caucasian
african
american
follow
antigen
neg
frequenc
higher
caucasian
popul
importantli
african
american
donor
sever
antigen
higher
publish
neg
antigen
frequenc
includ
follow
fy
co
yt
see
tabl
also
identifi
rare
donor
conclus
program
util
autom
molecular
assay
enabl
us
better
identifi
donor
scd
patient
popul
rare
donor
identifi
report
serolog
phenotyp
confirm
american
rare
donor
program
ardp
plan
continu
screen
process
next
sever
year
major
donor
base
molecularli
genotyp
backgroundcas
studi
maintain
adequ
platelet
inventori
mani
center
one
blood
product
supplier
differ
supplier
may
differ
manufactur
process
may
influenc
product
characterist
great
effort
put
understand
platelet
characterist
better
inform
clinic
practic
develop
hospit
level
platelet
activ
statu
use
character
platelet
compon
qualiti
function
studi
suggest
high
microparticl
mp
content
platelet
compon
indic
high
level
platelet
activ
may
limit
effect
prophylact
platelet
transfus
prepar
qualiti
improv
project
treat
hematologyoncolog
patient
low
mp
platelet
unit
investig
variabl
platelet
activ
rate
two
differ
blood
supplier
larg
academ
tertiari
care
center
studi
designmethod
platelet
activ
statu
determin
assess
microparticl
content
mp
use
dynam
light
scatter
thrombolux
lightintegra
technolog
inc
vancouv
canada
activ
statu
platelet
unit
report
base
threshold
mp
mp
content
equal
greater
consid
activ
platelet
fragment
exceed
predetermin
threshold
mp
identifi
blood
supplier
inform
captur
donat
identif
number
resultsfind
test
total
apheresi
platelet
product
plasma
consist
supplier
supplier
b
supplier
known
collect
platelet
amicu
cell
separ
supplier
b
use
trima
accel
platelet
collect
platelet
supplier
supplier
b
contain
mp
identifi
activ
first
month
qualiti
improv
initi
alloc
primarili
platelet
prophylact
transfus
averag
usag
platelet
per
patient
reduc
averag
baselin
usag
feb
may
conclus
found
high
variabl
platelet
activ
rate
base
mp
content
supplier
may
explain
differ
cell
separ
technolog
use
supplier
line
literatur
platelet
activ
statu
thu
residu
mp
may
higher
platelet
product
obtain
amicu
goal
continu
qualiti
improv
effort
determin
clinic
impact
test
platelet
activ
statu
alloc
platelet
treatment
hematologyoncolog
patient
backgroundcas
studi
sinc
emerg
aid
epidem
mani
advanc
blood
donat
screen
contribut
toward
blood
safeti
prevent
transfus
infect
howev
risk
still
exist
develop
pathogen
reduct
pr
technolog
provid
inactiv
mani
agent
target
regular
screen
routin
eg
zika
arbovirus
endem
countri
therefor
decid
adopt
proactiv
strategi
introduc
pr
technolog
platelet
compon
reduc
safeti
gap
emerg
pathogen
analyz
impact
technolog
routin
mainli
strength
weak
inventori
studi
designmethod
jan
mar
avail
platelet
apheresi
aph
random
donor
rd
treat
ceru
corpor
product
transfus
demand
compar
immedi
previou
year
resultsfind
pr
implement
total
platelet
dose
defin
avail
treat
intercept
total
transfus
transfusion
episod
te
due
pediatr
patient
requir
smaller
dose
whilst
discard
expir
untreat
transfus
dose
due
emerg
case
avail
treat
dose
moment
addit
te
partial
dose
tpd
transfus
due
limit
suppli
moment
prescript
agreement
prescrib
physician
prescrib
patient
period
transfus
total
partial
untreat
dose
period
implement
total
platelet
dose
avail
render
te
discard
also
tpd
due
limit
suppli
data
shown
tabl
conclus
despit
increas
number
transfus
platelet
pr
introduct
abl
reduc
number
discard
unit
period
dose
inventori
due
stringent
inventori
control
collect
transfus
reason
save
final
budget
due
high
cost
pr
great
challeng
assur
suppli
situat
greater
demand
disast
sinc
servic
countri
implement
technolog
far
backgroundcas
studi
american
rare
donor
program
ardp
membership
aabb
accredit
immunohematolog
refer
laboratori
irl
mani
ardp
member
frozen
donor
red
cell
product
interest
ardp
advisori
committe
determin
practic
freez
rare
red
cell
studi
designmethod
survey
sent
ardp
member
assess
practic
involv
rare
unit
donor
includ
freez
practic
expir
date
extens
donor
recruit
survey
consist
question
list
resultsfind
survey
respons
receiv
ardp
member
respond
member
freez
unit
neg
high
preval
antigen
facil
use
frequenc
decid
unit
freez
abo
type
play
role
decis
respond
freez
multipl
antigen
neg
rare
unit
rhce
variant
freez
autolog
unit
member
split
storag
time
freez
freez
within
day
store
expir
date
freez
unit
member
consid
either
option
depend
rariti
unit
concern
frozen
unit
unlicens
member
instrument
close
system
freez
thaw
use
member
facil
thought
implement
plan
implement
target
recruit
use
facil
respond
gener
rare
donor
recruit
use
older
unit
codabar
label
inventori
neg
antigen
high
preval
multipl
antigen
neg
facil
frozen
autolog
unit
member
facil
extend
expir
date
beyond
year
rare
product
conclus
practic
vari
greatli
throughout
membership
howev
appear
consensu
high
preval
antigen
neg
unit
frozen
possibl
donor
recruit
specif
target
member
half
member
extend
expir
date
rare
unit
retain
rare
type
inventori
beyond
gener
use
storag
time
backgroundcas
studi
hemorrhag
event
clinician
often
stockpil
blood
product
bedsid
abrupt
end
massiv
transfus
protocol
mtp
return
product
result
wast
rbc
wast
maintain
refriger
temperatur
plasma
brought
c
thaw
inevit
wast
cool
requir
c
implement
hemoroam
mobil
blood
storag
refriger
mbr
roemer
industri
sante
ca
transfus
event
univers
health
system
includ
hospit
level
trauma
center
obstetr
servic
liver
transplant
servic
inpati
bed
transfus
volum
rbc
unit
annual
evalu
impact
blood
product
wastag
studi
designmethod
approv
fund
obtain
hospit
administr
mbr
purchas
valid
new
standard
oper
procedur
sop
mbr
implement
blood
issu
sop
updat
mbr
pilot
liver
transplant
program
usag
subsequ
expand
entir
health
system
includ
mtp
transfus
event
upon
request
stakehold
includ
liver
transplant
team
oper
room
staff
receiv
train
use
mbr
usag
trend
wast
rbc
plasma
unit
month
august
march
august
march
mbr
implement
evalu
resultsfind
new
mbr
system
use
time
institut
august
march
liver
transplant
apheresi
either
plasma
rbc
exchang
trauma
remain
case
use
team
includ
emerg
medicin
obstetr
critic
care
usag
mbr
increas
time
overal
averag
timesday
rang
septemb
februari
wast
rbc
plasma
fraction
total
rbc
plasma
issu
averag
implement
rang
per
month
implement
rang
per
month
rate
decreas
plasma
decreas
rbc
decreas
cost
per
red
cell
unit
per
plasma
unit
cost
save
base
improv
averag
wastag
per
month
total
month
conclus
implement
mbr
mtp
transfus
decreas
wast
blood
product
larg
enabl
thaw
plasma
return
inventori
benefit
includ
save
technologist
time
discard
unit
receiv
new
unit
better
stewardship
donat
product
mbr
increasingli
util
clinician
backgroundcas
studi
public
address
sustain
red
blood
cell
suppli
suffici
differ
dynam
red
blood
cell
apheresi
platelet
usag
consid
separ
review
experi
meet
inventori
demand
product
although
challeng
meet
group
red
blood
cell
inventori
overal
red
blood
cell
demand
reduc
significantli
effect
patient
blood
manag
apheresi
platelet
howev
demand
sustain
reflect
fact
indic
often
prophylact
sinc
effect
time
age
red
blood
cell
donor
base
collect
demonstr
decid
see
similar
consider
appli
apheresi
donor
base
also
decid
find
extent
recent
restrict
donat
women
histori
pregnanc
effect
particip
apheresi
platelet
donor
studi
designmethod
review
apheresi
platelet
donor
apheresi
platelet
distribut
record
donor
classifi
age
gender
number
donor
differ
age
bracket
express
percentag
annual
total
number
donor
year
also
express
percentag
contribut
age
bracket
made
annual
total
apheresi
platelet
inventori
resultsfind
age
bracket
includ
apheresi
platelet
donor
increas
progress
year
bracket
year
year
apheresi
platelet
donor
year
age
older
percentag
rose
respect
increas
relianc
see
tabl
older
donor
percent
contribut
annual
inventori
year
old
donor
decreas
half
first
full
year
restrict
femal
donor
histori
pregnanc
compar
male
donor
apheresi
platelet
contribut
annual
inventori
increas
femal
contribut
decreas
conclus
signific
age
apheresi
donor
base
relianc
older
donor
thwart
near
futur
like
patient
like
continu
apheresi
donor
restrict
femal
donor
signific
effect
particip
apheresi
donor
ensur
sustain
apheresi
platelet
inventori
program
understand
donor
age
domin
contributor
previous
rel
inaccess
donor
backgroundcas
studi
industri
standard
insul
shipper
design
maintain
red
blood
cell
rbc
unit
c
transport
use
wet
ice
cool
sourc
rbc
bag
payload
direct
contact
wet
ice
detriment
effect
integr
red
blood
cell
maximum
allow
transport
durat
rbc
shipper
vari
base
amount
type
locat
cool
materi
develop
valid
blood
center
case
shipper
valid
requir
measur
temperatur
payload
requir
period
time
expos
fulli
pack
shipper
differ
ambient
profil
howev
placement
temperatur
probe
standard
therefor
vari
across
blood
center
studi
aim
understand
demonstr
effect
payload
volum
temperatur
probe
placement
shipper
valid
studi
designmethod
seri
experi
perform
cardboardstyrofoam
shipper
pack
lb
wet
ice
repres
volum
dimens
water
bag
use
substitut
rbc
unit
number
payload
unit
vari
determin
effect
payload
volum
measur
payload
temperatur
payload
unit
place
vertic
insid
payload
holder
bag
wet
ice
place
top
payload
holder
insid
shipper
nist
calibr
devic
use
record
temperatur
everi
minut
differ
locat
insid
shipper
shipper
place
insid
programm
environment
chamber
expos
transient
temperatur
profil
repres
summer
winter
condit
hour
simul
ambient
temperatur
transit
temperatur
payload
differ
locat
shipper
function
time
record
configur
numer
thermal
simul
use
finit
volum
method
fvm
softwar
also
perform
visual
temperatur
distribut
key
configur
comparison
insul
shipper
specif
design
phase
chang
materi
test
similar
ambient
condit
resultsfind
temperatur
record
cardboardstyrofoam
shipper
test
wet
ice
show
variat
payload
differ
locat
insid
shipper
summer
winter
ambient
test
respect
test
result
present
tabl
identifi
import
temperatur
probe
placement
shipper
valid
conclus
placement
temperatur
probe
signific
effect
shipper
valid
durat
data
corrobor
fvm
simul
demonstr
import
choos
appropri
point
temperatur
measur
also
consid
payload
volum
measur
method
backgroundcas
studi
develop
nation
remot
area
transport
blood
often
inconveni
owe
poor
infrastructur
geograph
barrier
issu
blood
unit
taken
back
blood
bank
concern
short
shelf
life
cold
chain
thu
dilemma
blood
storag
hospit
remot
area
blood
storag
littl
blood
suppli
shortag
blood
storag
much
much
higher
blood
expir
wast
result
caus
bottleneck
blood
suppli
decreas
blood
avail
promot
blood
suppli
manag
effici
ensur
blood
avail
remot
area
internet
thing
iot
blood
cold
chain
monitor
system
develop
studi
designmethod
rfid
card
attach
red
blood
cell
unit
bag
monitor
cold
chain
red
blood
cell
unit
store
remot
hospit
due
expir
day
taken
back
redistribut
nearbi
hospit
necessari
test
studi
collect
data
use
new
monitor
system
four
island
hospit
analyz
data
blood
expir
statist
method
resultsfind
sinc
new
monitor
system
deploy
among
four
hospit
remot
island
inhabit
red
blood
cell
unit
storag
increas
incid
emerg
blood
collect
suppli
decreas
eight
year
prior
use
new
monitor
system
one
year
sinc
use
new
monitor
system
thu
blood
avail
increas
significantli
also
comparison
time
span
number
expir
red
blood
cell
unit
decreas
expiri
rate
declin
differ
expiri
rate
hospit
use
new
monitor
system
signific
p
advers
report
reus
blood
unit
conclus
applic
internet
thing
promot
blood
avail
blood
suppli
manag
effici
remot
area
backgroundcas
studi
blood
inventori
manag
tricki
challeng
process
consid
absenc
real
constraint
control
blood
issu
upon
need
therefor
maintain
balanc
guarante
blood
avail
minim
wastag
continu
demand
make
sure
product
use
effect
effici
king
hussein
cancer
center
khcc
blood
bank
blood
unit
donat
year
cover
khcc
patient
demand
minimum
stock
limit
blood
type
govern
amount
donat
accept
daili
basi
accord
jordanian
abo
distribut
figur
daili
total
minimum
stock
limit
establish
base
current
patient
need
review
least
annual
blood
unit
adjust
twice
sinc
base
increas
demand
aim
studi
examin
khcc
inventori
manag
perform
order
consid
appropri
guidelin
best
practic
improv
effici
blood
bank
servic
studi
designmethod
retrospect
review
inventori
monitor
record
first
quarter
done
figur
analyz
use
two
import
measur
issuabl
stock
index
isi
approxim
number
day
unreserv
stock
blood
group
held
inventori
wastag
percentag
issu
wapi
present
stock
wastag
data
isi
wapi
calcul
base
follow
formula
isinumb
unreserv
red
cell
unit
group
number
red
cell
unit
issu
yearnumb
day
year
wapi
number
unit
wastednumb
unit
issu
anova
use
test
differ
three
mean
resultsfind
averag
isi
first
quarter
respect
wapi
percentag
vari
though
minimum
daili
stock
limit
increas
averag
isi
remain
compar
differ
also
compar
three
year
wapi
show
conclus
vital
respons
blood
bank
ensur
donat
blood
use
minim
wast
suffici
stock
avail
deal
emerg
effect
inventori
manag
procedur
relay
simpl
daili
monitor
blood
unit
stock
wast
patient
demand
vari
within
institut
time
time
also
taken
consider
avoid
either
increas
decreas
isi
wapi
valu
final
set
daili
unreserv
stock
limit
import
assur
scrutin
monitor
remedi
action
benefit
would
maxim
limit
set
upon
abo
hospit
demand
abo
distribut
percentag
popul
also
worth
note
keep
strong
donor
recruit
base
import
manag
inventori
flexibl
manner
base
daili
chang
backgroundcas
studi
receiv
blood
product
inventori
ship
blood
supplier
workflow
transfus
servic
step
includ
unpack
shipment
box
compar
paper
list
product
receiv
unit
scan
unit
transfus
servic
inform
system
tsi
set
rbc
final
place
product
inventori
antigen
test
unit
particularli
vulner
increas
time
error
result
manual
ad
product
entri
tsi
electron
pack
list
current
avail
move
specimen
around
without
need
manual
item
avail
blood
product
ship
outsid
supplier
sought
quantifi
time
benefit
electron
pack
list
measur
time
spent
receiv
blood
product
tsi
studi
designmethod
electron
deliveri
step
receiv
blood
time
random
staff
shift
week
period
larg
academ
tertiari
care
hospit
shift
technologist
experi
level
repres
unpack
segment
manag
exclud
measur
time
data
analysi
perform
microsoft
excel
redmond
wa
usa
deliveri
sd
mean
exclud
result
resultsfind
time
studi
captur
product
separ
deliveri
episod
mean
unit
per
episod
product
type
repres
major
rbc
averag
time
deliveri
across
product
sunit
compon
specif
deliveri
time
present
tabl
rbc
label
antigen
test
result
took
mean
sunit
use
year
inventori
data
averag
monthli
product
volum
compar
time
requir
bring
unit
calcul
predict
transfus
servic
spend
hour
per
month
comput
entri
blood
product
conclus
receiv
inventori
tsi
take
signific
laboratori
time
scannabl
pack
list
electron
deliveri
blood
product
list
could
provid
benefit
includ
increas
accuraci
antigen
result
free
valuabl
technologist
time
laboratori
activ
becom
especi
import
emerg
imped
patient
care
backgroundcas
studi
discard
unit
perish
blood
product
unfortun
infrequ
widespread
outcom
unit
gener
donat
volunt
donor
sever
studi
report
frequenc
mishap
individu
hospit
health
care
system
survey
conduct
colleg
american
pathologist
attempt
reduc
discard
commun
hospit
past
three
year
tabul
item
product
discard
three
blood
compon
pack
red
blood
cell
rbc
fresh
frozen
plasma
ffp
platelet
studi
designmethod
three
year
use
standard
item
list
reason
return
product
blood
bank
ffp
platelet
order
physician
identifi
resultsfind
prbc
wastag
significantli
lower
p
compar
percent
wast
unit
ffp
platelet
significantli
differ
three
year
tabl
reason
discard
blood
product
rbc
reason
unit
three
year
outdat
blood
supplier
credit
return
return
floor
rn
punctur
miscellan
autolog
total
unit
receiv
discard
rate
three
year
outdat
ab
unit
return
credit
blood
supplier
total
rbc
outdat
three
year
outdat
unit
receiv
outdat
rate
three
year
unus
ffp
identifi
provid
one
unus
unit
one
two
unus
unit
one
three
unus
unit
one
seven
unus
unit
five
patient
expir
transfus
three
ffp
bag
broke
unus
platelet
sixteen
provid
fourteen
one
unus
unit
one
provid
two
unus
unit
one
provid
three
unus
unit
blood
bank
technologist
involv
three
addit
unus
platelet
unit
conclus
signific
reduct
rbc
discard
compar
two
prior
year
due
new
real
time
blood
product
order
system
real
time
blood
product
order
system
blood
supplier
lesser
sustain
reduct
platelet
wastag
ffp
platelet
major
reason
discard
unit
order
use
reduct
blood
discard
requir
cooper
blood
bank
blood
supplier
awar
order
provid
confirm
necess
order
transfus
backgroundcas
studi
although
blood
program
number
differ
approach
provid
apheresi
platelet
inventori
hospit
includ
prohibit
return
larg
blood
center
elect
rotat
restock
apheresi
platelet
maintain
site
approxim
healthcar
facil
charg
servic
reli
mani
hospit
typic
experi
rel
high
daili
transfus
demand
apheresi
platelet
accept
shorter
date
unit
return
blood
center
daili
rotat
schedul
recent
howev
increas
number
request
facil
keep
onsit
inventori
apheresi
platelet
compli
anticip
matern
level
care
design
requir
massiv
transfus
protocol
trauma
level
design
background
continu
challeng
maintain
adequ
inventori
hospit
made
acut
increas
demand
product
age
apheresi
platelet
donor
base
decid
investig
rotat
restock
polici
close
want
pay
special
attent
proport
overal
apheresi
platelet
suppli
rotat
restock
manag
also
proport
inventori
eventu
lost
outdat
short
date
product
return
rotat
restock
hospit
transfus
busier
transfus
servic
studi
designmethod
review
annual
apheresi
platelet
suppli
rotat
hospit
select
special
attent
rotat
hospit
return
apheresi
platelet
stock
daili
averag
determin
number
hour
outdat
remain
apheresi
platelet
issu
return
evalu
carri
return
platelet
eventu
percentag
outdat
resultsfind
apheresi
platelet
distribut
hospit
distribut
provid
rotat
restock
hospit
hospit
platelet
rotat
restock
program
util
less
platelet
ship
averag
hour
remain
platelet
ship
hour
remain
outdat
platelet
return
total
number
platelet
distribut
hospit
use
remain
return
ultim
outdat
conclus
opportun
improv
effici
rotat
restock
polici
depend
approv
extend
outdat
apheresi
platelet
beyond
current
permiss
day
regard
cold
store
platelet
much
longer
shelf
life
would
significantli
reduc
transport
deliveri
cost
associ
inventori
rotat
schedul
also
decreas
number
short
date
product
risk
outdat
redistribut
hour
shelf
life
remain
hospit
busi
transfus
servic
